

Ioan Suiugan

Patient Health Summary, generated on Mar. 06, 2025

English - Written (Preferred)	White / Not Hispanic or Latino	Divorced							
Language	Race / Ethnicity	Marital Status							
Former (Aug. 01, 2023 - Aug. 28, 2023): 30541 DAWSON ST (Home) GARDEN CITY, MI 48135		ioanaabuic@gmail.com							
21207 Parker <i>(Home)</i> FARMINGTON HILLS, MI 48336	Ioan Suiugan	248-759-0294 (Home) 248-759-0294 (Mobile) ioanaabdic@gmail.com							
Patient Address	Patient Name	Communication							
Patient Demographics - Male; born Feb. 27, 1961									

Note from Beaumont Health (Before 7/21/2024) (Beaumont, Botsford, and Oakwood)

This document contains information that was shared with Ioan Suiugan. It may not contain the entire record from Beaumont Health (Before 7/21/2024) (Beaumont, Botsford, and Oakwood).

Allergies

Information not available to this user

Medications

acetaminophen (TYLENOL) 325 MG PO Tab (Started 8/29/2023) place 2 Tablets into the PEG tube every 4 hours as needed for F		
amiodarone (CORDARONE, PACERONE) 200 MG PO Tab (Starte		PAIN OF FOR FEVER.
place 1 Tablet into the PEG tube once daily.	20 0/30/2023)	
apixaban (ELIQUIS) 5 MG PO Tab (Started 8/29/2023)		
place 1 Tablet into the PEG tube twice daily.		
atorvastatin (LIPITOR) 40 MG PO Tab (Started 8/29/2023)		
place 1 Tablet into the PEG tube once every night at bedtime.		
clopidogrel (PLAVIX) 75 MG PO Tab (Started 8/29/2023)		
place 1 Tablet into the PEG tube once daily.		
LORazepam (INTENSOL) 2 MG/ML PO Conc (Started 8/29/2023		
administer 0.5 mL as directed every 6 hours as needed for FOR	AGITATION.	
metoprolol (LOPRESSOR) 25 MG PO Tab (Started 8/29/2023)		
place 1 Tablet into the PEG tube twice daily.		
OLANZapine (ZyPREXA) 10 MG PO Tab (Started 8/29/2023)		
place 1 Tablet into the PEG tube twice daily.		
clonazePAM (KlonoPIN) 1 MG PO Tab (Started 8/29/2023)		
place 1 Tablet into the PEG tube once every night at bedtime.		
clonazePAM (KlonoPIN) 0.5 MG PO Tab (Started 9/13/2023)		
place 1 Tablet into the PEG tube twice daily. valproate (DEPAKENE) 250 MG/5ML PO Solution (Started 9/13,	/2022)	
place 20 mL into the PEG tube twice daily.	(2023)	
Active Problems		
Information not available to this user		
Social History		
Sex and Gender Information	Value	Date Recorded
Sex Assigned at Birth	Not on file	

Last Filed Vital Signs

Vital Sign	Reading	Time Taken	Comments
Blood Pressure	114/79	09/14/2023 3:01 PM EDT	
Pulse	92	09/14/2023 3:01 PM EDT	
Temperature	36.6 °C (97.8 °F)	09/14/2023 3:01 PM EDT	
Respiratory Rate	20	09/14/2023 3:01 PM EDT	
Oxygen Saturation	95%	09/14/2023 3:01 PM EDT	
Inhaled Oxygen Concentration	-	-	
Weight	85 kg (187 lb 6.3 oz)	09/11/2023 8:00 AM EDT	
Height	188 cm (6' 2")	09/06/2023 3:17 PM EDT	
Body Mass Index	24.06	09/06/2023 3:17 PM EDT	

Procedures

ECG (Performed 9/10/2023) Performed for V-tach

CONTINUE SPEECH SERVICES PER PLAN OF CARE (Performed 9/7/2023)
CONSULT SPEECH & LANGUAGE PATHOLOGY (Performed 9/7/2023)
ECG (Performed 9/6/2023)
CHEST PHYSIOTHERAPY (Performed 8/29/2023)
CHEST PHYSIOTHERAPY (Performed 8/29/2023)
CHEST PHYSIOTHERAPY (Performed 8/28/2023)
CHEST PHYSIOTHERAPY (Performed 8/27/2023)
CHEST PHYSIOTHERAPY (Performed 8/27/2023)
CHEST PHYSIOTHERAPY (Performed 8/27/2023)
PROCEDURALIST LINE INSERTION (Performed 8/26/2023)
CHEST PHYSIOTHERAPY (Performed 8/26/2023)
CHEST PHYSIOTHERAPY (Performed 8/26/2023)
CHEST PHYSIOTHERAPY (Performed 8/26/2023)
CHEST PHYSIOTHERAPY (Performed 8/26/2023)
CHEST PHYSIOTHERAPY (Performed 8/25/2023)
CHEST PHYSIOTHERAPY (Performed 8/24/2023)
CHEST PHYSIOTHERAPY (Performed 8/24/2023)
CHEST PHYSIOTHERAPY (Performed 8/24/2023)
ECG (Performed 8/23/2023)
Performed for Sepsis without acute organ dysfunction, due to unspecified organism
CHEST PHYSIOTHERAPY (Performed 8/22/2023)
CHEST PHYSIOTHERAPY (Performed 8/22/2023)
CHEST PHYSIOTHERAPY (Performed 8/22/2023) PROCEDURALIST LINE INSERTION (Performed 8/5/2023)
EEG:ROUTINE (Performed 8/3/2023)
Performed for Altered mental status, unspecified altered mental status type
CONTINUE SPEECH SERVICES PER PLAN OF CARE (Performed 8/2/2023)
CONSULT SPEECH & LANGUAGE PATHOLOGY (Performed 8/2/2023)
ECG (Performed 8/1/2023)

Results						
(ABNORMAL) RENAL	FUNCTION PA		al result (09/13/202		DT)	
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Sodium	143	135 - 145 mmol/L		09/13/2023 8:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Potassium	4.0	3.5 - 5.2 mmol/L		09/13/2023 8:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	106	98 - 111 mmol/L		09/13/2023 8:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	30 (H)	20 - 29 mmol/L		09/13/2023 8:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	7	5 - 17		09/13/2023 8:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose	150 (H)	60 - 99 mg/dL		09/13/2023 8:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Fasting Blood Glucos Random Blood Glucose						
Blood Urea Nitrogen -BUN	20	7 - 25 mg/dL		09/13/2023 8:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.55 (L)	0.60 - 1.30 mg/ dL		09/13/2023 8:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	112	>60 mL/ min/ 1.73m2		09/13/2023 8:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Comment:

Calculation based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation refit without adjustment for race. Glomerular Filtration Rate is estimated from serum creatinine, age and gender using the CKD-EPI equation:

G1: Normal GFR: >=90
G2: Mildly decreased GFR: 60-89
G3a: Mildly to moderately decreased GFR: 45-59
G3b: Moderately to severely decreased GFR: 30-44
G4: Severely decreased GFR: 15-29
G5: Kidney failure GFR: <15</pre>

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Calcium	8.2 (L)	8.5 - 10.5 mg/dL		09/13/2023 8:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	<u> </u>
Phosphorus	2.6	2.3 - 4.4 mg/dL		09/13/2023 8:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Albumin	2.3 (L)	3.5 - 4.9 g/dL		09/13/2023 8:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U					09/13/2023 6:53 AM EDT
Narrative						
Authorizing Provider	Result Type					
Marissa H	BH LAB BLOOI	D ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		Farmington Hills, MI 48336	800-551-0488		
(ABNORMAL) CBC W/	AUTO DIFF - I	Final resu	lt (09/12/2023 6:26 /	AM EDT)		
		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
WBC	10.0	3.5 - 10.1 bil/L		09/12/2023 7:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RBC	4.47	4.31 - 5.48 tril/		09/12/2023 7:12 AM	BEAUMONT LABORATORY, EARMINGTON	

		5.48 tril/ L	7:12 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hemoglobin	13.3 (L)	13.5 - 17.0 g/ dL	09/12/2023 7:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hematocrit	43.2	40.1 - 50.1 %	09/12/2023 7:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
MCV	97	80 - 100 fL	09/12/2023 7:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
МСН	30	28 - 33 pg		09/12/2023 7:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСНС	31 (L)	32 - 36 g/dL		09/12/2023 7:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RDW-CV	18 (H)	12 - 15 %		09/12/2023 7:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Platelets	331	150 - 400 bil/L		09/12/2023 7:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Nucleated Red Blood Cells	0.0	<=0.0 %		09/12/2023 7:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Neutrophils	7.3 (H)	1.6 - 7.2 bil/L		09/12/2023 7:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Lymphocytes	1.5	1.1 - 4.0 bil/L		09/12/2023 7:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Monocytes	1.1 (H)	0.0 - 0.9 bil/L		09/12/2023 7:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Eosinophils	0.1	0.0 - 0.4 bil/L		09/12/2023 7:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.0	0.0 - 0.1 bil/L		09/12/2023 7:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.03	0.00 - 0.04 bil/L		09/12/2023 7:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %	0.3	%		09/12/2023 7:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Specimen (Source) Laterality Volume Collection Time Received Time Blood VENOUS BLOOD SPECIMEN / Unknown Venipuncture / Unknown 09/12/2023 5:26 AM EDT 09/12/2023 7:30 AM EDT Narrative Authorizing Provider Result Type Phone Number Phone Number Marisas H BH LAB BLOOD ORDERABLES Phone Number Phone Number Performing Organization Address City/State/2IP Code Phone Number RAMINOTON HILLS (CLIA #: 23D0363256) Ref Analysis Range Component Value Range Test Method Time Sodium 144 135 746 AM LABORATORY, FaxMINICTON Sodium 42 35 - 52 09/12/2023 BEAUMONT Tomo/L Est Method Time Pathologist Signature Sodium 144 135 Ta6 AM LABORATORY, FaxMINICTON HILLS (LLIA #: 230033256) Chloride 105 98 - 111 09/12/2023 BEAUMONT HILLS (CLIA #: 230033256) Chloride 105 98 - 111 746 AM LABORATORY, FAXMINICTON HILLS (L		Anatomical Lo	cation /	Collection Method /			
SPECIMEN / Unknown Narrative Authorizing Provider Result Type Marissa H BH LAB BLOOD ORDERABLES Performing Organization Address Ctry/State/ZIP Code Phone Number BEALMONT 20050 Grand River Ave Farmington Hills, MI 800-551-0488 Component Value Ref Analysis Performed At Pathologist Signature Sodium 144 145 7/24 AM Leadoval (09/12/2023 BEALMONT) Performed At Pathologist Signature Sodium 144 145 7/24 AM Leadoval (09/12/2023 BEALMONT) Performed At Pathologist Signature Sodium 144 145 7/24 AM Leadoval (09/12/2023 BEALMONT) Performed At Pathologist Signature Sodium 144 145 7/24 AM Leadoval (08/17/2023 BEALMONT) Performed At Pathologist Signature Component Value 89 - 111 99/12/2023 BEALMONT Pathologist Signature Boot Signature 99/12/2023 BEALMONT Pathologist Signature Pathologist Signature Component 104 242 3.5 2.0 99/12/20	Specimen (Source) Blood	Laterality VENOUS BLOC	חו	Volume Venipuncture / Unknow			Received Time
Authorizing Provider Result Type Marissa H BH LAB BLOOD ODERABLES Performing Organization Address City/State/ZIP.Code Phone Number BEAUMONT 28050 Grand River Ave Farnington Hills, Mil 800-551-0488 RAMINGTON HILLS Component Value Range Test Method Time Component Value Range Test Method Time Performed At Pathologist Signature Sodium 144 135 - 145 746 AM LABORATORY, FARMINGTON FLUE Sodium 144 135 - 145 746 AM LABORATORY, FARMINGTON FLUE Sodium 142 3.5 - 5.2 09/12/023 BEAUMONT 23D032360 Potassium 4.2 3.5 - 5.2 09/12/023 BEAUMONT FARMINGTON ILLS (CLLA #: 23D0323260) mmol/L 746 AM LABORATORY, FARMINGTON EDT Carbon Dioxide -CO2 32 (H) 20 - 29 mmol/L 09/12/023 BEAUMONT FARMINGTON Full 746 AM LABORATORY, FARMINGTON EDT	biood			venipulieture / olikilow	11 03/12/202	.5 0.207 (141 201	03/12/2023 1.00 / (W 201
Authorizing Provider Result Type Marissa H BH LAB BLOOD ODERABLES Performing Organization Address City/State/ZIP.Code Phone Number BEAUMONT 28050 Grand River Ave Farnington Hills, Mil 800-551-0488 RAMINGTON HILLS Component Value Range Test Method Time Component Value Range Test Method Time Performed At Pathologist Signature Sodium 144 135 - 145 746 AM LABORATORY, FARMINGTON FLUE Sodium 144 135 - 145 746 AM LABORATORY, FARMINGTON FLUE Sodium 142 3.5 - 5.2 09/12/023 BEAUMONT 23D032360 Potassium 4.2 3.5 - 5.2 09/12/023 BEAUMONT FARMINGTON ILLS (CLLA #: 23D0323260) mmol/L 746 AM LABORATORY, FARMINGTON EDT Carbon Dioxide -CO2 32 (H) 20 - 29 mmol/L 09/12/023 BEAUMONT FARMINGTON Full 746 AM LABORATORY, FARMINGTON EDT	Narrative						
Marissa H BH LAB BLOOD ORDERABLES Performing Organization Address City/Siste/ZIP Code Phone Number BEAUMONT LABORATORY, PARMINGTON HILLS (CLN + 23D0363256) 28050 Grand River Ave Assig Farmington Hills, MI Assig 800-551-0488 (ABNORMAL) RENAL FUNCTION PANEL - Final result (09/12/2023 GEA M EDT) Analysis Performed At Pathologist Signature Component Value Rafg Rafg Test Method Time 746 AM Performed At Pathologist Signature Sodium 144 135 - 145 746 AM LABORATORY, FARMINGTON Farmington Hills, MI Association Patassium 4.2 3.5 - 5.2 mmol/L 09/12/2023 BEAUMONT FARMINGTON, HILLS (CLI A # 23D0363256) Chloride 105 96 - 111 mmol/L 09/12/2023 BEAUMONT FARMINGTON, HILLS (CLI A # 23D0363256) Carbon Dioxide - CO2 32 (H) 20 - 29 mmol/L 746 AM LABORATORY, FARMINGTON HILLS (CLI A # 23D0363256) Glucose 147 (H) 60 - 99 mg/dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLI A # 23D0363256) Glucose 147 (H) 60 - 99 mg/dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLI A # 23D0363256) Glucose 60-19 mg/dL 746 AM LABORATORY, FARMINGTON HILLS (CLI A # 23D0363256) 200063256) Glucose 60-19 mg/dL 746 AM LABORATORY, FARMINGTON HILLS (CLI A # 23D0363							
Marissa H BH LAB BLOOD ORDERABLES Performing Organization Address City/Siste/ZIP Code Phone Number BEAUMONT LABORATORY, PARMINGTON HILLS (CLN + 23D0363256) 28050 Grand River Ave Assig Farmington Hills, MI Assig 800-551-0488 (ABNORMAL) RENAL FUNCTION PANEL - Final result (09/12/2023 GEA M EDT) Analysis Performed At Pathologist Signature Component Value Rafg Rafg Test Method Time 746 AM Performed At Pathologist Signature Sodium 144 135 - 145 746 AM LABORATORY, FARMINGTON Farmington Hills, MI Association Patassium 4.2 3.5 - 5.2 mmol/L 09/12/2023 BEAUMONT FARMINGTON, HILLS (CLI A # 23D0363256) Chloride 105 96 - 111 mmol/L 09/12/2023 BEAUMONT FARMINGTON, HILLS (CLI A # 23D0363256) Carbon Dioxide - CO2 32 (H) 20 - 29 mmol/L 746 AM LABORATORY, FARMINGTON HILLS (CLI A # 23D0363256) Glucose 147 (H) 60 - 99 mg/dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLI A # 23D0363256) Glucose 147 (H) 60 - 99 mg/dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLI A # 23D0363256) Glucose 60-19 mg/dL 746 AM LABORATORY, FARMINGTON HILLS (CLI A # 23D0363256) 200063256) Glucose 60-19 mg/dL 746 AM LABORATORY, FARMINGTON HILLS (CLI A # 23D0363	Authorizina Provider	Result Type					
BEALMONT LABORATORY, FAMINGTON HILLS (CLL #: 2300363256) 28050 Grand River Ave AB336 Faminigton Hills, MI 48336 800-551-0488 (ABNORMAL) RENAL FUNCTION PANEL - Final result (09/12/2023 6:26 AM EDT) Analysis Analysis Analysis (CLL #: 2300363256) Test Method Time Performed At. Pathologist Signature Sodium 144 135 - 145 Analysis Analysis Formation 144 135 - 145 7.46 AM LABORATORY, FARMINGTON HILLS (CLLA #: 2300363256) Potassium 4.2 3.5 - 5.2 mmol/L 09/12/2023 BEAUMONT FARMINGTON HILLS (CLLA #: 2300363256) Chloride 105 98 - 111 mmol/L 7.46 AM EDT LABORATORY, FARMINGTON HILLS (CLLA #: 2300363256) Carbon Dioxide -CO2 32 (H) 20 - 29 mmol/L 09/12/2023 BEAUMONT HILLS (CLLA #: 2300363256) Glucose 147 (H) 60 - 99 mg/dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLLA #: 2300363256) Glucose 60 - 99 mg/dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLLA #: 2300363256) Glucose 60 - 99 mg/dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLLA #: 2300363256) Glucose 60 - 139 mg/dL		21	ORDERA	BLES			
EAUMONT HABORATORY FARMINGTON HILLS (CLI #: 2300363256) 28050 Grand River Ave HABORATORY FARMINGTON HILLS Farmington Hills, MI 48336 800-551-0488 (ABNORMAL) RENAL FUNCTION PANEL - Final result (09/12/2023 6:26 AM EDT) Component Nale Range Value Analysis Range Test Method Analysis Time Performed At Pathologist Signature Sodium 144 135 - 145 mmol/L Test Method Of/12/2023 Potassium BEAUMONT HILLS (CLI #: 2300363256) Potassium 4.2 3.5 - 5.2 mmol/L 09/12/2023 Potassium BEAUMONT PARMINGTON HILLS (CLI #: 2300363256) Chloride 105 98 - 111 mmol/L 09/12/2023 Potassium BEAUMONT PARMINGTON HILLS (CLI #: 2300363256) Carbon Dioxide -CO2 32 (H) 20 - 29 mmol/L 09/12/2023 Potassium BEAUMONT PARMINGTON HILLS (CLI #: 2300363256) Glucose 147 (H) 60 - 99 mg/dL 09/12/2023 Potassizes BEAUMONT PARMINGTON HILLS (CLI #: 2300363256) Glucose 60 - 99 mg/dL 09/12/2023 Parkinic Parkinic Parki	Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) RENAL FUNCTION PANEL - Final result (09/12/2023 6:26 AM EDT) Ref Analysis Component Value Range Test Method Time Performed At Pathologist Signature Sodium 144 135 - 5:2 7/46 AM ABORATORY, FARMINGTON, HILLS (CLIA #: 23D0363256) Chloride 105 96 - 111 09/12/2023 BEAUMONT mool/L 20 - 29 09/12/2023 BEAUMONT Carbon Dioxide -CO2 32 (H) 20 - 29 09/12/2023 BEAUMONT mool/L 20 - 29 09/12/2023 BEAUMONT 200363256) Carbon Dioxide -CO2 32 (H) 20 - 29 09/12/2023 BEAUMONT mool/L 20 - 29 09/12/2023 BEAUMONT 200363256) Carbon Dioxide -CO2 32 (H) 20 - 29 09/12/2023 BEAUMONT mool/L 20 - 29 09/12/2023 BEAUMONT 23D0363256) Guicose 147 (H) 60	BEAUMONT		iver Ave	Farmington Hills, MI	800-551-0	488	
(ABNORMAL) RENAL FUNCTION PANEL - Final result (09/12/2023 6:26 AM EDT) Ref Component Value Ref rage Analysis Test Method Performed At Time Pathologist Signature Sodium 144 135 - 145 09/12/2023 BEALMONT Sodium 144 135 - 145 09/12/2023 BEALMONT Potassium 4.2 3.5 - 5.2 mmol/L 09/12/2023 BEALMONT Potassium 4.2 3.5 - 5.2 mmol/L 09/12/2023 BEALMONT Final Ministrict 105 98 - 111 09/12/2023 BEALMONT Final Ministrict 105 98 - 111 09/12/2023 BEALMONT mmol/L 105 98 - 111 09/12/2023 BEALMONT Ministrict 105 98 - 111 09/12/2023 BEALMONT Ministrict 144 145 145 1480RATORY, FARMINGTON 1480RATORY, FARMINGTON Laboratorize 105 98 - 111 09/12/2023 BEALMONT 1450KLita #: 2300363256) Carbon Dioxide -CO2 32 (H) 20 - 29 09/12/2023				48336			
Component Value Rarge Test Method Time Parformed At Pathologist Signature Sodium 144 135 - 145 99/12/2023 BEAUMONT LABORATORY, FARMINGTON, HILLS (CLIA #: 23D0363256) Potassium 4.2 3.5 - 5.2 09/12/2023 BEAUMONT LABORATORY, FARMINGTON, HILLS (CLIA #: 23D0363256) Choride 105 98 - 111 09/12/2023 BEAUMONT LABORATORY, FARMINGTON, HILLS (CLIA #: 23D0363256) Choride 105 98 - 111 09/12/2023 BEAUMONT LABORATORY, FARMINGTON, HILLS (CLIA #: 23D0363256) Carbon Dioxide -CO2 32 (H) 20 - 29 09/12/2023 BEAUMONT LABORATORY, FARMINGTON, HILLS (CLIA #: 23D0363256) Carbon Dioxide -CO2 32 (H) 20 - 29 09/12/2023 BEAUMONT LABORATORY, FARMINGTON, HILLS (CLIA #: 23D0363256) Carbon Dioxide -CO2 32 (H) 20 - 59 09/12/2023 BEAUMONT LABORATORY, FARMINGTON, HILLS (CLIA #: 23D0363256) Comment: Frasting Blood Glucose: 60 - 99 09/12/2023 BEAUMONT LABORATORY, FARMINGTON, HILLS (CLIA #: 23D0363256) Blood Urea Nitrogen 19 7	(CLIA #: 23D0363256)						
Component Value Ref ange Test Method Time Parformed At Pathologist Signature Sodium 144 135 - 145 09/12/2023 BEAUMONT LABORATORY, FARMINGTON, HULS, CLIA #: 230036256) Potassium 4.2 3.5 - 5.2 09/12/2023 BEAUMONT, LABORATORY, FARMINGTON, HULS, CLIA #: 230036256) Potassium 4.2 3.5 - 5.2 09/12/2023 BEAUMONT, LABORATORY, FARMINGTON, HULS, CLIA #: 230036256) Choride 105 98 - 111 09/12/2023 BEAUMONT, LABORATORY, FARMINGTON, HULS, CLIA #: 2300363256) Carbon Dioxide -CO2 32 (H) 20 - 29 09/12/2023 BEAUMONT, LABORATORY, FARMINGTON, HULS, CLIA #: 2300363256) Carbon Dioxide -CO2 32 (H) 20 - 29 09/12/2023 BEAUMONT, LABORATORY, FARMINGTON, HULS, CLIA #: 2300363256) Carbon Dioxide -CO2 32 (H) 20 - 29 mmol/L Portace Parf Ad AM Carbon Dioxide -CO2 32 (H) 20 - 29 mmol/L Parf Ad AM LABORATORY, FARMINGTON, HULS, CLIA #: 2300363256) Carbon Dioxide -CO2 32 (H) 5 - 17 Parf Ad AM EDT FARMINGTON, HULS, CLIA #: 2300363256)							
Component Value Range Test Method Time Performed At Pathologist Signature Sodium 144 135 - 145 09/12/202 BEAUMONT LABORATORY, FARMINGTON Potassium 4.2 3.5 - 5.2 09/12/2023 BEAUMONT LABORATORY, FARMINGTON Potassium 4.2 3.5 - 5.2 09/12/2023 BEAUMONT	(ABNORMAL) RENAL F	UNCTION PA				DT)	
145 7.46 AM FARMINGTON Potassium 4.2 3.5 - 5.2 09/12/2023 BEAUMONT 7.46 AM FARMINGTON FROMINGTON FROMINGTON Potassium 4.2 3.5 - 5.2 09/12/2023 BEAUMONT 7.46 AM FARMINGTON FROMINGTON FROMINGTON EDT FARMINGTON FROMINGTON FROMINGTON EDT FARMINGTON FROMINGTON FROMINGTON FOLDORIDA 09/12/2023 BEAUMONT FROMINGTON FOLDORIDA 98 - 111 mmol/L 09/12/2023 BEAUMONT 7.46 AM LABORATORY, EDT FARMINGTON FROMINGTON FOLDORIDA 20 - 29 mmol/L 09/12/2023 BEAUMONT FAGE 20 - 29 mmol/L 200363256) EDT FARMINGTON, FOLDORIDA POP POP/12/2023 BEAUMONT FAGE EDT FAGE Anion Gap 7 5 - 17 POP/12/2023 BEAUMONT FAGE EDT FAGE EDT FAGE EDT FAGE EDT FAGE EDT FA			Range	Test Method	Time		Pathologist Signature
mmol/L EDT FAILNGTON HILLS (CLIA #: 2D0363256) Potassium 4.2 3.5 - 5.2 mmol/L 99/12/2023 BEAUMONT HADRORY, EDT LABORATORY, EDT Chloride 105 98 - 111 mmol/L 99/12/2023 BEAUMONT HILLS (CLIA #: 2300363256) Carbon Dioxide - CO2 32 (H) 20 - 29 mmol/L 99/12/2023 BEAUMONT HILLS (CLIA #: 2300363256) Carbon Dioxide - CO2 32 (H) 20 - 29 mmol/L 7/46 AM Price LABORATORY, EDT Anion Gap 7 5 - 17 7/46 AM Price LABORATORY, EDT LABORATORY, HILLS (CLIA #: 2300363256) Glucose 147 (H) 60 - 99 mg/dL 99/12/2023 BEAUMONT Price Comment: Fastting Blood Glucose: 60 - 99 mg/dL 7/46 AM Price LABORATORY, EDT BEAUMONT Price Blood Urea Nitrogen 19 mg/dL 7 - 2 mg/dL 99/12/2023 BEAUMONT Price Blood Urea Nitrogen 0.54 (L) 0.60 - 1.30 mg/dL 99/12/2023 BEAUMONT Price Creatinin 0.54 (L) 0.60 - 1.30 mg/dL 99/12/2023 BEAUMONT Price BEAUMONT Price	Sodium	144					
Potassium 4.2 3.5 - 5.2 mmol/L 7.46 AM Potassium Potassium A.2						FARMINGTON	
Potassium 4.2 3.5 - 5.2 mmol/L 09/12/2023 FARMINGTON HILS (CLLA #: 23D0363256) BEAUMONT FARMINGTON HILS (CLLA #: 23D0363256) Chloride 105 98 - 111 mmol/L 09/12/2023 FARMINGTON HILS (CLLA #: 23D0363256) BEAUMONT FARMINGTON HILS (CLLA #: 23D0363256) Carbon Dioxide -CO2 32 (H) 20 - 29 mmol/L 09/12/2023 FARMINGTON HILS (CLLA #: 23D0363256) BEAUMONT FARMINGTON HILS (CLLA #: 23D0363256) Anion Gap 7 5 - 17 09/12/2023 FARMINGTON HILS (CLLA #: 23D0363256) BEAUMONT FARMINGTON HILS (CLLA #: 23D0363256) Glucose 60 - 99 mg/dL 09/12/2023 FALMONT 7.46 AM FARMINGTON HILS (CLLA #: 23D0363256) BEAUMONT FARMINGTON HILS (CLLA #: 23D0363256) Glucose: 60 - 99 mg/dL 09/12/2023 FALMONT 7.46 AM FARMINGTON HILS (CLLA #: 23D0363256) BEAUMONT FARMINGTON HILS (CLLA #: 23D0363256) Blood Urea Nitrogen -BUN 19 mg/dL 7 - 25 mg/dL 09/12/2023 FALMONT 7.46 AM FARMINGTON HILS (CLLA #: 23D0363256) Creatinine 0.54 (L) 0.60 - 1.30 mg/ dL 09/12/2023 FALMONT 7.46 AM FARMINGTON HILS (CLLA #: 23D0363256)							
EDT FARMINGTON HILLS (CLIA #: 200363256) Chloride 105 98 - 111 mmol/L 09/12/2023 EAUMONT BEAUMONT FARMINGTON HILLS (CLIA #: 200363256) Carbon Dioxide -CO2 32 (H) 20 - 29 mmol/L 09/12/2023 EAUMONT BEAUMONT FARMINGTON HILLS (CLIA #: 200363256) Anion Gap 7 5 - 17 09/12/2023 EAUMONT BEAUMONT FARMINGTON HILLS (CLIA #: 200363256) Glucose 147 (H) 60 - 99 mg/dL 09/12/2023 EAUMONT BEAUMONT FARMINGTON HILLS (CLIA #: 200363256) Glucose 147 (H) 60 - 99 mg/dL 09/12/2023 EAUMONT BEAUMONT FARMINGTON HILLS (CLIA #: 200363256) Comment: Fasting Blood Glucose: 60-99 mg/dL 7 - 25 mg/dL 09/12/2023 EAUMONT BEAUMONT FARMINGTON HILLS (CLIA #: 200363256) Blood Urea Nitrogen -BUN 19 mg/dL 7 - 25 mg/dL 09/12/2023 EAUMONT T/46 AM LABORATORY, EDT BEAUMONT FARMINGTON HILLS (CLIA #: 200363256) Creatinine 0.54 (L) 0.60 - 1.30 mg/ dL 09/12/2023 EAUMONT T/46 AM LABORATORY, EDT BEAUMONT FARMINGTON HILLS (CLIA #: 200363256)	Potassium	4.2				BEAUMONT	
Image: Constraint of the second sec			mmol/L				
Chloride 105 98 - 111 mmol/L 09/12/2023 BEAUMONT LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) Carbon Dioxide -CO2 32 (H) 20 - 29 mmol/L 09/12/2023 BEAUMONT Anion Gap 7 5 - 17 09/12/2023 BEAUMONT HILLS (CLIA #: 23D0363256) Glucose 147 (H) 60 - 99 mg/dL 09/12/2023 BEAUMONT HILLS (CLIA #: 23D0363256) Glucose 147 (H) 60 - 99 mg/dL 09/12/2023 mg/dL BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Blood Glucose: 60-99 mg/dL 09/12/2023 mg/dL BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Blood Urea Nitrogen -BUN 19 7 - 25 mg/dL 09/12/2023 09/12/2023 FARMINGTON HILLS (CLIA #: 23D0363256) Creatinine 0.54 (L) 0.60 - 1.30 mg/ dL 09/12/2023 FARMINGTON HILLS (CLIA #: 23D0363256)						•	
EDTFARMINGTON HILLS (CLIA #: 23D0363256)Carbon Dioxide -CO232 (H)20 - 29 mmol/L09/12/2023BEAUMONT FARMINGTON, HILLS (CLIA #: 23D0363256)Anion Gap75 - 1709/12/2023BEAUMONT FARMINGTON, HILLS (CLIA #: 23D0363256)Glucose147 (H)60 - 99 mg/dL09/12/2023BEAUMONT FARMINGTON, HILLS (CLIA #: 23D0363256)Glucose147 (H)60 - 99 mg/dL09/12/2023BEAUMONT FARMINGTON, HILLS (CLIA #: 23D0363256)Glucose147 (H)60 - 99 mg/dL09/12/2023BEAUMONT FARMINGTON, HILLS (CLIA #: 23D0363256)Comment: Fasting Blood Glucose:60 - 139 mg/dL09/12/2023BEAUMONT FARMINGTON, HILLS (CLIA #: 23D0363256)Blood Urea Nitrogen -BUN197 - 25 mg/dL09/12/2023BEAUMONT FARMINGTON, HILLS (CLIA #: 23D0363256)Creatinine0.54 (L)0.60 - 1.30 mg/ dL09/12/2023BEAUMONT FARMINGTON, HILLS (CLIA #: ADORATORY, FARMINGTON, HILLS (CLIA #: ADORATORY, HILLS (CLIA #: ADORATORY, FARMINGTON, HILLS (CLIA #: COMONT	Chloride	105				BEAUMONT	
Carbon Dioxide -CO2 32 (H) 20 - 29 mmol/L 09/12/2023 BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Anion Gap 7 5 - 17 09/12/2023 BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Glucose 147 (H) 60 - 99 mg/dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Glucose 147 (H) 60 - 99 mg/dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Comment: Formation of the second Fasting Blood Glucose: 60 - 99 mg/dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Blood Urea Nitrogen -BUN 19 7 - 25 mg/dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Creatinine 0.54 (L) 0.60 - 1.30 mg/ dL 0.60 - 1.30 mg/ dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256)			mmol/L				
Carbon Dioxide -CO2 32 (H) 20 - 29 mmol/L 09/12/2023 BEAUMONT LABORATORY, EDT CABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Anion Gap 7 5 - 17 09/12/2023 BEAUMONT 7.46 AM LABORATORY, LABORATORY, EDT BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Glucose 147 (H) 60 - 99 mg/dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Comment: Fasting Blood Glucose: 60-99 mg/dL Beaumont mg/dL BEAUMONT 7.46 AM LABORATORY, EDT Blood Urea Nitrogen -BUN 19 7 - 25 mg/dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Creatinine 0.54 (L) 0.60 - 1.30 mg/ dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256)							
EDT FARMINGTON HILLS (CLIA #: 23D0363256) Anion Gap 7 5 - 17 09/12/2023 BEAUMONT LABORATORY, EDT BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Glucose 147 (H) 60 - 99 mg/dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Glucose 147 (H) 60 - 99 mg/dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Comment: Fasting Blood Glucose: 60-139 mg/dL T46 AM FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Blood Urea Nitrogen -BUN 19 7 - 25 mg/dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Creatinine 0.54 (L) 0.60 - 1.30 mg/ dL 09/12/2023 BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256)	Carbon Dioxide -CO2	32 (H)	20 - 29		09/12/2023		
Anion Gap 7 5 - 17 09/12/2023 BEAUMONT Anion Gap 7 5 - 17 09/12/2023 BEAUMONT EDT FARMINGTON FARMINGTON FDT FARMINGTON HILLS (CLIA #: 23D0363256) Glucose 147 (H) 60 - 99 09/12/2023 BEAUMONT mg/dL 60 - 99 09/12/2023 BEAUMONT Fasting Blood Glucose: 60 - 99 mg/dL 7.46 AM LABORATORY, Fasting Blood Glucose: 60 - 139 mg/dL 09/12/2023 BEAUMONT Blood Urea Nitrogen 19 7 - 25 09/12/2023 BEAUMONT -BUN mg/dL 0.60 - 1.30 mg/ 09/12/2023 BEAUMONT Creatinine 0.54 (L) 0.60 - 1.30 mg/ 09/12/2023 BEAUMONT HILLS (CLIA #: 23D0363256) 0.54 (L) 0.60 - 1.30 mg/ 09/12/2023 BEAUMONT Creatinine 0.54 (L) 0.60 - 1.30 mg/ 09/12/2023 BEAUMONT HILLS (CLIA #: 23D0363256) DT FARMINGTON HILLS (CLIA #: 23D0363256)			mmol/L				
Anion Gap75 - 1709/12/2023 PARMINGTON HALS (CLIA #: 23D0363256)BEAUMONT LABORATORY, EDT 90/12/2023 EDT HILLS (CLIA #: 23D0363256)Glucose147 (H)60 - 99 mg/dL09/12/2023 Parming/dLBEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256)Glucose:60 - 99 mg/dL09/12/2023 mg/dLBEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256)Comment:Fasting Blood Glucose:60 - 99 mg/dLFasting Blood Glucose:60 - 139 mg/dLBlood Urea Nitrogen -BUN197 - 25 mg/dL09/12/2023 Parming/dLBlood Urea Nitrogen -BUN197 - 25 mg/dL09/12/2023 Parming/dLCreatinine0.54 (L)0.60 - 1.30 mg/ dL09/12/2023 Parming/dLBEAUMONT Parming/dLCreatinine0.54 (L)0.60 - 1.30 mg/ dL09/12/2023 Parming/dLBEAUMONT Parming/dLColumn0.54 (L)0.60 - 1.30 mg/ dL09/12/2023 Parming/dL09/12/2023 Parming/dLCreatinine0.54 (L)0.60 - Parming/dL09/12/2023 Parming/dL09/12						HILLS (CLIA #:	
And	Anion Gap	7	5 - 17		09/12/2023		
Glucose147 (H)60 - 99 mg/dL09/12/2023BEAUMONT ABORATORY, EDTComment: Fasting Blood Glucose:60 - 99 mg/dL7:46 AM EDTLABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)Comment: Fasting Blood Glucose:60 - 99 mg/dL5000363256)Blood Glucose:60 - 139 mg/dL5000363256)Blood Urea Nitrogen -BUN197 - 25 mg/dL09/12/2023BEAUMONT 7:46 AM EDTCreatinine0.54 (L)0.60 - 1.30 mg/ dL09/12/2023BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256)Creatinine0.54 (L)0.60 - 1.30 mg/ dL09/12/2023BEAUMONT FARMINGTON HILLS (CLIA #: EDT					7:46 AM	LABORATORY,	
Glucose 147 (H) 60 - 99 mg/dL 09/12/2023 BEAUMONT LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) Comment: Fasting Blood Glucose: 60-99 mg/dL 60-139 mg/dL 5000000000000000000000000000000000000					EDI		
mg/dL7:46 AM EDTLABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)Comment:Fasting Blood Glucose:60-99 mg/dLBlood Glucose:60-139 mg/dLBlood Urea Nitrogen197 - 2509/12/2023BEAUMONT-BUNmg/dL7:46 AM mg/dLLABORATORY, EDTEDT FARMINGTON HILLS (CLIA #: 23D0363256)Creatinine0.54 (L)0.60 - 1.30 mg/ dL09/12/2023BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256)	Glucose	147 (H)	60 - 99		09/12/2022		
HILLS (CLIA #: 23D0363256)Comment: Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dLVertical Strain S	Siucose	· · · · (II)			7:46 AM	LABORATORY,	
23D0363256) Comment: Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL 09/12/2023 BEAUMONT Blood Urea Nitrogen 19 7 - 25 09/12/2023 BEAUMONT -BUN mg/dL 7:46 AM LABORATORY, EDT EDT FARMINGTON HILLS (CLIA #: 23D0363256) Creatinine 0.54 (L) 0.60 - 1.30 mg/ dL 09/12/2023 BEAUMONT 1.30 mg/ dL 7:46 AM LABORATORY, EDT BADRATORY, FARMINGTON HILLS (CLIA #:					EDT		
Fasting Blood Glucose: 60-99 mg/dLBlood Urea Nitrogen -BUN197 - 25 mg/dL09/12/2023 EDTBEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256)Creatinine0.54 (L)0.60 - 1.30 mg/ dL09/12/2023 Club HitterBEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256)	Commente						
Blood Urea Nitrogen -BUN197 - 25 mg/dL09/12/2023 T:46 AM EDTBEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)Creatinine0.54 (L)0.60 - 1.30 mg/ dL0.9/12/2023 T:46 AM POIDBEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256)	Fasting Blood Glucose	-					
-BUN mg/dL 7:46 AM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) Creatinine 0.54 (L) 0.60 - 09/12/2023 BEAUMONT 1.30 mg/dL 7:46 AM LABORATORY, EDT FARMINGTON HILLS (CLIA #:		-			00/12/2022	REALINAONIT	
Creatinine0.54 (L)0.60 - 1.30 mg/ dL0.9/12/2023BEAUMONT LABORATORY, EDTHILLS (CLIA #: 23D0363256)		כו			7:46 AM	LABORATORY,	
Oreatinine 0.54 (L) 0.60 - 1.30 mg/ dL 09/12/2023 BEAUMONT EDT FARMINGTON HILLS (CLIA #: FARMINGTON					EDT		
1.30 mg/ 7:46 AM LABORATORY, dL EDT FARMINGTON HILLS (CLIA #:			0.00		00/10/200	23D0363256)	
dL EDT FARMINGTON HILLS (CLIA #:	Creatinine	0.54 (L)					
						FARMINGTON	

Comment		Ref		Analysis	Daufauna al At	Dath also sist Cine stores		
Component	Value	Range	Test Method	Time	BEAUMONT	Pathologist Signature		
eGFR By Creatinine	113	>60 mL/ min/		09/12/2023 7:46 AM	LABORATORY,			
		1.73m2		EDT	FARMINGTON			
					HILLS (CLIA #:			
Comment:					23D0363256)			
Calculation based on	the Chronic	Kidney Di	isease Epidemiology	Collaborati	on (CKD-EPI)	equation refit		
without adjustment f	or race. Glom	erular Fi				•		
gender using the CKD	-EPI equation	:						
G1: Normal GFR:	>=90							
-	eased GFR: 60							
G3a: Mildly to m								
G3b: Moderately G4: Severely de	creased GFR:		GFR: 30-44					
	ure GFR: <15							
Calcium	8.3 (L)	8.5 - 10.5 mg/dL		09/12/2023 7:46 AM	BEAUMONT LABORATORY,			
		ilig/uL		EDT	FARMINGTON			
					HILLS (CLIA #:			
Dheanhan	2.0	22 44		00/12/2022	23D0363256)			
Phosphorus	3.0	2.3 - 4.4 mg/dL		09/12/2023 7:46 AM	BEAUMONT LABORATORY,			
		iiig, al		EDT	FARMINGTON			
					HILLS (CLIA #:			
Albumin	2.3 (L)	3.5 - 4.9		09/12/2023	23D0363256) BEAUMONT			
Albumin	2.3 (L)	g/dL		7:46 AM	LABORATORY,			
		0		EDT	FARMINGTON			
					HILLS (CLIA #: 23D0363256)			
	Anatomical Lo	cation /	Collection Method /		2300303230)			
Specimen (Source)	Laterality		Volume	Collection		Received Time		
Blood	VENOUS BLOO		Venipuncture / Unknow	wn 09/12/202	23 6:26 AM EDT	09/12/2023 6:59 AM EDT		
	SPECIMEN / U	nknown						
Narrative								
Authorizing Provider	Result Type							
Marissa H	BH LAB BLOO	D ORDERA	BLES					
Performing Organization		<u>.</u>	City/State/ZIP Code	Phone Nu				
BEAUMONT LABORATORY,	28050 Grand F	kiver Ave	Farmington Hills, MI 48336	800-551-0	1488			
FARMINGTON HILLS			+0550					
(CLIA #: 23D0363256)								
(ABNORMAL) HEMOGLOBIN A1C - Final result (09/11/2023 6:29 AM EDT)								
(Ref		Analysis				
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature		
Hemoglobin A1C	6.7 (H)	4.0 - 5.6		09/11/2023				
		%		3:22 PM EDT	LABORATORY, ROYAL OAK			
					(CLIA#:			
					23D0667009)			
Estimated Average	146	mg/dL		09/11/2023				
Estimated Average Glucose	146	mg/dL		09/11/2023 3:22 PM EDT	BEAUMONT LABORATORY, ROYAL OAK			
<u> </u>	146	mg/dL		3:22 PM	LABORATORY,			

Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknow	n 09/11/202	23 6:29 AM EDT	09/11/2023 7:24 AM EDT
Narrative BEAUMONT LABORATORY, Increased risk for d Diabetes: > or =6.5%	ROYAL OAK (C iabetes (pred	LIA#: 23D iabetes):	0 667009) - 09/11/202 5.7-6.4%	3 3:22 PM	EDT	
When using Hemoglobin repeat measurement, - are affected by cond- seen with iron defic- anemias, unstable her transfusions.	fasting gluco itions that i iency or sple	se, or ot ncrease o nectomy.	her test for diagnos or decrease red blood Falsely normal or lo	ing diabet cell surv w results	es. All hemog ival. Falsely may be seen v	globin A1c methods / high results may be vith hemolytic
Authorizing Provider	Result Type					
Marissa H	BH LAB BLOOI	D ORDERAE	BLES			
Performing Organization BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	Address 3601 W. 13 Mi	le Rd	City/State/ZIP Code Royal Oak, MI 48073		Phone Number 800-551-0488	
(ABNORMAL) CBC W/		Ref		Analysis	Deufenned At	Dath da sist Cine Auro
Component WBC	Value 9.5	Range 3.5 - 10.1		Time		Pathologist Signature
WBC	9.5	5.5 - 10.1 bil/L		7:51 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RBC	4.09 (L)	4.31 - 5.48 tril/ L		09/11/2023 7:51 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	12.0 (L)	13.5 - 17.0 g/ dL		09/11/2023 7:51 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hematocrit	38.7 (L)	40.1 - 50.1 %		09/11/2023 7:51 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
MCV	95	80 - 100 fL		09/11/2023 7:51 AM	BEAUMONT LABORATORY,	

EDT

7:51 AM

EDT

MCH

29

28 - 33

pg

FARMINGTON HILLS (CLIA #: 23D0363256)

LABORATORY,

FARMINGTON HILLS (CLIA #: 23D0363256)

09/11/2023 BEAUMONT

		Ref	T (M ()	Analysis		
Component MCHC	Value 31 (L)	Range 32 - 36	Test Method	Time 09/11/2023		Pathologist Signature
		g/dL		7:51 AM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
RDW-CV	18 (H)	12 - 15 %		09/11/2023 7:51 AM	BEAUMONT LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
Platelets	306	150 -		09/11/2023	23D0363256)	
Flatelets	500	400 bil/L		7:51 AM EDT	LABORATORY, FARMINGTON	
				EDI	HILLS (CLIA #: 23D0363256)	
Nucleated Red Blood	0.0	<=0.0 %		09/11/2023 7:51 AM	BEAUMONT	
Cells				EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Neutrophils	6.0	1.6 - 7.2 bil/L		09/11/2023 7:51 AM	LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
Lymphocytes	1.7	1.1 - 4.0		09/11/2023	23D0363256) BEAUMONT	
		bil/L		7:51 AM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Monocytes	1.1 (H)	0.0 - 0.9 bil/L		09/11/2023 7:51 AM	BEAUMONT LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
Eosinophils	0.2	0.0 - 0.4		09/11/2023	23D0363256)	
Eosinophils	0.2	0.0 - 0.4 bil/L		7:51 AM	LABORATORY,	
				EDI	FARMINGTON HILLS (CLIA #:	
Basophils	0.0	0.0 - 0.1		09/11/2023		
		bil/L		7:51 AM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.50 (H)	0.00 - 0.04 bil/L		09/11/2023 7:51 AM	BEAUMONT LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
Immature Granulocyte %	5.3	%		09/11/2023	23D0363256) BEAUMONT	
		-		7:51 AM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection		Received Time
Blood	VENOUS BLOC					09/11/2023 7:24 AM EDT
	SPECIMEN / U	ικηοψη				
Narrative						

Authorizing Provider	Result Type					
Marissa H	BH LAB BLOO	D ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-(
(ABNORMAL) RENAL	FUNCTION PA	ANEL - Fir	nal result (09/11/202	3 6:29 AM E	DT)	
Commonweat	Value	Ref	Test Method	Analysis Time	Deufeune ed At	Dath allo aist Cianatura
Component Sodium	144	Range 135 - 145 mmol/L	Test Method	09/11/2023 7:47 AM EDT		Pathologist Signature
Potassium Comment: Sample is he	5.2	3.5 - 5.2 mmol/L	Icely increased	09/11/2023 7:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	109	98 - 111	isely increased.	09/11/2023	BEAUMONT	
		mmol/L		7:47 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	31 (H)	20 - 29 mmol/L		09/11/2023 7:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	4 (L)	5 - 17		09/11/2023 7:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose	172 (H)	60 - 99 mg/dL		09/11/2023 7:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Fasting Blood Glucos Random Blood Glucose						
Blood Urea Nitrogen -BUN	18	7 - 25 mg/dL		09/11/2023 7:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.53 (L)	0.60 - 1.30 mg/ dL		09/11/2023 7:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	113	>60 mL/ min/ 1.73m2		09/11/2023 7:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Comment: Calculation based on without adjustment fo gender using the CKD	or race. Glom -EPI equation	erular Fi				
G3a: Mildly to mo G3b: Moderately G4: Severely dec	eased GFR: 60 oderately dec	reased GF ecreased				
Calcium	8.0 (L)	8.5 - 10.5 mg/dL		09/11/2023 7:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Phosphorus	3.0	2.3 - 4.4 mg/dL		09/11/2023 7:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Sample is he Albumin	2.0 (L)	3.5 - 4.9	isely increased.	09/11/2023	BEAUMONT	
Albumin	2.0 (L)	g/dL		7:47 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	-	Received Time
Blood	VENOUS BLOO SPECIMEN / U		Venipuncture / Unknow	vn 09/11/202	3 6:29 AM EDI	09/11/2023 7:24 AM EDT
Narrative						
Authorizing Provider	Result Type					
Marissa H	BH LAB BLOOI	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0	488	
ECG - Final result (09/10)/2023 1:27 PN	1 EDT) Ref		Analysis	Performed	
Component	Value	Range	Test Method	Time	At	Pathologist Signature
QT INTERVAL	394	ms			MISYS	
QTC CALCULATION	460	ms			MISYS	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
				09/10/202	3 1:27 PM EDT	
Narrative						
MISYS - 09/11/2023 1	:41 PM EDT					

Narrative Test Reason : */* mmHG Blood Pressure : Vent. Rate : 82 BPM Atrial Rate : 82 BPM QRS Dur : 94 ms P-R Int : 140 ms QT Int : 394 ms P-R-T Axes : 11 18 18 degrees QTc Int : 460 ms Normal sinus rhythm Low voltage QRS Borderline ECG When compared with ECG of 06-SEP-2023 14:59, No significant change was found Confirmed by Hazergian, Gregory (497) on 9/11/2023 1:41:38 PM Referred By: Confirmed By: Gregory Hazergian Procedure Note Gregory Hazergian - 09/11/2023 Formatting of this note might be different from the original. Test Reason : Blood Pressure : */* mmHG Vent. Rate : 82 BPM Atrial Rate : 82 BPM P-R Int: 140 ms QRS Dur: 94 ms QT Int : 394 ms P-R-T Axes : 11 18 18 degrees QTc Int: 460 ms Normal sinus rhythm Low voltage QRS Borderline ECG When compared with ECG of 06-SEP-2023 14:59, No significant change was found Confirmed by Hazergian, Gregory (497) on 9/11/2023 1:41:38 PM Referred By: Confirmed By: Gregory Hazergian Authorizing Provider Result Type William Rudy WBH HBS CARD ECG

Performing Organization Address City/State/ZIP Code Phone Number	

MISYS

(ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (09/10/2023 11:56 AM EDT)

,	• • •	-				
		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	203 (H)	60 - 139 mg/dL		09/10/2023 12:03 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Turner, Javonnia NA			09/10/2023 12:03 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality	cationy	Volume	Collection	n Time	Received Time
Blood	WHOLE BLOO SPECIMEN / U			09/10/202 EDT	23 11:56 AM	09/10/2023 12:03 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg/	′d∟	A #: 23D0363256) -	09/10/2023	12:03 PM EDT	

Authorizing Provider	Result Type						
William Rudy	BH LAB POC T	BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS					
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mher		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-(
(ABNORMAL) RENAL	FUNCTION PA		al result (09/10/202		EDT)		
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature	
Sodium	145	135 - 145 mmol/L		09/10/2023 11:53 AM EDT			
Potassium Comment: Sample is he	4.9 molvzed. Result	3.5 - 5.2 mmol/L may be fa	lselv increased.	09/10/2023 11:53 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Chloride	109	98 - 111	isery increased.	09/10/2023	BEAUMONT		
		mmol/L		11:53 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Carbon Dioxide -CO2	26	20 - 29 mmol/L		09/10/2023 11:53 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Anion Gap	10	5 - 17		09/10/2023 11:53 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Glucose	205 (H)	60 - 99 mg/dL		09/10/2023 11:53 AM EDT			
Comment: Fasting Blood Glucos Random Blood Glucose	-						
Blood Urea Nitrogen -BUN	19	7 - 25 mg/dL		09/10/2023 11:53 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Creatinine	0.60	0.60 - 1.30 mg/ dL		09/10/2023 11:53 AM EDT			
eGFR By Creatinine	109	>60 mL/ min/ 1.73m2		09/10/2023 11:53 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Comment: Calculation based on without adjustment fo gender using the CKD	or race. Glom	<idney di<br="">erular Fi</idney>			on (CKD-EPI)	equation refit
G3a: Mildly to mo G3b: Moderately 1	eased GFR: 60 oderately dec to severely de creased GFR: 2	reased GF ecreased				
Calcium	8.1 (L)	8.5 - 10.5 mg/dL		09/10/2023 11:53 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Phosphorus	2.6	2.3 - 4.4 mg/dL		09/10/2023 11:53 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Sample is he	-	•	sely increased.			
Albumin	2.1 (L)	3.5 - 4.9 g/dL		09/10/2023 11:53 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /			
Specimen (Source)			Volume	Collection Time		Received Time
Blood	VENOUS BLOC SPECIMEN / Ur		Venipuncture / Unknow	EDT	3 TI:TU AIVI	09/10/2023 11:28 AM EDT
Narrative						
Authorizing Provider	Result Type					
Marissa H	BH LAB BLOOD	ORDERAE	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nur	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	
MAGNESIUM LEVEL - Fi		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Magnesium	2.2	1.7 - 2.5 mg/dL		09/10/2023 1:32 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Sample is he	molzyed. Result	may be fal	sely increased.			
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / Ur		Venipuncture / Unknow	n 09/10/202 EDT	3 11:10 AM	09/10/2023 11:28 AM EDT
				· •		•
Narrative						

Authorizing Provider William Rudy	Result Type BH LAB BLOOD ORDERA	BLES	
Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Address 28050 Grand River Ave	City/State/ZIP Code Farmington Hills, MI 48336	Phone Number 800-551-0488

(ABNORMAL) CBC W/AUTO DIFF - Final result (09/10/2023 8:49 AM EDT)

(ABNORMAL) CBC W		Ref	Analysis	
Component	Value	Range Test Meth		Performed At Pathologist Signature
WBC	13.0 (H)	3.5 - 10.1 bil/L	09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RBC	4.09 (L)	4.31 - 5.48 tril/ L	09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hemoglobin	12.0 (L)	13.5 - 17.0 g/ dL	09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hematocrit	38.2 (L)	40.1 - 50.1 %	09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
MCV	93	80 - 100 fL	09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСН	29	28 - 33 pg	09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСНС	31 (L)	32 - 36 g/dL	09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RDW-CV	17 (H)	12 - 15 %	09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Platelets	310	150 - 400 bil/L	09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Nucleated Red Blood Cells	0.0	<=0.0 %	09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

Component	Value	Ref Range	Test Method	Analysis Time	Parformad At	Pathologist Signature
Neutrophils	9.8 (H)	1.6 - 7.2 bil/L		09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Lymphocytes	1.5	1.1 - 4.0 bil/L		09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Monocytes	1.2 (H)	0.0 - 0.9 bil/L		09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Eosinophils	0.2	0.0 - 0.4 bil/L		09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.0	0.0 - 0.1 bil/L		09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.29 (H)	0.00 - 0.04 bil/L		09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %	2.2	%		09/10/2023 9:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /			
Specimen (Source) Blood	Laterality VENOUS BLOC SPECIMEN / Ur		Volume Venipuncture / Unknov	Collection vn 09/10/202		Received Time 09/10/2023 9:01 AM EDT
Narrative						
As the sinis s. Dues islas	De suite Trasse					
Authorizing Provider Marissa H	Result Type BH LAB BLOOD	ORDERAE	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mher	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0		
(ABNORMAL) CBC W//	AUTO DIFF - F	inal resu l Ref	lt (09/09/2023 12:51	PM EDT) Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
WBC	12.3 (H)	3.5 - 10.1 bil/L		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Component	Value	Ref Range	Test Method	Analysis Time	Performed At Pathologist Signature
RBC	3.75 (L)	4.31 - 5.48 tril/ L		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hemoglobin	11.1 (L)	13.5 - 17.0 g/ dL		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hematocrit	35.9 (L)	40.1 - 50.1 %		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
MCV	96	80 - 100 fL		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСН	30	28 - 33 pg		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСНС	31 (L)	32 - 36 g/dL		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RDW-CV	18 (H)	12 - 15 %		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Platelets	316	150 - 400 bil/L		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Nucleated Red Blood Cells	0.2 (H)	<=0.0 %		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Neutrophils	8.7 (H)	1.6 - 7.2 bil/L		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Lymphocytes	1.9	1.1 - 4.0 bil/L		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Monocytes	1.3 (H)	0.0 - 0.9 bil/L		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Eosinophils	0.2	0.0 - 0.4 bil/L		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.0	0.0 - 0.1 bil/L		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.21 (H)	0.00 - 0.04 bil/L		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %		%		09/09/2023 1:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / Ur		Venipuncture / Unknow			09/09/2023 12:56 PM EDT
Narrative						
Authorizing Provider	Result Type					
Marissa H	BH LAB BLOOD	ORDERA	BLES			
Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu 800-551-0		
CHEST 1 VIEW AP/PA - F			·			
Anatomical Region	Lateralit	У	Modality			
Chest			Radiograp	ohic Imaging		
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
				09/09/202 EDT	3 12:12 PM	
Narrative 09/09/2023 12:13 PM E	TOT					

09/09/2023 12:13 PM EDT

Narrative

TECHNIQUE: Single View of the chest.

INDICATION: Male 62 years old with a history of hypoxia, acute respiratory failure with hypoxia (CMS/HCC).

COMPARISON: Chest x-ray 9/6/2023.

FINDINGS: EKG leads overlie the chest and obscure detail.

Lungs: Clear of consolidation. Minimal bibasilar atelectasis.

Vasculature: Within normal limits.

Heart: Normal in size.

Mediastinum: within normal limits.

Musculoskeletal: The osseous structures are intact. Multilevel osteophytosis with endplate sclerosis is noted involving the thoracic spine.

IMPRESSION:

Bibasilar atelectasis.

Procedure Note

Rocky Saenz - 09/09/2023

Formatting of this note might be different from the original.

TECHNIQUE: Single View of the chest.

INDICATION: Male 62 years old with a history of hypoxia, acute respiratory failure with hypoxia (CMS/HCC).

COMPARISON: Chest x-ray 9/6/2023.

FINDINGS: EKG leads overlie the chest and obscure detail.

Lungs: Clear of consolidation. Minimal bibasilar atelectasis.

Vasculature: Within normal limits.

Heart: Normal in size.

Mediastinum: within normal limits.

Musculoskeletal: The osseous structures are intact. Multilevel osteophytosis with endplate sclerosis is noted involving the thoracic spine.

IMPRESSION:

Bibasilar atelectasis.

Authorizing Provider	Result Type
Marissa H	WBH IMG GENERAL ORDERABLES

(ABNORMAL) ELECTROLYTE PANEL (LYTES) - Final result (09/09/2023 6:21 AM EDT)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At Pathologist Signature
Sodium	150 (H)	135 - 145 mmol/L		09/09/2023 8:17 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Potassium	3.6	3.5 - 5.2 mmol/L	Test Method	09/09/2023 8:17 AM EDT		
Chloride	113 (H)	98 - 111 mmol/L		09/09/2023 8:17 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	31 (H)	20 - 29 mmol/L		09/09/2023 8:17 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	6	5 - 17		09/09/2023 8:17 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Timo	Received Time
Blood	VENOUS BLOC SPECIMEN / U					09/09/2023 7:48 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOO	D ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	

(ABNORMAL) ELECTROLYTE PANEL (LYTES) - Final result (09/09/2023 1:51 AM EDT)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Sodium	150 (H)	135 - 145 mmol/L		09/09/2023 2:21 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Potassium	4.0	3.5 - 5.2 mmol/L		09/09/2023 2:21 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	114 (H)	98 - 111 mmol/L		09/09/2023 2:21 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	29	20 - 29 mmol/L		09/09/2023 2:21 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		5 (
-		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Anion Gap	7	5 - 17		09/09/2023 2:21 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	VENOUS BLOO SPECIMEN / U		Venipuncture / Unknow	wn 09/09/202	23 1:51 AM EDT	09/09/2023 2:02 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOO	D ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand I	River Ave	Farmington Hills, MI 48336	800-551-0)488	

(ABNORMAL) ELECTROLYTE PANEL (LYTES) - Final result (09/08/2023 10:05 PM EDT)

(,,		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Sodium	151 (H)	135 - 145 mmol/L		09/08/2023 10:41 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Potassium	3.6	3.5 - 5.2 mmol/L		09/08/2023 10:41 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	115 (H)	98 - 111 mmol/L		09/08/2023 10:41 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	30 (H)	20 - 29 mmol/L		09/08/2023 10:41 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	6	5 - 17		09/08/2023 10:41 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknow			09/08/2023 10:16 PM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOI		DLES			

Performing Organization	Address	City/State/ZIP Code	Phone Number
BEAUMONT LABORATORY,	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0488
FARMINGTON HILLS (CLIA #: 23D0363256)			

(ABNORMAL) ELECTROLYTE PANEL (LYTES) - Final result (09/08/2023 6:00 PM EDT)

(, , , , , , , , , , , , , , ,		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Sodium	152 (H)	135 - 145 mmol/L		09/08/2023 6:47 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Potassium	3.5	3.5 - 5.2 mmol/L		09/08/2023 6:47 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	115 (H)	98 - 111 mmol/L		09/08/2023 6:47 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	31 (H)	20 - 29 mmol/L		09/08/2023 6:47 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	6	5 - 17		09/08/2023 6:47 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo	cation /	Collection Method / Volume	Collection	Timo	Received Time
Blood	Laterality VENOUS BLOC SPECIMEN / U					09/08/2023 6:27 PM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOD	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	

(ABNORMAL) ELECTROLYTE PANEL (LYTES) - Final result (09/08/2023 2:10 PM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Sodium	152 (H)	135 -		09/08/2023	BEAUMONT	
		145		3:15 PM	LABORATORY,	
		mmol/L		EDT	FARMINGTON	
					HILLS (CLIA #:	
					23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Potassium	3.3 (L)	3.5 - 5.2		09/08/2023		
		mmol/L		3:15 PM EDT	LABORATORY, FARMINGTON	
				EDT	HILLS (CLIA #:	
					23D0363256)	
Chloride	116 (H)	98 - 111		09/08/2023	BEAUMONT	
		mmol/L		3:15 PM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	30 (H)	20 - 29		09/08/2023	BEAUMONT	
		mmol/L		3:15 PM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Anion Gap	6	5 - 17		09/08/2023		
·				3:15 PM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /		,	
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	VENOUS BLOO		Venipuncture / Unknov	vn 09/08/202	23 2:10 PM EDT	09/08/2023 2:50 PM EDT
	SPECIMEN / U	nknown				
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOI		BLES			
			-			
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT	28050 Grand F	River Ave	Farmington Hills, MI	800-551-0	0488	
LABORATORY, FARMINGTON HILLS			48336			
(CLIA #: 23D0363256)						
(02.07.0.2000000200)						

(ABNORMAL) ELECTROLYTE PANEL (LYTES) - Final result (09/08/2023 10:20 AM EDT)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Sodium	153 (H)	135 - 145 mmol/L		09/08/2023 11:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	<u> </u>
Potassium	3.4 (L)	3.5 - 5.2 mmol/L		09/08/2023 11:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	118 (H)	98 - 111 mmol/L		09/08/2023 11:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	29	20 - 29 mmol/L		09/08/2023 11:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Anion Gap	6	5 - 17		09/08/2023 11:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Engerman (Source)	Anatomical Lo	cation /	Collection Method / Volume	Collection	Time	Received Time
Specimen (Source)	Laterality					
Blood	VENOUS BLOO SPECIMEN / U		Venipuncture / Unknow	n 09/08/202 EDT	23 10:20 AM	09/08/2023 10:41 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOO	D ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand I	River Ave	Farmington Hills, MI 48336	800-551-0)488	

(ABNORMAL) BASIC METABOLIC PANEL (BMP) - Final result (09/08/2023 6:09 AM EDT)

		Ref	,	Analysis	
Component	Value	Range	Test Method	Time	Performed At Pathologist Signature
Sodium	155 (H)	135 - 145 mmol/L		09/08/2023 7:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Potassium	3.7	3.5 - 5.2 mmol/L		09/08/2023 7:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Chloride	117 (H)	98 - 111 mmol/L		09/08/2023 7:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Carbon Dioxide -CO2	30 (H)	20 - 29 mmol/L		09/08/2023 7:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Anion Gap	8	5 - 17		09/08/2023 7:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Glucose	186 (H)	60 - 99 mg/dL		09/08/2023 7:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Comment: Fasting Blood Glucos Random Blood Glucose					

		Def		Arealist		
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Blood Urea Nitrogen -BUN	24	7 - 25 mg/dL		09/08/2023 7:37 AM EDT		<u> </u>
Creatinine	0.63	0.60 - 1.30 mg/ dL		09/08/2023 7:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine Comment: Calculation based on						
without adjustment fo gender using the CKD-			iltration Rate is es	timated fro	m serum creat	tinine, age and
gender using the CKD-	-EPI equation					
G1: Normal GFR: G2: Mildly decre G3a: Mildly to me G3b: Moderately f G4: Severely dee G5: Kidney faile	eased GFR: 60 oderately dec to severely d creased GFR:	reased GF lecreased				
Calcium	7.9 (L)	8.5 - 10.5 mg/dL		09/08/2023 7:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source) Blood	Laterality VENOUS BLOO SPECIMEN / U		Volume Venipuncture / Unknow	Collection wn 09/08/202		Received Time 09/08/2023 7:08 AM EDT
Narrative						
Narrative						
Authorizing Provider Liviu O	Result Type BH LAB BLOOI					
			DLEJ			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) GLUCOS	E, POINT OF	CARE (GL Ref	UCOSE, POC) - Final	result (09/0 Analysis	8/2023 6:02 /	AM EDT)
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	194 (H)	60 - 139 mg/dL		09/08/2023 6:09 AM EDT		

23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Performed By	McNitt, Isabela NA			09/08/2023 6:09 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loca	ation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Un			09/08/202	23 6:02 AM EDT	09/08/2023 6:09 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg/d	L	IA #: 23D0363256) -	09/08/2023	6:09 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCK	ED DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS	28050 Grand Riv	ver Ave	Farmington Hills, MI 48336	800-551-0)488	

(ABNORMAL) BASIC METABOLIC PANEL (BMP) - Final result (09/08/2023 12:24 AM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Sodium	153 (H)	135 - 145 mmol/L		09/08/2023 1:01 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Potassium	3.9	3.5 - 5.2 mmol/L		09/08/2023 1:01 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	117 (H)	98 - 111 mmol/L		09/08/2023 1:01 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	30 (H)	20 - 29 mmol/L		09/08/2023 1:01 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	6	5 - 17		09/08/2023 1:01 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose Comment: Fasting Blood Glucos	202 (H)	60 - 99 mg/dL		09/08/2023 1:01 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Random Blood Glucose						

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Blood Urea Nitrogen -BUN	26 (H)	7 - 25 mg/dL		09/08/2023 1:01 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.62	0.60 - 1.30 mg/ dL		09/08/2023 1:01 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	108	>60 mL/ min/ 1.73m2		09/08/2023 1:01 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Calculation based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation refit without adjustment for race. Glomerular Filtration Rate is estimated from serum creatinine, age and gender using the CKD-EPI equation:						

G1: Normal GFR: >=90
G2: Mildly decreased GFR: 60-89
G3a: Mildly to moderately decreased GFR: 45-59
G3b: Moderately to severely decreased GFR: 30-44
G4: Severely decreased GFR: 15-29
G5: Kidney failure GFR: <15</pre>

(CLIA #: 23D0363256)

Calcium	7.8 (L)	8.5 - 10.5 mg/dL		09/08/2023 1:01 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / Ur		Venipuncture / Unknowr	n 09/08/202 EDT	3 12:24 AM	09/08/2023 12:38 AM EDT
Narrative						
Authorizing Provider	Result Type					
Liviu O	BH LAB BLOOD	ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	

(ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (09/07/2023 8:15 PM EDT)

		Ref		Analysis	
Component	Value	Range	Test Method	Time	Performed At Pathologist Signature
Glucose	175 (H)	60 - 139		09/07/2023	BEAUMONT
		mg/dL		8:21 PM	LABORATORY,
		5		EDT	FARMINGTON
					HILLS (CLIA #:
					23D0363256)
Comment: Capillary					

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Performed By	McNitt, Isabela NA			09/07/2023 8:21 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur	_		09/07/202	3 8:15 PM EDT	09/07/2023 8:21 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg/	dL	IA #: 23D0363256) -	09/07/2023	8:21 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TI	EST DOCK	ED DEVICE UNSOLICITEI	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY,	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	

(ABNORMAL) BASIC METABOLIC PANEL (BMP) - Final result (09/07/2023 6:57 PM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Sodium	153 (H)	135 - 145 mmol/L		09/07/2023 7:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Potassium	4.1	3.5 - 5.2 mmol/L		09/07/2023 7:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	118 (H)	98 - 111 mmol/L		09/07/2023 7:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	31 (H)	20 - 29 mmol/L		09/07/2023 7:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	4 (L)	5 - 17		09/07/2023 7:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose Comment: Fasting Blood Glucos				09/07/2023 7:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Random Blood Glucose	: 60-139 mg	J/dL				

		D (A 1 *		
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Blood Urea Nitrogen -BUN	27 (H)	7 - 25 mg/dL		09/07/2023 7:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.61	0.60 - 1.30 mg/ dL		09/07/2023 7:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	109	>60 mL/ min/ 1.73m2		09/07/2023 7:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Calculation based on without adjustment for gender using the CKD-	or race. Glom	erular Fi				
G1: Normal GFR: G2: Mildly decre G3a: Mildly to mo G3b: Moderately 1 G4: Severely dec G5: Kidney failu	eased GFR: 60 oderately dec to severely d creased GFR:	reased GF ecreased				
Calcium	7.8 (L)	8.5 - 10.5 mg/dL		09/07/2023 7:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source) Blood	Laterality VENOUS BLOC SPECIMEN / U		Volume Venipuncture / Unknow	Collection wn 09/07/202		Received Time 09/07/2023 7:03 PM EDT
Narrative						
Authorizing Provider	Result Type					
Liviu O	BH LAB BLOOI	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0		
(ABNORMAL) BASIC N	IETABOLIC PA	NEL (BM Ref	P) - Final result (09/	07/2023 11: Analysis	43 AM EDT)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Sodium	151 (H)	135 - 145 mmol/L		09/07/2023 12:28 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

3.5 - 5.2

mmol/L

4.0

Potassium

23D0363256)

LABORATORY,

FARMINGTON HILLS (CLIA #: 23D0363256)

09/07/2023 BEAUMONT

12:28 PM

EDT

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Chloride	117 (H)	98 - 111 mmol/L		09/07/2023 12:28 PM EDT		
Carbon Dioxide -CO2	29	20 - 29 mmol/L		09/07/2023 12:28 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	5	5 - 17		09/07/2023 12:28 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose	202 (H)	60 - 99 mg/dL		09/07/2023 12:28 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Fasting Blood Glucos Random Blood Glucose						
Blood Urea Nitrogen -BUN	29 (H)	7 - 25 mg/dL		09/07/2023 12:28 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.63	0.60 - 1.30 mg/ dL		09/07/2023 12:28 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	108	>60 mL/ min/ 1.73m2		09/07/2023 12:28 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Comment:

Calculation based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation refit without adjustment for race. Glomerular Filtration Rate is estimated from serum creatinine, age and gender using the CKD-EPI equation:

G1: Normal GFR: >=90
G2: Mildly decreased GFR: 60-89
G3a: Mildly to moderately decreased GFR: 45-59
G3b: Moderately to severely decreased GFR: 30-44
G4: Severely decreased GFR: 15-29
G5: Kidney failure GFR: <15</pre>

Calcium	7.8 (L)	8.5 - 10.5 mg/dL		09/07/2023 12:28 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknow	n 09/07/202 EDT	23 11:43 AM	09/07/2023 11:59 AM EDT
Narrative						

Authorizing Provider	Result Type		
Liviu O	BH LAB BLOOD ORDERA	BLES	
Performing Organization	Address	City/State/ZIP Code	Phone Number
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0488

(ABNORMAL) BASIC METABOLIC PANEL (BMP) - Final result (09/07/2023 6:11 AM EDT)

(,		Ref	(03)	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Sodium	153 (H)	135 - 145 mmol/L		09/07/2023 8:09 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Potassium	3.6	3.5 - 5.2 mmol/L		09/07/2023 8:09 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	118 (H)	98 - 111 mmol/L		09/07/2023 8:09 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	27	20 - 29 mmol/L		09/07/2023 8:09 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	8	5 - 17		09/07/2023 8:09 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose	168 (H)	60 - 99 mg/dL		09/07/2023 8:09 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Fasting Blood Glucos Random Blood Glucose	•					
Blood Urea Nitrogen -BUN	25	7 - 25 mg/dL		09/07/2023 8:09 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.61	0.60 - 1.30 mg/ dL		09/07/2023 8:09 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	109	>60 mL/ min/ 1.73m2		09/07/2023 8:09 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis			
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature	
Comment: Calculation based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation refit without adjustment for race. Glomerular Filtration Rate is estimated from serum creatinine, age and gender using the CKD-EPI equation: G1: Normal GFR: >=90							
-	oderately dec	reased GF ecreased					
Calcium	7.8 (L)	8.5 - 10.5 mg/dL		09/07/2023 8:09 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Specimen (Source)	Anatomical Lo	cation /	Collection Method / Volume	Collection	Timo	Received Time	
Blood	Laterality VENOUS BLOC SPECIMEN / U					09/07/2023 6:56 AM EDT	
Narrative							
Authorizing Provider	Result Type						
Liviu O	BH LAB BLOOI	D ORDERAI	BLES				
Performing Organization			City/State/ZIP Code	Phone Nu			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, Ml 48336	800-551-(0488		
(ABNORMAL) COMPLI	ETE BLOOD C		nal result (09/07/20		EDT)		
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature	
WBC	14.9 (H)	3.5 - 10.1 bil/L		09/07/2023 7:16 AM EDT			
RBC	3.81 (L)	4.31 - 5.48 tril/ L		09/07/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Hemoglobin	11.0 (L)	13.5 - 17.0 g/ dL		09/07/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Hematocrit	38.0 (L)	40.1 - 50.1 %		09/07/2023 7:16 AM EDT			
MCV	100	80 - 100 fL		09/07/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
МСН	29	28 - 33 pg			BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	<u> </u>
МСНС	29 (L)	32 - 36 g/dL		09/07/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RDW-CV	19 (H)	12 - 15 %		09/07/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Platelets	404 (H)	150 - 400 bil/L		09/07/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Nucleated Red Blood Cells	0.0	<=0.0 %		09/07/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknow	/n 09/07/202	23 6:11 AM EDT	09/07/2023 6:59 AM EDT
Narrative						
Authorizing Provider	Result Type					
Liviu O	BH LAB BLOOI	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, Ml 48336	800-551-0)488	

(ABNORMAL) STAPHYLOCOCCUS AUREUS/MRSA BY PCR, NARES (STAPHYLOCOCCUS AUREUS/MRSA BY NAA, NARES) - Final result (09/07/2023 12:41 AM EDT)

That is a second	05/01/2025					
		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Staphylococcus aureus	Detected (A)	Not Detected		09/08/2023 12:30 PM EDT	BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	
Methicillin Resistant	Detected (A)	Not Detected		09/08/2023 12:30 PM EDT	BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Swab	ANTERIOR NA SWAB / Unkno		Non-blood Collection / Unknown	09/07/202 EDT	23 12:41 AM	09/07/2023 12:49 AM EDT

Narrative								
BEAUMONT LABORATORY, Methodology: Nucleid	ROYAL OAK (c acid amplit	CLIA#: 23 fication	D0667009) - 09/08/202 (FDA-approved)	23 12:30 PM	EDT			
Authorizing Provider	Result Type							
Haidar Al-Saadi	BH LAB MICR	H LAB MICROBIOLOGY - GENERAL ORDERABLES						
Deufeuncies Ourseisstice	۸ ما ما <u>بر</u> م م							
Performing Organization BEAUMONT	3601 W. 13 M	ile Rd	City/State/ZIP Code Royal Oak, MI 48073					
LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	5001 W. 15 W			000-331-0				
(ABNORMAL) SODIUM	1 - Final resu l Value	It (09/07/ Ref Range	2023 12:41 AM EDT) Test Method	Analysis Time	Performed At	Pathologist Signature		
Sodium	152 (H)	135 - 145 mmol/L		09/07/2023 1:04 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Specimen (Source)	Anatomical Lo Laterality	ocation /	Collection Method / Volume	Collection	Time	Received Time		
Blood	VENOUS BLOOD SPECIMEN / Unknown		Venipuncture / Unknow	n 09/07/2023 12:41 AM EDT		09/07/2023 12:49 AM EDT		
Narrative								
Authorizing Provider	Result Type							
Liviu O	BH LAB BLOO	D ORDERA	BLES					
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand	River Ave	Farmington Hills, MI 48336	800-551-0				
(ABNORMAL) ECG (09, Narrative	/06/2023 11:		DT)					

Haidar Al-Saadi - 09/06/2023 11:02 PM EDT

Narrative 9/6/2023 11:03 PM Alazem, Omar, DO ECG *Document ECG Separate from all other Procedures* Date/Time: 9/6/2023 11:02 PM Performed by: Alazem, Omar, DO Authorized by: Alazem, Omar, DO Previous ECG: Previous ECG: Compared to current Similarity: No change Interpretation: Interpretation: abnormal Quality: Tracing quality: Limited by artifact Rate: ECG rate: 115 ECG rate assessment: tachycardic Rhythm: Rhythm: sinus rhythm Ectopy: Ectopy: none QRS: QRS axis: Normal Conduction: Conduction: normal ST segments: ST segments: Normal T waves: T waves: normal Authorizing Provider Result Type Omar Alazem WBH HBS CARD ECG

Culture, Blood (CULTURE, BLOOD) - Final result (09/06/2023 9:36 PM EDT)

	L, DLOOD) - TH		05/00/2025 5.50 FIVE			
C		Ref	—	Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Culture, Blood	No growth at 5 days		CULTURE, BLOOD	09/12/2023 1:01 AM EDT	BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	
	Anatomical Loo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	VENIPUNCTUR BLOOD TEST /		Venipuncture / Unknow	n 09/06/202	3 9:36 PM EDT	09/06/2023 9:44 PM EDT
Narrative						
Authorizing Provider	Result Type					
Omar Alazem		BIOLOGY	- GENERAL ORDERABLES			
Performing Organization			City/State/ZIP Code	Phone Nur	mber	
BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	3601 W. 13 Mil	e Rd	Royal Oak, MI 48073	800-551-0	488	
Culture, Blood (CULTURI		Ref		DT) Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Culture, Blood	No growth at 5 days		CULTURE, BLOOD	09/12/2023 1:01 AM EDT	BEAUMONT LABORATORY, ROYAL OAK (CLIA#:	

23D0667009)

Anatomical Location /	Collection Method /		
Laterality	Volume	Collection Time	Received Time
VENIPUNCTURE FOR BLOOD TEST / Unknown	Venipuncture / Unknown	09/06/2023 9:36 PM EDT	09/06/2023 10:22 PM EDT
Result Type			
BH LAB MICROBIOLOGY	- GENERAL ORDERABLES		
Address	City/State/ZIP Code	Phone Number	
3601 W. 13 Mile Rd	Royal Oak, MI 48073	800-551-0488	
	Laterality VENIPUNCTURE FOR BLOOD TEST / Unknown Result Type BH LAB MICROBIOLOGY Address	Laterality Volume VENIPUNCTURE FOR BLOOD TEST / Unknown Venipuncture / Unknown Result Type Image: Comparison of the second secon	LateralityVolumeCollection TimeVENIPUNCTURE FOR BLOOD TEST / UnknownVenipuncture / Unknown09/06/2023 9:36 PM EDTResult TypeBH LAB MICROBIOLOGY - GENERAL ORDERABLESAddressCity/State/ZIP CodePhone Number

(ABNORMAL) TROPONIN I - Final result (09/06/2023 8:00 PM EDT)

		Ref		Analysis	
Component	Value	Range	Test Method	Time	Performed At Pathologist Signature
Troponin I	0.04 (H)	<=0.03 ng/mL	i2000SR	09/06/2023 8:28 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Comment:					

Normal: <0.04 Indeterminate: 0.04-0.29 Suggestive of Myocardial Damage: >=0.30

Troponin I is elevated in acute coronary syndromes with myocardial necrosis as well as ST elevation MI. Increases are also associated with direct myocardial damage (myocarditis, pericarditis, contusion, cardioversion), myocardial strain (CHF, pulmonary hypertension, pulmonary embolus) and demand ischemia (sepsis, hypotension, atrial fibrillation). Troponin may also be elevated with renal failure, intracranial hemorrhage and amyloidosis. The mechanism for the latter elevations is unclear. An elevated troponin level is a predictor for poor outcomes regardless of its cause. Ann Inter Med 2005;142:786-791.

Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time		
Blood	VENOUS BLOOD SPECIMEN / Unknown	Venipuncture / Unknown	09/06/2023 8:00 PM EDT	09/06/2023 8:02 PM EDT		
Narrative						
Authorizing Provider	Result Type					
Omar Alazem	BH LAB BLOOD ORDERA	BLES				
Performing Organization	Address	City/State/ZIP Code	Phone Number			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0488			
CTA PE PROTOCOL CHE	ST W IV CONTRAST - Fir Laterality	nal result (09/06/2023 7:4 Modality	48 PM EDT)			
Chest	Computed Tomography					
	Anatomical Location /	Collection Method /				
Specimen (Source)	Laterality	Volume	Collection Time	Received Time		
			09/06/2023 7:53 PM EDT			

Narrative

09/06/2023 7:57 PM EDT

CTA PE PROTOCOL CHEST W IV CONTRAST: 9/6/2023 7:30 PM

Indication: 62 year old male. Shortness of breath, concern for pulmonary embolism.

Comparison studies: CT chest 8/2/2023

Technique: Multiple contiguous axial images of the chest were obtained from the thoracic inlet through the upper abdomen following the administration of 75 mL Isovue 370. Coronal and sagittal reconstructions were performed. 3D images were obtained at an independent workstation to further evaluate the suspected abnormality of the pulmonary arteries. Total DLP administered 525 mGycm. One or more CT dose reduction strategies were utilized during this examination. Total CT examinations in the past 12 months prior to today: 2.

FINDINGS:

PULMONARY ARTERIAL VASCULATURE: There is suboptimal enhancement of the pulmonary arterial system, limiting evaluation of subsegmental pulmonary emboli. No central pulmonary embolism is identified.

LUNGS: Right lower lobe consolidative changes are seen with air bronchograms. Trace left pleural effusion seen with associated atelectasis. Centrilobular emphysematous changes are seen with paraseptal emphysematous changes seen toward the lung apices.

LARGE AIRWAYS: Central airways are patent.

HEART AND PERICARDIUM: Heart is normal in size. There is no pericardial effusion.

MEDIASTINUM AND HILA: There are a few nonspecific nonenlarged lymph nodes.

VESSELS: The thoracic aorta is normal in course and caliber.

CHEST WALL AND LOWER NECK: Normal.

UPPER ABDOMEN: Renal cortical cysts are seen in the upper kidneys.

BONES: No acute fracture, blastic or osteolytic lesion. Multilevel degenerative changes are seen within the spine.

IMPRESSION:

1. No evidence of central pulmonary embolism.

2. Right lower lobe airspace disease, correlate for pneumonia.

3. Emphysematous changes.

Procedure Note

Reehan Ali - 09/06/2023

Formatting of this note might be different from the original. CTA PE PROTOCOL CHEST W IV CONTRAST: 9/6/2023 7:30 PM

Indication: 62 year old male. Shortness of breath, concern for pulmonary embolism.

Comparison studies: CT chest 8/2/2023

Technique: Multiple contiguous axial images of the chest were obtained from the thoracic inlet through the upper abdomen following the administration of 75 mL Isovue 370. Coronal and sagittal reconstructions were performed. 3D images were obtained at an independent workstation to further evaluate the suspected abnormality of the pulmonary arteries. Total DLP administered 525 mGycm. One or more CT dose reduction strategies were utilized during this examination. Total CT examinations in the past 12 months prior to today: 2.

FINDINGS:

PULMONARY ARTERIAL VASCULATURE: There is suboptimal enhancement of the pulmonary arterial system, limiting evaluation of subsegmental pulmonary emboli. No central pulmonary embolism is identified.

LUNGS: Right lower lobe consolidative changes are seen with air bronchograms. Trace left pleural effusion seen with associated atelectasis. Centrilobular emphysematous changes are seen with paraseptal emphysematous changes seen toward the lung apices.

LARGE AIRWAYS: Central airways are patent.

HEART AND PERICARDIUM: Heart is normal in size. There is no pericardial effusion.

MEDIASTINUM AND HILA: There are a few nonspecific nonenlarged lymph nodes.

VESSELS: The thoracic aorta is normal in course and caliber.

CHEST WALL AND LOWER NECK: Normal.

UPPER ABDOMEN: Renal cortical cysts are seen in the upper kidneys.

BONES: No acute fracture, blastic or osteolytic lesion. Multilevel degenerative changes are seen within the spine.

IMPRESSION:

- 1. No evidence of central pulmonary embolism.
- 2. Right lower lobe airspace disease, correlate for pneumonia.
- 3. Emphysematous changes.

Authorizing Provider	Result Type
Omar Alazem	WBH IMG CT ORDERABLES

(ABNORMAL) TROPONIN I - Final result (09/06/2023 5:23 PM EDT)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Troponin I	0.04 (H)	<=0.03 ng/mL	i2000SR	09/06/2023 5:57 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Comment:						
Normal: <0.04 Indeterminate: 0.04-0	0.29					
Suggestive of Myocar		>=0.30				
Troponin I is elevate Increases are also as		-				
cardioversion), myoca						
(sepsis, hypotension						
intracranial hemorrha troponin level is a						
	Anatomical Loc	-	-			cu 2005,142.700 751.
Specimen (Source)	Laterality		Volume	Collection	n Time	Received Time
Blood	VENOUS BLOO SPECIMEN / Ur		Venipuncture / Unkr	10wn 09/06/20	23 5:23 PM EDT	09/06/2023 5:31 PM EDT
Narrative						
Authorizing Provider	Result Type					
Omar Alazem	BH LAB BLOOD	ORDERA	BLES			
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY,	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-	0488	
FARMINGTON HILLS			40550			
(CLIA #: 23D0363256)						
LACTIC ACID, PLASMA -	Final result (0)	2/06/202				
LACTIC ACID, I LASIMA	Tina result (0.	Ref	5 5.25 F W LDT)	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Lactic Acid	1.9	0.5 - 2.0			BEAUMONT	
		mmol/L		5:47 PM EDT	LABORATORY, FARMINGTON	
				LDT	HILLS (CLIA #:	
					23D0363256)	
	Anotomical Lo	ation /	Collection Mathed (
Specimen (Source)	Anatomical Loo Laterality	.ation /	Collection Method / Volume	Collectior	n Time	Received Time
Blood	VENOUS BLOO	D				09/06/2023 5:31 PM EDT
	SPECIMEN / Ur	nknown				
Narrative						
Authorizing Provider	Result Type					
Omar Alazem	BH LAB BLOOD	ORDERA	RFF2			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	ımber	
BEAUMONT	28050 Grand R	iver Ave	Farmington Hills, MI			
			48336			
FARMINGTON HILLS (CLIA #: 23D0363256)						
CHEST 1 VIEW AP/PA - I				4 .		
Anatomical Region	Laterality	У	Modali	, ,		
Chest			кааюд	raphic Imaging		

	Anatomical Location /	Collection Method /		
Specimen (Source)	Laterality	Volume	Collection Time 09/06/2023 5:43 PM	Received Time
			03/00/2023 3.43 1 101	
Narrative 09/06/2023 5:45 PM	FDT			
TECHNIQUE: Single V				
	2 years old with a hist	cory of hypoxia.		
COMPARISON: Chest x	-			
FINDINGS: EKG leads	s overlie the chest and	d obscure detail.		
	nsolidation. Incidenta Llung. Minimal bibasil			
Vasculature: Within	n normal limits.			
Heart: Normal in si	ze.			
Mediastinum: within	n normal limits.			
	ne osseous structures a rosis is noted involvir			
IMPRESSION:				
Minimal bibasilar a	atelectasis versus chro	onic scarring.		
Procedure Note				
Rocky Saenz - 09/06/2 Formatting of this note	2023 • might be different from the	e original.		
TECHNIQUE: Single Vie	ew of the chest.			
INDICATION: Male 62 y	vears old with a history of h	ypoxia.		
COMPARISON: Chest x-	-ray 8/26/2023.			
FINDINGS: EKG leads o	verlie the chest and obscure	e detail.		
	dation. Incidental skinfold n g. Minimal bibasilar atelecta			
Vasculature: Within nor	rmal limits.			
Heart: Normal in size.				

Mediastinum: within normal limits.

Musculoskeletal: The osseous structures are intact. Multilevel osteophytosis with endplate sclerosis is noted involving the thoracic spine.

IMPRESSION:

Minimal bibasilar atelectasis versus chronic scarring.

Authorizing Provider	Result Type
Omar Alazem	WBH IMG GENERAL ORDERABLES

(ABNORMAL) TROPONIN I - Final result (09/06/2023 3:41 PM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Troponin I	0.06 (H)	<=0.03 ng/mL	i2000SR	09/06/2023 4:17 PM	BEAUMONT LABORATORY,	
		<u>J</u> .		EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	
Comment: Normal: <0.04						
Indeterminate: 0.04-0 Suggestive of Myocard		>=0.30				
Troponin I is elevat						
Increases are also as cardioversion), myoca	ardial strain	(CHF, pu	Imonary hypertension	n, pulmonar	y embolus) ar	nd demand ischemia
(sepsis, hypotension intracranial hemorrh	age and amylo	idosis. T	he mechanism for the	e latter el	evations is u	unclear. An elevated
troponin level is a p		-	comes regardless of Collection Method /	its cause.	Ann Inter Me	ed 2005;142:786-791.
Specimen (Source)	Laterality	cation /	Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / UI		Venipuncture / Unknow	n 09/06/202	23 3:41 PM EDT	09/06/2023 3:46 PM EDT
Narrative						
INdifiduive						
Authorizing Provider	Result Type					
Omar Alazem	BH LAB BLOOD) ORDERA	BLES			
Performing Organization			City/State/ZIP Code	Phone Number		
BEAUMONT LABORATORY,	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
FARMINGTON HILLS			40550			
(CLIA #: 23D0363256)						
COVID-19, FLU, RSV BY	NAA - Final res	sult (09/06 Ref	5/2023 3:41 PM EDT)	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Influenza A	Not Detected	Not				
		Detected		4:31 PM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #:	
Influenza B	Not Detected	Not		09/06/2023	23D0363256) BEAUMONT	
		Detected		4:31 PM	LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
	NID	N1 ·		00/06/0600	23D0363256)	
RSV	Not Detected	Not Detected		09/06/2023 4:31 PM	BEAUMONT LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
SARS-CoV-2 -COVID-19	Not Detected	Not			BEAUMONT	
by NAA, Micro		Detected		4:31 PM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
	A				2320303230)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Swab	NASOPHARYN	-	Non-blood Collection /			09/06/2023 3:46 PM EDT
	SWAB / Unkno	wn	Unknown			

Narrative

BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 09/06/2023 4:31 PM EDT Methodology: Nucleic Acid Amplification(NAA)/Polymerase Chain Reaction(PCR)

The SARS-CoV-2 (COVID-19) test is for in vitro diagnostic use under the FDA Emergency Use Authorization (EUA) for US laboratories certified under CLIA to perform high complexity testing. This test has not been FDA cleared or approved.

Authorizing Provider	Result Type		
Omar Alazem	BH LAB MICROBIOLOGY	- GENERAL ORDERABLES	
Performing Organization	Address	City/State/ZIP Code	Phone Number
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0488

(ABNORMAL) CBC W/AUTO DIFF - Final result (09/06/2023 3:41 PM EDT)

		Ref	Analysis	
Component	Value	Range Test Method	Time	Performed At Pathologist Signature
WBC	13.5 (H)	3.5 - 10.1 bil/L	09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RBC	4.69	4.31 - 5.48 tril/ L	09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hemoglobin	13.8	13.5 - 17.0 g/ dL	09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hematocrit	45.4	40.1 - 50.1 %	09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
MCV	97	80 - 100 fL	09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСН	29	28 - 33 pg	09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСНС	30 (L)	32 - 36 g/dL	09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RDW-CV	19 (H)	12 - 15 %	09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Platelets	556 (H)	150 - 400 bil/L	09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Nucleated Red Blood Cells	0.0	<=0.0 %		09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Neutrophils	9.8 (H)	1.6 - 7.2 bil/L		09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Lymphocytes	1.9	1.1 - 4.0 bil/L		09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Monocytes	1.7 (H)	0.0 - 0.9 bil/L		09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Eosinophils	0.0	0.0 - 0.4 bil/L		09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.0	0.0 - 0.1 bil/L		09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.05 (H)	0.00 - 0.04 bil/L		09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %	0.4	%		09/06/2023 4:16 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U					09/06/2023 3:46 PM EDT
Narrative						
Authorizing Provider	Result Type					
Omar Alazem	BH LAB BLOOI) ORDERAI	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	
TSH WITH REFLEX TO F	۲4 - Final resul	t (09/06/2	023 3:41 PM EDT)			

		Ref	T . M	Analysis		
Component	Value	Range 0.40 -	Test Method i2000SR	Time		Pathologist Signature
Thyroid Stimulating Hormone	2.36	0.40 - 4.50 uIU/ mL	12000SR	09/06/2023 4:31 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment:					2500505250)	
TSH result within ref	Ference range Anatomical Lo		yroxine not perform Collection Method/	ed.		
Specimen (Source)	Laterality	,	Volume	Collection	Time	Received Time
Blood	VENOUS BLOO SPECIMEN / U		Venipuncture / Unknov	vn 09/06/202	3 3:41 PM EDT	09/06/2023 3:46 PM EDT
Narrative						
Authorizing Provider	Result Type					
Omar Alazem	BH LAB BLOO	d ordera	BLES			
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0	1488	
(ABNORMAL) LACTIC	ACID, PLASM	A - Final Ref		:41 PM EDT) Analysis)	
Component	Value	Range	Test Method	Time		Pathologist Signature
Lactic Acid	2.3 (H)	0.5 - 2.0 mmol/L		09/06/2023 4:09 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /	Collection	Time	Descived Times
Specimen (Source) Blood	Laterality VENOUS BLOO	חר	Volume Collection Time Venipuncture / Unknown 09/06/2023 3:41 PM EDT			Received Time
blood	SPECIMEN / U					03/00/2023 3.40 FIN EDT
Narrative						
Authorizing Provider	Result Type					
Omar Alazem	BH LAB BLOO	d Ordera	3LE2			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0	488	
PHOSPHORUS LEVEL - F	inal result (09		3:41 PM EDT)	Applysia		
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Phosphorus	3.6	2.3 - 4.4 mg/dL		09/06/2023 4:13 PM EDT		

Specimen (Source) Laterality Volume Collection Time Received Blood VENOUS BLOOD SPECIMEN / Unknown Venipuncture / Unknown 09/06/2023 3:41 PM EDT 09/06/2023 Narrative Venipuncture / Unknown Venipuncture / Unknown Venipuncture / Unknown Venipuncture / Unknown	
SPECIMEN / Unknown	
Narrative	
Authorizing Provider Result Type	
Omar Alazem BH LAB BLOOD ORDERABLES	
Performing Organization Address City/State/ZIP Code Phone Number	
BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488	
LABORATORY, 48336 FARMINGTON HILLS	
(CLIA #: 23D0363256)	
MAGNESIUM LEVEL - Final result (09/06/2023 3:41 PM EDT)	
Ref Analysis Component Value Range Test Method Time Performed At Pathologi	ist Signature
Magnesium 2.5 1.7 - 2.5 09/06/2023 BEAUMONT	
mg/dL 4:13 PM LABORATORY, EDT FARMINGTON	
HILLS (CLIA #:	
23D0363256)	
Anatomical Location / Collection Method /	Τ
Specimen (Source)LateralityVolumeCollection TimeReceivedBloodVENOUS BLOODVenipuncture / Unknown09/06/2023 3:41 PM EDT09/06/2023	
SPECIMEN / Unknown	23 3.40 1 101 201
Narrative	
Authorizing Provider Result Type	
Omar Alazem BH LAB BLOOD ORDERABLES	
Performing Organization Address City/State/ZIP Code Phone Number	
BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488	
LABORATORY, 48336 FARMINGTON HILLS	
(CLIA #: 23D0363256)	
(ABNORMAL) HEPATIC FUNCTION PANEL - Final result (09/06/2023 3:41 PM EDT)	
Ref Analysis Component Value Range Test Method Time Performed At Pathologi	ict Signatura
Component Value Range Test Method Time Performed At Patrologi Albumin 2.8 (L) 3.5 - 4.9 09/06/2023 BEAUMONT	
g/dL 4:13 PM LABORATORY,	
EDT FARMINGTON HILLS (CLIA #:	
23D0363256)	
Globulin 4.9 (H) 2.2 - 3.7 09/06/2023 BEAUMONT g/dL 4:13 PM LABORATORY,	
EDT FARMINGTON	
HILLS (CLIA #: 23D0363256)	
Albumin/Globulin Ratio 0.6 09/06/2023 BEAUMONT	
4:13 PM LABORATORY,	
EDT FARMINGTON HILLS (CLIA #:	

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Alkaline Phosphatase	86	33 - 120 U/L		09/06/2023 4:13 PM EDT		
Aspartate Aminotransferase -AST	47 (H)	<35 U/L		09/06/2023 4:13 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Alanine Aminotransferase -ALT	29	9 - 47 U/ L		09/06/2023 4:13 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Bilirubin Total	0.4	0.3 - 1.2 mg/dL		09/06/2023 4:13 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Bilirubin Direct	0.2	0.0 - 0.4 mg/dL		09/06/2023 4:13 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Protein Total	7.7	6.2 - 8.1 g/dL		09/06/2023 4:13 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection		Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknown 09/06/2023 3:4			
Narrative						
Authorizing Provider	Result Type					
Omar Alazem	BH LAB BLOO	D ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0	0488	

(ABNORMAL) BASIC METABOLIC PANEL (BMP) - Final result (09/06/2023 3:41 PM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Sodium	151 (H)	135 - 145 mmol/L		09/06/2023 4:13 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Potassium	4.2	3.5 - 5.2 mmol/L		09/06/2023 4:13 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist S	ionature
Chloride	113 (H)	98 - 111 mmol/L		09/06/2023 4:13 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Tuthologist 5	ignature
Carbon Dioxide -CO2	29	20 - 29 mmol/L		09/06/2023 4:13 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Anion Gap	9	5 - 17		09/06/2023 4:13 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Glucose	156 (H)	60 - 99 mg/dL		09/06/2023 4:13 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Comment: Fasting Blood Glucos Random Blood Glucose							
Blood Urea Nitrogen -BUN	23	7 - 25 mg/dL		09/06/2023 4:13 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Creatinine	0.72	0.60 - 1.30 mg/ dL		09/06/2023 4:13 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
eGFR By Creatinine	103	>60 mL/ min/ 1.73m2		09/06/2023 4:13 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Comment:							.

Calculation based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation refit without adjustment for race. Glomerular Filtration Rate is estimated from serum creatinine, age and gender using the CKD-EPI equation:

G1: Normal GFR: >=90
G2: Mildly decreased GFR: 60-89
G3a: Mildly to moderately decreased GFR: 45-59
G3b: Moderately to severely decreased GFR: 30-44
G4: Severely decreased GFR: 15-29
G5: Kidney failure GFR: <15</pre>

Calcium	8.6	8.5 - 10.5 mg/dL		09/06/2023 4:13 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical I Laterality	Location /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLO SPECIMEN /		Venipuncture / Unknow	n 09/06/202	23 3:41 PM EDT	09/06/2023 3:46 PM EDT
Narrative						

Authorizing Provider	Result Type					
Omar Alazem	BH LAB BLOOI	D ORDERA	,BLES			
Duferraise Organization	A .		City (Ctate (ZID Code	Dhana Nu	L	
Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	≀iver Ave	City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu 800-551-0		
(ABNORMAL) B TYPE I	NATRIURETIC	C PEPTIDE Ref	: (BNP) - Final result	(09/06/2023 Analysis	3 3:41 PM ED [.]	т)
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
B Type Natriuretic Peptide -BNP	154 (H)	0 - 100 pg/mL	i2000SR	09/06/2023 4:17 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)			Volume	Collection		Received Time
Blood	VENOUS BLOO SPECIMEN / U		Venipuncture / Unknov	vn 09/06/202	23 3:41 PM EDT	09/06/2023 3:46 PM EDT
Narrative						
Narrative						
Authorizing Provider	Result Type					
Omar Alazem	BH LAB BLOOI	D ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	≀iver Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) D-DIME	R - Final resu	lt (09/06,	/2023 3:41 PM EDT)			
		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
D-Dimer	1,189 (H)	0 - 499 ng/mL FEU		09/06/2023 3:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment:						
>499 Positive* 0-599 Normal Range**						
* The 499 cut-off was	s established	for EXC	LUSION of DVT/PE in	patients wi	th low clinid	cal probability.
** For patients being	g evaluated f	for condi	tions other than DVT	/PE, values	of	
<600 may be considere						
tested for DVT/PE, ar conditions (i.e. DIC,				ation of ot	her appropria	ate medical
	-		itive and may be pos	itivo in o	number of cou	ditions with low

Note that this D-Dimer assay is very sensitive and may be positive in a number of conditions with low levels of thrombin generation, including infectious or inflammatory disorders, malignancy, post-operative wound healing and pregnancy (including post-partum).

Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time
Blood	VENOUS BLOOD SPECIMEN / Unknown	Venipuncture / Unknown	09/06/2023 3:41 PM EDT	09/06/2023 3:46 PM EDT

Narrative

Authorizing Provider	Result Type	Result Type						
Omar Alazem	BH LAB BLOOD	H LAB BLOOD ORDERABLES						
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		8050 Grand River Ave Farmington Hills, MI 800-551-0488 48336)488				
GLUCOSE, POINT OF CA	.RE (GLUCOSE,	POC) - Fi Ref	nal result (08/29/2023	1:27 PM ED Analysis	T)			
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature		
Glucose	135	60 - 139 mg/dL		08/29/2023 1:34 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Comment: Capillary					-			
Performed By	Vasser, Ashley NA			08/29/2023 1:34 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
	Anatomical Loc	ation /	Collection Method /					
Specimen (Source)	Laterality		Volume	Collection Time		Received Time		
Blood	WHOLE BLOOD SPECIMEN / Un			08/29/202	23 1:27 PM EDT	08/29/2023 1:34 PM EDT		
Narrative								
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/c	1L	A #: 23D0363256) - (08/29/2023	1:34 PM EDT			
Authorizing Provider	Result Type							
William Rudy	BH LAB POC TE	ST DOCKE	D DEVICE UNSOLICITED	RESULTS				
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Ri	iver Ave	Farmington Hills, MI 48336	800-551-0)488			
(ABNORMAL) CBC W//		Ref		Analysis				
Component	Value	Range	Test Method	Time		Pathologist Signature		
WBC	6.9	3.5 - 10.1 bil/L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			

				HILLS (CLIA #: 23D0363256)
RBC	4.15 (L)	4.31 - 5.48 tril/ L	08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hemoglobin	12.0 (L)	13.5 - 17.0 g/ dL	08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At Pathologist Signature
Hematocrit	38.4 (L)	40.1 - 50.1 %		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
MCV	93	80 - 100 fL		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСН	29	28 - 33 pg		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСНС	31 (L)	32 - 36 g/dL		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RDW-CV	17 (H)	12 - 15 %		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Platelets	294	150 - 400 bil/L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Nucleated Red Blood Cells	0.0	<=0.0 %		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Neutrophils	4.2	1.6 - 7.2 bil/L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Lymphocytes	1.0 (L)	1.1 - 4.0 bil/L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Monocytes	1.4 (H)	0.0 - 0.9 bil/L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Eosinophils	0.2	0.0 - 0.4 bil/L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Basophils	0.0	0.0 - 0.1 bil/L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Immature Granulocytes	0.12 (H)	0.00 - 0.04 bil/L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %	1.7	%		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
_Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknow	wn 08/29/202	3 6:01 AM EDT	08/29/2023 6:32 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOD) ORDERAI	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	River Ave	Farmington Hills, MI 48336	800-551-0)488	
PHOSPHORUS LEVEL - F	- inal result (08,		6:01 AM EDT)			
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Phosphorus	2.8	2.3 - 4.4 mg/dL		08/29/2023 8:40 AM EDT		
	Anatomical Lo	cation /	Collection Method /			S . 17
Specimen (Source) Blood	Laterality VENOUS BLOC		Volume	Collection		Received Time 08/29/2023 6:42 AM EDT
ыооч	SPECIMEN / U		venipuncture / Onknov	WII 00/29/202		06/29/2025 0.42 ANI EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOD) ORDERAI	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	River Ave	Farmington Hills, MI 48336	800-551-0	9488	
MAGNESIUM LEVEL - Fi	nal result (08/2	29/2023 6 Ref	:01 AM EDT)	Applycic		
Component	Value	Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Magnesium	1.9	1.7 - 2.5 mg/dL		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON	
					HILLS (CLIA #: 23D0363256)	

Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time
Blood	VENOUS BLOOD SPECIMEN / Unknown	Venipuncture / Unknown	08/29/2023 6:01 AM EDT	08/29/2023 6:42 AM EDT
Narrative				
Authorizing Provider	Result Type			
Danielle S	BH LAB BLOOD ORDERA	BLES		
Performing Organization	Address	City/State/ZIP Code	Phone Number	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0488	

(ABNORMAL) BASIC METABOLIC PANEL (BMP) - Final result (08/29/2023 6:01 AM EDT)

(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Ref		Analysis	
Component	Value	Range	Test Method	Time	Performed At Pathologist Signature
Sodium	137	135 - 145 mmol/L		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Potassium	3.4 (L)	3.5 - 5.2 mmol/L		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Chloride	103	98 - 111 mmol/L		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Carbon Dioxide -CO2	27	20 - 29 mmol/L		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Anion Gap	7	5 - 17		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Glucose	124 (H)	60 - 99 mg/dL		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Comment: Fasting Blood Glucos Random Blood Glucose					
Blood Urea Nitrogen -BUN	10	7 - 25 mg/dL		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Creatinine	0.59 (L)	0.60 - 1.30 mg/ dL		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
eGFR By Creatinine	110	>60 mL/ min/ 1.73m2		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Calculation based on without adjustment fo gender using the CKD- G1: Normal GFR:	or race. Glom -EPI equation >=90	erular Fi :				
G3a: Mildly to mo G3b: Moderately t	to severely d creased GFR:	reased GF ecreased				
Calcium	8.0 (L)	8.5 - 10.5 mg/dL		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U					08/29/2023 6:42 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOI	O ORDERAE	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, Ml 48336	800-551-0)488	
(ABNORMAL) GLUCOS	E, POINT OF	CARE (GL Ref	UCOSE, POC) - Final	result (08/2 Analysis	9/2023 5:50 /	AM EDT)
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	145 (H)	60 - 139 mg/dL		08/29/2023 5:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary	· · -·			00/00/0000		
Performed By	Mmwiry, Elena NA TN			08/29/2023 5:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOI SPECIMEN / U			08/29/202	23 5:50 AM EDT	08/29/2023 5:57 AM EDT

5.1						
Ν	а	rr	'A	t	I١	ρ
1 1	u		u	· u	ιv	\sim

BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/29/2023 5:57 AM EDT

Narrative						
Fasting Blood Glucose Random Blood Glucose:						
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCKE	D DEVICE UNSOLICITED	RESULTS		
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi Ref	nal result (08/29/2023		DI)	
Component	Value	Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	128	60 - 139 mg/dL		08/29/2023 12:23 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Mmwiry, Elena NA TN			08/29/2023 12:23 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loc	ation /	Collection Method /			
Specimen (Source)	Laterality	ation /	Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/29/202 EDT	3 12:16 AM	08/29/2023 12:23 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/o	۲. ۲	A #: 23D0363256) - (08/29/2023	12:23 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCKE	D DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	
GLUCOSE, POINT OF CA		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose Comment: Capillary	114	60 - 139 mg/dL		08/28/2023 6:42 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Kewley, Tesia NA TN			08/28/2023 6:42 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

	Anatomical Loc	ation /	Collection Method /			
Specimen (Source)	Laterality	,	Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Un			08/28/202	3 6:35 PM EDT	08/28/2023 6:42 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/d	L	A #: 23D0363256) - (08/28/2023	6:42 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCKE	D DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Ri	ver Ave	Farmington Hills, MI 48336	800-551-0	1488	
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi _{Ref}	nal result (08/28/2023	12:23 PM El Analysis	DT)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	139	60 - 139 mg/dL		08/28/2023 12:29 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Kewley, Tesia NA TN			08/28/2023 12:29 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loc	ation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Un			08/28/202 EDT	3 12:23 PM	08/28/2023 12:29 PM EDT
Narrative BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose Authorizing Provider	e: 60-99 mg/d	L	A #: 23D0363256) - (08/28/2023	12:29 PM EDT	
William Rudy	21		D DEVICE UNSOLICITED	RESULTS		
	DIT LAD I OC TE	JI DUCKE		INESOLI S		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Ri	ver Ave	Farmington Hills, MI 48336	800-551-0	1488	
(ABNORMAL) CBC W/A	AUTO DIFF - F		lt (08/28/2023 6:20 A			
Component		Ref	Toot Motherd	Analysis	Doute was a -L A -	Dath alogist Cinestowe
Component WBC		Range 3.5 - 10.1 bil/L	Test Method	Time 08/28/2023 7:16 AM EDT		Pathologist Signature

FARMINGTON HILLS (CLIA #: 23D0363256)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At Pathologist Signature
RBC	3.53 (L)	4.31 - 5.48 tril/ L		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hemoglobin	10.5 (L)	13.5 - 17.0 g/ dL		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hematocrit	32.6 (L)	40.1 - 50.1 %		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
MCV	92	80 - 100 fL		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСН	30	28 - 33 pg		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСНС	32	32 - 36 g/dL		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RDW-CV	16 (H)	12 - 15 %		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Platelets	191	150 - 400 bil/L		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Nucleated Red Blood Cells	0.0	<=0.0 %		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Neutrophils	3.7	1.6 - 7.2 bil/L		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Lymphocytes	0.8 (L)	1.1 - 4.0 bil/L		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Monocytes	1.0 (H)	0.0 - 0.9 bil/L		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Eosinophils	0.1	0.0 - 0.4 bil/L		7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.0	0.0 - 0.1 bil/L		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.07 (H)	0.00 - 0.04 bil/L		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %	1.2 Anatomical Lo	%	Collection Method /	08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Laterality	cation /	Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknov	vn 08/28/202	23 6:20 AM EDT	08/28/2023 6:41 AM EDT
Narrative						
Authorizing Provider	Docult Turoo					
Danielle S	Result Type BH LAB BLOOI					
Dumene S						
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	liver Ave	Farmington Hills, MI 48336	800-551-0)488	
PHOSPHORUS LEVEL - F	inal result (08,	/28/2023 Ref	6:20 AM EDT)	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Phosphorus	2.6	2.3 - 4.4 mg/dL		08/28/2023 7:38 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknov	vn 08/28/202	23 6:20 AM EDT	08/28/2023 6:44 AM EDT
Narrative						
Authorizing Drovidor	Decult Turpe					
Authorizing Provider Danielle S	Result Type BH LAB BLOOI		3I FS			
Performing Organization		ONDERVI	City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	liver Ave	Farmington Hills, MI 48336	800-551-0		

	Value	Ref	Test Method	Analysis Time	Dorformed A+	Pathologist Signature
Component Magnesium	1.7	Range 1.7 - 2.5 mg/dL	Test Method	08/28/2023 7:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Pathologist Signature
Specimen (Source)	Anatomical Lo Laterality		Collection Method / Volume	Collection		Received Time
Blood	VENOUS BLOC SPECIMEN / U		venipuncture / Onkno	WII 00/20/202	23 6.20 AIVI EDI	08/28/2023 6:44 AM EE
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOI) ORDERA	BLES			
Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Address 28050 Grand F	River Ave	City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu 800-551-0		
(ABNORMAL) BASIC N	IETABOLIC PA Value	NEL (BM Ref Range	P) - Final result (08/ Test Method	28/2023 6:2 Analysis Time	-	Pathologist Signature
Sodium	139	135 -		08/28/2023	BEAUMONT	
		145 mmol/L		7:39 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Potassium	3.3 (L)				FARMINGTON HILLS (CLIA #:	
Potassium Chloride	3.3 (L) 106	mmol/L 3.5 - 5.2		EDT 08/28/2023 7:39 AM	FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	
		mmol/L 3.5 - 5.2 mmol/L 98 - 111		EDT 08/28/2023 7:39 AM EDT 08/28/2023 7:39 AM	FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	
Chloride	106	mmol/L 3.5 - 5.2 mmol/L 98 - 111 mmol/L 20 - 29		EDT 08/28/2023 7:39 AM EDT 08/28/2023 7:39 AM EDT 08/28/2023 7:39 AM	FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Blood Urea Nitrogen -BUN	12	7 - 25 mg/dL		08/28/2023 7:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	
					23D0363256)	
Creatinine	0.50 (L)	0.60 - 1.30 mg/ dL		08/28/2023 7:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	115	>60 mL/ min/ 1.73m2		08/28/2023 7:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Calculation based on without adjustment fo gender using the CKD-	or race. Glom	erular Fi				
G1: Normal GFR: G2: Mildly decre G3a: Mildly to mo G3b: Moderately 1 G4: Severely dec G5: Kidney failu	eased GFR: 60 oderately dec to severely d creased GFR:	reased GF ecreased				
Calcium	7.8 (L)	8.5 - 10.5 mg/dL		08/28/2023 7:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U					08/28/2023 6:44 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOD	ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0		
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi Ref	nal result (08/28/2023	5:59 AM ED Analysis	T)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	137	60 - 139 mg/dL		08/28/2023 6:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Performed By	Jackson, Regina NA			08/28/2023 6:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/28/202	23 5:59 AM EDT	08/28/2023 6:06 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/d	ΊL	A #: 23D0363256) -	08/28/2023	6:06 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCKE	D DEVICE UNSOLICITED	O RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	9488	
GLUCOSE, POINT OF CA	RE (GLUCOSE, Value	POC) - Fi Ref Range	nal result (08/27/2023 Test Method	3 11:52 PM El Analysis Time		Pathologist Signature
Glucose	137	60 - 139 mg/dL			BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	<u> </u>
Comment: Capillary				00/07/0000		
Performed By	Jackson, Regina NA			08/27/2023 11:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
		,				
Specimen (Source)	Anatomical Loc Laterality	lation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur				23 11:52 PM	08/27/2023 11:59 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/o	ΊL	A #: 23D0363256) -	08/27/2023	11:59 PM EDT	
Authorizing Provider	Result Type					
William Rudy		ST DOCKE	D DEVICE UNSOLICITED	O RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488	

Component	Value	Ref Range	Test Method	Analysis Time	Porformed At	Pathologist Signature
Glucose	131	60 - 139 mg/dL			BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Dunmore, Androni NA			08/27/2023 6:15 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOO SPECIMEN / U			08/27/202	23 6:08 PM EDT	08/27/2023 6:15 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	08/27/2023	6:15 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKE	ED DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) CBC W/	AUTO DIFF - I		lt (08/27/2023 4:08	-		
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
WBC	7.3	3.5 - 10.1 bil/L		08/27/2023 4:20 PM EDT		
RBC	3.67 (L)	4.31 - 5.48 tril/ L		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	10.8 (L)	13.5 - 17.0 g/ dL		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hematocrit	34.0 (L)	40.1 - 50.1 %		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
MCV	93	80 - 100 fL		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
МСН	29	28 - 33 pg		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСНС	32	32 - 36 g/dL		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RDW-CV	16 (H)	12 - 15 %		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Platelets	193	150 - 400 bil/L		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Nucleated Red Blood Cells	0.0	<=0.0 %		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Neutrophils	5.0	1.6 - 7.2 bil/L		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Lymphocytes	0.8 (L)	1.1 - 4.0 bil/L		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Monocytes	1.3 (H)	0.0 - 0.9 bil/L		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Eosinophils	0.2	0.0 - 0.4 bil/L		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.0	0.0 - 0.1 bil/L		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.08 (H)	0.00 - 0.04 bil/L		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %	1.1	%		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

	Anatomical Location	on /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	VENOUS BLOOD SPECIMEN / Unkno	own	Venipuncture / Unknowi	n 08/27/202	3 4:08 PM EDT	08/27/2023 4:14 PM EDT
Narrative						
Authorizing Provider	Result Type					
William Rudy	BH LAB BLOOD OF	RDERAB	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River	r Ave	Farmington Hills, MI 48336	800-551-0	488	
Lactic acid, plasma -	Final result (08/2			Analysis		
Component		nge		Time	Performed At	Pathologist Signature
Lactic Acid		5 - 2.0 mol/L		08/27/2023 4:40 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Location	on /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOOD SPECIMEN / Unkno	own	Venipuncture / Unknown	n 08/27/202	3 4:08 PM EDT	08/27/2023 4:14 PM EDT
Narrative						
Authorizing Provider	Result Type					
William Rudy	BH LAB BLOOD OF	RDERAB	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River	r Ave	Farmington Hills, MI 48336	800-551-0	488	
PHOSPHORUS LEVEL - F	Re	f		Analysis Time	Derformed At	Dath alogist Cignatura
Component Phosphorus		nge 3 - 4.4		08/27/2023	BEAUMONT	Pathologist Signature
rnosphorus		g/dL		4:42 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Locatio	on /	Collection Method /		T ime -	Denotional T
Specimen (Source) Blood	Laterality VENOUS BLOOD SPECIMEN / Unkno	own	Volume Venipuncture / Unknown	Collection n 08/27/202		Received Time 08/27/2023 4:14 PM EDT
Narrative						
Authorizing Provider	Result Type					
William Rudy	BH LAB BLOOD OF	RDERAB	BLES			

Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0	1488	
MAGNESIUM LEVEL - Fi	nal result (08/2	27/2023 4 Ref	:08 PM EDT)	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Magnesium	1.8	1.7 - 2.5 mg/dL		08/27/2023 4:45 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /	- II		- 1 1
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	VENOUS BLOC SPECIMEN / Ur		Venipuncture / Unknow	wn 08/27/202	:3 4:08 PM EDT	08/27/2023 4:14 PM EDT
Narrative						
Authorizing Drovidor	Decult Turpe					
Authorizing Provider William Rudy	Result Type BH LAB BLOOD					
William Ruuy			DLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Address 28050 Grand R	liver Ave	City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu 800-551-0		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R		Farmington Hills, MI 48336	800-551-0)488	
BEAUMONT LABORATORY, FARMINGTON HILLS	28050 Grand R	ANEL (BM	Farmington Hills, MI 48336	800-551-0 2 7/2023 4:0)488	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) BASIC N	28050 Grand R	NEL (BM Ref	Farmington Hills, MI 48336 IP) - Final result (08/	800-551-0 2 7/2023 4:0 Analysis)488) 8 PM EDT)	Pathologist Signature
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	ANEL (BM	Farmington Hills, MI 48336	800-551-0 2 7/2023 4:0	0488 0 8 PM EDT) Performed At	Pathologist Signature
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) BASIC N Component	28050 Grand R METABOLIC PA Value	NEL (BM Ref Range 135 - 145	Farmington Hills, MI 48336 IP) - Final result (08/	800-551-0 27/2023 4:0 Analysis Time 08/27/2023 4:43 PM	0488 8 PM EDT) Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Pathologist Signature
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) BASIC N Component Sodium	28050 Grand R AETABOLIC PA Value 138	NEL (BM Ref Range 135 - 145 mmol/L 3.5 - 5.2	Farmington Hills, MI 48336 IP) - Final result (08/	800-551-0 27/2023 4:0 Analysis Time 08/27/2023 4:43 PM EDT 08/27/2023 4:43 PM	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Pathologist Signature

Carbon Dioxide -CO2 27 20 - 29 08/27/2023 BEAUMONT mmol/L 4:43 PM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) 6 5 - 17 Anion Gap 08/27/2023 BEAUMONT 4:43 PM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis				
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature		
Glucose Comment: Fasting Blood Glucos	108 (H) e: 60-99 mg/	60 - 99 mg/dL ′dL		08/27/2023 4:43 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Random Blood Glucose	-	ı∕d∟						
Blood Urea Nitrogen -BUN	14	7 - 25 mg/dL		08/27/2023 4:43 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Creatinine	0.58 (L)	0.60 - 1.30 mg/ dL		08/27/2023 4:43 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
eGFR By Creatinine	110	>60 mL/ min/ 1.73m2		08/27/2023 4:43 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Comment: Calculation based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation refit without adjustment for race. Glomerular Filtration Rate is estimated from serum creatinine, age and gender using the CKD-EPI equation: G1: Normal GFR: >=90 G2: Mildly decreased GFR: 60-89 G3a: Mildly to moderately decreased GFR: 45-59								
G3b: Moderately	to severely c creased GFR:	lecreased						
Calcium	7.8 (L)	8.5 - 10.5 mg/dL		08/27/2023 4:43 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Timo	Received Time		
Blood	VENOUS BLOG SPECIMEN / U					08/27/2023 4:14 PM EDT		
Narrative								
Authorizing Provider	Result Type							
William Rudy	BH LAB BLOO	U ORDERAI	BLES					
Performing Organization			City/State/ZIP Code	Phone Nu				
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand I	River Ave	Farmington Hills, MI 48336	800-551-0)488			
GLUCOSE, POINT OF CA	ARE (GLUCOSE	, POC) - Fi	nal result (08/27/2023	3 12:08 PM E	DT)			

		Ref		Ar	nalysis		
Component	Value	Range	Test Method		ne	Performed At	Pathologist Signature
Glucose Comment: Capillary	129	60 - 139 mg/dL			:14 PM	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Dunmore,			08	/27/2023	BEAUMONT	
	Androni NA			12 ED	:14 PM	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Metho Volume		Collection	Time	Received Time
Blood	WHOLE BLOOI SPECIMEN / U				08/27/202 EDT	3 12:08 PM	08/27/2023 12:14 PM EDT
Narrative							
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256	5) - 08/	27/2023	12:14 PM EDT	
Authorizing Provider	Result Type						
William Rudy	BH LAB POC T	EST DOCKI	D DEVICE UNSOLI	CITED RE	SULTS		
Performing Organization	Address		City/State/ZIP Cod	de	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, 48336	MI	800-551-0	488	
(00							
GLUCOSE, POINT OF CA	NRE (GLUCOSE,					T)	
Component	Value		Tast Mathad		,	Darfarmad At	Pathologist Signature
Component Glucose	117	Range 60 - 139	Test Method		ne /27/2022	BEAUMONT	
Comment: Capillary	117	mg/dL			50 AM	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Jackson,			08	/27/2023	BEAUMONT	
	Regina NA				50 AM	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method Volume	-	Collection	Time	Received Time
Blood	WHOLE BLOOI)					08/27/2023 1:50 AM EDT
	SPECIMEN / U						
Narrative							
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256	5) - 08/	27/2023	1:50 AM EDT	
Authorizing Provider	Result Type						
William Rudy	BH LAB POC T	EST DOCK	D DEVICE UNSOLI	CITED RE	SULTS		

Performing Organization	Address		City/State/ZIP Code	Phone Nu			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0488			
(CLIA #. 2300303230)							
(ABNORMAL) LACTIC	ACID, PLASM		result (08/26/2023 8)		
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature	
Lactic Acid	2.2 (H)	0.5 - 2.0 mmol/L			BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time	
Blood	VENOUS BLOC SPECIMEN / U					08/26/2023 8:51 PM EDT	
Narrative							
Authorizing Provider William Rudy	Result Type BH LAB BLOOI		BLES				
, , , , , , , , , , , , , , , , , , ,							
Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Address 28050 Grand River Ave		City/State/ZIP Code Farmington Hills, MI 48336	Phone Number 800-551-0488			
GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/26/2023 5:52 PM EDT) Ref Analysis							
Component	Value	Range 60 - 139	Test Method	Time		Pathologist Signature	
Glucose Comment: Capillary	125	mg/dL		5:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Performed By	Dunmore, Androni NA			08/26/2023 5:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time	
Blood	WHOLE BLOO SPECIMEN / U			08/26/202	23 5:52 PM EDT	08/26/2023 5:59 PM EDT	
Narrative							
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	IA #: 23D0363256) -	08/26/2023	5:59 PM EDT		
Authorizing Provider	Result Type						
William Rudy	BH LAB POC T	EST DOCK	ED DEVICE UNSOLICITE	D RESULTS			

Performing Organization	Address		City/State/ZIP Code	Phone Nu	Phone Number		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	tiver Ave	Farmington Hills, MI 48336	800-551-0)488		
(ABNORMAL) LACTIC	ACID, PLASM	I A - Final Ref	result (08/26/2023 5	-)		
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature	
Lactic Acid	2.4 (H)	0.5 - 2.0 mmol/L	1000 1110 112 1		BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Comment: Sample is her	molzyed. Result	. may be fa	Isely increased.				
Specimen (Source)	Anatomical Location / Laterality		Collection Method / Volume	Collection	n Time	Received Time	
Blood	VENOUS BLOOD SPECIMEN / Unknown			Venipuncture / Unknown 08/26/2023 5:44 PM EDT			
Narrative							
Authorizing Provider	Result Type						
William Rudy	BH LAB BLOOD) ORDERA	.BLES				
Performing Organization			City/State/ZIP Code	Phone Nu			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0	1488		
PROCEDURALIST LINE INSERTION (Proceduralist Line Insertion) - Final result (08/26/2023 4:46 PM EDT) Narrative Kelli v - 08/26/2023 4:46 PM EDT							

Narrative Vanoverbeke, Kelli M, RN 8/26/2023 4:49 PM Proceduralist Line Insertion Date/Time: 8/26/2023 4:46 PM Performed by: Vanoverbeke, Kelli M, RN Authorized by: Rudy, William M, DO Select Line: Extended Dwell (no IVTBD) Indications for Midline/PICC: Difficult Access/Blood Draws Patient Properly Positioned: Yes Hand Hygiene Completed: Yes Maximum Barrier Used: Yes Chlorhexidine Used Immediately Prior: Yes Sterile technique maintained: Yes Local Anesthetic: None Inserted By: RN FMH-IV Team Team: Supervising Physician: Na Catheter size (Fr): 18 (gauge) Vein diameter (mm): Na Catheter to Vein percentage: 29% Catheter type: Non-valved, Non-tunneled and Power injectable Lot#/: REHQ4269 Manufacturer and Device type: BARD/POWERGLIDE PRO MIDLINE Catheter length (cm): 10 Initial Exposed Catheter: Initial Extremity Circumference: 33 Custom cut tip: No Orientation: Right Location: Brachial Pertinent clinical contraindications to site location use: No Contraindications Placement Verified: Ultrasound Confirmation Ultrasound used? US use required for placement unless subclavian: Yes Securement Method: Securement device (stat lock) Acknowledge the guidewire was removed: Yes (part of device) Name of person who acknowledged guidewire was removed: NA Guidewire integrity intact: Yes Insertion attempts: 2 Complications: Successful insertion (comment) Patient tolerance: Tolerated well Patient / family / significant other educated: Yes Authorizing Provider Result Type BH IP BEDSIDE ORDERABLE William Rudy

(ABNORMAL) LACTIC ACID, PLASMA - Final result (08/26/2023 3:56 PM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Lactic Acid	2.5 (H)	0.5 - 2.0 mmol/L		08/26/2023 4:58 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	ocation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Volume Collection Time		Received Time
Blood	VENOUS BLOOD SPECIMEN / Unknown		Venipuncture / Unknov	vn 08/26/202	23 3:56 PM EDT	08/26/2023 4:26 PM EDT
Narrative						
Authorizing Provider	Result Type					
William Rudy	BH LAB BLOO	D ORDERAI	BLES			

Performing Organization	Address	City/State/ZIP Code	Phone Number					
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0488					
CHEST 1 VIEW AP/PA -								
Anatomical Region Chest	on Laterality Modality Radiographic Imaging							
Chest		Raulograp	The imaging					
	Anatomical Location /	Collection Method /						
Specimen (Source)	Laterality	Volume	Collection Time	Received Time				
			08/26/2023 12:33 PM EDT					
Narrative								
08/26/2023 12:34 PM	EDT							
INDICATION: Fever.								
COMPARISON: Chest ra	diograph 8/23/2023, 8	/21/2023						
TECHNIQUE: Frontal p 8/26/2023	ortable chest radiogr	aph obtained at 1224	hours on					
FINDINGS: Patient is	rotated to the left.							
Lungs: Persistent st exam. Left lung rema	reaky opacities at th ins clear. No pleural	e right lung base fro effusions or pneumot	m most recent horax.					
Vasculature: Normal.								
Heart: Normal in siz	e.							
Mediastinum: within	normal limits.							
Musculoskeletal: Degenerative changes throughout the spine. No acute osseous process.								
Other findings: No significant.								
IMPRESSION: Persistent right basilar streaky opacities again either from subsegmental atelectasis versus airspace process.								
Procedure Note								
Timothy McKnight - 08	/26/2023							

Procedure Note										
	ight be different from the	original.								
INDICATION: Fever.										
COMPARISON: Chest radiograph 8/23/2023, 8/21/2023.										
TECHNIQUE: Frontal portable chest radiograph obtained at 1224 hours on 8/26/2023										
FINDINGS: Patient is rotat	FINDINGS: Patient is rotated to the left.									
	opacities at the right lung l lear. No pleural effusions c									
Vasculature: Normal.										
Heart: Normal in size.										
Mediastinum: within norn	nal limits.									
Musculoskeletal: Degener process.	rative changes throughout	the spine. No acute ossee	ous							
Other findings: No signific	cant.									
IMPRESSION:	eaky opacities again either	from subsegmental								
atelectasis versus airspace		C C								
Authorizing Provider	Result Type									
Manju G	WBH IMG GENERAL ORD	ERABLES								
Culture, Blood (CULTUR	E, BLOOD) - Final result (08/26/2023 12:31 PM E	EDT)							
	Ref		Analysis							
Component	Value Range		Time		Pathologist Signature					
Culture, Blood	No growth at 5 days		08/31/2023 6:00 PM EDT	BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)						
Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection	Time	Received Time					
Blood	VENIPUNCTURE FOR BLOOD TEST / Unknown	Venipuncture / Unknowr			08/26/2023 12:38 PM EDT					
Narrative										
Authorizing Provider	Result Type									
Manju G	BH LAB MICROBIOLOGY -	GENERAL ORDERABLES								
Performing Organization	Address	City/State/ZIP Code	Phone Nur	nber						
BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	3601 W. 13 Mile Rd	Royal Oak, MI 48073	800-551-0	488						
/										

(ABNORMAL) CBC W/AUTO DIFF - Final result (08/26/2023 12:30 PM EDT)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
WBC	7.0	3.5 - 10.1 bil/L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RBC	4.04 (L)	4.31 - 5.48 tril/ L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	11.6 (L)	13.5 - 17.0 g/ dL		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hematocrit	36.7 (L)	40.1 - 50.1 %		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
MCV	91	80 - 100 fL		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСН	29	28 - 33 pg		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСНС	32	32 - 36 g/dL		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RDW-CV	16 (H)	12 - 15 %		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Platelets	189	150 - 400 bil/L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Nucleated Red Blood Cells	0.0	<=0.0 %		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Neutrophils	5.0	1.6 - 7.2 bil/L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Lymphocytes	0.6 (L)	1.1 - 4.0 bil/L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range		Time	Performed At	Pathologist Signature
Monocytes	1.3 (H)	0.0 - 0.9 bil/L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Eosinophils	0.1	0.0 - 0.4 bil/L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.0	0.0 - 0.1 bil/L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.05 (H)	0.00 - 0.04 bil/L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %		%		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method / Volume	Callesting	T ¹	Densities of Times
Specimen (Source) Blood	Laterality VENOUS BLOOD SPECIMEN / Unknown		VolumeCollection TimeVenipuncture / Unknown08/26/2023 12:30 PMEDT		Received Time 08/26/2023 12:37 PM EDT	
Narrative						
Authorizina Provider	Result Type					
Authorizing Provider Manju G	Result Type BH LAB BLOOE) ORDERAI	BLES			
Manju G	BH LAB BLOOD) orderai		Phone Nu	mbor	
0	BH LAB BLOOD		3LES City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu 800-551-0		
Manju G Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS	BH LAB BLOOD Address 28050 Grand R	liver Ave	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0		
Manju G Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	BH LAB BLOOD Address 28050 Grand R	River Ave	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0 EDT)	488	Pathologist Signature
Manju G Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Culture, Blood (CULTURI	BH LAB BLOOE Address 28050 Grand R E, BLOOD) - Fir	River Ave nal result Ref	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0 EDT) Analysis	488 Performed At	Pathologist Signature
Manju G Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Culture, Blood (CULTURI Component Culture, Blood	BH LAB BLOOD Address 28050 Grand R 28050 Grand R E, BLOOD) - Fin Value No growth at 5 days	Nal result Ref Range	City/State/ZIP Code Farmington Hills, MI 48336 (08/26/2023 12:30 PM Test Method CULTURE, BLOOD	800-551-0 EDT) Analysis Time 08/31/2023 6:00 PM EDT	488 Performed At BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	
Manju G Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Culture, Blood (CULTURI Component Culture, Blood	BH LAB BLOOD Address 28050 Grand R 28050 Grand R E, BLOOD) - Fin Value No growth at 5 days Anatomical Loc Laterality	River Ave	City/State/ZIP Code Farmington Hills, MI 48336 (08/26/2023 12:30 PM Test Method CULTURE, BLOOD Collection Method / Volume	800-551-0 EDT) Analysis Time 08/31/2023 6:00 PM EDT Collection	488 Performed At BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009) Time	Received Time
Manju G Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Culture, Blood (CULTURI Component Culture, Blood	BH LAB BLOOD Address 28050 Grand R 28050 Grand R E, BLOOD) - Fin Value No growth at 5 days	River Ave	City/State/ZIP Code Farmington Hills, MI 48336 (08/26/2023 12:30 PM Test Method CULTURE, BLOOD	800-551-0 EDT) Analysis Time 08/31/2023 6:00 PM EDT Collection	488 Performed At BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009) Time	
Manju G Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Culture, Blood (CULTURI Component Culture, Blood	BH LAB BLOOD Address 28050 Grand R 28050 Grand R E, BLOOD) - Fin Value No growth at 5 days Anatomical Loc Laterality VENIPUNCTUR	River Ave	City/State/ZIP Code Farmington Hills, MI 48336 (08/26/2023 12:30 PM Test Method CULTURE, BLOOD Collection Method / Volume	800-551-0 EDT) Analysis Time 08/31/2023 6:00 PM EDT Collection n 08/26/202	488 Performed At BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009) Time	Received Time
Manju G Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Culture, Blood (CULTURI Component Culture, Blood Specimen (Source) Blood	BH LAB BLOOD Address 28050 Grand R 28050 Grand R E, BLOOD) - Fin Value No growth at 5 days Anatomical Loc Laterality VENIPUNCTUR	River Ave	City/State/ZIP Code Farmington Hills, MI 48336 (08/26/2023 12:30 PM Test Method CULTURE, BLOOD Collection Method / Volume	800-551-0 EDT) Analysis Time 08/31/2023 6:00 PM EDT Collection n 08/26/202	488 Performed At BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009) Time	Received Time
Manju G Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Culture, Blood (CULTURI Component Culture, Blood Specimen (Source) Blood	BH LAB BLOOD Address 28050 Grand R 28050 Grand R E, BLOOD) - Fin Value No growth at 5 days Anatomical Loc Laterality VENIPUNCTUR	River Ave	City/State/ZIP Code Farmington Hills, MI 48336 (08/26/2023 12:30 PM Test Method CULTURE, BLOOD Collection Method / Volume	800-551-0 EDT) Analysis Time 08/31/2023 6:00 PM EDT Collection n 08/26/202	488 Performed At BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009) Time	Received Time
Manju G Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Culture, Blood (CULTURI Component Culture, Blood Specimen (Source) Blood Narrative	BH LAB BLOOD Address 28050 Grand R 28050 Grand R E, BLOOD) - Fin Value No growth at 5 days Anatomical Loc Laterality VENIPUNCTUR BLOOD TEST / Result Type	River Ave	City/State/ZIP Code Farmington Hills, MI 48336 (08/26/2023 12:30 PM Test Method CULTURE, BLOOD Collection Method / Volume	800-551-0 EDT) Analysis Time 08/31/2023 6:00 PM EDT Collection n 08/26/202 EDT	488 Performed At BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009) Time	Received Time

Performing Organization Address			City/State/ZIP Code	Phone Number			
BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	3601 W. 13 M	ile Rd	Royal Oak, MI 48073	800-551-0	488		
PHOSPHORUS LEVEL - I	Final result (08	8/26/2023 Ref	12:30 PM EDT)	Analysis			
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature	
Phosphorus	2.5	2.3 - 4.4 mg/dL		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Specimen (Source)	Anatomical Lo Laterality	ocation /	Collection Method / Volume	Collection	Time	Received Time	
Blood	VENOUS BLO	DD	Venipuncture / Unknow			08/26/2023 12:38 PM	
	SPECIMEN / U		,	EDT		EDT	
Narrative							
Authorizing Provider	Result Type						
Manju G	BH LAB BLOO	D ORDERA	RTF2				
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand	River Ave	Farmington Hills, MI 48336	800-551-0	488		
MAGNESIUM LEVEL - Fi	nal result (08/	26/2023 1 Ref	2:30 PM EDT)	Analysis			
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature	
Magnesium	1.7	1.7 - 2.5 mg/dL		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
	Anatomical Lo	ocation /	Collection Method /				
Specimen (Source)			Volume	Collection		Received Time	
Blood	VENOUS BLO SPECIMEN / U		Venipuncture / Unknow	vn 08/26/202 EDT	3 12:30 PM	08/26/2023 12:38 PM EDT	
Narrative							
Authorizing Provider	Result Type						
Manju G	BH LAB BLOO	D ORDERA	BLES				
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand	River Ave	Farmington Hills, MI 48336	800-551-0	488		
(ABNORMAL) COMPR	EHENSIVE M	ETABOLIC	PANEL (CMP) - Final	result (08/2	26/2023 12:3	0 PM EDT)	

Comment		Ref	To at Martha al	Analysis	Deuferment At Dethele sist Cimetan
Component Sodium	Value 136	Range 135 - 145 mmol/L	Test Method	Time 08/26/2023 1:26 PM EDT	Performed At Pathologist Signature BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Potassium	3.0 (L)	3.5 - 5.2 mmol/L		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Chloride	103	98 - 111 mmol/L		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Carbon Dioxide -CO2	23	20 - 29 mmol/L		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Anion Gap	10	5 - 17		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Glucose	131 (H)	60 - 99 mg/dL		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Comment: Fasting Blood Glucos Random Blood Glucose					
Blood Urea Nitrogen -BUN	12	7 - 25 mg/dL		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Creatinine	0.57 (L)	0.60 - 1.30 mg/ dL		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
eGFR By Creatinine	111	>60 mL/ min/ 1.73m2		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Comment:					

Comment:

Calculation based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation refit without adjustment for race. Glomerular Filtration Rate is estimated from serum creatinine, age and gender using the CKD-EPI equation:

G1: Normal GFR: >=90
G2: Mildly decreased GFR: 60-89
G3a: Mildly to moderately decreased GFR: 45-59
G3b: Moderately to severely decreased GFR: 30-44
G4: Severely decreased GFR: 15-29
G5: Kidney failure GFR: <15</pre>

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Calcium	8.2 (L)	8.5 - 10.5 mg/dL		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Protein Total	6.0 (L)	6.2 - 8.1 g/dL		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Albumin	2.4 (L)	3.5 - 4.9 g/dL		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Globulin	3.6	2.2 - 3.7 g/dL		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Albumin/Globulin Ratio	0.7			08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Alkaline Phosphatase	123 (H)	33 - 120 U/L		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Aspartate Aminotransferase -AST	46 (H)	<35 U/L		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Alanine Aminotransferase -ALT	39	9 - 47 U/ L		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Bilirubin Total	0.2 (L)	0.3 - 1.2 mg/dL		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Spacimon (Source)	Anatomical Lo	cation /	Collection Method / Volume	Collection	Time	Received Time
Specimen (Source) Blood	Laterality VENOUS BLOC SPECIMEN / U		Venipuncture / Unknow			08/26/2023 12:38 PM EDT
Narrative						
Authorizing Provider	Result Type					
Manju G	BH LAB BLOOI	D ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0		

GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/26/2023 11:32 AM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	120	60 - 139 mg/dL		08/26/2023 11:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Dunmore,			08/26/2023	BEAUMONT	
	Androni NA			11:39 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method Volume	/ Collectior	n Time	Received Time
Blood	WHOLE BLOOI SPECIMEN / U			08/26/202 EDT	23 11:32 AM	08/26/2023 11:39 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256)	- 08/26/2023	11:39 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKE	D DEVICE UNSOLICI	TED RESULTS		
Performing Organization	Address		City/State/ZIP Code	e Phone Nu	ımber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, M 48336	II 800-551-(0488	
(CEIA ". 2300303230)						
GLUCOSE, POINT OF CA	ARE (GLUCOSE,				DT)	
Component	Value		Test Method	,	Darformed At	Pathologist Signature
Component Glucose	128	Range 60 - 139	lest Method	Time	BEAUMONT	Pathologist Signature
Comment: Capillary	120	mg/dL		5:31 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Vinales, Robin			08/26/2023	BEAUMONT	
	NA			5:31 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method Volume	/ Collectior	n Time	Received Time
Blood	WHOLE BLOOI)				08/26/2023 5:31 AM EDT
2.000	SPECIMEN / U			00, 20, 20,		
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256)	- 08/26/2023	5:31 AM EDT	
Authorizing Provider	Result Type					
William Rudy		EST DOCK	D DEVICE UNSOLICI	TED RESULTS		

Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT	28050 Grand R	liver Ave	Farmington Hills, MI	800-551-0	488			
LABORATORY,			48336					
FARMINGTON HILLS (CLIA #: 23D0363256)								
(CLIA #. 25D0505250)								
GLUCOSE, POINT OF CA	ARE (GLUCOSE,	POC) - F	inal result (08/26/2023	3 12:15 AM E	DT)			
		Ref		Analysis				
Component	Value	Range	Test Method	Time		Pathologist Signature		
Glucose	115	60 - 139			BEAUMONT			
		mg/dL		12:21 AM EDT	LABORATORY, FARMINGTON			
					HILLS (CLIA #:			
					23D0363256)			
Comment: Capillary								
Performed By	Anderson,				BEAUMONT			
	Shamika NA			12:21 AM EDT	LABORATORY, FARMINGTON			
				EDT	HILLS (CLIA #:			
					23D0363256)			
					,			
	Anatomical Lo	cation /	Collection Method /		- .			
Specimen (Source)	Laterality		Volume	Collection		Received Time		
Blood	WHOLE BLOOD SPECIMEN / UI			08/26/202 EDT	3 12:15 AM	08/26/2023 12:21 AM EDT		
	SPECIMEN / U	IKHOWH		EDT		EDI		
Narrative								
BEAUMONT LABORATORY,	FARMINGTON H	ILLS (CL	EA #: 23D0363256) -	08/26/2023	12:21 AM EDT			
Fasting Blood Glucos Random Blood Glucose								
	• ••• ±•• mg	/ 42						
Authorizing Provider	Result Type							
William Rudy	BH LAB POC T	EST DOCK	ED DEVICE UNSOLICITE	O RESULTS				
Performing Organization		· •	City/State/ZIP Code	Phone Nu				
BEAUMONT LABORATORY,	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0	1488			
FARMINGTON HILLS			40550					
(CLIA #: 23D0363256)								
CHICOCE DOINT OF C					T \			
GLUCOSE, POINT OF CA	ARE (GLUCOSE,		inal result (08/25/2023		1)			
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature		
Glucose	129	60 - 139	iest methou		BEAUMONT			
Sideose		mg/dL		5:43 PM	LABORATORY,			
		J.		EDT	FARMINGTON			
					HILLS (CLIA #:			
Destau					23D0363256)			
Performed By	MALLORY, DANYEL NA			08/25/2023 5:43 PM	BEAUMONT LABORATORY,			
				EDT	FARMINGTON			
					HILLS (CLIA #:			
					23D0363256)			
	Apotomical	cotion /	Collection Mathed /					
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time		
Blood	WHOLE BLOOI)	, oranno			08/25/2023 5:43 PM EDT		
	SPECIMEN / U			00, L0, L0L		,,		
Narrative			//. 00-0000-00	00/25/2005	F - 40			
BEAUMONT LABORATORY, Fasting Blood Glucos			LA #: 23D0363256) -	08/25/2023	5:43 PM EDT			
Random Blood Glucose								

Authorizing Provider	Result Type								
William Rudy	BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS								
Performing Organization	Address		City/State/ZIP Code	Phone Number					
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Ri	ver Ave	Farmington Hills, MI 48336	800-551-0)488				
GLUCOSE, POINT OF CA	GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/25/2023 11:56 AM EDT)								
Component	Value	Ref	Test Method	Analysis Time	Dorformod At	Pathologist Signature			
Glucose	126	Range 60 - 139	lest method		BEAUMONT	Pathologist Signature			
	120	mg/dL		12:02 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)				
Comment: Capillary									
Performed By	Vasser, Ashley NA			08/25/2023 12:02 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)				
Specimen (Source)	Anatomical Loc Laterality	ation /	Collection Method / Volume	Collection	Time	Received Time			
Blood	WHOLE BLOOD SPECIMEN / Un		volume		23 11:56 AM	08/25/2023 12:02 PM EDT			
Narrative									
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/c : 60-139 mg/	1L	A #: 23D0363256) - (08/25/2023	12:02 PM EDT				
Authorizing Provider									
William Rudy		ST DOCKE	D DEVICE UNSOLICITED						
Performing Organization			City/State/ZIP Code	Phone Nu					
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Ri	ver Ave	Farmington Hills, MI 48336	800-551-0	1488				
GLUCOSE, POINT OF CA	ARE (GLUCOSE,	POC) - Fi Ref	nal result (08/25/2023	6:04 AM ED Analysis	T)				
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature			
Glucose	89	60 - 139 mg/dL		08/25/2023 6:10 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)				
Comment: Capillary									
Performed By	Anderson, Shamika NA			08/25/2023 6:10 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)				
	Anatomical Loc	ation /	Collection Method /						
Specimen (Source) Blood	Laterality WHOLE BLOOD SPECIMEN / Un		Volume	Collection 08/25/202		Received Time 08/25/2023 6:10 AM EDT			

Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose			IA #: 23D0363256) -	08/25/2023	6:10 AM EDT	
Random Blood Glucose						
Authorizin e Dussidou	Description of					
Authorizing Provider William Rudy	Result Type					
William Ruuy	DH LAD POC H	EST DOCK		JRESULIS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT	28050 Grand R	iver Ave	Farmington Hills, MI	800-551-0)488	
LABORATORY, FARMINGTON HILLS			48336			
(CLIA #: 23D0363256)						
(0)						
GLUCOSE, POINT OF CA	RE (GLUCOSE,		nal result (08/25/2023		DT)	
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	115	60 - 139			BEAUMONT	
Glacose	115	mg/dL		12:32 AM	LABORATORY,	
		0		EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Comment: Capillary					2300303230)	
Performed By	Anderson,			08/25/2023	BEAUMONT	
	Shamika NA			12:32 AM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
					2320303230)	
	Anatomical Loo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/25/202 EDT	23 12:24 AM	08/25/2023 12:32 AM EDT
	SI ECHVIEN / OI	IKHOWH		LDT		
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose			IA #: 23D0363256) -	08/25/2023	12:32 AM EDT	
Random Blood Glucose						
Authorizing Provider	Result Type					
William Rudy	BH LAB PUC II	ST DOCK		JRESULIS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT	28050 Grand R	iver Ave	Farmington Hills, MI	800-551-0)488	
			48336			
FARMINGTON HILLS (CLIA #: 23D0363256)						
(0)						
(ABNORMAL) GLUCOS	E, POINT OF		UCOSE, POC) - Final		4/2023 6:05	PM EDT)
Component	Value	Ref Range	Test Method	Analysis Time	Porformed At	Pathologist Signature
Glucose	150 (H)	60 - 139	lest Method		BEAUMONT	
Glacose	150 (11)	mg/dL		6:12 PM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Comment: Capillary					2300003230)	
Performed By	Vasser, Ashley			08/24/2023	BEAUMONT	
	NA			6:12 PM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	

	Anatomical Loc	cation /	Collection Method /			
Specimen (Source)	Laterality	,	Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/24/202	23 6:05 PM EDT	08/24/2023 6:12 PM EDT
Narrative						
BEAUMONT LABORATORY,			A #: 23D0363256) -	08/24/2023	6:12 PM EDT	
Fasting Blood Glucose Random Blood Glucose						
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	EST DOCKE	ED DEVICE UNSOLICITED	O RESULTS		
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA	KE (GLUCOSE,	POC) - Fi Ref	nal result (08/24/2023	3 12:05 PM El Analysis	וט)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	105	60 - 139 mg/dL		08/24/2023 12:12 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	<u> </u>
Commont: Capillary					23D0363256)	
Comment: Capillary Performed By	Vasser, Ashley			08/24/2023	BEAUMONT	
renormed by	NA			12:12 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loc Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur				3 12:05 PM	08/24/2023 12:12 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucoses	e: 60-99 mg/d	dL	A #: 23D0363256) -	08/24/2023	12:12 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	EST DOCKE	ED DEVICE UNSOLICITED	O RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0		
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi Ref	nal result (08/24/2023	3 5:19 AM ED Analysis	T)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	106	60 - 139 mg/dL		08/24/2023 5:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary					2320303230)	

		Ref		Analysis				
Component	Value	Range	Test Method	Time		Pathologist Signature		
Performed By	Harvey, Jaice NA			08/24/2023 5:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Specimen (Source)	Anatomical Loc Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time		
Blood	WHOLE BLOOD SPECIMEN / Ur			08/24/202	23 5:19 AM EDT	08/24/2023 5:25 AM EDT		
Narrative								
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/o	dL	A #: 23D0363256) -	08/24/2023	5:25 AM EDT			
Authorizing Provider	Result Type							
William Rudy	BH LAB POC TE	EST DOCKE	D DEVICE UNSOLICITED	O RESULTS				
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	9488			
GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/24/2023 1:17 AM EDT) Ref Analysis Compared to Defense of Athenesist Circulated								
Component	Value	Range	Test Method	Time		Pathologist Signature		
Glucose	108	60 - 139 mg/dL		08/24/2023 1:23 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Comment: Capillary								
Performed By	Harvey, Jaice NA			08/24/2023 1:23 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
		,						
Specimen (Source)	Anatomical Loc Laterality	lation /	Collection Method / Volume	Collection	Time	Received Time		
Blood	WHOLE BLOOD SPECIMEN / Ur					08/24/2023 1:23 AM EDT		
Narrative								
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/o	dL	A #: 23D0363256) - 0	08/24/2023	1:23 AM EDT			
Authorizing Provider	Result Type							
William Rudy	BH LAB POC TE	est docke	D DEVICE UNSOLICITED	O RESULTS				
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488			

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	127	60 - 139 mg/dL		08/23/2023 4:24 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Carr, Kennadi			08/23/2023	BEAUMONT	
	NA			4:24 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loc Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/23/202	23 4:17 PM EDT	08/23/2023 4:24 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	dL	A #: 23D0363256) -	- 08/23/2023	4:24 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TI	EST DOCKE	D DEVICE UNSOLICITI	ED RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
(,						
GLUCOSE, POINT OF CA	RE (GLUCOSE,				DT)	
Component	Value	Ret Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	119	60 - 139	lest method		BEAUMONT	
Comment: Capillary		mg/dL		11:39 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Jones, Yazmyn			08/23/2023	BEAUMONT	
renormed by	NA			11:39 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD)			23 11:33 AM	08/23/2023 11:39 AM
	SPECIMEN / Ur			EDT		EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	08/23/2023	11:39 AM EDT	
Authorizing Provider	Result Type					
William Rudy	21	EST DOCKE	D DEVICE UNSOLICITI	ED RESULTS		
-						

Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	
GLUCOSE, POINT OF CA	ARE (GLUCOSE,	, POC) - Fi Ref	nal result (08/23/2023	3 5:38 AM ED Analysis)T)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	111	60 - 139 mg/dL			BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Harvey, Jaice			08/23/2023	BEAUMONT	
	NA			5:44 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loc	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/23/202	.3 5:38 AM EDT	08/23/2023 5:44 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/c	d∟	:A #: 23D0363256) - (08/23/2023	5:44 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	EST DOCKE	ED DEVICE UNSOLICITED	> RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	imber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0		
LACTIC ACID, PLASMA -	- Final result (0 [,]	8/23/2025	3 4:27 AM EDT)			
	-	Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Lactic Acid	1.6	0.5 - 2.0 mmol/L		08/23/2023 4:53 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loc	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	VENOUS BLOO SPECIMEN / Ur		Venipuncture / Unknow	vn 08/23/202	.3 4:27 AM EDT	08/23/2023 4:35 AM EDT
Narrative						
Authorizing Provider	Result Type					
Sara W	BH LAB BLOOD) ORDFRA	BLES			

Performing Organization	Address	City/State/ZIP Code	Phone Number			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0488			
CHEST 1 VIEW AP/PA - F	inal result (08/23/2023					
Anatomical Region	Laterality	Modality				
Chest	,	Radiograph	ic Imaging			
Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time		
opeennen (boarce)	Lateranty	Volume	08/23/2023 6:50 AM EDT			
Narrative 08/23/2023 6:52 AM EE	Т					
INDICATION: Evaluate	for aspiration.					
COMPARISON: Chest rac	liograph 8/21/2023 8	/1/2023				
8/23/2023	ortable chest radiogra	aph obtained at 0316 h	iours on			
FINDINGS: Patient is	rotated to the right					
Lungs: Streaky right effusions or pneumoth	basilar opacities ard norax.	e new. Left lung is cl	ear. No pleural			
Vasculature: Normal.						
Heart: Normal in size	2.					
Mediastinum: within r	normal limits.					
Musculoskeletal: The	osseous structures a	re intact.				
Other findings: No si	ignificant.					
IMPRESSION: New streaky right basilar opacities either from subsegmental atelectasis or airspace process such as pneumonitis/pneumonia						
Procedure Note						
Timothy McKnight - 08/	/23/2023					

Procedure Note
Formatting of this note might be different from the original.
INDICATION: Evaluate for aspiration.
COMPARISON: Chest radiograph 8/21/2023, 8/1/2023.
TECHNIQUE: Frontal portable chest radiograph obtained at 0316 hours on 8/23/2023
FINDINGS: Patient is rotated to the right
Lungs: Streaky right basilar opacities are new. Left lung is clear. No pleural effusions or pneumothorax.
Vasculature: Normal.
Heart: Normal in size.
Mediastinum: within normal limits.
Musculoskeletal: The osseous structures are intact.
Other findings: No significant.
IMPRESSION: New streaky right basilar opacities either from subsegmental atelectasis or airspace process such as pneumonitis/pneumonia
Authorizing Provider Result Type Camilla A WBH IMG GENERAL ORDERABLES
ABDOMEN KUB OR ABDOMEN 1 VIEW - Final result (08/23/2023 3:56 AM EDT) Anatomical Region Laterality Modality
Abdomen Radiographic Imaging
Anatomical Location / Collection Method / Specimen (Source) Laterality Volume Collection Time Received Time
08/23/2023 6:49 AM EDT
Narrative 08/23/2023 6:50 AM EDT
CLINICAL INDICATION: Concern for ileus, altered mental status and sepsis
COMPARISON: Chest radiographs 8/23/2023 and 8/21/2023
TECHNIQUE: Single view frontal supine radiographs of the abdomen obtained portably at 0318 hours on 3/23/2023.
FINDINGS: PEG tube projects over the left upper abdomen. Air-filled loops of colon and small bowel without abnormal dilatation are scattered throughout the abdomen and pelvis. There is no evidence for organomegaly. No abnormal calcifications. The osseous structures are intact.
IMPRESSION
1. No current radiographic evidence for acute process
2. PEG tube present

Procedure Note Timothy McKnight - 08/23/2023 Formatting of this note might be different from the original. CLINICAL INDICATION: Concern for ileus, altered mental status and sepsis COMPARISON: Chest radiographs 8/23/2023 and 8/21/2023 TECHNIQUE: Single view frontal supine radiographs of the abdomen obtained portably at 0318 hours on 3/23/2023. FINDINGS: PEG tube projects over the left upper abdomen. Air-filled loops of colon and small bowel without abnormal dilatation are scattered throughout the abdomen and pelvis. There is no evidence for organomegaly. No abnormal calcifications. The osseous structures are intact. **IMPRESSION** 1. No current radiographic evidence for acute process 2. PEG tube present Authorizing Provider **Result Type** Camilla A WBH IMG GENERAL ORDERABLES (ABNORMAL) LACTIC ACID, PLASMA - Final result (08/23/2023 2:31 AM EDT) Ref Analysis Component Value Range Test Method Time Performed At Pathologist Signature 08/23/2023 BEAUMONT Lactic Acid 2.1 (H) 0.5 - 2.0 mmol/L 3:15 AM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) Collection Method / Anatomical Location / Collection Time Specimen (Source) Laterality Volume **Received Time** Blood **VENOUS BLOOD** Venipuncture / Unknown 08/23/2023 2:31 AM EDT 08/23/2023 2:48 AM EDT SPECIMEN / Unknown Narrative Authorizing Provider **Result Type** Sara W BH LAB BLOOD ORDERABLES . . .

Performing Organization	Address	City/State/ZIP Code	Phone Number
BEAUMONT	28050 Grand River Ave	Farmington Hills, MI	800-551-0488
LABORATORY,		48336	
FARMINGTON HILLS			
(CLIA #: 23D0363256)			

ECG - Final result (08/23/2023 2:20 AM EDT)

		Ref		Analysis	Performed	
Component	Value	Range	Test Method	Time	At	Pathologist Signature
QT INTERVAL	322	ms			MISYS	
QTC CALCULATION	460	ms			MISYS	

	Anatomical Location /	Collection Method /			
Specimen (Source)	Laterality	Volume	Collection		Received Time
			08/23/2023	3 2:20 AM EDT	
Narrative					
MISYS - 08/25/2023 10):45 AM EDT				
Test Reason : Blood Pressure : */ Vent. Rate : 123 BPM P-R Int : 148 ms QT Int : 322 ms QTC Int : 460 ms	/* mmHG Atrial Rate : 123 QRS Dur : 88	ms			
No significant change	CG of 01-AUG-2023 17:3				
Referred By:	Confirmed By: Robe	ert Grodman			
Procedure Note	F (2022)				
Test Reason : Blood Pressure : */* mmH Vent. Rate : 123 BPM Atria P-R Int : 148 ms QRS Dur QT Int : 322 ms P-R-T Axe QTc Int : 460 ms Sinus tachycardia Nonspecific ST abnormali Abnormal ECG When compared with ECC No significant change wa	ight be different from the IG al Rate : 123 BPM : 88 ms es : 63 68 69 degrees ity G of 01-AUG-2023 17:39, s found Robert (486) on 8/25/2023				
Daufaunaia a Ousanization	Adduces	City (Ctata /ZID Cada	Dis an a Nive		
Performing Organization MISYS	Address	City/State/ZIP Code	Phone Nur	nber	
Culture, Blood (CULTUR Component Culture, Blood	E, BLOOD) - Final result (Ref Value Range No growth at 5 days	Test Method	Analysis Time	Performed At BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	Pathologist Signature
Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection	Time	Received Time
Blood	VENIPUNCTURE FOR BLOOD TEST / Unknown	Venipuncture / Unknow	n 08/23/2023 EDT	3 12:42 AM	08/23/2023 12:53 AM EDT
Narrative					
Authorizing Provider	Result Type				
Sara W	BH LAB MICROBIOLOGY	- GENERAL ORDERABLES			

Performing Organization	Address	City/State/ZIP Code	Phone Number
BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	3601 W. 13 Mile Rd	Royal Oak, MI 48073	800-551-0488

(ABNORMAL) BLOOD GASES, VENOUS (VBG) - Final result (08/23/2023 12:36 AM EDT)

(ADNORWAL) BLOOD	GASES, VENO	Ref	- Thai result (00	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Sample Type	Blood, venous			08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
рН	7.51 (H)	7.32 - 7.42		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
PCO2	35 (L)	41 - 51 mmHg		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Bicarbonate	28 (H)	19 - 27 mmol/L		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Total CO2	29	20 - 29 mmol/L		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Base Excess	5	-5 - 5 mmol/L		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Oxyhemoglobin	76	55 - 85 %		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carboxyhemoglobin Comment: Non-smoker: Less tha Heavy smoker: Less t	han 9%	<1.5 %		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Toxic: Greater than Methemoglobin	0.4	0.0 - 2.0		08/23/2023	BEAUMONT	
methemoglobin	0.7	%		12:59 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	15.0	13.5 - 17.0 g/ dL		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood, Whole	VENOUS BLOC		Volume	08/23/202	3 12:36 AM	08/23/2023 12:51 AM
	SPECIMEN / UI	nknown		EDT		EDT
Narrative						
Authorizing Provider	Result Type					
Sara W	BH LAB BLOOD	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nur	nber	
BEAUMONT	28050 Grand R	liver Ave	Farmington Hills, MI	800-551-0	488	
LABORATORY, FARMINGTON HILLS			48336			
(CLIA #: 23D0363256)						
Culture, Blood (CULTURI	E, BLOOD) - Fir	nal result	(08/23/2023 12:36 AM	EDT)		
Component	Value	Ref	Test Method	Analysis Time	Porformed At	Pathologist Signature
Component Culture, Blood	No growth at	Range	CULTURE, BLOOD	08/28/2023	BEAUMONT	
	5 days			11:01 AM	LABORATORY,	
				EDT	Royal oak (Clia#:	
					23D0667009)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time 08/23/2023 12:54 AM
Blood	VENIPUNCTUR BLOOD TEST /	-	Venipuncture / Unknow	Venipuncture / Unknown 08/23/2023 12:36 AM EDT		
Narrative						
Authorizing Provider Sara W	Result Type BH LAB MICRC	BIOLOGY	- GENERAL ORDERABLES	5		
Performing Organization BEAUMONT	Address 3601 W. 13 Mil	la Rd	City/State/ZIP Code Royal Oak, MI 48073	Phone Nur 800-551-0		
LABORATORY, ROYAL	5001 44. 15 1411		Royal Oak, Ivil 40075	000-331-0	400	
OAK (CLIA#: 23D0667009)						
(ABNORMAL) PROCAL		ΔSMΔ - F	inal result (08/23/202	ΣΣ 12·36 ΔΜ		
		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Procalcitonin, Plasma	0.27 (H)	0.00 - 0.25 ng/	i2000SR	08/23/2023 3:59 AM	BEAUMONT LABORATORY,	
		mL		EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
					 	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC	D	Venipuncture / Unknow			08/23/2023 12:54 AM
	SPECIMEN / UI	nknown		EDT		EDT
Narrative						
BEAUMONT LABORATORY,	FARMINGTON H	ILLS (CLI	A #: 23D0363256) - (08/23/2023	3:59 AM EDT	

Narrative						
Interpretive criteria	a for results	:				
If using as an aid ir infections, providers - PCT <0.10 ng/mL - a - PCT 0.10-0.25 ng/mL - PCT 0.26-0.50 ng/mL - PCT > 0.50 ng/mL -	s should use antibiotics s - antibiotic - antibiotic	the follo trongly o cs discou cs encour	owing guidance: Hiscouraged Hraged raged	ibiotics fo	r lower respi	ratory tract
If using as an aid ir sepsis, providers sho - PCT <= 0.50 ng/mL o - antibiotics - PCT > 0.50 ng/mL ar - antibiotics	ould use the or > 80% decre discouraged nd < 80% decre	following ease from	g guidance: n peak/baseline valu	е	ics for suspe	ected/confirmed
Authorizing Provider	Result Type					
Camilla A	BH LAB BLOOD	ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) LACTIC	ACID, PLASM	A - Final Ref Range	result (08/23/2023 1 2 Test Method	2:36 AM ED Analysis Time	-	Pathologist Signature
Lactic Acid	2.4 (H)	0.5 - 2.0 mmol/L		08/23/2023 1:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	VENOUS BLOC SPECIMEN / Ur		Venipuncture / Unknow	vn 08/23/202 EDT	23 12:36 AM	08/23/2023 12:54 AM EDT
Narrative						
Authorizing Provider	Result Type					
Sara W	BH LAB BLOOD	ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, Ml 48336	800-551-0	9488	
						

(ABNORMAL) BASIC METABOLIC PANEL (BMP) - Final result (08/23/2023 12:36 AM EDT)

C I		Ref	TIM	Analysis	
Component	Value	Range	Test Method	Time	Performed At Pathologist Signature
Sodium	135	135 - 145 mmol/L		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Potassium	4.1	3.5 - 5.2 mmol/L		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Chloride	101	98 - 111 mmol/L		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	24	20 - 29 mmol/L		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	10	5 - 17		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose	176 (H)	60 - 99 mg/dL		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Fasting Blood Glucos Random Blood Glucose						
Blood Urea Nitrogen -BUN	16	7 - 25 mg/dL		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.64	0.60 - 1.30 mg/ dL		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	107	>60 mL/ min/ 1.73m2		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Comment:

Calculation based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation refit without adjustment for race. Glomerular Filtration Rate is estimated from serum creatinine, age and gender using the CKD-EPI equation:

G1: Normal GFR: >=90
G2: Mildly decreased GFR: 60-89
G3a: Mildly to moderately decreased GFR: 45-59
G3b: Moderately to severely decreased GFR: 30-44
G4: Severely decreased GFR: 15-29
G5: Kidney failure GFR: <15</pre>

Calcium	8.6	8.5 - 10.5 mg/dL		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknow	n 08/23/202 EDT	23 12:36 AM	08/23/2023 12:54 AM EDT
Narrative						

Authorizing Provider	Result Type					
Sara W	BH LAB BLOOD ORDERABLES					
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand I	River Ave	Farmington Hills, MI 48336	800-551-0	0488	
(ABNORMAL) COMPL	ETE BLOOD C		inal result (08/23/20		/I EDT)	
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
WBC	12.4 (H)	3.5 - 10.1 bil/L		08/23/2023 1:12 AM EDT		5 5
RBC	4.91	4.31 - 5.48 tril/ L		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	14.5	13.5 - 17.0 g/ dL		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hematocrit	45.1	40.1 - 50.1 %		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
MCV	92	80 - 100 fL		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСН	30	28 - 33 pg		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСНС	32	32 - 36 g/dL		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RDW-CV	16 (H)	12 - 15 %		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Platelets	201	150 - 400 bil/L		08/23/2023 1:12 AM EDT		
Nucleated Red Blood Cells	0.0	<=0.0 %		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

	Anatomical Loo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	VENOUS BLOC SPECIMEN / Ur		Venipuncture / Unknow	n 08/23/202 EDT	23 12:36 AM	08/23/2023 12:54 AM EDT
Narrative						
Authorizing Provider	Result Type					
Sara W	BH LAB BLOOD	ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) GLUCOS	E, POINT OF	-	UCOSE, POC) - Final r	•	2/2023 11:51	PM EDT)
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	159 (H)	60 - 139 mg/dL			BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Harvey, Jaice NA			08/22/2023 11:58 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/22/202 EDT	23 11:51 PM	08/22/2023 11:58 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/0	dL	IA #: 23D0363256) - 0	08/22/2023	11:58 PM EDT	
Authorizing Provider	Result Type					
William Rudy	21	EST DOCKI	ED DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) GLUCOS	E, POINT OF	CARE (GL Ref	UCOSE, POC) - Final r	r esult (08/2 Analysis	2/2023 3:46	PM EDT)
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	179 (H)	60 - 139 mg/dL		08/22/2023 3:53 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Commont: Capillary						

Component		Ref	To at Matha a	Analysis	Deufeure ed At	Dath allo aist Cianatura
Component	Value	Range	Test Method	Time		Pathologist Signature
Performed By	Jones, Yazmyn NA			08/22/2023 3:53 PM	BEAUMONT LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #:	
					23D0363256)	
	Anatomical Lo	cation /	Collection Method /		- :	D . IT.
Specimen (Source)	Laterality	D	Volume	Collection		Received Time
Blood	WHOLE BLOO SPECIMEN / U			08/22/202	23 3:46 PIVI EDT	08/22/2023 3:53 PM EDT
	STECHNEN / O					
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg/	′d∟	IA #: 23D0363256) -	08/22/2023	3:53 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCK	ED DEVICE UNSOLICITEI	O RESULTS		
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand I	River Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) GLUCO	SE, POINT OF	CARE (GL	UCOSE, POC) - Final	result (08/2	2/2023 11:21	AM EDT)
6		Ref	—	Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose	186 (H)	60 - 139			BEAUMONT	
		mg/dL		11:27 AM EDT	LABORATORY, FARMINGTON	
				EDT	HILLS (CLIA #:	
					23D0363256)	
Comment: Capillary					,	
Performed By	Jones, Yazmyn			08/22/2023	BEAUMONT	
	NA			11:27 AM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #:	
					23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOO	D			23 11:21 AM	08/22/2023 11:27 AM
	SPECIMEN / U			EDT		EDT

Narrative

William Rudy

BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/22/2023 11:27 AM EDT Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL

BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS

Authorizing Provider Result Type

Performing Organization	Address	City/State/ZIP Code	Phone Number
BEAUMONT LABORATORY,	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0488
FARMINGTON HILLS		-0550	
(CLIA #: 23D0363256)			

(ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/22/2023 6:04 AM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	142 (H)	60 - 139 mg/dL		08/22/2023 6:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary				00/22/2022		
Performed By	Hall, LaKeela NA			08/22/2023 6:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOO SPECIMEN / U			08/22/202	23 6:04 AM EDT	08/22/2023 6:11 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	08/22/2023	6:11 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCK	ED DEVICE UNSOLICITEI	O RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, Ml 48336	800-551-0)488	
(ABNORMAL) GLUCOS	E, POINT OF	CARE (GL	UCOSE, POC) - Final	result (08/2	1/2023 8:28	PM EDT)
		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose Comment: Capillary	157 (H)	60 - 139 mg/dL		08/21/2023 8:34 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Hall, LaKeela			08/21/2023	BEAUMONT	
Tenomica by	NA			8:34 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOO SPECIMEN / U					08/21/2023 8:34 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	′d∟	A #: 23D0363256) -	08/21/2023	8:34 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCK	D DEVICE UNSOLICITE	D RESULTS		

Performing Organization	Address		City/State/ZIP Code	Phone Number		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		Farmington Hills, MI 48336	800-551-0488		
GLUCOSE, POINT OF CA		POC) - Fi Ref	nal result (08/21/202	3 4:18 PM ED Analysis	T)	
Component		Range	Test Method	Time	Performed At	Pathologist Signature
Glucose		60 - 139 mg/dL		08/21/2023 4:24 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Jones, Yazmyn NA			08/21/2023 4:24 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loca	ation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	WHOLE BLOOD SPECIMEN / Unk	known		08/21/202	3 4:18 PM EDT	08/21/2023 4:24 PM EDT
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/dl : 60-139 mg/d	L	A #: 23D0363256) -	08/21/2023	4:24 PM EDT	
Authorizing Provider William Rudy	Result Type					
	BH LAD FOC TES	DOCK		D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Riv	ver Ave	Farmington Hills, MI 48336	800-551-0	488	
CHEST 1 VIEW AP/PA - I Anatomical Region	Final result (08/2 Laterality	21/2023	Modality			
Chest			Radiogra	phic Imaging		
Specimen (Source)	Anatomical Loca Laterality	ation /	Collection Method / Volume	Collection	Time 3 1:04 PM EDT	Received Time
Narrative				00/21/202		
08/21/2023 1:05 PM EI CLINICAL INDICATION:						
COMPARISON: 8/1/2023						
TECHNIQUE: Single vie	ew chest in ser	miuprigh	t AP projection			
FINDINGS: Cardiac siz No focal airspace opa effusion/pneumothora	acities identi	fied bil	ateral lungs. No pl	leural	iated.	
IMPRESSION: No acute cardiopulmon	nary process					
Procedure Note Naveen Malay - 08/21/2	2023					

Procedure Note

Formatting of this note might be different from the original. CLINICAL INDICATION: Other cough

COMPARISON: 8/1/2023

TECHNIQUE: Single view chest in semiupright AP projection

FINDINGS: Cardiac size appears normal. The trachea is not abnormally deviated. No focal airspace opacities identified bilateral lungs. No pleural effusion/pneumothorax seen. Soft tissues and bony cage appear normal.

IMPRESSION:

No acute cardiopulmonary process

Authorizing Provider	Result Type
Danielle S	WBH IMG GENERAL ORDERABLES

(ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/21/2023 12:01 PM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	179 (H)	60 - 139 mg/dL		08/21/2023 12:08 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Jones, Yazmyn NA			08/21/2023 12:08 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/21/202 EDT	23 12:01 PM	08/21/2023 12:08 PM EDT
Blood Narrative					23 12:01 PM	
Narrative BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	SPECIMEN / Un FARMINGTON H e: 60-99 mg/ : 60-139 mg,	nknown ILLS (CLI dL	A #: 23D0363256) -	EDT		
Narrative BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose Authorizing Provider	SPECIMEN / Un FARMINGTON H : 60-99 mg/ : 60-139 mg Result Type	nknown ILLS (CLI dL /dL		EDT 08/21/2023		
Narrative BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	SPECIMEN / Un FARMINGTON H : 60-99 mg/ : 60-139 mg Result Type	nknown ILLS (CLI dL /dL	A #: 23D0363256) –	EDT 08/21/2023		
Narrative BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose Authorizing Provider	SPECIMEN / Un FARMINGTON Hi e: 60-99 mg/ : 60-139 mg, Result Type BH LAB POC TI	nknown ILLS (CLI dL /dL		EDT 08/21/2023	12:08 PM EDT	

(ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/21/2023 5:46 AM EDT)

Component	Value	Ref Range Test Method	Analysis Time Performed At Pathologist Signature
Glucose Comment: Capillary	154 (H)	60 - 139 mg/dL	08/21/2023 BEAUMONT 5:53 AM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Performed By	Floyd, Jesse NA			08/21/2023 5:53 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loc Laterality	ation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/21/202	3 5:46 AM EDT	08/21/2023 5:53 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/c	1L	A #: 23D0363256) - (08/21/2023	5:53 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCKE	D DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	
GLUCOSE, POINT OF CA	RE (GLUCOSE, Value	POC) - Fi Ref Range	nal result (08/20/2023 Test Method	11:29 PM EI Analysis Time		Pathologist Signature
Glucose	139	60 - 139 mg/dL		08/20/2023 11:35 PM EDT		
Comment: Capillary						
Performed By	Floyd, Jesse NA			08/20/2023 11:35 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
		,				
Specimen (Source)	Anatomical Loc Laterality	ation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur				3 11:29 PM	08/20/2023 11:35 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/c	1L	A #: 23D0363256) - (08/20/2023	11:35 PM EDT	
Authorizing Provider	Result Type					
William Rudy	21	ST DOCKE	D DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	

GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/20/2023 7:27 PM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	129	60 - 139 mg/dL		08/20/2023 7:34 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Floyd, Jesse			08/20/2023	BEAUMONT	
Tenomica by	NĂ			7:34 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Metho Volume	d / Collection	Time	Received Time
Blood	WHOLE BLOOI SPECIMEN / U			08/20/202	23 7:27 PM EDT	08/20/2023 7:34 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256	5) - 08/20/2023	7:34 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKI	D DEVICE UNSOLI	CITED RESULTS		
Performing Organization	Address		City/State/ZIP Co	de Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, 48336	MI 800-551-0)488	
GLUCOSE, POINT OF CA	RE (GLUCOSE,				T)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	120	60 - 139 mg/dL			BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Johnson, Rachel NA			08/20/2023 4:23 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimon (Source)	Anatomical Lo	cation /	Collection Metho Volume	d / Collection	Time	Passived Time
Specimen (Source) Blood	Laterality WHOLE BLOOI	ר	VUITILE			Received Time 08/20/2023 4:23 PM EDT
BIOOU	SPECIMEN / U			00/20/202		00/20/2023 4.23 FWI EDI
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256	5) - 08/20/2023	4:23 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKE	D DEVICE UNSOLI	CITED RESULTS		

Performing Organization	Address	City/State/ZIP Code	Phone Number
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, Ml 48336	800-551-0488

(ABNORMAL) CBC W/AUTO DIFF - Final result (08/20/2023 2:17 PM EDT)

(ADNORWAL) CDC W		Ref	-	Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
WBC	9.8	3.5 - 10.1 bil/L		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RBC	4.70	4.31 - 5.48 tril/ L		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	13.8	13.5 - 17.0 g/ dL		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hematocrit	43.7	40.1 - 50.1 %		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
MCV	93	80 - 100 fL		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСН	29	28 - 33 pg		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСНС	32	32 - 36 g/dL		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RDW-CV	16 (H)	12 - 15 %		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Platelets	216	150 - 400 bil/L		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Nucleated Red Blood Cells	0.0	<=0.0 %		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Neutrophils	6.3	1.6 - 7.2 bil/L		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Lymphocytes	1.6	1.1 - 4.0 bil/L		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Monocytes	1.5 (H)	0.0 - 0.9 bil/L		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Eosinophils	0.3	0.0 - 0.4 bil/L		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.1	0.0 - 0.1 bil/L		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.03	0.00 - 0.04 bil/L		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %	0.3	%		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
					2500505250)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection		Received Time
Specimen (Source) Blood)D	Volume		Time	Received Time 08/20/2023 2:51 PM EDT
	Laterality VENOUS BLOC)D	Volume		Time	
Blood	Laterality VENOUS BLOC)D	Volume		Time	
Blood Narrative Authorizing Provider	Laterality VENOUS BLOC SPECIMEN / Un Result Type)D nknown	Volume Venipuncture / Unknow		Time	
Blood	Laterality VENOUS BLOC SPECIMEN / U)D nknown	Volume Venipuncture / Unknow		Time	
Blood Narrative Authorizing Provider	Laterality VENOUS BLOC SPECIMEN / Un Result Type BH LAB BLOOD)D nknown	Volume Venipuncture / Unknow		Time 3 2:17 PM EDT	
Blood Narrative Authorizing Provider Emily G	Laterality VENOUS BLOC SPECIMEN / Un Result Type BH LAB BLOOD)D nknown D ORDERAE	Volume Venipuncture / Unknov	vn 08/20/202	Time 3 2:17 PM EDT	
Blood Narrative Authorizing Provider Emily G Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS	Laterality VENOUS BLOC SPECIMEN / Un Result Type BH LAB BLOOD Address 28050 Grand R	DD nknown D ORDERAE River Ave	Volume Venipuncture / Unknow BLES City/State/ZIP Code Farmington Hills, MI 48336	vn 08/20/202 Phone Nu 800-551-0	Time 3 2:17 PM EDT	
Blood Narrative Authorizing Provider Emily G Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Laterality VENOUS BLOC SPECIMEN / Un Result Type BH LAB BLOOD Address 28050 Grand R	D D D ORDERAE	Volume Venipuncture / Unknow BLES City/State/ZIP Code Farmington Hills, MI 48336	vn 08/20/202 Phone Nu	Time 3 2:17 PM EDT mber 488	
Blood Narrative Authorizing Provider Emily G Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) MAGNESIUM LEVEL - Fin	Laterality VENOUS BLOC SPECIMEN / Un Result Type BH LAB BLOOD Address 28050 Grand R nal result (08/2	DD nknown D ORDERAE River Ave 20/2023 2: Ref	Volume Venipuncture / Unknow BLES <u>City/State/ZIP Code</u> Farmington Hills, MI 48336	vn 08/20/202 Phone Nu 800-551-0 Analysis	Time 3 2:17 PM EDT mber 488	08/20/2023 2:51 PM EDT
Blood Narrative Authorizing Provider Emily G Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) MAGNESIUM LEVEL - Fin Component Magnesium	Laterality VENOUS BLOC SPECIMEN / Un Result Type BH LAB BLOOD Address 28050 Grand R nal result (08/2 Value 2.0	D D nknown D ORDERAE River Ave River Ave 20/2023 2: Ref Range 1.7 - 2.5 mg/dL	Volume Venipuncture / Unknow BLES City/State/ZIP Code Farmington Hills, MI 48336 17 PM EDT) Test Method Collection Method /	vn 08/20/202 Phone Nu 800-551-0 Analysis Time 08/20/2023 3:22 PM EDT	Time 3 2:17 PM EDT mber 488 Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	08/20/2023 2:51 PM EDT
Blood Narrative Authorizing Provider Emily G Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) MAGNESIUM LEVEL - Fin Component	Laterality VENOUS BLOC SPECIMEN / Un Result Type BH LAB BLOOD Address 28050 Grand R nal result (08/2 Value 2.0	DD nknown D ORDERAE River Ave 20/2023 2: Ref Range 1.7 - 2.5 mg/dL cation /	Volume Venipuncture / Unknow BLES City/State/ZIP Code Farmington Hills, MI 48336 17 PM EDT) Test Method Collection Method / Volume	vn 08/20/202 Phone Nu 800-551-0 Analysis Time 08/20/2023 3:22 PM EDT Collection	Time 3 2:17 PM EDT mber 488 Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Time	08/20/2023 2:51 PM EDT

Narrative

Result Type		
BH LAB BLOOD ORDERAE	BLES	
Address	City/State/ZIP Code	Phone Number
28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0488
	BH LAB BLOOD ORDERAE	BH LAB BLOOD ORDERABLES Address City/State/ZIP Code 28050 Grand River Ave Farmington Hills, MI

(ABNORMAL) COMPREHENSIVE METABOLIC PANEL (CMP) - Final result (08/20/2023 2:17 PM EDT)

(Ref		Analysis		
Component Sodium	Value 139	Range 135 -	Test Method	Time 08/20/2023	BEAUMONT	athologist Signature
South	135	145		3:22 PM	LABORATORY,	
		mmol/L		EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Potassium	3.6	3.5 - 5.2		08/20/2023	BEAUMONT	
		mmol/L		3:22 PM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #:	
Chloride	104	00 111		00/20/2022	23D0363256)	
Chioride	104	98 - 111 mmol/L		08/20/2023 3:22 PM	BEAUMONT LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	25	20 - 29		08/20/2023	BEAUMONT	
		mmol/L		3:22 PM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #:	
Anion Gap	10	5 - 17		08/20/2023	23D0363256) BEAUMONT	
	10	5 - 17		3:22 PM	LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	
Glucose	135 (H)	60 - 99		08/20/2023	BEAUMONT	
		mg/dL		3:22 PM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #:	
Comment:					23D0363256)	
Fasting Blood Glucos Random Blood Glucose						
Blood Urea Nitrogen	13	7 - 25			BEAUMONT	
-BUN		mg/dL		3:22 PM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #:	
Creatinine	0.60	0.60 -		08/20/2023	23D0363256) BEAUMONT	
creatinine	0.00	1.30 mg/		3:22 PM	LABORATORY,	
		dL		EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	
eGFR By Creatinine	109	>60 mL/		08/20/2023	BEAUMONT	
		min/ 1.73m2		3:22 PM EDT	laboratory, Farmington	
					HILLS (CLIA #:	
					23D0363256)	

Component	Value	Ref	Tast Mathad	Analysis Time	Derfermed At	Dath alogist Cignature
Component Comment:		Range	Test Method			Pathologist Signature
Calculation based on without adjustment f gender using the CKD	or race. Glom	erular Fi				
G3a: Mildly to m G3b: Moderately G4: Severely de	eased GFR: 60 oderately dec	reased G ecreased				
Calcium	8.3 (L)	8.5 - 10.5 mg/dL		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Protein Total	6.3	6.2 - 8.1 g/dL		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Albumin	2.6 (L)	3.5 - 4.9 g/dL		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Globulin	3.7	2.2 - 3.7 g/dL		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Albumin/Globulin Ratio	0.7			08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Alkaline Phosphatase	133 (H)	33 - 120 U/L		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Aspartate Aminotransferase -AST	24	<35 U/L		08/20/2023 3:22 PM EDT		
Alanine Aminotransferase -ALT	19	9 - 47 U/ L		08/20/2023 3:22 PM EDT		
Bilirubin Total	0.3	0.3 - 1.2 mg/dL		08/20/2023 3:22 PM EDT	-	
Specimon (Source)	Anatomical Lo	cation /	Collection Method / Volume	Collection	Time	Received Time
Specimen (Source) Blood	Laterality VENOUS BLOO SPECIMEN / U					08/20/2023 2:51 PM EE
Narrative						

Authorizing Provider	Result Type							
Emily G	21	BH LAB BLOOD ORDERABLES						
Performing Organization				Dhono Nu	mhor			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		City/State/ZIP Code Farmington Hills, MI 48336	Phone Number 800-551-0488				
(ABNORMAL) GLUCOS	E, POINT OF		UCOSE, POC) - Final		0/2023 10:54	AM EDT)		
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature		
Glucose	143 (H)	60 - 139 mg/dL		08/20/2023 11:01 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Comment: Capillary	lahasaa			00/20/2022				
Performed By	Johnson, Rachel NA			08/20/2023 11:01 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
	Anatomical Lo	cation /	Collection Method /					
Specimen (Source) Blood	Laterality WHOLE BLOOD		Volume	Collection		Received Time		
вюоа	SPECIMEN / U			68/20/202 EDT	3 10:54 AM	08/20/2023 11:01 AM EDT		
Narrative								
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	08/20/2023	11:01 AM EDT			
Authorizing Provider	Result Type							
William Rudy	21	EST DOCKI	ED DEVICE UNSOLICITE	D RESULTS				
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0	488			
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi Ref	nal result (08/20/202	3 5:55 AM ED Analysis	T)			
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature		
Glucose	137	60 - 139 mg/dL			BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Comment: Capillary				00/20/2022				
Performed By	Floyd, Jesse NA			08/20/2023 6:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
	Anatomical Lo	cation /	Collection Method /					
Specimen (Source)	Laterality		Volume	Collection		Received Time		
Blood	WHOLE BLOOD SPECIMEN / UI			08/20/202	3 5:55 AM EDT	08/20/2023 6:02 AM EDT		

Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose			A #: 23D0363256) -	08/20/2023	6:02 AM EDT	
Random Blood Glucose						
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCKE	ED DEVICE UNSOLICITED	RESULIS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT	28050 Grand R	iver Ave	Farmington Hills, MI	800-551-0	488	
			48336			
FARMINGTON HILLS (CLIA #: 23D0363256)						
(CEI/(#: 2500505250)						
GLUCOSE, POINT OF CA	RE (GLUCOSE,		nal result (08/19/2023		Τ)	
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	123	60 - 139	lest method	08/19/2023		
		mg/dL		7:50 PM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Comment: Capillary					2320303230)	
Performed By	Floyd, Jesse			08/19/2023	BEAUMONT	
· ·	NA			7:50 PM	LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	
					,	
	Anatomical Loo	cation /	Collection Method /	C all a sti a s	T :	Dessional Times
Specimen (Source) Blood		<u> </u>	Volume	Collection		Received Time
вюоа	WHOLE BLOOD SPECIMEN / Ur			08/19/202	.3 7:42 PIVI EDT	08/19/2023 7:50 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose	FARMINGTON H ≥: 60-99 mg/0	CLLS (CLI	:A #: 23D0363256) - (08/19/2023	7:50 PM EDT	
Random Blood Glucose						
Authorizing Drevider	De eult Ture e					
Authorizing Provider William Rudy	Result Type					
william Rudy	BIT LAD I OC II	JI DOCK	DEVICE ONSOLICITED	/ RESOLIS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT	28050 Grand R	iver Ave	Farmington Hills, MI	800-551-0	488	
LABORATORY, FARMINGTON HILLS			48336			
(CLIA #: 23D0363256)						
(0)						
		:			_	
GLUCOSE, POINT OF CA	RE (GLUCOSE,		nal result (08/19/2023		T)	
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	125	60 - 139	lest method		BEAUMONT	
Glacose	125	mg/dL		5:01 PM	LABORATORY,	
		0		EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Comment: Capillary					(220000200)	
Performed By	Jenkins,			08/19/2023	BEAUMONT	
	Diamond NA			5:01 PM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
					2320303230)	

	Anatomical Loc	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Unknown			08/19/202	3 4:54 PM EDT	08/19/2023 5:01 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/o	ΊL	A #: 23D0363256) - (08/19/2023	5:01 PM EDT	
Authorizing Provider	Result Type					
William Rudy	21	ST DOCKE	D DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mher	
BEAUMONT	28050 Grand R	iver Ave	Farmington Hills, MI	800-551-0		
LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			48336			
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi Ref	nal result (08/19/2023	11:34 AM E Analysis	DT)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	134	60 - 139 mg/dL		08/19/2023 11:41 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Johnson, Rachel NA			08/19/2023 11:41 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
					,	
Specimen (Source)	Anatomical Loc Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur				3 11:34 AM	08/19/2023 11:41 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/o	jr .	A #: 23D0363256) - (08/19/2023	11:41 AM EDT	
Authorizing Provider	Result Type					
William Rudy	21	ST DOCKE	D DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	
GLUCOSE, POINT OF CA	RE (GLUCOSE,		nal result (08/19/2023		T)	
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	120	60 - 139 mg/dL			BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						

Component Value Bange Test Method Time Performed AP Participation Performed By Greenbay, Alexis NA OR 19/2023 BEALMONT FARMINGTON HILLS (CLI A #: 230363256) Specimen (Source) Laterality Volume Collection Method / Volume Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/19/2023 5:58 AM EDT 08/19/2023 6:04 AM EDT Fasting 510:06 (Licose: 60-95 mg/dL Anatomical Location / Pasting 510:06 (Licose: 60-95 mg/dL Am EDT Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/19/2023 6:04 AM EDT Received Time Marative Eexampt Collection Method / Volume Collection Method / Pasting 510:06 (Licose: 60-95 mg/dL Authorizing Provider Result Type Farmington Hills, MI B00-551-0488 EDT Performing Organization Address City/State/ZIP Code Phone Number Bradingtion Provider Reset Farmington Hills, MI B00-551-0488 GULCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) Analogis Component Value Range </th <th>Component</th> <th>Value</th> <th>Ref Range</th> <th>Test Method</th> <th>Analysis Time</th> <th>Dorformed At</th> <th>Pathologist Signature</th>	Component	Value	Ref Range	Test Method	Analysis Time	Dorformed At	Pathologist Signature
EDT FARMINIGTON HLLS (CLU & #: 23D0363256) Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/19/2023 5:58 AM EDT 08/19/2023 6:04 AM EDT Narrative Beautwort Leboratory, Famitheron MitLLS (ELLA #: 2300363256) - 06/19/2023 6:04 AM EDT Family Batamon Elo do Clucose: 60-39 mg/dL Family Family William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Family BetAuthorizing Provider Result Type Family (In Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS BetAuthorizing Provider Result Type Family (In Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS BetAuthORT 28050 Grand River Ave Family (In Rudy Family (In Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) Analysis Component Value Range Test Method Time Glucose 139 60 - 139 Go/14/2023 Glucose 139 60 - 139 Analysis Ferformed By Greenbay, Anatomical Location / Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/18/2023 8:29 PM EDT			Kange	lest Method			
Anatomical Location / Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD 08/19/2023 5:58 AM EDT 08/19/2023 6:04 AM EDT SPECIMEN / Unknown Narathive Becompart LABORATORY, FAMILTORY MULLES (CLLA #: 2300363256) - 08/19/2023 6:04 AM EDT SPECIMEN / Unknown Narathive Becompart LABORATORY FAMILTORY MULLES (CLLA #: 2300363256) - 08/19/2023 6:04 AM EDT Random Blood Glucose: 60-139 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) Ref TestMink GTON HILLS (CLLA #: 2300363256) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) Ref TestMink GTON HILLS (CLLA #: 2300363256) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) Ref TestMink GTON HILLS (CLLA #: 2300363256) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) Ref TestMink GTON HILLS (CLLA #: 2300363256) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) Ref TestMink GTON HILLS (CLLA #: 2300363256) GLUCOSE 139 60 - 139 Rg/dL 8:50 PM LABORATORY, EDT FARMINGTON HILLS (CLLA #: 2300363256) SPECIMEN / Unknown Narathive Blood WHOLE BLOOD SPECIMEN / Unknown Narathive Blood WHOLE BLOOD SPECIMEN / Unknown Narathive Blood SPECIMEN / U	,						
Anatomical Location / Specimen (Source) Anatomical Location / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/19/2023 5:58 AM EDT 08/19/2023 6:04 AM EDT Narrative Beamowr LaBook TORY, FAMINGTON HILLS (CLTA #: 2300363256) - 08/19/2023 6:04 AM EDT FARENDAME Authorizing Provider Result Type FARENDAME TO SUPPORT (State 2000) FARENDAME TO SUPPORT (State 2000) William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, (CLLA #: 23D0363256) Farmington Hills, MI 800-551-0488 Farmington Hills, Ref Analysis GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) Ref Farmington Hills, Maryal Farmington Hills, Ref Analysis Component Value Range Biso PM LABORATORY, FARMINGTON HILLS (CLLA #: 23D0363256) Performed At Pathologist Signature Glucose 139 60-138 08/18/2023 BEAUMONT ADROMATORY, EDT Received Time 2000363256) Specimen (Source) Anatomical Location / SPECIMEN / Unknown Collection Method / Volume Collection Time Received Time					EDI		
Specimen (Source) Laterality Volume Collection Time Received Time Blood WH02 BLOO 08/19/2023 5:58 AM EDT 08/19/2023 6:04 AM EDT Namative 08/19/2023 5:58 AM EDT 08/19/2023 6:04 AM EDT Readow Time 08/19/2023 5:58 AM EDT 08/19/2023 6:04 AM EDT Readow Time 08/19/2023 5:58 AM EDT 08/19/2023 6:04 AM EDT Readow Time 60-99 mg/dt. Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT A8035 48336 GluCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) Analysis Analysis Component Value Rafe Time Performed At Pathologist Signature Glucose 139 60 - 139 08/18/2023 BEAUMONT 48076070, FARMINGTON, HILLS (CLLA #: 2300363256) Specimen (Source) Anatomical Location / Volume Collection Time Received Time Blood WH02 BLOOD 08/18/2023 8:42 PM EDT Anatomical Location / Volume		Americally		Callestian Mathead /		23D0363256)	
Narrative SPECIMEN / Unknown Narrative SPECIMEN / Unknown Narrative SPECIMEN / Unknown Narrative SPECIMEN / Unknown SPECIMEN /	Specimen (Source)		cation /		Collection	Time	Received Time
Narretive EEAUMONT LABORATORY, FARWINGTON HILLS (CLLA #: 2300363256) - 08/19/2023 6:04 AM EDT Fastring Blood Glucose: 60-99 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number EEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 FARMINGTON HILLS (CLLA #: 23D0363256) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) Ref Component Value Range Test Method Time Performed At Pathologist Signature Glucose 139 Greenbay, Alexis NA	Blood				08/19/202	23 5:58 AM EDT	08/19/2023 6:04 AM EDT
BEALMONT LABORATORY, FARMINGTON HTLLS (CLLA #: 23D0363256) - 08/19/2023 6:04 AM EDT Fasting Blood Glucose: 60-39 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, Farmington Hills, MI 800-551-0488 LABORATORY Farmington Hills, MI 800-551-0488 CULOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) Analysis Component Value Range Test Method Time Performed By Greenbay, 60 - 139 08/18/2023 BEAUMONT Stop ML LABORATORY, EDT Farmington HILLS (CLLA #: 23D0363256) Performed By Greenbay, 04/18/2023 BEAUMONT BEAUMONT Stop ML LABORATORY, EDT FarMINGTON HILLS (CLLA #: 23D0363256) Performed By Greenbay, Alexis NA 04/18/2023 BEAUMONT BEAUMONT Blood WHAUE BLOOD O8/18/2023		SPECIMEN / U	nknown				
Fasting Blood Glucose: 60-139 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave FARMINGTON HILLS 28050 Grand River Ave GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) Component Value Ref Analygis Component Value Ref Time Glucose 139 60 - 139 08/18/2023 mg/dL 850 PM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 2300363256) Performed By Greenbay, Alexis NA 08/18/2023 Specimen (Source) Anatomical Location / Velue Collection Method / Volume Collection Time Rereived Time Beautonon 08/18/2023 8:42 PM EDT Faramington Hills, Rid Blood WHOLE BLOOD 08/18/2023 8:42 PM EDT 08/18/2023 8:50 PM EDT Specimen (Source) Laterality Volume Collection Time Received Time Blood WHOLE BLOOD <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 ABORATORY, FARMINGTON HILLS Rafe Analysis CLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) Ref Analysis Component Value Range Test Method Time Glucose 139 60 - 139 08/18/2023 BEAUMONT BS0 PM LABORATORY, mg/dL 850 PM LABORATORY, 23D0363256) Performed By Greenbay, Alexis NA 08/18/2023 BEAUMONT 23D0363256) Specimen (Source) Anatomical Location / Collection Method / 23D0363256) 23D0363256) Specimen (Source) Anatomical Location / Collection Method / 23D0363256) - 08/18/2023 8:50 PM EDT So PM EDT Narrative BEAUMONT LABORATORY, FAMINGTON HILLS (CLLA #: 23D0363256) - 08/18/2023 8:50 PM EDT So PM EDT Random Blood Glucose: 60-99 mg/dL #23D0363256) - 08/18/2023 8:50 PM EDT Fasting Blood Glucose: 60-99 mg/dL	Fasting Blood Glucose	e: 60-99 mg/	d∟	[A #: 23D0363256) -	08/19/2023	6:04 AM EDT	
Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 48336 ARAMINGTON HILLS CILIA #: 23D0363256) 800-551-0488 GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 842 PM EDT) Analysis Component Value Rafg Test Method Glucose 139 60 - 139 08/18/2023 BEAUMONT Glucose 139 60 - 139 08/18/2023 BEAUMONT Microse 139 60 - 139 08/18/2023 BEAUMONT Beaumont LaBORATORY, EDT FarMINGTON, Performed By Greenbay, Alexis NA 8:50 PM LBORATORY, EDT FarMINGTON HILLS (CILA #: 23D0363256) EAUMONT LBORATORY, Specimen (Source) Anatomical Location / Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SpecIMEN / Unknown 08/18/2023 8:50 PM EDT Sea PM EDT 08/18/2023 8:50 PM EDT Narrative BEAUMONT LABORATORY, FARMINGTON HILLS (CILA #: 23D0363256) - 08/18/2023 8:50 PM EDT Sea PM EDT 08/18/2023 8:50 PM EDT <td>Authorizing Provider</td> <td>Result Type</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Authorizing Provider	Result Type					
BEAUMONT 28050 Grand River Ave LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Farmington Hills, MI 48336 800-551-0488 GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) (CLIA #: 23D0363256) Ref Analysis Analysis GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) Ref Analysis Performed At Pathologist Signature Glucose 139 60 - 139 08/18/2023 B4MUNONT HILLS (CLIA #: 23D0363256) Performed By Greenbay, Alexis NA 8:50 PM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/18/2023 8:50 PM EDT 08/18/2023 8:50 PM EDT Narrative BeauMONT LABORATORY, FarkTing Elood Glucose: 60-139 mg/dL 08/18/2023 8:50 PM EDT 08/18/2023 8:50 PM EDT Performing Organization Address City/State/ZIP Code Phone Number E BeAUMONT 28050 Grand River Ave Farmington Hills, MI LABORATORY, FARMINGTON HILLS Farmington Hills, MI 48336 800-551-0488	William Rudy	BH LAB POC T	EST DOCKI	ED DEVICE UNSOLICITE	O RESULTS		
BEAUMONT 28050 Grand River Ave LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Farmington Hills, MI 48336 800-551-0488 GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) (CLIA #: 23D0363256) Ref Analysis Analysis GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) Ref Analysis Performed At Pathologist Signature Glucose 139 60 - 139 08/18/2023 B4MUNONT HILLS (CLIA #: 23D0363256) Performed By Greenbay, Alexis NA 8:50 PM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/18/2023 8:50 PM EDT 08/18/2023 8:50 PM EDT Narrative BeauMONT LABORATORY, FarkTing Elood Glucose: 60-139 mg/dL 08/18/2023 8:50 PM EDT 08/18/2023 8:50 PM EDT Performing Organization Address City/State/ZIP Code Phone Number E BeAUMONT 28050 Grand River Ave Farmington Hills, MI LABORATORY, FARMINGTON HILLS Farmington Hills, MI 48336 800-551-0488	Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
FARMINGTON HILLS (CLIA #: 23D0363256) Fef Analysis Component Value Range Test Method Time Performed At Pathologist Signature 08/18/2023 BEAUMONT ABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) Performed By Greenbay, Alexis NA Specimen (Source) Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMENT / Unknown Narrative BEAMMONT LABORATORY, FARMINGTON HILLS CLIA #: 23D0363256) - 08/18/2023 8:50 PM EDT PARMINGTON HILLS CLIA #: 23D0363256) - 08/18/2023 8:50 PM EDT PARMINGTON HILLS CLIA #: 23D0363256) - 08/18/2023 BEAMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/18/2023	BEAUMONT		liver Ave	Farmington Hills, MI	800-551-0)488	
GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 8:42 PM EDT) Ref Analysis Performed At Pathologist Signature Glucose 139 60 - 139 08/18/2023 BEAUMONT Biso PM LABORATORY, EDT EADUMONT 8:50 PM LABORATORY, EDT FARMINGTON, HILLS (CLIA #: 23D0363256) Performed By Greenbay, Alexis NA 08/18/2023 BEAUMONT #S:50 PM LABORATORY, EDT EADUATORY, FARMINGTON, HILLS (CLIA #: 23D0363256) Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOE BLOOD SPECIMEN / Unknown 08/18/2023 8:42 PM EDT 08/18/2023 8:50 PM EDT Farming To 08/18/2023 8:50 PM EDT Narrative Beavemore to 0-139 mg/dL Collection Device UNSOLICITED RESULTS EADUAGATORY, Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave LABORATORY, EADUAGATORY, Section HILLS Farmington Hills, MI 48336 800-551-0488 A00-551-0488				48336			
ComponentValueRef RangeAnalysis Test MethodPerformed At TimePathologist SignatureGlucose13960 - 139 mg/dL08/18/2023BEAUMONT ABORATORY, EDTABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)Performed ByGreenbay, Alexis NAGreenbay, Alexis NA08/18/2023BEAUMONT HILLS (CLIA #: 23D0363256)Specimen (Source)Anatomical Location / LateralityCollection Method / VolumeCollection Time Collection TimeReceived TimeBloodWHOLE BLOOD SPECIMEN / Unknown08/18/20238:50 PM EDTBEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256)08/18/20238:50 PM EDTNarrativeBEAUMONT LABORATORY, FASTINg Blood Glucose:60-139 mg/dL08/18/20238:50 PM EDTPerforming OrganizationResult TypeVisite CLIA #: 48336230363256)08/18/20238:50 PM EDTPerforming OrganizationAddressCity/State/ZIP Code 48336Phone NumberEAUMONT 48336800-551-0488LABORATORY, FARMINGTON HILLSCLIA #: 4833623053250-0488300-551-0488	(CLIA #: 23D0363256)						
ComponentValueRef RangeAnalysis Test MethodPerformed At TimePathologist SignatureGlucose13960 - 139 mg/dL06/18/2023BEAUMONT ABORATORY, EDTABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)Performed ByGreenbay, Alexis NAGreenbay, Alexis NA08/18/2023BEAUMONT ABORATORY, EDTBABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)Specimen (Source)Anatomical Location / LateralityCollection Method / VolumeCollection Time Collection TimeReceived TimeBloodWHOLE BLOOD SPECIMEN / Unknown08/18/20238:50 PM EDTBABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)08/18/20238:50 PM EDTNarrativeBEAUMONT LABORATORY, SPECIMEN / UnknownCollection Method / Volume08/18/202308/18/20238:50 PM EDTNarrativeBEAUMONT LABORATORY, SPECIMEN / UnknownFARMINGTON HILLS(CLIA #: 23D0363256) - 08/18/20238:50 PM EDTFARMINGTON FARMINGTON HILLSAuthorizing ProviderResult TypeEUEUEUEUEUWilliam RudyBH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTSPerforming Organization 48336800-551-0488EUBEAUMONT LABORATORY, FARMINGTON HILLS28050 Grand River Ave 48336Farmington Hills, MI 48336800-551-0488							
Component Value Range Test Method Time Performed At Pathologist Signature Glucose 139 60 - 139 00/18/2023 BEAUMONT 8:50 PM LABORATORY, EDT FARMINGTON Performed By Greenbay, Alexis NA 08/18/2023 BEAUMONT 2300363256) Performed Ry Greenbay, Alexis NA 08/18/2023 BEAUMONT 2300363256) Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD 08/18/2023 8:42 PM EDT 08/18/2023 8:50 PM EDT Narrative BEAUMONT Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD 08/18/2023 8:42 PM EDT 08/18/2023 8:50 PM EDT Random Blood Glucose: 60-99 mg/dL #: 23D0363256) - 08/18/2023 8:50 PM EDT Farmington Hills William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS E E E Performing Organization Address City/State/ZIP Code Phone Number E BEAUMONT 28050 G	GLUCOSE, POINT OF CA	RE (GLUCOSE,		nal result (08/18/2023	3 8:42 PM ED	T)	
Glucose 139 60 - 139 mg/dL 08/18/2023 BEAUMONT Bisto PM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) 23D0363256) Performed By Greenbay, Alexis NA 08/18/2023 BEAUMONT Alexis NA 8:50 PM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) Specimen (Source) Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/18/2023 8:42 PM EDT 08/18/2023 8:50 PM EDT Narrative BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/18/2023 8:50 PM EDT Fasting Blood Glucose: 60-139 mg/dL Authorizing Provider Result Type Veloce DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave FARMINGTON HILLS Farmington Hills, MI 48336 800-551-0488 48336	Component	Value		Tast Mathad		Dorformod At	Pathologist Signaturo
EDT FARMINGTON HILLS (CLIA #: 23D0363256) Performed By Greenbay, Alexis NA 08/18/2023 BEAUMONT 8:50 PM LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/18/2023 8:42 PM EDT 08/18/2023 Narrative BEAUMONT LABORATORY, FARMINGTON HILLS (CLTA #: 23D0363256) - 08/18/2023 8:50 PM EDT FARMINGTON HILLS Authorizing Provider Result Type Volume Volume Volume William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Volume Volume BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 48336 CILLA #: 23D0363256) Vertica # Farmington Hills, MI 800-551-0488 Vertica # Farmington Hills, MI			0	lest Method			
Performed By Greenbay, Alexis NA 08/18/2023 8:50 PM EDT BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood MHOLE BLOOD SPECIMEN / Unknown 08/18/2023 Volume 08/18/2023 Volume 08/18/2023 Volume 08/18/2023 Volume 08/18/2023 Volume BEAUMONT LABORATORY, Fasting Blood Glucose: 60-139 mg/dL Random Blood Glucose: 60-139 mg/dL Volume Volume Volume Volume Authorizing Provider Result Type Viliam Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Volume Volume Performing Organization Address City/State/ZIP Code Phone Number Volume BEAUMONT LABORATORY, FARMINGTON HILLS 28050 Grand River Ave City/State/ZIP Code Phone Number Viliam Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Volume Volume Volume Viliam Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Volume Volume Volume LABORATORY, FARMINGTON HILLS City/State/ZIP Code Phone Number Volume Volume			mg/dL				
Performed By Greenbay, Alexis NA 08/18/2023 BEAUMONT 8:50 PM EDT LABORATORY, FARMINGTON, HILLS (CLIA #: 23D0363256) Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/18/2023 8:42 PM EDT 08/18/2023 8:50 PM EDT Narrative BEAUMONT LABORATORY, Fasting Blood Glucose: 60-99 mg/dL 60-99 mg/dL ************************************					EDI		
Alexis NÁ 8:50 PM LABORATORY, EDT FARMINGTON, HILLS (CLIA #: 23D0363256) Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/18/2023 8:42 PM EDT 08/18/2023 8:50 PM EDT Narrative SPECIMEN / Unknown 08/18/2023 8:50 PM EDT 08/18/2023 8:50 PM EDT Narrative Fasting Blood Glucose: 60-99 mg/dL 60-139 mg/dL Authorizing Provider Result Type VICLE UNSOLICITED RESULTS Villiam Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave 48336 800-551-0488 LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) VICLA #: 23D0363256) VICLA #: 23D0363256)						,	
EDT FARMINGTON HILLS (CLIA #: 23D0363256) Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/18/2023 8:42 PM EDT 08/18/2023 8:50 PM EDT Narrative Specimen (Source): 60-99 mg/dL 08/18/2023 8:50 PM EDT Fasting Blood Glucose: 60-139 mg/dL - - Authorizing Provider Result Type - - William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS - - Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) 28050 Grand River Ave 48336 800-551-0488 -	Performed By						
Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/18/2023 8:42 PM EDT 08/18/2023 8:50 PM EDT Narrative BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/18/2023 8:50 PM EDT Second Pm EDT BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/18/2023 8:50 PM EDT Fasting Blood Glucose: 60-99 mg/dL Authorizing Provider Result Type Fasting Det Granization Address William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Farmington Hills, MI 800-551-0488 LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Farmington Hills, MI 800-551-0488 Farmington Hills, MI						FARMINGTON	
Anatomical Location / Specimen (Source)Anatomical Location / LateralityCollection Method / VolumeCollection TimeReceived TimeBloodWHOLE BLOOD SPECIMEN / Unknown08/18/2023 8:42 PM EDT08/18/2023 8:42 PM EDT08/18/2023 8:50 PM EDTNarrativeBEAUMONT LABORATORY, FARMINGTON HILLS (CLTA #: 23D0363256) - 08/18/2023 8:50 PM EDT Fasting Blood Glucose:60-99 mg/dLEAuthorizing ProviderResult TypeWilliam RudyBH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTSPerforming OrganizationAddressCity/State/ZIP CodePhone NumberBEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)28050 Grand River Ave 48336800-551-0488LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)EXAMPLEEXAMPLE						•	
Specimen (Source)LateralityVolumeCollection TimeReceived TimeBloodWHOLE BLOOD SPECIMEN / Unknown08/18/2023 8:42 PM EDT08/18/2023 8:50 PM EDTNarrativeBEAUMONT LABORATORY, FASTIng Blood Glucose:60-99 mg/dL 60-139 mg/dL*********************************						,	
Blood WHOLE BLOOD SPECIMEN / Unknown 08/18/2023 8:42 PM EDT 08/18/2023 8:50 PM EDT Narrative BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/18/2023 8:50 PM EDT Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL 60-139 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, 48336 FARMINGTON HILLS (CLIA #: 23D0363256)	Specimen (Source)		cation /		Collection	Time	Received Time
Narrative BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/18/2023 8:50 PM EDT Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, 48336 48336 FARMINGTON HILLS (CLIA #: 23D0363256) 48336		WHOLE BLOOD			08/18/202	23 8:42 PM EDT	
BEAUMONT LABORATORY, Fasting Blood Glucose:FARMINGTON HILLS (CLIA #: 23D0363256) - 08/18/2023 8:50 PM EDTFasting Blood Glucose:60-99 mg/dLAuthorizing ProviderResult TypeWilliam RudyBH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTSPerforming OrganizationAddressCity/State/ZIP CodePhone NumberBEAUMONT28050 Grand River Ave 48336FARMINGTON HILLS (CLIA #: 23D0363256)Farmington Hills, MI 48336		SPECIMEN / U	nknown				
Fasting Blood Glucose:60-99 mg/dLRandom Blood Glucose:60-139 mg/dLAuthorizing ProviderResult TypeWilliam RudyBH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTSPerforming OrganizationAddressCity/State/ZIP CodePhone NumberBEAUMONT28050 Grand River Ave 48336FARMINGTON HILLS (CLIA #: 23D0363256)Farmington Hills, MI 48336							
Random Blood Glucose:60-139 mg/dLAuthorizing ProviderResult TypeWilliam RudyBH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTSPerforming OrganizationAddressCity/State/ZIP CodePhone NumberBEAUMONT28050 Grand River AveFarmington Hills, MI800-551-0488LABORATORY,4833648336FARMINGTON HILLS	Fasting Blood Glucose	e: 60-99 mg/	d∟	IA #: 23D0363256) -	08/18/2023	8:50 PM EDT	
William RudyBH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTSPerforming OrganizationAddressCity/State/ZIP CodePhone NumberBEAUMONT28050 Grand River AveFarmington Hills, MI800-551-0488LABORATORY,4833648336FARMINGTON HILLS(CLIA #: 23D0363256)	Random Blood Glucose:	: 60-139 mg					
Performing OrganizationAddressCity/State/ZIP CodePhone NumberBEAUMONT28050 Grand River Ave LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)Farmington Hills, MI 48336800-551-0488	Authorizing Provider	Result Type					
BEAUMONT28050 Grand River Ave Haboratory,Farmington Hills, MI 48336800-551-0488FARMINGTON HILLS (CLIA #: 23D0363256)	William Rudy	BH LAB POC T	EST DOCK	ED DEVICE UNSOLICITE	O RESULTS		
BEAUMONT28050 Grand River Ave Haboratory,Farmington Hills, MI 48336800-551-0488FARMINGTON HILLS (CLIA #: 23D0363256)	Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
FARMINGTON HILLS (CLIA #: 23D0363256)	BEAUMONT		liver Ave	Farmington Hills, MI	800-551-0)488	
(CLIA #: 23D0363256)				48336			
GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 3:45 PM EDT)							
GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 3:45 PM EDT)							
	GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi	nal result (08/18/2023	3 3:45 PM ED	T)	

		Ref		Analysis				
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature		
Glucose Comment: Capillary	126	60 - 139 mg/dL		08/18/2023 3:52 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Performed By	Smith, Noah			08/18/2023	BEAUMONT			
renormed by	NA A		Collection Mathematic	3:52 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time		
Blood	WHOLE BLOO SPECIMEN / U			08/18/202	23 3:45 PM EDT	08/18/2023 3:52 PM EDT		
Narrative								
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	08/18/2023	3:52 PM EDT			
Authorizing Provider	Result Type							
William Rudy	BH LAB POC T	3H LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS						
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0	9488			
(ABNORMAL) GLUCOS	E, POINT OF		UCOSE, POC) - Final		8/2023 11:01	AM EDT)		
Component	Value	Ref Range	Test Method	Analysis Time	Porformed At	Pathologist Signature		
Glucose	153 (H)	60 - 139	lest Method	08/18/2023				
Comment: Capillary	135 (11)	mg/dL		11:08 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Performed By	Smith, Noah			08/18/2023	BEAUMONT			
	NA A			11:08 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time		
Blood	WHOLE BLOO	D			23 11:01 AM	08/18/2023 11:08 AM		
	SPECIMEN / U			EDT		EDT		
Narrative								
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	08/18/2023	11:08 AM EDT			
Authorizing Provider	Result Type							
William Rudy	BH LAB POC T	EST DOCK	D DEVICE UNSOLICITE	D RESULTS				

Performing Organization	Address		City/State/ZIP Code	Phone Number		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		Farmington Hills, MI 48336	800-551-0488		
(ABNORMAL) GLUCOS		ARE (GL Ref	UCOSE, POC) - Final	result (08/1 Analysis	8/2023 5:21 /	AM EDT)
Component	Value R	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary		50 - 139 ng/dL		08/18/2023 5:27 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Flagg, LaTora NA			08/18/2023 5:27 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Locat Laterality	tion /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Unk	nown		08/18/202	:3 5:21 AM EDT	08/18/2023 5:27 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/d∟	-	A #: 23D0363256) -	08/18/2023	5:27 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TES	T DOCKE	ED DEVICE UNSOLICITED) RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Rive	er Ave	Farmington Hills, MI 48336	800-551-0	1488	

(ABNORMAL) CBC W/AUTO DIFF - Final result (08/18/2023 4:03 AM EDT)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
WBC	8.8	3.5 - 10.1 bil/L		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RBC	4.49	4.31 - 5.48 tril/ L		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	13.1 (L)	13.5 - 17.0 g/ dL		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hematocrit	41.9	40.1 - 50.1 %		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Component	Value	Ref Range	Test Method	Analysis Time	Performed At Pathologist Signature
MCV	93	80 - 100 fL		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСН	29	28 - 33 pg		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСНС	31 (L)	32 - 36 g/dL		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RDW-CV	16 (H)	12 - 15 %		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Platelets	256	150 - 400 bil/L		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Nucleated Red Blood Cells	0.0	<=0.0 %		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Neutrophils	5.3	1.6 - 7.2 bil/L		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Lymphocytes	2.0	1.1 - 4.0 bil/L		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Monocytes	1.1 (H)	0.0 - 0.9 bil/L		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Eosinophils	0.3	0.0 - 0.4 bil/L		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Basophils	0.0	0.0 - 0.1 bil/L		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Immature Granulocytes	0.02	0.00 - 0.04 bil/L		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Immature Granulocyte %	0.2	%		08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection		Received Time
Blood	VENOUS BLOC SPECIMEN / U					08/18/2023 4:18 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOI	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) RENAL F	FUNCTION PA	NEL - Fin	al result (08/18/2023	3 4:03 AM E Analysis	DT)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Sodium	138	135 - 145 mmol/L		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Potassium	3.6	3.5 - 5.2 mmol/L			BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	105	98 - 111 mmol/L		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	26	20 - 29 mmol/L		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	7	5 - 17		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose	133 (H)	60 - 99 mg/dL		08/18/2023 4:47 AM EDT		
Comment: Fasting Blood Glucose Random Blood Glucose						
Blood Urea Nitrogen -BUN	13	7 - 25 mg/dL		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Creatinine	0.62	0.60 - 1.30 mg/ dL		08/18/2023 4:47 AM EDT		
eGFR By Creatinine	108	>60 mL/ min/ 1.73m2		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Comment:

Calculation based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation refit without adjustment for race. Glomerular Filtration Rate is estimated from serum creatinine, age and gender using the CKD-EPI equation:

G1: Normal GFR: >=90
G2: Mildly decreased GFR: 60-89
G3a: Mildly to moderately decreased GFR: 45-59
G3b: Moderately to severely decreased GFR: 30-44
G4: Severely decreased GFR: 15-29
G5: Kidney failure GFR: <15</pre>

Calcium	8.6	8.5 - 10.5 mg/dL		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Phosphorus	3.5	2.3 - 4.4 mg/dL		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Albumin	2.6 (L)	3.5 - 4.9 g/dL		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Timo	Received Time
	· · · · · · · · · · · · · · · · · · ·					
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknow	wn 08/18/202	23 4:03 AM EDT	08/18/2023 4:18 AM EDT
Narrative						
Authorizing Drovidor	Decult Tures					
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOI	J ORDERAI	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		Farmington Hills, MI 48336	800-551-0)488	
MAGNESIUM LEVEL - Final result (08/18/2023 4:03 AM EDT) Ref Analysis						
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Magnesium	1.9	1.7 - 2.5 mg/dL		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Specimen (Source)	Anatomical Lo Laterality	ocation /	Collection Method / Volume	Collection Time		Received Time
Blood	VENOUS BLOO SPECIMEN / U		Venipuncture / Unknow	n 08/18/202	23 4:03 AM EDT	08/18/2023 4:18 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOO	D ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) GLUCOS	E, POINT OF	CARE (GI Ref	UCOSE, POC) - Final r	r esult (08/1 Analysis	7/2023 9:32	PM EDT)
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	142 (H)	60 - 139 mg/dL		08/17/2023 9:39 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Flagg, LaTora NA			08/17/2023 9:39 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Amotomicalla	antine (Callestien Mathead (
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOO SPECIMEN / U					08/17/2023 9:39 PM EDT
Narrative BEAUMONT LABORATORY,			TA #• 2300363256) _ 0	8/17/2023	0.30 DM EDT	
Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	′d∟	IA #. 23003032307 - 0	10/ 17/ 2023	9. <i>39 PM</i> EDI	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCK	ED DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		Farmington Hills, MI 48336	800-551-0488		
(ABNORMAL) GLUCOS	E, POINT OF	CARE (GI	UCOSE, POC) - Final r	esult (08/1	7/2023 4:18	PM EDT)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	144 (H)	60 - 139 mg/dL		08/17/2023 4:25 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Performed By	Venkatesan, Kavitha NA			08/17/2023 4:25 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/17/202	3 4:18 PM EDT	08/17/2023 4:25 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/0	dL	A #: 23D0363256) -	08/17/2023	4:25 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	EST DOCKE	D DEVICE UNSOLICITED	O RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	
GLUCOSE, POINT OF CA	RE (GLUCOSE, Value	POC) - Fi Ref Range	nal result (08/17/2023 Test Method	3 11:19 AM E Analysis Time		Pathologist Signature
Glucose	127	60 - 139 mg/dL		08/17/2023 11:25 AM EDT		
Comment: Capillary	N/ 1 /			00/17/2022		
Performed By	Venkatesan, Kavitha NA			08/17/2023 11:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /			
Specimen (Source)	Laterality	-	Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/17/202 EDT	3 11:19 AM	08/17/2023 11:25 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/0	dL	A #: 23D0363256) -	08/17/2023	11:25 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKE	D DEVICE UNSOLICITED	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	

GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/17/2023 5:32 AM EDT)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature		
Glucose Comment: Capillary	114	60 - 139 mg/dL		08/17/2023 5:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Performed By	Flagg, LaTora NA			08/17/2023 5:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
_Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time		
Blood	WHOLE BLOO SPECIMEN / U			08/17/202	23 5:32 AM EDT	08/17/2023 5:40 AM EDT		
Narrative								
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	′d∟	A #: 23D0363256) -	08/17/2023	5:40 AM EDT			
Authorizing Provider	Result Type							
William Rudy	BH LAB POC T	3H LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS						
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		Farmington Hills, MI 48336	800-551-0)488			
(ABNORMAL) CBC W/	AUTO DIFF -	Final resu	lt (08/17/2023 3:10	AM EDT)				
		Ref		Analysis				
Component	Value	Range	Test Method	Time		Pathologist Signature		
WBC	9.7	3.5 - 10.1 bil/L		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
RBC	4.44	4.31 - 5.48 tril/ L		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Hemoglobin	13.0 (L)	13.5 - 17.0 g/ dL		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Hematocrit	41.8	40.1 - 50.1 %		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
MCV	94	80 - 100 fL		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			

Component		Ref		Analysis	Deutenneed At Dethele sist Cisuastum
Component MCH	Value 29	Range 28 - 33	Test Method	Time 08/17/2023	Performed At Pathologist Signature BEAUMONT
		pg		4:11 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСНС	31 (L)	32 - 36 g/dL		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RDW-CV	16 (H)	12 - 15 %		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Platelets	286	150 - 400 bil/L		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Nucleated Red Blood Cells	0.0	<=0.0 %		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Neutrophils	5.7	1.6 - 7.2 bil/L		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Lymphocytes	2.6	1.1 - 4.0 bil/L		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Monocytes	1.0 (H)	0.0 - 0.9 bil/L		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Eosinophils	0.3	0.0 - 0.4 bil/L		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Basophils	0.0	0.0 - 0.1 bil/L		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Immature Granulocytes	0.01	0.00 - 0.04 bil/L		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Immature Granulocyte %	0.1	%		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time	
Blood	VENOUS BLOOD SPECIMEN / Unknown		Venipuncture / Unknowr	ר 08/17/2023 3:10 AM ED		08/17/2023 4:06 AM EDT	
Narrative							
Authorizing Provider	Result Type						
Danielle S	BH LAB BLOOD	BH LAB BLOOD ORDERABLES					
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		Farmington Hills, Ml 48336	800-551-0488			
(ABNORMAL) RENAL F	UNCTION PA		• • •		DT)		
Component	Value	Ref Range		Analysis Time	Performed At	Pathologist Signature	
Sodium	140	135 - 145 mmol/L		08/17/2023 4:35 AM EDT			

		mmol/L	EDT	FARMINGTON HILLS (CLIA #: 23D0363256)			
Potassium	4.6	3.5 - 5.2 mmol/L	08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Chloride	104	98 - 111 mmol/L	08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Carbon Dioxide -CO2	28	20 - 29 mmol/L	08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Anion Gap	8	5 - 17	08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Glucose	126 (H)	60 - 99 mg/dL	08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Comment: Fasting Blood Glucos Random Blood Glucose	Fasting Blood Glucose: 60-99 mg/dL						
Blood Urea Nitrogen -BUN	16	7 - 25 mg/dL	08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Creatinine	0.65	0.60 - 1.30 mg/ dL	08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
eGFR By Creatinine	107	>60 mL/ min/ 1.73m2		08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
G3a: Mildly to mo G3b: Moderately	or race. Glom -EPI equation >=90 eased GFR: 60 oderately dec to severely d creased GFR:	erular Fi : -89 reased GF ecreased	ltration Rate is es			-
Calcium	8.4 (L)	8.5 - 10.5 mg/dL		08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Phosphorus	3.3	2.3 - 4.4 mg/dL		08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Albumin	2.6 (L)	3.5 - 4.9 g/dL		08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loc Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / UI		Venipuncture / Unknow	wn 08/17/202	23 3:10 AM EDT	08/17/2023 4:06 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOD	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	River Ave	Farmington Hills, MI 48336	800-551-0		
MAGNESIUM LEVEL - Fi	nal result (08/1		:10 AM EDT)			
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Magnesium	1.9	1.7 - 2.5 mg/dL		08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	VENOUS BLOC SPECIMEN / UI		Venipuncture / Unknow	wn 08/17/202	23 3:10 AM EDT	08/17/2023 4:06 AM EDT

Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOI	3H LAB BLOOD ORDERABLES				
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) GLUCOS	E, POINT OF	, POINT OF CARE (GLUCOSE, POC) - Final result (08/17/2023 12:08				
Campagant	Value	Ref	To at Matha al	Analysis	Deuteure ed At	Dathala sist Cisuatura
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose	142 (H)	60 - 139 mg/dL		08/17/2023 12:17 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Vedolich, Holly RN			08/17/2023 12:17 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Timo	Received Time
Blood	,		volume	08/17/2023 12:08 AM		08/17/2023 12:17 AM
Blood	WHOLE BLOOD SPECIMEN / Unknown			EDT	5 12.00 AIVI	EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	IA #: 23D0363256) -	08/17/2023	12:17 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKI	ED DEVICE UNSOLICITED	O RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose Comment: Capillary	117	60 - 139 mg/dL		08/16/2023 8:54 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Flagg, LaTora			08/16/2023	BEAUMONT	
	NA			8:54 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Narrative

	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOI SPECIMEN / U			08/16/202	23 8:47 PM EDT	08/16/2023 8:54 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/	d∟	IA #: 23D0363256) -	08/16/2023	8:54 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCK	ED DEVICE UNSOLICITE	D RESULTS		
Performing Organization			City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) GLUCOS	E, POINT OF	CARE (GL Ref	UCOSE, POC) - Fina	l result (08/1 Analysis	6/2023 3:57 I	PM EDT)
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose Comment: Capillary	153 (H)	60 - 139 mg/dL		08/16/2023 4:04 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Smith, Noah			08/16/2023	BEAUMONT	
	NAA			4:04 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	WHOLE BLOOI SPECIMEN / U			08/16/202	!3 3:57 PM EDT	08/16/2023 4:04 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/	′d∟	ia #: 23d0363256) -	08/16/2023	4:04 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKI	ED DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) GLUCOS	E, POINT OF	CARE (GL	UCOSE, POC) - Fina	l result (08/1	6/2023 12:22	PM EDT)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	153 (H)	60 - 139 mg/dL		08/16/2023 12:29 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Performed By	Khoshaba, Rawaa NA			08/16/2023 12:29 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/16/202 EDT	3 12:22 PM	08/16/2023 12:29 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/0	dL	A #: 23D0363256) -	08/16/2023	12:29 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	est docke	D DEVICE UNSOLICITED	O RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	9488	
GLUCOSE, POINT OF CA	RE (GLUCOSE, Value	POC) - Fi Ref Range	nal result (08/16/2023 Test Method	3 5:52 AM ED Analysis Time		Pathologist Signature
Glucose	122	60 - 139	lest Method		BEAUMONT	
Glucose	122	mg/dL		6:00 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Barber, Annette NA TN			08/16/2023 6:00 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loc Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/16/202	23 5:52 AM EDT	08/16/2023 6:00 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/d	dL	A #: 23D0363256) -	08/16/2023	6:00 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCKE	D DEVICE UNSOLICITED	O RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	9488	

(ABNORMAL) CBC W/AUTO DIFF - Final result (08/16/2023 3:13 AM EDT)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
WBC	9.7	3.5 - 10.1 bil/L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RBC	4.36	4.31 - 5.48 tril/ L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	13.0 (L)	13.5 - 17.0 g/ dL		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hematocrit	40.8	40.1 - 50.1 %		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
MCV	94	80 - 100 fL		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСН	30	28 - 33 pg		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСНС	32	32 - 36 g/dL		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RDW-CV	16 (H)	12 - 15 %		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Platelets	284	150 - 400 bil/L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Nucleated Red Blood Cells	0.0	<=0.0 %		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Neutrophils	5.9	1.6 - 7.2 bil/L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Lymphocytes	2.4	1.1 - 4.0 bil/L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Monocytes	1.0 (H)	0.0 - 0.9 bil/L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Eosinophils	0.4	0.0 - 0.4 bil/L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.0	0.0 - 0.1 bil/L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.03	0.00 - 0.04 bil/L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %	0.3	%		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Specimen (Source) Blood)D	Volume			Received Time 08/16/2023 3:33 AM EDT
	Laterality VENOUS BLOC)D	Volume			
Blood	Laterality VENOUS BLOC)D	Volume			
Blood Narrative Authorizing Provider	Laterality VENOUS BLOC SPECIMEN / Ur Result Type)D nknown	Volume Venipuncture / Unknow			
Blood	Laterality VENOUS BLOC SPECIMEN / Ur)D nknown	Volume Venipuncture / Unknow			
Blood Narrative Authorizing Provider	Laterality VENOUS BLOC SPECIMEN / Ur Result Type BH LAB BLOOD)D nknown	Volume Venipuncture / Unknow		23 3:13 AM EDT	
Blood Narrative Authorizing Provider Danielle S	Laterality VENOUS BLOC SPECIMEN / Ur Result Type BH LAB BLOOD	D nknown D ORDERAE	Volume Venipuncture / Unknov	vn 08/16/202	3 3:13 AM EDT	
Blood Narrative Authorizing Provider Danielle S Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) RENAL F	Laterality VENOUS BLOC SPECIMEN / Ur Result Type BH LAB BLOOD Address 28050 Grand R	D ORDERAE	Volume Venipuncture / Unknow BLES City/State/ZIP Code Farmington Hills, MI 48336	vn 08/16/202 Phone Nu 800-551-0 3 3:13 AM E Analysis	23 3:13 AM EDT mber 0488 DT)	08/16/2023 3:33 AM EDT
Blood Narrative Authorizing Provider Danielle S Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Laterality VENOUS BLOC SPECIMEN / Ur Result Type BH LAB BLOOD Address 28050 Grand R	D D D ORDERAE tiver Ave	Volume Venipuncture / Unknow BLES <u>City/State/ZIP Code</u> Farmington Hills, MI 48336	vn 08/16/202 Phone Nu 800-551-0 3 3:13 AM E Analysis Time	23 3:13 AM EDT mber 0488 DT)	

		mmol/L	EDI	FARMINGTON HILLS (CLIA #: 23D0363256)
Potassium	3.7	3.5 - 5.2 mmol/L	08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Chloride	106	98 - 111 mmol/L	08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Carbon Dioxide -CO2	25	20 - 29 mmol/L		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	7	5 - 17		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose	123 (H)	60 - 99 mg/dL		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Fasting Blood Glucos Random Blood Glucose	-					
Blood Urea Nitrogen -BUN	17	7 - 25 mg/dL		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.61	0.60 - 1.30 mg/ dL		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	109	>60 mL/ min/ 1.73m2		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Calculation based on without adjustment f gender using the CKD	or race. Glom	erular Fi			on (CKD-EPI)	•
G3a: Mildly to m G3b: Moderately G4: Severely de	eased GFR: 60 oderately dec	reased GF ecreased				
Calcium	8.3 (L)	8.5 - 10.5 mg/dL		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Phosphorus	3.3	2.3 - 4.4 mg/dL		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Albumin	2.5 (L)	3.5 - 4.9 g/dL		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood		חר				08/16/2023 3·33 AM EDT

Blood VENOUS BLOOD Venipuncture / Unknown 08/16/2023 3:13 AM EDT 08/16/2023 3:33 AM EDT SPECIMEN / Unknown

Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOO	D ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		Farmington Hills, Ml 48336)488		
MAGNESIUM LEVEL - Fi	nal result (08/		:13 AM EDT)			
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Magnesium	2.0	1.7 - 2.5 mg/dL		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	VENOUS BLOO SPECIMEN / U		Venipuncture / Unkno	wn 08/16/202	23 3:13 AM EDT	08/16/2023 3:33 AM EDT
Narrative						
Authorizing Provider	Result Type BH LAB BLOO					
Danielle S	BH LAB BLOO	D ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand I	River Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) GLUCOS		Ref	-	Analysis		-
Component Glucose	Value 164 (H)	Range 60 - 139	Test Method	Time 08/16/2023	Performed At BEAUMONT	Pathologist Signature
Comment: Capillary	104 (11)	mg/dL		12:12 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Barber, Annette NA TN			08/16/2023 12:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	ocation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOO SPECIMEN / U			08/16/202 EDT	23 12:05 AM	08/16/2023 12:12 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	′d∟	IA #: 23D0363256) -	08/16/2023	12:12 AM EDT	

Authorizing Provider	Result Type						
William Rudy	BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS						
Performing Organization	Address		City/State/ZIP Code	Phone Number			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0)488		
GLUCOSE, POINT OF CA	RE (GLUCOSE,		nal result (08/15/2023		T)		
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature	
Glucose	127	60 - 139		08/15/2023			
		mg/dL		4:35 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Comment: Capillary	De ala Alava			00/15/0000			
Performed By	Poole, Alana NA			08/15/2023 4:35 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
	Ametersicalla	antinu (Collection Mathead /				
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time	
Blood	WHOLE BLOOD SPECIMEN / U					08/15/2023 4:35 PM EDT	
Narrative							
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	ia #: 23d0363256) -	08/15/2023	4:35 PM EDT		
Authorizing Provider	Result Type						
William Rudy	BH LAB POC T	EST DOCKI	ED DEVICE UNSOLICITE	O RESULTS			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0)488		
(ABNORMAL) GLUCOS			LICOSE BOC) - Final	rocult (08/1	5/2023 11.30		
		Ref	0003E, 1 0C) - 1 mai	Analysis	5/2025 11.55		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature	
Glucose	180 (H)	60 - 139 mg/dL		08/15/2023 11:48 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Comment: Capillary Performed By	Poolo Alana			08/15/2022	BEAUMONT		
Performed By	Poole, Alana NA			08/15/2023 11:48 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
	Anatomical Lo	cation /	Collection Method /				
Specimen (Source)	Laterality		Volume	Collection		Received Time	
Blood	WHOLE BLOOI SPECIMEN / U			08/15/202 EDT	23 11:39 AM	08/15/2023 11:48 AM EDT	
I							

Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose			A #: 23D0363256) -	08/15/2023	11:48 AM EDT	
Random Blood Glucose:						
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	EST DOCKE	ED DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mher	
BEAUMONT	28050 Grand R	iver Ave	Farmington Hills, MI	800-551-0		
LABORATORY,			48336	000 551 0	-00	
FARMINGTON HILLS						
(CLIA #: 23D0363256)						
GLUCOSE, POINT OF CA		POC) - Fi	nal result (08/15/2023	5.27 AM FD	T)	
		Ref	nu result (00, 15, 2025	Analysis	•)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	102	60 - 139		08/15/2023	BEAUMONT	<u> </u>
		mg/dL		5:34 AM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Comment: Capillary					2500505250)	
Performed By	TYYNISMAA,			08/15/2023	BEAUMONT	
,	Monique RN			5:34 AM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #:	
					23D0363256)	
	Anatomical Loo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD			08/15/202	23 5:27 AM EDT	08/15/2023 5:34 AM EDT
	SPECIMEN / Ur	nknown				
Narrative						
BEAUMONT LABORATORY,	FARMINGTON H	ILLS (CLI	IA #: 23D0363256) -	08/15/2023	5:34 AM EDT	
Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/0	dL				
Random Blood Glucose:	60-139 mg,	aL				
Authorizing Provider	Result Type					
William Rudy		ST DOCK	D DEVICE UNSOLICITED	RESULTS		
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	
LABORATORY, FARMINGTON HILLS			40330			
(CLIA #: 23D0363256)						
			_			
(ABNORMAL) CBC W/	AUTO DIFF - F		lt (08/15/2023 4:21 /			
Component	Value	Ref Range	Test Method	Analysis Time	Porformed At	Pathologist Signature
WBC	9.6	3.5 - 10.1	lest method	08/15/2023		
WDC	2.0	5.5 - 10.1 bil/L		4:37 AM	LABORATORY,	
		•		EDT	FARMINGTON	
					HILLS (CLIA #:	
226		1.2.1		00// = // = /	23D0363256)	
RBC	4.47	4.31 -		08/15/2023		
		5.48 tril/ I		4:37 AM EDT	LABORATORY, FARMINGTON	
		-			HILLS (CLIA #:	
					23D0363256)	

Component	Value	Ref Range	Test Method	Analysis Time	Performed At Pathologist Signature
Hemoglobin	13.2 (L)	13.5 - 17.0 g/ dL		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hematocrit	41.4	40.1 - 50.1 %		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
MCV	93	80 - 100 fL		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСН	30	28 - 33 pg		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСНС	32	32 - 36 g/dL		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RDW-CV	17 (H)	12 - 15 %		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Platelets	316	150 - 400 bil/L		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Nucleated Red Blood Cells	0.0	<=0.0 %		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Neutrophils	5.4	1.6 - 7.2 bil/L		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Lymphocytes	2.7	1.1 - 4.0 bil/L		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Monocytes	1.0 (H)	0.0 - 0.9 bil/L		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Eosinophils	0.4	0.0 - 0.4 bil/L		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Basophils	0.0	0.0 - 0.1 bil/L		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.03	0.00 - 0.04 bil/L		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %		%		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknow	wn 08/15/202	23 4:21 AM EDT	08/15/2023 4:33 AM EDT
Narrative						
Authorizing Provider	Result Type					
Fawaz Habba	BH LAB BLOOD) ORDERAI	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY,	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0)488	
FARMINGTON HILLS (CLIA #: 23D0363256)						
	UNCTION PA	NEL - Fin	al result (08/15/202	3 4:21 AM E	DT)	
(CLIA #: 23D0363256) (ABNORMAL) RENAL I		Ref	-	Analysis		Dathologist Cignoture
(CLIA #: 23D0363256)	FUNCTION PA Value 141		a l result (08/15/202 Test Method			Pathologist Signature
(CLIA #: 23D0363256) (ABNORMAL) RENAL I Component	Value	Ref Range 135 - 145	-	Analysis Time 08/15/2023 5:02 AM	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	Pathologist Signature
(CLIA #: 23D0363256) (ABNORMAL) RENAL I Component Sodium	Value 141	Ref Range 135 - 145 mmol/L 3.5 - 5.2	-	Analysis Time 08/15/2023 5:02 AM EDT 08/15/2023 5:02 AM	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Pathologist Signature
(CLIA #: 23D0363256) (ABNORMAL) RENAL I Component Sodium Potassium	Value 141 3.7	Ref Range 135 - 145 mmol/L 3.5 - 5.2 mmol/L 98 - 111	-	Analysis Time 08/15/2023 5:02 AM EDT 08/15/2023 5:02 AM EDT 08/15/2023 5:02 AM	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	Pathologist Signature
(CLIA #: 23D0363256) (ABNORMAL) RENAL I Component Sodium Potassium Chloride	Value 141 3.7 108	Ref Range 135 - 145 mmol/L 3.5 - 5.2 mmol/L 98 - 111 mmol/L 20 - 29	-	Analysis Time 08/15/2023 5:02 AM EDT 08/15/2023 5:02 AM EDT 08/15/2023 5:02 AM EDT 08/15/2023 5:02 AM	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	Pathologist Signature

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose Comment: Fasting Blood Glucos Random Blood Glucose	-			08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Blood Urea Nitrogen	13	7 - 25		08/15/2023	BEAUMONT	
-BUN		mg/dL		5:02 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.56 (L)	0.60 - 1.30 mg/ dL		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	111	>60 mL/ min/ 1.73m2		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
G3a: Mildly to m G3b: Moderately G4: Severely de G5: Kidney fail	For race. Glom >=90 reased GFR: 60 noderately ded to severely de ecreased GFR: ure GFR: <15	nerular Fi D-89 Creased GF decreased 15-29	Tration Rate is es R: 45-59 GFR: 30-44	timated fro	m serum creat	
Calcium	8.5	8.5 - 10.5 mg/dL		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Phosphorus	3.7	2.3 - 4.4 mg/dL		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Albumin	2.6 (L)	3.5 - 4.9 g/dL		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	ocation /	Collection Method /	Callard	Time	Dessived Times
Specimen (Source) Blood	Laterality VENOUS BLO SPECIMEN / U		Volume Venipuncture / Unknow	Collection wn 08/15/202		Received Time 08/15/2023 4:33 AM EDT
Narrative						
Authorizing Provider	Result Type					
	2.1		RIES			

BH LAB BLOOD ORDERABLES

Fawaz Habba

Performing Organization	n Address		City/State/ZIP Code	Phone Number			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0488			
MAGNESIUM LEVEL - Fi	nal result (08/1	5/2023 4 Ref	:21 AM EDT)	Analysis			
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature	
Magnesium	2.0	1.7 - 2.5 mg/dL		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time	
Blood	VENOUS BLOC SPECIMEN / Ur					08/15/2023 4:33 AM EDT	
Narrative							
Authorizing Provider	Result Type						
Fawaz Habba	BH LAB BLOOD	ORDERA	BLES				
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488		
GLUCOSE, POINT OF CA	ARE (GLUCOSE,	POC) - Fi Ref	nal result (08/14/2023	11:45 PM El Analysis	OT)		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature	
Glucose Comment: Capillary	118	60 - 139 mg/dL		08/14/2023 11:51 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Performed By	TYYNISMAA, Monique RN			08/14/2023 11:51 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time	
Blood	WHOLE BLOOD SPECIMEN / Ur				3 11:45 PM	08/14/2023 11:51 PM EDT	
Narrative							
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	dL	IA #: 23D0363256) - (08/14/2023	11:51 PM EDT		
Authorizing Provider	Result Type						
William Rudy	BH LAB POC TI	EST DOCKI	ED DEVICE UNSOLICITED	RESULTS			

Performing Organization	n Address		City/State/ZIP Code Phone Number			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave Farmington Hills, MI 800-551-0488 48336)488			
(ABNORMAL) GLUCOS	SE, POINT OF (CARE (GL Ref	UCOSE, POC) - Fina	l result (08/1 Analysis	4/2023 6:36	PM EDT)
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	141 (H)	60 - 139 mg/dL		08/14/2023 6:45 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary	Callana			00/14/2022		
Performed By	Galloway, Jennifer RN			08/14/2023 6:45 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur	_		08/14/202	23 6:36 PM EDT	08/14/2023 6:45 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg/	dL	:A #: 23D0363256) -	08/14/2023	6:45 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TI	EST DOCKI	ED DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA	ARE (GLUCOSE,	POC) - Fi Ref	nal result (08/14/202	3 12:00 PM E Analysis	DT)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	135	60 - 139 mg/dL		08/14/2023 12:07 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Poole, Alana			08/14/2023	BEAUMONT	
	NA			12:07 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /	_		
Specimen (Source)		<u>ר</u>	Volume	Collection		Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/14/202 EDT	23 12:00 PM	08/14/2023 12:07 PM EDT
Narrative BEAUMONT LABORATORY, Fasting Blood Glucos			A #: 23D0363256) -	08/14/2023	12:07 PM EDT	
Random Blood Glucose						

Authorizing Provider	Result Type				
William Rudy	BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS				
Performing Organization	Addrocc	City/State/7IB Code	Phone Number		
Performing Organization	Address	City/State/ZIP Code			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0488		

(ABNORMAL) CBC W/AUTO DIFF - Final result (08/14/2023 2:58 AM EDT)

		Ref	Analysis	
Component	Value	Range Test M		Performed At Pathologist Signature
WBC	10.6 (H)	3.5 - 10.1 bil/L	08/14/202 4:14 AM EDT	3 BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RBC	4.51	4.31 - 5.48 tril/ L	08/14/202 4:14 AM EDT	3 BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hemoglobin	13.2 (L)	13.5 - 17.0 g/ dL	08/14/202 4:14 AM EDT	3 BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hematocrit	42.0	40.1 - 50.1 %	08/14/202 4:14 AM EDT	3 BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
MCV	93	80 - 100 fL	08/14/202 4:14 AM EDT	3 BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСН	29	28 - 33 pg	08/14/202 4:14 AM EDT	3 BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСНС	31 (L)	32 - 36 g/dL	08/14/202 4:14 AM EDT	3 BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RDW-CV	17 (H)	12 - 15 %	08/14/202 4:14 AM EDT	3 BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Platelets	319	150 - 400 bil/L	08/14/202 4:14 AM EDT	3 BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Nucleated Red Blood Cells	0.0	<=0.0 %	08/14/202 4:14 AM EDT	3 BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

Component	Value	Ref Range	Test Method	Analysis Time	Performed A+	Pathologist Signature
Neutrophils	6.6	1.6 - 7.2		08/14/2023		
Neutrophils	0.0	bil/L		4:14 AM	LABORATORY,	
		·		EDT	FARMINGTON	
					HILLS (CLIA #:	
	<u> </u>			0.0.11.1.10.0.0.0	23D0363256)	
Lymphocytes	2.4	1.1 - 4.0 bil/L		08/14/2023 4:14 AM	BEAUMONT LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #:	
					23D0363256)	
Monocytes	1.1 (H)	0.0 - 0.9		08/14/2023		
		bil/L		4:14 AM EDT	LABORATORY, FARMINGTON	
				201	HILLS (CLIA #:	
					23D0363256)	
Eosinophils	0.4	0.0 - 0.4		08/14/2023		
		bil/L		4:14 AM EDT	LABORATORY, FARMINGTON	
				LDT	HILLS (CLIA #:	
					23D0363256)	
Basophils	0.0	0.0 - 0.1		08/14/2023		
		bil/L		4:14 AM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #:	
					23D0363256)	
Immature Granulocytes	0.05 (H)	0.00 -		08/14/2023	BEAUMONT	
		0.04 bil/L		4:14 AM EDT	LABORATORY, FARMINGTON	
				LUT	HILLS (CLIA #:	
					23D0363256)	
Immature Granulocyte %	0.5	%		08/14/2023		
				4:14 AM EDT	LABORATORY, FARMINGTON	
				EDI	HILLS (CLIA #:	
					23D0363256)	
Specimen (Source)	Anatomical Loc Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOO	D			-	08/14/2023 4:11 AM EDT
	SPECIMEN / Ur	nknown	1 1			
Newstine						
Narrative						
Authorizing Provider	Result Type	0000000				
Fawaz Habba	BH LAB BLOOD	ORDERA	3LE2			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT	28050 Grand R	iver Ave	Farmington Hills, MI	800-551-0)488	
			48336			
FARMINGTON HILLS (CLIA #: 23D0363256)						
(ABNORMAL) RENAL F	UNCTION PA		al result (08/14/202		DT)	
Component	Value	Ref	Test Method	Analysis Time	Derformed A+	Pathologist Signature
Sodium	140	Range 135 -		08/14/2023		
Joulum	170	145		4:39 AM	LABORATORY,	
		mmol/L		EDT	FARMINGTON	
					HILLS (CLIA #:	
					23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Potassium	3.8	3.5 - 5.2 mmol/L		08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	105	98 - 111 mmol/L		08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	27	20 - 29 mmol/L		08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	8	5 - 17		08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose	119 (H)	60 - 99 mg/dL		08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Fasting Blood Glucos Random Blood Glucose						
Blood Urea Nitrogen -BUN	12	7 - 25 mg/dL		08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.64	0.60 - 1.30 mg/ dL		08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	107	>60 mL/ min/ 1.73m2		08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Calculation based on without adjustment f gender using the CKD	or race. Glom	nerular Fi				
G3a: Mildly to m G3b: Moderately G4: Severely de	eased GFR: 60 oderately dec	reased GF lecreased				
Calcium	8.3 (L)	8.5 - 10.5		08/14/2023		

Calcium 8.3 (L) 8.5 - 10.5 mg/dL	08/14/2023 BEAUMONT 4:39 AM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256)
--	---

Comment) / - l	Ref		Analysis	Daufaura al At	Dath also sist Cine stores
Component	Value	Range	Test Method	Time		Pathologist Signature
Phosphorus	3.2	2.3 - 4.4 mg/dL		08/14/2023 4:39 AM	BEAUMONT LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	
Albumin	2.7 (L)	3.5 - 4.9		08/14/2023	BEAUMONT	
		g/dL		4:39 AM EDT	LABORATORY, FARMINGTON	
				LUI	HILLS (CLIA #:	
					23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	ocation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLO	OD				08/14/2023 4:11 AM EDT
	SPECIMEN / U	Inknown				
Narrative						
Handive						
Authorizing Duryiday	De sult Turs s					
Authorizing Provider Fawaz Habba	Result Type BH LAB BLOO		RI FS			
	DITEAD DEOO	DONDENA				
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY,	28050 Grand	River Ave	Farmington Hills, MI 48336	800-551-0	0488	
FARMINGTON HILLS			40550			
(CLIA #: 23D0363256)						
MAGNESIUM LEVEL - Fi	nal result (08/	14/2023 2	:58 AM EDT)			
		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Magnesium	2.0	1.7 - 2.5 mg/dL		08/14/2023 4:39 AM	BEAUMONT LABORATORY,	
		ilig/uL		EDT	FARMINGTON	
					HILLS (CLIA #:	
					23D0363256)	
	Anatomical Lo	ocation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	VENOUS BLOG	-	Venipuncture / Unkno	wn 08/14/202	23 2:58 AM EDT	08/14/2023 4:11 AM EDT
	STECHNER / C					
Narrative						
Authorizing Provider	Result Type					
Fawaz Habba	BH LAB BLOO	D ORDERA	BLES			
Porforming Organization	Addrocc		City/State/7ID Code	Phone Nu	mbor	
Performing Organization BEAUMONT	28050 Grand	River Ave	City/State/ZIP Code Farmington Hills, MI	800-551-0		
LABORATORY,	20050 Grana		48336	000 551 0		
FARMINGTON HILLS						
(CLIA #: 23D0363256)						
(ABNORMAL) GLUCOS	E, POINT OF		UCOSE, POC) - Final		3/2023 11:21	PM EDT)
Component	Value	Ref Range	Test Method	Analysis Time	Performed A+	Pathologist Signature
Glucose	141 (H)	60 - 139		08/13/2023		
	<u> </u>	mg/dL		11:29 PM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
					,	

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Comment: Capillary				00/12/2022		
Performed By	Harvey, Jaice NA			08/13/2023 11:29 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOI SPECIMEN / U			08/13/202 EDT	23 11:21 PM	08/13/2023 11:29 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	ia #: 23d0363256) -	08/13/2023	11:29 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCK	ED DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	River Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) GLUCOS	E, POINT OF	CARE (GL Ref	UCOSE, POC) - Fina	l result (08/1 Analysis	3/2023 6:00	PM EDT)
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	159 (H)	60 - 139 mg/dL		08/13/2023 6:07 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Dunmore,			08/13/2023	BEAUMONT	
	Androni NA			6:07 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality	,	Volume	Collection	Time	Received Time
Blood	WHOLE BLOOI SPECIMEN / U			08/13/202	23 6:00 PM EDT	08/13/2023 6:07 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	IA #: 23D0363256) -	08/13/2023	6:07 PM EDT	
Authorizing Provider	Result Type					
William Rudy		EST DOCK	ED DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	

(ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/13/2023 1:40 PM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	160 (H)	60 - 139 mg/dL		08/13/2023 1:47 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Dunmore,			08/13/2023	BEAUMONT	
Tenomica by	Androni NA			1:47 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOO SPECIMEN / U			08/13/202	23 1:40 PM EDT	08/13/2023 1:47 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	08/13/2023	1:47 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKI	D DEVICE UNSOLICITE	ED RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-()488	
(0						
GLUCOSE, POINT OF CA	RE (GLUCOSE				DT)	
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	134	60 - 139			BEAUMONT	
Comment: Capillary		mg/dL		5:39 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Harvey, Jaice			08/13/2023	BEAUMONT	
	NA			5:39 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source) Blood	Laterality WHOLE BLOO		Volume	Collection		Received Time 08/13/2023 5:39 AM EDT
ыооа	SPECIMEN / U			06/13/202	23 5.27 AIVI EDT	06/13/2023 5.39 AWI EDI
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	08/13/2023	5:39 AM EDT	
Authorizing Provider	Result Type					
William Rudy	21	EST DOCKE	D DEVICE UNSOLICITE	D RESULTS		

Performing Organization	Address	City/State/ZIP Code	Phone Number
BEAUMONT	28050 Grand River Ave	Farmington Hills, MI	800-551-0488
LABORATORY,		48336	
FARMINGTON HILLS			
(CLIA #: 23D0363256)			

(ABNORMAL) CBC W/AUTO DIFF - Final result (08/13/2023 3:23 AM EDT)

(ADNORIVIAL) CBC W,		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
WBC	9.8	3.5 - 10.1 bil/L		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RBC	4.26 (L)	4.31 - 5.48 tril/ L		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	12.6 (L)	13.5 - 17.0 g/ dL		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hematocrit	39.7 (L)	40.1 - 50.1 %		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
MCV	93	80 - 100 fL		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСН	30	28 - 33 pg		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСНС	32	32 - 36 g/dL		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RDW-CV	17 (H)	12 - 15 %		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Platelets	306	150 - 400 bil/L		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Nucleated Red Blood Cells	0.0	<=0.0 %		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Neutrophils	5.5	1.6 - 7.2 bil/L		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

_		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Lymphocytes	2.8	1.1 - 4.0 bil/L		08/13/2023 4:56 AM	BEAUMONT LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Monocytes	0.9	0.0 - 0.9		08/13/2023		
		bil/L		4:56 AM EDT	LABORATORY, FARMINGTON	
				LUT	HILLS (CLIA #:	
E 1 11	0.5.(11)	0.0 0.4		00/12/2022	23D0363256)	
Eosinophils	0.5 (H)	0.0 - 0.4 bil/L		08/13/2023 4:56 AM	BEAUMONT LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Basophils	0.1	0.0 - 0.1		08/13/2023	BEAUMONT	
		bil/L		4:56 AM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #:	
leave the Council of the	0.02	0.00		00/12/2022	23D0363256)	
Immature Granulocytes	0.03	0.00 - 0.04 bil/L		08/13/2023 4:56 AM	BEAUMONT LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %	0.3	%		08/13/2023	BEAUMONT	
				4:56 AM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #:	
	Anatomical Lo	cation /	Collection Method /		23D0363256)	
Specimen (Source)	Laterality	cation /	Volume	Collection	Time	Received Time
Blood	VENOUS BLOC		Venipuncture / Unknow	vn 08/13/202	3 3:23 AM EDT	08/13/2023 4:53 AM EDT
	SPECIMEN / U	IIKHOWH				
Narrative						
Authorizing Provider	Result Type					
Fawaz Habba	BH LAB BLOOD) ORDERAI	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY,	28050 Grand R	River Ave	Farmington Hills, MI 48336	800-551-0	488	
FARMINGTON HILLS			-0000			
(CLIA #: 23D0363256)						

(ABNORMAL) RENAL FUNCTION PANEL - Final result (08/13/2023 3:23 AM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Sodium	138	135 - 145 mmol/L		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Potassium	3.3 (L)	3.5 - 5.2 mmol/L		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Chloride	104	98 - 111 mmol/L		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	27	20 - 29 mmol/L		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	7	5 - 17		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose	103 (H)	60 - 99 mg/dL		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Fasting Blood Glucos Random Blood Glucose						
Blood Urea Nitrogen -BUN	14	7 - 25 mg/dL		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.56 (L)	0.60 - 1.30 mg/ dL		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	111	>60 mL/ min/ 1.73m2		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Comment:

Calculation based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation refit without adjustment for race. Glomerular Filtration Rate is estimated from serum creatinine, age and gender using the CKD-EPI equation:

G1: Normal GFR: >=90
G2: Mildly decreased GFR: 60-89
G3a: Mildly to moderately decreased GFR: 45-59
G3b: Moderately to severely decreased GFR: 30-44
G4: Severely decreased GFR: 15-29
G5: Kidney failure GFR: <15</pre>

Calcium	8.0 (L)	8.5 - 10.5 mg/dL	08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Phosphorus	3.0	2.3 - 4.4 mg/dL	08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Albumin	2.6 (L)	3.5 - 4.9 g/dL		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /	Callestian	Τ'	Received Time
Specimen (Source) Blood	Laterality VENOUS BLOC SPECIMEN / U		Volume Venipuncture / Unknow	Collection vn 08/13/202		08/13/2023 4:52 AM EDT
Narrative						
Authorizing Provider	Result Type					
Fawaz Habba	BH LAB BLOOD	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	liver Ave	Farmington Hills, MI 48336	800-551-0	9488	
MAGNESIUM LEVEL - Fir	nal result (08/ ⁻	13/2023 3 Ref	:23 AM EDT)	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Magnesium	2.0	1.7 - 2.5 mg/dL		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /		- .	
Specimen (Source) Blood	Laterality VENOUS BLOC SPECIMEN / U		Volume Venipuncture / Unknow	Collection vn 08/13/202		Received Time 08/13/2023 4:52 AM EDT
Narrative						
Authorizing Provider	Result Type					
Fawaz Habba	BH LAB BLOOD	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	liver Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA		POC) - Fi Ref		11:29 PM El Analysis	DT)	
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose	136	60 - 139 mg/dL		08/12/2023 11:36 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	
Comment: Capillary					23D0363256)	

Comment) (- · · -	Ref	To at Martha al	Analysis	Deufeure et At	Dath also sist Cine at us
Component	Value	Range	Test Method	Time		Pathologist Signature
Performed By	Harvey, Jaice NA			08/12/2023 11:36 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	ocation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOO SPECIMEN / U			08/12/202 EDT	23 11:29 PM	08/12/2023 11:36 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	∕d∟	IA #: 23D0363256) -	08/12/2023	11:36 PM EDT	
Authorizing Provider	Result Type					
William Rudy	21	EST DOCK	ED DEVICE UNSOLICITE	ED RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand I	River Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) GLUCOS Component Glucose	Value 148 (H)	CARE (GL Ref Range 60 - 139 mg/dL	UCOSE, POC) - Fina	I result (08/1 Analysis Time 08/12/2023 4:55 PM EDT	Performed At	Pathologist Signature
					HILLS (CLIA #: 23D0363256)	
Comment: Capillary	Laudina			00/12/2022		
Performed By	Jenkins, Diamond NA			08/12/2023 4:55 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lc Laterality	ocation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOO SPECIMEN / U					08/12/2023 4:55 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	∕d∟	fa #: 23d0363256) -	08/12/2023	4:55 PM EDT	
Authorizing Provider	Result Type					
William Rudy	21	EST DOCK	ED DEVICE UNSOLICITE	ED RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS	28050 Grand I	River Ave	Farmington Hills, MI 48336	800-551-0)488	

(ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/12/2023 11:18 AM EDT)

FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	152 (H)	60 - 139 mg/dL		08/12/2023 11:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Jenkins,			08/12/2023	BEAUMONT	
	Diamond NA			11:25 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOO SPECIMEN / U			08/12/202 EDT	23 11:18 AM	08/12/2023 11:25 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	IA #: 23D0363256) -	- 08/12/2023	11:25 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKI	ED DEVICE UNSOLICIT	ED RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-()488	
(02						
GLUCOSE, POINT OF CA	ARE (GLUCOSE,				DT)	
Component	Value	Ret Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	127	60 - 139	lest Method		BEAUMONT	
Comment: Capillary		mg/dL		5:53 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Harvey, Jaice			08/12/2023	BEAUMONT	
Tenomica by	NA			5:53 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Timo	Received Time
Blood	WHOLE BLOO		volume			08/12/2023 5:53 AM EDT
blood	SPECIMEN / U			00/12/202		00/12/2025 5.55 AW LD1
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	- 08/12/2023	5:53 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCK	D DEVICE UNSOLICIT	ED RESULTS		

Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) GLUCOS	SE, POINT OF	CARE (GL Ref	UCOSE, POC) - Final	result (08/1 Analysis	2/2023 12:03	AM EDT)
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	149 (H)	60 - 139 mg/dL			BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Harvey, Jaice NA			08/12/2023 12:10 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / U	-		08/12/202 EDT	23 12:03 AM	08/12/2023 12:10 AM EDT
Narrative			"	20 /12 /2022	10 10 M FDT	
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	′d∟	[A #: 23DU363236 <i>]</i> -	08/12/2023	12:10 AM EDI	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKE	ED DEVICE UNSOLICITEI	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) GLUCOS	SE, POINT OF		UCOSE, POC) - Final	-	1/2023 6:01	PM EDT)
Component	Value	Ref Range	Test Method	Analysis Time	Derformed At	Pathologist Signature
Glucose Comment: Capillary	150 (H)	60 - 139 mg/dL		08/11/2023 6:10 PM EDT		<u> </u>
Performed By	Johnson,			08/11/2023	BEAUMONT	
	Rachel NA			6:10 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /	Callastian	 .	D. I. I.Thurs
Specimen (Source) Blood	Laterality WHOLE BLOOI SPECIMEN / U		Volume	Collection 08/11/202		Received Time 08/11/2023 6:10 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	′d∟	IA #: 23D0363256) -	08/11/2023	6:10 PM EDT	

Authorizing Provider	Result Type					
William Rudy	BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS					
Performing Organization	Address	City/State/ZIP Code	Phone Nu	Imber		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-()488		
(ABNORMAL) STAPHY NARES) - Final result (((STAPHYLC Analysis	DCOCCUS AUREUS/MRSA BY NAA,		
Component	Value Dange	Tast Mathad	Time	Derformed At Dethelegist Cigneture		

		I CI				
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Staphylococcus aureus	Detected (A)	Not Detected		08/12/2023 1:50 PM EDT	BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	
Methicillin Resistant	Detected (A)	Not Detected		08/12/2023 1:50 PM EDT	BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	
	Ameteorical La	antions (Collection Mathead (
Specimen (Source)	Anatomical Loo Laterality	tation /	Collection Method / Volume	Collection	Time	Received Time
Swab	ANTERIOR NAI SWAB / Unkno		Non-blood Collection / Unknown	08/11/202 EDT	3 11:25 AM	08/11/2023 11:53 AM EDT
Narrative						
BEAUMONT LABORATORY, Methodology: Nucleic	c acid amplif	L IA#: 23D ication (0667009) - 08/12/202 FDA-approved)	23 1:50 PM	EDT	
BEAUMONT LABORATORY, Methodology: Nucleic Authorizing Provider	c acid amplif	ication (FDA-approved)		EDT	
BEAUMONT LABORATORY, Methodology: Nucleic	c acid amplif	ication (0667009) - 08/12/202 FDA-approved) · GENERAL ORDERABLES		EDT	
BEAUMONT LABORATORY, Methodology: Nucleic Authorizing Provider	acid amplif Result Type BH LAB MICRC	ication (FDA-approved)			

(ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/11/2023 11:15 AM EDT)

		Ref	T (1 1 1	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	143 (H)	60 - 139 mg/dL		08/11/2023 11:22 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	labaaaa			00/11/2022		
Performed By	Johnson, Rachel NA			08/11/2023 11:22 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOI SPECIMEN / UI			08/11/202 EDT	23 11:15 AM	08/11/2023 11:22 AM EDT

Texamon Laborations, PARNINGTON HILLS (CLLA #: 2300363256) - 08/11/2023 11:22 AM EDT Pasting Browider Result Type Authorizing Provider Result Type William Rudy DPL LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEALMONT 28050 Grand River Ave Farmington Hills, MI 48336 Component Value Random River Ave Farmington Hills, MI 48336 Result (08/11/2023 5:37 AM EDT) Ref Analysis Component Value Random River Ave Farmington Hills Ref Component Value Random River Ave Farmington Hills 08/11/2023 BEAUMONT Sc44 AM Analysis Comment: Capillary Ref Performed By Alagon, Elaine NA Collection Method / Value Collection Method / Value Specimen (Source) Latardition / Latardition Collection Method / Value Collection Time Result Type WHOLE BLOOD 08/11/2023 5:44 AM EDT Specimen (Source) Farbing Blood Buccese: 60/33 mg/dL Authorizing Provider Result Type Value	Narrative						
Random #10od Glucose: 60-139 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Faminington Hills, MI 800-551-0488 ADORATORY 28050 Grand River Ave Faminington Hills, MI 800-551-0488 Component Value Rarge Test Method Component Value Rarge Test Method Mildon BLAMONT Laboratorky, Faministron Malaysis Comment: Capillary Collection Method / Performed By NA Specimen (Source) Anatomical Location / Collection Method / Specimen (Source) Laboratory, FARCING Method / Value Specimen (Source) Anatomical Location / Collection Method / Specimen (Source) Laboratory, FARCING Methol / Value Specimen (Source) Laboratory, FARCING Methol / Value Specimen (Source) Laboratory, FARCING Methol / Value	BEAUMONT LABORATORY,	FARMINGTON H		A #: 23D0363256) -	08/11/2023	11:22 AM EDT	
William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LADORATORY LABORATORY Adaption Hills, MI 800-551-0488 CLIA et 2010063256) Set Method Time Performed At. Pathologist Signature GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/11/2023 5:37 AM EDT) Ref Analysis Component Value Range Test Method Time Performed At. Pathologist Signature Glucose 104 60 - 139 08/11/2023 BEAUMONT S44 AM LABORATORY, EDT Comment: Capillary Performed By Alagon, Elaine 08/11/2023 BEAUMONT S44 AM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 2300363256) Collection Time Received Time Blood WHOLE BLOOD 08/11/2023 S1:44 AM EDT 08/11/2023 S1:44 AM EDT Narrative EAUMONT 2800363256) 08/11/2023 S1:44 AM EDT Received Time Blood WHOLE BLOOD 08/11/2023 S1:44 AM EDT Received Time							
Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT LADORNIORN FARMINGTON HILLS CLA #: 2200363256) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/11/2023 5:37 AM EDT) Ref Component Value Range Test Method Time Performed At Pathologist Signature Glucose 104 60 - 139 mg/dL 544 AM LABORATORY EDT FARMINGTOR HILLS CLA #: 2200363256) GUTORUS EDT FARMINGTOR HILLS CLA #: 2200363256) GUTORUS EDT FARMINGTOR HILLS CLA #: 2200363256) GUTORUS EDT FARMINGTOR HILLS CLA #: 2200363256) Anatomical Location / Collection Method / Volume Collection Time Received Time Blood VHOLE BLODD SPECIMEN/ Unknown Narrative BEAUMONT LABORATORY FARMINGTON HILLS CLIA #: 2300363256) CALL Address City/State/ZIP Code Phone Number EDT Fast Ing slood Clucose: 60-93 mg/dL Authorizing Provider Result Type HILLS CLIA #: 2300363256) VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) Component Value Range Test Method Collection Method Collection Address City/State/ZIP Code Phone Number EDT Fast Ing slood Clucose: 60-93 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITER RESULTS Performing Organization Address City/State/ZIP Code Phone Number EDT Fast Ing Elocod S00 - Collection Method Collection City Collection Ci	Authorizing Provider	Result Type					
BEALWONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 ABORATORY FARMINGTON HILLS 28050 Grand River Ave Farmington Hills, MI 800-551-0488 GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/11/2023 5.37 AM EDT) Analysis GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/11/2023 5.37 AM EDT) Analysis Glucose 104 60 - 139 08/11/2023 BEAUMONT Glucose 104 60 - 139 08/11/2023 BEAUMONT Ferformed By Alagon, Elaine 08/11/2023 BEAUMONT FARMINGTOR NA Stat Ad M LABRATORK, EDT FARMINGTOR Performed By Alagon, Elaine 08/11/2023 BEAUMONT FARMINGTOR NA Specimen (Source) Laterality Volume Collection Time Received Time Blood WHOLE BLOOD 08/11/2023 5:37 AM EDT 08/11/2023 5:44 AM EDT Farsting Blood Glucose: 60-33 mg/dL Authorizing Provider Result Type Farsting Blood Glucose: 60-33 mg/dL 800-551-0488 Valuer Ref City/State/ZIP Code Phone Number BEAUMONT Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28036 Grand River Ave Farmington Hills, MI 800-551-0488 VALPROIC ACID LE	William Rudy	BH LAB POC TE	ST DOCK	ED DEVICE UNSOLICITEI	O RESULTS		
LABORATORY, 48336 ° ARAMINGTON HILLS (CLIA +: 23D0363256) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/11/2023 5:37 AM EDT) Ref Analysis Component Value Range Test Method Time Performed At Pathologist Signature (Glucose 104 60 - 139 mg/dL 5:44 AM FARMINGTON HILLS (CLIA +: 23D0363256) Comment Capillary Performed By Alagon, Elaine NA EDT ARAMINGTON HILLS (CLIA +: 23D0363256) Comment Capillary Performed By Alagon, Elaine NA EDT ARAMINGTON HILLS (CLIA +: 23D0363256) Comment Capillary Performed By Alagon, Elaine NA EDT Est Method / Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown Na EDT Biod Glucose: 60-39 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performed AL Pathologist Signature EADMONT 22050 Grand River Ave Farmington Hills, MI 49336 VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) Valproic Acid 69.0 50.0 - 09/11/2023 5:24 AM EDT Farting Blood Succes: 60-39 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) Component Value Range Test Method / 09/11/2023 BEAUMONT Laterality Volume Collection Time Received AL Pathologist Signature Valproic Acid 69.0 50.0 - 09/11/2023 5:44 AM EDT Fasting Blood VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) Component Value Range Test Method / 09/11/2023 BEAUMONT Laterality Volume Collection Time Received Time Blood VENOUS BLOOD Valproic Acid 69.0 50.0 - 09/11/2023 5:41 AM EDT Fasting Blood Succes: Final result (08/11/2023 1:21 AM EDT) Component Value Range Test Method / Collection Time Received Time Blood VENOUS BLOOD Valproic Acid 69.0 50.0 - 09/11/2023 1:21 AM EDT Section Performed AL Pathologist Signature Valproic Acid 69.0 50.0 - 09/11/2023 1:21 AM EDT Section Performed AL Pathologist Signature Valproic Acid 69.0 50.0 - 00/11/2023 1:21 AM EDT Section Performed AL Pathologist Signature Valproic Acid 69.0 50.0 - 00/11/2023 1:21 AM EDT Section Performed AL				·			
Component Value Range Test Method Time Performed At Pathologist Signature Glucose 104 60 - 139 mg/dL 08/11/2023 BEAUMONT Scata AM LABORATORY, EDT FARMINGTON, HILLS (CLIA #: 23D0363256) Comment: Capillary Alagon, Elaine NA 08/11/2023 BEAUMONT Scata AM LABORATORY, EDT Performed By Alagon, Elaine NA Collection Method / Laterality Collection Method / Volume Collection Time Received Time Blood MHOLE BLOOD SPECIMEN / Unknown 08/11/2023 5:37 AM EDT 08/11/2023 5:44 AM Narrative EEAUMONT Collection Time Received Time 08/11/2023 5:37 AM EDT 08/11/2023 5:44 AM EDT Narrative EEAUMONT Collection Time Received Time EEAUMONT 28/00363256) 08/11/2023 5:44 AM EDT Fasting Blood Glucose: 60 - 39 mg/dL Authorizing Provider Result Type EXAUMONT 28/050 Grand River Ave Earlington Hills, MI 48/336 EAUMONT 28/050 Grand River Ave Earlington Hills, MI	LABORATORY, FARMINGTON HILLS	28050 Grand R	iver Ave		800-551-0	1488	
Component Value Range Test Method Time Performed At Pathologist Signature Glucose 104 60 - 139 08/11/2023 BEAUMONT LABORATORY, FARMINGTON FARMINGTON Performed By Alagon, Elaine NA S44 AM LABORATORY, EDT FARMINGTON Performed By Alagon, Elaine NA Collection Method / Volume Collection Time Received Time Blood Anatomical Location / Vertore Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/11/2023 5:44 AM EDT FARMINGTON HILLS (CLLA #: 2300363256) - 08/11/2023 5:44 AM EDT Pastring Blood Glucose: 60-39 mg/dL Random Blood Glucose: 60-39 mg/dL -	GLUCOSE, POINT OF CA	RE (GLUCOSE,		nal result (08/11/2023		T)	
Glucose 104 60 - 139 mg/dL 08/11/2023 BEAUMONT SA4 AM LABORATORY, EDT Farming Torment: Capillary Performed By Alagon, Elaine NA 08/11/2023 BEAUMONT SA4 AM LABORATORY, EDT FARMINGTON HILLS (CLA #: 23D0363256) Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown Collection Time Received Time Narrative BEAUMONT 5:44 AM EDT Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/11/2023 5:37 AM EDT 08/11/2023 5:44 AM EDT Narrative BEAUMONT Edd Locase: 60-99 mg/dL Random Blood Glucose: 60-99 mg/dL 800-151-0488 Edd Locase: William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performed At Pathologist Signature Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 Farthologist Signature VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) Ref Analysis Performed At Pathologist Signature Valproic Acid 69.0 </td <td>Component</td> <td>Value</td> <td></td> <td>Test Method</td> <td><i>,</i></td> <td>Performed At</td> <td>Pathologist Signature</td>	Component	Value		Test Method	<i>,</i>	Performed At	Pathologist Signature
Comment: Capillary Alagon, Elaine NA 08/11/2023 BEAUMONT S44 AM EDT BEAUMONT S44 AM EDT BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/11/2023 5:37 AM EDT 08/11/2023 Narrative BeAUMONT LABORATORY, Fasting Blood Glucose: 60-39 mg/dL 60-139 mg/dL # 23D0363256) - 08/11/2023 5:44 AM EDT Pasting Blood Glucose: 60-139 mg/dL # 23D0363256) - 08/11/2023 5:44 AM EDT Authorizing Provider Result Type Itagon Aldress City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) 2800 Grand River Ave 48336 Performed At Pathologist Signature VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) Value Ref Anatomical Location / 100.0 2:14 AM LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Performed At Pathologist Signature Value Rage Test Method 2:14 AM LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Performed At Pathologist Signature Value Rage Test Method Collection Time Performed At Pathologist Signature Performed At Pathologist Si			60 - 139		08/11/2023 5:44 AM	BEAUMONT LABORATORY, FARMINGTON	
Performed By Alagon, Elaine NA 08/11/2023 BEAUMONT S:44 AM LaBORATORY, EDT FARMINGTON, HILLS (CLIA #; 23D0363256) Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD 08/11/2023 5:37 AM EDT 08/11/2023 5:37 AM EDT 08/11/2023 5:44 AM EDT Narrative BEAUMONT LABORATORY, FASTing Blood Glucose: 60-99 mg/dL 08/11/2023 5:44 AM EDT 08/11/2023 5:44 AM EDT Valtorizing Provider Result Type Clity/State/ZIP Code Phone Number Performing Organization Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 48336 800-551-0488 VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) Time Performed At Pathologist Signature Valproic Acid 69.0 50.0 - 08/11/2023 BEAUMONT 100.0 2:14 AM LABORATORY, EDT Pathologist Signature Valproic Acid 69.0 50.0 - 08/11/2023 BEAUMONT 100.0 2:14 AM LABORATORY, EDT Pathologist Signature Valproic Acid 69.0 50.0 - 08/11/2023 BEAUMONT HILLS (CLIA #; 23D0363256						23D0363256)	
NA 5.44 AM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/11/2023 5:37 AM EDT 08/11/2023 5:44 AM EDT Narrative BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/11/2023 5:44 AM EDT Fasting Blood Glucose: 60-99 mg/dL Authorizing Provider Result Type Edumont LaBORATORY, William Rudy Edumont Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave LABORATORY, FARMINGTON HILLS Farmington Hills, MI 48336 800-551-0488 VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) Ref Analysis Component Value Range Test Method Time Time Performed At Pathologist Signature Valproic Acid Valproic Acid 69.0 50.0 - 100.0 08/11/2023 BEAUMONT 2:14 AM LABORATORY, LABORATORY, EDT Farthologist Signature Value Valproic Acid 69.0 50.0 - 100.0 08/11/2023 BEAUMONT 2:14 AM LABORATORY, LABORATORY, EDT Farthologist Signature Value Valproic Acid 69.0 50.0 - 100.0 Collection Time Received Time Blood VENOUS					00/11/00000	55 A H A A A A T	
Specimen (Source) Laterality Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/11/2023 5:37 AM EDT 08/11/2023 5:37 AM EDT 08/11/2023 5:44 AM EDT Narrative BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/11/2023 5:44 AM EDT Fast ing Blood Glucose: 60-99 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, FARMINGTON HILLS Kef Analysis CULIA #: 23D0363256) Ref Analysis VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) Ref Analysis Component Value Range Test Method Time Performed At Pathologist Signature Valproic Acid 69.0 50.0 - 08/11/2023 BEAUMONT LABORATORY, Ug/mL EDT FARMINGTON HILLS LABORATORY, LABORATORY, Valproic Acid 69.0 <t< td=""><td>Performed By</td><td>J</td><td></td><td></td><td>5:44 AM</td><td>LABORATORY, FARMINGTON HILLS (CLIA #:</td><td></td></t<>	Performed By	J			5:44 AM	LABORATORY, FARMINGTON HILLS (CLIA #:	
Blood WHOLE BLOOD SPECIMEN / Unknown 08/11/2023 5:37 AM EDT 08/11/2023 5:44 AM EDT Narrative BEAUMONT LABORATORY, FARMINCTON HILLS (CLIA #: 23D0363256) - 08/11/2023 5:44 AM EDT Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 A8336 FARMINGTON HILLS (CLIA #: 23D0363256) VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) Ref Analysis Component Value Range Test Method Time Performed At Pathologist Signature Valproic Acid 69.0 50.0 - 08/11/2023 BEAUMONT 100.0 2:14 AM LABORATORY, HILLS (CLIA #: 23D0363256) Valproic Acid 69.0 50.0 - 08/11/2023 BEAUMONT 23D0363256) Valproic Acid 69.0 50.0 - 08/11/2023 BEAUMONT 23D0363256) Specimen (Source) Anatomical Location / Collection Method / 23D0363256) 23D0363256) Specimen (Source)<			ation /				
SPECIMEN / Unknown Narrative BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/11/2023 5:44 AM EDT Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, 48336 48336 FARMINGTON HILLS CLIA #: 23D0363256) Performed At Pathologist Signature VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) Ref Analysis Performed At Pathologist Signature Valproic Acid 69.0 50.0 - 08/11/2023 BEAUMONT Valproic Acid 69.0 50.0 - 08/11/2023 BEAUMONT Ug/mL EDT FARMINGTON HILLS (CLIA #: 23D0363256) Specimen (Source) Laterality Volume Collection Time Received Time		, ,	<u></u>	Volume			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/11/2023 5:44 AM EDT Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave FARMINGTON HILLS (CLIA #: 23D0363256) VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) Ref Analysis Component Value Value Range Test Method Time Valproic Acid 69.0 50.0 - 08/11/2023 BEAUMONT ug/mL EDT FARMINGTON ug/mL EDT FARMINGTON Value Anatomical Location / Collection Method / 23D0363256)	вюоа				08/11/202	3 5:37 AM EDI	08/11/2023 5:44 AM EDI
Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, FARMINGTON HILLS 48336 (CLIA #: 23D0363256) Ref Analysis VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) Ref Analysis Component Value Range Test Method Time Performed At Pathologist Signature Valproic Acid 69.0 50.0 - 08/11/2023 BEAUMONT 2:14 AM LABORATORY, ug/mL EDT FARMINGTON HILLS (CLIA #: 23D0363256) 23D0363256)							
William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, 48336 48336 FARMINGTON HILLS (CLIA #: 23D0363256) VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) Ref Analysis Component Value Range Test Method Time Performed At Pathologist Signature Valproic Acid 69.0 50.0 - 08/11/2023 BEAUMONT ug/mL EDT FARMINGTON HILLS (CLIA #: 23D0363256) Specimen (Source) Anatomical Location / Collection Method / Volume Collection Time Received Time Blood VENOUS BLOOD Venipuncture / Unknown 08/11/2023 1:21 AM EDT 08/11/2023 1:21 AM EDT	Fasting Blood Glucose	e: 60-99 mg/o	dL .	:A #: 23D0363256) -	08/11/2023	5:44 AM EDT	
William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, 48336 48336 FARMINGTON HILLS (CLIA #: 23D0363256) VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) Ref Analysis Component Value Range Test Method Time Performed At Pathologist Signature Valproic Acid 69.0 50.0 - 08/11/2023 BEAUMONT ug/mL EDT FARMINGTON HILLS (CLIA #: 23D0363256) Specimen (Source) Anatomical Location / Collection Method / Volume Collection Time Received Time Blood VENOUS BLOOD Venipuncture / Unknown 08/11/2023 1:21 AM EDT 08/11/2023 1:21 AM EDT	Authorizing Provider	Result Type					
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) 28050 Grand River Ave 48336 Farmington Hills, MI 48336 800-551-0488 VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) 48336 Analysis Component Value Range Test Method Valproic Acid 69.0 50.0 - 100.0 08/11/2023 BEAUMONT 2:14 AM LABORATORY, LABORATORY, Ug/mL Valproic Acid 69.0 50.0 - 100.0 08/11/2023 BEAUMONT 2:14 AM LABORATORY, LABORATORY, Ug/mL EDT FARMINGTON HILLS (CLIA #: 23D0363256) Anatomical Location / Volume Collection Time Received Time Blood VENOUS BLOOD Venipuncture / Unknown 08/11/2023 1:21 AM EDT 08/11/2023	U		ST DOCK	ED DEVICE UNSOLICITE	O RESULTS		
LABORATORY, 48336 FARMINGTON HILLS (CLIA #: 23D0363256) 48336 VALPROIC ACID LEVEL - Final result (08/11/2023 1:21 AM EDT) Ref Analysis Component Value Range Test Method Valproic Acid 69.0 50.0 - 08/11/2023 100.0 2:14 AM LABORATORY, ug/mL EDT FARMINGTON HILLS (CLIA #: 23D0363256)	Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
Component Value Ref Range Test Method Time Performed At Pathologist Signature Valproic Acid 69.0 50.0 - 100.0 ug/mL 08/11/2023 BEAUMONT 2:14 AM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood VENOUS BLOOD Venipuncture / Unknown 08/11/2023 1:21 AM EDT 08/11/2023 1:50 AM EDT	LABORATORY, FARMINGTON HILLS	28050 Grand R	iver Ave		800-551-0	1488	
ComponentValueRangeTest MethodTimePerformed AtPathologist SignatureValproic Acid69.050.0 - 100.0 ug/mL08/11/2023BEAUMONT LABORATORY, EDTLABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)Specimen (Source)Anatomical Location / LateralityCollection Method / VolumeCollection TimeReceived TimeBloodVENOUS BLOODVenipuncture / Unknown08/11/20231:21 AM EDT08/11/20231:50 AM EE	VALPROIC ACID LEVEL -	Final result (08		3 1:21 AM EDT)	Analysis		
Valproic Acid 69.0 50.0 - 100.0 08/11/2023 BEAUMONT ug/mL 2:14 AM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) 23D0363256) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood VENOUS BLOOD Venipuncture / Unknown 08/11/2023 1:21 AM EDT 08/11/2023	Component	Value		Test Method	<i>,</i>	Performed At	Pathologist Signature
Specimen (Source)LateralityVolumeCollection TimeReceived TimeBloodVENOUS BLOODVenipuncture / Unknown08/11/2023 1:21 AM EDT08/11/2023 1:50 AM ED			50.0 - 100.0		08/11/2023 2:14 AM	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	<u> </u>
Blood VENOUS BLOOD Venipuncture / Unknown 08/11/2023 1:21 AM EDT 08/11/2023 1:50 AM EE	Specimen (Source)		cation /		Collection	Time	Received Time
		VENOUS BLOO		Venipuncture / Unknor	wn 08/11/202	3 1:21 AM EDT	08/11/2023 1:50 AM EDT
Narrative	Narrative						

Authorizing Provider	Result Type							
Igor Paris		BH LAB BLOOD ORDERABLES						
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488			
GLUCOSE, POINT OF CA	RE (GLUCOSE,		nal result (08/11/2023		DT)			
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature		
Glucose Comment: Capillary	122	60 - 139 mg/dL			BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Performed By	Alagon, Elaine			08/11/2023	BEAUMONT			
	NA			12:19 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
	Anatomical Loc	cation /	Collection Method /					
Specimen (Source)	Laterality		Volume	Collection	_	Received Time		
Blood	WHOLE BLOOD SPECIMEN / Ur			08/11/202 EDT	23 12:12 AM	08/11/2023 12:19 AM EDT		
Narrative								
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/o	dL	A #: 23D0363256) -	08/11/2023	12:19 AM EDT			
Authorizing Provider	Result Type							
William Rudy	~ .	ST DOCK	ED DEVICE UNSOLICITE	O RESULTS				
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	9488			
(ABNORMAL) GLUCOS	E, POINT OF C	CARE (GL	UCOSE, POC) - Final	result (08/1	0/2023 4:52 I	PM EDT)		
6		Ref	T	Analysis —-				
Component	Value	Range	Test Method	Time		Pathologist Signature		
Glucose	162 (H)	60 - 139 mg/dL		08/10/2023 4:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Comment: Capillary Performed By	Johnson, Jack			08/10/2023	BEAUMONT			
renormed by	NA			4:59 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Specimen (Source)	Anatomical Loc Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time		
Blood	WHOLE BLOOD SPECIMEN / Ur		volume			08/10/2023 4:59 PM EDT		

Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose			IA #: 23D0363256) -	08/10/2023	4:59 PM EDT	
Random Blood Glucose	: 60-139 mg	/dL				
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCK	ED DEVICE UNSOLICITED	O RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT	28050 Grand R	liver Ave	Farmington Hills, MI	800-551-0)488	
LABORATORY, FARMINGTON HILLS			48336			
(CLIA #: 23D0363256)						
(ABNORMAL) GLUCOS	SE, POINT OF	-	UCOSE, POC) - Final		0/2023 12:52	PM EDT)
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	163 (H)	60 - 139	lest method		BEAUMONT	
		mg/dL		12:59 PM	LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	
Comment: Capillary						
Performed By	Hatcher,				BEAUMONT	
	Camille NA			12:59 PM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #:	
					23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality	cationy	Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD				23 12:52 PM	08/10/2023 12:59 PM
	SPECIMEN / UI	nknown		EDT		EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose	FARMINGTON H	ILLS (CLI	IA #: 23D0363256) -	08/10/2023	12:59 PM EDT	
Random Blood Glucose						
Authorizing Provider	Result Type					
William Rudy		EST DOCK	ED DEVICE UNSOLICITED	O RESULTS		
				_		
Performing Organization	Address 28050 Grand R		City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY,	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0	1488	
FARMINGTON HILLS						
(CLIA #: 23D0363256)						
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi	nal result (08/10/2023	3 6:31 AM ED	T)	
C		Ref	T (M (1)	Analysis		
Component Glucose	Value 120	Range 60 - 139	Test Method	Time 08/10/2023		Pathologist Signature
Glucose	120	mg/dL		6:37 AM	LABORATORY,	
		<i>.</i>		EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Comment: Capillary					23030303230)	
Performed By	Heaven,			08/10/2023	BEAUMONT	
,	Lauren NA			6:37 AM	LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	

(Course)	Anatomical Location /	Collection Method /		Descional Times
Specimen (Source)	Laterality	Volume	Collection Time	Received Time
Blood	WHOLE BLOOD		08/10/2023 6:31 AM EDT	08/10/2023 6:37 AM EDT
	SPECIMEN / Unknown			
Narrative				
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/d∟	IA #: 23D0363256) - (08/10/2023 6:37 AM EDT	
Authorizing Provider	Result Type			
William Rudy	BH LAB POC TEST DOCK	ED DEVICE UNSOLICITED	RESULTS	
Performing Organization	Address	City/State/ZIP Code	Phone Number	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0488	

(ABNORMAL) CBC W/AUTO DIFF - Final result (08/10/2023 3:00 AM EDT)

(,		Ref	Analysis		
Component	Value	Range Test Method		Performed At	Pathologist Signature
WBC	11.6 (H)	3.5 - 10.1 bil/L	08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RBC	4.43	4.31 - 5.48 tril/ L	08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	13.0 (L)	13.5 - 17.0 g/ dL	08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hematocrit	41.5	40.1 - 50.1 %	08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
MCV	94	80 - 100 fL	08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСН	29	28 - 33 pg	08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСНС	31 (L)	32 - 36 g/dL	08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RDW-CV	17 (H)	12 - 15 %	08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Platelets	310	150 - 400 bil/L		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Nucleated Red Blood Cells	0.0	<=0.0 %		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Neutrophils	7.9 (H)	1.6 - 7.2 bil/L		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Lymphocytes	2.3	1.1 - 4.0 bil/L		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Monocytes	1.1 (H)	0.0 - 0.9 bil/L		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Eosinophils	0.3	0.0 - 0.4 bil/L		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.0	0.0 - 0.1 bil/L		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.04	0.00 - 0.04 bil/L		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %		%		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U					08/10/2023 3:22 AM EDT
Narrative						
Authorizing Provider	Docult Turce					
Authorizing Provider Danielle S	Result Type BH LAB BLOOD	ORDERA	BLES			
Portorming Organization	Address			Dhone Mr.	mhor	
Performing Organization BEAUMONT	Address 28050 Grand R	iver Ave	City/State/ZIP Code Farmington Hills, MI	Phone Nu 800-551-0		
LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			48336			

(ABNORMAL) RENAL	FUNCTION PA	NEL - Fir	nal result (08/10/202	3 3:00 AM E	DT)
		Ref		Analysis	
Component	Value	Range	Test Method	Time	Performed At Pathologist Signature
Sodium	138	135 -		08/10/2023	BEAUMONT
		145		3:49 AM	
		mmol/L		EDT	FARMINGTON HILLS (CLIA #:
					23D0363256)
Potassium	3.8	3.5 - 5.2		08/10/2023	BEAUMONT
		mmol/L		3:49 AM	LABORATORY,
				EDT	FARMINGTON
					HILLS (CLIA #:
Chloride	105	98 - 111		08/10/2023	23D0363256) BEAUMONT
Chionae	105	mmol/L		3:49 AM	LABORATORY,
				EDT	FARMINGTON
					HILLS (CLIA #:
					23D0363256)
Carbon Dioxide -CO2	27	20 - 29		08/10/2023	BEAUMONT
		mmol/L		3:49 AM EDT	LABORATORY, FARMINGTON
				LUI	HILLS (CLIA #:
					23D0363256)
Anion Gap	6	5 - 17		08/10/2023	BEAUMONT
				3:49 AM	LABORATORY,
				EDT	FARMINGTON
					HILLS (CLIA #: 23D0363256)
Glucose	130 (H)	60 - 99		08/10/2023	BEAUMONT
	,	mg/dL		3:49 AM	LABORATORY,
		5		EDT	FARMINGTON
					HILLS (CLIA #:
Comment					23D0363256)
Comment: Fasting Blood Glucos	e: 60-99 mg/	'dı			
Random Blood Glucose					
Blood Urea Nitrogen	13	7 - 25		08/10/2023	BEAUMONT
-BUN		mg/dL		3:49 AM	LABORATORY,
				EDT	FARMINGTON
					HILLS (CLIA #: 23D0363256)
Creatinine	0.59 (L)	0.60 -		08/10/2023	BEAUMONT
Creddinine	0.000 (_)	1.30 mg/		3:49 AM	LABORATORY,
		dL		EDT	FARMINGTON
					HILLS (CLIA #:
	110			00/10/0000	23D0363256)
eGFR By Creatinine	110	>60 mL/ min/		08/10/2023 3:49 AM	BEAUMONT LABORATORY,
		1.73m2		EDT	FARMINGTON
					HILLS (CLIA #:
					23D0363256)
Comment [.]					

Comment:

Calculation based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation refit without adjustment for race. Glomerular Filtration Rate is estimated from serum creatinine, age and gender using the CKD-EPI equation:

G1: Normal GFR: >=90
G2: Mildly decreased GFR: 60-89
G3a: Mildly to moderately decreased GFR: 45-59
G3b: Moderately to severely decreased GFR: 30-44
G4: Severely decreased GFR: 15-29
G5: Kidney failure GFR: <15</pre>

		Ref		Analysis				
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature		
Calcium	8.1 (L)	8.5 - 10.5 mg/dL		08/10/2023 3:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Phosphorus	3.0	2.3 - 4.4 mg/dL		08/10/2023 3:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Albumin	2.6 (L)	3.5 - 4.9 g/dL		08/10/2023 3:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time		
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknov	vn 08/10/202	3 3:00 AM EDT	08/10/2023 3:22 AM EDT		
Narrative								
Authorizing Provider	Result Type							
Danielle S	21	BH LAB BLOOD ORDERABLES						
Performing Organization	Address	Address City/State/ZIP Code Phone Number						
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0				
MAGNESIUM LEVEL - Fin	•	Ref	·	Analysis				
Component	Value	Range	Test Method	Time		Pathologist Signature		
Magnesium	1.9	1.7 - 2.5 mg/dL		08/10/2023 3:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time		
Blood	VENOUS BLOC SPECIMEN / U					08/10/2023 3:22 AM EDT		
Narrative								
Authorizing Provider	Result Type							
Authorizing Provider Danielle S	Result Type BH LAB BLOOI) ORDERAE	BLES					
Danielle S	BH LAB BLOOD	ORDERAE						
Danielle S Performing Organization	BH LAB BLOOD		City/State/ZIP Code	Phone Nu				
Danielle S	BH LAB BLOOD			Phone Nu 800-551-0				

GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/10/2023 12:14 AM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	128	60 - 139 mg/dL		08/10/2023 12:21 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Heaven,			08/10/2023	BEAUMONT	
	Lauren NA			12:21 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOI SPECIMEN / U			08/10/202 EDT	23 12:14 AM	08/10/2023 12:21 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg/	d∟	IA #: 23D0363256) -	08/10/2023	12:21 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKI	ED DEVICE UNSOLICITE	ED RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	
(
GLUCOSE, POINT OF CA	ARE (GLUCOSE,				T)	
Component	Value		Test Methesd	2	Deufeure ed At	Dethele sist Cinneture
Component Glucose	Value 130	Range 60 - 139	Test Method	Time	BEAUMONT	Pathologist Signature
Comment: Capillary	130	mg/dL		8:58 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Heaven,			08/09/2023	BEAUMONT	
Tenomica by	Lauren NA			8:58 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOI)				08/09/2023 8:58 PM EDT
biood	SPECIMEN / U			00,00,202	.5 0.511101201	00,03,2023 0.30 FW ED F
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	IA #: 23D0363256) -	08/09/2023	8:58 PM EDT	
Authorizing Provider	Result Type					
William Rudy		EST DOCK	ED DEVICE UNSOLICITE	D RESULTS		

Performing Organization	Address		City/State/ZIP Code	Phone Number		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0488		
(ABNORMAL) GLUCOS	SE, POINT OF	CARE (GL Ref	UCOSE, POC) - Final	result (08/0 Analysis	9/2023 6:25	PM EDT)
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	204 (H)	60 - 139 mg/dL		08/09/2023 6:34 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary					,	
Performed By	Davis, Brooke NT			08/09/2023 6:34 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality	-	Volume	Collection		Received Time
Blood	WHOLE BLOO SPECIMEN / U	_		08/09/202	23 6:25 PM EDT	08/09/2023 6:34 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg/	d∟	:A #: 23D0363256) -	08/09/2023	6:34 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCK	ED DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0		
(ABNORMAL) GLUCOS	SE, POINT OF	CARE (GL Ref Range	UCOSE, POC) - Final Test Method	result (08/0 Analysis Time		P M EDT) Pathologist Signature
Glucose	164 (H)	60 - 139			BEAUMONT	
	104 (11)	mg/dL		12:16 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary Performed By	Brown, Diaja			08/00/2022	BEAUMONT	
Performed by	NA			12:16 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	WHOLE BLOO SPECIMEN / U			08/09/202 EDT	23 12:09 PM	08/09/2023 12:16 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg/	d∟	:A #: 23D0363256) -	08/09/2023	12:16 PM EDT	

Authorizing Provider	Result Type						
William Rudy		EST DOCKE	ED DEVICE UNSOLICITED	O RESULTS			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River A		Farmington Hills, MI 48336	800-551-0			
GLUCOSE, POINT OF CA	.RE (GLUCOSE,	POC) - Fi	nal result (08/09/2023	3 6:31 AM ED	T)		
,	, , , , , , , , , , , , , , , , , , ,	Ref	• • •	Analysis			
Component	Value	Range	Test Method	Time		Pathologist Signature	
Glucose Comment: Capillary	118	60 - 139 mg/dL		08/09/2023 6:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Performed By	Cole, Ebonie			08/09/2023	BEAUMONT		
Tenomica by	NA			6:39 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
	Anatomical Loo	cation /	Collection Method /			5	
Specimen (Source) Blood		<u> </u>	Volume	Collection	-	Received Time	
вюоа	WHOLE BLOOD SPECIMEN / Ur			08/09/202	3 631 AW EDI	08/09/2023 6:39 AM EDT	
Narrative							
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/	dL	:A #: 23D0363256) -	08/09/2023	6:39 AM EDT		
Authorizing Provider	Result Type						
William Rudy		ST DOCK	D DEVICE UNSOLICITED	O RESULTS			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	9488		
(ABNORMAL) CBC W/A	AUTO DIFF - F	inal resu	lt (08/09/2023 3:39 /	AM EDT)			
Composit	Value	Ref	Toot Motherd	Analysis	Doute was a -L A.	Dathalagist Cigrature	
Component WBC	Value 12.8 (H)	Range 3.5 - 10.1	Test Method	Time 08/09/2023		Pathologist Signature	
WBC	I2.0 (П)	5.5 - 10.1 bil/L		4:31 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
RBC	4.11 (L)	4.31 - 5.48 tril/ L		08/09/2023 4:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Hemoglobin	12.2 (L)	13.5 - 17.0 g/ dL		08/09/2023 4:31 AM EDT			

Component	Value	Ref Range	Test Method	Analysis Time	Performed At Pathologist Signature
Hematocrit	38.2 (L)	40.1 - 50.1 %		08/09/2023 4:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
MCV	93	80 - 100 fL		08/09/2023 4:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСН	30	28 - 33 pg		08/09/2023 4:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСНС	32	32 - 36 g/dL		08/09/2023 4:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RDW-CV	17 (H)	12 - 15 %		08/09/2023 4:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Platelets	269	150 - 400 bil/L		08/09/2023 4:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Nucleated Red Blood Cells	0.0	<=0.0 %		08/09/2023 4:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Neutrophils	8.0 (H)	1.6 - 7.2 bil/L		08/09/2023 4:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Lymphocytes	2.7	1.1 - 4.0 bil/L		08/09/2023 4:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Monocytes	1.7 (H)	0.0 - 0.9 bil/L		08/09/2023 4:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Eosinophils	0.3	0.0 - 0.4 bil/L		08/09/2023 4:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Basophils	0.1	0.0 - 0.1 bil/L		08/09/2023 4:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

-		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Immature Granulocytes	0.06 (H)	0.00 - 0.04 bil/L		08/09/2023 4:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %	0.5	%		08/09/2023 4:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Location /		Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	VENOUS BLOOD SPECIMEN / Unknown		Venipuncture / Unknov	nipuncture / Unknown 08/09/2023 3:39 AM EDT		08/09/2023 4:20 AM EDT
Narrative						
Narrative Authorizing Provider	Result Type					
	Result Type BH LAB BLOOI) ORDERAE	BLES			
Authorizing Provider) ORDERAE	BLES			
Authorizing Provider	BH LAB BLOOD) ORDERAE	BLES City/State/ZIP Code	Phone Nu	mber	
Authorizing Provider Danielle S	BH LAB BLOOD			Phone Nu 800-551-0		

(ABNORMAL) RENAL FUNCTION PANEL - Final result (08/09/2023 3:39 AM EDT)

C I		Ref	T	Analysis		
Component Sodium	Value 139	Range 135 - 145 mmol/L	Test Method	Time 08/09/2023 5:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Pathologist Signature
Potassium	3.7	3.5 - 5.2 mmol/L		08/09/2023 5:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	108	98 - 111 mmol/L		08/09/2023 5:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	26	20 - 29 mmol/L		08/09/2023 5:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	5	5 - 17		08/09/2023 5:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose	119 (H)	60 - 99 mg/dL		08/09/2023 5:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Fasting Blood Glucos Random Blood Glucos	-					

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Blood Urea Nitrogen -BUN	11	7 - 25 mg/dL		08/09/2023 5:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.55 (L)	0.60 - 1.30 mg/ dL		08/09/2023 5:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	112	>60 mL/ min/ 1.73m2		08/09/2023 5:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Comment:

Calculation based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation refit without adjustment for race. Glomerular Filtration Rate is estimated from serum creatinine, age and gender using the CKD-EPI equation:

G1: Normal GFR: >=90
G2: Mildly decreased GFR: 60-89
G3a: Mildly to moderately decreased GFR: 45-59
G3b: Moderately to severely decreased GFR: 30-44
G4: Severely decreased GFR: 15-29
G5: Kidney failure GFR: <15</pre>

Calcium	7.8 (L)	8.5 - 10.5 mg/dL		08/09/2023 5:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Phosphorus	2.5	2.3 - 4.4 mg/dL		08/09/2023 5:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Albumin	2.5 (L)	3.5 - 4.9 g/dL		08/09/2023 5:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Location /		Collection Method / Volume	Collection	Timo	Received Time
Blood	Laterality VENOUS BLOOD SPECIMEN / Unknown		Venipuncture / Unknown 08/09/2023 3:39			
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOD	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	

MAGNESIUM LEVEL - Final result (08/09/2023 3:39 AM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Magnesium	2.0	1.7 - 2.5 mg/dL		08/09/2023 5:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC)D	Venipuncture / Unknor	wn 08/09/202	3 3:39 AM EDT	08/09/2023 4:20 AM EDT
	SPECIMEN / U	nknown				
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOD) ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT	28050 Grand R	liver Ave	Farmington Hills, MI	800-551-0	488	
LABORATORY, FARMINGTON HILLS			48336			
(CLIA #: 23D0363256)						
(ABNORMAL) GLUCOS			LICOSE DOC) - Einal	result (08/0	9/2023 12.30	
		Ref	0003L, 1 00) - 1 mai	Analysis	5/2025 12.50	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	153 (H)	60 - 139			BEAUMONT	
		mg/dL		12:36 AM EDT	LABORATORY, FARMINGTON	
				LDT	HILLS (CLIA #:	
					23D0363256)	
Comment: Capillary Performed By	Cole, Ebonie			00/00/2022	BEAUMONT	
Реполнеа ву	NA			12:36 AM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #:	
					23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	WHOLE BLOOI SPECIMEN / U			08/09/202 EDT	3 12:30 AM	08/09/2023 12:36 AM EDT
	Si Echileri y Ol			LDT		
Narrative	P 4 51 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		·····	00 /00 /2022	12.26	
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	LA #: 23DU363256) -	08/09/2023	12:30 AM EDT	
Authorizing Provider	Result Type					
William Rudy		EST DOCKI	ED DEVICE UNSOLICITE	D RESULTS		
,						
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY,	28050 Grand R	aver Ave	Farmington Hills, MI 48336	800-551-0	488	
FARMINGTON HILLS						
(CLIA #: 23D0363256)						

(ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/08/2023 6:27 PM EDT)

		Ref		Analysis					
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature			
Glucose	151 (H)	60 - 139 mg/dL		08/08/2023 6:40 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)				
Comment: Capillary				00/00/2022					
Performed By	Fleming, Lizzie RN			08/08/2023 6:40 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)				
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time			
Blood	WHOLE BLOO SPECIMEN / U			08/08/202	23 6:27 PM EDT	08/08/2023 6:40 PM EDT			
Narrative									
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	IA #: 23D0363256) -	08/08/2023	6:40 PM EDT				
Authorizing Provider	Result Type								
William Rudy	BH LAB POC T	BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS							
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber				
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488				
(ABNORMAL) GLUCOS	E, POINT OF	-	UCOSE, POC) - Final		8/2023 11:59	AM EDT)			
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature			
Glucose	141 (H)	60 - 139		08/08/2023					
Comment: Capillary		mg/dL		12:06 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)				
Performed By	Brown,			08/08/2023	BEAUMONT				
Tenomica by	Stephanie NA			12:06 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)				
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time			
Blood	WHOLE BLOO SPECIMEN / U				23 11:59 AM	08/08/2023 12:06 PM EDT			
NL C									
Narrative BEAUMONT LABORATORY,			A #: 2300363256) -	08/08/2023	12:06 PM EDT				
Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	′d∟		00/00/2025					
Authorizing Provider	Result Type								
William Rudy	BH LAB POC T	EST DOCKI	ED DEVICE UNSOLICITE	D RESULTS					

Performing Organization	Address	City/State/ZIP Code	Phone Number		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) List stopped at 200 resu	28050 Grand River Ave	Farmington Hills, MI 48336 mitted.	800-551-0488		
	,				
Care Teams					
Team Member None None	Relationship PCP - General	Specialty		Start Date 9/6/23	End Date
None None				576725	
Document Inform	ation				
Primary Care Provider		0.	her Service Providers:	Document Co	verage Dates
None None (Sep. 06, 202) Beaumont Health (Befor Oakwood) 3601 W. 13 Mile Rd Royal Oak, MI 48073 Custodian Organization		t, Botsford, and		Feb. 27, 1961	- Mar. 06, 2025
Beaumont Health (Befor 3601 W. 13 Mile Rd Royal Oak, MI 48073 Legal Authenticator	e 7/21/2024) (Beaumon	t, Botsford, and Oakwoo	od)		
Susan T					



If you take your Lucy record on a thumb drive to a different doctor, he or she might be able to use his computer to read the file electronically. Your downloaded, machine-readable Personal Health Summary document is in a format called "CDA." If your doctor has a computer that understands CDA, your information is a folder on your thumb drive called **MachineReadable_XDMFormat**. You might need to enter a password before your doctor can use this file.

Copyright ©2025 Epic

Patient Demographics - Male; born Feb. 27, 1961					
Patient Address	Patient Name	Communication			
21207 Parker <i>(Home)</i> FARMINGTON HILLS, MI 48336	Ioan Suiugan	248-759-0294 (Home) 248-759-0294 (Mobile) ioanaabdic@gmail.com			
Former (Aug. 01, 2023 - Aug. 28, 2023): 30541 DAWSON ST (Home) GARDEN CITY, MI 48135					
Language	Race / Ethnicity	Marital Status			
English - Written (Preferred)	White / Not Hispanic or Latino	Divorced			

Note from Beaumont Health (Before 7/21/2024) (Beaumont, Botsford, and Oakwood)

This document contains information that was shared with Ioan Suiugan. It may not contain the entire record from Beaumont Health (Before 7/21/2024) (Beaumont, Botsford, and Oakwood).

Reason for Visit Reason Altered Mental Status Auth/Cert (Routine) Specialty Diagnoses / Procedures **Referred By Contact Referred To Contact** Emergency Diagnoses **Emergency Center Fh** Altered mental status, 28050 Grand River Ave unspecified altered mental Farmington Hills, MI 48336-5933 status type

					Phone: 947-521-8566 Fax: 248-615-7390	
Referral ID	Status	Reason	Start Date	Expiration Date	Visits Requested	Visits Authorized
16897171						

Encounter l	Details
-------------	---------

Date Type 08/01/2023 Hospital 5:23 PM Encounter EDT 08/29/2023 2:39 PM EDT

Department

Corewell Health Farmington Hills Hospital 4 South 28050 Grand River Ave Farmington Hills, MI 48336-5933 947-521-8587

Care Team (Latest Contact Info) Description

Diane Kaiser Alexander 28050 Grand River Ave. Farmington Hills, MI 48336 248-471-8564 (Work) 248-615-7390 (Fax)

Armen Korkigian

2635 Coolidge Hwy Berkley, MI 48072-0921 248-541-2512 (Work) 248-541-0232 (Fax)

William Rudy

2635 Coolidge Hwy Berkley, MI 48072-0921 248-541-2512 (Work) 248-541-0232 (Fax)

Christine Carline

28050 Grand River Ave FARMINGTON HILLS, MI 48336 248-471-8566 (Work) 248-615-7266 (Fax)

Catherine G

Brynn H

Michael C

Netra V

Katie L

Nadia L

Holly F

Michelle A

Carley A

Sarah I

William Boudouris

28595 Orchard Lake Rd #200 Farmington Hills, MI 48334 248-553-0010 (Work) 248-553-5957 (Fax)

Sabiha Omar

28592 Orchard Lake Rd #333 Farmington Hills, MI 48334 248-865-7271 (Work) 248-865-7274 (Fax)

Dasha R

Amal Khalife

28080 Grand River Ave Ste 306N FARMINGTON HILLS, MI 48336 947-521-8920 (Work) 248-471-8864 (Fax)

- Home - Health Care Svc

Discharge Disposition: z coding

Danitra A

Date	Туре	Department	Care Team (Latest Contact Info) Description
			Sara R
			Tiffanie C
			Samantha C
			Katherine F
			Melanie H
			Lori S
			Shaniqua H
			Brianna M
			Kelsey W
			Sarah P
			Christopher M
			Brooke D
			Timika S
			Fatema B
			Camille H
			Dragica S
			Lourdes Q
			Mansoora A
			Maria L
			Christine B
			Deborah A
			Angelina B
			Hala R
			Joan O
			Shaterica B
			Denise B
			Gloria B
			Jennifer G
			Alana P
			Shelly P
			Monique T
			Andrew M
			Vinod D
			Kimberly C

Medications - documente	d as of this encounter (statuse	s as of 03/06/2025)			
Medication	Sig	Dispensed		End Date	Status
acetaminophen (TYLENOL) 325 MG PO Tab	place 2 Tablets into the PEG tube every 4 hours as needed for FOR MODERATE PAIN, FOR MILD PAIN or FOR FEVER.		08/29/2023		Active
amiodarone (CORDARONE, PACERONE) 200 MG PO Tab	place 1 Tablet into the PEG tube once daily.	30 Tablet	08/30/2023		Active
apixaban (ELIQUIS) 5 MG PO Tab	place 1 Tablet into the PEG tube twice daily.	60 Tablet	08/29/2023		Active
atorvastatin (LIPITOR) 40 MG PO Tab	place 1 Tablet into the PEG tube once every night at bedtime.	30 Tablet	08/29/2023		Active
clopidogrel (PLAVIX) 75 MG PO Tab	place 1 Tablet into the PEG tube once daily.	30 Tablet	08/29/2023		Active
LORazepam (INTENSOL) 2 MG/ ML PO Conc	administer 0.5 mL as directed every 6 hours as needed for FOR AGITATION.	30 mL	08/29/2023		Active
metoprolol (LOPRESSOR) 25 MG PO Tab	place 1 Tablet into the PEG tube twice daily.	60 Tablet	08/29/2023		Active
OLANZapine (ZyPREXA) 10 MG PO Tab	place 1 Tablet into the PEG tube twice daily.	60 Tablet	08/29/2023		Active
clonazePAM (KlonoPIN) 1 MG PO Tab	place 1 Tablet into the PEG tube once every night at bedtime.	30 Tablet	08/29/2023		Active
acetaminophen (TYLENOL) 325 MG PO Tab	2 Tablets every 4 hours as needed.			08/29/2023	Discontinued (Reorder)
amiodarone (CORDARONE, PACERONE) 200 MG PO Tab	1 Tablet once daily.			08/29/2023	Discontinued
apixaban (ELIQUIS) 5 MG PO Tab	take 1 Tablet by mouth twice daily.			08/29/2023	Discontinued (Reorder)
Ascorbic Acid 250 MG PO Tab	1 Tablet once daily.			08/29/2023	Discontinued
atorvastatin (LIPITOR) 40 MG PO Tab	1 Tablet once every night at bedtime.			08/29/2023	Discontinued (Reorder)
clopidogrel (PLAVIX) 75 MG PO Tab	1 Tablet once daily.			08/29/2023	Discontinued (Reorder)
HYDROcodone-acetaminophen (NORCO) 5-325 MG PO Tab	days		07/26/2023	08/09/2023	Discontinued
insulin lispro (HumaLOG) 100 UNIT/ML INJ Solution	inject 1-6 Units into the skin 4 times daily. Sliding scale			08/09/2023	Discontinued
LORazepam (INTENSOL) 2 MG/ ML PO Conc	0.5 mL every 6 hours as needed for FOR AGITATION.			08/29/2023	Discontinued (Reorder)
metoprolol (LOPRESSOR) 25 MG PO Tab	1 Tablet twice daily.			08/29/2023	Discontinued (Reorder)
nicotine (NICODERM) 14 mg/ 24hr TRANSDERM PATCH 24 HR	place 1 Patch onto the skin every 24 hours.			08/29/2023	Discontinued
OLANZapine (ZyPREXA) 10 MG PO Tab	1 Tablet twice daily.			08/29/2023	Discontinued (Reorder)
polyethylene glycol 3350 (MIRALAX) 17 GM/SCOOP PO Powder	take 17 g by mouth once daily.			08/29/2023	Discontinued
tamsulosin (Flomax) 0.4 MG PO Cap	take 1 Capsule by mouth once daily. Take 30 minutes after the same meal each day.			08/29/2023	Discontinued
valproate (DEPAKENE) 250 MG/ 5ML PO Solution	take 20 mL by mouth twice daily.			08/09/2023	Discontinued
valproate (DEPAKENE) 250 MG/ 5ML PO Solution	10 mL once daily.			08/09/2023	Discontinued
valproate (DEPAKENE) 250 MG/ 5ML PO Solution	take 20 mL by mouth twice daily.	600 mL	08/09/2023	08/29/2023	Discontinued (Reorder)

Medication	Sig	Dispensed	Start Date	End Date	Status
insulin regular human (HumuLIN R, NovoLIN R) 100 UNIT/ML INJ Solution	inject 2-5 Units into the skin every 6 hours.		08/09/2023	08/29/2023	Discontinued
clonazePAM (KlonoPIN) 1 MG PO Tab	place 1 Tablet into the PEG tube once every night at bedtime.	30 Tablet	08/29/2023	08/29/2023	Discontinued (Reorder)
clonazePAM (KlonoPIN) 0.5 MG PO Tab	take 1 Tablet by mouth once daily.	30 Tablet	08/29/2023	08/29/2023	Discontinued
clonazePAM (KlonoPIN) 0.5 MG PO Tab	take 1 Tablet by mouth twice daily.	60 Tablet	08/29/2023	08/29/2023	Discontinued (Reorder)
valproate (DEPAKENE) 250 MG/ 5ML PO Solution	take 20 mL by mouth twice daily.	1200 mL	08/29/2023	09/13/2023	Discontinued (Reorder)
clonazePAM (KlonoPIN) 0.5 MG PO Tab	take 1 Tablet by mouth twice daily.	60 Tablet	08/29/2023	09/13/2023	Discontinued (Reorder)
Nutritional Supplements (Glucerna 1.5 Cal) PO Liquid	70 cc/hr via peg	10000 mL	08/29/2023	08/29/2024	Expired

Active Problems - documented as of this encounter (statuses as of 03/06/2025)

Information not available to this user

Social History - documented as of this encounter

Sex and Gender Information	Value	Date Recorded
Sex Assigned at Birth	Not on file	

Last Filed Vital Signs - documented in this encounter

Vital Sign	Reading	Time Taken	Comments
Blood Pressure	132/61	08/29/2023 11:21 AM EDT	
Pulse	88	08/29/2023 11:21 AM EDT	
Temperature	36.9 °C (98.5 °F)	08/29/2023 11:21 AM EDT	
Respiratory Rate	18	08/29/2023 11:21 AM EDT	
Oxygen Saturation	95%	08/29/2023 11:21 AM EDT	
Inhaled Oxygen Concentration	-	-	
Weight	87.1 kg (192 lb 0.3 oz)	08/23/2023 6:00 AM EDT	
Height	188 cm (6' 2.02")	08/10/2023 11:00 PM EDT	
Body Mass Index	24.64	08/10/2023 11:00 PM EDT	

Discharge Summaries - documented in this encounter

Danielle S - 08/29/2023 11:49 AM EDT

Formatting of this note is different from the original. Images from the original note were not included. Discharge Summary

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Date of Discharge: 8/29/2023

Hospital Principal Problem (Discharge Diagnoses): Altered mental status, unspecified altered mental status type

All Hospital Problems (Other Diagnoses): Active Hospital Problems Diagnosis Principal Problem: Altered mental status, unspecified altered mental status type Sepsis without acute organ dysfunction (CMS/HCC) Assessment & Plan Note: Presentation to ED 8/1 with altered mental status S/p CPA 5/2023, low grade temp in ED 100.6 Hx MDR enterobacter 7/2023 from urine cx CT chest with L sided pleural effusion, oxygenating well on RA

?aspiration vs GU vs other

Check procalcitonin, legionella/pneumococcal Ag, MRSA screen Consider CTAP Continue current abx for now

8/4: procal 0.50. Await MRSA screen. Continue current abx for now

8/7 MRSA screen not collected, WBC trending down. Remains on broad spectrum abx; anticipate today is the last day of antibiotics with IV cefepime and flagyl (7 days) of empiric treatment. Strep and legionella are negative; urine cutlure with Enterobacter from 8/1. Will stop IV vancomycin given lack of staph aureus on cultures.

Urinary tract infection associated with indwelling urethral catheter (CMS/HCC) Community acquired pneumonia Altered mental status

Resolved Hospital Problems No resolved problems to display.

Consultants:

Provider Role Specialty From To Contact Number Contact Number Boudouris, William D, DO Consulting Physician Neurology 08/02/23 0940 08/02/23 1503 248-553-0010 248-400-7170

Omar, Sabiha J, MD Consulting Physician Psychiatry 08/02/23 0940 -- 248-865-7271 248-400-3422

Khalife, Amal A, DO Consulting Physician Infectious Disease 08/03/23 0848 08/07/23 1236 947-521-8920 --

Evaluation on Day of Discharge: stable General: Alert, non-toxic appearing. Appears in NAD. Cardio: RRR, S1 S2. No murmurs. Respiratory: Lungs clear to auscultation bilaterally. No retractions or accessory muscle use. Abdomen: Bowel sounds present X 4 quadrants. Soft, NT/ND.

Hospital Course:

The patient presented to the hospital with chief complaint of altered mental status. He was found to have toxic metabolic encephalopathy superimposed on anoxic brain injury secondary to sepsis / UTI. He was treated with full 8 day course of IV antibiotic therapy per ID recommendation, Dr. Khalife. No further antibiotics need on DC. Lytes supplemented as appropriate. Patient stabilized for discharge return to ECF WBA. No acute hospital related complications. Exceedingly high expectation for recurrent hospital admissions 2/2 mentation and underlying co morbidities.

Discharge Instructions:

Current Discharge Medication List

START taking these medications

Refills AM Noon PM Bedtime * clonazePAM 1 MG Tabs place 1 Tablet into the PEG tube once every night at bedtime. Quantity: 30 Tablet Commonly known as: KlonoPIN

Refills: 0

* clonazePAM 0.5 MG Tabs take 1 Tablet by mouth twice daily. Quantity: 60 Tablet Commonly known as: KlonoPIN

Refills: 0

* This list has 2 medication(s) that are the same as other medications prescribed for you. Read the directions carefully, and ask your doctor or other care provider to review them with you.

CHANGE how you take these medications

Refills AM Noon PM Bedtime acetaminophen 325 MG Tabs place 2 Tablets into the PEG tube every 4 hours as needed for FOR MODERATE PAIN, FOR MILD PAIN or FOR FEVER. What changed: how to take this reasons to take this Commonly known as: TYLENOL

Refills: 0

amiodarone 200 MG Tabs place 1 Tablet into the PEG tube once daily. Quantity: 30 Tablet What changed: how to take this Commonly known as: CORDARONE, PACERONE

Start taking on: August 30, 2023 Refills: 0

apixaban 5 MG Tabs place 1 Tablet into the PEG tube twice daily. Quantity: 60 Tablet What changed: how to take this Commonly known as: ELIQUIS

Refills: 0

atorvastatin 40 MG Tabs place 1 Tablet into the PEG tube once every night at bedtime. Quantity: 30 Tablet What changed: how to take this Commonly known as: LIPITOR

Refills: 0

clopidogrel 75 MG Tabs place 1 Tablet into the PEG tube once daily. Quantity: 30 Tablet What changed: how to take this Commonly known as: PLAVIX

Refills: 0

LORazepam 2 MG/ML Conc administer 0.5 mL as directed every 6 hours as needed for FOR AGITATION. Quantity: 30 mL What changed: how to take this Commonly known as: INTENSOL

Refills: 0

metoprolol 25 MG Tabs place 1 Tablet into the PEG tube twice daily. Quantity: 60 Tablet What changed: how to take this Commonly known as: LOPRESSOR

Refills: 0

OLANZapine 10 MG Tabs place 1 Tablet into the PEG tube twice daily. Quantity: 60 Tablet What changed: how to take this Commonly known as: ZyPREXA

Refills: 0

valproate 250 MG/5ML Soln take 20 mL by mouth twice daily. Quantity: 1200 mL What changed: Another medication with the same name was removed. Continue taking this medication, and follow the directions you see here. Commonly known as: DEPAKENE

Refills: 0

STOP taking these medications

Ascorbic Acid 250 MG Tabs

Flomax 0.4 MG Caps Generic drug: tamsulosin

HYDROcodone-acetaminophen 5-325 MG Tabs Commonly known as: NORCO insulin lispro 100 UNIT/ML Soln Commonly known as: HumaLOG

nicotine 14 mg/24hr Pt24 Commonly known as: NICODERM

polyethylene glycol 3350 17 GM/SCOOP Powd Commonly known as: MIRALAX

Discharge Procedure Orders Diet Other - see comment Order Comments: Glucerna @ 70 ml/hr with 75 ml/hr FWF + Dysphagia diet 1;1 assist Small bites, pleasure feed only

HOME ACTIVITY AS TOLERATED WITH ASSISTANCE

CONTACT YOUR DOCTOR IF Order Comments: you have shortness of breath you have angina (chest pain) or return to the Emergency Center your temperature is over 100.5 F you are unable to urinate you have nausea and vomiting you gain 2-3 pounds in one day or 5 pounds in 5 days you have increased swelling in your hands, feet or stomach you have increased redness, swelling, drainage or warmth to incision/ exam site your pain is not relieved by prescribed pain medication you have swelling or redness in one or both calves you have bleeding that does not stop Sudden changes in vision

SPECIAL DISCHARGE INSTRUCTIONS Order Comments: Maintain MITTS on discharge

EXTENDED CARE FACILITY ORDERS Order Comments: Registered Dietitian Social Work Speech Pathology

Order Specific Question Answer Comments Hospital code status was: No Code

Electronically signed by William Rudy at 09/05/2023 12:46 PM EDT

Discharge Instructions - documented in this encounter Discharge Instructions Christine B - 08/29/2023 2:04 PM EDT Formatting of this note might be different from the original. Corpore Sano Home Health Care INC 734-454-3488 Electronically signed by Christine B at 08/29/2023 2:04 PM EDT

Medications at Time of Discharge - documented as of this encounter

Medication	Sig	Dispensed	Start Date	End Date
acetaminophen (TYLENOL) 325 MG PO Tab	place 2 Tablets into the PEG tube every 4 hours as needed for FOR MODERATE PAIN, FOR MILD PAIN or FOR FEVER.		08/29/2023	
amiodarone (CORDARONE, PACERONE) 200 MG PO Tab	place 1 Tablet into the PEG tube once daily.	30 Tablet	08/30/2023	
apixaban (ELIQUIS) 5 MG PO Tab	place 1 Tablet into the PEG tube twice daily.	60 Tablet	08/29/2023	
atorvastatin (LIPITOR) 40 MG PO Tab	place 1 Tablet into the PEG tube once every night at bedtime.	30 Tablet	08/29/2023	
clonazePAM (KlonoPIN) 1 MG PO Tab	place 1 Tablet into the PEG tube once every night at bedtime.	30 Tablet	08/29/2023	
clopidogrel (PLAVIX) 75 MG PO Tab	place 1 Tablet into the PEG tube once daily.	30 Tablet	08/29/2023	
LORazepam (INTENSOL) 2 MG/ ML PO Conc	administer 0.5 mL as directed every 6 hours as needed for FOR AGITATION.	30 mL	08/29/2023	
metoprolol (LOPRESSOR) 25 MG PO Tab	place 1 Tablet into the PEG tube twice daily.	60 Tablet	08/29/2023	
OLANZapine (ZyPREXA) 10 MG PO Tab	place 1 Tablet into the PEG tube twice daily.	60 Tablet	08/29/2023	
Nutritional Supplements (Glucerna 1.5 Cal) PO Liquid	70 cc/hr via peg	10000 mL	08/29/2023	08/29/2024
clonazePAM (KlonoPIN) 0.5 MG PO Tab	take 1 Tablet by mouth twice daily.	60 Tablet	08/29/2023	09/13/2023
valproate (DEPAKENE) 250 MG/ 5ML PO Solution	take 20 mL by mouth twice daily.	1200 mL	08/29/2023	09/13/2023

Ordered Prescriptions - documented in this encounter

Prescription	Sig	Dispensed	Start Date	End Date
clonazePAM (KlonoPIN) 1 MG PO Tab	place 1 Tablet into the PEG tube once every night at bedtime.	30 Tablet	08/29/2023	
OLANZapine (ZyPREXA) 10 MG PO Tab	place 1 Tablet into the PEG tube twice daily.	60 Tablet	08/29/2023	
metoprolol (LOPRESSOR) 25 MG PO Tab	place 1 Tablet into the PEG tube twice daily.	60 Tablet	08/29/2023	
LORazepam (INTENSOL) 2 MG/ ML PO Conc	administer 0.5 mL as directed every 6 hours as needed for FOR AGITATION.	30 mL	08/29/2023	
clopidogrel (PLAVIX) 75 MG PO Tab	place 1 Tablet into the PEG tube once daily.	30 Tablet	08/29/2023	
atorvastatin (LIPITOR) 40 MG PO Tab	place 1 Tablet into the PEG tube once every night at bedtime.	30 Tablet	08/29/2023	
apixaban (ELIQUIS) 5 MG PO Tab	place 1 Tablet into the PEG tube twice daily.	60 Tablet	08/29/2023	
amiodarone (CORDARONE, PACERONE) 200 MG PO Tab	place 1 Tablet into the PEG tube once daily.	30 Tablet	08/30/2023	
acetaminophen (TYLENOL) 325 MG PO Tab	place 2 Tablets into the PEG tube every 4 hours as needed for FOR MODERATE PAIN, FOR MILD PAIN or FOR FEVER.		08/29/2023	
Nutritional Supplements (Glucerna 1.5 Cal) PO Liquid	70 cc/hr via peg	10000 mL	08/29/2023	08/29/2024
clonazePAM (KlonoPIN) 0.5 MG PO Tab	take 1 Tablet by mouth twice daily.	60 Tablet	08/29/2023	09/13/2023
valproate (DEPAKENE) 250 MG/ 5ML PO Solution	take 20 mL by mouth twice daily.	1200 mL	08/29/2023	09/13/2023
clonazePAM (KlonoPIN) 0.5 MG PO Tab	take 1 Tablet by mouth twice daily.	60 Tablet	08/29/2023	08/29/2023
clonazePAM (KlonoPIN) 0.5 MG PO Tab	take 1 Tablet by mouth once daily.	30 Tablet	08/29/2023	08/29/2023
clonazePAM (KlonoPIN) 1 MG PO Tab	place 1 Tablet into the PEG tube once every night at bedtime.	30 Tablet	08/29/2023	08/29/2023
insulin regular human (HumuLIN R, NovoLIN R) 100 UNIT/ML INJ Solution	inject 2-5 Units into the skin every 6 hours.		08/09/2023	08/29/2023
valproate (DEPAKENE) 250 MG/ 5ML PO Solution	take 20 mL by mouth twice daily.	600 mL	08/09/2023	08/29/2023

Progress Notes - documented in this encounter

Danielle S - 08/29/2023 11:47 AM EDT

Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined resting in no acute distress. He is drowsy but easily awakens. Somewhat restless and attempting to cover himself with a blanket. Appears comfortable.

Objective:

Vitals: Blood pressure 132/61, pulse 88, temperature 98.5 °F (36.9 °C), temperature source Axillary, resp. rate 18, height 188 cm (6' 2.02"), weight 87.1 kg (192 lb 0.3 oz), SpO2 95 %. Body mass index is 24.64 kg/m².

Intake/Output Summary (Last 24 hours) at 8/29/2023 1147 Last data filed at 8/29/2023 0600 Gross per 24 hour Intake --Output 3382 ml Net -3382 ml Physical Examination: General: Non-toxic chronically ill appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam. Eyes: EOMI. No scleral icterus. ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally with few scattered rhonchi right greater than left no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all quadrants, soft, NT/ND. + PEG tube. Ext: No clubbing, cyanosis, or edema. Psychiatric: Sedated. Appears calm and comfortable. Neurologic: Somnolent on exam. Spontaneous movement of extremities. Skin: No gross rashes. **Current Medications: Current Facility-Administered Medications** Medication acetaminophen (TYLENOL) tablet 650 mg albuterol-ipratropium (DUONEB) nebulizer solution 3 mL albuterol-ipratropium (DUONEB) nebulizer solution 3 mL amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg clonazePAM (KlonoPIN) tablet 0.5 mg clonazePAM (KlonoPIN) tablet 1 mg clopidogrel (PLAVIX) tablet 75 mg insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units LORazepam (ATIVAN) tablet 0.5 mg metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

Recent Labs Component 08/29/23 0601 08/28/23 0620 08/27/23 1608 08/02/23 0632 08/01/23 1731 WBC 6.9 5.6 7.3 < > 13.7* RBC 4.15* 3.53* 3.67* < > 4.45 HGB 12.0* 10.5* 10.8* < > 13.0* MCV 93 92 93 < > 96 PLT 294 191 193 < > 283 INR -- -- -- 1.2 < > = values in this interval not displayed.

*Asterisks denote abnormal values Recent Labs Component 08/29/23 0601 08/29/23 0550 08/29/23 0016 08/28/23 1223 08/28/23

0620 08/27/23 1808 08/27/23 1608 08/26/23 1752 08/26/23 1230 08/20/23 1617 08/20/23 1417 08/18/23 0521 08/18/23 0403 08/02/23 0602 08/02/23 0541 NA 137 -- -- 139 -- 138 -- 136 < > 139 -- 138 < > 148* K 3.4* -- -- 3.3* -- 3.4* -- 3.0* < > 3.6 -- 3.6 < > 4.0 CL 103 -- -- 106 -- 105 -- 103 < > 104 -- 105 < > 117* CO2 27 -- -- 24 -- 27 -- 23 < > 25 -- 26 < > 26 ANIONGAP 7 -- -- 9 -- 6 -- 10 < > 10 -- 7 < > 5 BUN 10 -- -- 12 -- 14 -- 12 < > 13 -- 13 < > 24 CREAT 0.59* -- -- 0.50* -- 0.58* -- 0.57* < > 0.60 -- 0.62 < > 0.67 ALB -- -- -- -- -- 2.4* -- 2.6* -- 2.6* < > 2.7* | 2.7* GLOBULIN -- -- -- -- -- 3.6 -- 3.7 -- -- 4.1* AGRATIO -- -- -- -- -- 0.7 -- 0.7 -- 0.7 ALP -- -- -- -- -- -- 123* -- 133* -- -- 90 AST -- -- -- -- -- 46* -- 24 -- -- 17 ALT -- -- -- -- -- 39 -- 19 -- -- 12 BILITOTAL -- -- -- -- -- 0.2* -- 0.3 -- -- 0.5 GLU 124* 145* 128 < > 124* < > 108* < > 131* < > 135* < > 133* < > 137* < > = values in this interval not displayed.

*Asterisks denoteabnormal values

Assessment/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Penile edema Generalized weakness / Chronic debility Aspiration event 8/23 following NP suctioning causing emesis Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury - Foley catheter exchanged 8/24. Maintain Q 4 week exchanges.

Plan:

- Clinically stable off antibiotic therapy

- Continue scheduled sedative medications and utilized PRN orders if patient is agitated or restless.

Medically stable for discharge return to group home 8/29

Danielle Saunders, AGPCNP-BC Internal Medicine

Electronically signed by William Rudy at 08/29/2023 12:09 PM EDT

Associated attestation - William Rudy - 08/29/2023 12:09 PM EDT Formatting of this note might be different from the original. Patient was seen and examined on rounds Case discussed with Danielle Saunders, RN, NP-C Reviewed progress note as documented Agree in principle with documentation

Patient appears medically stable for discharge although the likelihood of readmission in the hospital in the near future is exceedingly high

Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

No complaints offered by the patient. Staff reports that he tried to get out of the bed middle of the day yesterday and was not directable. Ativan was given.

Objective:

Last Filed Vitals: Temp 99 °F (37.2 °C) (08/29/23 0803) Source Axillary (08/29/23 0803) BP 112/79 (08/29/23 0803) Heart Rate 95 (08/29/23 0803) Resp 18 (08/29/23 0803) O2 (L/min) 2 L/min (08/24/23 0702) SpO2 96 % (08/29/23 0803) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/23/23 0600) BMI 24.6 (08/23/23 0600)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior: alert; cooperative Motor Activity & Musculoskeletal: normal motor activity; no abnormal movements Speech & Language: Nodes head when spoken to Gait & Station: In bed Mood: Euthymic Affect: appropriate to setting Thought Content: Unable to assess due to limited communication

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other

Mood disorder (CMS/HCC) Assessment & Plan Add Klonopin 0.5 mg middle of the day as before to reduce restlessness and impulsive behavior.

Electronically signed by Sabiha Omar at 08/29/2023 10:13 AM EDT

Jessica Lofgren - 08/28/2023 12:47 PM EDT Formatting of this note is different from the original. Images from the original note were not included. INFECTIOUS DISEASE PROGRESS NOTE

Patient Name: Ioan Suiugan; Patient MRN: 9942681 Admission Date: 8/1/2023; Hospital Day: 28

ID Consultant: Jessica M Lofgren, DO Date: 8/28/2023 Time: 12:48 PM

Interval History: Patient seen in follow up for Fever

Tmax 99.5 Noted to have misplaced Foley yesterday afternoon, repositioned with 1L urine output and improvement in BP and temps since that time.

Current Antibiotics: Vanco day 2 Rocephin day # 3 Azithro day# 3 Current Facility-Administered Medications

Medication Dose Route Frequency

- albuterol-ipratropium (DUONEB) nebulizer solution 3 mL 3 mL Inhalation RT-QID
- amiodarone (CORDARONE, PACERONE) tablet 200 mg 200 mg PEG Tube DAILY
- apixaban (ELIQUIS) tablet 5 mg 5 mg Oral Q 12 H
- atorvastatin (LIPITOR) tablet 40 mg 40 mg PEG Tube Q HS
- azithromycin (ZITHROMAX) 500 mg in sodium chloride 0.9 % 255 mL IVPB 500 mg Intravenous Q 24 H
- cefTRIAXone (ROCEPHIN) 1 g in sodium chloride 0.9 % 100 mL IVPB 1 g Intravenous Q 24 H
- clonazePAM (KlonoPIN) tablet 0.5 mg 0.5 mg Oral DAILY
- clonazePAM (KlonoPIN) tablet 1 mg 1 mg PEG Tube Q HS
- clopidogrel (PLAVIX) tablet 75 mg 75 mg Oral DAILY
- gentamicin (GARAMYCIN) 0.1 % cream Topical TID
- insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units 2-5 Units Subcutaneous Q 6 H
- metoprolol (LOPRESSOR) tablet 25 mg 25 mg PEG Tube BID
- metroNIDAZOLE (FLAGYL) infusion 500 mg 500 mg Intravenous Q 8 H
- OLANZapine (ZyPREXA) tablet 10 mg 10 mg Oral BID
- potassium chloride 20 mEq IVPB 20 mEq Intravenous Once
- sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Q 12 H
- sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Q 12 H
- valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg 1,000 mg Oral BID
- vancomycin (VANCOCIN) 1,250 mg in sodium chloride 0.9 % 275 mL IVPB 1,250 mg Intravenous Q 12 H

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate

Physical Exam:

Temp 97.3 °F (36.3 °C) (08/28/23 0751) Source Axillary (08/28/23 0751) BP 108/81 (08/28/23 0751) Heart Rate 84 (08/28/23 0751) Resp 18 (08/28/23 0751) O2 (L/min) 2 L/min (08/24/23 0702) SpO2 98 % (08/28/23 0757) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/23/23 0600) BMI 24.6 (08/23/23 0600)

Flowsheet Data Statistics (last 36 hours)

Flowsheet Row Name Min Max BP: Systolic 79 [manual bp] 134 BP: Diastolic 45 [manual bp] 81 Temp 97.3 °F (36.3 °C) 100.1 °F (37.8 °C) Heart Rate 84 106 Resp 16 18 SpO2 93 % 98 %

General - He appears NAD, nontoxic, oxygenating 98% on RA HEENT - NCAT, eyes anicteric, mucosa moist Neck - Supple Chest - CTAB Heart - RRR Abdomen - Soft, no grimace to palpation, Foley with clear yellow urine, PEG site ok Extremities - NO c/c/e Skin - No acute rashes Neuropsych - Alert, confused

Indwelling Devices: PIV, RUE Powerglide

New Labs:

Recent Labs Component 08/28/23 0620 08/27/23 1608 08/26/23 1230 WBC 5.6 7.3 7.0 RBC 3.53* 3.67* 4.04* HGB 10.5* 10.8* 11.6* MCV 92 93 91 PLT 191 193 189 *Asterisks denote abnormal values Recent Labs Component 08/28/23 0620 08/27/23 1608 08/26/23 1230 08/23/23 0036 08/20/23 1417 08/18/23 0403 08/03/23 0626 08/02/23 0541 NA 139 138 136 < > 139 138 < > 148* K 3.3* 3.4* 3.0* < > 3.6 3.6 < > 4.0 CL 106 105 103 < > 104 105 < > 117* CO2 24 27 23 < > 25 26 < > 26 ANIONGAP 9 6 10 < > 10 7 < > 5 BUN 12 14 12 < > 13 13 < > 24 CREAT 0.50* 0.58* 0.57* < > 0.60 0.62 < > 0.67 ALB -- -- 2.4* -- 2.6* 2.6* < > 2.7* | 2.7* GLOBULIN -- -- 3.6 -- 3.7 -- -- 4.1* AGRATIO -- -- 0.7 -- 0.7 -- -- 0.7 ALP -- -- 123* -- 133* -- -- 90 AST -- -- 46* -- 24 -- -- 17 ALT -- -- 39 -- 19 -- -- 12 BILITOTAL -- -- 0.2* -- 0.3 -- -- 0.5 <> = values in this interval not displayed. *Asterisks denote abnormal values New Culture Data: 8/26 BC no growth New Imaging and Other Diagnostics: CXR with atelectasis

Assessment & Plan: Other Sepsis without acute organ dysfunction (CMS/HCC) Assessment & Plan Presentation to ED 8/1 with altered mental status S/p CPA 5/2023, low grade temp in ED 100.6 Hx MDR enterobacter 7/2023 from urine cx CT chest with L sided pleural effusion, oxygenating well on RA

?aspiration vs GU vs other Check procalcitonin, legionella/pneumococcal Ag, MRSA screen Consider CTAP Continue current abx for now

8/4: procal 0.50. Await MRSA screen. Continue current abx for now

8/7 MRSA screen not collected, WBC trending down. Remains on broad spectrum abx; anticipate today is the last day of antibiotics with IV cefepime and flagyl (7 days) of empiric treatment. Strep and legionella are negative; urine cutlure with Enterobacter from 8/1. Will stop IV vancomycin given lack of staph aureus on cultures.

8/27 Asked to reeval pt given new onset fever. Continue IV ceftriaxone/flagyl; will initiate IV azithromycin and vancomycin today. Follow up repeat blood cultures which are in process. Noted repeat CXR, likely persistent PNA process at play. If continues to be febrile with negative cultures, would obtain repeat imaging with CT CAP.

8/28 Temps improved/resolved, WBC wnl, BC with no growth. CXR without consolidative changes, oxygenating 98% on RA, clinically doubt pneumonia. Noted to have >1L UR yesterday due to mispositioned Foley, suspect that this was likely the cause of patient's fevers. Prior UCx with MDR Enterobacter, patient improving without targeted Abx. DC Abx and monitor.

Electronically signed by Jessica Lofgren at 08/28/2023 1:01 PM EDT Sabiha Omar - 08/28/2023 11:45 AM EDT Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient is sedated. It seems that when he is awake he starts to pull on catheter and IV and the other tubings. Blood pressure had been running low yesterday.

Objective:

Last Filed Vitals: Temp 97.3 °F (36.3 °C) (08/28/23 0751) Source Axillary (08/28/23 0751) BP 108/81 (08/28/23 0751) Heart Rate 84 (08/28/23 0751) Resp 18 (08/28/23 0751) O2 (L/min) 2 L/min (08/24/23 0702) SpO2 98 % (08/28/23 0757) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/23/23 0600) BMI 24.6 (08/23/23 0600)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior:. Sedated

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other Mood disorder (CMS/HCC) Assessment & Plan No change in medications for now.

Electronically signed by Sabiha Omar at 08/28/2023 11:45 AM EDT Danielle S - 08/28/2023 9:50 AM EDT

Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined at bedside. He is sleeping comfortably in no acute distress. Afebrile X 24 hours. Maintains on room air.

Objective:

Vitals: Blood pressure 108/81, pulse 84, temperature 97.3 °F (36.3 °C), temperature source Axillary, resp. rate 18, height 188 cm (6' 2.02"), weight 87.1 kg (192 lb 0.3 oz), SpO2 98 %. Body mass index is 24.64 kg/m².

Intake/Output Summary (Last 24 hours) at 8/28/2023 0950 Last data filed at 8/28/2023 0150 Gross per 24 hour Intake 1575 ml Output 2100 ml Net -525 ml

Physical Examination: General: Non-toxic chronically ill appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam. Eyes: EOMI. No scleral icterus. ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally with few scattered rhonchi right greater than left no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all guadrants, soft, NT/ND. + PEG tube. Ext: No clubbing, cyanosis, or edema. Psychiatric: Sedated. Appears calm and comfortable. Neurologic: Somnolent on exam. Spontaneous movement of extremities. Skin: No gross rashes. **Current Medications: Current Facility-Administered Medications** Medication acetaminophen (TYLENOL) tablet 650 mg albuterol-ipratropium (DUONEB) nebulizer solution 3 mL albuterol-ipratropium (DUONEB) nebulizer solution 3 mL amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg azithromycin (ZITHROMAX) 500 mg in sodium chloride 0.9 % 255 mL IVPB cefTRIAXone (ROCEPHIN) 1 g in sodium chloride 0.9 % 100 mL IVPB clonazePAM (KlonoPIN) tablet 0.5 mg clonazePAM (KlonoPIN) tablet 1 mg clopidogrel (PLAVIX) tablet 75 mg gentamicin (GARAMYCIN) 0.1 % cream insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units LORazepam (ATIVAN) tablet 0.5 mg metoprolol (LOPRESSOR) tablet 25 mg metroNIDAZOLE (FLAGYL) infusion 500 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL

sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg vancomycin (VANCOCIN) 1,250 mg in sodium chloride 0.9 % 275 mL IVPB

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

Recent Labs Component 08/28/23 0620 08/27/23 1608 08/26/23 1230 08/02/23 0632 08/01/23 1731 WBC 5.6 7.3 7.0 < > 13.7* RBC 3.53* 3.67* 4.04* < > 4.45 HGB 10.5* 10.8* 11.6* < > 13.0* MCV 92 93 91 < > 96 PLT 191 193 189 < > 283 INR -- -- -- 1.2 < > = values in this interval not displayed.

sodium chloride 0.9 % flush injection 20 mL

Asterisks denote abnormal values Recent Labs Component 08/28/23 0620 08/28/23 0559 08/27/23 2352 08/27/23 1808 08/27/23 1608 08/26/23 1752 08/26/23 1230 08/20/23 1617 08/20/23 1417 08/18/23 0521 08/18/23 0403 08/02/23 0602 08/02/23 0541 NA 139 -- -- 138 -- 136 < > 139 -- 138 < > 148 K 3.3* -- -- 3.4* -- 3.0* < > 3.6 -- 3.6 < > 4.0 CL 106 -- -- 105 -- 103 < > 104 -- 105 < > 117* CO2 24 -- -- 27 -- 23 < > 25 -- 26 < > 26 ANIONGAP 9 -- -- 6 -- 10 < > 10 -- 7 < > 5 BUN 12 -- -- 14 -- 12 < > 13 -- 13 < > 24 CREAT 0.50* -- -- 0.58* -- 0.57* < > 0.60 -- 0.62 < > 0.67 ALB -- -- -- 2.4* -- 2.6* -- 2.6* < > 2.7* | 2.7* GLOBULIN -- -- -- -- 3.6 -- 3.7 -- -- 4.1* AGRATIO -- -- -- -- 0.7 -- 0.7 -- 0.7 ALP -- -- -- -- 123* -- 133* -- -- 90 AST -- -- -- -- 46* -- 24 -- -- 17 ALT -- -- -- -- 39 -- 19 -- -- 12 BILITOTAL -- -- -- 0.2* -- 0.3 -- -- 0.5 GLU 124* 137 137 < > 108* < > 131* < > 135* < > 133* < > 137* < > = values in this interval not displayed.

*Asterisks denoteabnormal values

Assessment/Plan:

Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Penile edema Generalized weakness / Chronic debility Aspiration event 8/23 following NP suctioning causing emesis Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury - Foley catheter exchanged 8/24. Maintain Q 4 week exchanges.

Plan:

- Antibiotics: Rocephin / Azithromycin / Flagyl per ID.
- Repeat CT CAP pending
- Blood cultures pending, negative to date
- Supplement KCl PO + IV
- Continue scheduled sedative medications and utilized PRN orders if patient is agitated or restless.
- DC plan to return to group home when medically stable.

Danielle Saunders, AGPCNP-BC Internal Medicine

Electronically signed by William Rudy at 08/28/2023 5:42 PM EDT

Associated attestation - William Rudy - 08/28/2023 5:42 PM EDT Formatting of this note might be different from the original. Patient was seen and examined on rounds Case discussed with Danielle Saunders, RN, NP-C Reviewed progress note as documented Agree in principle with documentation

Igor Paris - 08/27/2023 2:30 PM EDT

Formatting of this note is different from the original. Psychiatric Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient seen. Chart reviewed. Patient sleepy but arousable. Confused. Redirectable.

Objective:

Today's Hospital Course (include current psychotropics response and today's proposed discharge plans): Patient Vitals for the past 24 hrs (Last 3 readings): BP Temp Temp src Pulse Resp SpO2 08/27/23 0715 126/64 100.1 °F (37.8 °C) Axillary 106 18 97 % 08/26/23 2336 104/52 -- -- 92 18 --08/26/23 2335 110/54 -- -- 88 -- --08/26/23 2322 (!) 89/55 -- -- 90 18 94 % 08/26/23 2031 156/85 98.8 °F (37.1 °C) Axillary 110 18 93 % 08/26/23 1800 101/65 98.2 °F (36.8 °C) Axillary 91 18 97 % **Current Facility-Administered Medications** Medication Dose Route Frequency Last Rate albuterol-ipratropium (DUONEB) nebulizer solution 3 mL 3 mL Inhalation RT-QID amiodarone (CORDARONE, PACERONE) tablet 200 mg 200 mg PEG Tube DAILY apixaban (ELIQUIS) tablet 5 mg 5 mg Oral Q 12 H atorvastatin (LIPITOR) tablet 40 mg 40 mg PEG Tube Q HS azithromycin (ZITHROMAX) 500 mg in sodium chloride 0.9 % 255 mL IVPB 500 mg Intravenous Q 24 H Stopped (08/27/23 1359) cefTRIAXone (ROCEPHIN) 1 g in sodium chloride 0.9 % 100 mL IVPB 1 g Intravenous Q 24 H Stopped (08/26/23 1718) clonazePAM (KlonoPIN) tablet 0.5 mg 0.5 mg Oral DAILY clonazePAM (KlonoPIN) tablet 1 mg 1 mg PEG Tube Q HS clopidogrel (PLAVIX) tablet 75 mg 75 mg Oral DAILY gentamicin (GARAMYCIN) 0.1 % cream Topical TID insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units 2-5 Units Subcutaneous Q 6 H metoprolol (LOPRESSOR) tablet 25 mg 25 mg PEG Tube BID metroNIDAZOLE (FLAGYL) infusion 500 mg 500 mg Intravenous Q 8 H 500 mg (08/27/23 1359) OLANZapine (ZyPREXA) tablet 10 mg 10 mg Oral BID sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Q 12 H sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Q 12 H valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg 1,000 mg Oral BID vancomycin (VANCOCIN) 1,250 mg in sodium chloride 0.9 % 275 mL IVPB 1,250 mg Intravenous Q 12 H 1,250 mg (08/27/23 1334) **Current Facility-Administered Medications** Medication Dose Route Frequency Last Rate acetaminophen (TYLENOL) tablet 650 mg 650 mg PEG Tube Q 4 H PRN albuterol-ipratropium (DUONEB) nebulizer solution 3 mL 3 mL Inhalation Q 4 H PRN LORazepam (ATIVAN) tablet 0.5 mg 0.5 mg Oral Q 6 H PRN sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Per Administration Instructions

sodium chloride 0.9 % flush injection 20 mL 20 mL Intravenous Per Administration Instructions

sodium chloride 0.9 % flush injection 20 mL 20 mL Intravenous Per Administration Instructions

sodium chloride 0.9 % flush injection 3 mL 3 mL Intravenous PRN

sodium chloride 0.9% flush injection 10 mL 10 mL Intravenous ONCE PRN

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate

No past medical history on file.

Not on File

WBC Hgb Hct Plt

NA K CI CO2

BUN Creat Glucose

Today's Brief Mental Status: Grooming: adequate Speech: Clear Concentration: impaired Affect: Labile Thought process: confused, Memory: impaired Assessment/Plan: Will cont current tx

Encounter Diagnoses Name Primary? Altered mental status, unspecified altered mental status type Yes Community acquired pneumonia, unspecified laterality Urinary tract infection associated with indwelling urethral catheter, initial encounter (CMS/HCC) Sepsis without acute organ dysfunction, due to unspecified organism (CMS/HCC) Other cough Respiratory failure, unspecified chronicity, unspecified whether with hypoxia or hypercapnia (CMS/HCC) Fever, unspecified fever cause

This dictation was prepared using Dragon Medical voice recognition software. As a result, errors may occur. When identified, these transcriptional errors have been corrected. While every attempt is made to correct errors during dictation, errors may still exist. Electronically signed by Igor Paris at 08/27/2023 2:31 PM EDT

Armen Korkigian - 08/27/2023 10:28 AM EDT

Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined at bedside. He is awake and sitting up in bed, appears calm and cooperative. He attempts to kiss examiners hand. Nursing staff at bedside reports he was restless and did not sleep overnight.

Objective:

Vitals: Blood pressure 126/64, pulse 106, temperature 100.1 °F (37.8 °C), temperature source Axillary, resp. rate 18, height 188 cm (6' 2.02"), weight 87.1 kg (192 lb 0.3 oz), SpO2 97 %. Body mass index is 24.64 kg/m².

Intake/Output Summary (Last 24 hours) at 8/27/2023 1358 Last data filed at 8/27/2023 0500 Gross per 24 hour Intake 100 ml Output 1500 ml Net -1400 ml

Physical Examination: General: Non-toxic chronically ill appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam. Eyes: EOMI. No scleral icterus. ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally with few scattered rhonchi right greater than left no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all quadrants, soft, NT/ND. + PEG tube. Ext: No clubbing, cyanosis, or edema. Psychiatric: Sedated. Appears calm and comfortable. Neurologic: Somnolent on exam. Spontaneous movement of extremities. Skin: No gross rashes.

Current Medications: Current Facility-Administered Medications Medication acetaminophen (TYLENOL) tablet 650 mg albuterol-ipratropium (DUONEB) nebulizer solution 3 mL albuterol-ipratropium (DUONEB) nebulizer solution 3 mL amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg azithromycin (ZITHROMAX) 500 mg in sodium chloride 0.9 % 255 mL IVPB cefTRIAXone (ROCEPHIN) 1 g in sodium chloride 0.9 % 100 mL IVPB clonazePAM (KlonoPIN) tablet 0.5 mg clonazePAM (KlonoPIN) tablet 1 mg clopidogrel (PLAVIX) tablet 75 mg gentamicin (GARAMYCIN) 0.1 % cream insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units LORazepam (ATIVAN) tablet 0.5 mg metoprolol (LOPRESSOR) tablet 25 mg metroNIDAZOLE (FLAGYL) infusion 500 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg vancomycin (VANCOCIN) 1,250 mg in sodium chloride 0.9 % 275 mL IVPB

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

```
Recent Labs
Component 08/26/23
1230 08/23/23
0036 08/20/23
1417 08/02/23
0632 08/01/23
1731
WBC 7.0 12.4* 9.8 < > 13.7*
RBC 4.04* 4.91 4.70 < > 4.45
HGB 11.6* 14.5 13.8 < > 13.0*
MCV 91 92 93 < > 96
PLT 189 201 216 < > 283
INR -- -- 1.2
<> = values in this interval not displayed.
*Asterisks denote abnormal values
Recent Labs
Component 08/27/23
1208 08/27/23
0142 08/26/23
1752 08/26/23
1230 08/23/23
0538 08/23/23
0036 08/20/23
1617 08/20/23
1417 08/18/23
0521 08/18/23
0403 08/02/23
0602 08/02/23
0541
NA -- -- 136 -- 135 -- 139 -- 138 < > 148*
K -- -- 3.0* -- 4.1 -- 3.6 -- 3.6 < > 4.0
CL -- -- 103 -- 101 -- 104 -- 105 < > 117*
CO2 -- -- 23 -- 24 -- 25 -- 26 < > 26
ANIONGAP -- -- 10 -- 10 -- 10 -- 7 < > 5
BUN -- -- 12 -- 16 -- 13 -- 13 < > 24
CREAT -- -- 0.57* -- 0.64 -- 0.60 -- 0.62 < > 0.67
ALB -- -- 2.4* -- -- 2.6* -- 2.6* < > 2.7* | 2.7*
GLOBULIN -- -- -- 3.6 -- -- -- 3.7 -- -- 4.1*
AGRATIO -- -- 0.7 -- -- 0.7 -- -- 0.7
ALP -- -- 123* -- -- 133* -- -- 90
AST -- -- 46* -- -- 24 -- -- 17
ALT -- -- 39 -- -- 19 -- -- 12
BILITOTAL -- -- 0.2* -- -- 0.3 -- -- 0.5
GLU 129 117 125 131* < > 176* < > 135* < > 133* < > 137*
<> = values in this interval not displayed.
*Asterisks denoteabnormal values
```

Assessment/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Penile edema Generalized weakness / Chronic debility Aspiration event 8/23 following NP suctioning causing emesis Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury - Foley catheter exchanged 8/24. Maintain Q 4 week exchanges.

Plan:

- Antibiotics: Rocephin / Azithromycin / Flagyl per ID.

- Continue Klonopin 0.5 mg Q AM and 1 mg Q PM. Continue Zyprexa 10 mg BID, and Depakene 1 g BID, and Ativan 0.5 mg Q 6 hours PRN per psychiatry recommendation. Do not hold sedation RX.

- Maintain abdominal binder AAT for line/tube protection.

- Patient now sitter and restraint free > 24 hours.

Remains medically stable for discharge since 8/25 - CM assisting with LTC placement vs return to sister's group home.

Danielle Saunders, AGPCNP-BC Internal Medicine Internal Medicine Attending 8/27/2023 Progress note reviewed. Care plan discussed with resident and or PA/NP team. Agree with documentation as written without amendments. Patient seen, examined and discussed with residents. See resident note above for full details. Armen A Korkigian, DO Face-to-face with patient and resident performed during rounds. Rrr.-pmi/cta,increased APD/abd, soft, nt, +BS/ ext nt ,with out increasing edema /nnlnd/ skin SMW

Electronically signed by Armen Korkigian at 08/27/2023 2:00 PM EDT

Igor Paris - 08/26/2023 1:15 PM EDT

Formatting of this note is different from the original. Psychiatric Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient seen. Chart reviewed. Noted fever. Patient seems comfortable no acute distress Objective:

Today's Hospital Course (include current psychotropics response and today's proposed discharge plans): Patient Vitals for the past 24 hrs (Last 3 readings): BP Temp Temp src Pulse Resp SpO2 08/26/23 1139 116/64 (!) 101.3 °F (38.5 °C) Axillary 115 22 --08/26/23 0722 95/66 98.3 °F (36.8 °C) Axillary 89 18 96 % 08/25/23 2331 116/79 98.2 °F (36.8 °C) Axillary 92 18 98 % 08/25/23 1932 117/66 97.6 °F (36.4 °C) Axillary 97 19 97 %

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate albuterol-ipratropium (DUONEB) nebulizer solution 3 mL 3 mL Inhalation RT-QID amiodarone (CORDARONE, PACERONE) tablet 200 mg 200 mg PEG Tube DAILY apixaban (ELIQUIS) tablet 5 mg 5 mg Oral Q 12 H atorvastatin (LIPITOR) tablet 40 mg 40 mg PEG Tube Q HS azithromycin (ZITHROMAX) 500 mg in sodium chloride 0.9 % 255 mL IVPB 500 mg Intravenous Q 24 H cefTRIAXone (ROCEPHIN) 1 g in sodium chloride 0.9 % 100 mL IVPB 1 g Intravenous Q 24 H clonazePAM (KlonoPIN) tablet 0.5 mg 0.5 mg Oral DAILY clonazePAM (KlonoPIN) tablet 1 mg 1 mg PEG Tube Q HS clopidogrel (PLAVIX) tablet 75 mg 75 mg Oral DAILY gentamicin (GARAMYCIN) 0.1 % cream Topical TID hydrocortisone (HYTONE) 1 % ointment Topical DAILY insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units 2-5 Units Subcutaneous Q 6 H metoprolol (LOPRESSOR) tablet 25 mg 25 mg PEG Tube BID metroNIDAZOLE (FLAGYL) infusion 500 mg 500 mg Intravenous Q 8 H OLANZapine (ZyPREXA) tablet 10 mg 10 mg Oral BID sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Q 12 H valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg 1,000 mg Oral BID

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate acetaminophen (TYLENOL) tablet 650 mg 650 mg PEG Tube Q 4 H PRN albuterol-ipratropium (DUONEB) nebulizer solution 3 mL 3 mL Inhalation Q 4 H PRN LORazepam (ATIVAN) tablet 0.5 mg 0.5 mg Oral Q 6 H PRN sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 20 mL 20 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 3 mL 3 mL Intravenous PRN sodium chloride 0.9% flush injection 10 mL 10 mL Intravenous ONCE PRN

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate

No past medical history on file.

Not on File

WBC Hgb Hct Plt 7.0 (08/26 1230) 11.6 (08/26 1230) 36.7 (08/26 1230) 189 (08/26 1230) NA K CI CO2

BUN Creat Glucose

Today's Brief Mental Status: Grooming: adequate Speech: nonverbal Concentration: impaired Affect: blunted Thought process: confused, disorganized Memory: impaired

Assessment/Plan: Will cont current tx

Encounter Diagnoses Name Primary? Altered mental status, unspecified altered mental status type Yes Community acquired pneumonia, unspecified laterality Urinary tract infection associated with indwelling urethral catheter, initial encounter (CMS/HCC) Sepsis without acute organ dysfunction, due to unspecified organism (CMS/HCC) Other cough Respiratory failure, unspecified chronicity, unspecified whether with hypoxia or hypercapnia (CMS/HCC) Fever, unspecified fever cause

This dictation was prepared using Dragon Medical voice recognition software. As a result, errors may occur. When identified, these transcriptional errors have been corrected. While every attempt is made to correct errors during dictation, errors may still exist. Electronically signed by Igor Paris at 08/26/2023 1:16 PM EDT

Amal Khalife - 08/26/2023 1:04 PM EDT

Formatting of this note might be different from the original. Brief infectious disease note: Consulted for new onset fever, 101.3F. Formal note to follow. Will add on IV flagyl, cont present treatment with rocephin/azithro per primary team. Noted repeat cultures in progress.

Amal A Khalife, DO 1:08 PM 08/26/23 Electronically signed by Amal Khalife at 08/26/2023 1:10 PM EDT

Manju G - 08/26/2023 12:36 PM EDT

Formatting of this note might be different from the original.

Notified by RN that patient having a temperature of 101.3, respiration 22, heart rate 115. Reviewed patient chart patient came in here for altered mental status, leukocytosis, A-fib, anoxic brain injury, treated for sepsis possible aspiration pneumonia with the cefepime and azithromycin, last dose on 8/24. Blood cultures were taken at that time which is negative no growth until today however patient febrile with a temperature of 101.3 today repeat CBC, CMP, magnesium, phosphorus ordered. Blood cultures, chest x-ray ordered. Case discussed with the attending physician Dr. Rudy who recommended to initiate on ceftriaxone and azithromycin. Infectious disease consult in place for further recommendations. We will keep the patient n.p.o. suspecting possible aspiration. Continue to monitor at this time.

Manju George, RN NP-C

Electronically signed by Manju G at 08/26/2023 12:38 PM EDT

Armen Korkigian - 08/26/2023 11:09 AM EDT

Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined at bedside. He appears comfortable sleeping in no acute distress. No noted behaviors or events overnight. Tube feeds infusing.

Objective:

Vitals: Blood pressure 95/66, pulse 89, temperature 98.3 °F (36.8 °C), temperature source Axillary, resp. rate 18, height 188 cm (6' 2.02"), weight 87.1 kg (192 lb 0.3 oz), SpO2 96 %. Body mass index is 24.64 kg/m².

Intake/Output Summary (Last 24 hours) at 8/26/2023 1109 Last data filed at 8/26/2023 0600 Gross per 24 hour Intake 1905 ml Output 2100 ml Net -195 ml

Physical Examination:

General: Non-toxic chronically ill appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam.

Eyes: EOMI. No scleral icterus.

ENT: Neck is supple, mucous membranes are moist

Chest: Clear to auscultation bilaterally with few scattered rhonchi right greater than left no wheezing, no rales

Cardiac: RRR, S1, S2, no murmurs

Abdomen: Bowel sounds are present in all quadrants, soft, NT/ND. + PEG tube.

Ext: No clubbing, cyanosis, or edema.

Psychiatric: Sedated. Appears calm and comfortable.

Neurologic: Somnolent on exam. Spontaneous movement of extremities.

Skin: No gross rashes.

Current Medications: **Current Facility-Administered Medications** Medication acetaminophen (TYLENOL) tablet 650 mg albuterol-ipratropium (DUONEB) nebulizer solution 3 mL albuterol-ipratropium (DUONEB) nebulizer solution 3 mL amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg clonazePAM (KlonoPIN) tablet 0.5 mg clonazePAM (KlonoPIN) tablet 1 mg clopidogrel (PLAVIX) tablet 75 mg gentamicin (GARAMYCIN) 0.1 % cream hydrocortisone (HYTONE) 1 % ointment insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units LORazepam (ATIVAN) tablet 0.5 mg metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL

sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

Recent Labs Component 08/23/23 0036 08/20/23 1417 08/18/23 0403 08/02/23 0632 08/01/23 1731 WBC 12.4* 9.8 8.8 < > 13.7* RBC 4.91 4.70 4.49 < > 4.45 HGB 14.5 13.8 13.1* < > 13.0* MCV 92 93 93 < > 96 PLT 201 216 256 < > 283 INR -- -- -- 1.2 < > = values in this interval not displayed.

*Asterisks denote abnormal values **Recent Labs** Component 08/26/23 0523 08/26/23 0015 08/25/23 1736 08/23/23 0538 08/23/23 0036 08/20/23 1617 08/20/23 1417 08/18/23 0521 08/18/23 0403 08/17/23 0532 08/17/23 0310 08/02/23 0602 08/02/23 0541 08/02/23 0159 08/01/23 1731 NA -- -- -- 135 -- 139 -- 138 -- 140 < > 148* -- 142 K -- -- 4.1 -- 3.6 -- 3.6 -- 4.6 < > 4.0 -- 4.6 CL -- -- -- 101 -- 104 -- 105 -- 104 < > 117* -- 112* CO2 -- -- 24 -- 25 -- 26 -- 28 < > 26 -- 23 ANIONGAP -- -- -- 10 -- 10 -- 7 -- 8 < > 5 -- 7 BUN -- -- -- 16 -- 13 -- 13 -- 16 < > 24 -- 23 CREAT -- -- -- 0.64 -- 0.60 -- 0.62 -- 0.65 < > 0.67 -- 0.77 ALB -- -- -- -- 2.6* -- 2.6* -- 2.6* < > 2.7* | 2.7* -- 2.9* GLOBULIN -- -- -- -- 3.7 -- -- -- 4.1* -- 4.2* AGRATIO -- -- -- -- 0.7 -- -- -- 0.7 -- 0.7 ALP -- -- -- -- 133* -- -- -- 90 -- 113 AST -- -- 17 -- 24 -- -- -- 17 -- 21 ALT -- -- -- -- 19 -- -- -- 12 -- 14 BILITOTAL -- -- -- -- 0.3 -- -- -- 0.5 -- 0.3 GLU 128 115 129 < > 176* < > 135* < > 133* < > 126* < > 137* < > 432* <> = values in this interval not displayed.

*Asterisks denoteabnormal values

Assessment/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Penile edema Generalized weakness / Chronic debility Aspiration event 8/23 following NP suctioning causing emesis Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

- Foley catheter exchanged 8/24. Maintain Q 4 week exchanges.

Plan:

- Continue Klonopin 0.5 mg Q AM and 1 mg Q PM. Continue Zyprexa 10 mg BID, and Depakene 1 g BID, and Ativan 0.5 mg Q 6 hours PRN per psychiatry recommendation. Do not hold sedation RX.

- Maintain abdominal binder AAT for line/tube protection.

- Patient now sitter and restraint free X 24 hours.

Remains medically stable for discharge since 8/25 - CM assisting with LTC placement vs return to sister's group home.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat Internal Medicine Attending 8/26/2023 Progress note reviewed. Care plan discussed with resident and or PA/NP team. Agree with documentation as written without amendments. Patient seen, examined and discussed with residents. See resident note above for full details. Armen A Korkigian, DO Face-to-face with patient and resident performed during rounds. Rrr,-pmi/cta,increased APD/abd, soft, nt, +BS/ ext nt ,with out increasing edema /nnlnd/ skin SMW Remains ready for discharge to SAR

Electronically signed by Armen Korkigian at 08/26/2023 2:04 PM EDT

Danielle S - 08/25/2023 10:43 AM EDT

Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined at bedside. He was found sleeping in no acute distress. Documentation the patient slept well overnight. Sitter at bedside denies acute events this morning. Remains unrestrained.

Objective:

Vitals: Blood pressure 149/71, pulse 81, temperature 98.2 °F (36.8 °C), temperature source Axillary, resp. rate 20, height 188 cm (6' 2.02"), weight 87.1 kg (192 lb 0.3 oz), SpO2 100 %. Body mass index is 24.64 kg/m².

Intake/Output Summary (Last 24 hours) at 8/25/2023 1043 Last data filed at 8/25/2023 0000 Gross per 24 hour Intake 155 ml Output 600 ml Net -445 ml

Physical Examination:

General: Non-toxic chronically ill appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam. Eyes: EOMI. No scleral icterus. ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally with few scattered rhonchi right greater than left no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all quadrants, soft, NT/ND. + PEG tube. Ext: No clubbing, cyanosis, or edema. Psychiatric: Sedated. Appears calm and comfortable. Neurologic: Somnolent on exam. Spontaneous movement of extremities. Skin: No gross rashes.

Current Medications:

Current Facility-Administered Medications Medication acetaminophen (TYLENOL) tablet 650 mg albuterol-ipratropium (DUONEB) nebulizer solution 3 mL albuterol-ipratropium (DUONEB) nebulizer solution 3 mL amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg [START ON 8/26/2023] clonazePAM (KlonoPIN) tablet 0.5 mg clonazePAM (KlonoPIN) tablet 1 mg clopidogrel (PLAVIX) tablet 75 mg gentamicin (GARAMYCIN) 0.1 % cream hydrocortisone (HYTONE) 1 % ointment insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units LORazepam (ATIVAN) tablet 0.5 mg metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

Recent Labs Component 08/23/23 0036 08/20/23 1417 08/18/23 0403 08/02/23 0632 08/01/23 1731 WBC 12.4* 9.8 8.8 < > 13.7* RBC 4.91 4.70 4.49 < > 4.45 HGB 14.5 13.8 13.1* < > 13.0* MCV 92 93 93 < > 96 PLT 201 216 256 < > 283 INR -- -- -- 1.2 <> = values in this interval not displayed. *Asterisks denote abnormal values Recent Labs Component 08/25/23 0604 08/25/23 0024 08/24/23 1805 08/23/23 0538 08/23/23 0036 08/20/23 1617 08/20/23 1417 08/18/23 0521 08/18/23 0403 08/17/23 0532 08/17/23 0310 08/02/23 0602 08/02/23 0541 08/02/23 0159 08/01/23 1731 NA -- -- -- 135 -- 139 -- 138 -- 140 < > 148* -- 142 K -- -- 4.1 -- 3.6 -- 3.6 -- 4.6 < > 4.0 -- 4.6 CL -- -- -- 101 -- 104 -- 105 -- 104 < > 117* -- 112* CO2 -- -- -- 24 -- 25 -- 26 -- 28 < > 26 -- 23 ANIONGAP -- -- -- 10 -- 10 -- 7 -- 8 < > 5 -- 7 BUN -- -- -- 16 -- 13 -- 13 -- 16 < > 24 -- 23 CREAT -- -- -- 0.64 -- 0.60 -- 0.62 -- 0.65 < > 0.67 -- 0.77 ALB -- -- -- 2.6* -- 2.6* -- 2.6* < > 2.7* | 2.7* -- 2.9* GLOBULIN -- -- -- -- 3.7 -- -- -- 4.1* -- 4.2*

 $\begin{array}{l} \mathsf{AGRATIO} \ --\ --\ --\ 0.7\ --\ 0.7\ --\ 0.7\ --\ 0.7\ --\ 0.7\ \\ \mathsf{ALP} \ --\ --\ --\ 133^*\ --\ --\ --\ 90\ --\ 113\ \\ \mathsf{AST} \ --\ --\ --\ 24\ --\ --\ --\ 17\ --\ 21\ \\ \mathsf{ALT} \ --\ --\ --\ --\ 19\ --\ --\ --\ 12\ --\ 14\ \\ \mathsf{BILITOTAL} \ --\ --\ --\ --\ 0.3\ --\ --\ --\ 0.5\ --\ 0.3\ \\ \mathsf{GLU} \ 89\ 115\ 150^*\ <\ >\ 176^*\ <\ >\ 135^*\ <\ >\ 133^*\ <\ >\ 126^*\ <\ >\ 137^*\ <\ >\ 432^*\ \\ <\ >\ =\ values\ in\ this\ interval\ not\ displayed. \end{array}$

*Asterisks denoteabnormal values

Assessment/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Penile edema Generalized weakness / Chronic debility Aspiration event 8/23 following NP suctioning causing emesis Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

Plan:

- Clinically stable off antibiotic therapy

- Foley catheter exchanged by urology 8/24. Recommendations to keep foley off tension. Started on topical bacitracin and topical steroid X 3 days. OP f/u with Dr. McIntosh.

- Klonopin adjusted to 0.5 mg Q AM and 1 mg Q PM. Continue Zyprexa 10 mg BID, and Depakene 1 g BID, and Ativan 0.5 mg Q 6 hours PRN per psychiatry recommendation. Do not hold sedation RX.

- Maintain abdominal binder AAT for line/tube protection.

Discontinue 1:1 sitter. Medically stable for discharge 8/25. CM to assist with LTC placement.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat

Electronically signed by William Rudy at 08/25/2023 4:33 PM EDT

Associated attestation - William Rudy - 08/25/2023 4:33 PM EDT Formatting of this note might be different from the original. Patient was seen and examined on rounds Agree in principle with Internal medicine progress note as documented by Danielle Saunders, RN, NP-C Case discussed as well

Savannah Grandy - 08/25/2023 10:25 AM EDT Formatting of this note is different from the original.

Name: Ioan Suiugan Age: 62 yrs MRN: 9942681

Provider: Savannah Grandy, DO Date of service: 8/25/2023

Subjective Patient seen, examined.

Last Filed Vitals: Temp 98.2 °F (36.8 °C) (08/25/23 0736) Source Axillary (08/25/23 0736) BP 149/71 (08/25/23 0736) Heart Rate 81 (08/25/23 0736) Resp 20 (08/25/23 0736) O2 (L/min) 2 L/min (08/24/23 0702) SpO2 100 % (08/25/23 0736) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/23/23 0600) BMI 24.6 (08/23/23 0600)

Temp Min: 97 °F (36.1 °C) Min taken time: 08/15/23 0350 Max: 101.6 °F (38.7 °C) Max taken time: 08/22/23 2252

Physical Examination Gen: NAD, A&O Respiratory: Unlabored, no respiratory distress GI: Soft, nondistended, non tender, no rebound/rigidity/guarding GU: 16 F Foley - clear/yellow, penile foreskin without edema, foreskin retracted- replaced by urology, no skin breakdown or penile glans erythema/discharge EXT: No cyanosis, No clubbing, No edema Neurologic: CN2-12 grossly intact

Labs

Recent Labs Component 08/23/23 0036 08/20/23 1417 08/18/23 0403 08/17/23 0310 WBC 12.4* 9.8 8.8 9.7 RBC 4.91 4.70 4.49 4.44 HGB 14.5 13.8 13.1* 13.0* MCV 92 93 93 94 PLT 201 216 256 286 MONO -- 1.5* 1.1* 1.0* IMMGRAN -- 0.03 0.02 0.01 **Recent Labs** Component 08/25/23 0604 08/25/23 0024 08/24/23 1805 08/23/23 0538 08/23/23 0036 08/20/23 1617 08/20/23 1417 08/18/23 0521 08/18/23 0403 08/17/23 0532 08/17/23 0310 08/02/23 0602 08/02/23 0541 08/02/23 0159 08/01/23 1731 NA -- -- -- 135 -- 139 -- 138 -- 140 < > 148* -- 142 K -- -- 4.1 -- 3.6 -- 3.6 -- 4.6 < > 4.0 -- 4.6 CL -- -- -- 101 -- 104 -- 105 -- 104 < > 117* -- 112* CO2 -- -- 24 -- 25 -- 26 -- 28 < > 26 -- 23 ANIONGAP -- -- -- 10 -- 10 -- 7 -- 8 < > 5 -- 7 GLU 89 115 150* < > 176* < > 135* < > 133* < > 126* < > 137* < > 432* BUN -- -- -- 16 -- 13 -- 13 -- 16 < > 24 -- 23 CREAT -- -- -- 0.64 -- 0.60 -- 0.62 -- 0.65 < > 0.67 -- 0.77 ALB -- -- -- -- 2.6* -- 2.6* -- 2.6* < > 2.7* | 2.7* -- 2.9* GLOBULIN -- -- -- -- 3.7 -- -- -- 4.1* -- 4.2* AGRATIO -- -- -- -- 0.7 -- -- -- 0.7 -- 0.7 ALP -- -- -- -- 133* -- -- -- 90 -- 113 AST -- -- 17 -- 24 -- -- 17 -- 21 ALT -- -- 12 -- 19 -- -- -- 12 -- 14 BILITOTAL -- -- -- -- 0.3 -- -- -- 0.5 -- 0.3 <> = values in this interval not displayed.

Assessment/Plan:

Urinary Balanitis Assessment & Plan Inflammation resolved on exam today

-Exchange foley catheter today
-Keep foley off tension
-Daily pericare
-Topical antibacterial ointment per primary
-3 days of topical steroid
-Replace foreskin daily to avoid paraphimosis

Other Chronic indwelling Foley catheter Assessment & Plan 2/2 NGB per chart review 16 F replaced 8/24, yellow (Ucx + Enterobacter 8/1)

-Resume monthly exchanges-Annual cystoscopy-F/u outpt with Dr. McIntosh or established urologist

Urology to sign off, to reevaluate at your request

Savannah Grandy, DO Urologic Surgery, PGY3 5868560058 Available on MH

Electronically signed by Katie Rosen at 08/26/2023 10:56 AM EDT

Sabiha Omar - 08/25/2023 10:06 AM EDT Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient is more awake today. He did not answer any questions. He had slept reasonably well last night.

Objective:

Last Filed Vitals: Temp 98.2 °F (36.8 °C) (08/25/23 0736) Source Axillary (08/25/23 0736) BP 149/71 (08/25/23 0736) Heart Rate 81 (08/25/23 0736) Resp 20 (08/25/23 0736) O2 (L/min) 2 L/min (08/24/23 0702) SpO2 100 % (08/25/23 0736) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/23/23 0600) BMI 24.6 (08/23/23 0600)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior: Awake, calm but did not communicate.

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other Mood disorder (CMS/HCC) Assessment & Plan Reduce Klonopin daytime dose 0.5 mg in the morning only and continue 1 mg at bedtime. Sabiha Omar - 08/24/2023 12:00 PM EDT Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient sedated at this time. Per staff he was handful this morning. He he tried to pull everything. While during the night. Klonopin was not given last night. He did not get Klonopin this morning either.

Objective:

Last Filed Vitals: Temp 99.4 °F (37.4 °C) (08/24/23 0800) Source Axillary (08/24/23 0800) BP 111/77 (08/24/23 0800) Heart Rate 107 (08/24/23 0800) Resp 20 (08/24/23 0800) O2 (L/min) 2 L/min (08/24/23 0702) SpO2 93 % (08/24/23 0848) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/23/23 0600) BMI 24.6 (08/23/23 0600)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior:. Sedated

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other Mood disorder (CMS/HCC) Assessment & Plan It is clear that he cannot be managed without being sedated. Strongly suggest not to hold Klonopin. When patient awake we have a difficult patient and had who pulls on everything.

Electronically signed by Sabiha Omar at 08/25/2023 10:07 AM EDT

Danielle S - 08/24/2023 10:22 AM EDT Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined at bedside. He is found sedated; slept through exam. Sitter at bedside reports he was agitated this AM and was trying to climb out of bed and grabbing at IV pole at bedside.

Objective:

Vitals: Blood pressure 111/77, pulse 107, temperature 99.4 °F (37.4 °C), temperature source Axillary, resp. rate 20, height 188 cm (6' 2.02"), weight 87.1 kg (192 lb 0.3 oz), SpO2 93 %. Body mass index is 24.64 kg/m².

Intake/Output Summary (Last 24 hours) at 8/24/2023 1022 Last data filed at 8/24/2023 0600 Gross per 24 hour Intake 195 ml Output 1450 ml Net -1255 ml

Physical Examination: General: Non-toxic chronically ill appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam. Eyes: EOMI. No scleral icterus. ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally with few scattered rhonchi right greater than left no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all guadrants, soft, NT/ND. + PEG tube. Ext: No clubbing, cyanosis, or edema. Psychiatric: Sedated. Appears calm and comfortable. Neurologic: Somnolent on exam. Spontaneous movement of extremities. Skin: No gross rashes. **Current Medications: Current Facility-Administered Medications** Medication acetaminophen (TYLENOL) tablet 650 mg albuterol-ipratropium (DUONEB) nebulizer solution 3 mL albuterol-ipratropium (DUONEB) nebulizer solution 3 mL amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg azithromycin (ZITHROMAX) 500 mg in sodium chloride 0.9 % 255 mL IVPB cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB clonazePAM (KlonoPIN) tablet 0.5 mg clonazePAM (KlonoPIN) tablet 1 mg clopidogrel (PLAVIX) tablet 75 mg gentamicin (GARAMYCIN) 0.1 % cream hydrocortisone (HYTONE) 1 % ointment insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units LORazepam (ATIVAN) tablet 0.5 mg metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

Recent Labs Component 08/23/23 0036 08/20/23 1417 08/18/23 0403 08/02/23 0632 08/01/23 1731 WBC 12.4* 9.8 8.8 < > 13.7* RBC 4.91 4.70 4.49 < > 4.45 HGB 14.5 13.8 13.1* < > 13.0* MCV 92 93 93 < > 96 PLT 201 216 256 < > 283 INR -- -- -- 1.2 < > = values in this interval not displayed.

Asterisks denote abnormal values Recent Labs Component 08/24/23 0519 08/24/23 0117 08/23/23 1617 08/23/23 0538 08/23/23 0036 08/20/23 1617 08/20/23 1617 08/18/23 0521 08/18/23 0403 08/17/23 0532 08/17/23 0310 08/02/23 0602 08/02/23 0541 08/02/23 0159 08/01/23 1731 NA -- -- 135 -- 139 -- 138 -- 140 < > 148 -- 142 K -- -- -- 4.1 -- 3.6 -- 3.6 -- 4.6 < > 4.0 -- 4.6 CL -- -- -- 101 -- 104 -- 105 -- 104 < > 117* -- 112* CO2 -- -- 24 -- 25 -- 26 -- 28 < > 26 -- 23 ANIONGAP -- -- -- 10 -- 10 -- 7 -- 8 < > 5 -- 7 BUN -- -- -- 16 -- 13 -- 13 -- 16 < > 24 -- 23 CREAT -- -- -- 0.64 -- 0.60 -- 0.62 -- 0.65 < > 0.67 -- 0.77 ALB -- -- -- 2.6* -- 2.6* -- 2.6* < > 2.7* | 2.7* -- 2.9* GLOBULIN -- -- -- -- 3.7 -- -- -- 4.1* -- 4.2* AGRATIO -- -- -- -- 0.7 -- -- -- 0.7 -- 0.7 ALP -- -- -- -- 133* -- -- -- 90 -- 113 AST -- -- 17 -- 24 -- -- -- 17 -- 21 ALT -- -- -- -- 19 -- -- -- 12 -- 14 BILITOTAL -- -- -- -- 0.3 -- -- -- 0.5 -- 0.3 GLU 106 108 127 < > 176* < > 135* < > 133* < > 126* < > 137* < > 432* <> = values in this interval not displayed.

*Asterisks denoteabnormal values

Assessment/Plan:

Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Penile edema Generalized weakness / Chronic debility Aspiration event 8/23 following NP suctioning causing emesis Hypernatremia Hypokalemia **Essential HTN** Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

Plan:

- Foley catheter exchanged by urology 8/24. Recommendations to keep foley off tension. Started on topical bacitracin and topical steroid X 3 days. OP f/u with Dr. McIntosh.

- CXR with R basilar streak, likely pneumonitis. Remains afebrile. Has since been weaned to room air. DC antibiotics and clinically monitor.

- Continue Klonopin 1 mg TID, Zyprexa 10 mg BID, and Depakene 1 g BID, and Ativan 0.5 mg Q 6 hours PRN per psychiatry recommendation. Do not hold sedation RX.

- Maintain abdominal binder AAT for line/tube protection.

Notably the patient's Klonopin was held by nursing staff last night and this morning. He subsequently was pulling at lines and attempting to get out of bed.

Agree with psychiatry. Do NOT hold Klonopin or scheduled psych medications.

Discharge further delayed as nursing staff is holding medications despite scheduled orders. Anticipate discontinuation of sitter in the next 24 hours.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat

Electronically signed by William Rudy at 08/24/2023 5:05 PM EDT

Associated attestation - William Rudy - 08/24/2023 5:05 PM EDT Formatting of this note might be different from the original. Reviewed IM progress note Patient seen and examined on rounds, case discussed with Danielle Saunders, RN, NP-C Concur in principle with documentation as provided

Formatting of this note might be different from the original. Called by RN re: penile edema

Referral to mental status secondary to toxic metabolic encephalopathy superimposed on anoxic brain injury from VT cardiac arrest 5/2023. Contacted by nursing regarding penile edema and erythema as well as drainage. Patient currently being treated for suspected aspiration pneumonia with cefepime and azithromycin. He currently has an indwelling Foley catheter. Nursing noted that the distal tip of the penis is edematous and erythematous and has changed over the past 2 days. They also note some drainage around the Foley catheter as well as skin excoriation and mild erythema to the scrotum. Patient is unable to provide any further history. No reported trauma or injury by nursing staff.

Blood pressure 116/79, pulse 108, temperature 98.4 °F (36.9 °C), temperature source Axillary, resp. rate 20, height 188 cm (6' 2.02"), weight 87.1 kg (192 lb 0.3 oz), SpO2 96 %.

Physical Exam:

Constitutional: Awake and alert. Does not respond to direct questions or commands, baseline.

Pulm: Auscultation reveals clear breath sounds throughout. No wheezing rhochi or rales. No accessroy muscle use or retractions. Cardio: RRR. No murmurs.

GU: Patient is uncircumcised. Inferential edematous distal end of the foreskin. Skin is corrugated. There is mild clear to purulent drainage at the urethral meatus. No appears minimally erythematous. Skin is flaking.

A/P: Penile foreskin edema Indwelling Foley catheter

Case with attending physician via phone, updated on physical exam findings. We will add gentamicin ointment 3 times daily. Urology consult placed and requested by attending to Dr. Schock.

Will continue to monitor closely. Rosalind Jones, PA-C, #4344

Electronically signed by Rosalind J at 08/23/2023 10:07 PM EDT

William Rudy - 08/23/2023 10:18 AM EDT Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined at bedside. He is found sleeping comfortably in no acute distress. Currently on 2L nasal cannula following suction induced aspiration event last night. Afebrile this morning.

Objective:

Vitals: Blood pressure 123/77, pulse 109, temperature 98.8 °F (37.1 °C), temperature source Axillary, resp. rate 20, height 188 cm (6' 2.02"), weight 87.1 kg (192 lb 0.3 oz), SpO2 94 %. Body mass index is 24.64 kg/m².

Intake/Output Summary (Last 24 hours) at 8/23/2023 1018 Last data filed at 8/23/2023 0600 Gross per 24 hour Intake --Output 2400 ml Net -2400 ml

Physical Examination:
General: Non-toxic chronically ill appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam.
Eyes: EOMI. No scleral icterus.
ENT: Neck is supple, mucous membranes are moist
Chest: Clear to auscultation bilaterally with few scattered rhonchi right greater than left no wheezing, no rales
Cardiac: RRR, S1, S2, no murmurs
Abdomen: Bowel sounds are present in all quadrants, soft, NT/ND. + PEG tube.
Ext: No clubbing, cyanosis, or edema.
Psychiatric: Affect is appropriate
Neurologic: Lethargic . Speech is mumbled and incoherent. Withdrawals appropriately to painful stimuli. Does not follow commands. Appears somnolent on exam.
Skin: No gross rashes.

Current Medications: Current Facility-Administered Medications Medication acetaminophen (TYLENOL) tablet 650 mg albuterol-ipratropium (DUONEB) nebulizer solution 3 mL amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg azithromycin (ZITHROMAX) 500 mg in sodium chloride 0.9 % 255 mL IVPB cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB clonazePAM (KlonoPIN) tablet 0.5 mg clonazePAM (KlonoPIN) tablet 1 mg clopidogrel (PLAVIX) tablet 75 mg insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units LORazepam (ATIVAN) tablet 0.5 mg metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg vancomycin (VANCOCIN) 1,000 mg in sodium chloride 0.9 % 250 mL IVPB

Diagnostic Studies: These were all reviewed and interpreted in EPIC

```
New Labs:
```

0403 08/17/23

```
Recent Labs
Component 08/23/23
0036 08/20/23
1417 08/18/23
0403 08/02/23
0632 08/01/23
1731
WBC 12.4* 9.8 8.8 < > 13.7*
RBC 4.91 4.70 4.49 < > 4.45
HGB 14.5 13.8 13.1* < > 13.0*
MCV 92 93 93 < > 96
PLT 201 216 256 < > 283
INR -- -- 1.2
<> = values in this interval not displayed.
*Asterisks denote abnormal values
Recent Labs
Component 08/23/23
0538 08/23/23
0036 08/22/23
2351 08/20/23
1617 08/20/23
1417 08/18/23
0521 08/18/23
```

0532 08/17/23 0310 08/02/23 0602 08/02/23 0541 08/02/23 0159 08/01/23 1731 NA -- 135 -- -- 139 -- 138 -- 140 <> 148* -- 142 K -- 4.1 -- -- 3.6 -- 3.6 -- 4.6 <> 4.0 -- 4.6 CL -- 101 -- -- 104 -- 105 -- 104 <> 117* -- 112* CO2 -- 24 -- -- 25 -- 26 -- 28 <> 26 -- 23 ANIONGAP -- 10 -- -- 10 -- 7 -- 8 <> 5 -- 7 BUN -- 16 -- -- 13 -- 13 -- 16 <> 24 -- 23 CREAT -- 0.64 -- -- 0.60 -- 0.62 -- 0.65 <> 0.67 -- 0.77 ALB -- -- 2.6* -- 2.6* <> 2.7* | 2.7* -- 2.9* GLOBULIN -- -- -- 3.7 -- -- -- 4.1* -- 4.2* AGRATIO -- -- 0.7 -- 0.7 -- 0.7 -- 0.7 ALP -- -- 133* -- -- 90 -- 113 AST -- -- 24 -- -- 17 -- 21 ALT -- -- 19 -- -- 12 -- 14 BILITOTAL -- -- 0.3 -- -- 0.5 -- 0.3 GLU 111 176* 159* <> 135* <> 133* <> 126* <> 137* <> 432* <> = values in this interval not displayed.

*Asterisks denoteabnormal values

Assessment/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Aspiration event 8/23 following NP suctioning causing emesis Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

Plan:

- Noted events of nasopharyngeal suctioning overnight causing episode of emesis and subsequent aspiration event.

- Repeat CXR in AM

- Wean supplemental O2 as able

- Initiated by Cefepime, Azithromycin, & Vancomycin by B-service for aspiration event. Will DC Vanco today. Anticipate antibiotic discontinuation tomorrow if patient remains afebrile.

- Start DuoNebs Q 6 hours ATC

- Continue Klonopin 1 mg TID, Zyprexa 10 mg BID, and Depakene 1 g BID, and Ativan 0.5 mg Q 6 hours PRN per psychiatry recommendation. No changes in RX today.

- Maintain abdominal binder AAT for line/tube protection.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat

Electronically signed by William Rudy at 08/23/2023 12:43 PM EDT Sabiha Omar - 08/23/2023 10:04 AM EDT Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient is sedated. Staff reports no management issues. He has slept all night. Klonopin was held due to sedation.

Objective:

Last Filed Vitals: Temp 98.8 °F (37.1 °C) (08/23/23 0700) Source Axillary (08/23/23 0700) BP 123/77 (08/23/23 0700) Heart Rate 109 (08/23/23 0700) Resp 20 (08/23/23 0700) O2 (L/min) 4 L/min (08/23/23 0809) SpO2 94 % (08/23/23 0809) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/23/23 0600) BMI 24.6 (08/23/23 0600)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior: Sedated

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other

Mood disorder (CMS/HCC)

Assessment & Plan

Patient's mentation has been fluctuating recently. Yesterday he was restless and agitated and today he appears to be overly sedated. There has not not been any change in medications. Klonopin had been held. Reduce morning dose of Klonopin 0.5 mg

Electronically signed by Sabiha Omar at 08/23/2023 10:04 AM EDT

Danielle S - 08/22/2023 12:12 PM EDT

Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined. He is found resting in bed, appears comfortable. He is mildly restless but non-agitated and is not observed pulling at lines. Out of all restraints.

Objective:

Vitals: Blood pressure 95/82, pulse 115, temperature 98.4 °F (36.9 °C), temperature source Axillary, resp. rate 22, height 188 cm (6' 2.02"), weight 87.1 kg (192 lb 0.3 oz), SpO2 98 %. Body mass index is 24.64 kg/m².

Intake/Output Summary (Last 24 hours) at 8/22/2023 1212 Last data filed at 8/21/2023 1807 Gross per 24 hour Intake --Output 800 ml Net -800 ml

Physical Examination: General: Non-toxic chronically ill appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam. Eyes: EOMI. No scleral icterus. ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally, no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all quadrants, soft, NT/ND. + PEG tube. Ext: No clubbing, cyanosis, or edema. Psychiatric: Affect is appropriate Neurologic: Alert and oriented X0. Speech is mumbled and incoherent. Withdrawals appropriately to painful stimuli. Does not follow commands. Appears somnolent on exam. Skin: No gross rashes.

Current Medications: Current Facility-Administered Medications Medication acetaminophen (TYLENOL) tablet 650 mg amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg clonazePAM (KlonoPIN) tablet 1 mg clopidogrel (PLAVIX) tablet 75 mg insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units LORazepam (ATIVAN) tablet 0.5 mg metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

```
Recent Labs

Component 08/20/23

1417 08/18/23

0403 08/17/23

0310 08/02/23

0632 08/01/23

1731

WBC 9.8 8.8 9.7 <> 13.7*

RBC 4.70 4.49 4.44 <> 4.45

HGB 13.8 13.1* 13.0* <> 13.0*

MCV 93 93 94 <> 96

PLT 216 256 286 <> 283

INR -- -- -- 1.2

< > = values in this interval not displayed.
```

```
*Asterisks denote abnormal values
Recent Labs
Component 08/22/23
1121 08/22/23
0604 08/21/23
2028 08/20/23
1617 08/20/23
1417 08/18/23
0521 08/18/23
0403 08/17/23
0532 08/17/23
0310 08/02/23
0602 08/02/23
0541 08/02/23
0159 08/01/23
1731
NA -- -- -- 139 -- 138 -- 140 < > 148* -- 142
K -- -- -- 3.6 -- 3.6 -- 4.6 < > 4.0 -- 4.6
CL -- -- -- 104 -- 105 -- 104 < > 117* -- 112*
CO2 -- -- 25 -- 26 -- 28 < > 26 -- 23
ANIONGAP -- -- -- 10 -- 7 -- 8 < > 5 -- 7
BUN -- -- -- 13 -- 13 -- 16 < > 24 -- 23
```

CREAT --- --- 0.60 -- 0.62 -- 0.65 < > 0.67 -- 0.77 ALB --- -- 2.6* -- 2.6* -- 2.6* < > 2.7* | 2.7* -- 2.9* GLOBULIN --- -- 3.7 -- -- -- 4.1* -- 4.2* AGRATIO --- -- 0.7 -- 0.7 -- 0.7 ALP --- -- 133* -- -- 90 -- 113 AST --- -- 24 -- -- 17 -- 21 ALT -- -- 19 -- -- 12 -- 14 BILITOTAL --- 0.3 -- -- 0.5 -- 0.3 GLU 186* 142* 157* < > 135* < > 133* < > 126* < > 137* < > 432* < > = values in this interval not displayed.

*Asterisks denoteabnormal values

Assessment/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

Plan:

- Continue Klonopin 1 mg TID, Zyprexa 10 mg BID, and Depakene 1 g BID, and Ativan 0.5 mg Q 6 hours PRN per psychiatry recommendation. No changes in RX today.

- Maintain abdominal binder AAT for line/tube protection.
- Discontinue 1:1 sitter today
- DC planning: CM to secure LTC placement.

The patient has been and is stable for discharge from internal medicine standpoint since 8/9/23. Discharge delay 2/2 psychiatric component and psych interventions.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat

Electronically signed by William Rudy at 08/22/2023 12:34 PM EDT

Associated attestation - William Rudy - 08/22/2023 12:34 PM EDT Formatting of this note might be different from the original. Patient was seen and examined on rounds Agree in principle with Internal medicine progress note as documented by Danielle Saunders, RN, NP-C Case discussed as well

Sabiha Omar - 08/22/2023 11:13 AM EDT

Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient had interrupted sleep last night. He is without mittens and without restraints. He is moaning and a bit restless.

Objective:

Last Filed Vitals: Temp 98.3 °F (36.8 °C) (08/22/23 0819) Source Axillary (08/22/23 0819) BP 122/83 (08/22/23 0819) Heart Rate 117 (08/22/23 0819) Resp 22 (08/22/23 0819) O2 (L/min) (not recorded) SpO2 97 % (08/22/23 0819) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/11/23 0800) BMI 24.6 (08/11/23 0800)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior: As above

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other Mood disorder (CMS/HCC) Assessment & Plan No change in medications suggested.

Electronically signed by Sabiha Omar at 08/22/2023 11:13 AM EDT Sabiha Omar - 08/21/2023 12:06 PM EDT Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient is resting. he is without mittens. He had slept all night.

Objective:

Last Filed Vitals: Temp 98.6 °F (37 °C) (08/21/23 1158) Source Axillary (08/21/23 1158) BP 139/93 (08/21/23 1158) Heart Rate 99 (08/21/23 1158) Resp 19 (08/21/23 1158) O2 (L/min) (not recorded) SpO2 95 % (08/21/23 1158) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/11/23 0800) BMI 24.6 (08/11/23 0800)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior: Sleeping

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other Mood disorder (CMS/HCC) Assessment & Plan No change in medications suggested.

Electronically signed by Sabiha Omar at 08/21/2023 12:06 PM EDT Yevhen Drobot - 08/21/2023 10:53 AM EDT Formatting of this note is different from the original.

Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined. He was found sedated and in no apparent distress. Noted upper airway congestion on exam. Currently out of mitts. 1:1 sitter at bedside states he had some agitation with pulling blankets overnight but slept the majority of the night.

Objective:

Vitals: Blood pressure 135/89, pulse 104, temperature 98.5 °F (36.9 °C), temperature source Axillary, resp. rate 19, height 188 cm (6' 2.02"), weight 87.1 kg (192 lb 0.3 oz), SpO2 93 %. Body mass index is 24.64 kg/m².

Intake/Output Summary (Last 24 hours) at 8/21/2023 1053 Last data filed at 8/21/2023 0600 Gross per 24 hour Intake 1870 ml Output 1900 ml Net -30 ml

Physical Examination: General: Non-toxic chronically ill appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam. Eyes: EOMI. No scleral icterus. ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally, no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all quadrants, soft, NT/ND. + PEG tube. Ext: No clubbing, cyanosis, or edema. Psychiatric: Affect is appropriate Neurologic: Alert and oriented X0. Speech is mumbled and incoherent. Withdrawals appropriately to painful stimuli. Does not follow commands. Appears somnolent on exam. Skin: No gross rashes.

Current Medications: Current Facility-Administered Medications Medication acetaminophen (TYLENOL) tablet 650 mg amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg clonazePAM (KlonoPIN) tablet 1 mg clopidogrel (PLAVIX) tablet 75 mg insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units LORazepam (ATIVAN) tablet 0.5 mg metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

```
Recent Labs

Component 08/20/23

1417 08/18/23

0403 08/17/23

0310 08/02/23

0632 08/01/23

1731

WBC 9.8 8.8 9.7 <> 13.7*

RBC 4.70 4.49 4.44 <> 4.45

HGB 13.8 13.1* 13.0* <> 13.0*

MCV 93 93 94 <> 96

PLT 216 256 286 <> 283

INR -- -- -- 1.2

< > = values in this interval not displayed.
```

```
*Asterisks denote abnormal values
Recent Labs
Component 08/21/23
0546 08/20/23
2329 08/20/23
1927 08/20/23
1617 08/20/23
1417 08/18/23
0521 08/18/23
0403 08/17/23
0532 08/17/23
0310 08/02/23
0602 08/02/23
0541 08/02/23
0159 08/01/23
1731
NA -- -- -- 139 -- 138 -- 140 < > 148* -- 142
K -- -- -- 3.6 -- 3.6 -- 4.6 < > 4.0 -- 4.6
CL -- -- -- 104 -- 105 -- 104 < > 117* -- 112*
CO2 -- -- 25 -- 26 -- 28 < > 26 -- 23
ANIONGAP -- -- -- 10 -- 7 -- 8 < > 5 -- 7
BUN -- -- -- 13 -- 13 -- 16 < > 24 -- 23
```

CREAT --- --- 0.60 -- 0.62 -- 0.65 < > 0.67 -- 0.77 ALB --- -- 2.6* -- 2.6* -- 2.6* < > 2.7* | 2.7* -- 2.9*GLOBULIN --- --- 3.7 --- --- 4.1* -- 4.2* AGRATIO --- --- 0.7 -- --- 0.7 -- 0.7 ALP --- --- 133* --- --- 90 -- 113 AST --- --- 24 --- --- 17 -- 21 ALT --- --- 19 --- --- 12 --- 14 BILITOTAL --- --- 0.3 --- --- 0.5 -- 0.3 GLU 154* 139 129 < > 135* < > 133* < > 126* < > 137* < > 432* < > = values in this interval not displayed.

*Asterisks denoteabnormal values

Assessment/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

Plan:

- Continue Klonopin 1 mg TID, Zyprexa 10 mg BID, and Depakene 1 g BID, and Ativan 0.5 mg Q 6 hours PRN per psychiatry recommendation.

 Will check CXR for completeness sake; however, congestion appears to be upper airway. Lungs bilaterally CTA. Respirations even and unlabored without accessory muscle use. No WBC count, stable SPO2 on room air, afebrile, normal RR. Will monitor.
 Maintains with 1:1 sitter. Discontinue when able.

- Maintain abdominal binder AAT for line/tube protection.

The patient has been and is stable for discharge from internal medicine perspective since 8/9/23. Discharge delay 2/2 psychiatric component and psych interventions.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat

Internal Medicine Attending 8/21/2023

Long conversation with patient's son at bedside who is going to reach out to his sister. Discussions regarding goals of care and quality of life. Although son agrees that patient does not have great quality of life and would not want to be on prolonged tube feeds he states he cannot stop the tube feeds. We will evaluate/discuss someone check their evaluation for potential informational visit with hospice if tube feeds can be continued. Attempt to wean restraints as able

PE: Cooperative, NAD, no scleral icterus, RRR, no respiratory distress, no abdominal tenderness with palpation, bilateral LE pitting edema, No LE tenderness with palpation

I was physically present for the service provided. I have personally examined and evaluated this patient. I performed the key elements of the history and physical examination. Verified and agree with the findings and plan as documented in the above note. Exceptions and clarifications have been amended in this document as needed. Please see note above for full details.

Yevhen Drobot, D.O. Internal Medicine Page #8010 Mobile Heartbeat

Electronically signed by Yevhen Drobot at 08/21/2023 2:25 PM EDT Yevhen Drobot - 08/20/2023 11:15 AM EDT Formatting of this note is different from the original. Internal Medicine Progress Note

Attending Physician: Rudy, William M, DO

Patient's Name: Ioan Suiugan MRN: 9942681 Date of Birth: 2/27/1961 Age: 62 yrs Date of service: 8/20/2023 Provider: Emily A Gopoian, RN NP-C

Interval History: Patient seen and examined this morning calm resting in bed with sitter at bedside.

Current Medications/Allergies Medication Administration Record Allergies reviewed. Patient has no allergy information on record. Current Facility-Administered Medications Medication Dose Route Frequency Last Rate amiodarone (CORDARONE, PACERONE) tablet 200 mg 200 mg PEG Tube DAILY apixaban (ELIQUIS) tablet 5 mg 5 mg Oral Q 12 H atorvastatin (LIPITOR) tablet 40 mg 40 mg PEG Tube Q HS clonazePAM (KlonoPIN) tablet 1 mg 1 mg PEG Tube TID clopidogrel (PLAVIX) tablet 75 mg 75 mg Oral DAILY insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units 2-5 Units Subcutaneous Q 6 H metoprolol (LOPRESSOR) tablet 25 mg 25 mg PEG Tube BID OLANZapine (ZyPREXA) tablet 10 mg 10 mg Oral BID sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Q 12 H valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg 1,000 mg Oral BID

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate acetaminophen (TYLENOL) tablet 650 mg 650 mg PEG Tube Q 4 H PRN LORazepam (ATIVAN) tablet 0.5 mg 0.5 mg Oral Q 6 H PRN sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 20 mL 20 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 3 mL 3 mL Intravenous PRN sodium chloride 0.9% flush injection 10 mL 10 mL Intravenous ONCE PRN

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate

Physical Exam: Vitals were reviewed Last Filed Vitals: Temp 98.2 °F (36.8 °C) (08/20/23 0727) Source Axillary (08/20/23 0727) BP 103/71 (08/20/23 0727) Heart Rate 92 (08/20/23 0727) Resp 18 (08/20/23 0727) O2 (L/min) (not recorded) SpO2 95 % (08/20/23 0745) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/11/23 0800) BMI 24.6 (08/11/23 0800)

Temp Min: 97 °F (36.1 °C) Min taken time: 08/15/23 0350 Max: 100.6 °F (38.1 °C) Max taken time: 08/01/23 1805 Intake/Output:

Intake/Output Summary (Last 24 hours) at 8/20/2023 1115 Last data filed at 8/20/2023 0940 Gross per 24 hour Intake 330 ml Output 2300 ml Net -1970 ml

GENERAL: NAD, appears stated age

HEENT: NC/AT. PERRLA, EOMI, sclera without ictera, nares patent, throat clear.

NECK: Supple. No JVD. No lymphadenopathy. Trachea midline, no bruit.

COR: RRR, no S3, no S4. No rub. No murmur.

LUNGS: CTA without wheezing, rhonchi, rales or crackles.

ABDOMEN: Soft, non tender, positive bowel sounds x 4, No rebound, guarding or rigidity. No organomegaly.

SKIN: Warm and dry.

```
EXTREMITIES: No edema, cyanosis or clubbing.
```

Diagnostic Studies: 11:15 AM: **Recent Labs** Component 08/18/23 0403 08/17/23 0310 08/16/23 0313 WBC 8.8 9.7 9.7 HGB 13.1* 13.0* 13.0* HCT 41.9 41.8 40.8 MCV 93 94 94 PLT 256 286 284 **Recent Labs** Component 08/20/23 1054 08/20/23 0555 08/19/23 1942 08/18/23 0521 08/18/23 0403 08/17/23 0532 08/17/23 0310 08/16/23 0552 08/16/23 0313 NA -- -- 138 -- 140 -- 138 K --- -- 3.6 -- 4.6 -- 3.7 CL -- -- -- 105 -- 104 -- 106 CO2 -- -- -- 26 -- 28 -- 25 BUN -- -- -- 13 -- 16 -- 17 CREAT -- -- -- 0.62 -- 0.65 -- 0.61 GLU 143* 137 123 < > 133* < > 126* < > 123* < > = values in this interval not displayed. Abdominal Labs **Recent Labs** Component 08/18/23 0403 08/17/23 0310 08/16/23 0313 08/03/23 0626 08/02/23 0541 08/01/23 1731 ALP -- -- -- 90 113 AST -- -- 17 21 ALT -- -- 12 14 LIPASE --- --- 10 BILITOTAL -- -- -- 0.5 0.3 BILIDIRECT -- -- 0.2 0.2 ALB 2.6* 2.6* 2.5* < > 2.7* | 2.7* 2.9* < > = values in this interval not displayed. Glucose **Recent Labs** Lab 08/20/23 1054 08/20/23 0555 08/19/23 1942 08/19/23 1654 GLU 143* 137 123 125 INR Recent Labs Lab 08/01/23 1731

INR 1.2

Iron Studies Recent Labs Component 08/02/23 0224 **IRON 52*** FERRITIN 385* TIBC 304 Imaging No results found. Impression/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

DC in planning

Emily Gopoian, RN, NP-C Internal Medicine

Internal Medicine Attending 8/20/2023

Wean restraints as able

PE: Somnolent/sedated, NAD, no scleral icterus, RRR, no respiratory distress, no abdominal tenderness with palpation, no bilateral LE pitting edema, No LE tenderness with palpation

I was physically present for the service provided. I have personally examined and evaluated this patient. I performed the key elements of the history and physical examination. Verified and agree with the findings and plan as documented in the above note. Exceptions and clarifications have been amended in this document as needed. Please see note above for full details.

Yevhen Drobot, D.O. Internal Medicine Page #8010 Mobile Heartbeat

Electronically signed by Yevhen Drobot at 08/20/2023 2:19 PM EDT Juan H - 08/20/2023 7:16 AM EDT Formatting of this note might be different from the original. B-Service Restraint NOTE:

Called to assess loan Suiugan a need of restraint secondary to danger to self. Currently the patient has been reported to be agitation. Mitt on both hands have been placed at this time.

BP 103/71 | Pulse 92 | Temp 98.2 °F (36.8 °C) (Axillary) | Resp 18 | Ht 188 cm (6' 2.02") | Wt 87.1 kg (192 lb 0.3 oz) | SpO2 95% | BMI 24.64 kg/m²

loan Suiugan after restraint placement is stable. previous medical and behavior modifiers prior to restraint use include reorientaiton. Will keep restraints in place with nursing monitoring for patient safety and appropriate discontinuation as soon as possible.

Juan Huang, RN NP-C B Service Pager Number: 4509 8/20/2023 8:30 AM

Electronically signed by Juan H at 08/20/2023 8:32 AM EDT Yevhen Drobot - 08/19/2023 12:19 PM EDT

Formatting of this note is different from the original. Internal Medicine Progress Note

Attending Physician: Rudy, William M, DO

Patient's Name: Ioan Suiugan MRN: 9942681 Date of Birth: 2/27/1961 Age: 62 yrs Date of service: 8/19/2023 Provider: Emily A Gopoian, RN NP-C

Interval History: Patient seen and examined this morning calm resting in bed with sitter at bedside.

Current Medications/Allergies Medication Administration Record Allergies reviewed. Patient has no allergy information on record. Current Facility-Administered Medications Medication Dose Route Frequency Last Rate amiodarone (CORDARONE, PACERONE) tablet 200 mg 200 mg PEG Tube DAILY apixaban (ELIQUIS) tablet 5 mg 5 mg Oral Q 12 H atorvastatin (LIPITOR) tablet 40 mg 40 mg PEG Tube Q HS clonazePAM (KlonoPIN) tablet 1 mg 1 mg PEG Tube TID clopidogrel (PLAVIX) tablet 75 mg 75 mg Oral DAILY insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units 2-5 Units Subcutaneous Q 6 H metoprolol (LOPRESSOR) tablet 25 mg 25 mg PEG Tube BID OLANZapine (ZyPREXA) tablet 10 mg 10 mg Oral BID sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Q 12 H valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg 1,000 mg Oral BID

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate acetaminophen (TYLENOL) tablet 650 mg 650 mg PEG Tube Q 4 H PRN LORazepam (ATIVAN) tablet 0.5 mg 0.5 mg Oral Q 6 H PRN sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 20 mL 20 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 3 mL 3 mL Intravenous PRN sodium chloride 0.9% flush injection 10 mL 10 mL Intravenous ONCE PRN

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate

Physical Exam: Vitals were reviewed Last Filed Vitals: Temp 98 °F (36.7 °C) (08/19/23 1136) Source Axillary (08/19/23 1136) BP 109/81 (08/19/23 1136) Heart Rate 88 (08/19/23 1136) Resp 18 (08/19/23 1136) O2 (L/min) (not recorded) SpO2 96 % (08/19/23 1136) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/11/23 0800) BMI 24.6 (08/11/23 0800)

Temp Min: 97 °F (36.1 °C) Min taken time: 08/15/23 0350 Max: 100.6 °F (38.1 °C) Max taken time: 08/01/23 1805 Intake/Output:

Intake/Output Summary (Last 24 hours) at 8/19/2023 1220 Last data filed at 8/19/2023 0902 Gross per 24 hour Intake 1915 ml Output 1200 ml Net 715 ml

GENERAL: NAD, appears stated age AXO 0 mumbled and incoherent

HEENT: NC/AT. PERRLA, EOMI, sclera without ictera, nares patent, throat clear.

NECK: Supple. No JVD. No lymphadenopathy. Trachea midline, no bruit.

COR: RRR, no S3, no S4. No rub. No murmur.

LUNGS: CTA without wheezing, rhonchi, rales or crackles.

ABDOMEN: Soft, non tender, positive bowel sounds x 4, No rebound, guarding or rigidity. No organomegaly.

SKIN: Warm and dry.

EXTREMITIES: No edema, cyanosis or clubbing.

Diagnostic Studies:

12:20 PM: **Recent Labs** Component 08/18/23 0403 08/17/23 0310 08/16/23 0313 WBC 8.8 9.7 9.7 HGB 13.1* 13.0* 13.0* HCT 41.9 41.8 40.8 MCV 93 94 94 PLT 256 286 284 Recent Labs Component 08/19/23 1134 08/19/23 0558 08/18/23 2042 08/18/23 0521 08/18/23 0403 08/17/23 0532 08/17/23 0310 08/16/23 0552 08/16/23 0313 NA -- -- 138 -- 140 -- 138 К -- -- 3.6 -- 4.6 -- 3.7 CL -- -- -- 105 -- 104 -- 106 CO2 -- -- -- 26 -- 28 -- 25 BUN -- -- -- 13 -- 16 -- 17 CREAT -- -- -- 0.62 -- 0.65 -- 0.61 GLU 134 120 139 < > 133* < > 126* < > 123* < > = values in this interval not displayed. Abdominal Labs Recent Labs Component 08/18/23 0403 08/17/23 0310 08/16/23 0313 08/03/23 0626 08/02/23

0541 08/01/23 1731 ALP -- -- -- 90 113 AST -- -- 17 21 ALT -- -- 12 14 LIPASE -- -- -- -- 10 BILITOTAL -- -- -- 0.5 0.3 BILIDIRECT -- -- -- 0.2 0.2 ALB 2.6* 2.6* 2.5* < > 2.7* | 2.7* 2.9* < > = values in this interval not displayed. Glucose Recent Labs Lab 08/19/23 1134 08/19/23 0558 08/18/23 2042 08/18/23 1545 GLU 134 120 139 126 INR Recent Labs Lab 08/01/23 1731 INR 1.2 Iron Studies **Recent Labs** Component 08/02/23 0224 **IRON 52*** FERRITIN 385* TIBC 304 Imaging No results found. Impression/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Hypernatremia Hypokalemia **Essential HTN** Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury DC in planning Emily Gopoian, RN, NP-C

Internal Medicine

Internal Medicine Attending 8/19/2023

Attempt to wean patient off restraints as able Psychiatry recommendations appreciated

PE: Cooperative, NAD, no scleral icterus, RRR, no respiratory distress, no abdominal tenderness with palpation, no bilateral LE pitting edema, No LE tenderness with palpation

I was physically present for the service provided. I have personally examined and evaluated this patient. I performed the key elements of the history and physical examination. Verified and agree with the findings and plan as documented in the above note. Exceptions and clarifications have been amended in this document as needed. Please see note above for full details.

Yevhen Drobot, D.O. Internal Medicine Page #8010 Mobile Heartbeat

Electronically signed by Yevhen Drobot at 08/19/2023 4:12 PM EDT

Amanda K - 08/19/2023 8:00 AM EDT

Formatting of this note might be different from the original. B-Service Restraint NOTE:

Called to assess loan Suiugan for a need for restraint secondary to danger to self. Currently the patient has been reported to be confused, pulling on lines and tubing and PEG tube. Secured mitt: both have been maintained at this time.

BP 116/85 | Pulse 96 | Temp 98 °F (36.7 °C) (Axillary) | Resp 18 | Ht 188 cm (6' 2.02") | Wt 87.1 kg (192 lb 0.3 oz) | SpO2 96% | BMI 24.64 kg/m²

loan Suiugan after restraint placement is stable. Previous medical and behavior modifiers prior to restraint use include calm environment, frequent reorientation and redirection. Will keep restraints in place with nursing monitoring for patient safety and appropriate discontinuation as soon as possible.

Diagnosis: Confusion

Amanda Kress NP-BC - B Service Available on mobile heartbeat or call "B Service" on call if offline 8/19/2023 8:00 AM Electronically signed by Amanda K at 08/19/2023 8:01 AM EDT Danielle S - 08/18/2023 9:13 AM EDT Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined. He was found sleeping in no acute distress. Upon examination today the patient began swatting. Currently in bilateral mitts and with 1:1 sitter.

Objective:

Vitals: Blood pressure 100/79, pulse 86, temperature 98 °F (36.7 °C), temperature source Axillary, resp. rate 18, height 188 cm (6' 2.02"), weight 87.1 kg (192 lb 0.3 oz), SpO2 100 %. Body mass index is 24.64 kg/m².

Intake/Output Summary (Last 24 hours) at 8/18/2023 0913 Last data filed at 8/18/2023 0600 Gross per 24 hour Intake 240 ml Output 3200 ml Net -2960 ml

Physical Examination:

General: Non-toxic appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam.

Eyes: EOMI. No scleral icterus.

ENT: Neck is supple, mucous membranes are moist

Chest: Clear to auscultation bilaterally, no wheezing, no rales

Cardiac: RRR, S1, S2, no murmurs

Abdomen: Bowel sounds are present in all quadrants, soft, NT/ND. + PEG tube.

Ext: No clubbing, cyanosis, or edema.

Psychiatric: Affect is appropriate

Neurologic: Alert and oriented X0. Speech is mumbled and incoherent. Withdrawals appropriately to painful stimuli. Does not follow commands. Appears somnolent on exam. Skin: No gross rashes.

Current Medications: Current Facility-Administered Medications Medication acetaminophen (TYLENOL) tablet 650 mg amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg clonazePAM (KlonoPIN) tablet 1 mg clopidogrel (PLAVIX) tablet 75 mg insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units LORazepam (ATIVAN) tablet 0.5 mg metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

Recent Labs Component 08/18/23 0403 08/17/23 0310 08/16/23 0313 08/02/23 0632 08/01/23 1731 WBC 8.8 9.7 9.7 < > 13.7* RBC 4.49 4.44 4.36 < > 4.45 HGB 13.1* 13.0* 13.0* < > 13.0* MCV 93 94 94 < > 96 PLT 256 286 284 < > 283 INR -- -- - 1.2 < > = values in this interval not displayed.

```
*Asterisks denote abnormal values
Recent Labs
Component 08/18/23
0521 08/18/23
0403 08/17/23
2132 08/17/23
0532 08/17/23
0310 08/16/23
0552 08/16/23
0313 08/02/23
0602 08/02/23
0541 08/02/23
0159 08/01/23
1731
NA -- 138 -- -- 140 -- 138 < > 148* -- 142
K -- 3.6 -- -- 4.6 -- 3.7 < > 4.0 -- 4.6
CL -- 105 -- -- 104 -- 106 < > 117* -- 112*
CO2 -- 26 -- -- 28 -- 25 < > 26 -- 23
ANIONGAP -- 7 -- -- 8 -- 7 < > 5 -- 7
BUN -- 13 -- -- 16 -- 17 < > 24 -- 23
CREAT -- 0.62 -- -- 0.65 -- 0.61 < > 0.67 -- 0.77
ALB -- 2.6* -- -- 2.6* -- 2.5* < > 2.7* | 2.7* -- 2.9*
GLOBULIN -- -- -- -- -- 4.1* -- 4.2*
AGRATIO -- -- -- -- -- 0.7 -- 0.7
ALP -- -- -- -- -- -- 90 -- 113
AST -- -- -- -- -- 17 -- 21
ALT -- -- -- -- -- -- 12 -- 14
BILITOTAL -- -- -- -- -- 0.5 -- 0.3
GLU 147* 133* 142* < > 126* < > 123* < > 137* < > 432*
<> = values in this interval not displayed.
```

*Asterisks denoteabnormal values

Assessment/Plan:

Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

Plan:

- Psychiatry following re: medication adjustments for behaviors. Recommending Klonopin 1 mg TID, Zyprexa 10 mg BID, Depakote
- 1 g BID, Ativan 0.5 mg Q 6 hours PRN. No RX changes advised today.
- Remains in mitts given behaviors. Discontinue when able.
- Maintains with 1:1 sitter. Discontinue when able.
- Maintain abdominal binder AAT for line/tube protection.

Discussed with SW manager today. Plans to reach out to psych re: medication adjustments. The patient has been and is stable for discharge from internal medicine perspective since 8/9/23. Discharge delay 2/2 psychiatric component and psych interventions.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat

Electronically signed by Armen Korkigian at 08/18/2023 10:23 AM EDT

Associated attestation - Armen Korkigian - 08/18/2023 10:23 AM EDT Formatting of this note might be different from the original. Internal Medicine Attending 8/18/2023 Progress note reviewed. Care plan discussed with resident and or PA/NP team. Agree with documentation as written without amendments. Patient seen, examined and discussed with residents. See resident note above for full details. Armen A Korkigian, DO Face-to-face with patient and resident performed during rounds. Rrr,-pmi/cta,increased APD/abd, soft, nt, +BS/ ext nt ,with out increasing edema /nnInd/ skin SMW Remains agitated and in protective mitts Sabiha Omar - 08/18/2023 7:59 AM EDT

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient is sedated. Staff has not noted any management issues. He is still in mittens

Objective:

Last Filed Vitals: Temp 98 °F (36.7 °C) (08/18/23 0749) Source Axillary (08/18/23 0749) BP 100/79 (08/18/23 0749) Heart Rate 86 (08/18/23 0749) Resp 18 (08/18/23 0749) O2 (L/min) (not recorded) SpO2 100 % (08/18/23 0749) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/11/23 0800) BMI 24.6 (08/11/23 0800)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior: Sedated

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other Mood disorder (CMS/HCC) Assessment & Plan No change in medications suggested.

Electronically signed by Sabiha Omar at 08/18/2023 7:59 AM EDT Sabiha Omar - 08/17/2023 11:27 AM EDT

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient is sedated. Sitter reports that she he is sleeping a lot. At times he stirs in the bed tries to grab the side rails. He is brought the food tray regularly though he is not eating. Patient is still in bilateral mittens but not in restraints anymore.

Objective:

Last Filed Vitals: Temp 97.1 °F (36.2 °C) (08/17/23 0700) Source Axillary (08/16/23 2227) BP 113/78 (08/17/23 1100) Heart Rate 83 (08/17/23 1100) Resp 18 (08/17/23 1100) O2 (L/min) (not recorded) SpO2 95 % (08/17/23 1100) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/11/23 0800) BMI 24.6 (08/11/23 0800)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior: Resting comfortably

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other Mood disorder (CMS/HCC) Assessment & Plan No change in medications suggested. Collaborated care with medical team.

Electronically signed by Sabiha Omar at 08/17/2023 11:27 AM EDT

Danielle S - 08/17/2023 9:11 AM EDT

Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined. He appears to be sedated in bed. Maintains in bilateral mitts. 1:1 sitter at bedside without reported concerns this morning.

Objective: Vitals: Blood pressure 137/88, pulse 85, temperature 97.1 °F (36.2 °C), resp. rate 18, height 188 cm (6' 2.02"), weight 87.1 kg (192 lb 0.3 oz), SpO2 99 %. Body mass index is 24.64 kg/m².

Intake/Output Summary (Last 24 hours) at 8/17/2023 0911 Last data filed at 8/17/2023 0904 Gross per 24 hour Intake 0 ml Output 3950 ml Net -3950 ml

Physical Examination: General: Non-toxic appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam. Eyes: EOMI. No scleral icterus. ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally, no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all quadrants, soft, NT/ND. + PEG tube. Ext: No clubbing, cyanosis, or edema. Psychiatric: Affect is appropriate Neurologic: Alert and oriented X0. Speech is mumbled and incoherent. Withdrawals appropriately to painful stimuli. Does not follow commands. Appears somnolent on exam. Skin: No gross rashes.

Current Medications: Current Facility-Administered Medications Medication acetaminophen (TYLENOL) tablet 650 mg amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg clonazePAM (KlonoPIN) tablet 1 mg clopidogrel (PLAVIX) tablet 75 mg insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units LORazepam (ATIVAN) tablet 0.5 mg metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

```
Recent Labs
Component 08/17/23
0310 08/16/23
0313 08/15/23
0421 08/02/23
0632 08/01/23
1731
WBC 9.7 9.7 9.6 < > 13.7*
RBC 4.44 4.36 4.47 < > 4.45
HGB 13.0* 13.0* 13.2* < > 13.0*
MCV 94 94 93 < > 96
PLT 286 284 316 < > 283
INR -- -- 1.2
< > = values in this interval not displayed.
*Asterisks denote abnormal values
Recent Labs
Component 08/17/23
0532 08/17/23
0310 08/17/23
0008 08/16/23
0552 08/16/23
0313 08/15/23
0527 08/15/23
0421 08/02/23
0602 08/02/23
0541 08/02/23
0159 08/01/23
1731
NA -- 140 -- -- 138 -- 141 < > 148* -- 142
K -- 4.6 -- -- 3.7 -- 3.7 < > 4.0 -- 4.6
CL -- 104 -- -- 106 -- 108 < > 117* -- 112*
CO2 -- 28 -- -- 25 -- 26 < > 26 -- 23
ANIONGAP -- 8 -- -- 7 -- 7 < > 5 -- 7
BUN -- 16 -- -- 17 -- 13 < > 24 -- 23
CREAT -- 0.65 -- -- 0.61 -- 0.56* < > 0.67 -- 0.77
```

ALB -- 2.6^* -- 2.5^* -- 2.6^* <> $2.7^* | 2.7^* -- 2.9^*$ GLOBULIN -- -- $2.5^* -- 2.6^* <> 2.7^* | 2.7^* -- 2.9^*$ AGRATIO -- -- $2.5^* -- 4.1^* -- 4.2^*$ AGRATIO -- -- 0.7 -- 0.7ALP -- -- 0.7 -- 0.7ALP -- -- 0.7 -- 0.7ALT -- 0.7 -- 21ALT -- 0.7 -- 17 -- 21ALT -- 0.7 -- 12 -- 14BILITOTAL -- 0.5 -- 0.3GLU 114 126* 142* <> 123* <> 97 <> 137* <> 432* <> = values in this interval not displayed.

*Asterisks denoteabnormal values

Assessment/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

Plan:

- Psychiatry following re: medication adjustments for behaviors. Recommending Klonopin 1 mg TID, Zyprexa 10 mg BID, Depakote
- 1 g BID, Ativan 0.5 mg Q 6 hours PRN. No RX changes advised yesterday.
- Will attempt to discontinue Mitts today. Maintain 1:1 sitter.
- Maintain abdominal binder AAT for line/tube protection.

CM assist with DC placement to SNF once out of restraints.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat

Electronically signed by Armen Korkigian at 08/17/2023 10:47 AM EDT

Associated attestation - Armen Korkigian - 08/17/2023 10:47 AM EDT Formatting of this note might be different from the original. Internal Medicine Attending 8/17/2023 Progress note reviewed. Care plan discussed with resident and or PA/NP team. Agree with documentation as written without amendments. Patient seen, examined and discussed with residents. See resident note above for full details. Armen A Korkigian, DO Face-to-face with patient and resident performed during rounds. Rrr,-pmi/cta,increased APD/abd, soft, nt, +BS/ ext nt ,with out increasing edema /nnlnd/ skin SMW Did not sleep all night and was agitated will increase atypical

Sabiha Omar - 08/16/2023 9:48 AM EDT

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient is sedated. He slept 3 hours last night. He is not in restraints but still have mittens.

Objective:

Last Filed Vitals: Temp 98 °F (36.7 °C) (08/16/23 0801) Source Axillary (08/16/23 0801) BP 107/75 (08/16/23 0801) Heart Rate 80 (08/16/23 0801) Resp 17 (08/16/23 0801) O2 (L/min) (not recorded) SpO2 95 % (08/16/23 0801) O2% 21 % (08/13/23 0741) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/11/23 0800) BMI 24.6 (08/11/23 0800)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior: Sedated

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other * Altered mental status, unspecified altered mental status type Assessment & Plan No change in medications for now.

Electronically signed by Sabiha Omar at 08/16/2023 9:48 AM EDT Danielle S - 08/16/2023 9:05 AM EDT

Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined. He maintains in bilateral mitt restraints. Reported intermittent episodes of agitation; however, he does seem to be responsive to medications. 1:1 sitter maintained.

Objective:

Vitals: Blood pressure 107/75, pulse 80, temperature 98 °F (36.7 °C), temperature source Axillary, resp. rate 17, height 188 cm (6' 2.02"), weight 87.1 kg (192 lb 0.3 oz), SpO2 95 %. Body mass index is 24.64 kg/m².

Intake/Output Summary (Last 24 hours) at 8/16/2023 0905 Last data filed at 8/16/2023 0559 Gross per 24 hour Intake --Output 150 ml Net -150 ml

Physical Examination: General: Non-toxic appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam. Eyes: EOMI. No scleral icterus. ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally, no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all quadrants, soft, NT/ND. + PEG tube. Ext: No clubbing, cyanosis, or edema. Psychiatric: Affect is appropriate Neurologic: Alert and oriented X0. Speech is mumbled and incoherent. Withdrawals appropriately to painful stimuli. Does not follow commands. Appears somnolent on exam. Skin: No gross rashes.

Current Medications: Current Facility-Administered Medications Medication acetaminophen (TYLENOL) tablet 650 mg amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg clonazePAM (KlonoPIN) tablet 1 mg clopidogrel (PLAVIX) tablet 75 mg insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units LORazepam (ATIVAN) tablet 0.5 mg metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

```
Recent Labs

Component 08/16/23

0313 08/15/23

0421 08/14/23

0258 08/02/23

0632 08/01/23

1731

WBC 9.7 9.6 10.6* < > 13.7*

RBC 4.36 4.47 4.51 < > 4.45

HGB 13.0* 13.2* 13.2* < > 13.0*

MCV 94 93 93 < > 96

PLT 284 316 319 < > 283

INR -- -- - - 1.2

< > = values in this interval not displayed.
```

*Asterisks denote abnormal values **Recent Labs** Component 08/16/23 0552 08/16/23 0313 08/16/23 0005 08/15/23 0527 08/15/23 0421 08/14/23 1200 08/14/23 0258 08/02/23 0602 08/02/23 0541 08/02/23 0159 08/01/23 1731 NA -- 138 -- -- 141 -- 140 < > 148* -- 142 K -- 3.7 -- -- 3.7 -- 3.8 < > 4.0 -- 4.6 CL -- 106 -- -- 108 -- 105 < > 117* -- 112* CO2 -- 25 -- -- 26 -- 27 < > 26 -- 23 ANIONGAP -- 7 -- 7 -- 8 < > 5 -- 7 BUN -- 17 -- -- 13 -- 12 < > 24 -- 23 CREAT -- 0.61 -- -- 0.56* -- 0.64 < > 0.67 -- 0.77 ALB -- 2.5* -- -- 2.6* -- 2.7* < > 2.7* | 2.7* -- 2.9* GLOBULIN -- -- -- -- -- 4.1* -- 4.2* AGRATIO -- -- -- -- 0.7 -- 0.7 ALP -- -- -- -- 90 -- 113 AST -- -- -- -- 17 -- 21 ALT -- -- -- -- 12 -- 14 BILITOTAL -- -- -- -- 12 -- 14 BILITOTAL -- -- -- -- 0.5 -- 0.3 GLU 122 123* 164* <> 97 <> 119* <> 137* <> 432* <> = values in this interval not displayed.

*Asterisks denoteabnormal values

Assessment/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

Plan:

- Psychiatry following re: medication adjustments for behaviors. Recommending Klonopin 1 mg TID, Zyprexa 10 mg BID, Depakote
- 1 g BID, Ativan 0.5 mg Q 6 hours PRN.
- Maintains in bilateral mitts. Discontinue when able.
- Maintain abdominal binder AAT for line/tube protection.

CM assist with DC placement to SNF once out of restraints.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat

Electronically signed by Armen Korkigian at 08/16/2023 11:23 AM EDT

Associated attestation - Armen Korkigian - 08/16/2023 11:23 AM EDT Formatting of this note might be different from the original. Internal Medicine Attending 8/16/2023 Progress note reviewed. Care plan discussed with resident and or PA/NP team. Agree with documentation as written without amendments. Patient seen, examined and discussed with residents. See resident note above for full details. Armen A Korkigian, DO Face-to-face with patient and resident performed during rounds. Rrr,-pmi/cta,increased APD/abd, soft, nt, +BS/ ext nt ,with out increasing edema /nnlnd/ skin SMW

Sabiha Omar - 08/15/2023 11:18 AM EDT

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Started to sleep better. However every time staff tries to discontinue restraints he starts to pull on things. Yesterday he disconnected to feeding and he was put in restraints again along with mittens.

Objective:

Last Filed Vitals: Temp 97.8 °F (36.6 °C) (08/15/23 0720) Source Axillary (08/15/23 0720) BP 119/88 (08/15/23 0720) Heart Rate 78 (08/15/23 0720) Resp 17 (08/15/23 0720) O2 (L/min) (not recorded) SpO2 99 % (08/15/23 0735) O2% 21 % (08/13/23 0741) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/11/23 0800) BMI 24.6 (08/11/23 0800)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior: Sleeping

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other

Mood disorder (CMS/HCC) Assessment & Plan Patient continues to pull on the PEG tube when he is awake. Increase Klonopin 1 mg 3 times a day. Sedation might be an option to keep his hands off the tubings.

Electronically signed by Sabiha Omar at 08/15/2023 11:18 AM EDT

Yevhen Drobot - 08/15/2023 9:39 AM EDT

Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined. He is found sleeping comfortably in no acute distress. Maintains in bilateral SWR and mitts. Sitter at bedside reports no behaviors this morning. Reported agitation overnight but he was calm after receiving medications.

Objective:

Vitals: Blood pressure 119/88, pulse 78, temperature 97.8 °F (36.6 °C), temperature source Axillary, resp. rate 17, height 188 cm (6' 2.02"), weight 87.1 kg (192 lb 0.3 oz), SpO2 99 %. Body mass index is 24.64 kg/m².

Intake/Output Summary (Last 24 hours) at 8/15/2023 0939 Last data filed at 8/15/2023 0500 Gross per 24 hour Intake 145 ml Output 2300 ml Net -2155 ml

Physical Examination: General: Non-toxic appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam. Eyes: EOMI. No scleral icterus. ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally, no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all quadrants, soft, NT/ND. + PEG tube. Ext: No clubbing, cyanosis, or edema. Psychiatric: Affect is appropriate Neurologic: Alert and oriented X0. Speech is mumbled and incoherent. Withdrawals appropriately to painful stimuli. Does not follow commands. Appears somnolent on exam. Skin: No gross rashes.

Current Medications: Current Facility-Administered Medications Medication acetaminophen (TYLENOL) tablet 650 mg amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg clonazePAM (KlonoPIN) tablet 0.5 mg clonazePAM (KlonoPIN) tablet 1 mg clopidogrel (PLAVIX) tablet 75 mg insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units LORazepam (ATIVAN) tablet 0.5 mg metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

```
Recent Labs
Component 08/15/23
0421 08/14/23
0258 08/13/23
0323 08/02/23
0632 08/01/23
1731
WBC 9.6 10.6* 9.8 < > 13.7*
RBC 4.47 4.51 4.26* < > 4.45
HGB 13.2* 13.2* 12.6* < > 13.0*
MCV 93 93 93 < > 96
PLT 316 319 306 < > 283
INR -- -- -- 1.2
< > = values in this interval not displayed.
```

```
*Asterisks denote abnormal values
Recent Labs
Component 08/15/23
0527 08/15/23
0421 08/14/23
2345 08/14/23
1200 08/14/23
0258 08/13/23
0527 08/13/23
0323 08/02/23
0602 08/02/23
0541 08/02/23
0159 08/01/23
1731
NA -- 141 -- -- 140 -- 138 < > 148* -- 142
K -- 3.7 -- -- 3.8 -- 3.3* < > 4.0 -- 4.6
CL -- 108 -- -- 105 -- 104 < > 117* -- 112*
CO2 -- 26 -- -- 27 -- 27 < > 26 -- 23
ANIONGAP -- 7 -- -- 8 -- 7 < > 5 -- 7
BUN -- 13 -- -- 12 -- 14 < > 24 -- 23
```

CREAT -- 0.56* -- -- 0.64 -- 0.56* <> 0.67 -- 0.77 ALB -- 2.6* -- -- 2.7* -- 2.6* <> 2.7* | 2.7* -- 2.9* GLOBULIN -- -- -- -- -- 4.1* -- 4.2* AGRATIO -- -- -- -- -- 0.7 -- 0.7 ALP -- -- -- -- -- 90 -- 113 AST -- -- -- 17 -- 21 ALT -- -- -- -- 12 -- 14 BILITOTAL -- -- -- -- 0.5 -- 0.3 GLU 102 97 118 <> 119* <> 103* <> 137* <> 432* <> = values in this interval not displayed.

*Asterisks denoteabnormal values

Assessment/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

Plan:

- Psychiatry following re: medication adjustments for behaviors. Klonopin increased to 1 mg TID for restlessness/agitation.
- Discontinue bilateral SWR today. Maintain Mitts for now and discontinue when able.
- Order placed for abdominal binder to be maintained AAT.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat

Internal Medicine Attending 8/15/2023

Wean patient off restraints as able. Psychiatry recommendations appreciated Discussed with family status of power of attorney and goals of care.

PE: Cooperative, NAD, no scleral icterus, RRR, no respiratory distress, no abdominal tenderness with palpation, no bilateral LE pitting edema, No LE tenderness with palpation

I was physically present for the service provided. I have personally examined and evaluated this patient. I performed the key elements of the history and physical examination. Verified and agree with the findings and plan as documented in the above note. Exceptions and clarifications have been amended in this document as needed. Please see note above for full details.

Yevhen Drobot, D.O. Internal Medicine Page #8010 Mobile Heartbeat

Electronically signed by Yevhen Drobot at 08/15/2023 12:05 PM EDT Sabiha Omar - 08/14/2023 12:08 PM EDT

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Continues to pull on the PEG tube when he is awake. He is still in mittens and in soft restraints.

Objective:

Last Filed Vitals: Temp 98 °F (36.7 °C) (08/14/23 0725) Source Axillary (08/14/23 0725) BP 129/86 (08/14/23 0725) Heart Rate 84 (08/14/23 0725) Resp 17 (08/14/23 0725) O2 (L/min) (not recorded) SpO2 96 % (08/14/23 0739) O2% 21 % (08/13/23 0741) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/11/23 0800) BMI 24.6 (08/11/23 0800)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior: Sleeping

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other * Altered mental status, unspecified altered mental status type Assessment & Plan Please Klonopin 0.5 mg in the morning and 1 mg at bedtime to reduce restlessness

Electronically signed by Sabiha Omar at 08/14/2023 12:08 PM EDT

Yevhen Drobot - 08/14/2023 10:00 AM EDT Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined resting in bed in no acute distress. He is found sleeping. 1:1 sitter at bedside. Reports when SWR are removed he rubs his hands against his thighs. Intermittently yelling out per report. Currently in BL SWR and with bilateral mitts in place.

Objective:

Vitals: Blood pressure 129/86, pulse 84, temperature 98 °F (36.7 °C), temperature source Axillary, resp. rate 17, height 188 cm (6' 2.02"), weight 87.1 kg (192 lb 0.3 oz), SpO2 96 %. Body mass index is 24.64 kg/m².

Intake/Output Summary (Last 24 hours) at 8/14/2023 1201 Last data filed at 8/14/2023 0950 Gross per 24 hour Intake 405 ml Output 2450 ml Net -2045 ml

Physical Examination: General: Non-toxic appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam. Eyes: EOMI. No scleral icterus. ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally, no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all quadrants, soft, NT/ND. + PEG tube. Ext: No clubbing, cyanosis, or edema. Psychiatric: Affect is appropriate Neurologic: Alert and oriented X0. Speech is mumbled and incoherent. Withdrawals appropriately to painful stimuli. Does not follow commands. Skin: No gross rashes.

Current Medications: Current Facility-Administered Medications Medication acetaminophen (TYLENOL) tablet 650 mg amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg clonazePAM (KlonoPIN) tablet 0.5 mg clopidogrel (PLAVIX) tablet 75 mg insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units LORazepam (ATIVAN) tablet 0.5 mg metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

```
Recent Labs

Component 08/14/23

0258 08/13/23

0323 08/10/23

0300 08/02/23

0632 08/01/23

1731

WBC 10.6* 9.8 11.6* < > 13.7*

RBC 4.51 4.26* 4.43 < > 4.45

HGB 13.2* 12.6* 13.0* < > 13.0*

MCV 93 93 94 < > 96

PLT 319 306 310 < > 283

INR -- -- - - 1.2

< > = values in this interval not displayed.
```

```
*Asterisks denote abnormal values
Recent Labs
Component 08/14/23
0258 08/13/23
2321 08/13/23
1800 08/13/23
0527 08/13/23
0323 08/10/23
0631 08/10/23
0300 08/02/23
0602 08/02/23
0541 08/02/23
0159 08/01/23
1731
NA 140 -- -- 138 -- 138 < > 148* -- 142
K 3.8 -- -- 3.3* -- 3.8 < > 4.0 -- 4.6
CL 105 -- -- 104 -- 105 < > 117* -- 112*
CO2 27 -- -- 27 -- 27 < > 26 -- 23
ANIONGAP 8 -- -- 7 -- 6 < > 5 -- 7
BUN 12 -- -- 14 -- 13 < > 24 -- 23
CREAT 0.64 -- -- 0.56* -- 0.59* < > 0.67 -- 0.77
ALB 2.7* -- -- 2.6* -- 2.6* < > 2.7* | 2.7* -- 2.9*
```

GLOBULIN -- -- -- -- -- 4.1* -- 4.2* AGRATIO -- -- -- -- 0.7 -- 0.7 ALP -- -- -- -- 90 -- 113 AST -- -- -- -- -- 17 -- 21 ALT -- -- -- -- -- 12 -- 14 BILITOTAL -- -- -- -- 0.5 -- 0.3 GLU 119* 141* 159* <> 103* <> 130* <> 137* <> 432* <> = values in this interval not displayed.

*Asterisks denoteabnormal values

Assessment/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

Plan:

- Continue tube feeds
- Psychiatry following re: medication adjustments for behaviors.

Medically stable for discharge to ECF facility WBA 8/9 - DC delay 8/14: Await further psych recommendations re: RX changes. Documentation noted re: the patient being restless, pulling at lines/tubes.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat

Internal Medicine Attending 8/14/2023

Discontinue restraints and monitor. Psychiatry recommendations appreciated, continue with 0.5 mg Klonopin in the morning and 1 mg at bedtime.

PE: Somnolent, NAD, no scleral icterus, RRR, no respiratory distress, no abdominal tenderness with palpation, no bilateral LE pitting edema, No LE tenderness with palpation

I was physically present for the service provided. I have personally examined and evaluated this patient. I performed the key elements of the history and physical examination. Verified and agree with the findings and plan as documented in the above note. Exceptions and clarifications have been amended in this document as needed. Please see note above for full details.

Yevhen Drobot, D.O. Internal Medicine Page #8010 Mobile Heartbeat

Electronically signed by Yevhen Drobot at 08/14/2023 4:12 PM EDT

Fawaz H - 08/13/2023 11:16 AM EDT

Formatting of this note is different from the original. Progress Note

Name: Ioan Suiugan Age: 62 yrs MRN: 9942681 Attending Physician: Rudy, William M, DO

Author: Margaret L Wallace, PA-C Date of service: 8/13/2023

Subjective:

Pt seen/examined. 1:1 sitter. Sleeping. NAD.

Objective: Vitals: Temp 98.9 °F (37.2 °C) (08/13/23 0812) Source Axillary (08/13/23 0812) BP 128/89 (08/13/23 0812) Heart Rate 95 (08/13/23 0812) Resp 18 (08/13/23 0812) O2 (L/min) (not recorded) SpO2 96 % (08/13/23 0741) O2% 21 % (08/13/23 0741) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/11/23 0800) BMI 24.6 (08/11/23 0800) Body mass index is 24.64 kg/m². Intake/Output Summary (Last 24 hours) at 8/13/2023 1116 Last data filed at 8/13/2023 0600 Gross per 24 hour Intake 1270 ml Output 2500 ml Net -1230 ml Physical Examination: General: NAD, sleeping HEENT: NC/AT, moist oral mucosa Cardiovascular: RRR, nL s1, S2, no m/r/g, d No heaves/lifts/thrills Respiratory: unlabored , no amu.Lungs CTAclear no wh/r/rh GI: +BS, ND, NT, +peg tube no r/g/rigidity Neurologic: not following commands Extremities: No clubbing, cyanosis, edema **Current Medications:** Current Facility-Administered Medications Medication acetaminophen (TYLENOL) tablet 650 mg amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg clonazePAM (KlonoPIN) tablet 0.5 mg clopidogrel (PLAVIX) tablet 75 mg insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units LORazepam (ATIVAN) tablet 0.5 mg metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg Diagnostic Studies: These were all reviewed and interpreted in EPIC New Labs: Recent Labs

```
Component 08/13/23
0323 08/10/23
0300 08/09/23
0339 08/02/23
0632 08/01/23
1731
WBC 9.8 11.6* 12.8* < > 13.7*
RBC 4.26* 4.43 4.11* < > 4.45
HGB 12.6* 13.0* 12.2* < > 13.0*
MCV 93 94 93 < > 96
PLT 306 310 269 < > 283
INR -- -- -- 1.2
< > = values in this interval not displayed.
```

*Asterisks denote abnormal values Recent Labs Component 08/13/23

0527 08/13/23 0323 08/12/23 2329 08/10/23 0631 08/10/23 0300 08/09/23 0631 08/09/23 0339 08/02/23 0602 08/02/23 0541 08/02/23 0159 08/01/23 1731 NA -- 138 -- -- 138 -- 139 < > 148* -- 142 K -- 3.3* -- -- 3.8 -- 3.7 < > 4.0 -- 4.6 CL -- 104 -- -- 105 -- 108 < > 117* -- 112* CO2 -- 27 -- -27 -- 26 < > 26 -- 23 ANIONGAP -- 7 -- -- 6 -- 5 < > 5 -- 7 BUN -- 14 -- -- 13 -- 11 < > 24 -- 23 CREAT -- 0.56* -- -- 0.59* -- 0.55* < > 0.67 -- 0.77 ALB -- 2.6* -- -- 2.6* -- 2.5* < > 2.7* | 2.7* -- 2.9* GLOBULIN -- -- -- -- -- 4.1* -- 4.2* AGRATIO -- -- -- -- -- -- 0.7 -- 0.7 ALP -- -- -- -- -- -- 90 -- 113 AST -- -- -- -- -- -- 17 -- 21 ALT -- -- -- -- -- -- 12 -- 14 BILITOTAL -- -- -- -- -- 0.5 -- 0.3 GLU 134 103* 136 < > 130* < > 119* < > 137* < > 432* < > = values in this interval not displayed.

*Asterisks denote abnormal values

Assessment/Plan:

AMS TME Anxoic brain injury Chronic debility HTN DM2 Aflutter- eliquis Hx agitation Neurogenic bladder Hypokalemia - supp

Psych recs appreciated, restraints to be discontinued

Margaret L Wallace, PA-C Mobile Heartbeat

Progress note reviewed. Care plan discussed with PA/NP team. Agree with documentation as written without amendments. Patient seen and examined.

Fawaz Habba, DO Internal Medicine Electronically signed by Fawaz H at 08/13/2023 1:57 PM EDT Sabiha Omar - 08/13/2023 9:17 AM EDT

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient is sleeping. He had good night sleep last night. He still is in soft restraints and has both hands in mittens. Has not documented any management issues.

Objective:

Last Filed Vitals: Temp 98.9 °F (37.2 °C) (08/13/23 0812) Source Axillary (08/13/23 0812) BP 128/89 (08/13/23 0812) Heart Rate 95 (08/13/23 0812) Resp 18 (08/13/23 0812) O2 (L/min) (not recorded) SpO2 96 % (08/13/23 0741) O2% 21 % (08/13/23 0741) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/11/23 0800) BMI 24.6 (08/11/23 0800)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior: Sleeping

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other

* Altered mental status, unspecified altered mental status type Assessment & Plan Staff advised to release restraints and if he still peeds a restraint

Staff advised to release restraints and if he still needs a restraints, I would like to see some documentation in order for me to adjust medications.

Electronically signed by Sabiha Omar at 08/13/2023 9:17 AM EDT

Fawaz H - 08/12/2023 10:48 AM EDT

Formatting of this note is different from the original. Progress Note

Name: Ioan Suiugan Age: 62 yrs MRN: 9942681 Attending Physician: Rudy, William M, DO

Author: Margaret L Wallace, PA-C Date of service: 8/12/2023

Subjective:

Patient seen and evaluated. Sleeping. NAD. 1:1 sitter present, mitts.

Objective: Vitals: Temp 98.2 °F (36.8 °C) (08/12/23 0730) Source Axillary (08/12/23 0730) BP 158/95 (08/12/23 0730) Heart Rate 84 (08/12/23 0730) Resp 18 (08/12/23 0730) O2 (L/min) (not recorded) SpO2 98 % (08/12/23 0814) O2% 21 % (08/12/23 0814) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/11/23 0800) BMI 24.6 (08/11/23 0800)

Body mass index is 24.64 kg/m².

Intake/Output Summary (Last 24 hours) at 8/12/2023 1053 Last data filed at 8/12/2023 0600 Gross per 24 hour Intake 2386 ml Output 1900 ml Net 486 ml

Physical Examination: General: sleeping NAD HEENT: NC/AT, moist oral mucosa Cardiovascular: RRR, nL s1, S2, no m/r/g, d No heaves/lifts/thrills Respiratory: Unlabored , no accessory muscle use.Lungs CTA, no wh/r/rh GI: +BS, ND, NT,+peg tube no r/g/rigidity Neurologic: does not follow commands Extremities: No clubbing, cyanosis, edema

Current Medications: Current Facility-Administered Medications Medication acetaminophen (TYLENOL) tablet 650 mg amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg clonazePAM (KlonoPIN) tablet 0.5 mg clopidogrel (PLAVIX) tablet 75 mg insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units LORazepam (ATIVAN) tablet 0.5 mg metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

Recent Labs Component 08/10/23 0300 08/09/23 0339 08/08/23 0322 08/02/23 0632 08/01/23 1731 WBC 11.6* 12.8* 11.2* < > 13.7* RBC 4.43 4.11* 4.14* < > 4.45 HGB 13.0* 12.2* 12.1* < > 13.0* MCV 94 93 92 < > 96 PLT 310 269 253 < > 283 INR -- -- 1.2 < > = values in this interval not displayed. *Asterisks denote abnormal values Recent Labs Component 08/12/23 0539 08/12/23 0003 08/11/23 1801 08/10/23 0631 08/10/23 0300 08/09/23 0631 08/09/23 0339 08/08/23 0555 08/08/23 0322 08/02/23 0602 08/02/23 0541 08/02/23 0159 08/01/23 1731 NA -- -- -- 138 -- 139 -- 141 < > 148* -- 142 K -- -- -- 3.8 -- 3.7 -- 3.3* < > 4.0 -- 4.6 CL -- -- -- 105 -- 108 -- 111 < > 117* -- 112* CO2 --- -- 27 -- 26 -- 24 <> 26 -- 23 ANIONGAP --- -- 6 -- 5 -- 6 <> 5 -- 7 BUN -- -- -- 13 -- 11 -- 11 <> 24 -- 23 CREAT -- -- -- 0.59* -- 0.55* -- 0.58* <> 0.67 -- 0.77 ALB -- -- -- 2.6* -- 2.5* -- 2.4* <> 2.7* | 2.7* -- 2.9*GLOBULIN -- -- -- -- 4.1* -- 4.2* AGRATIO -- -- -- -- 90 -- 113 AST -- -- -- 90 -- 113 AST -- -- -- 17 -- 21 ALT -- -- -- 12 -- 14 BILITOTAL -- -- -- 0.5 -- 0.3 GLU 127 149* 150* <> 130* <> 119* <> 136* <> 137* <> 432* <> = values in this interval not displayed. *Asterisks denote abnormal values

Assessment/Plan:

AMS TME Anxoic brain injury Chronic debility HTN DM2 Aflutter- eliquis Hx agitation Neurogenic bladder

Psych recs appreciated

Margaret L Wallace, PA-C Mobile Heartbeat

Progress note reviewed. Care plan discussed with PA/NP team. Agree with documentation as written without amendments. Patient seen and examined.

Fawaz Habba, DO Internal Medicine Electronically signed by Fawaz H at 08/12/2023 3:11 PM EDT Sabiha Omar - 08/12/2023 9:38 AM EDT

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient is currently sleeping. Staff reports that whenever he is awake he starts to pull on PEG tube and IVs. He still is in restraints and he still needs to wear mittens otherwise he grabs what ever comes in his hand. He apparently had not been sleeping. Though last night he slept well. Yesterday staff informed me that he had been agitated and restless. Ativan was given in the afternoon. This may have improved sleep last night.

Objective:

Last Filed Vitals: Temp 98.2 °F (36.8 °C) (08/12/23 0730) Source Axillary (08/12/23 0730) BP 158/95 (08/12/23 0730) Heart Rate 84 (08/12/23 0730) Resp 18 (08/12/23 0730) O2 (L/min) (not recorded) SpO2 98 % (08/12/23 0814) O2% 21 % (08/12/23 0814) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/11/23 0800) BMI 24.6 (08/11/23 0800)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior: Fast asleep

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other

* Altered mental status, unspecified altered mental status type

Assessment & Plan

I will add Klonopin 0.5 mg at bedtime. Discontinue Atarax. I will adjust the dose of Klonopin according to the need to reduce agitation and restlessness.

Electronically signed by Sabiha Omar at 08/12/2023 9:38 AM EDT

Danielle S - 08/11/2023 12:22 PM EDT

Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined. He again is found sleeping comfortably in bed in no acute distress. Maintains in bilateral SWR and mitts. Tube feeds infusing.

Objective:

Vitals: Blood pressure 118/84, pulse 88, temperature 98.4 °F (36.9 °C), temperature source Axillary, resp. rate 18, height 188 cm (6' 2.02"), weight 87.1 kg (192 lb 0.3 oz), SpO2 98 %. Body mass index is 24.64 kg/m².

Intake/Output Summary (Last 24 hours) at 8/11/2023 1222 Last data filed at 8/11/2023 1100 Gross per 24 hour Intake 1075 ml Output 1800 ml Net -725 ml

Physical Examination: General: Non-toxic appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam. Eyes: EOMI. No scleral icterus. ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally, no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all quadrants, soft, NT/ND. + PEG tube. Ext: No clubbing, cyanosis, or edema. Psychiatric: Affect is appropriate Neurologic: Alert and oriented X0. Speech is mumbled and incoherent. Withdrawals appropriately to painful stimuli. Does not follow commands. Skin: No gross rashes.

Current Medications: Current Facility-Administered Medications Medication acetaminophen (TYLENOL) tablet 650 mg amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg clopidogrel (PLAVIX) tablet 75 mg insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

```
Recent Labs
Component 08/10/23
0300 08/09/23
0339 08/08/23
0322 08/02/23
0632 08/01/23
1731
WBC 11.6* 12.8* 11.2* < > 13.7*
RBC 4.43 4.11* 4.14* < > 4.45
HGB 13.0* 12.2* 12.1* < > 13.0*
MCV 94 93 92 < > 96
PLT 310 269 253 < > 283
INR -- -- 1.2
< > = values in this interval not displayed.
*Asterisks denote abnormal values
Recent Labs
Component 08/11/23
1115 08/11/23
0537 08/11/23
0012 08/10/23
0631 08/10/23
0300 08/09/23
0631 08/09/23
0339 08/08/23
0555 08/08/23
0322 08/02/23
0602 08/02/23
0541 08/02/23
0159 08/01/23
1731
NA -- -- -- 138 -- 139 -- 141 < > 148* -- 142
K --- -- 3.8 -- 3.7 -- 3.3* < > 4.0 -- 4.6
CL -- -- -- 105 -- 108 -- 111 < > 117* -- 112*
CO2 -- -- 27 -- 26 -- 24 < > 26 -- 23
ANIONGAP -- -- -- 6 -- 5 -- 6 < > 5 -- 7
```

*Asterisks denoteabnormal values

Assessment/Plan:

Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

Plan:

- Discontinue MITTS today. Discussed with nursing staff.
- Continue tube feeds
- Psychiatry following re: medication adjustments for behaviors.

Medically stable for discharge to ECF facility WBA 8/9

- DC delay 8/10: Remains restrained; psych adjusting RX.
- DC delay 8/11: Mitts discontinued. No RX changes per psych.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat Electronically signed by William Rudy at 08/11/2023 3:55 PM EDT

Associated attestation - William Rudy - 08/11/2023 3:55 PM EDT Formatting of this note might be different from the original. Patient was seen and examined on rounds Progress note as documented by Danielle Saunders RN NP-C reviewed Concur in principle with documentation

Sister was at bedside Case was discussed If the patient remains stable including during the night will reconsider taking patient back to her group home

The patient however must not be screaming yelling or acting out particularly at night in order for this to occur Sabiha Omar - 08/11/2023 10:27 AM EDT

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient currently is resting. Staff reports that PEG tube was pulled out and one of the mitten was off the other times.

Objective:

Last Filed Vitals: Temp 98.2 °F (36.8 °C) (08/11/23 0820) Source Axillary (08/11/23 0820) BP 139/92 (08/11/23 0820) Heart Rate 69 (08/11/23 0820) Resp 18 (08/11/23 0820) O2 (L/min) (not recorded) SpO2 98 % (08/11/23 0820) O2% 21 % (08/08/23 0740) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 84.8 kg (186 lb 15.2 oz) (08/10/23 2300) BMI 24 (08/10/23 2300)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior: Sleeping

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other

* Altered mental status, unspecified altered mental status type Assessment & Plan No change in medications suggested.

Electronically signed by Sabiha Omar at 08/11/2023 10:27 AM EDT

Judith W - 08/10/2023 10:43 PM EDT

Formatting of this note is different from the original. PCU NP Restraint NOTE: Face-To-Face Evaluation (Restraint/Seclusion)

Called to assess the Patient for a need of restraint

Evaluation of the patient's immediate situation:

Pulling at tubes/dressing and unable to follow safety instructions. Medical and behavior modifiers prior to restraint use including reorientation and frequent rounding are ineffective. Restrict movement to facilitate healing and keep life sustaining devices in place

Plan: Continue soft restraints: Right wrist, Left wrist, left mitten, right mitten

Patient's reaction to the intervention: Calm

Patient's medical and behavioral condition:

BP 120/81 | Pulse 90 | Temp 97.4 °F (36.3 °C) (Axillary) | Resp 18 | Ht 188 cm (6' 2") | Wt 86.8 kg (191 lb 5.8 oz) | SpO2 98% | BMI 24.57 kg/m²

No physical distress, No injuries, redness or edema at point of restraints.

Patient after restraint placement is stable. Will keep restraints in place with nursing monitoring for patient safety and appropriate discontinuation as soon as possible.

Judy Wesley, NP-BC

Danielle S - 08/10/2023 12:00 PM EDT Formatting of this note is different from the original. **Progress Note** Attending Physician: Rudy, William M, DO Date of Admission:8/1/2023 Subjective: Patient seen and examined. He is found sleeping comfortably in bed in no acute distress this morning. Remains in bilateral SWR and mitts. Objective: Vitals: Blood pressure 109/74, pulse 72, temperature 97.7 °F (36.5 °C), temperature source Axillary, resp. rate 18, height 188 cm (6' 2"), weight 86.8 kg (191 lb 5.8 oz), SpO2 98 %. Body mass index is 24.57 kg/m². Intake/Output Summary (Last 24 hours) at 8/10/2023 1200 Last data filed at 8/10/2023 0500 Gross per 24 hour Intake 1450 ml Output 1900 ml Net -450 ml Physical Examination: General: Non-toxic appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam. Eyes: EOMI. No scleral icterus. ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally, no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all guadrants, soft, NT. Mild distention noted. Ext: No clubbing, cyanosis, or edema. Psychiatric: Affect is appropriate Neurologic: Alert and oriented X0. Speech is mumbled and incoherent. Withdrawals appropriately to painful stimuli. Does not follow commands. Skin: No gross rashes. **Current Medications: Current Facility-Administered Medications** Medication acetaminophen (TYLENOL) tablet 650 mg amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg clopidogrel (PLAVIX) tablet 75 mg insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg Diagnostic Studies: These were all reviewed and interpreted in EPIC New Labs:

Recent Labs Component 08/10/23 0300 08/09/23 0329 08/08/23 0322 08/02/23 0632 08/01/23 1731 WBC 11.6* 12.8* 11.2* < > 13.7*

RBC 4.43 4.11* 4.14* < > 4.45 HGB 13.0* 12.2* 12.1* < > 13.0* MCV 94 93 92 < > 96 PLT 310 269 253 < > 283 INR -- -- 1.2 < > = values in this interval not displayed. *Asterisks denote abnormal values **Recent Labs** Component 08/10/23 0631 08/10/23 0300 08/10/23 0014 08/09/23 0631 08/09/23 0339 08/08/23 0555 08/08/23 0322 08/02/23 0602 08/02/23 0541 08/02/23 0159 08/01/23 1731 NA -- 138 -- -- 139 -- 141 < > 148* -- 142 K -- 3.8 -- -- 3.7 -- 3.3* < > 4.0 -- 4.6 CL -- 105 -- -- 108 -- 111 < > 117* -- 112* CO2 -- 27 -- -- 26 -- 24 < > 26 -- 23 ANIONGAP -- 6 -- -- 5 -- 6 < > 5 -- 7 BUN -- 13 -- -- 11 -- 11 < > 24 -- 23 CREAT -- 0.59* -- -- 0.55* -- 0.58* < > 0.67 -- 0.77 ALB -- 2.6* -- -- 2.5* -- 2.4* < > 2.7* | 2.7* -- 2.9* GLOBULIN -- -- -- -- -- 4.1* -- 4.2* AGRATIO -- -- -- -- -- -- 0.7 -- 0.7 ALP -- -- -- -- -- -- 90 -- 113 AST -- -- -- -- -- 17 -- 21 ALT -- -- -- -- -- -- 12 -- 14 BILITOTAL -- -- -- -- -- 0.5 -- 0.3 GLU 120 130* 128 < > 119* < > 136* < > 137* < > 432* < > = values in this interval not displayed. *Asterisks denoteabnormal values Assessment/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Hypernatremia Hypokalemia **Essential HTN** Type 2 DM

Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

Plan:

- Labs reviewed stable
- Continue tube feeds
- Psychiatry following re: medication adjustments for behaviors.

Medically stable for discharge to ECF facility WBA 8/9 - Will need LTC medicaid bed. Facility unwilling to accept the patient in mitts despite the need he has had for mitts since May following anoxic brain injury.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat Electronically signed by William Rudy at 08/10/2023 12:08 PM EDT

Associated attestation - William Rudy - 08/10/2023 12:08 PM EDT Formatting of this note might be different from the original. Reviewed IM progress note Patient seen and examined on rounds, case discussed with Danielle Saunders, RN, NP-C Concur in principle with documentation as provided

Care management note appreciated from yesterday and today

Day #2 medically stable for discharge

Igor Paris - 08/10/2023 9:25 AM EDT Formatting of this note is different from the original. Psychiatric Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient seen. Chart reviewed. Patient required soft restraint during the night. Patient trying to pull off lines.. Difficult to redirect

Objective:

Today's Hospital Course (include current psychotropics response and today's proposed discharge plans): Patient Vitals for the past 24 hrs (Last 3 readings): BP Temp Temp src Pulse Resp SpO2 Weight 08/10/23 0759 -- -- -- 97 % --08/10/23 0756 (!) 130/106 97.7 °F (36.5 °C) Axillary 81 18 96 % --08/10/23 0437 -- -- -- 86.8 kg (191 lb 5.8 oz) 08/10/23 0432 117/85 97.6 °F (36.4 °C) Axillary 84 18 96 % --08/10/23 0007 148/97 98 °F (36.7 °C) Axillary 74 18 99 % --08/09/23 2018 142/99 98 °F (36.7 °C) Axillary 80 18 98 % --08/09/23 1459 113/73 98.4 °F (36.9 °C) Axillary 86 18 98 % --08/09/23 1120 129/83 98.3 °F (36.8 °C) Axillary 80 19 100 % --

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate amiodarone (CORDARONE, PACERONE) tablet 200 mg 200 mg PEG Tube DAILY apixaban (ELIQUIS) tablet 5 mg 5 mg Oral Q 12 H atorvastatin (LIPITOR) tablet 40 mg 40 mg PEG Tube Q HS clopidogrel (PLAVIX) tablet 75 mg 75 mg Oral DAILY insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units 2-5 Units Subcutaneous Q 6 H metoprolol (LOPRESSOR) tablet 25 mg 25 mg PEG Tube BID OLANZapine (ZyPREXA) tablet 10 mg 10 mg Oral BID sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Q 12 H valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg 1,000 mg Oral BID

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate acetaminophen (TYLENOL) tablet 650 mg 650 mg PEG Tube Q 4 H PRN sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 20 mL 20 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 3 mL 3 mL Intravenous PRN sodium chloride 0.9% flush injection 10 mL 10 mL Intravenous ONCE PRN

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate

No past medical history on file.

Not on File

WBC Hgb Hct Plt 11.6 (08/10 0300) 13.0 (08/10 0300) 41.5 (08/10 0300) 310 (08/10 0300) NA K Cl CO2 138 (08/10 0300) 3.8 (08/10 0300) 105 (08/10 0300) 27 (08/10 0300) BUN Creat Glucose 13 (08/10 0300) 0.59 (08/10 0300) 130 (08/10 0300)

Today's Brief Mental Status: Grooming: adequate Speech: Clear Concentration: impaired Affect: labile Thought process: confused, disorganized Memory: impaired Poor Insight and judgment Assessment/Plan: Will check Valproic acid level

Encounter Diagnoses Name Primary? Altered mental status, unspecified altered mental status type Yes Community acquired pneumonia, unspecified laterality Urinary tract infection associated with indwelling urethral catheter, initial encounter (CMS/HCC) Sepsis without acute organ dysfunction, due to unspecified organism (CMS/HCC)

This dictation was prepared using Dragon Medical voice recognition software. As a result, errors may occur. When identified, these transcriptional errors have been corrected. While every attempt is made to correct errors during dictation, errors may still exist. Electronically signed by Igor Paris at 08/10/2023 9:28 AM EDT

Melissa R - 08/09/2023 8:32 PM EDT

Formatting of this note might be different from the original. House Service NOTE:

Called to assess loan Suiugan for a need for restraint. Ioan is danger to self. Currently the patient has been reported to be pulling at lines, drains and is unable to be redirected at this time. Secured mitt: both and Soft restraint: right wrist and left wrist have been placed at this time.

BP 142/99 | Pulse 80 | Temp 98 °F (36.7 °C) (Axillary) | Resp 18 | Ht 188 cm (6' 2") | Wt 85.3 kg (188 lb 0.8 oz) | SpO2 98% | BMI 24.14 kg/m²

loan Suiugan is currently stable with restraints in place. Will keep restraints in place for up to 24 hours. The patient's safety will be reevaluated within that time.

Diagnosis: agitation and restlessness

Melissa Royston, AGACNP-BC Pager 2037

Electronically signed by Melissa R at 08/09/2023 8:34 PM EDT Sabiha Omar - 08/09/2023 10:59 AM EDT

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient is fast asleep. He is in soft restraints and mittens. Staff reports that he tries to pull off IVs.

Objective:

Last Filed Vitals: Temp 98.2 °F (36.8 °C) (08/09/23 0848) Source Axillary (08/09/23 0848) BP 140/97 (08/09/23 0848) Heart Rate 80 (08/09/23 0848) Resp 20 (08/09/23 0848) O2 (L/min) (not recorded) SpO2 100 % (08/09/23 0848) O2% 21 % (08/08/23 0740) Height 188 cm (6' 2") (08/01/23 1727) Weight 85.3 kg (188 lb 0.8 oz) (08/08/23 0600) BMI 24.1 (08/08/23 0600)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior: Sleeping

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other * Altered mental status, unspecified altered mental status type Assessment & Plan No change in medications suggested.

Electronically signed by Sabiha Omar at 08/09/2023 10:59 AM EDT

Danielle S - 08/09/2023 9:26 AM EDT

Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined. He is found sleeping comfortably in bed in no acute distress; allowed therapeutic rest. Tube feeds infusing. No noted events overnight.

Objective:

Vitals: Blood pressure 140/97, pulse 80, temperature 98.2 °F (36.8 °C), temperature source Axillary, resp. rate 20, height 188 cm (6' 2"), weight 85.3 kg (188 lb 0.8 oz), SpO2 100 %. Body mass index is 24.14 kg/m².

Intake/Output Summary (Last 24 hours) at 8/9/2023 0926 Last data filed at 8/9/2023 0657 Gross per 24 hour Intake 3258.33 ml Output 1970 ml Net 1288.33 ml

Physical Examination: General: Non-toxic appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam.

Eyes: EOMI. No scleral icterus. ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally, no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all quadrants, soft, NT. Mild distention noted. Ext: No clubbing, cyanosis, or edema. Psychiatric: Affect is appropriate Neurologic: Alert and oriented X0. Speech is mumbled and incoherent. Withdrawals appropriately to painful stimuli. Does not follow commands. Skin: No gross rashes.

Current Medications: Current Facility-Administered Medications Medication acetaminophen (TYLENOL) tablet 650 mg amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg clopidogrel (PLAVIX) tablet 75 mg insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg

Diagnostic Studies: These were all reviewed and interpreted in EPIC

```
New Labs:
```

```
Recent Labs
Component 08/09/23
0339 08/08/23
0322 08/07/23
0331 08/02/23
0632 08/01/23
1731
WBC 12.8* 11.2* 12.9* < > 13.7*
RBC 4.11* 4.14* 4.16* < > 4.45
HGB 12.2* 12.1* 12.3* < > 13.0*
MCV 93 92 92 < > 96
PLT 269 253 266 < > 283
INR -- -- 1.2
<> = values in this interval not displayed.
*Asterisks denote abnormal values
Recent Labs
Component 08/09/23
0631 08/09/23
0339 08/09/23
0030 08/08/23
0555 08/08/23
0322 08/07/23
0557 08/07/23
0331 08/02/23
0602 08/02/23
0541 08/02/23
0159 08/01/23
1731
NA -- 139 -- -- 141 -- 143 < > 148* -- 142
K -- 3.7 -- -- 3.3* -- 2.9* < > 4.0 -- 4.6
CL -- 108 -- -- 111 -- 112* < > 117* -- 112*
CO2 -- 26 -- -- 24 -- 24 < > 26 -- 23
ANIONGAP -- 5 -- -- 6 -- 7 < > 5 -- 7
BUN -- 11 -- -- 11 -- 12 < > 24 -- 23
CREAT -- 0.55* -- -- 0.58* -- 0.55* < > 0.67 -- 0.77
ALB -- 2.5* -- -- 2.4* -- 2.5* < > 2.7* | 2.7* -- 2.9*
GLOBULIN -- -- -- -- -- 4.1* -- 4.2*
AGRATIO -- -- -- -- -- 0.7 -- 0.7
ALP -- -- -- -- -- 90 -- 113
```

AST -- -- -- -- -- -- -- -- -- -- -- 21 ALT -- -- -- -- -- -- -- -- -- -- 12 -- -- 14 BILITOTAL -- -- -- -- -- -- -- 0.5 -- 0.3 GLU 118 119* 153* < > 136* < > 116* < > 137* < > 432* < > = values in this interval not displayed.

*Asterisks denoteabnormal values

Assessment/Plan:

Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

Plan:

- Labs reviewed stable
- Continue tube feeds
- Maintain restraints for safety / line protection. DC with mitts.

Medically stable for discharge to ECF facility WBA 8/9

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat Electronically signed by William Rudy at 08/09/2023 12:04 PM EDT

Associated attestation - William Rudy - 08/09/2023 12:04 PM EDT Formatting of this note might be different from the original. Patient was seen and examined on rounds Progress note as documented by Danielle Saunders RN NP-C reviewed Concur in principle with documentation

Patient patient appears medically stable for discharge Overall prognosis appears fair to poor due to the patient's underlying psych issues Danielle S - 08/08/2023 9:37 AM EDT

Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined. He is resting in bed in no acute distress; awake and confused. Remains restrained. Appears comfortable. ROS unobtainable.

Objective:

Vitals: Blood pressure 132/84, pulse 79, temperature 97.5 °F (36.4 °C), temperature source Axillary, resp. rate 18, height 188 cm (6' 2"), weight 85.3 kg (188 lb 0.8 oz), SpO2 100 %. Body mass index is 24.14 kg/m².

Intake/Output Summary (Last 24 hours) at 8/8/2023 0937 Last data filed at 8/8/2023 0803 Gross per 24 hour Intake 2445 ml Output 4250 ml Net -1805 ml

Physical Examination: General: Non-toxic appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam. Eyes: EOMI. No scleral icterus. ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally, no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all quadrants, soft, NT. Mild distention noted. Ext: No clubbing, cyanosis, or edema. Psychiatric: Affect is appropriate Neurologic: Alert and oriented X0. Speech is mumbled and incoherent. Withdrawals appropriately to painful stimuli. Does not follow commands. Skin: No gross rashes.

Current Medications: Current Facility-Administered Medications Medication acetaminophen (TYLENOL) tablet 650 mg amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg clopidogrel (PLAVIX) tablet 75 mg dextrose 5 % infusion insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units metoprolol (LOPRESSOR) tablet 25 mg OLANZapine (ZyPREXA) tablet 10 mg sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

```
Recent Labs
Component 08/08/23
0322 08/07/23
0331 08/06/23
1630 08/02/23
0632 08/01/23
1731
WBC 11.2* 12.9* 10.1 < > 13.7*
RBC 4.14* 4.16* 4.10* < > 4.45
HGB 12.1* 12.3* 12.0* < > 13.0*
MCV 92 92 94 < > 96
PLT 253 266 245 < > 283
INR -- -- 1.2
< > = values in this interval not displayed.
*Asterisks denote abnormal values
Recent Labs
Component 08/08/23
0555 08/08/23
0322 08/08/23
0052 08/07/23
0557 08/07/23
0331 08/06/23
1712 08/06/23
1630 08/02/23
0602 08/02/23
0541 08/02/23
0159 08/01/23
1731
NA -- 141 -- -- 143 -- 143 < > 148* -- 142
K -- 3.3* -- -- 2.9* -- 3.5 < > 4.0 -- 4.6
CL -- 111 -- -- 112* -- 112* < > 117* -- 112*
CO2 -- 24 -- -- 24 -- 25 < > 26 -- 23
ANIONGAP -- 6 -- -- 7 -- 6 < > 5 -- 7
BUN -- 11 -- -- 12 -- 16 < > 24 -- 23
CREAT -- 0.58* -- -- 0.55* -- 0.63 < > 0.67 -- 0.77
```

ALB -- 2.4* -- - 2.5* -- 2.6* < > 2.7* | 2.7* -- 2.9* GLOBULIN -- -- -- -- -- 4.1* -- 4.2* AGRATIO -- -- -- -- 0.7 -- 0.7 ALP -- -- -- -- 90 -- 113 AST -- -- -- 17 -- 21 ALT -- -- -- 12 -- 14 BILITOTAL -- -- -- 12 -- 14 BILITOTAL -- -- 0.5 -- 0.3 GLU 153* 136* 142* < > 116* < > 146* < > 137* < > 432* < > = values in this interval not displayed.

*Asterisks denoteabnormal values

Assessment/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

Plan:

- Sodium has normalized. Increase FWF to 75 ml/hr and hep lock IVF. Monitor repeat Na levels in AM.
- Supplement KCl via PEG X 2 doses and IV X 1 bag.
- Completed 7 day course of IV antibiotics 8/7 per ID recommendation.
- Maintain restraints for safety / line protection. Renewed order provided.
- Consult CM re: DC planning.

Hopeful for DC in the next 24 hours pending clinical course and stabilized labs.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat Electronically signed by William Rudy at 08/08/2023 12:48 PM EDT

Associated attestation - William Rudy - 08/08/2023 12:48 PM EDT Formatting of this note might be different from the original. Patient was seen and examined on rounds Case discussed with Danielle Saunders, RN, NP-C Reviewed progress note as documented Agree in principle with documentation

Sabiha Omar - 08/08/2023 9:27 AM EDT

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

"I am going to Romania today. We are you from?" Patient makes a statement. Staff has not noted any management issues. He is still in soft restraints. no complaints offered by the patient

Objective:

Last Filed Vitals: Temp 97.5 °F (36.4 °C) (08/08/23 0756) Source Axillary (08/08/23 0756) BP 132/84 (08/08/23 0756) Heart Rate 79 (08/08/23 0756) Resp 18 (08/08/23 0756) O2 (L/min) (not recorded) SpO2 100 % (08/08/23 0740) O2% 21 % (08/08/23 0740) Height 188 cm (6' 2") (08/01/23 1727) Weight 85.3 kg (188 lb 0.8 oz) (08/08/23 0600) BMI 24.1 (08/08/23 0600)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior: alert; cooperative Motor Activity & Musculoskeletal: normal motor activity; purposeless movements of the hands and arms Speech & Language: normal rate amount and comprehension Gait & Station: In bed Mood: Mildly apprehensive Affect: appropriate to setting Thought Content: Focused on going to Romania on today Suicidal Ideation: None Homicidal Ideation: None Thought Process & Associations: linear Perceptions: Normal Orientation: Oriented to person; disoriented to place; to time; Attention & Concentration: Fair Recent Memory : Poor Insight: None

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other

* Altered mental status, unspecified altered mental status type Assessment & Plan Patient is not showing any behavioral issues. No change in medications suggested.

Electronically signed by Sabiha Omar at 08/08/2023 9:27 AM EDT

Danielle S - 08/07/2023 12:13 PM EDT Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined. He was found sleeping comfortably in bed in no acute distress. Appears comfortable. Tube feeds infusing. Remains in bilateral SWR and mitts.

Objective:

Vitals: Blood pressure 147/80, pulse 82, temperature 98.4 °F (36.9 °C), temperature source Oral, resp. rate 18, height 188 cm (6' 2"), weight 87.4 kg (192 lb 10.9 oz), SpO2 100 %.

Body mass index is 24.74 kg/m². Intake/Output Summary (Last 24 hours) at 8/7/2023 1213 Last data filed at 8/7/2023 0940 Gross per 24 hour Intake 565 ml Output 2000 ml Net -1435 ml Physical Examination: General: Non-toxic appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam. Eyes: EOMI. No scleral icterus. ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally, no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all guadrants, soft, NT. Mild distention noted. Ext: No clubbing, cyanosis, or edema. Psychiatric: Affect is appropriate Neurologic: Alert and oriented X0. Speech is mumbled and incoherent. Withdrawals appropriately to painful stimuli. Does not follow commands. Skin: No gross rashes. **Current Medications: Current Facility-Administered Medications** Medication acetaminophen (TYLENOL) tablet 650 mg amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB clopidogrel (PLAVIX) tablet 75 mg dextrose 5 % infusion insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units metoprolol (LOPRESSOR) tablet 25 mg metroNIDAZOLE (FLAGYL) infusion 500 mg OLANZapine (ZyPREXA) tablet 10 mg potassium chloride 20 mEq IVPB sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 10 mL sodium chloride 0.9 % flush injection 20 mL sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg Diagnostic Studies: These were all reviewed and interpreted in EPIC New Labs:

Recent Labs Component 08/07/23 0331 08/06/23 1630 08/04/23 0614 08/02/23 0632 08/01/23 1731 WBC 12.9* 10.1 13.3* < > 13.7* RBC 4.16* 4.10* 4.28* < > 4.45 HGB 12.3* 12.0* 12.3* < > 13.0* MCV 92 94 95 < > 96 PLT 266 245 285 < > 283 INR -- -- -- 1.2 < > = values in this interval not displayed. *Asterisks denote abnormal values

Recent Labs Component 08/07/23 0331 08/06/23 2335 08/06/23

1712 08/06/23 1630 08/05/23 0011 08/04/23 2201 08/04/23 0621 08/04/23 0614 08/02/23 0602 08/02/23 0541 08/02/23 0159 08/01/23 1731 NA -- 143 -- -- 143 -- 150* -- 151* < > 148* -- 142 K -- 2.9* -- -- 3.5 -- 3.9 -- 3.3* < > 4.0 -- 4.6 CL -- 112* -- -- 112* -- 120* -- 122* < > 117* -- 112* CO2 -- 24 -- -- 25 -- 23 -- 22 < > 26 -- 23 ANIONGAP -- 7 -- - 6 -- 7 -- 7 < > 5 -- 7 BUN -- 12 -- -- 16 -- -- 26* < > 24 -- 23 CREAT -- 0.55* -- -- 0.63 -- -- 0.64 < > 0.67 -- 0.77 ALB -- 2.5* -- -- 2.6* -- -- 2.7* < > 2.7* | 2.7* -- 2.9* GLOBULIN -- -- -- -- -- -- -- 4.1* -- 4.2* AGRATIO -- -- -- -- -- -- -- 0.7 -- 0.7 ALP -- -- -- -- -- -- -- -- 90 -- 113 AST -- -- -- -- -- -- -- 17 -- 21 ALT -- -- -- -- -- -- -- -- 12 -- 14 BILITOTAL -- -- -- -- -- -- 0.5 -- 0.3 GLU 131 116* 115 < > 146* < > -- < > 145* < > 137* < > 432* < > = values in this interval not displayed.

*Asterisks denoteabnormal values

Assessment/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Hypernatremia Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

Plan:

- Sodium has normalized. Increase FWF to 60 ml/hr and decrease D5 IVF to 50 ml/hr. Monitor Na levels.

- Supplement KCl IV X 2 bags + via PEG X 1
- Antibiotics: Cefepime, & Flagyl, day #6 per ID management.

- Maintain restraints for safety / line protection. Renewed order provided.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat Electronically signed by William Rudy at 08/07/2023 4:10 PM EDT

Associated attestation - William Rudy - 08/07/2023 4:10 PM EDT Formatting of this note might be different from the original. Patient was seen and examined on rounds Agree in principle with Internal medicine progress note as documented by Danielle Saunders, RN, NP-C Case discussed as well

Amal Khalife - 08/07/2023 10:05 AM EDT

Formatting of this note is different from the original. Images from the original note were not included.

INFECTIOUS DISEASE PROGRESS NOTE

Patient Name: Ioan Suiugan; Patient MRN: 9942681 Admission Date: 8/1/2023; Hospital Day: 7 ID Consultant: Amal A Khalife, DO Date: 8/7/2023 Time Seen: 10:05 AM

Assessment & Plan: Other Sepsis without acute organ dysfunction (CMS/HCC) Assessment & Plan Presentation to ED 8/1 with altered mental status S/p CPA 5/2023, low grade temp in ED 100.6 Hx MDR enterobacter 7/2023 from urine cx CT chest with L sided pleural effusion, oxygenating well on RA

?aspiration vs GU vs other Check procalcitonin, legionella/pneumococcal Ag, MRSA screen Consider CTAP Continue current abx for now

8/4: procal 0.50. Await MRSA screen. Continue current abx for now

8/7 MRSA screen not collected, WBC trending down. Remains on broad spectrum abx; anticipate today is the last day of antibiotics with IV cefepime and flagyl (7 days) of empiric treatment. Strep and legionella are negative; urine cutlure with Enterobacter from 8/1. Will stop IV vancomycin given lack of staph aureus on cultures.

As plan is in place, and patient is stable/improved ID service will sign off Please call with questions

Active Hospital Problems

Diagnosis

- Altered mental status, unspecified altered mental status type
- Sepsis without acute organ dysfunction (CMS/HCC)
- Urinary tract infection associated with indwelling urethral catheter (CMS/HCC)
- Community acquired pneumonia
- Altered mental status

Amal A Khalife, DO 10:05 AM 08/07/23

Interval History: Patient seen in follow up for leukocytosis

WBC down to 12 today Remains on broad spectrum abx Confused, loose stools over the weekend Day 7 of antibiotics No new cultures, enterobacter on urine from 8/1

Current Anti-infectives: IV vancomycin IV cefepime IV flagyl

Current Facility-Administered Medications:

• acetaminophen (TYLENOL) tablet 650 mg, 650 mg, PEG Tube, Q 4 H PRN, Hubbard, Cameron Christopher, DO, 650 mg at 08/06/23 0104

• amiodarone (CORDARONE, PACERONE) tablet 200 mg, 200 mg, PEG Tube, DAILY, Hubbard, Cameron Christopher, DO, 200 mg at 08/07/23 0853

• apixaban (ELIQUIS) tablet 5 mg, 5 mg, Oral, Q 12 H, Marchewka, Tiffany Christine, DO, 5 mg at 08/07/23 0853

- atorvastatin (LIPITOR) tablet 40 mg, 40 mg, PEG Tube, Q HS, Hubbard, Cameron Christopher, DO, 40 mg at 08/06/23 2026
- cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB, 2 g, Intravenous, Q 8 H, Derderian, Kristin M, DO, Stopped at 08/07/23 0454
- clopidogrel (PLAVIX) tablet 75 mg, 75 mg, Oral, DAILY, Marchewka, Tiffany Christine, DO, 75 mg at 08/07/23 0853

• dextrose 5 % infusion, , Intravenous, Continuous, Katzman, Steven M, DO, Last Rate: 75 mL/hr at 08/06/23 2308, New Bag at 08/06/23 2308

• insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units, 2-5 Units, Subcutaneous, Q 6 H, Marchewka, Tiffany Christine, DO

metoprolol (LOPRESSOR) tablet 25 mg, 25 mg, PEG Tube, BID, Hubbard, Cameron Christopher, DO, 25 mg at 08/07/23 0853
 metroNIDAZOLE (FLAGYL) infusion 500 mg, 500 mg, Intravenous, Q 8 H, Derderian, Kristin M, DO, Stopped at 08/07/23 0924

- OLANZapine (ZyPREXA) tablet 10 mg, 10 mg, Oral, BID, Saunders, Danielle M, RN NP-C, 10 mg at 08/07/23 0852
- sodium chloride 0.9 % flush injection 10 mL, 10 mL, Intravenous, Per Administration Instructions, Rudy, William M, DO
- sodium chloride 0.9 % flush injection 10 mL, 10 mL, Intravenous, Q 12 H, Rudy, William M, DO, 10 mL at 08/07/23 0924
- sodium chloride 0.9 % flush injection 20 mL, 20 mL, Intravenous, Per Administration Instructions, Rudy, William M, DO
- sodium chloride 0.9 % flush injection 3 mL, 3 mL, Intravenous, PRN, Hubbard, Cameron Christopher, DO
- sodium chloride 0.9% flush injection 10 mL, 10 mL, Intravenous, ONCE PRN, Kaiser Alexander, Diane L, DO

• valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg, 1,000 mg, Oral, BID, Saunders, Danielle M, RN NP-C, 1,000 mg at 08/07/23 0852

• vancomycin (VANCOCIN) 1,250 mg in sodium chloride 0.9 % 275 mL IVPB, 1,250 mg, Intravenous, Q 12 H, Rudy, William M, DO, Stopped at 08/07/23 1022

Physical Exam:

Temp 98.4 °F (36.9 °C) (08/07/23 0643) Source Oral (08/07/23 0643) BP 148/94 (08/07/23 0853) Heart Rate 79 (08/07/23 0853) Resp 18 (08/07/23 0643) O2 (L/min) (not recorded) SpO2 99 % (08/07/23 0643) O2% 21 % (08/03/23 0724) Height 188 cm (6' 2") (08/01/23 1727) Weight 87.4 kg (192 lb 10.9 oz) (08/07/23 0549) BMI 24.7 (08/07/23 0549)

Flowsheet Data Statistics (last 36 hours)

Flowsheet Row Name Min Max BP: Systolic 116 177 BP: Diastolic 78 107 Temp 98.2 °F (36.8 °C) 98.7 °F (37.1 °C) Heart Rate 56 82 Resp 18 18 SpO2 98 % 100 % Weight 85.2 kg (187 lb 13.3 oz) 87.4 kg (192 lb 10.9 oz)

Date 08/06/23 0700 - 08/07/23 0659 08/07/23 0700 - 08/08/23 0659 Shift 0700-1459 1500-2259 2300-0659 24 Hour Total 0700-1459 1500-2259 2300-0659 24 Hour Total INTAKE I.V.(mL/kg) 385(4.4) 385(4.4) Other 120 120 NG/GT 60 60 Shift Total(mL/kg) 565(6.5) 565(6.5) OUTPUT Urine(mL/kg/hr) 600(0.9) 600(0.9) 1200(0.6) 1400 1400 Shift Total(mL/kg) 600(7) 600(6.9) 1200(13.7) 1400(16) 1400(16) NET -600 -600 -1200 -835 -835 Weight (kg) 85.2 85.2 87.4 87.4 87.4 87.4 87.4 87.4

Constitutional: Appears NAD, no acute distress.chronically ill appearing HENT: no supplemental O2MM moist Eyes: no conjunctival injection or hemorrhages, no pallor. Cardiovascular: Regular rate and rhythm, no murmurs, rubs or gallops Pulmonary/Chest: No use of accessory muscle, CTAB, no wheezing, no crackles. Gastrointestinal: Abdomen was soft, non-tender, non-distended, BS x4 Musculoskeletal: No cyanosis, Skin: No acute skin rash. Neuro/Psychiatric: AoxO

IndwellingDevices: Lines, Drains, and Airways

Drain Duration

Gastrostomy/Enterostomy Percutaneous endoscopic gastrostomy-jejunal (PEG/J) LUQ 5 days Urethral Catheter Temperature probe 126 Fr. 5 days Pressure Injury 08/02/23 Sacrum Center 5 days

Wound Duration

Wound 08/02/23 Abrasion Right; Anterior Knee 5 days

Midline Duration

Midline Single Lumen 08/05/23 Right Brachial 2 days

New Labs:

Recent Labs Component 08/07/23 0331 08/06/23 1630 08/04/23 0614 WBC 12.9* 10.1 13.3* RBC 4.16* 4.10* 4.28* HGB 12.3* 12.0* 12.3* MCV 92 94 95 MCHCC 32 31* 30* PLT 266 245 285 MONO 1.5* 1.0* 1.2* *Asterisks denote abnormal values **Recent Labs** Component 08/07/23 0331 08/06/23 1630 08/04/23 2201 08/04/23 0614 08/03/23 0626 08/02/23 0541 08/01/23 1731 NA 143 143 150* 151* < > 148* 142 K 2.9* 3.5 3.9 3.3* < > 4.0 4.6 CL 112* 112* 120* 122* < > 117* 112* CO2 24 25 23 22 < > 26 23 ANIONGAP 7 6 7 7 < > 5 7 BUN 12 16 -- 26* < > 24 23 CREAT 0.55* 0.63 -- 0.64 < > 0.67 0.77 ALB 2.5* 2.6* -- 2.7* < > 2.7* | 2.7* 2.9* GLOBULIN -- -- -- 4.1* 4.2* AGRATIO -- -- -- 0.7 0.7 ALP -- -- -- 90 113 AST -- -- -- 17 21 ALT -- -- 12 14 BILITOTAL -- -- -- 0.5 0.3 < > = values in this interval not displayed. *Asterisks denote abnormal values URINALYSIS **Recent Labs** Component 08/01/23 1731 **COLOR Yellow** CLARITY Cloudy*

GLUCOSEUR > =500* BILIUR Negative KETONES Negative SPECGRAVUR 1.010 BLOODUR 3+* PHUR 7.5 PROTEINUR 10* UROBILUR <2.0 NITRITESUR Negative LEUKESTUR 3+* WBCUR >50* SQUAMEPIUR 6-30 HYALCASTUR 0-2 (Negative) BACTERIAUR 2+*

New Culture Data:

None new Urine culture 8/1 Enterobacter

New Imaging and Other Diagnostics: No results found.

Electronically signed by Amal Khalife at 08/07/2023 12:35 PM EDT

Sabiha Omar - 08/07/2023 10:00 AM EDT Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient is resting. He is in bilateral soft restraints. Staff has not documented any major behavioral problems during the night.

Objective:

Last Filed Vitals: Temp 98.4 °F (36.9 °C) (08/07/23 0643) Source Oral (08/07/23 0643) BP 147/80 (08/07/23 1125) Heart Rate 82 (08/07/23 1125) Resp 18 (08/07/23 0643) O2 (L/min) (not recorded) SpO2 100 % (08/07/23 1125) O2% 21 % (08/03/23 0724) Height 188 cm (6' 2") (08/01/23 1727) Weight 87.4 kg (192 lb 10.9 oz) (08/07/23 0549) BMI 24.7 (08/07/23 0549)

MENTAL STATUS EXAM:

General Appearance: looks stated age; dressed in hospital garb Attitude & Behavior: Sleeping

Labs: Reviewed all relevant labs to current date/time

Assessment and Plan:

Other Altered mental status Assessment & Plan Continue your treatment. No change in medications suggested.

Electronically signed by Sabiha Omar at 08/07/2023 3:33 PM EDT

Igor Paris - 08/06/2023 3:53 PM EDT Formatting of this note is different from the original. Psychiatric Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

No new problems reported. Patient still confused. Patient's sister was available to translate. Patient insisted that he is in Romania but named building as "GM building". Objective:

Today's Hospital Course (include current psychotropics response and today's proposed discharge plans): Patient Vitals for the past 24 hrs (Last 3 readings): BP Temp Temp src Pulse Resp SpO2 Weight 08/06/23 1519 139/91 98.7 °F (37.1 °C) -- 66 18 100 % --08/06/23 0716 -- -- -- -- 99 % --08/06/23 0424 -- -- -- -- 85.2 kg (187 lb 13.3 oz) 08/06/23 0423 116/84 98.2 °F (36.8 °C) Axillary 63 18 98 % --08/06/23 0015 121/78 98.6 °F (37 °C) Axillary 56 18 99 % --08/05/23 2152 140/86 -- -- 76 -- -- --08/05/23 2100 140/86 98.8 °F (37.1 °C) -- 65 -- ---08/05/23 2008 140/86 98 °F (36.7 °C) Axillary 65 21 98 % --

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate amiodarone (CORDARONE, PACERONE) tablet 200 mg 200 mg PEG Tube DAILY apixaban (ELIQUIS) tablet 5 mg 5 mg Oral Q 12 H atorvastatin (LIPITOR) tablet 40 mg 40 mg PEG Tube Q HS cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB 2 g Intravenous Q 8 H Stopped (08/06/23 1453) clopidogrel (PLAVIX) tablet 75 mg 75 mg Oral DAILY insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units 2-5 Units Subcutaneous Q 6 H metoprolol (LOPRESSOR) tablet 25 mg 25 mg PEG Tube BID metroNIDAZOLE (FLAGYL) infusion 500 mg 500 mg Intravenous Q 8 H Stopped (08/06/23 1051) OLANZapine (ZyPREXA) tablet 10 mg 10 mg Oral BID sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Q 12 H valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg 1,000 mg Oral BID vancomycin (VANCOCIN) 1,250 mg in sodium chloride 0.9 % 275 mL IVPB 1,250 mg Intravenous Q 12 H Stopped (08/06/23 1145)

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate acetaminophen (TYLENOL) tablet 650 mg 650 mg PEG Tube Q 4 H PRN sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 20 mL 20 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 3 mL 3 mL Intravenous PRN sodium chloride 0.9% flush injection 10 mL 10 mL Intravenous ONCE PRN

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate dextrose 5 % infusion Intravenous Continuous 75 mL/hr at 08/06/23 0500

No past medical history on file.

Not on File

WBC Hgb Hct Plt

NA K CI CO2

BUN Creat Glucose

Today's Brief Mental Status: Grooming: adequate Speech: Clear Concentration: impaired Affect: Labile Thought process: confused, disorganized Memory: impaired Poor inside and judgment. Assessment/Plan: Will cont current tx Discussed with patient's sister, all questions answered.

Encounter Diagnoses Name Primary? Altered mental status, unspecified altered mental status type Yes Community acquired pneumonia, unspecified laterality Urinary tract infection associated with indwelling urethral catheter, initial encounter (CMS/HCC) Sepsis without acute organ dysfunction, due to unspecified organism (CMS/HCC)

This dictation was prepared using Dragon Medical voice recognition software. As a result, errors may occur. When identified, these transcriptional errors have been corrected. While every attempt is made to correct errors during dictation, errors may still exist. Electronically signed by Igor Paris at 08/06/2023 3:59 PM EDT

Steven Katzman - 08/06/2023 11:03 AM EDT

Formatting of this note is different from the original. Internal Medicine Progress Note STEVEN KATZMAN D.O. 2055

Patient's Name: Ioan Suiugan MRN: 9942681 Date of Birth: 2/27/1961 Age: 62 yrs Date of service: 8/6/2023 Provider: Steven M Katzman, DO

Interval History: Patient seen this morning. Patient was sleeping. No new events per staff

Current Medications/Allergies Medication Administration Record Allergies reviewed. Patient has no allergy information on record. **Current Facility-Administered Medications** Medication Dose Route Frequency Last Rate amiodarone (CORDARONE, PACERONE) tablet 200 mg 200 mg PEG Tube DAILY apixaban (ELIQUIS) tablet 5 mg 5 mg Oral Q 12 H atorvastatin (LIPITOR) tablet 40 mg 40 mg PEG Tube Q HS cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB 2 g Intravenous Q 8 H Stopped (08/06/23 0550) clopidogrel (PLAVIX) tablet 75 mg 75 mg Oral DAILY insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units 2-5 Units Subcutaneous Q 6 H metoprolol (LOPRESSOR) tablet 25 mg 25 mg PEG Tube BID metroNIDAZOLE (FLAGYL) infusion 500 mg 500 mg Intravenous Q 8 H 500 mg (08/06/23 1021) OLANZapine (ZyPREXA) tablet 10 mg 10 mg Oral BID sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Q 12 H valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg 1,000 mg Oral BID vancomycin (VANCOCIN) 1,250 mg in sodium chloride 0.9 % 275 mL IVPB 1,250 mg Intravenous Q 12 H 1,250 mg (08/06/23 1013)

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate acetaminophen (TYLENOL) tablet 650 mg 650 mg PEG Tube Q 4 H PRN sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 20 mL 20 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 3 mL 3 mL Intravenous PRN sodium chloride 0.9% flush injection 10 mL 10 mL Intravenous ONCE PRN

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate dextrose 5 % infusion Intravenous Continuous 75 mL/hr at 08/06/23 0500

Physical Exam: Vitals were reviewed Temp 98.2 °F (36.8 °C) (08/06/23 0423) Source Axillary (08/06/23 0423) BP 116/84 (08/06/23 0423) Heart Rate 63 (08/06/23 0423) Resp 18 (08/06/23 0423) O2 (L/min) (not recorded) SpO2 99 % (08/06/23 0716) O2% 21 % (08/03/23 0724) Height 188 cm (6' 2") (08/01/23 1727) Weight 85.2 kg (187 lb 13.3 oz) (08/06/23 0424) BMI 24.1 (08/06/23 0424)

Temp Min: 97 °F (36.1 °C) Min taken time: 08/02/23 0425 Max: 100.6 °F (38.1 °C) Max taken time: 08/01/23 1805

Intake/Output Summary (Last 24 hours) at 8/6/2023 1103 Last data filed at 8/6/2023 1037 Gross per 24 hour Intake 1010 ml Output 3100 ml Net -2090 ml

NECK: Supple. No JVD. No lymphadenopathy. No Bruit. Trachea midline

COR: RRR, no S3, no S4. No rub. No murmur.

LUNGS: Decreased breath sounds at bases

ABDOMEN: Soft, obese, non tender, positive bowel sounds x 4, No rebound, guarding or rigidity. No organomegaly.

EXTREMITIES: 1+ edema, cyanosis or clubbing.

NEUROLOGIC: CN 2-12 grossly intact. No focal deficits.

Diagnostic Studies:

11:03 AM: **Recent Labs** Component 08/04/23 0614 08/03/23 0626 08/02/23 0632 WBC 13.3* 16.0* 11.4* HGB 12.3* 13.0* 12.3* HCT 40.8 41.2 40.5 MCV 95 94 97 PLT 285 310 286 **Recent Labs** Component 08/06/23 0625 08/05/23 1809 08/05/23 1309 08/05/23 0011 08/04/23 2201 08/04/23 0621 08/04/23 0614 08/03/23 1714 08/03/23 0626 08/02/23 0602 08/02/23 0541 NA -- -- 150* -- 151* -- 146* -- 148* K -- -- 3.9 -- 3.3* -- 3.4* -- 4.0 CL -- -- -- 120* -- 122* -- 117* -- 117* CO2 -- -- 23 -- 22 -- 24 -- 26 BUN -- -- -- -- 26* -- 27* -- 24 CREAT -- -- -- -- 0.64 -- 0.73 -- 0.67 GLU 118 131 134 < > -- < > 145* < > 176* < > 137* < > = values in this interval not displayed. Abdominal Labs Recent Labs Component 08/04/23 0614 08/03/23 0626 08/02/23 0541 08/01/23 1731 ALP -- -- 90 113 AST -- -- 17 21 ALT -- -- 12 14 LIPASE -- -- 10 BILITOTAL -- -- 0.5 0.3 BILIDIRECT -- -- 0.2 0.2 ALB 2.7* 2.9* 2.7* | 2.7* 2.9* Glucose **Recent Labs**

Lab 08/06/23 0625 08/05/23 1809 08/05/23 1309 08/05/23 0651 GLU 118 131 134 162* INR Recent Labs Lab 08/01/23 1731 INR 1.2 Iron Studies Recent Labs Component 08/02/23 0224 **IRON 52*** FERRITIN 385* TIBC 304 Impression/Plan Sepsis/improving Mental status change secondary to TME Type 2 diabetes mellitus/stable Hypertension Anoxic brain injury Possible aspiration Hypernatremia. IV fluids adjusted yesterday. There is no labs back today as of 11:04 AM!!!! We will monitor sodium closely once it becomes available.

Steven Katzman DO, FACOI

This dictation was prepared using Dragon Medical voice recognition software. As a result, errors may occur. When identified, these transcriptional errors have been corrected. While every attempt is made to correct errors during dictation, errors may still exist.

Electronically signed by Steven Katzman at 08/06/2023 11:05 AM EDT

Steven Katzman - 08/05/2023 11:51 AM EDT

Formatting of this note is different from the original. Internal Medicine Progress Note STEVEN KATZMAN D.O. 2055

Patient's Name: Ioan Suiugan MRN: 9942681 Date of Birth: 2/27/1961 Age: 62 yrs Date of service: 8/5/2023 Provider: Steven M Katzman, DO

Interval History: Patient seen this morning Patient remains confused Patient with loose stools per nursing

No Cp/sob/n/v//m/h

Current Medications/Allergies Medication Administration Record Allergies reviewed. Patient has no allergy information on record. Current Facility-Administered Medications Medication Dose Route Frequency Last Rate amiodarone (CORDARONE, PACERONE) tablet 200 mg 200 mg PEG Tube DAILY apixaban (ELIQUIS) tablet 5 mg 5 mg Oral Q 12 H atorvastatin (LIPITOR) tablet 40 mg 40 mg PEG Tube Q HS cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB 2 g Intravenous Q 8 H Stopped (08/04/23 1411) clopidogrel (PLAVIX) tablet 75 mg 75 mg Oral DAILY insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units 2-5 Units Subcutaneous Q 6 H metoprolol (LOPRESSOR) tablet 25 mg 25 mg PEG Tube BID metroNIDAZOLE (FLAGYL) infusion 500 mg 500 mg Intravenous Q 8 H 500 mg (08/05/23 1020) OLANZapine (ZyPREXA) tablet 10 mg 10 mg Oral BID sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Q 12 H valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg 1,000 mg Oral BID vancomycin (VANCOCIN) 1,500 mg in sodium chloride 0.9 % 280 mL IVPB 1,500 mg Intravenous Q 12 H 1,500 mg (08/05/23 1021)

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate acetaminophen (TYLENOL) tablet 650 mg 650 mg PEG Tube Q 4 H PRN sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 20 mL 20 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 3 mL 3 mL Intravenous PRN sodium chloride 0.9% flush injection 10 mL 10 mL Intravenous ONCE PRN

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate

Physical Exam: Vitals were reviewed Temp 97.8 °F (36.6 °C) (08/05/23 0827) Source Axillary (08/05/23 0400) BP 145/82 (08/05/23 0827) Heart Rate 78 (08/05/23 0827) Resp 20 (08/05/23 0827) O2 (L/min) (not recorded) SpO2 98 % (08/05/23 0827) O2% 21 % (08/03/23 0724) Height 188 cm (6' 2") (08/01/23 1727) Weight 85.2 kg (187 lb 13.3 oz) (08/05/23 0340) BMI 24.1 (08/05/23 0340)

Temp Min: 97 °F (36.1 °C) Min taken time: 08/02/23 0425 Max: 100.6 °F (38.1 °C) Max taken time: 08/01/23 1805

Intake/Output Summary (Last 24 hours) at 8/5/2023 1151 Last data filed at 8/5/2023 0340 Gross per 24 hour Intake 290 ml Output 1400 ml Net -1110 ml

NECK: Supple. No JVD. No lymphadenopathy. No Bruit. Trachea midline

COR: RRR, no S3, no S4. No rub. No murmur.

LUNGS: CTA decreased breath sounds at bases

ABDOMEN: Soft, non tender, obese, positive PEG, positive bowel sounds x 4, No rebound, guarding or rigidity. No organomegaly.

EXTREMITIES: Trace edema, cyanosis or clubbing.

Diagnostic Studies:

11:51 AM:

Recent Labs Component 08/04/23 0614 08/03/23 0626 08/02/23 0632 WBC 13.3* 16.0* 11.4* HGB 12.3* 13.0* 12.3* HCT 40.8 41.2 40.5 MCV 95 94 97 PLT 285 310 286 Recent Labs Component 08/05/23 0651 08/05/23 0011 08/04/23 2201 08/04/23 1708 08/04/23 0621 08/04/23 0614 08/03/23 1714 08/03/23 0626 08/02/23 0602 08/02/23 0541

```
NA -- -- 150* -- -- 151* -- 146* -- 148*
K -- -- 3.9 -- -- 3.3* -- 3.4* -- 4.0
CL -- -- 120* -- -- 122* -- 117* -- 117*
CO2 -- -- 23 -- -- 22 -- 24 -- 26
BUN -- -- -- 26* -- 27* -- 24
CREAT -- -- -- 0.64 -- 0.73 -- 0.67
GLU 162* 167* -- 142* < > 145* < > 176* < > 137*
< > = values in this interval not displayed.
Abdominal Labs
Recent Labs
Component 08/04/23
0614 08/03/23
0626 08/02/23
0541 08/01/23
1731
ALP -- -- 90 113
AST -- -- 17 21
ALT -- -- 12 14
LIPASE -- -- 10
BILITOTAL -- -- 0.5 0.3
BILIDIRECT -- -- 0.2 0.2
ALB 2.7* 2.9* 2.7* | 2.7* 2.9*
Glucose
Recent Labs
Lab 08/05/23
0651 08/05/23
0011 08/04/23
1708 08/04/23
1352
GLU 162* 167* 142* 157*
INR
Recent Labs
Lab 08/01/23
1731
INR 1.2
Iron Studies
Recent Labs
Component 08/02/23
0224
IRON 52*
FERRITIN 385*
TIBC 304
Impression/Plan
Sepsis
Mental status change probable TME
Electrolyte imbalance
Hypertension
Type 2 diabetes mellitus
Anoxic brain injury
Possible aspiration
Hypernatremia/adjust IV fluids to D5W
See orders
Steven Katzman DO, FACOI
```

This dictation was prepared using Dragon Medical voice recognition software. As a result, errors may occur. When identified, these transcriptional errors have been corrected. While every attempt is made to correct errors during dictation, errors may still exist.

Electronically signed by Steven Katzman at 08/05/2023 11:54 AM EDT Igor Paris - 08/05/2023 11:02 AM EDT Formatting of this note is different from the original. Psychiatric Progress Note Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient seen. Chart reviewed. Confused, anxious Objective:

Today's Hospital Course (include current psychotropics response and today's proposed discharge plans): Patient Vitals for the past 24 hrs (Last 3 readings): BP Temp Temp src Pulse Resp SpO2 Weight 08/05/23 0827 145/82 97.8 °F (36.6 °C) -- 78 20 98 % --08/05/23 0648 -- -- -- 98 % --08/05/23 0400 133/78 98.3 °F (36.8 °C) Axillary 71 20 98 % --08/05/23 0340 -- -- -- -- 85.2 kg (187 lb 13.3 oz) 08/05/23 0006 138/83 98 °F (36.7 °C) Axillary 74 18 97 % --08/04/23 2129 137/89 -- -- 88 -- -- --08/04/23 2100 137/89 98.8 °F (37.1 °C) -- 88 -- -- --08/04/23 2054 137/89 97.7 °F (36.5 °C) Axillary 85 18 98 % --08/04/23 1200 130/96 -- -- - 18 96 % --

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate amiodarone (CORDARONE, PACERONE) tablet 200 mg 200 mg PEG Tube DAILY apixaban (ELIQUIS) tablet 5 mg 5 mg Oral Q 12 H atorvastatin (LIPITOR) tablet 40 mg 40 mg PEG Tube Q HS cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB 2 g Intravenous Q 8 H Stopped (08/04/23 1411) clopidogrel (PLAVIX) tablet 75 mg 75 mg Oral DAILY insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units 2-5 Units Subcutaneous Q 6 H metoprolol (LOPRESSOR) tablet 25 mg 25 mg PEG Tube BID metroNIDAZOLE (FLAGYL) infusion 500 mg 500 mg Intravenous Q 8 H 500 mg (08/05/23 1020) OLANZapine (ZyPREXA) tablet 10 mg 10 mg Oral BID sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Q 12 H valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg 1,000 mg Oral BID vancomycin (VANCOCIN) 1,500 mg in sodium chloride 0.9 % 280 mL IVPB 1,500 mg Intravenous Q 12 H 1,500 mg (08/05/23 1021)

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate acetaminophen (TYLENOL) tablet 650 mg 650 mg PEG Tube Q 4 H PRN sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 20 mL 20 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 3 mL 3 mL Intravenous PRN sodium chloride 0.9% flush injection 10 mL 10 mL Intravenous ONCE PRN

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate

No past medical history on file.

Not on File

WBC Hgb Hct Plt

NA K CI CO2 150 (08/04 2201) 3.9 (08/04 2201) 120 (08/04 2201) 23 (08/04 2201) BUN Creat Glucose

Today's Brief Mental Status: Grooming: adequate Speech:

clear Concentration: impaired Affect: labile Thought process: confused, disorganized Memory: impaired

Assessment/Plan: Will cont current tx

Encounter Diagnoses Name Primary? Altered mental status, unspecified altered mental status type Yes Community acquired pneumonia, unspecified laterality Urinary tract infection associated with indwelling urethral catheter, initial encounter (CMS/HCC) Sepsis without acute organ dysfunction, due to unspecified organism (CMS/HCC)

This dictation was prepared using Dragon Medical voice recognition software. As a result, errors may occur. When identified, these transcriptional errors have been corrected. While every attempt is made to correct errors during dictation, errors may still exist. Electronically signed by Igor Paris at 08/05/2023 11:03 AM EDT

Igor Paris - 08/04/2023 8:37 PM EDT

Formatting of this note is different from the original. Psychiatric Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient seen. Chart reviewed. Patient confused. Difficult to redirect.

Objective:

Today's Hospital Course (include current psychotropics response and today's proposed discharge plans): Patient Vitals for the past 24 hrs (Last 3 readings): BP Temp Temp src Pulse Resp SpO2 08/04/23 1200 130/96 -- -- -- 18 96 % 08/04/23 0747 144/78 97.6 °F (36.4 °C) -- 85 18 95 % 08/04/23 0722 -- -- -- 98 % 08/04/23 0443 123/83 98 °F (36.7 °C) Axillary 87 18 97 % 08/03/23 2322 134/87 98.8 °F (37.1 °C) Axillary 85 18 98 % 08/03/23 2100 (!) 138/120 98.9 °F (37.2 °C) Axillary 92 18 96 %

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate amiodarone (CORDARONE, PACERONE) tablet 200 mg 200 mg PEG Tube DAILY apixaban (ELIQUIS) tablet 5 mg 5 mg Oral Q 12 H atorvastatin (LIPITOR) tablet 40 mg 40 mg PEG Tube Q HS cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB 2 g Intravenous Q 8 H Stopped (08/04/23 1411) clopidogrel (PLAVIX) tablet 75 mg 75 mg Oral DAILY insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units 2-5 Units Subcutaneous Q 6 H metoprolol (LOPRESSOR) tablet 25 mg 25 mg PEG Tube BID metroNIDAZOLE (FLAGYL) infusion 500 mg 500 mg Intravenous Q 8 H Stopped (08/04/23 1020) OLANZapine (ZyPREXA) tablet 10 mg 10 mg Oral BID potassium chloride (KCL) 20 MEQ/15ML (10%) oral liquid 1.33mEq/mL 40 mEq 40 mEq PEG Tube BID valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg 1,000 mg Oral BID vancomycin (VANCOCIN) 1,500 mg in sodium chloride 0.9 % 280 mL IVPB 1,500 mg Intravenous Q 12 H Stopped (08/04/23 1120)

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate acetaminophen (TYLENOL) tablet 650 mg 650 mg PEG Tube Q 4 H PRN sodium chloride 0.9 % flush injection 3 mL 3 mL Intravenous PRN sodium chloride 0.9% flush injection 10 mL 10 mL Intravenous ONCE PRN

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate

No past medical history on file.

Not on File

WBC Hgb Hct Plt 13.3 (08/04 0614) 12.3 (08/04 0614) 40.8 (08/04 0614) 285 (08/04 0614) NA K Cl CO2 151 (08/04 0614) 3.3 (08/04 0614) 122 (08/04 0614) 22 (08/04 0614) BUN Creat Glucose 26 (08/04 0614) 0.64 (08/04 0614) 145 (08/04 0614)

Today's Brief Mental Status: Grooming: adequate Speech: Clear Concentration: impaired Affect: labile Thought process: confused, disorganized Memory: impaired Poor Insight and judgment Assessment/Plan: Will cont current tx

Encounter Diagnoses Name Primary? Altered mental status, unspecified altered mental status type Yes Community acquired pneumonia, unspecified laterality Urinary tract infection associated with indwelling urethral catheter, initial encounter (CMS/HCC) Sepsis without acute organ dysfunction, due to unspecified organism (CMS/HCC)

This dictation was prepared using Dragon Medical voice recognition software. As a result, errors may occur. When identified, these transcriptional errors have been corrected. While every attempt is made to correct errors during dictation, errors may still exist. Electronically signed by Igor Paris at 08/04/2023 8:38 PM EDT

Kristin Derderian - 08/04/2023 12:14 PM EDT

Formatting of this note is different from the original. Images from the original note were not included. INFECTIOUS DISEASE PROGRESS NOTE

Patient Name: Ioan Suiugan; Patient MRN: 9942681 Admission Date: 8/1/2023; Hospital Day: 4

ID Consultant: Kristin M Derderian, DO Date: 8/4/2023 Time: 12:11 PM

Interval History: Patient seen in follow up for leukocytosis Afebrile, O2 sat 96%RA Awake, appears comfortable

Current Antibiotics: Vanco, cefepime, flagyl

Current Facility-Administered Medications Medication Dose Route Frequency amiodarone (CORDARONE, PACERONE) tablet 200 mg 200 mg PEG Tube DAILY apixaban (ELIQUIS) tablet 5 mg 5 mg Oral Q 12 H atorvastatin (LIPITOR) tablet 40 mg 40 mg PEG Tube Q HS cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB 2 g Intravenous Q 8 H clopidogrel (PLAVIX) tablet 75 mg 75 mg Oral DAILY insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units 2-5 Units Subcutaneous Q 6 H metoprolol (LOPRESSOR) tablet 25 mg 25 mg PEG Tube BID metroNIDAZOLE (FLAGYL) infusion 500 mg 500 mg Intravenous Q 8 H OLANZapine (ZyPREXA) tablet 10 mg 10 mg Oral BID potassium chloride (KCL) 20 MEQ/15ML (10%) oral liquid 1.33mEq/mL 40 mEq 40 mEq PEG Tube BID valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg 1,000 mg Oral BID vancomycin (VANCOCIN) 1,500 mg in sodium chloride 0.9 % 280 mL IVPB 1,500 mg Intravenous Q 12 H

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate dextrose 5 % infusion Intravenous Continuous 100 mL/hr at 08/04/23 0948 Physical Exam:

Temp 97.6 °F (36.4 °C) (08/04/23 0747) Source Axillary (08/04/23 0443) BP 130/96 (08/04/23 1200) Heart Rate 85 (08/04/23 0747) Resp 18 (08/04/23 1200) O2 (L/min) (not recorded) SpO2 96 % (08/04/23 1200) O2% 21 % (08/03/23 0724) Height 188 cm (6' 2") (08/01/23 1727) Weight 99.8 kg (220 lb) (08/02/23 0300) BMI 28.2 (08/02/23 0300)

Flowsheet Data Statistics (last 36 hours)

Flowsheet Row Name Min Max BP: Systolic 123 159 BP: Diastolic 78 120 Temp 97.6 °F (36.4 °C) 98.9 °F (37.2 °C) Heart Rate 85 98 Resp 18 20 SpO2 95 % 100 %

General - He appears chronically ill, NAD O2 sat 96%RA HEENT - NCAT, mucosa moist, no icterus Neck - trachea midline Chest - diminished bibasilar BS Heart - reg Abdomen - soft, min distended, peg site without erythema Extremities - warm Skin - no acute rashes Neuropsych -awake

Indwelling Devices: PIV

New Labs:

Recent Labs Component 08/04/23 0614 08/03/23 0626 08/02/23 0632 WBC 13.3* 16.0* 11.4* RBC 4.28* 4.39 4.19* HGB 12.3* 13.0* 12.3* MCV 95 94 97 PLT 285 310 286 *Asterisks denote abnormal values Recent Labs Component 08/04/23 0614 08/03/23 0626 08/02/23 0541 08/01/23 1731 NA 151* 146* 148* 142 K 3.3* 3.4* 4.0 4.6 CL 122* 117* 117* 112* CO2 22 24 26 23 ANIONGAP 7 5 5 7 BUN 26* 27* 24 23 CREAT 0.64 0.73 0.67 0.77 ALB 2.7* 2.9* 2.7* | 2.7* 2.9* GLOBULIN -- -- 4.1* 4.2* AGRATIO -- -- 0.7 0.7 ALP -- -- 90 113 AST -- -- 17 21 ALT -- -- 12 14 BILITOTAL -- -- 0.5 0.3 *Asterisks denote abnormal values New Culture Data: Legionella/pneumococcal Ag neg

Culture, Urine

Order: 1442857483 Status: Final result

Visible to patient: Yes (not seen)

Next appt: None Specimen Information: Urine, Clean Catch 0 Result Notes Culture, Urine 10,000-100,000 CFU/ml Enterobacter cloacae complex Abnormal

Susceptibility

Enterobacter cloacae complex (1) Antibiotic MIC Interpretation Amoxicillin/K Clavulanate >16/8 Resistant Ampicillin >16 Resistant Ampicillin/Sulbactam >16/8 Resistant Cefazolin >16 Resistant Cefepime <=2 Susceptible Cefotaxime * >16 Cefotaxime/K Clavulanate * >4 Ceftazidime * >16 Resistant Ceftazidime/Avibactam * <=4 Susceptible Ceftazidime/K Clavulanate * >2 Ceftriaxone >2 Resistant For severe disease or pyelonephritis, avoid ceftriaxone due to potential for emergence of resistance on treatment. Ciprofloxacin <=0.25 Susceptible Eravacycline * <=0.5 Susceptible Ertapenem * <=0.5 Susceptible Gentamicin <=4 Susceptible Imipenem * <=1 Susceptible Levofloxacin <=0.5 Susceptible Meropenem <=1 Susceptible Meropenem/Vaborbactam * <=2 Susceptible Nitrofurantoin <=32 Susceptible Piperacillin/Tazobactam * 64 Intermediate Tobramycin <=4 Susceptible Trimethoprim/Sulfa <=2/38 Susceptible

* Suppressed Antibiotic

Specimen Collected: 08/01/23 10:52 PM Last Resulted: 08/04/23 9:53 AM

New Imaging and Other Diagnostics: Blood cx neg

Assessment & Plan:

Other Sepsis without acute organ dysfunction (CMS/HCC) Assessment & Plan Presentation to ED 8/1 with altered mental status S/p CPA 5/2023, low grade temp in ED 100.6 Hx MDR enterobacter 7/2023 from urine cx CT chest with L sided pleural effusion, oxygenating well on RA

?aspiration vs GU vs other Check procalcitonin, legionella/pneumococcal Ag, MRSA screen Consider CTAP Continue current abx for now

8/4: procal 0.50. Await MRSA screen.

Continue current abx for now

Electronically signed by Kristin Derderian at 08/04/2023 12:14 PM EDT

Danielle S - 08/04/2023 10:55 AM EDT Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023


Subjective:

Patient seen and examined. He is resting in bed awake. Unobtainable ROS as the patient incorrectly answers "yes" to every question asked. Appears comfortable. Remains in bilateral SWR and mitts. Nursing at bedside.

Objective:

Vitals: Blood pressure 144/78, pulse 85, temperature 97.6 °F (36.4 °C), resp. rate 18, height 188 cm (6' 2"), weight 99.8 kg (220 lb), SpO2 95 %.

Body mass index is 28.25 kg/m².



amiodarone (CORDARONE, PACERONE) tablet 200 mg

apixaban (ELIQUIS) tablet 5 mg

atorvastatin (LIPITOR) tablet 40 mg

cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB

clopidogrel (PLAVIX) tablet 75 mg dextrose 5 % infusion

insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units

metoprolol (LOPRESSOR) tablet 25 mg

metroNIDAZOLE (FLAGYL) infusion 500 mg OLANZapine (ZyPREXA) tablet 10 mg

sodium chloride 0.9 % flush injection 3 mL

sodium chloride 0.9% flush injection 10 mL

valproate (DEPAKENE) svrup 250 mg/5 mL 1,000 mg

vancomycin (VANCOCIN) 1,500 mg in sodium chloride 0.9 % 280 mL IVPB

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

Recent Labs Component 08/04/23 0614 08/03/23

0626 08/02/23 0632 08/01/23 1731 WBC 13.3* 16.0* 11.4* 13.7* RBC 4.28* 4.39 4.19* 4.45 HGB 12.3* 13.0* 12.3* 13.0* MCV 95 94 97 96 PLT 285 310 286 283 INR -- -- 1.2 *Asterisks denote abnormal values Recent Labs Component 08/04/23 0621 08/04/23 0614 08/03/23 2317 08/03/23 1714 08/03/23 0626 08/02/23 0602 08/02/23 0541 08/02/23 0159 08/01/23 1731 NA -- 151* -- -- 146* -- 148* -- 142 K -- 3.3* -- -- 3.4* -- 4.0 -- 4.6 CL -- 122* -- -- 117* -- 117* -- 112* CO2 -- 22 -- -- 24 -- 26 -- 23 ANIONGAP -- 7 -- -- 5 -- 5 -- 7 BUN -- 26* -- -- 27* -- 24 -- 23 CREAT -- 0.64 -- -- 0.73 -- 0.67 -- 0.77 ALB -- 2.7* -- -- 2.9* -- 2.7* | 2.7* -- 2.9* GLOBULIN -- -- -- -- 4.1* -- 4.2* AGRATIO -- -- -- -- 0.7 -- 0.7 ALP -- -- -- -- 90 -- 113 AST -- -- -- 17 -- 21 ALT -- -- -- -- 12 -- 14 BILITOTAL -- -- -- -- 0.5 -- 0.3 GLU 143* 145* 165* < > 176* < > 137* < > 432* < > = values in this interval not displayed. *Asterisks denoteabnormal values Assessment/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Hypokalemia **Essential HTN** Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury Plan:

- EEG in process. Awaiting neurology comment.
- Psychiatry following. Continue Zyprexa and Depakote.
- Supplement KCl 40 mEq via peg X 2 doses.
- Increase FWF to 40 ml/hr given hypernatremia. Additionally D5 IVF @ 100 ml/hr X 8 hours ordered.
- ID evaluation appreciated. Suspecting aspiration vs GU vs other.
- Antibiotics: Vanco, Cefepime, & Flagyl, day #3
- Urine culture with 10-100k enterobacter cloacae complex.
- Discussed with nursing staff at bedside. Will attempt to remove mitts today. Bilateral SWR order renewed.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat Electronically signed by William Rudy at 08/04/2023 5:13 PM EDT

Associated attestation - William Rudy - 08/04/2023 5:13 PM EDT Formatting of this note might be different from the original.

Patient was seen and examined on rounds Case discussed with Danielle Saunders, RN, NP-C Reviewed progress note as documented Agree in principle with documentation

Thomas E - 08/03/2023 5:16 PM EDT

Formatting of this note might be different from the original. B-Service Restraint NOTE:

Called to assess loan Suiugan for a need for restraint secondary to danger to self. Currently the patient has been reported to be confused, pulling at tubes/IV/Peg tube, and other medical equipment. Soft restraint: right wrist and left wrist have been placed at this time.

BP 142/88 | Pulse 87 | Temp 98.6 °F (37 °C) | Resp 20 | Ht 188 cm (6' 2") | Wt 99.8 kg (220 lb) | SpO2 100% | BMI 28.25 kg/m²

loan Suiugan after restraint placement is stable. Previous medical and behavior modifiers prior to restraint use include calm environment, consideration of family staying with patient, frequent reorientation and redirection. Will keep restraints in place with nursing monitoring for patient safety and appropriate discontinuation as soon as possible.

Thomas Engle PA-C - IM B-Service Mobile Heartbeat: (947)521-7550/Pager: 311093 Use B Service on-call if I am 'off-line' 08/03/23 5:17 PM

Electronically signed by Thomas E at 08/03/2023 6:01 PM EDT

Igor Paris - 08/03/2023 2:11 PM EDT Formatting of this note is different from the original.

Psychiatric Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission: 8/1/2023

Subjective:

Patient sleepy but arousable. No acute distress.

Objective:

Today's Hospital Course (include current psychotropics response and today's proposed discharge plans): Patient Vitals for the past 24 hrs (Last 3 readings): BP Temp Temp src Pulse Resp SpO2 08/03/23 0843 132/91 98.2 °F (36.8 °C) Oral 93 20 99 % 08/03/23 0724 -- -- -- 97 % 08/03/23 0532 148/99 -- -- 98 -- --08/03/23 0406 159/94 97.7 °F (36.5 °C) Axillary 94 18 98 % 08/02/23 2357 134/94 97.7 °F (36.5 °C) Axillary 89 18 99 %

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate amiodarone (CORDARONE, PACERONE) tablet 200 mg 200 mg PEG Tube DAILY apixaban (ELIQUIS) tablet 5 mg 5 mg Oral Q 12 H atorvastatin (LIPITOR) tablet 40 mg 40 mg PEG Tube Q HS cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB 2 g Intravenous Q 8 H Stopped (08/03/23 1403) clopidogrel (PLAVIX) tablet 75 mg 75 mg Oral DAILY insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units 2-5 Units Subcutaneous Q 6 H metoprolol (LOPRESSOR) tablet 25 mg 25 mg PEG Tube BID metroNIDAZOLE (FLAGYL) infusion 500 mg 500 mg Intravenous Q 8 H Stopped (08/03/23 0942) OLANZapine (ZyPREXA) tablet 10 mg 10 mg Oral BID valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg 1,000 mg Oral BID vancomycin (VANCOCIN) 1,500 mg in sodium chloride 0.9 % 280 mL IVPB 1,500 mg Intravenous Q 12 H Stopped (08/03/23 1042)

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate acetaminophen (TYLENOL) tablet 650 mg 650 mg PEG Tube Q 4 H PRN sodium chloride 0.9 % flush injection 3 mL 3 mL Intravenous PRN sodium chloride 0.9% flush injection 10 mL 10 mL Intravenous ONCE PRN Current Facility-Administered Medications Medication Dose Route Frequency Last Rate

No past medical history on file.

Not on File

WBC Hgb Hct Plt 16.0 (08/03 0626) 13.0 (08/03 0626) 41.2 (08/03 0626) 310 (08/03 0626) NA K CI CO2 146 (08/03 0626) 3.4 (08/03 0626) 117 (08/03 0626) 24 (08/03 0626) BUN Creat Glucose 27 (08/03 0626) 0.73 (08/03 0626) 176 (08/03 0626)

Today's Brief Mental Status: Grooming: adequate Speech: Clear Concentration: impaired Affect: blunted Thought process: confused, Memory: impaired

Assessment/Plan: Will cont current tx

Encounter Diagnoses Name Primary? Altered mental status, unspecified altered mental status type Yes Community acquired pneumonia, unspecified laterality Urinary tract infection associated with indwelling urethral catheter, initial encounter (CMS/HCC) Sepsis without acute organ dysfunction, due to unspecified organism (CMS/HCC)

This dictation was prepared using Dragon Medical voice recognition software. As a result, errors may occur. When identified, these transcriptional errors have been corrected. While every attempt is made to correct errors during dictation, errors may still exist. Electronically signed by Igor Paris at 08/03/2023 2:12 PM EDT

Danielle S - 08/03/2023 8:33 AM EDT Formatting of this note is different from the original. Progress Note

Attending Physician: Rudy, William M, DO

Date of Admission:8/1/2023

Subjective:

Patient seen and examined. He is resting in bed in no acute distress. Remains with periods of agitation. Currently in bilateral SWR. Appears comfortable.

Objective:

Vitals: Blood pressure 148/99, pulse 98, temperature 97.7 °F (36.5 °C), temperature source Axillary, resp. rate 18, height 188 cm (6' 2"), weight 99.8 kg (220 lb), SpO2 97 %. Body mass index is 28.25 kg/m².

Intake/Output Summary (Last 24 hours) at 8/3/2023 0833 Last data filed at 8/3/2023 0700 Gross per 24 hour Intake 1420 ml Output 750 ml Net 670 ml

Physical Examination: General: Non-toxic appearing Caucasian male in no acute distress. Responds and withdrawals to pain. Appears comfortable at time of exam. Eyes: EOMI. No scleral icterus.

ENT: Neck is supple, mucous membranes are moist Chest: Clear to auscultation bilaterally, no wheezing, no rales Cardiac: RRR, S1, S2, no murmurs Abdomen: Bowel sounds are present in all quadrants, soft, NT. Mild distention noted. Ext: No clubbing, cyanosis, or edema. Psychiatric: Affect is appropriate Neurologic: Alert and oriented X0. Speech is mumbled and incoherent. Withdrawals appropriately to painful stimuli. Does not follow commands. Skin: No gross rashes.

Current Medications: Current Facility-Administered Medications Medication acetaminophen (TYLENOL) tablet 650 mg amiodarone (CORDARONE, PACERONE) tablet 200 mg apixaban (ELIQUIS) tablet 5 mg atorvastatin (LIPITOR) tablet 40 mg cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB clopidogrel (PLAVIX) tablet 75 mg insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units metoprolol (LOPRESSOR) tablet 25 mg metroNIDAZOLE (FLAGYL) infusion 500 mg sodium chloride 0.9 % flush injection 3 mL sodium chloride 0.9% flush injection 10 mL vancomycin (VANCOCIN) 1,500 mg in sodium chloride 0.9 % 280 mL IVPB

Diagnostic Studies: These were all reviewed and interpreted in EPIC

New Labs:

Recent Labs Component 08/03/23 0626 08/02/23 0632 08/01/23 1731 WBC 16.0* 11.4* 13.7* RBC 4.39 4.19* 4.45 HGB 13.0* 12.3* 13.0* MCV 94 97 96 PLT 310 286 283 INR -- -- 1.2 *Asterisks denote abnormal values **Recent Labs** Component 08/03/23 0626 08/03/23 0555 08/03/23 0001 08/02/23 0602 08/02/23 0541 08/02/23 0159 08/01/23 1731 NA 146* -- -- 148* -- 142 К 3.4* -- -- 4.0 -- 4.6 CL 117* -- -- 117* -- 112* CO2 24 -- -- 26 -- 23 ANIONGAP 5 -- -- 5 -- 7 BUN 27* -- -- 24 -- 23 CREAT 0.73 -- -- 0.67 -- 0.77 ALB 2.9* -- -- 2.7* | 2.7* -- 2.9* GLOBULIN -- -- -- 4.1* -- 4.2* AGRATIO -- -- -- 0.7 -- 0.7 ALP -- -- -- 90 -- 113 AST -- -- -- 17 -- 21 ALT -- -- -- 12 -- 14 BILITOTAL -- -- -- 0.5 -- 0.3 GLU 176* 174* 166* < > 137* < > 432* <> = values in this interval not displayed. *Asterisks denoteabnormal values

Assessment/Plan: Altered mental status 2/2 toxic metabolic encephalopathy superimposed on anoxic brain injury Neutrophilic Leukocytosis Generalized weakness / Chronic debility Hypokalemia Essential HTN Type 2 DM Atrial flutter on Eliquis Anoxic brain injury 5/2023 following VT cardiac arrest with delayed ROSC ~ 60 minutes. HX Agitation / Aggressive behavior Neurogenic bladder 2/2 anoxic brain injury

Plan:

- Neurology evaluation appreciated. EEG ordered and pending.
- Psychiatry evaluation appreciated. Recommendations to restart home Zyprexa and Depakote doses for behavioral management.
- Resume Zyprexa 10 mg PO BID and Depakote 1000 mg BID. Monitor.
- Antibiotics: Vanco, Cefepime, & Flagyl, day #2
- Blood and urine cultures pending.
- Consult ID Dr. Khalife re: up-trending WBC count and HX MDRO.
- Supplement KCl 40 mEq liquid PO X 1.

Danielle Saunders, AGPCNP-BC Internal Medicine Mobile Heartbeat

Electronically signed by William Rudy at 08/03/2023 11:34 AM EDT

Associated attestation - William Rudy - 08/03/2023 11:34 AM EDT Formatting of this note might be different from the original. Patient was seen and examined on rounds Agree in principle with Internal medicine progress note as documented by Danielle Saunders, RN, NP-C Case discussed as well

Patient appears awake patient did answer several questions regarding pain and shortness of breath with head nod still uncertain as to patient's full comprehension

Sam Ajluni - 08/02/2023 8:00 PM EDT

Formatting of this note might be different from the original.

Pt seen, consult to be dictated. Case discussed with sister who was present. He has been agitated since TBI and she says he is currently calmer because he is weaker due to infection. He is on zyprexa and depakote prior to admission, unclear why these meds were discontinued so I recommend restarting these meds at their PTA doses. Electronically signed by Sam Ajluni at 08/03/2023 12:19 AM EDT

James Hebden - 08/02/2023 5:23 PM EDT

Formatting of this note might be different from the original. Restraint Note

Called to assess loan Suiugan for a need for restraint. Ioan is danger to self; attempting to remove lines and equipment. Bilateral soft wrist restraints and mitts have been placed for safety.

BP 145/93 | Pulse 102 | Temp 97.8 °F (36.6 °C) (Axillary) | Resp 18 | Ht 188 cm (6' 2") | Wt 99.8 kg (220 lb) | SpO2 100% | BMI 28.25 kg/m²

loan Suiugan is currently comfortable and in no distress with restraints in place. Will keep restraints in place for 24 hours. The patient's safety will be reevaluated at that time.

Jamie Hebden Emergency Medicine | PGY-3

Electronically signed by James Hebden at 08/02/2023 5:23 PM EDT

H&P Notes - documented in this encounter Cameron Hubbard - 08/02/2023 5:37 AM EDT

Formatting of this note is different from the original. History and Physical

Attending Physician: Korkigian, Armen A, DO

Date of Admission: 8/1/2023

Chief Complaint:

Altered mental status

Source of Information: Available medical record and family

History of Present Illness:

This is a 62y.o. male with past medical history of type 2 diabetes, atrial flutter, urinary retention and prior V. tach arrest with resulting anoxic brain injury on 5/23 who presents with altered mental status over the last several days. History was significantly limited secondary to lack of reliable historians at bedside, as well as trouble reaching the primary caretaker via phone. Per patient's son, patient had been at an acute care facility for brain injury from 5/11 until 6/16, at which time he was intubated, and was later discharged to SAR for rehabilitation. At SAR, patient was noted to have agitation and impulsive behavior and became combative with staff - necessitating restraints and the addition of psychiatric medication. At that time, it was suggested that this might be the patient's new baseline. However, family has been concerned that the patient has progressively worsened and that he has been cared for inadequately and may require arrangements for a new facility. On arrival, patient was noted to be severely agitated as well and was pulling lines, leading to placement of restraints.

ED course Vitals: 119/80, pulse 89, temp 99.1, RR 12 Labs: -BMP: Chloride 112, glucose 432 -VBG: pH 7.4, PCO2 48, bicarb 29, CO2 30 -UA: LE 3+, WBC greater than 50, 2+ bacteria -CBC: WBC 13.7 -Procalcitonin: 0.47 Imaging: -CXR: Bibasilar atelectasis Meds: none Consultants: none

No past medical history on file. No past surgical history on file. No family history on file. Social History

Socioeconomic History Marital status: Divorced

Medications: Home Medications

Reviewed by Hunter, Pamela J on 08/01/23 at 2133

Med Sig Last Dose Dt/Time

acetaminophen (TYLENOL) 325 MG PO Tab 2 Tablets every 4 hours as needed. Unknown amiodarone (CORDARONE, PACERONE) 200 MG PO Tab 1 Tablet once daily. Unknown apixaban (ELIQUIS) 5 MG PO Tab take 1 Tablet by mouth twice daily. Unknown Ascorbic Acid 250 MG PO Tab 1 Tablet once daily. Unknown atorvastatin (LIPITOR) 40 MG PO Tab 1 Tablet once every night at bedtime. Unknown clopidogrel (PLAVIX) 75 MG PO Tab 1 Tablet once daily. Unknown HYDROcodone-acetaminophen (NORCO) 5-325 MG PO Tab 1 Tablet 3 times daily. X 7 days Unknown insulin lispro (HumaLOG) 100 UNIT/ML INJ Solution inject 1-6 Units into the skin 4 times daily. Sliding scale Unknown LORazepam (INTENSOL) 2 MG/ML PO Conc 0.5 mL every 6 hours as needed for FOR AGITATION. Unknown metoprolol (LOPRESSOR) 25 MG PO Tab 1 Tablet twice daily. Unknown nicotine (NICODERM) 14 mg/24hr TRANSDERM PATCH 24 HR place 1 Patch onto the skin every 24 hours. Unknown OLANZapine (ZyPREXA) 10 MG PO Tab 1 Tablet twice daily. Unknown polyethylene glycol 3350 (MIRALAX) 17 GM/SCOOP PO Powder take 17 g by mouth once daily. Unknown tamsulosin (Flomax) 0.4 MG PO Cap take 1 Capsule by mouth once daily. Take 30 minutes after the same meal each day. Unknown valproate (DEPAKENE) 250 MG/5ML PO Solution take 20 mL by mouth twice daily. Unknown valproate (DEPAKENE) 250 MG/5ML PO Solution 10 mL once daily. Unknown

Hospital Medications: Current Facility-Administered Medications Medication Dose Route Frequency Provider Last Rate Last Admin acetaminophen (TYLENOL) tablet 650 mg 650 mg PEG Tube Q 4 H PRN Hubbard, Cameron Christopher, DO amiodarone (CORDARONE, PACERONE) tablet 200 mg 200 mg PEG Tube DAILY Hubbard, Cameron Christopher, DO apixaban (ELIQUIS) tablet 5 mg 5 mg Oral Q 12 H Marchewka, Tiffany Christine, DO 5 mg at 08/02/23 0227 atorvastatin (LIPITOR) tablet 40 mg 40 mg PEG Tube Q HS Hubbard, Cameron Christopher, DO cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB 2 g Intravenous Q 8 H Hubbard, Cameron Christopher, DO 200 mL/hr at 08/02/23 0440 2 g at 08/02/23 0440 clopidogrel (PLAVIX) tablet 75 mg 75 mg Oral DAILY Marchewka, Tiffany Christine, DO

insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units 2-5 Units Subcutaneous Q 6 H Marchewka, Tiffany Christine, DO

metoprolol (LOPRESSOR) tablet 25 mg 25 mg PEG Tube BID Hubbard, Cameron Christopher, DO metroNIDAZOLE (FLAGYL) infusion 500 mg 500 mg Intravenous Q 8 H Hubbard, Cameron Christopher, DO Stopped at 08/02/23 0257

sodium chloride 0.9 % flush injection 3 mL 3 mL Intravenous PRN Hubbard, Cameron Christopher, DO sodium chloride 0.9% flush injection 10 mL 10 mL Intravenous ONCE PRN Kaiser Alexander, Diane L, DO vancomycin (VANCOCIN) 1,500 mg in sodium chloride 0.9 % 280 mL IVPB 1,500 mg Intravenous Q 12 H Hubbard, Cameron Christopher, DO

Allergies:

Not on File

Review of Systems: Significantly limited secondary to lack of reliable historians at bedside and difficulty reaching the primary caretaker, the patient's daughter. History was obtained from medical records, outside health systems, and limited history from the patient's son.

General: No changes in weight, no changes in appetite.

Skin: No jaundice, No rashes. No lesions.

HEENT/Neck: No dizzy/lightheaded, no recent head injury/trauma.

Cardiovascular: Denies chest pain at rest or with exertion, No dyspnea with exertion, no PND, no murmurs, no palpitations, no cold extremities, no edema.

Respiratory: No known difficulty breathing, no hemoptysis.

GI: No abdominal pain, vomiting.

GU: No known dysuria, frequency, or burning

Endocrine: No polyuria

Neurological: + Prior neurological deficits and changes in mental status secondary to anoxic brain injury on 5/23

Musculoskeletal: No new arthralgias or myalgias.

Psychological: Unable to assess.

Objective: Blood pressure 120/86, pulse 90, temperature 97 °F (36.1 °C), temperature source Axillary, resp. rate 18, height 188 cm (6' 2"), weight 99.8 kg (220 lb), SpO2 99 %.

General: Middle-age male who is sleeping on entry and difficult to arouse fully. Patient does respond and withdraws to pain with some mumbling speech, however does not respond in full sentences and cannot follow commands currently. Patient does not appear to be in any distress at this time.

Head/eyes/ear/nose/throat: NC/AT, PERRLA, EOM intact, No injection or pallor of conjunctivae. No sclera icterus. Oral mucosa moist and pink.

Neck: Supple with no meningismus. Trachea midline. No lymphadenopathy.

Skin: Warm and dry with no rashes, lesions, or ecchymosis.

Respiratory: Lungs CTA bilaterally with no adventitious sounds. Mildly decreased airflow, otherwise normal

Cardiovascular: Regular rate and rhythm. No murmurs, rubs, clicks, or gallops. No signs of edema.

GI/Abdomen: Mild abdominal distention, but otherwise soft, nontender with normal bowel sounds in all four quadrants and no rebound, guarding or masses on palpation.

GU/Renal: No suprapubic distension. No suprapubic tenderness. No CVA tenderness.

Musculoskeletal: No edema. No pallor. No cyanosis.

Neurology: Unable to fully assess. Patient does withdraw to pain in multiple extremities and is able to moan incomprehensibly in response to speech. Patient is spontaneously moving all 4 extremities to some degree, as well as facial muscles.

Labs: Recent

Recent Results (from the past 24 hour(s)) Glucose, POC Collection Time: 08/01/23 5:24 PM Result Value Ref Range Glucose 400 (H) 60 - 139 mg/dL Performed By Anderson, Shawna ET Basic Metabolic Panel (BMP) Collection Time: 08/01/23 5:31 PM Result Value Ref Range Sodium 142 135 - 145 mmol/L Potassium 4.6 3.5 - 5.2 mmol/L Chloride 112 (H) 98 - 111 mmol/L Carbon Dioxide -CO2 23 20 - 29 mmol/L Anion Gap 7 5 - 17 Glucose 432 (H) 60 - 99 mg/dL Blood Urea Nitrogen -BUN 23 7 - 25 mg/dL Creatinine 0.77 0.60 - 1.30 mg/dL eGFR By Creatinine 101 mL/min/1.73m2 Calcium 8.3 (L) 8.5 - 10.5 mg/dL Protime and aPTT Collection Time: 08/01/23 5:31 PM **Result Value Ref Range** Protime 13.7 (H) 9.2 - 13.5 Seconds INR 1.2 APTT 26.8 25.0 - 38.0 Seconds Lactic Acid, Plasma Collection Time: 08/01/23 5:31 PM Result Value Ref Range Lactic Acid 1.8 0.5 - 2.0 mmol/L Hepatic Function Panel Collection Time: 08/01/23 5:31 PM Result Value Ref Range Albumin 2.9 (L) 3.5 - 4.9 g/dL Globulin 4.2 (H) 2.2 - 3.7 g/dL Albumin/Globulin Ratio 0.7 Alkaline Phosphatase 113 33 - 120 U/L Aspartate Aminotransferase -AST 21 <35 U/L Alanine Aminotransferase -ALT 14 9 - 47 U/L Bilirubin Total 0.3 0.3 - 1.2 mg/dL Bilirubin Direct 0.2 0.0 - 0.4 mg/dL Protein Total 7.1 6.2 - 8.1 g/dL Lipase Collection Time: 08/01/23 5:31 PM Result Value Ref Range Lipase 10 7 - 60 U/L Troponin I Collection Time: 08/01/23 5:31 PM Result Value Ref Range Troponin I 0.01 <=0.03 ng/mL Magnesium Level Collection Time: 08/01/23 5:31 PM Result Value Ref Range Magnesium 2.1 1.7 - 2.5 mg/dL Phosphorus Level Collection Time: 08/01/23 5:31 PM Result Value Ref Range Phosphorus 2.7 2.3 - 4.4 mg/dL Urinalysis Collection Time: 08/01/23 5:31 PM Result Value Ref Range Color Yellow Clarity Cloudy (A) Clear Glucose >=500 (A) Negative mg/dL **Bilirubin Negative Negative** Ketones Negative Negative mg/dL Specific Gravity, Urine 1.010 1.005 - 1.030 Blood 3+ (A) Negative pH 7.5 5.0 - 8.0 Protein 10 (A) Negative mg/dL Urobilinogen <2.0 <2.0 mg/dL Nitrites Negative Negative Leukocyte Esterase 3+ (A) Negative RBC >20 (A) 0-2 (Negative) /hpf WBC >50 (A) 0-5 (Negative) /hpf Epithelial, Squamous 6-30 Negative /lpf Casts, Hyaline 0-2 (Negative) 0-2 (Negative) /lpf Bacteria 2+ (A) Negative /hpf Covid-19, Flu, RSV by NAA Collection Time: 08/01/23 5:31 PM Specimen: Nasopharyngeal; Swab Result Value Ref Range Influenza A Not Detected Not Detected

Influenza B Not Detected Not Detected **RSV Not Detected Not Detected** SARS-CoV-2 -COVID-19 by NAA, Micro Not Detected Not Detected Complete Blood Count (CBC) W/Auto Diff Collection Time: 08/01/23 5:31 PM Result Value Ref Range WBC 13.7 (H) 3.5 - 10.1 bil/L RBC 4.45 4.31 - 5.48 tril/L Hemoglobin 13.0 (L) 13.5 - 17.0 g/dL Hematocrit 42.6 40.1 - 50.1 % MCV 96 80 - 100 fL MCH 29 28 - 33 pg MCHC 31 (L) 32 - 36 g/dL RDW-CV 16 (H) 12 - 15 % Platelets 283 150 - 400 bil/L Nucleated Red Blood Cells 0.0 <=0.0 % Neutrophils 10.5 (H) 1.6 - 7.2 bil/L Lymphocytes 2.0 1.1 - 4.0 bil/L Monocytes 1.2 (H) 0.0 - 0.9 bil/L Eosinophils 0.0 0.0 - 0.4 bil/L Basophils 0.0 0.0 - 0.1 bil/L Immature Granulocytes 0.06 (H) 0.00 - 0.04 bil/L Immature Granulocyte % 0.4 % Blood Gases, Venous (VBG) Collection Time: 08/01/23 5:32 PM Result Value Ref Range Sample Type Blood, venous pH 7.40 7.32 - 7.42 PCO2 48 41 - 51 mmHg Bicarbonate 29 (H) 19 - 27 mmol/L Total CO2 30 (H) 20 - 29 mmol/L Base Excess 4 -5 - 5 mmol/L Oxyhemoglobin 73 55 - 85 % Carboxyhemoglobin 1.3 < 1.5 % Methemoglobin 0.6 0.0 - 2.0 % Hemoglobin 13.2 (L) 13.5 - 17.0 g/dL Thyroid Stimulating Hormon (TSH) With Reflex to Free Thyroxine (FT4) Collection Time: 08/01/23 5:32 PM **Result Value Ref Range** Thyroid Stimulating Hormone 1.85 0.40 - 4.50 uIU/mL Troponin I Collection Time: 08/01/23 6:42 PM Result Value Ref Range Troponin I 0.02 <=0.03 ng/mL Procalcitonin, Plasma Collection Time: 08/01/23 6:42 PM Result Value Ref Range Procalcitonin, Plasma 0.47 (H) 0.00 - 0.25 ng/mL Troponin I Collection Time: 08/01/23 8:38 PM Result Value Ref Range Troponin I 0.02 <=0.03 ng/mL Beta Hydroxybutyrate (3OH Butyric Acid) Collection Time: 08/01/23 8:38 PM Result Value Ref Range Beta Hydroxybutyrate (3-OH Butyric Acid) 0.09 0.02 - 0.27 mmol/L Alcohol (ETOH) Collection Time: 08/01/23 8:38 PM Result Value Ref Range Alcohol (ETOH) <10 0 - 10 mg/dL Glucose, POC Collection Time: 08/02/23 1:59 AM Result Value Ref Range Glucose 143 (H) 60 - 139 mg/dL Performed By Gjini, Malva NA Valproic Acid Level Collection Time: 08/02/23 2:24 AM **Result Value Ref Range** Valproic Acid 27.0 (L) 50.0 - 100.0 ug/mL Last Dose Date, Valproic Acid 8/2/2023 MM/DD/YYYY

Last Dose Time, Valproic Acid 2:21 AM HH:MM Iron and Transferrin Saturation Collection Time: 08/02/23 2:24 AM Result Value Ref Range Iron (Fe) Level 52 (L) 65 - 175 mcg/dL Transferrin 217 163 - 382 mg/dL Total Iron Binding Capacity, Calculated 304 250 - 425 mcg/dL % Transferrin Saturation 17 15 - 50 % Ferritin Collection Time: 08/02/23 2:24 AM Result Value Ref Range Ferritin 385 (H) 14 - 338 ng/mL Vitamin B12 and Folate Levels Collection Time: 08/02/23 2:24 AM Result Value Ref Range Vitamin B12 1,073 (H) 271 - 1,000 pg/mL Folate 10.3 > 5.4 ng/mL

Diagnostic Studies: CT CHEST IV CONTRAST ONLY

Result Date: 8/2/2023

INDICATION: Patient age:Male; 62 years old; Reason for study: Sepsis without acute organ dysfunction, due to unspecified organism (CMS/HCC); Aspiration, . COMPARISON: None. TECHNIQUE: Multiple axial images were obtained through the chest following the administration of 75 cc of Isovue 370. One or more CT dose reduction strategies were utilized during this examination. Coronal and sagittal reformatted images were obtained for review. Total DLP administered was 565 mGycm. Total number of CT examinations in past 12 months prior to today: 0. FINDINGS: Beam hardening artifacts present secondary to upper extremities adjacent to the scanned field, which obscures detail limits evaluation. LUNGS/ PLEURA: Trace left-sided pleural effusion. Centrilobular and emphysematous changes are noted bilaterally, predominantly affecting the lung apices. There is scarring versus atelectasis noted within the right lung base. AIRWAY: The central airway is patent.. HEART: Size within normal limits. . MEDIASTINUM: No gross evidence of adenopathy. VASCULATURE: No aortic aneurysm. MUSCULOSKELETAL: Mild degenerative disc disease changes are present throughout the thoracolumbar spine. SOFT TISSUES/LYMPH NODES: Unremarkable. LOWER NECK: No significant findings. UPPER ABDOMEN: 3.1 cm simple fluid attenuating cyst at the left upper pole. Partially visualized PEG tube seen in appropriate positioning. Small accessory splenule is noted just medial to the spleen. The bilateral adrenal glands appear slightly hypertrophic without appreciable evidence of adrenal nodules IMPRESSION: 1. Trace left-sided pleural effusion with associated passive atelectasis. 2. Emphysematous changes. 3. Left renal simple cyst, 3.1 cm. 4. PEG tube noted, in appropriate positioning. 5. Hypertrophic bilateral adrenal glands.

CT HEAD W/O IV CONTRAST

Result Date: 8/1/2023

INDICATION: Patient age:Male; 62 years old; Reason for study: Altered mental status. COMPARISON: None. TECHNIQUE: Multiple axial CT images of the brain were obtained without IV contrast. One or more CT dose reduction strategies were utilized during this examination. Coronal and sagittal reformats were also obtained. Total DLP administered was 883 mGycm. Total number of CT examinations in past 12 months prior to today: 0. FINDINGS: Extra-axial spaces: No abnormal extra-axial fluid collections. Ventricular system: Dilatation in proportion to cerebral atrophy. Cerebral parenchyma: Cerebral atrophy. No acute intraparenchymal hemorrhage or mass effect. The gray-white junction is well differentiated. Patchy hypoattenuating areas within the periventricular and subcortical white matter. Cerebellum: Unremarkable. Mass effect: No evidence of midline shift. Intracranial vasculature: unremarkable Soft tissues: Normal. Calvarium/osseous structures: No depressed skull fracture. Paranasal sinuses and mastoid air cells: Clear. Visualized orbits: Orbital contents are intact. IMPRESSION: 1. No acute intracranial process. 2. Nonspecific white matter changes, likely secondary to chronic small vessel ischemic disease.

CHEST 1 VIEW AP/PA

Result Date: 8/1/2023

CLINICAL INDICATION: Shortness of breath COMPARISON: None TECHNIQUE: Single frontal radiograph of the chest was obtained portably. FINDINGS: The lungs are clear with no evidence for pneumothorax, pleural effusion, or focal consolidation. Bibasilar atelectasis. The cardiomediastinal silhouette is within normal limits. There is no acute osseous pathology. IMPRESSION Bibasilar atelectasis.

ECG

Result Date: 8/1/2023

Kaiser Alexander, Diane L, DO 8/1/2023 5:48 PM ECG Date/Time: 8/1/2023 5:47 PM Performed by: Kaiser Alexander, Diane L, DO Authorized by: Carline, Christine, DO Contemporaneously ECG reviewed by ED Physician in the absence of a cardiologist: yes Interpretation: Interpretation: non-specific Rate: ECG rate assessment: tachycardic Rhythm: Rhythm: sinus tachycardia Ectopy: Ectopy: none QRS: QRS axis: Right Conduction: Conduction: normal ST segments: ST segments: Normal T waves: T waves: normal

Active Hospital Problems Diagnosis Altered mental status, unspecified altered mental status type Sepsis without acute organ dysfunction (CMS/HCC) Urinary tract infection associated with indwelling urethral catheter (CMS/HCC) Community acquired pneumonia Altered mental status

Problem List:

Hx of Anoxic brain injury: AMS and Debility: -Patient with change in baseline mental status and daily activity -Suspect 2/2 new baseline vs. Polypharmacy vs. other -Family with concern regarding patient current care plan -Patient is status post anoxic brain injury on 5/23, following V. tach arrest with delayed return of ROSC until 60 minutes -Prior baseline was ambulatory, employed, and fully functioning; new baseline -ABG, LA, troponin, TSH, beta hydroxybutyrate all grossly WNL -CT head: Negative for acute intracranial process -SLP for swallow evaluation, nutrition for management -Consult PMR, PTOT to evaluate -Consult Neurology for medication management and baseline determination; note prior hx of seizures. Leukocytosis, unknown etiology: -Patient with altered mental status, no known sources of infection -WBC 13.7 on admission, Pro-Cal 0.42 -CXR: Bibasilar infiltrate -UA: LE 3+, WBC greater than 50, 2+ bacteria -Patient prior urine culture positive for MDR organism (Enterobacter), which was noted to be resistant to Zosyn, but sensitive to cefepime -CT chest: Trace left-sided pleural effusion with associated passive atelectasis -Urine, blood cultures pending -Initially placed on Vanc, Zosyn for suspected HAP -Changed antibiotic regimen to vanc, cefepime, and Flagyl (see reason above) -Consider consult to infectious disease for further antibiotic management Atrial flutter: History of V-tach arrest: -Patient with history of atrial flutter on Eliquis -V. tach arrest on 5/21 with return of ROSC after 60 minutes and subsequent anoxic brain injury -Patient follows with cardiology -Continue on home amiodarone, Eliquis, Plavix, and Lopressor home while admitted with holding parameters -Consider consult to cardiology and continue to monitor T2DM: -Patient baseline A1c and hemoglobin unknown -Consider A1c this admission -Glucose 432 on admission, later decreased to 137 -Patient trialed on low-dose sliding scale Urinary retention: -Patient with history of urinary retention secondary to neurogenic bladder from anoxic brain injury -Added regular bladder scans -Maintain Foley catheter during admission Maintenance Care: Pain Mgmt: Multimodal GI PPx: Protonix Diet: N.p.o. IVF: None I/Os: Monitor as needed Glucose: (goal is <180, >140) Vitals per floor protocol AM labs include: CBC, Mg, RFP Patient Safety:

DVT prophylaxis: Subcutaneous heparin Infection risks (IV, foley): IV, Foley Activity: Other (sitter, fall risk, TMS, procautions): High risk fall precautions Code Status/DPOA: DNI/DNR PT/OT to evaluate and treat Case management for discharge planning

Sepsis reassessment completed on 8/2/2023 at 5:37 AM/sepsis not suspected at this time

Cameron Hubbard, DO Internal Medicine | PGY-1 Mobile Heartbeat // #314842

Electronically signed by William Rudy at 08/02/2023 11:26 AM EDT

Associated attestation - William Rudy - 08/02/2023 11:26 AM EDT Formatting of this note might be different from the original. Patient was seen and examined on rounds Reviewed H&P as documented by Dr. Hubbard concur in principle with documentation

Procedure Notes - documented in this encounter Kelli V - 08/26/2023 4:46 PM EDT

Associated Order(s): Proceduralist Line Insertion Formatting of this note might be different from the original. Patient name: Ioan Suiugan Patient MRN: 9942681 Date:8/26/2023

Person Inserting Line:KVanoverbeke,RN

Proceduralist Line Insertion

Date/Time: 8/26/2023 4:46 PM

Performed by: Vanoverbeke, Kelli M, RN

Authorized by: Rudy, William M, DO

Select Line: Extended Dwell (no IVTBD) Indications for Midline/PICC: Difficult Access/Blood Draws Patient Properly Positioned: Yes Hand Hygiene Completed: Yes Maximum Barrier Used: Yes Chlorhexidine Used Immediately Prior: Yes Sterile technique maintained: Yes Local Anesthetic: None

Inserted By: RN Team: FMH-IV Team Supervising Physician: Na Catheter size (Fr): 18 (gauge) Vein diameter (mm): Na Catheter to Vein percentage: 29% Catheter type: Non-valved, Non-tunneled and Power injectable Lot#/: REHQ4269 Manufacturer and Device type: BARD/POWERGLIDE PRO MIDLINE Catheter length (cm): 10 Initial Exposed Catheter: 0 Initial Extremity Circumference: 33 Custom cut tip: No Orientation: Right Location: Brachial

Pertinent clinical contraindications to site location use: No Contraindications Placement Verified: Ultrasound Confirmation Ultrasound used? US use required for placement unless subclavian: Yes Securement Method: Securement device (stat lock) Acknowledge the guidewire was removed: Yes (part of device) Name of person who acknowledged guidewire was removed: NA Guidewire integrity intact: Yes Insertion attempts: 2 Complications: Successful insertion (comment) Patient tolerance: Tolerated well Patient / family / significant other educated: Yes

Procedure Notes/Comments:

Person Completing Form: Kelli VanOverbeke, RN Electronically signed by Kelli V at 08/26/2023 4:49 PM EDT Daniesa A - 08/05/2023 9:27 AM EDT Associated Order(s): Proceduralist Line Insertion

Formatting of this note might be different from the original. Patient name: Ioan Suiugan Patient MRN: 9942681 Date:8/5/2023

Person Inserting Line:D.AARON, RN

Proceduralist Line Insertion

Date/Time: 8/5/2023 9:27 AM

Performed by: Aaron, Daniesa M, RN

Authorized by: Rudy, William M, DO

Select Line: Midline Single Lumen (POWERGLIDE, ABX, NO IVTBD) Indications for Midline/PICC: Antibiotics Patient Properly Positioned: Yes Hand Hygiene Completed: Yes Maximum Barrier Used: Yes Chlorhexidine Used Immediately Prior: Yes Sterile technique maintained: Yes : NA.

Inserted By: RN Team: FMH-IV Team Supervising Physician: Rudy Catheter size (Fr): 18 Vein diameter (mm): NA Catheter to Vein percentage: 28% Catheter type: Non-valved and Power injectable Lot#/: REHS3815 Manufacturer and Device type: BARD/POWERGLIDE Catheter length (cm): 10 Initial Exposed Catheter: 0 Initial Extremity Circumference: 29 Custom cut tip: No Orientation: Right Location: Brachial If femoral chosen, were other sites considered?: No Pertinent clinical contraindications to site location use: No Contraindications Placement Verified: Ultrasound Confirmation Ultrasound used? US use required for placement unless subclavian: Yes Securement Method: Securement device Acknowledge the guidewire was removed: Yes Name of person who acknowledged guidewire was removed: NA Guidewire integrity intact: Yes Insertion attempts: 1 Complications: Successful insertion (comment) Patient tolerance: Tolerated well Patient / family / significant other educated: Yes

Procedure Notes/Comments:

Person Completing Form: Daniesa M Aaron, RN Electronically signed by Daniesa A at 08/05/2023 9:29 AM EDT

Consult Notes - documented in this encounter

Amal Khalife - 08/27/2023 9:54 AM EDT

Associated Order(s): CONSULT TO PHYSICIAN

Formatting of this note is different from the original. Images from the original note were not included. INFECTIOUS DISEASES NEW CONSULTATION NOTE Patient Name: Ioan Suiugan; Patient MRN: 9942681 Admission Date: 8/1/2023; Hospital Day: 26

Attending: Rudy, William M, DO ID Attending: Amal A Khalife, DO Date of Consultation: 8/26/2023 Time of Consultation: 1:29 PM

Reason for Consultation: New fever, recently completed abx course

Assessments & Plan:

Other

Sepsis without acute organ dysfunction (CMS/HCC) Assessment & Plan Presentation to ED 8/1 with altered mental status S/p CPA 5/2023, low grade temp in ED 100.6 Hx MDR enterobacter 7/2023 from urine cx CT chest with L sided pleural effusion, oxygenating well on RA

?aspiration vs GU vs other Check procalcitonin, legionella/pneumococcal Ag, MRSA screen Consider CTAP Continue current abx for now

8/4: procal 0.50. Await MRSA screen. Continue current abx for now

8/7 MRSA screen not collected, WBC trending down. Remains on broad spectrum abx; anticipate today is the last day of antibiotics with IV cefepime and flagyl (7 days) of empiric treatment. Strep and legionella are negative; urine cutlure with Enterobacter from 8/1. Will stop IV vancomycin given lack of staph aureus on cultures.

8/27 Asked to reeval pt given new onset fever. Continue IV ceftriaxone/flagyl; will initiate IV azithromycin and vancomycin today. Follow up repeat blood cultures which are in process. Noted repeat CXR, likely persistent PNA process at play. If continues to be febrile with negative cultures, would obtain repeat imaging with CT CAP.

Please obtain weekly labs while on IV antibiotics, CBCD BUN Crt LFT to monitor for meylo, hepato and renal toxicities

Amal A Khalife, DO 1:29 PM 08/26/23

History of Present Illness: Mr. Suiugan is a 62y.o. year old male with a history noted below

Pt is seen by ID most recently on 8/7 for sepsis - he presented altered, and CT chest noted left sided pleural effusion; concern for aspiration vs GU source - and completed 7d of IV cefepime and flagyl in addition to IV vancomycin.

He had new fever yesterday, and ID was re-consulted. Tmax 101.3 and again this AM 100.1. He was started on IV ceftriaxone, flagyl and azithromycin. Repeat blood cultures are presently in process. MRSA nares pending - but was positive as of 8/11. Blood cultures on 8/23 are negative to date.CXR yesterday noted persistent R basilar streaky opacities.

RRT called for fever, pt was lethargic, Tmax 101.3 Tube feeds held

Review of Systems:

See HPI

Past Medical and Surgical History: No past medical history on file. No past surgical history on file.

Allergies: Not on File

Home Medications:

Medications Prior to Admission Medication Sig Dispense Refill Last Dose acetaminophen (TYLENOL) 325 MG PO Tab 2 Tablets every 4 hours as needed. Unknown amiodarone (CORDARONE, PACERONE) 200 MG PO Tab 1 Tablet once daily. Unknown apixaban (ELIQUIS) 5 MG PO Tab take 1 Tablet by mouth twice daily. Unknown Ascorbic Acid 250 MG PO Tab 1 Tablet once daily. Unknown atorvastatin (LIPITOR) 40 MG PO Tab 1 Tablet once every night at bedtime. Unknown clopidogrel (PLAVIX) 75 MG PO Tab 1 Tablet once daily. Unknown LORazepam (INTENSOL) 2 MG/ML PO Conc 0.5 mL every 6 hours as needed for FOR AGITATION. Unknown metoprolol (LOPRESSOR) 25 MG PO Tab 1 Tablet twice daily. Unknown nicotine (NICODERM) 14 mg/24hr TRANSDERM PATCH 24 HR place 1 Patch onto the skin every 24 hours. Unknown OLANZapine (ZyPREXA) 10 MG PO Tab 1 Tablet twice daily. Unknown polyethylene glycol 3350 (MIRALAX) 17 GM/SCOOP PO Powder take 17 g by mouth once daily. Unknown tamsulosin (Flomax) 0.4 MG PO Cap take 1 Capsule by mouth once daily. Take 30 minutes after the same meal each day. Unknown [DISCONTINUED] HYDROcodone-acetaminophen (NORCO) 5-325 MG PO Tab 1 Tablet 3 times daily. X 7 days Unknown [DISCONTINUED] insulin lispro (HumaLOG) 100 UNIT/ML INJ Solution inject 1-6 Units into the skin 4 times daily. Sliding scale Unknown [DISCONTINUED] valproate (DEPAKENE) 250 MG/5ML PO Solution take 20 mL by mouth twice daily. Unknown [DISCONTINUED] valproate (DEPAKENE) 250 MG/5ML PO Solution 10 mL once daily. Unknown **Current Medications: Current Facility-Administered Medications** Medication Dose Route Frequency albuterol-ipratropium (DUONEB) nebulizer solution 3 mL 3 mL Inhalation RT-QID amiodarone (CORDARONE, PACERONE) tablet 200 mg 200 mg PEG Tube DAILY apixaban (ELIQUIS) tablet 5 mg 5 mg Oral Q 12 H atorvastatin (LIPITOR) tablet 40 mg 40 mg PEG Tube Q HS azithromycin (ZITHROMAX) 500 mg in sodium chloride 0.9 % 255 mL IVPB 500 mg Intravenous Q 24 H cefTRIAXone (ROCEPHIN) 1 g in sodium chloride 0.9 % 100 mL IVPB 1 g Intravenous Q 24 H clonazePAM (KlonoPIN) tablet 0.5 mg 0.5 mg Oral DAILY clonazePAM (KlonoPIN) tablet 1 mg 1 mg PEG Tube Q HS clopidogrel (PLAVIX) tablet 75 mg 75 mg Oral DAILY gentamicin (GARAMYCIN) 0.1 % cream Topical TID hydrocortisone (HYTONE) 1 % ointment Topical DAILY insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units 2-5 Units Subcutaneous Q 6 H metoprolol (LOPRESSOR) tablet 25 mg 25 mg PEG Tube BID metroNIDAZOLE (FLAGYL) infusion 500 mg 500 mg Intravenous Q 8 H OLANZapine (ZyPREXA) tablet 10 mg 10 mg Oral BID sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Q 12 H valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg 1,000 mg Oral BID

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate

Current Facility-Administered Medications Medication Dose Route Frequency Last Rate acetaminophen (TYLENOL) tablet 650 mg 650 mg PEG Tube Q 4 H PRN albuterol-ipratropium (DUONEB) nebulizer solution 3 mL 3 mL Inhalation Q 4 H PRN LORazepam (ATIVAN) tablet 0.5 mg 0.5 mg Oral Q 6 H PRN sodium chloride 0.9 % flush injection 10 mL 10 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 20 mL 20 mL Intravenous Per Administration Instructions sodium chloride 0.9 % flush injection 3 mL 3 mL Intravenous PRN sodium chloride 0.9% flush injection 10 mL 10 mL Intravenous ONCE PRN

Immunizations:

There is no immunization history on file for this patient.

Social History:

Social History

Socioeconomic History Marital status: Divorced

Family History: No family history on file.

Physical Examination:

Temp (!) 101.3 °F (38.5 °C) (08/26/23 1139) Source Axillary (08/26/23 1139) BP 116/64 (08/26/23 1139) Heart Rate 115 (08/26/23 1139) Resp 22 (08/26/23 1139) O2 (L/min) 2 L/min (08/24/23 0702) SpO2 96 % (08/26/23 0722) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/23/23 0600) BMI 24.6 (08/23/23 0600) Flowsheet Data Statistics (last 36 hours)

Flowsheet Row Name Min Max BP: Systolic 95 149 BP: Diastolic 64 79 Temp 97.6 °F (36.4 °C) 101.3 °F (38.5 °C) Heart Rate 81 115 Resp 18 22 SpO2 93 % 100 %

Constitutional: Appears lethargic HENT: NC, nasal cannula Eyes: no icterus, no conjunctival injection or hemorrhages, no pallor. Cardiovascular: Regular rate and rhythm, no murmurs, rubs or gallops, Pulmonary/Chest: No use of accessory muscle, CTAB, diminished BS, and rhonchi, Gastrointestinal: Abdomen was soft, non-tender, non-distended, BS x4,PEG in place Musculoskeletal: No cyanosi Neurological: Alert Skin: No acute skin rash.

Indwelling Devices: Lines, Drains, and Airways

Drain Duration

Gastrostomy/Enterostomy Percutaneous endoscopic gastrostomy-jejunal (PEG/J) LUQ 24 days Urethral Catheter Temperature probe 126 Fr. 24 days

Pressure Injury Duration

Pressure Injury 08/02/23 Sacrum Center 24 days

Wound Duration

Wound 08/02/23 Abrasion Right; Anterior Knee 24 days

Laboratory Data:

Recent Labs Component 08/26/23 1230 08/23/23 0036 08/20/23 1417 08/18/23 0403 WBC 7.0 12.4* 9.8 8.8 RBC 4.04* 4.91 4.70 4.49 HGB 11.6* 14.5 13.8 13.1* MCV 91 92 93 93 MCHCC 32 32 32 31* PLT 189 201 216 256 MONO 1.3* -- 1.5* 1.1* *Asterisks denote abnormal values Recent Labs

```
Component 08/26/23
1230 08/23/23
0036 08/20/23
1417 08/18/23
0403 08/03/23
0626 08/02/23
0541
NA 136 135 139 138 < > 148*
K 3.0* 4.1 3.6 3.6 < > 4.0
CL 103 101 104 105 < > 117*
CO2 23 24 25 26 < > 26
ANIONGAP 10 10 10 7 < > 5
BUN 12 16 13 13 < > 24
CREAT 0.57* 0.64 0.60 0.62 < > 0.67
ALB 2.4* -- 2.6* 2.6* < > 2.7* | 2.7*
GLOBULIN 3.6 -- 3.7 -- -- 4.1*
AGRATIO 0.7 -- 0.7 -- -- 0.7
ALP 123* -- 133* -- -- 90
AST 46* -- 24 -- -- 17
ALT 39 -- 19 -- -- 12
BILITOTAL 0.2* -- 0.3 -- -- 0.5
< > = values in this interval not displayed.
*Asterisks denote abnormal values
URINALYSIS
Recent Labs
Component 08/01/23
1731
COLOR Yellow
CLARITY Cloudy*
GLUCOSEUR >=500*
BILIUR Negative
KETONES Negative
SPECGRAVUR 1.010
BLOODUR 3+*
PHUR 7.5
PROTEINUR 10*
UROBILUR < 2.0
NITRITESUR Negative
LEUKESTUR 3+*
WBCUR > 50*
SQUAMEPIUR 6-30
HYALCASTUR 0-2 (Negative)
BACTERIAUR 2+*
```

Microbiology and Molecular:

Blood cultures 8/27 in process

Imaging and Other Diagnostic Data:

CHEST 1 VIEW AP/PA

Result Date: 8/26/2023

INDICATION: Fever. COMPARISON: Chest radiograph 8/23/2023, 8/21/2023. TECHNIQUE: Frontal portable chest radiograph obtained at 1224 hours on 8/26/2023 FINDINGS: Patient is rotated to the left. Lungs: Persistent streaky opacities at the right lung base from most recent exam. Left lung remains clear. No pleural effusions or pneumothorax. Vasculature: Normal. Heart: Normal in size. Mediastinum: within normal limits. Musculoskeletal: Degenerative changes throughout the spine. No acute osseous process. Other findings: No significant. IMPRESSION: Persistent right basilar streaky opacities again either from subsegmental atelectasis versus airspace process.

ECG

Result Date: 8/25/2023

Test Reason : Blood Pressure : */* mmHG Vent. Rate : 123 BPM Atrial Rate : 123 BPM P-R Int : 148 ms QRS Dur : 88 ms QT Int : 322 ms P-R-T Axes : 63 68 69 degrees QTc Int : 460 ms Sinus tachycardia Nonspecific ST abnormality Abnormal ECG When compared with ECG of 01-AUG-2023 17:39, No significant change was found Confirmed by Grodman, Robert (486) on 8/25/2023 10:45:47 AM Referred By: Confirmed By: Robert Grodman

Result Date: 8/23/2023

INDICATION: Evaluate for aspiration. COMPARISON: Chest radiograph 8/21/2023, 8/1/2023. TECHNIQUE: Frontal portable chest radiograph obtained at 0316 hours on 8/23/2023 FINDINGS: Patient is rotated to the right Lungs: Streaky right basilar opacities are new. Left lung is clear. No pleural effusions or pneumothorax. Vasculature: Normal. Heart: Normal in size. Mediastinum: within normal limits. Musculoskeletal: The osseous structures are intact. Other findings: No significant. IMPRESSION: New streaky right basilar opacities either from subsegmental atelectasis or airspace process such as pneumonitis/pneumonia

ABDOMEN KUB OR ABDOMEN 1 VIEW

Result Date: 8/23/2023

CLINICAL INDICATION: Concern for ileus, altered mental status and sepsis COMPARISON: Chest radiographs 8/23/2023 and 8/21/2023 TECHNIQUE: Single view frontal supine radiographs of the abdomen obtained portably at 0318 hours on 3/23/2023. FINDINGS: PEG tube projects over the left upper abdomen. Air-filled loops of colon and small bowel without abnormal dilatation are scattered throughout the abdomen and pelvis. There is no evidence for organomegaly. No abnormal calcifications. The osseous structures are intact. IMPRESSION 1. No current radiographic evidence for acute process 2. PEG tube present

CHEST 1 VIEW AP/PA

Result Date: 8/21/2023

CLINICAL INDICATION: Other cough COMPARISON: 8/1/2023 TECHNIQUE: Single view chest in semiupright AP projection FINDINGS: Cardiac size appears normal. The trachea is not abnormally deviated. No focal airspace opacities identified bilateral lungs. No pleural effusion/pneumothorax seen. Soft tissues and bony cage appear normal. IMPRESSION: No acute cardiopulmonary process

ELECTROENCEPHALOGRAM

Result Date: 8/4/2023

PROCEDURE DATE: 08/03/2023 STUDY: THIS IS A 17-CHANNEL EEG RECORDED USING THE INTERNATIONAL 10/20 SYSTEM AND WAS REVIEWED IN BOTH REFERENTIAL AND BIPOLAR MONTAGES. EEG #: 230570. CLINICAL HISTORY: This is a 62-year-old male with anoxic encephalopathy and agitation, evaluate for epileptiform correlation. EEG DESCRIPTION: This EEG was obtained during awake and drowsy states. During periods of maximal wakefulness, there was a background of symmetric, low voltage, poorly-modulated and disorganized activity with a background that is difficult to discern. The recording was obscured by lead artifact. During drowsiness, there was symmetric attenuation of the background rhythm. Stepwise photic stimulation did not result in significant posterior driving response. Hyperventilation was not performed due to the patient's clinical condition. EKG was regular rhythm. EEG DIAGNOSIS: This EEG is abnormal due to the presence of: Diffuse background slowing and disorganization. CLINICAL INTERPRETATION: The diffuse slowing mentioned above is indicative of a severe encephalopathy, which could be of toxic, metabolic, or vascular etiology. Clinical correlation is recommended. It is noted that the recording is limited due to artifact. If seizure remains of strong clinical consideration, then a repeat or prolonged study may be of benefit. There were no epileptiform discharges noted. DD: 08/04/2023 09:31:54 DT: 08/04/2023 09:53:56 Job #: 382958/1001474254 Revision #:

CT CHEST IV CONTRAST ONLY

Result Date: 8/2/2023

INDICATION: Patient age:Male; 62 years old; Reason for study: Sepsis without acute organ dysfunction, due to unspecified organism (CMS/HCC); Aspiration, . COMPARISON: None. TECHNIQUE: Multiple axial images were obtained through the chest following the administration of 75 cc of Isovue 370. One or more CT dose reduction strategies were utilized during this examination. Coronal and sagittal reformatted images were obtained for review. Total DLP administered was 565 mGycm. Total number of CT examinations in past 12 months prior to today: 0. FINDINGS: Beam hardening artifacts present secondary to upper extremities adjacent to the scanned field, which obscures detail limits evaluation. LUNGS/ PLEURA: Trace left-sided pleural effusion. Centrilobular and emphysematous changes are noted bilaterally, predominantly affecting the lung apices. There is scarring versus atelectasis noted within the right lung base. AIRWAY: The central airway is patent.. HEART: Size within normal limits. . MEDIASTINUM: No gross evidence of adenopathy. VASCULATURE: No aortic aneurysm. MUSCULOSKELETAL: Mild degenerative disc disease changes are present throughout the thoracolumbar spine. SOFT TISSUES/LYMPH NODES: Unremarkable. LOWER NECK: No significant findings. UPPER ABDOMEN: 3.1 cm simple fluid attenuating cyst at the left upper pole. Partially visualized PEG tube seen in appropriate positioning. Small accessory splenule is noted just medial to the spleen. The bilateral adrenal glands appear slightly hypertrophic without appreciable evidence of adrenal nodules IMPRESSION: 1. Trace left-sided pleural effusion with associated passive atelectasis. 2. Emphysematous changes. 3. Left renal simple cyst, 3.1 cm. 4. PEG tube noted, in appropriate positioning. 5. Hypertrophic bilateral adrenal glands.

CT HEAD W/O IV CONTRAST

Result Date: 8/1/2023

INDICATION: Patient age:Male; 62 years old; Reason for study: Altered mental status. COMPARISON: None. TECHNIQUE: Multiple axial CT images of the brain were obtained without IV contrast. One or more CT dose reduction strategies were utilized during this examination. Coronal and sagittal reformats were also obtained. Total DLP administered was 883 mGycm. Total number of CT examinations in past 12 months prior to today: 0. FINDINGS: Extra-axial spaces: No abnormal extra-axial fluid collections. Ventricular system: Dilatation in proportion to cerebral atrophy. Cerebral parenchyma: Cerebral atrophy. No acute intraparenchymal hemorrhage or mass effect. The gray-white junction is well differentiated. Patchy hypoattenuating areas within the periventricular and subcortical white matter. Cerebellum: Unremarkable. Mass effect: No evidence of midline shift. Intracranial vasculature: unremarkable Soft tissues: Normal. Calvarium/osseous structures: No depressed skull fracture. Paranasal sinuses and mastoid air

cells: Clear. Visualized orbits: Orbital contents are intact. IMPRESSION: 1. No acute intracranial process. 2. Nonspecific white matter changes, likely secondary to chronic small vessel ischemic disease.

CHEST 1 VIEW AP/PA

Result Date: 8/1/2023

CLINICAL INDICATION: Shortness of breath COMPARISON: None TECHNIQUE: Single frontal radiograph of the chest was obtained portably. FINDINGS: The lungs are clear with no evidence for pneumothorax, pleural effusion, or focal consolidation. Bibasilar atelectasis. The cardiomediastinal silhouette is within normal limits. There is no acute osseous pathology. IMPRESSION Bibasilar atelectasis.

ECG

Result Date: 8/1/2023

Kaiser Alexander, Diane L, DO 8/1/2023 5:48 PM ECG Date/Time: 8/1/2023 5:47 PM Performed by: Kaiser Alexander, Diane L, DO Authorized by: Carline, Christine, DO Contemporaneously ECG reviewed by ED Physician in the absence of a cardiologist: yes Interpretation: Interpretation: non-specific Rate: ECG rate assessment: tachycardic Rhythm: Rhythm: sinus tachycardia Ectopy: Ectopy: none QRS: QRS axis: Right Conduction: Conduction: normal ST segments: ST segments: Normal T waves: T waves: normal

Electronically signed by Amal Khalife at 08/27/2023 12:48 PM EDT

Savannah Grandy - 08/24/2023 8:48 AM EDT

Associated Order(s): CONSULT TO PHYSICIAN Formatting of this note is different from the original.

ATTENDING PHYSICIAN: Rudy, William M, DO

CONSULTATION INFORMATION: Consultant: Dr. McIntosh Specialty: Urology Reason for consultation: Penile edema Date of Admission: 8/1/2023

Chief Complaint: AMS

History of present Illness: This a 62y.o., male, presents from group home for AMS. Urology consulted for penile edema.

No past medical history on file. No past surgical history on file. No family history on file. Social History

Socioeconomic History Marital status: Divorced

Current Facility-Administered Medications:

acetaminophen (TYLENOL) tablet 650 mg, 650 mg, PEG Tube, Q 4 H PRN, Hubbard, Cameron Christopher, DO, 650 mg at 08/23/23 0103

albuterol-ipratropium (DUONEB) nebulizer solution 3 mL, 3 mL, Inhalation, Q 4 H PRN, Whitcomb, Sara M, RN NP-C, 3 mL at 08/23/23 0805

albuterol-ipratropium (DUONEB) nebulizer solution 3 mL, 3 mL, Inhalation, RT-QID, Saunders, Danielle M, RN NP-C, 3 mL at 08/23/23 1945

amiodarone (CORDARONE, PACERONE) tablet 200 mg, 200 mg, PEG Tube, DAILY, Hubbard, Cameron Christopher, DO, 200 mg at 08/23/23 0955

apixaban (ELIQUIS) tablet 5 mg, 5 mg, Oral, Q 12 H, Marchewka, Tiffany Christine, DO, 5 mg at 08/23/23 2050

atorvastatin (LIPITOR) tablet 40 mg, 40 mg, PEG Tube, Q HS, Hubbard, Cameron Christopher, DO, 40 mg at 08/23/23 2050

azithromycin (ZITHROMAX) 500 mg in sodium chloride 0.9 % 255 mL IVPB, 500 mg, Intravenous, Q 24 H, Arcand, Camilla T, RN NP-C, Stopped at 08/24/23 0445

cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB, 2 g, Intravenous, Q 8 H, Arcand, Camilla T, RN NP-C, Stopped at 08/24/23 0404

clonazePAM (KlonoPIN) tablet 0.5 mg, 0.5 mg, Oral, BID, Omar, Sabiha J, MD, 0.5 mg at 08/23/23 1323

clonazePAM (KlonoPIN) tablet 1 mg, 1 mg, PEG Tube, Q HS, Omar, Sabiha J, MD

clopidogrel (PLAVIX) tablet 75 mg, 75 mg, Oral, DAILY, Marchewka, Tiffany Christine, DO, 75 mg at 08/23/23 0954

gentamicin (GARAMYCIN) 0.1 % cream, , Topical, TID, Jones, Rosalind S, PA-C, Given at 08/24/23 0627

hydrocortisone (HYTONE) 1 % ointment, , Topical, DAILY, Grandy, Savannah, DO

insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units, 2-5 Units, Subcutaneous, Q 6 H, Marchewka, Tiffany Christine, DO, 2 Units at 08/09/23 1836

LORazepam (ATIVAN) tablet 0.5 mg, 0.5 mg, Oral, Q 6 H PRN, Omar, Sabiha J, MD, 0.5 mg at 08/23/23 1530 metoprolol (LOPRESSOR) tablet 25 mg, 25 mg, PEG Tube, BID, Hubbard, Cameron Christopher, DO, 25 mg at 08/23/23 2050

OLANZapine (ZyPREXA) tablet 10 mg, 10 mg, Oral, BID, Saunders, Danielle M, RN NP-C, 10 mg at 08/24/23 0846 sodium chloride 0.9 % flush injection 10 mL, 10 mL, Intravenous, Per Administration Instructions, Rudy, William M, DO sodium chloride 0.9 % flush injection 20 mL, 20 mL, Intravenous, Q 12 H, Rudy, William M, DO, 10 mL at 08/23/23 2051 sodium chloride 0.9 % flush injection 20 mL, 20 mL, Intravenous, Per Administration Instructions, Rudy, William M, DO sodium chloride 0.9 % flush injection 3 mL, 3 mL, Intravenous, Per Administration Instructions, Rudy, William M, DO sodium chloride 0.9 % flush injection 3 mL, 3 mL, Intravenous, PRN, Hubbard, Cameron Christopher, DO sodium chloride 0.9% flush injection 10 mL, 10 mL, Intravenous, ONCE PRN, Kaiser Alexander, Diane L, DO valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg, 1,000 mg, Oral, BID, Saunders, Danielle M, RN NP-C, 1,000 mg at 08/23/23 2050 Not on File

Review of Systems: A full review of 12 systems is completed and otherwise normal except as listed above. General ROS: no fever, chills, weakness, fatigue Respiratory ROS: no sob, cough Cardiovascular ROS: no cp, palpitations Gastrointestinal ROS: no nausea, emesis, diarrhea, constipation, abd pain, melena Genito-Urinary ROS: no dysuria, frequency, UI, urgency, hematuria, flank pain Musculoskeletal ROS: no pain, injury, nl ROM Neurological ROS: no parasthesias, weakness Dermatological ROS: no rash, pruritis, new lesions

Physical Examination: Vitals: 08/23/23 2010 08/23/23 2322 08/24/23 0702 08/24/23 0800 BP: 116/79 118/57 111/77 Pulse: 108 118 107 Resp: 20 20 20 Temp: 98.4 °F (36.9 °C) 99.5 °F (37.5 °C) 99.4 °F (37.4 °C) TempSrc: Axillary Axillary Axillary SpO2: 96% 96% 93% 91% Weight: Height: GENERAL ASSESSMENT: NAD, well nourished SKIN: normal color, no lesions HEAD: atraumatic, normocephalic MOUTH: normal mouth and throat and moist mucosa NECK: normal, supple, full range of motion CHEST: respiratory effort normal with no retractions, AP diameter appropriate HEART: capillary return brisk ABDOMEN: soft, non-distended, non-tender, no rebound/guarding GU: bladder soft, no flank tenderness, uncirc, test desc b/l and atrophic, NT, no masses, no ext genital lesions, 16 F yellow on tight tension w/ 3rd port cut, some excoriation about the penile foreskin/irritation EXTREMITY: no joint swelling NEURO: cranial nerves 2-12 normal, gross motor exam normal by observation

Labs Recent Labs Component 08/23/23 0036 08/20/23 1417 08/18/23 0403 WBC 12.4* 9.8 8.8 RBC 4.91 4.70 4.49 HGB 14.5 13.8 13.1* HCT 45.1 43.7 41.9 MCV 92 93 93 MCH 30 29 29 MCHCC 32 32 31* PLT 201 216 256 *Asterisks denote abnormal values

Recent Labs Component 08/24/23 0519 08/24/23 0117 08/23/23 1617 08/23/23 0538 08/23/23 0036 08/20/23 1617 08/20/23

1417 08/18/23 0521 08/18/23 0403 08/17/23 0532 08/17/23 0310 08/02/23 0602 08/02/23 0541 08/02/23 0159 08/01/23 1731 NA -- -- -- 135 -- 139 -- 138 -- 140 < > 148* -- 142 K -- -- -- 4.1 -- 3.6 -- 3.6 -- 4.6 < > 4.0 -- 4.6 CL -- -- -- 101 -- 104 -- 105 -- 104 < > 117* -- 112* CO2 -- -- 24 -- 25 -- 26 -- 28 < > 26 -- 23 ANIONGAP -- -- -- 10 -- 10 -- 7 -- 8 < > 5 -- 7 GLU 106 108 127 < > 176* < > 135* < > 133* < > 126* < > 137* < > 432* BUN -- -- -- 16 -- 13 -- 13 -- 16 < > 24 -- 23 CREAT -- -- -- 0.64 -- 0.60 -- 0.62 -- 0.65 < > 0.67 -- 0.77 ALB -- -- -- -- 2.6* -- 2.6* -- 2.6* < > 2.7* | 2.7* -- 2.9* GLOBULIN -- -- -- -- 3.7 -- -- -- 4.1* -- 4.2* AGRATIO -- -- -- -- 0.7 -- -- -- 0.7 -- 0.7 ALP -- -- -- -- 133* -- -- -- 90 -- 113 AST -- -- 17 -- 24 -- -- -- 17 -- 21 ALT -- -- 12 -- 19 -- -- -- 12 -- 14 BILITOTAL -- -- -- -- 0.3 -- -- -- 0.5 -- 0.3 < > = values in this interval not displayed. *Asterisks denote abnormal values

Assessment and Recommendation:

Urinary Balanitis Assessment & Plan 16 F 8/1 (Ucx + Enterobacter 8/1)

-Exchange foley catheter today

-Keep foley off tension

-Daily pericare

-Topical bacitracin per primary

-Will add 3 days of topical steroid

-F/u outpt with established urologist or Dr. McIntosh

Thank you for the opportunity to participate in your patient's care

Savannah Grandy, DO Urologic Surgery, PGY3 5868560058 Available on MH

Electronically signed by Gregory McIntosh at 08/24/2023 2:18 PM EDT

Associated attestation - Gregory McIntosh - 08/24/2023 2:18 PM EDT Formatting of this note is different from the original.

TEACHING PHYSICIAN ADDENDUM

I personally examined and evaluated the patient and discussed the case with the resident. I performed or was physically present during the critical and key portions of any findings. I reviewed the resident's interpretation. I confirmed the findings and agree with the assessment and plan of care for the patient and participated in the care and management, Any exceptions are noted.

Gregory McIntosh, DO Michigan Institute of Urology

Kristin Derderian - 08/03/2023 11:48 AM EDT

Associated Order(s): CONSULT TO PHYSICIAN Formatting of this note is different from the original. Images from the original note were not included.

INFECTIOUS DISEASES

NEW CONSULTATION NOTE Patient Name: Ioan Suiugan; Patient MRN: 9942681

AdmissionDate: 8/1/2023; Hospital Day: 3

Attending: Rudy, William M, DO ID Attending: Kristin M Derderian, DO

Date of Consultation: 8/3/2023 Time of Consultation: 11:07 AM

Reason for Consultation: leukocytosis

History of Present Illness: Mr. Suiugan is a62y.o. year old male who presented to the ED 8/1 with altered mental status. Hx anoxic brain injury s/p CPA 5/2023. Chart reviewed. Temp 100.6 in ED, O2 sat 99%RA Initially started on vancomycin and zosyn. Now receiving vancomycin, cefepime, flagyl

Review of Systems: In addition to the pertinent findings noted in the history, Review of systems not obtained due to patient factors.

Past Medical and Surgical History: No past medical history on file. No past surgical history on file.

PMH: CPA, anoxic brain injury, DM

Allergies: Not on File None per Trinity health Home Medications:

Medications Prior to Admission Medication Sig Dispense Refill Last Dose acetaminophen (TYLENOL) 325 MG PO Tab 2 Tablets every 4 hours as needed. Unknown amiodarone (CORDARONE, PACERONE) 200 MG PO Tab 1 Tablet once daily. Unknown apixaban (ELIQUIS) 5 MG PO Tab take 1 Tablet by mouth twice daily. Unknown Ascorbic Acid 250 MG PO Tab 1 Tablet once daily. Unknown atorvastatin (LIPITOR) 40 MG PO Tab 1 Tablet once every night at bedtime. Unknown clopidogrel (PLAVIX) 75 MG PO Tab 1 Tablet once daily. Unknown HYDROcodone-acetaminophen (NORCO) 5-325 MG PO Tab 1 Tablet 3 times daily. X 7 days Unknown insulin lispro (HumaLOG) 100 UNIT/ML INJ Solution inject 1-6 Units into the skin 4 times daily. Sliding scale Unknown LORazepam (INTENSOL) 2 MG/ML PO Conc 0.5 mL every 6 hours as needed for FOR AGITATION. Unknown metoprolol (LOPRESSOR) 25 MG PO Tab 1 Tablet twice daily. Unknown nicotine (NICODERM) 14 mg/24hr TRANSDERM PATCH 24 HR place 1 Patch onto the skin every 24 hours. Unknown OLANZapine (ZyPREXA) 10 MG PO Tab 1 Tablet twice daily. Unknown polyethylene glycol 3350 (MIRALAX) 17 GM/SCOOP PO Powder take 17 g by mouth once daily. Unknown tamsulosin (Flomax) 0.4 MG PO Cap take 1 Capsule by mouth once daily. Take 30 minutes after the same meal each day. Unknown valproate (DEPAKENE) 250 MG/5ML PO Solution take 20 mL by mouth twice daily. Unknown valproate (DEPAKENE) 250 MG/5ML PO Solution 10 mL once daily. Unknown **Current Medications:**

Current Facility-Administered Medications Medication Dose Route Frequency amiodarone (CORDARONE, PACERONE) tablet 200 mg 200 mg PEG Tube DAILY apixaban (ELIQUIS) tablet 5 mg 5 mg Oral Q 12 H atorvastatin (LIPITOR) tablet 40 mg 40 mg PEG Tube Q HS cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB 2 g Intravenous Q 8 H clopidogrel (PLAVIX) tablet 75 mg 75 mg Oral DAILY insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units 2-5 Units Subcutaneous Q 6 H metoprolol (LOPRESSOR) tablet 25 mg 25 mg PEG Tube BID metroNIDAZOLE (FLAGYL) infusion 500 mg 500 mg Intravenous Q 8 H OLANZapine (ZyPREXA) tablet 10 mg 10 mg Oral BID valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg 1,000 mg Oral BID vancomycin (VANCOCIN) 1,500 mg in sodium chloride 0.9 % 280 mL IVPB 1,500 mg Intravenous Q 12 H

Immunizations:

There is no immunization history on file for this patient.

Social History:

Social History

Socioeconomic History Marital status: Divorced

Family History: No family history on file.

Physical Examination:

Temp 98.2 °F (36.8 °C) (08/03/23 0843) Source Oral (08/03/23 0843) BP 132/91 (08/03/23 0843) Heart Rate 93 (08/03/23 0843) Resp 20 (08/03/23 0843) O2 (L/min) (not recorded) SpO2 99 % (08/03/23 0843) O2% 21 % (08/03/23 0724) Height 188 cm (6' 2'') (08/01/23 1727) Weight 99.8 kg (220 lb) (08/02/23 0300) BMI 28.2 (08/02/23 0300)

Flowsheet Data Statistics (last 36 hours)

Flowsheet Row Name Min Max BP: Systolic 120 159 BP: Diastolic 81 99 Temp 97 °F (36.1 °C) 99.1 °F (37.3 °C) Heart Rate 87 102 Resp 16 20 SpO2 92 % 100 % Weight 99.8 kg (220 lb) 99.8 kg (220 lb)

General - He appears chronically ill, NAD O2 sat 99%RA HEENT - NCAT, mucosa moist, no icterus Neck - trachea midline Chest - diminished bibasilar BS Heart - reg Abdomen - soft, min distended, peg site without erythema Extremities - warm Skin - no acute rashes Neuropsych -somnolent

Indwelling Devices: PIV

Laboratory Data:

Recent Labs Component 08/03/23 0626 08/02/23 0632 08/01/23 1731 WBC 16.0* 11.4* 13.7* RBC 4.39 4.19* 4.45 HGB 13.0* 12.3* 13.0* MCV 94 97 96 PLT 310 286 283 *Asterisks denote abnormal values Recent Labs Component 08/03/23 0626 08/02/23 0541 08/01/23 1731 NA 146* 148* 142 K 3.4* 4.0 4.6 CL 117* 117* 112* CO2 24 26 23 ANIONGAP 5 5 7 BUN 27* 24 23 CREAT 0.73 0.67 0.77 ALB 2.9* 2.7* | 2.7* 2.9*

GLOBULIN -- 4.1* 4.2* AGRATIO -- 0.7 0.7 ALP -- 90 113 AST -- 17 21 ALT -- 12 14 BILITOTAL -- 0.5 0.3 *denote abnormal values

Culture Data: COVID neg Blood cx neg thus far

Culture, Urine Order: 1442857483 Status: Preliminary result

Visible to patient: No (not released)

Next appt: None Specimen Information: Urine, Clean Catch 0 Result Notes Culture, Urine 10,000-100,000 CFU/ml Gram negative bacilli, oxidase negative Abnormal

Specimen Collected: 08/01/23 10:52 PM Last Resulted: 08/03/23 9:13 AM

Component 3 wk ago Comments Culture, Urine 100,000 CFU/mL Enterobacter cloacae-CRE Abnormal Organism phenotype suggests carbapenemase production.

This is an edited result. Previous organism was Gram negative bacilli on 7/13/2023 at 1124 EDT. Edited result: Previously reported as Enterobacter cloacae on 7/14/2023 at 1124 EDT. Result component has been updated to reportable to State Health. Resulting Agency TRINITY HEALTH ANN ARBOR HOSPITAL LABORATORY (SJAA) Susceptibility

Organism Antibiotic Method Susceptibility Enterobacter cloacae-CRE Aztreonam MIC >=64: Resistant Enterobacter cloacae-CRE Cefazolin MIC >=64: Resistant Enterobacter cloacae-CRE Cefepime MIC 2: Susceptible Enterobacter cloacae-CRE Ceftriaxone MIC >=64: Resistant Enterobacter cloacae-CRE Ceftriaxone MIC >=64: Resistant Enterobacter cloacae-CRE Ciprofloxacin MIC <=0.25: Susceptible Enterobacter cloacae-CRE Ertapenem MIC 4: Resistant Enterobacter cloacae-CRE Gentamicin MIC <=1: Susceptible Enterobacter cloacae-CRE Meropenem MIC <=0.25: Resistant Enterobacter cloacae-CRE Nitrofurantoin MIC 64: Intermediate Enterobacter cloacae-CRE Piperacillin/Tazobactam MIC >=128: Resistant Enterobacter cloacae-CRE Trimethoprim/Sulfamethoxazole MIC <=20: Susceptible Specimen Collected: 07/12/23 12:09 AM Last Resulted: 07/14/23 10:16 PM Received From: Trinity Health Result Received: 08/01/23 6:15 PM

Imaging and Other Diagnostic Data:

CT CHEST IV CONTRAST ONLY Exam Ended: 08/02/2023 1:34 AM Order #: 1442928230 Accession #: A33273177 Performing Department: RAD CT FH Associated Diagnoses: Sepsis without acute organ dysfunction, due to unspecified organism (CMS/HCC) Location: BOTSFORD HOSPITAL Reason for Exam: Aspiration

PACS Images

Show images for CT CHEST IV CONTRAST ONLY Study Result Narrative & Impression INDICATION: Patient age:Male; 62 years old; Reason for study: Sepsis without acute organ dysfunction, due to unspecified organism (CMS/HCC); Aspiration, .

COMPARISON: None.

TECHNIQUE: Multiple axial images were obtained through the chest following the administration of 75 cc of Isovue 370. One or more CT dose reduction strategies were utilized during this examination. Coronal and sagittal reformatted images were obtained for review. Total DLP administered was 565 mGycm.

Total number of CT examinations in past 12 months prior to today: 0.

FINDINGS:

Beam hardening artifacts present secondary to upper extremities adjacent to the scanned field, which obscures detail limits evaluation.

LUNGS/ PLEURA: Trace left-sided pleural effusion. Centrilobular and emphysematous changes are noted bilaterally, predominantly affecting the lung apices. There is scarring versus atelectasis noted within the right lung base. AIRWAY: The central airway is patent..

HEART: Size within normal limits. . MEDIASTINUM: No gross evidence of adenopathy. VASCULATURE: No aortic aneurysm.

MUSCULOSKELETAL: Mild degenerative disc disease changes are present throughout the thoracolumbar spine. SOFT TISSUES/LYMPH NODES: Unremarkable. LOWER NECK: No significant findings.

UPPER ABDOMEN: 3.1 cm simple fluid attenuating cyst at the left upper pole. Partially visualized PEG tube seen in appropriate positioning. Small accessory splenule is noted just medial to the spleen. The bilateral adrenal glands appear slightly hypertrophic without appreciable evidence of adrenal nodules

IMPRESSION:

1. Trace left-sided pleural effusion with associated passive atelectasis.

- 2. Emphysematous changes.
- 3. Left renal simple cyst, 3.1 cm.
- 4. PEG tube noted, in appropriate positioning.
- 5. Hypertrophic bilateral adrenal glands.

Assessment & Plan:

Other

Sepsis without acute organ dysfunction (CMS/HCC) Assessment & Plan Presentation to ED 8/1 with altered mental status S/p CPA 5/2023, low grade temp in ED 100.6 Hx MDR enterobacter 7/2023 from urine cx CT chest with L sided pleural effusion, oxygenating well on RA

?aspiration vs GU vs other Check procalcitonin, legionella/pneumococcal Ag, MRSA screen Consider CTAP Continue current abx for now Formatting of this note might be different from the original.

PSYCHIATRY CONSULTATION

DATE OF CONSULT: 08/02/2023

ATTENDING PHYSICIAN: William M Rudy, DO CONSULTING PHYSICIAN: Sam K Ajluni, MD

Inpatient Psychiatric Consultation

Time spent on consultation is 50 minutes with 50% of the time spent in coordination of care.

CHIEF COMPLAINT/HISTORY OF PRESENT ILLNESS: The patient is a 62-year-old Caucasian male, who is from Romania, who is a poor historian and history is provided by the patient's sister, who is present. The patient had an anoxic brain injury in May 2023 and has had altered mental status. Since that time, he has been having periods of agitation and aggression and has been combative with staff at his extended care facility. He has been progressively worse. He was brought into the hospital and his sister says he has actually been weaker, so he has been less of a behavioral problem since he has had an infection with his medical issues. The patient is unable to provide any history, as his thoughts are illogical and loose and very disorganized and is not able to answer questions appropriately.

PAST PSYCHIATRIC HISTORY: None.

FAMILY HISTORY: None.

SOCIAL HISTORY: The patient is divorced, with 2 children. He used to work as a truck driver and denies any heavy alcohol or drug use per the sister.

MENTAL STATUS EXAM: The patient is very disorganized and loose. He is in restraints and he is not able to answer questions and is speaking illogically and disorganized and is not able to answer questions on orientation, though he did answer that his name was John.

DIAGNOSES: Axis I: Mood disorder secondary to general medical condition. Axis II: Deferred. Axis III: Your diagnosis. Axis IV: Severe. Axis V: 30.

PLAN: Continue the patient on current medications and will be followed by the Psychiatric team for further behavioral stability.

Thank you for allowing me to participate in the care of this interesting patient.

DD: 08/03/2023 04:29:12 DT: 08/03/2023 05:30:47 Job #: 380520/1001340100 Revision #:

Electronically signed by Sam Ajluni at 08/31/2023 11:47 PM EDT

Vuk V - 08/02/2023 12:18 PM EDT

Associated Order(s): CONSULT NUTRITION SERVICES (DIETITIAN)

Formatting of this note is different from the original.

NUTRITION SERVICES CONSULT NOTE - ASSESSMENT Name: Ioan Suiugan-62y.o.Male MRN: 9942681 LOS: 1 Room:219A/B/219A Reason for Visit: Provider Consult Nutrition Therapy Protocol Yes

Objective: 62y.o.M presented to ED c/o altered mental status. Per Emergency Medicine Resident 8/1, pt is A&Ox1 and had a V. Tach cardiac arrest with subsequent anoxic brain injury in May 2023. Per Internal medicine Resident H&P 8/2, pt is currently on

restraints. Pt hyperglycemic upon admission but decreased glucose levels to 137.

Subjective: Pt visited, lying in bed. Dietetic intern asked pt questions, pt not being able to contribute. PEG tube in place running on 20 mL/hr. ECF show that pt was on Glucerna 1.2 at 75 mL/hr.

HISTORY OF PRESENT ILLNESS Chief Complaint Patient presents with • Altered Mental Status Patient arrived to ER from group home via EMS. Per EMS pts baseline is a+ox1+combative, family says he has been a+ox0 for the last 24 hours. POC at group home was 32 1 amp given by EMS

Active Hospital Problems

Diagnosis

- Altered mental status, unspecified altered mental status type
- Sepsis without acute organ dysfunction (CMS/HCC)
- Urinary tract infection associated with indwelling urethral catheter (CMS/HCC)
- Community acquired pneumonia
- Altered mental status

PATIENT RELATED HISTORY No past medical history on file. No past surgical history on file.

FOOD AND NUTRITION HISTORY:

Current Diet Order:

Orders Placed This Encounter

Adult Diet - Diet Consistency: Dysphagia; Dysphagia Diet: Pureed; Additional Restrictions: 1:1 Feed; Non Room Service Tube Feeding with Oral Diet - Tube Feed: Tube Feeding,; Product: Glucerna 1.5; Rate Goal ml/hr: 20; Tube Feeding Bolus Frequency: QID; Tube Feeding Water Flush (mL): 10; Water Flush Frequency: Other (specify) (q1hr); Non Room Service

Food Allergies: NKFA per chart.

Cultural/Religious Practices: Na

Appetite: TF Intake: Limited Epic history. Chewing/Swallowing: na

GI: na Skin: PI Stage II Sacrum Center, Wound r anterior knee per chart. Edema: None per chart.

```
BIOCHEMICAL DATA/ MEDICATIONS / TESTS / PROCEDURES:
Recent Labs
08/01/23
1731 08/02/23
0159 08/02/23
0541 08/02/23
0602 08/02/23
1017
NA 142 -- 148* -- --
K 4.6 -- 4.0 -- --
CL 112* -- 117* -- --
CO2 23 -- 26 -- --
GLU 432* < > 137* 132 157*
BUN 23 -- 24 -- --
CREAT 0.77 -- 0.67 -- --
EGFR 101 -- 106 -- --
CALCIUM 8.3* -- 8.2* -- --
MG 2.1 -- 2.1 -- --
PHOS 2.7 -- 3.2 -- --
ALB 2.9* -- 2.7* | 2.7* -- --
AST 21 -- 17 -- --
ALT 14 -- 12 -- --
ALP 113 -- 90 -- --
LIPASE 10 -- -- --
< > = values in this interval not displayed.
```

Medications: SCHEDULED: amiodarone, 200 mg, PEG Tube, DAILY apixaban (ELIQUIS) tablet DVT/PE TREATMENT CONTINUATION BEYOND 7 DAYS, 5 mg, Oral, Q 12 H atorvastatin, 40 mg, PEG Tube, Q HS cefepime (MAXIPIME) IVPB, 2 g, Intravenous, Q 8 H clopidogrel, 75 mg, Oral, DAILY insulin regular human, 2-5 Units, Subcutaneous, Q 6 H metoprolol, 25 mg, PEG Tube, BID metroNIDAZOLE (FLAGYL) intermittent infusion, 500 mg, Intravenous, Q 8 H vancomycin, 1,500 mg, Intravenous, Q 12 H

IVF:

PRN:

- acetaminophen
- sodium chloride
- sodium chloride 0.9%

Tests/Procedures:

8/2 CT chest IV contrast - pleural effusion, emphysematous changes, L renal simple cyst, and PEG tube noted in appropriate positioning.

NUTRITION FOCUSED PHYSICAL FINDINGS: Nutrition Focused Physical Exam: Visual Subcutaneous Fat Depletion Musculoskeletal Depletion Classification: Mild [x] Orbital region [x] Upper arm region -triceps/biceps [] Thoracic & lumbar region - ribs, lower back, midaxillary line Classification: Mild [x] Temporalis [x] Clavicle & acromion bone region [x] Clavicle bone region [] Scapular bone region [] Dorsal hand [x] Patellar region [x] Anterior thigh region [x] Posterior calf region

ANTHROPOMETRICS: Height: 188 cm (6' 2") Admit Weight: 99.8 kg (220 lb), Weight Source: Bed scale Body mass index is 28.25 kg/m². BMI Classification: Overweight

Amputation/Loss of Limb: None noted

Current Weight: 99.8 kg (220 lb), Weight Source: Bed scale IBW: 86.4 kg %IBW: 115 % UBW: na kg %UBW: na %

Wt Readings from Last 10 Encounters: 08/02/23 99.8 kg (220 lb)

Weight Change: Limited weight history in Epic.

ESTIMATED NUTRITIONAL NEEDS:

Calories: 2495+ kcal/day based on 25 kcal/kg using current body weight Protein: 125-150 gm/day based on 1.25-1.5 gm/kg using current body weight note PI stage II Fluid: 2495-2994 mL based on 1 mL/kcal or per provider. Adjust fluids based on intake and output to maintain fluid balance and hemodynamic stability

NUTRITION DIAGNOSIS: Inadequate enteral infusion related to altered mental status as evidenced by TF not meeting goal.

Increased protein needs related to wounds as evidenced by Pressure injury Stage II center Sacrum.

INTERVENTIONS Interventions: Saw pt /consult completed. Chart reviewed. Adjusted TF

Goals: TF to provide >90% nutrient needs. Prevent significant/unintentional weight loss. Pt to have evidence of wound healing.

MONITORING & EVALUATING TF tolerance. Pertinent labs. Weight trends.

Nutrition related discharge needs at this time - Pending clinical course.

Follow Up Range: unstable enteral nutrition 1-3 days

RECOMMENDATIONS: Recommendations: Glucerna 1.5 goal = 70 mL/hr. TF at goal provides: 2520 kcal, 138 gm protein, 1276 mL free H2O Enteral H2O: 40cc/hr Aspiration precautions, HOB > 30-45 degrees at all times. Add MVI.

Dietetic Intern: Vuk Vuckovic Available via Mobile Heartbeat" Electronically signed by Natalie F at 08/02/2023 2:42 PM EDT

Associated attestation - Natalie F - 08/02/2023 2:42 PM EDT Formatting of this note might be different from the original. 219A/B/219A Name: Ioan Suiugan MRN: 9942681 DOB: 2/27/1961

I saw and evaluated the patient. Discussed with the dietetic intern and agree with the dietetic intern's findings and plan as documented in the dietetic intern's note.

Saw pt with SLP in room, was on pureed/thin liquids for pleasure and ok to resume currently. PEG was primary source of nutrition.

Mild depletions observed in physical exam, suspect likely component of debilitated state, as pt does receive adequate TF at ECF. Will follow for oral intake, if contributory to nutrition will adjust TF accordingly.

No BM yet, will monitor. Will start standard 20cc/hr H2O flush. Defer advancement to physician. Katherine Ross - 08/02/2023 10:37 AM EDT

Associated Order(s): CONSULT TO PHYSICIAN

Formatting of this note is different from the original. Images from the original note were not included.

Michigan Institute For Neurological Disorders 28595 Orchard Lake Road ? Suite 200 ? Farmington Hills, MI 48334 (248) 553-0010 ? Fax: (248) 553-5957

Neurology Consultation

Patient's Name: Ioan Suiugan MRN: 9942681 Date of Birth: 2/27/1961 Age: 62 yrs Date of Admission: 8/1/2023 Date of Service: 8/2/2023 Attending Provider: Rudy, William M, DO Consulting Provider: Katherine E Ross, DO Primary Care Provider: Unknown, Per Patient

Reason for Consultation:

AMS

History of Present Illness:

This is a 62 year old male with PMH of anoxic brain injury in May of 2023 s/p Vtach arrest, DMII, atrial flutter on eliquis, and urinary retention that presented on 8/1 with the chief complaint of AMS. He was hospitalized from 5/11-6/16 for Vtach arrest with resulting anoxic brain injury. He was discharged to SAR following hospitalization but returned to an outside hospital for worsening mental status. Following this he was discharged to a group home. Per notes prior to discharge to group home, he was agitated, aggressive, and minimally interactive. At that time, patient was on depakote and zyprexa. Per family, he has progressively worsened since being discharged and there were concerns that he was not being cared for properly. His daughter stated that he was flailing his arms and yelling, which he reportedly does not do though this was documented on prior hospitalization. On EMS arrival, glucose was 32.

Upon arrival, vital signs were stable. Lab work was remarkable for WBC 13.7, glucose 432. UA contaminated though possibly consistent with infection. CT head showed no acute process. He currently is on antibiotics for concern of UTI vs. HAP. His depakote and zyprexa are currently held.

Past Medical History: No past medical history on file.

Past Surgical History: No past surgical history on file.

Allergies:

Not on File

Medications: Medication Administration Record reviewed.

Prior to Admission Medications Prescriptions Last Dose Informant Patient Reported? Taking? Ascorbic Acid 250 MG PO Tab Unknown Home Med List Yes Yes Sig: 1 Tablet once daily. HYDROcodone-acetaminophen (NORCO) 5-325 MG PO Tab Unknown Home Med List Yes Yes Sig: 1 Tablet 3 times daily. X 7 days LORazepam (INTENSOL) 2 MG/ML PO Conc Unknown Home Med List Yes Yes Sig: 0.5 mL every 6 hours as needed for FOR AGITATION. OLANZapine (ZyPREXA) 10 MG PO Tab Unknown Home Med List Yes Yes Sig: 1 Tablet twice daily. acetaminophen (TYLENOL) 325 MG PO Tab Unknown Home Med List Yes Yes Sig: 2 Tablets every 4 hours as needed. amiodarone (CORDARONE, PACERONE) 200 MG PO Tab Unknown Home Med List Yes Yes Sig: 1 Tablet once daily. apixaban (ELIQUIS) 5 MG PO Tab Unknown Home Med List Yes Yes Sig: take 1 Tablet by mouth twice daily. atorvastatin (LIPITOR) 40 MG PO Tab Unknown Home Med List Yes Yes Sig: 1 Tablet once every night at bedtime. clopidogrel (PLAVIX) 75 MG PO Tab Unknown Home Med List Yes Yes Sig: 1 Tablet once daily. insulin lispro (HumaLOG) 100 UNIT/ML INJ Solution Unknown Home Med List Yes Yes Sig: inject 1-6 Units into the skin 4 times daily. Sliding scale metoprolol (LOPRESSOR) 25 MG PO Tab Unknown Home Med List Yes Yes Sig: 1 Tablet twice daily. nicotine (NICODERM) 14 mg/24hr TRANSDERM PATCH 24 HR Unknown Home Med List Yes Yes Sig: place 1 Patch onto the skin every 24 hours. polyethylene glycol 3350 (MIRALAX) 17 GM/SCOOP PO Powder Unknown Home Med List Yes Yes Sig: take 17 g by mouth once daily. tamsulosin (Flomax) 0.4 MG PO Cap Unknown Home Med List Yes Yes Sig: take 1 Capsule by mouth once daily. Take 30 minutes after the same meal each day. valproate (DEPAKENE) 250 MG/5ML PO Solution Unknown Home Med List Yes Yes Sig: take 20 mL by mouth twice daily. valproate (DEPAKENE) 250 MG/5ML PO Solution Unknown Home Med List Yes Yes Sig: 10 mL once daily.

Facility-Administered Medications: None

Social History:

Family History:

family history is not on file.

Review of Systems:

Unable to obtain due to patient mentation

Physical Exam:

VS: BP 127/98 | Pulse 93 | Temp 97.6 °F (36.4 °C) (Axillary) | Resp 18 | Ht 188 cm (6' 2") | Wt 99.8 kg (220 lb) | SpO2 99% | BMI 28.25 kg/m²

General Exam:

CONSTITUTIONAL: Restless in bed. EYES: No conjunctival erythema. HENT: Head is normocephalic, atraumatic. CARDIOVASCULAR: Regular rate. RESPIRATORY: No use of accessory muscles. No audible wheezes. SKIN: Warm and dry. MUSCULOSKELETAL: No clubbing or cyanosis.Mitts and restraints in place. PSYCHIATRIC: Judgement and insight impaired. Restless in bed.

Complete Neurological Exam:

Mental Status: The patient is awake and alert. He does not answer questions. He attempts to speak at times but unable to understand speech. Not following commands.

Cranial Nerves:

I - Not examined

II, III - Difficult to assess pupils as patient volitionally closes his eyes and turns his head. However, appear reactive and equal on limited exam.

III, IV, VI - Extra-ocular muscles appear intact with tracking.

V - Grimaces to pinprick bilaterally

VII - No appreciable facial asymmetry at rest

VIII - Hearing appears grossly intact to voice

IX,X - Unable to assess

XI - Sternocleidomastoid and trapezius strength appears intact

XII - Unable to assess

Sensory: Intact to noxious stimuli in bilateral upper extremities.

Cerebellar: Unable to assess

Motor: Moving bilateral upper extremities spontaneously without difficulty. Does not withdraw bilateral LE to noxious stimuli. No adventitious movements. Plantar response equivocal bilaterally.

Gait: Casual gait is not assessed.

Diagnostic Studies:

CBC/Coags Metabolic Panel LFTs/Misc Recent Labs Component 08/02/23 0632 08/01/23 1731 WBC 11.4* 13.7* HGB 12.3* 13.0* HCT 40.5 42.6 MCV 97 96 MCH 29 29 MCHCC 30* 31* PLT 286 283 PT -- 13.7* INR -- 1.2 **Recent Labs** Component 08/02/23 0541

NA 148* K 4.0 CL 117* CO2 26 **BUN 24 CREAT 0.67** CALCIUM 8.2* **PHOS 3.2** MG 2.1 ANIONGAP 5 Recent Labs Component 08/02/23 0541 **ALP 90** AST 17 ALT 12 **BILITOTAL 0.5** ALB 2.7* | 2.7* GLOBULIN 4.1*

Imaging Studies:

Results for orders placed or performed during the hospital encounter of 08/01/23 CHEST 1 VIEW AP/PA Narrative CLINICAL INDICATION: Shortness of breath

COMPARISON: None

TECHNIQUE: Single frontal radiograph of the chest was obtained portably.

FINDINGS: The lungs are clear with no evidence for pneumothorax, pleural effusion, or focal consolidation. Bibasilar atelectasis. The cardiomediastinal silhouette is within normal limits. There is no acute osseous pathology.

IMPRESSION Bibasilar atelectasis.

CT HEAD W/O IV CONTRAST Narrative INDICATION: Patient age:Male; 62 years old; Reason for study: Altered mental status.

COMPARISON: None.

TECHNIQUE: Multiple axial CT images of the brain were obtained without IV contrast. One or more CT dose reduction strategies were utilized during this examination. Coronal and sagittal reformats were also obtained. Total DLP administered was 883 mGycm. Total number of CT examinations in past 12 months prior to today: 0.

FINDINGS:

Extra-axial spaces: No abnormal extra-axial fluid collections. Ventricular system: Dilatation in proportion to cerebral atrophy. Cerebral parenchyma: Cerebral atrophy. No acute intraparenchymal hemorrhage or mass effect. The gray-white junction is well differentiated. Patchy hypoattenuating areas within the periventricular and subcortical white matter.

Cerebellum: Unremarkable. Mass effect: No evidence of midline shift. Intracranial vasculature: unremarkable Soft tissues: Normal. Calvarium/osseous structures: No depressed skull fracture. Paranasal sinuses and mastoid air cells: Clear. Visualized orbits: Orbital contents are intact. IMPRESSION:

1. No acute intracranial process.

2. Nonspecific white matter changes, likely secondary to chronic small vessel ischemic disease.

CT CHEST IV CONTRAST ONLY Narrative INDICATION: Patient age:Male; 62 years old; Reason for study: Sepsis without acute organ dysfunction, due to unspecified organism (CMS/HCC); Aspiration, .

COMPARISON: None.

TECHNIQUE: Multiple axial images were obtained through the chest following the administration of 75 cc of Isovue 370. One or more CT dose reduction strategies were utilized during this examination. Coronal and sagittal reformatted images were obtained for review. Total DLP administered was 565 mGycm.

Total number of CT examinations in past 12 months prior to today: 0.

FINDINGS:

Beam hardening artifacts present secondary to upper extremities adjacent to the scanned field, which obscures detail limits evaluation.

LUNGS/ PLEURA: Trace left-sided pleural effusion. Centrilobular and emphysematous changes are noted bilaterally, predominantly affecting the lung apices. There is scarring versus atelectasis noted within the right lung base. AIRWAY: The central airway is patent..

HEART: Size within normal limits. . MEDIASTINUM: No gross evidence of adenopathy. VASCULATURE: No aortic aneurysm.

MUSCULOSKELETAL: Mild degenerative disc disease changes are present throughout the thoracolumbar spine. SOFT TISSUES/LYMPH NODES: Unremarkable. LOWER NECK: No significant findings.

UPPER ABDOMEN: 3.1 cm simple fluid attenuating cyst at the left upper pole. Partially visualized PEG tube seen in appropriate positioning. Small accessory splenule is noted just medial to the spleen. The bilateral adrenal glands appear slightly hypertrophic without appreciable evidence of adrenal nodules

IMPRESSION:

- 1. Trace left-sided pleural effusion with associated passive atelectasis.
- 2. Emphysematous changes.
- 3. Left renal simple cyst, 3.1 cm.
- 4. PEG tube noted, in appropriate positioning.
- 5. Hypertrophic bilateral adrenal glands.

Impression:

62 year old male seen in neurologic evaluation regarding AMS. He sustained an anoxic brain injury in May of 2023 s/p Vtach arrest and ultimately was discharged to a group home. Per care everywhere, he was agitated, aggressive, and minimally interactive when discharged from the hospital. There was also documented bilateral LE weakness. Family was concerned his mental status and agitation had increased while in the group home. There were also concerns that he was not being cared for properly. He was hypoglycemic on EMS arrival and had an elevated WBC count. He currently is on antibiotics for possible underlying infection. CT head showed no acute process.

Altered mental status - primary diagnostic consideration is given to TME in the setting of infection and hypoglycemia superimposed on known anoxic brain injury. Low suspicion for epileptiform correlate but will check EEG for completeness. Bilateral lower extremity weakness - chronic

Recommendations: Your medical management CT head personally reviewed EEG ordered Patient previously on depakote and zyprexa for agitation. Consider restarting these medications but will defer to psychiatry Psychiatry recommendations appreciated PT/OT/SLP as able Will follow peripherally for results of EEG and will comment if epileptiform Please call with questions

Katherine Ross, D.O. Neurology PGY4 Electronically signed by Robert Pierce at 08/02/2023 3:02 PM EDT

Associated attestation - Robert Pierce - 08/02/2023 3:02 PM EDT

Formatting of this note might be different from the original.

Patient seen and examined. Patient with advanced anoxic encephalopathy, agitated and aggressive on admission. Patient nods to questioning today but largely nonverbal. Suspect toxic metabolic encephalopathy superimposed on anoxic brain injury. We will check EEG for completeness. Call with questions

Attending Attestation:

I saw and evaluated the patient on 8/2/2023. I performed key elements of the history, physical examination and have discussed them and the plan of care with the resident as reflected on the chart. The medical evaluation, management, services, and procedures described herein were performed in the presence of and under the direct supervision of myself. The involved resident's findings, impression and plan have been reviewed and verified by myself with revisions as necessary.

Robert P Pierce, DO 8/2/2023, 3:02 PM

Time signed does not necessarily represent time patient seen.

ED Notes - documented in this encounter

Diane Kaiser Alexander - 08/01/2023 5:14 PM EDT Formatting of this note is different from the original.

Chief Complaint

Patient presents with

Altered Mental Status Patient arrived to ER from group home via EMS. Per EMS pts baseline is a+ox1+combative, family says he has been a+ox0 for the last 24 hours. POC at group home was 32 1 amp given by EMS

HPI

Patient is a 62-year-old male with past medical history of V. tach cardiac arrest with subsequent anoxic brain injury presents the ED from a group home via EMS with altered mental status. Per EMS, as external historians, patient's baseline is alert and oriented x1 and is normally combative however patient's family told EMS that he was alert and oriented x0. Daughter presented later and she stated that the patient was acting differently as he was yelling and moving flailing his arms which he does not normally do. At the group home his POC glucose was 32. 1 amp was given by EMS. Patient not answering any questions. Patient's Medications New Prescriptions No medications on file **Previous Medications** ACETAMINOPHEN (TYLENOL) 325 MG PO TAB 2 Tablets every 4 hours as needed. AMIODARONE (CORDARONE, PACERONE) 200 MG PO TAB 1 Tablet once daily. APIXABAN (ELIQUIS) 5 MG PO TAB take 1 Tablet by mouth twice daily. ASCORBIC ACID 250 MG PO TAB 1 Tablet once daily. ATORVASTATIN (LIPITOR) 40 MG PO TAB 1 Tablet once every night at bedtime. CLOPIDOGREL (PLAVIX) 75 MG PO TAB 1 Tablet once daily. HYDROCODONE-ACETAMINOPHEN (NORCO) 5-325 MG PO TAB 1 Tablet 3 times daily. X 7 days INSULIN LISPRO (HUMALOG) 100 UNIT/ML INJ SOLUTION inject 1-6 Units into the skin 4 times daily. Sliding scale LORAZEPAM (INTENSOL) 2 MG/ML PO CONC 0.5 mL every 6 hours as needed for FOR AGITATION. METOPROLOL (LOPRESSOR) 25 MG PO TAB 1 Tablet twice daily. NICOTINE (NICODERM) 14 MG/24HR TRANSDERM PATCH 24 HR place 1 Patch onto the skin every 24 hours. OLANZAPINE (ZYPREXA) 10 MG PO TAB 1 Tablet twice daily. POLYETHYLENE GLYCOL 3350 (MIRALAX) 17 GM/SCOOP PO POWDER take 17 g by mouth once daily. TAMSULOSIN (FLOMAX) 0.4 MG PO CAP take 1 Capsule by mouth once daily. Take 30 minutes after the same meal each day. VALPROATE (DEPAKENE) 250 MG/5ML PO SOLUTION take 20 mL by mouth twice daily. VALPROATE (DEPAKENE) 250 MG/5ML PO SOLUTION 10 mL once daily. Modified Medications No medications on file

Discontinued Medications

No medications on file

Not on File

No past medical history on file. No past medical history pertinent negatives. No past surgical history on file. No past surgical history pertinent negatives on file.

Social History

Socioeconomic History Marital status: Divorced

No family history on file.

BP 119/80 | Pulse 89 | Temp 99.1 °F (37.3 °C) | Resp 12 | Ht 188 cm (6' 2") | Wt 99.8 kg (220 lb) | SpO2 95% | BMI 28.25 kg/m²

Physical Exam Vitals reviewed. Constitutional: General: He is not in acute distress. Appearance: He is not ill-appearing, toxic-appearing or diaphoretic. Comments: Patient has a gag reflex HENT: Head: Normocephalic and atraumatic. Right Ear: External ear normal. Left Ear: External ear normal. Nose: Nose normal. Mouth/Throat: Mouth: Mucous membranes are moist. Pharynx: Oropharynx is clear. Eyes: Extraocular Movements: Extraocular movements intact. Pupils: Pupils are equal, round, and reactive to light. Comments: Patient's eyes equal and reactive and brisk to light. 1 mm bilaterally. Cardiovascular: Rate and Rhythm: Regular rhythm. Tachycardia present. Pulses: Normal pulses. Heart sounds: Normal heart sounds. Pulmonary: Effort: Pulmonary effort is normal. Comments: Coarse breath sounds throughout. Gurgling sounds Abdominal: General: Abdomen is flat. Palpations: Abdomen is soft. Tenderness: There is no abdominal tenderness. There is no guarding or rebound. Comments: PEG tube Genitourinary: Comments: Foley in place Musculoskeletal: General: Normal range of motion. Cervical back: Normal range of motion and neck supple. Right lower leg: No edema. Left lower leg: No edema. Skin: General: Skin is warm and dry. Findings: No erythema. Neurological: Mental Status: He is alert. Comments: Patient moves his arms however has mittens on his hands as he normally picks at his PEG tube and fights. **Psychiatric:** Mood and Affect: Mood normal. Behavior: Behavior normal.

Procedures

Other ED Provider Notes

Results for orders placed or performed during the hospital encounter of 08/01/23 CHEST 1 VIEW AP/PA Narrative CLINICAL INDICATION: Shortness of breath

COMPARISON: None

TECHNIQUE: Single frontal radiograph of the chest was obtained portably.

FINDINGS: The lungs are clear with no evidence for pneumothorax, pleural effusion, or focal consolidation. Bibasilar atelectasis. The cardiomediastinal silhouette is within normal limits. There is no acute osseous pathology.

IMPRESSION Bibasilar atelectasis.

CT HEAD W/O IV CONTRAST Narrative INDICATION: Patient age:Male; 62 years old; Reason for study: Altered mental status.

COMPARISON: None.

TECHNIQUE: Multiple axial CT images of the brain were obtained without IV contrast. One or more CT dose reduction strategies were utilized during this examination. Coronal and sagittal reformats were also obtained. Total DLP administered was 883 mGycm. Total number of CT examinations in past 12 months prior to today: 0.

FINDINGS:

Extra-axial spaces: No abnormal extra-axial fluid collections. Ventricular system: Dilatation in proportion to cerebral atrophy. Cerebral parenchyma: Cerebral atrophy. No acute intraparenchymal hemorrhage or mass effect. The gray-white junction is well differentiated. Patchy hypoattenuating areas within the periventricular and subcortical white matter.

Cerebellum: Unremarkable. Mass effect: No evidence of midline shift. Intracranial vasculature: unremarkable Soft tissues: Normal. Calvarium/osseous structures: No depressed skull fracture. Paranasal sinuses and mastoid air cells: Clear. Visualized orbits: Orbital contents are intact.

IMPRESSION:

No acute intracranial process.
 Nonspecific white matter changes, likely secondary to chronic small vessel ischemic disease.

Complete Blood Count (CBC) W Diff

Narrative The following orders were created for panel order Complete Blood Count (CBC) W Diff. Procedure Abnormality Status

Complete Blood Count (C...[1442857486] Abnormal Final result

Please view results for these tests on the individual orders. Basic Metabolic Panel (BMP) Result Value Ref Range Sodium 142 135 - 145 mmol/L Potassium 4.6 3.5 - 5.2 mmol/L Chloride 112 (H) 98 - 111 mmol/L Carbon Dioxide -CO2 23 20 - 29 mmol/L Anion Gap 7 5 - 17 Glucose 432 (H) 60 - 99 mg/dL Blood Urea Nitrogen -BUN 23 7 - 25 mg/dL Creatinine 0.77 0.60 - 1.30 mg/dL eGFR By Creatinine 101 mL/min/1.73m2 Calcium 8.3 (L) 8.5 - 10.5 mg/dL Blood Gases, Venous (VBG) **Result Value Ref Range** Sample Type Blood, venous pH 7.40 7.32 - 7.42 PCO2 48 41 - 51 mmHg Bicarbonate 29 (H) 19 - 27 mmol/L Total CO2 30 (H) 20 - 29 mmol/L Base Excess 4 -5 - 5 mmol/L Oxyhemoglobin 73 55 - 85 % Carboxyhemoglobin 1.3 < 1.5 % Methemoglobin 0.6 0.0 - 2.0 % Hemoglobin 13.2 (L) 13.5 - 17.0 g/dL Protime and aPTT Result Value Ref Range Protime 13.7 (H) 9.2 - 13.5 Seconds INR 1.2 APTT 26.8 25.0 - 38.0 Seconds Lactic Acid, Plasma Result Value Ref Range Lactic Acid 1.8 0.5 - 2.0 mmol/L Hepatic Function Panel **Result Value Ref Range** Albumin 2.9 (L) 3.5 - 4.9 g/dL Globulin 4.2 (H) 2.2 - 3.7 g/dL Albumin/Globulin Ratio 0.7 Alkaline Phosphatase 113 33 - 120 U/L Aspartate Aminotransferase -AST 21 <35 U/L Alanine Aminotransferase -ALT 14 9 - 47 U/L Bilirubin Total 0.3 0.3 - 1.2 mg/dL Bilirubin Direct 0.2 0.0 - 0.4 mg/dL Protein Total 7.1 6.2 - 8.1 g/dL Lipase Result Value Ref Range Lipase 10 7 - 60 U/L Troponin I Result Value Ref Range Troponin I 0.01 <=0.03 ng/mL Troponin I Result Value Ref Range Troponin I 0.02 <=0.03 ng/mL Thyroid Stimulating Hormon (TSH) With Reflex to Free Thyroxine (FT4) Result Value Ref Range Thyroid Stimulating Hormone 1.85 0.40 - 4.50 uIU/mL Magnesium Level Result Value Ref Range Magnesium 2.1 1.7 - 2.5 mg/dL **Phosphorus Level** Result Value Ref Range Phosphorus 2.7 2.3 - 4.4 mg/dL Urinalysis **Result Value Ref Range** Color Yellow Clarity Cloudy (A) Clear Glucose >=500 (A) Negative mg/dL **Bilirubin Negative Negative** Ketones Negative Negative mg/dL Specific Gravity, Urine 1.010 1.005 - 1.030 Blood 3+ (A) Negative pH 7.5 5.0 - 8.0 Protein 10 (A) Negative mg/dL Urobilinogen <2.0 <2.0 mg/dL Nitrites Negative Negative Leukocyte Esterase 3+ (A) Negative RBC >20 (A) 0-2 (Negative) /hpf WBC > 50 (A) 0-5 (Negative) /hpf Epithelial, Squamous 6-30 Negative /lpf Casts, Hyaline 0-2 (Negative) 0-2 (Negative) /lpf

Bacteria 2+ (A) Negative /hpf Complete Blood Count (CBC) W/Auto Diff Result Value Ref Range WBC 13.7 (H) 3.5 - 10.1 bil/L RBC 4.45 4.31 - 5.48 tril/L Hemoglobin 13.0 (L) 13.5 - 17.0 g/dL Hematocrit 42.6 40.1 - 50.1 % MCV 96 80 - 100 fL MCH 29 28 - 33 pg MCHC 31 (L) 32 - 36 g/dL RDW-CV 16 (H) 12 - 15 % Platelets 283 150 - 400 bil/L Nucleated Red Blood Cells 0.0 <=0.0 % Neutrophils 10.5 (H) 1.6 - 7.2 bil/L Lymphocytes 2.0 1.1 - 4.0 bil/L Monocytes 1.2 (H) 0.0 - 0.9 bil/L Eosinophils 0.0 0.0 - 0.4 bil/L Basophils 0.0 0.0 - 0.1 bil/L Immature Granulocytes 0.06 (H) 0.00 - 0.04 bil/L Immature Granulocyte % 0.4 % Troponin I Result Value Ref Range Troponin I 0.02 <=0.03 ng/mL Procalcitonin, Plasma Result Value Ref Range Procalcitonin, Plasma 0.47 (H) 0.00 - 0.25 ng/mL Narrative Interpretive criteria for results:

If using as an aid in deciding on whether or not to start antibiotics for lower respiratory tract infections, providers should use the following guidance:

- PCT <0.10 ng/mL - antibiotics strongly discouraged

- PCT 0.10-0.25 ng/mL - antibiotics discouraged

- PCT 0.26-0.50 ng/mL - antibiotics encouraged

- PCT > 0.50 ng/mL - antibiotics strongly encouraged

If using as an aid in deciding on whether or not to discontinue antibiotics for suspected/confirmed sepsis, providers should use the following guidance:

- PCT <= 0.50 ng/mL or > 80% decrease from peak/baseline value

- antibiotics discouraged

- PCT > 0.50 ng/mL and < 80% decrease from peak/baseline value
- antibiotics encouraged

Glucose, POC **Result Value Ref Range** Glucose 400 (H) 60 - 139 mg/dL Performed By Anderson, Shawna ET Narrative Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL Covid-19, Flu, RSV by NAA Specimen: Nasopharyngeal; Swab Result Value Ref Range Influenza A Not Detected Not Detected Influenza B Not Detected Not Detected **RSV Not Detected Not Detected** SARS-CoV-2 -COVID-19 by NAA, Micro Not Detected Not Detected Narrative Methodology: Nucleic Acid Amplification(NAA)/Polymerase Chain Reaction(PCR) The SARS-CoV-2 (COVID-19) test is for in vitro diagnostic use under the FDA Emergency Use Authorization (EUA) for US laboratories certified under CLIA to perform high complexity testing. This test has not been FDA cleared or approved. Culture, Blood Specimen: Blood, Venipuncture Narrative

The following orders were created for panel order Culture, Blood. Procedure Abnormality Status

Culture, Blood[1442857488] In process

Please view results for these tests on the individual orders. Culture, Blood Specimen: Blood, Venipuncture Narrative The following orders were created for panel order Culture, Blood. Procedure Abnormality Status Culture, Blood[1442857490] In process Please view results for these tests on the individual orders. ECG Narrative Kaiser Alexander, Diane L, DO 8/1/2023 5:48 PM ECG Date/Time: 8/1/2023 5:47 PM Performed by: Kaiser Alexander, Diane L, DO Authorized by: Carline, Christine, DO Contemporaneously ECG reviewed by ED Physician in the absence of a cardiologist: yes Interpretation: Interpretation: non-specific Rate: ECG rate assessment: tachycardic Rhythm: Rhythm: sinus tachycardia Ectopy:

Rate: ECG rate assessment: tachycard Rhythm: Rhythm: sinus tachycardia Ectopy: Ectopy: none QRS: QRS axis: Right Conduction: Conduction: normal ST segments: ST segments: Normal T waves:

T waves: normal

I have reviewed the following: All lab and radiology studies performed

ED Course:

I reviewed patient's vitals. Vitals notable for temperature of 100.6 at tachycardic rate of 101. Patient treated with Tylenol. History obtained per EMS which is independent story and states that patient is coming from his sister's group home. Chronic conditions affecting care include history of V. tach cardiac arrest with subsequent anoxic brain injury, agitation at baseline with a baseline of alert and oriented x1 to self. Due to patient's vitals and concern for aspiration due to his gurgling on exam, sepsis order used and Zosyn and vancomycin started with blood cultures obtained before hand. Upon reevaluation patient's temperature improved to 99.7.

I reviewed patient's chart where "Mr. Ioan Suiugan is a 62-year-old trucker with a past medical history significant for DM2 and renal disorder who was recently found down in a parking lot in Buffalo New York due to V. tach arrest. ROSC was achieved after 60 minutes of resuscitation efforts. The patient then stayed in an ICU in New York from 5/11/2023 to 6/16/2023 before transfer to Regency in Michigan for subacute rehab. Patient's behavior was too agitated and impulsive for the rehab facility to manage and he was thus transferred to THLH 6/21/2023.

During his stay the following problems were treated:

#Acute encephalopathy superimposed on known anoxic encephalopathy of the brain from prior cardiac arrest

- Patient received Haldol and Ativan in the ED and was placed on soft restraints
- Work-up for alternate causes of agitation was completed: TSH within normal limits. Ammonia within normal limits. Negative UDS Psychiatry was consulted for recommendations regarding antipsychotic medications. Patient arrived with zyprexa 5mg BID and
- Ativan 0.5mg Q6 PRN. Zyprexa was initially held due to patient's elevated Qtc.
- -Scheduled Depakote was added per neurology recommendations and titrated up as tolerated.
- -Serial EKGs were ordered. Zyprexa was restarted and then tritiated up following normalization of Qtc.

-Patient refused oral food and medications. PEG tube placed with family consent 7/7

-Patient pulled out the PEG tube overnight 7/10. It was replaced by GI 7/11 following a one-time dose of ancef.

-NORCO 5 tid was added for back pain at the family's request.

- Patient continued to require restraints, mitts, and a one-to-one sitter for the duration of his stay. Posey bed was briefly attempted, but not tolerated."

differential diagnoses include but not limited to to aspiration pneumonia, UTI. I independently interpret patient's EKG as sinus tachycardia without STEMI criteria. I independently interpret patient's chest x-ray as notable for bibasilar atelectasis, likely started

pneumonia. I independently interpreted patient CT head as chronic changes however no acute process such as bleed. Patient does have a leukocytosis of 13.7. Patient's urine shows 2+ bacteria and 3+ leukocyte esterase with greater than 50 white blood cells but is contaminated. Patient does have a chronic Foley. Patient is altered therefore patient is treated for UTI as well. Patient's Pro-Cal 0.47. Per patient's sister who has been taking care of him, she states that he had some friends visited him last night who encouraged him to drink orally. Then patient had some aspiration sounds. Concern for aspiration causing pneumonia. Concern for community-acquired pneumonia as cause for commune acquired pneumonia. Discussed CODE STATUS with patient's daughter and patient's sister who state the patient is a no code no CPR no intubation however yes to vasopressors, antiarrhythmics and cardioversion. Patient on room air. Upon reevaluation patient's vitals much improved with heart rate of 89 afebrile, on room air and not hypotensive. Discussed patient with Dr. Drobott who accepts patient on behalf of Dr. Korkigian for likely aspiration pneumonia versus pneumonitis and altered mental status.

Discussed Case with: Dr. Drobot

Medical Decision Making Information:

Medical Decision Making Amount and/or Complexity of Data Reviewed Labs: ordered. Radiology: ordered. ECG/medicine tests: ordered.

Risk OTC drugs. Prescription drug management. Decision regarding hospitalization.

Disposition: Admission

Final Impression: Core Measure

Encounter Diagnoses Name Primary? Altered mental status, unspecified altered mental status type Yes Community acquired pneumonia, unspecified laterality Urinary tract infection associated with indwelling urethral catheter, initial encounter (CMS/HCC) Sepsis without acute organ dysfunction, due to unspecified organism (CMS/HCC)

Active Hospital Problems Diagnosis Date Noted Sepsis without acute organ dysfunction (CMS/HCC) 08/01/2023 Urinary tract infection associated with indwelling urethral catheter (CMS/HCC) 08/01/2023 Community acquired pneumonia 08/01/2023 Altered mental status 08/01/2023 Altered mental status, unspecified altered mental status type 08/01/2023

Midlevel Provider No providers found Resident Provider ED Resident: Carline, Christine, DO Attending Provider: Kaiser Alexander, Diane L, DO Attending Provider: Korkigian, Armen A, DO

PQRS/Critical Care:

Patient was initially evaluated by the resident physician. I independently evaluated this patient and made all treatment, diagnostic and disposition decisions. I also reviewed the residents note and agree with the findings documented unless otherwise indicated within my medical decision making note. Please see the residents details of the evaluation.

I, Diane Kaiser Alexander, DO, provided critical care. The failure to initiate these interventions on an urgent basis would likely (high probability) result in sudden, clinically significant or life threatening deterioration in the patient's condition. All critical care time is in addition to any procedures, teaching, or resident work performed. Critical care time was spent at the bedside, reviewing test (s), and discussing care with staff. Critical care time spent was 31 minutes. The organ system(s) / conditions impaired: Sepsis. PQRS: Blood pressure noted to be elevated and patient told to follow up with PCP in 1 to 2 days.

Carline, Christine, DO Resident 08/01/23 2343 Kaiser Alexander, Diane L, DO 08/02/23 1237

Electronically signed by Diane Kaiser Alexander at 08/02/2023 12:37 PM EDT

Miscellaneous Notes - documented in this encounter Care Management - Christine B - 08/29/2023 3:12 PM EDT Formatting of this note is different from the original.

Care Management Case Closing Discharge Assessment

FINAL DISCHARGE PLAN Final disposition: Home - Health Care Svc

Patient/Family aware and agreeable to the discharge plan: Yes

COMMENTS / SUMMARY Patient discharged group home with skilled home care, with the following services Skilled nursing, Nutrition/Dietician, Social service, Speech pathology

Accepting home care agency: CORPORE SANO HOME HEALTH CARE PLYMOUTH 239254.

ROC confirmed between patient and agency withi 24-48 hours

AVS and HC orders sent via Allscripts by PACC.

Home infusion agency secured with: (Sheldon Medical Equipment provides tube feeding/ supplies) Supplies delivered: Patient currently has supplies at Group Home.

Transportation provided by Ambulance.

Case closed. Yes

Signed: Christine Balian-Albrecht, RN PACC Pager/Phone: 248-331-7362 Date/Time: 8/29/2023, 3:13 PM

Electronically signed by Christine B at 08/29/2023 3:14 PM EDT Nsg Discharge Note - Mariluna B - 08/29/2023 2:46 PM EDT Formatting of this note might be different from the original. RN Discharge Note

See Care Plan for status of patient problems

Patient discharged to: Home With Home Care: Home care orders on AVS CM/PACC confirmed set up

DME orders on AVS: none and other bolus feeding via PEG tube

Oxygen: None

Wound Care/ Drains: Instructions on AVS. Reviewed with pt/family.

Infusions: None

Diet: Instructions included on AVS & reviewed with pt/family

Activity: Instructions on AVS & reviewed with pt/family

SNF/ECF: N/A

Follow up Appointments: AVS includes follow up appts with Dr name and contact info. Pt instructed to make appts. Pt instructed on follow up lab draws.

Status of chief complaint: appropriate for discharge

Discharge instructions/AVS given to and reviewed with: n/a

Meds to Bed: Offered - Declined at Admission

Potential Medication Side Effects reviewed with: Facility

Prescriptions given to: Facility.

Mode of discharge: ems

Patient accompanied by: ems

Patient discharge Delay reason:n/a

Notes: Rebecca fr DME called writer that order for peg tube feeding should be bolus. Clinical Liaison Balian, informed/aware. Same message was sent to NP Saunders through MHB, informed, awaiting reply.

Patient/Significant Other verbalized understanding of discharge instructions/AVS. All belongings sent with patient and/or significant other. LDAs addressed

Electronically signed by Mariluna B at 08/29/2023 2:50 PM EDT Nutr Serv Progress Note - Rima C - 08/29/2023 2:01 PM EDT Formatting of this note is different from the original.

NUTRITION SERVICES - FOLLOW-UP ASSESSMENT Name: Ioan Suiugan-62y.o.Male MRN: 9942681 LOS: 28 Room:475/475 Reason for Visit: Nutrition Reassessment Nutrition Therapy Protocol Yes 8/29- d/c planning back to group home 8/18- stable for discharge from internal medicine perspective since 8/9/23. D

8/18- stable for discharge from internal medicine perspective since 8/9/23. Discharge delay 2/2 psychiatric component and psych interventions. Per IM goals of care discussions ongoing,hospice vs sons hesitation to stop TF.

8/15 - With agitation pt pulling at PEG tube. Pt with 1:1 sitter. Per case management 8/13, planning for pt discharge to SNF once pt is restraint and sitter free for 24 hrs.

8/9 - Pt had toxic metabolic encephalopathy superimposed on anoxic brain injury secondary to sepsis/UTI per Internal medicine NP. Pt is still disoriented and aggressive, is on restraints, and requires TF. Per Internal Medicine Physician, no acute medical problems. Antibiotics completed, adjusted IVF, dc planning.

HPI: 62y.o.M presented to ED c/o altered mental status. Per Emergency Medicine Resident 8/1, pt is A&Ox1 and had a V. Tach cardiac arrest with subsequent anoxic brain injury in May 2023. Per Internal medicine Resident H&P 8/2, pt is currently on restraints. Pt hyperglycemic upon admission but decreased glucose levels to 137.

Subjective: Pt visited, RN in room. Patient tolerating TF at goal 70 mL/hr. Per RN tolerating well, no concerns/complaints. Oral diet

was dc'd relying solely on TF. Prior to NPO oral intake was negligible. FOOD AND NUTRITION HISTORY: Current Diet Order Orders Placed This Encounter NPO Diet - NPO: Sips with Meds Tube Feeding with Oral Diet - Tube Feed: Tube Feeding,; Product: Glucerna 1.5; Rate Goal ml/hr: 70; Tube Feeding Water Flush (mL): 75; Water Flush Frequency: Other (specify) (q1hr); Non Room Service Food Allergies: NKFA per chart. Cultural/Religious Practices: na Appetite: na Intake: Pt's current Glucerna 1.5 is 70 mL/hr and 75 mL water flush. Chewing/Swallowing: na GI: LBM 8/28 per chart. Skin: PI Stage 1 sacrum, Wound r anterior knee per chart. Edema: RLE +1 and LLE +1 per chart. BIOCHEMICAL DATA/ MEDICATIONS/ TESTS / PROCEDURES: Recent Labs 08/27/23 1608 08/27/23 1808 08/28/23 0620 08/28/23 1223 08/29/23 0550 08/29/23 0601 08/29/23 1327 NA 138 -- 139 -- -- 137 --К 3.4* -- 3.3* -- -- 3.4* --CL 105 -- 106 -- -- 103 --CO2 27 -- 24 -- -- 27 --GLU 108* < > 124* < > 145* 124* 135 BUN 14 -- 12 -- -- 10 --CREAT 0.58* -- 0.50* -- -- 0.59* --EGFR 110 -- 115 -- -- 110 --CALCIUM 7.8* -- 7.8* -- -- 8.0* --MG 1.8 -- 1.7 -- -- 1.9 --PHOS 2.5 -- 2.6 -- -- 2.8 --<> = values in this interval not displayed. Medications: SCHEDULED: albuterol-ipratropium, 3 mL, Inhalation, RT-QID amiodarone, 200 mg, PEG Tube, DAILY apixaban (ELIQUIS) tablet DVT/PE TREATMENT CONTINUATION BEYOND 7 DAYS, 5 mg, Oral, Q 12 H atorvastatin, 40 mg, PEG Tube, Q HS clonazePAM, 0.5 mg, Oral, BID clonazePAM, 1 mg, PEG Tube, Q HS clopidogrel, 75 mg, Oral, DAILY insulin regular human, 2-5 Units, Subcutaneous, Q 6 H metoprolol, 25 mg, PEG Tube, BID OLANZapine, 10 mg, Oral, BID sodium chloride, 10 mL, Intravenous, Q 12 H sodium chloride, 10 mL, Intravenous, Q 12 H valproate, 1,000 mg, Oral, BID IVF:

PRN:

- acetaminophen
- albuterol-ipratropium
- LORazepam
- sodium chloride
- sodium chloride
- sodium chloride
- sodium chloride

sodium chloride

• sodium chloride 0.9%

Tests/Procedures:

8/2 CT chest IV contrast - pleural effusion, emphysematous changes, L renal simple cyst, and PEG tube noted in appropriate positioning.

NUTRITION FOCUSED PHYSICAL FINDINGS: Nutrition Focused Physical Exam: per previous NPFE's. Pt resting upon f/u Subcutaneous Fat Depletion Musculoskeletal Depletion Classification: Moderate [x] Orbital region [x] Upper arm region -triceps/biceps [] Thoracic & lumbar region - ribs, lower back, midaxillary line Classification: Moderate [x] Temporalis [x] Clavicle & acromion bone region [x] Clavicle bone region [x] Clavicle bone region [] Scapular bone region [] Dorsal hand [x] Patellar region [x] Anterior thigh region

[x] Posterior calf region

ANTHROPOMETRICS: Admit Weight: 99.8 kg (220 lb), Weight Source: Bed scale Current Weight: 87.1 kg (192 lb 0.3 oz), Weight Source: Bed scale Body mass index is 24.64 kg/m². BMI Classification: WNL

IBW: 86.4 kg UBW: na kg All weight readings from this encounter 08/23/23 0600 87.1 kg (192 lb 0.3 oz) 08/11/23 0800 87.1 kg (192 lb 0.3 oz) 08/10/23 2300 84.8 kg (186 lb 15.2 oz) 08/08/23 0600 85.3 kg (188 lb 0.8 oz) 08/07/23 0549 87.4 kg (192 lb 10.9 oz) 08/06/23 0424 85.2 kg (187 lb 13.3 oz) 08/05/23 0340 85.2 kg (187 lb 13.3 oz) 08/02/23 0300 99.8 kg (220 lb) 08/01/23 1727 99.8 kg (220 lb)

Weight Trend: 12.7% weight loss in the last 1.5 weeks per Epic weight history. Weight seems to improve. Question previous weight bed scale accuracy. Pt appears thinner than previous visit suspect fluid related.

ESTIMATED NUTRITIONAL NEEDS:

Calories: 2177+ kcal/day based on 25 kcal/kg using current body weight (87.1 kg) Protein: 105-131 gm/day based on 1.2-1.5 gm/kg using current body weight Fluid: 2177 mL based on 1 mL/kcal or per provider. Adjust fluids based on intake and output to maintain fluid balance and hemodynamic stability

NUTRITION DIAGNOSIS:

Increased protein needs related to wounds as evidenced by Pressure injury Stage II center Sacrum. - N/A pressure injury now documented as stage 1

Alteration in GI function related to dysphagia/mental status as evidenced by need for alternate means of nutrition, modified textures and consistencies. [Status: ACTIVE] NPO relaying of TF for nutrition

INTERVENTION: Intervention(s): Saw pt, follow-up completed. Chart reviewed. Assessed TF

Goal(s): TF to provide >90% nutrient needs. - met, ongoing. Prevent significant/unintentional weight loss. - met, ongoing. Pt to have evidence of wound healing. - now noted to be stage 1, improvement

MONITORING & EVALUATING

TF tolerance. Pertinent labs. Weight trends.

Nutrition related discharge needs at this time - TF

Follow Up Range: based on patient care goals, 5-7 days

RECOMMENDATIONS: Continue TF: Glucerna 1.5 at 70 mL/hr. TF at goal provides: 2520 kcal, 138 gm protein, 1276 mL free H2O Enteral H2O: defer to provider. Aspiration precautions, HOB > 30-45 degrees at all times.

At discharge can continue bolus feeds Recommend: Glucerna 1.5 240 mL x 7 bolus feeds daily to provide 2492 kcal, 137 g pro, 1260 mL free water Flush 50 mls pre/ 50 mls post bolus (daily total 700 mls). Additional (up to) 500 mls free water with meds/ etc.

947-521-8220 Available via Mobile Heartbeat" Electronically signed by Rima C at 08/29/2023 2:58 PM EDT Care Management - Christine B - 08/29/2023 1:08 PM EDT Formatting of this note is different from the original. START PACC NOTE

Home Health Referral

Home Care pending DC disposition (need MD order), homebound status, if home care benefits are a covered benefit from their insurance, and agency acceptance.

Patient and Group Home Vicki educated on home care and services available.

Agreeable to Skilled nursing, Social service, Speech pathology, Nutrition/Dietician services.

Provided choice and selected Corpore Sano Home Care agency as first choice, or any agency in network with insurance.

Referral sent to Corpore Sano Home Care ACCEPTED AVS faxed with referral. Current tube feeding orders faxed to Sheldon Medical

DME Choice DME Company: MSC

Current Home DME: Dependent lift, Hospital bed, Feeding equipment

DME Ordered/Needed: N/A

DME Delivery location: N/A

START PATIENT REGISTRATION INFORMATION

Order Information Order Signing Physician: Rudy, William M, DO Phone #: (248)541-2512 Service Ordered RN ?: Yes Service Ordered PT ?: No Service Ordered OT ?: No Service Ordered ST ?: Yes Service Ordered MSW?: Yes Service Ordered HHA?: No Following Physician: TBD Following Physician: TBD Following Physician: N/A (Required for Residents only) Agreeable to Follow? yes Spoke with: Date/Time of Call: 08/29/23 1:09 PM Care Coordination Same Day SOC?: No Primary Care Physician: Unknown, Per Patient, DO Primary Care Physician Phone: None Primary Care Physician Address: No address on file PCP NPI: 1134888118 Visit Instructions: N/A Service Discharge Location Type: Home Service Facility Name: N/A Service Floor Facility: N/A Service Room No: N/A

Demographics Patient Last Name: Suiugan Patient First Name: Ioan Language/Communication Barrier: Altered Mental Status Service Address: 21207 Parker Farmington Hills MI 48336 Service Home Phone: 248-759-0294 (home) Other phone numbers: Telephone Information: Mobile 248-759-0294

Emergency Contact: Extended Emergency Contact Information Primary Emergency Contact: ABDIC,IOANA Mobile Phone: 248-759-0294 Relation: Daughter Secondary Emergency Contact: boboc,vicki Mobile Phone: 248-778-7799 Relation: Sister

Admission Information Admit Date: 8/1/2023 Patient status at discharge: Inpatient Admitting Diagnosis: Altered mental status, unspecified altered mental status type [R41.82] Respiratory failure (CMS/HCC) [J96.90]

Caregiver Information Caregiver First Name: Vicki Caregiver Last Name: N/A Caregiver Relationship to Patient: Group Home Manager Caregiver Phone Number: N/A Caregiver Notes: N/A

Insurance Information Primary Visit Coverage

Payer Plan Group Number MEDICAID MCD HMP

Primary Visit Coverage Subscriber

Subscriber Name Pat Rel to Sub Subscriber ID Subscriber DOB SUIUGAN, IOAN Self 1284902967 2/27/1961

END PATIENT REGISTRATION INFORMATION

Pt Home Health Goal

Start PACC Summary General Report/ Additional Comments Patient lives in Group Home Address on facesheet Vicki- Group Home Manager Please call dtr Ioana Abdic to set up care 248-759-0294

Consulting Physicians: Treatment Team: Attending Provider: Rudy, William M, DO Consulting Physician: Omar, Sabiha J, MD Consulting Physician: Derderian, Kristin M, DO

End PACC Summary

Discharge Date: 8/29/2023

Referral Source PACC: Christine Balian-Albrecht, RN Hospital: Beaumont Corewell FH Unit: 4S Room #: 475/475 Date: 08/29/23 1:09 PM

END PACC NOTE

Electronically signed by Christine B at 08/29/2023 2:04 PM EDT

Care Management - Deborah A - 08/29/2023 12:54 PM EDT

Formatting of this note might be different from the original.

Patient cleared for discharge today- confirmed with NP Saunders. Spoke with Vicki at group home. Confirmed able to accept patient today. Vicki confirmed has patient's tube feeding at group home. Reports uses Corpore Sano Home Health Care for services- PACC advised. Vicki requesting ambulance transport to group home address: 21207 Parker Farmington Hills, MI 48336. Did advise can not guarantee insurance coverage for transport. Ambulance arranged. Also wants medications sent to Farmington Drugs Pharmacy - NP Saunders updated. Nurse, Mariluna, updated. Ph 521-7800

Electronically signed by Deborah A at 08/29/2023 12:58 PM EDT Care Plan Note - Amy H - 08/29/2023 7:16 AM EDT

Formatting of this note might be different from the original.

Problem: Pulmonary Goal: Oxygenation and Ventilation to Baseline Outcome: Progressing

Electronically signed by Amy H at 08/29/2023 7:16 AM EDT Care Plan Note - Ashley N - 08/29/2023 3:27 AM EDT Formatting of this note might be different from the original.

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent infection will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Will remain free from infection Description: World Health Organization (WHO) identifies hands as the main mode of germ transmission in health care. Hand hygiene may be considered the most important measure performed to avoid transmission of germs and prevent health care associated infection. Outcome: Progressing

Problem: Respiratory: Goal: Will remain free from respiratory infection Outcome: Progressing

Problem: Skin Integrity: Goal: Remain free from infection at wound or surgical site Outcome: Progressing

Problem: Urinary Elimination: Goal: Will remain free from infection Description: See the Catheter-Associated Urinary Tract Infection Prevention module for interventions specific to this topic Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Not Progressing

Problem: Coping: Goal: Coping ability will improve Outcome: Progressing

Problem: Fluid Volume: Goal: Ability to maintain a balanced intake and output will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Signs and symptoms of infection will decrease Outcome: Progressing Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing

Problem: Respiratory: Goal: Will regain and/or maintain adequate ventilation Outcome: Progressing

Problem: Sensory: Goal: General experience of comfort will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve

Outcome: Progressing

Electronically signed by Ashley N at 08/29/2023 3:27 AM EDT

Nsg Progress Note - Dale J - 08/28/2023 6:10 PM EDT Formatting of this note might be different from the original. Patient throughout shift agitated when approached by staff swinging trying to get out of bed. Avasure at bedside, bed alarm on. Patient not receptive when educated about safety. Patient given prn dose of ativan. Patient refused multiple attempts of turns and oral care treatment. Will continue to monitor. Electronically signed by Dale J at 08/28/2023 6:14 PM EDT Care Plan Note - Dale J - 08/28/2023 5:58 PM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve

Problem: Coping: Goal: Coping ability will improve Outcome: Progressing

Outcome: Progressing

Problem: Fluid Volume: Goal: Ability to maintain a balanced intake and output will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Signs and symptoms of infection will decrease Outcome: Progressing Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing

Problem: Respiratory: Goal: Will regain and/or maintain adequate ventilation Outcome: Progressing

Problem: Sensory: Goal: General experience of comfort will improve Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent infection will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Will remain free from infection Description: World Health Organization (WHO) identifies hands as the main mode of germ transmission in health care. Hand hygiene may be considered the most important measure performed to avoid transmission of germs and prevent health care associated infection. Outcome: Progressing

Problem: Respiratory: Goal: Will remain free from respiratory infection Outcome: Progressing

Problem: Skin Integrity: Goal: Remain free from infection at wound or surgical site Outcome: Progressing

Problem: Urinary Elimination: Goal: Will remain free from infection Description: See the Catheter-Associated Urinary Tract Infection Prevention module for interventions specific to this topic Outcome: Progressing

Electronically signed by Dale J at 08/28/2023 5:59 PM EDT Care Management - Deborah A - 08/28/2023 4:08 PM EDT Formatting of this note might be different from the original. Care management note reviewed- from 8/27. Message to Dr Rudy to advise if medically cleared or if discharge is still canceled at this time- await response. Department following. Ph 521-7800 Electronically signed by Deborah A at 08/28/2023 4:09 PM EDT PT/OT Progress Note - Shelly P - 08/28/2023 10:00 AM EDT Formatting of this note is different from the original.

08/28/23 1000 Time Detail PT Visit Number 6 (seen in 475) Time Eval/Tx Initiated 1000 Total Eval/Tx Time (min) - individual 23 min **Event/Subjective** PT Received On 08/28/23 Event Note AMS, CT Brain (-), hx of anoxic brain injury, DM Subjective Alert , non - verbal Patient Goal unable to state Observation In Bed before Treatment: Bed Alarm Assessment Assessment Tolerated eval/tx poor Tolerated eval/tx poor additional detail No participation with therapy Therapy Problem List Impaired Bed Mobility; Impaired Transfers; Impaired Functional Mobility; Impaired Gait Skills; Impaired Balance; Impaired Strength; Impaired Functional Endurance **Rehab Potential Poor** (quarded) Goals Discussed With NA How is your pain at the end of the therapy session? 0 Recommendation PT Discharge Instructions In progress PT Discharge Recommendations Back to group home PT DME Recommendations To be determined

PT/OT Post Treatment Post tx patient left in bed;Post tx left patient with lines intact;Post tx call light/phone within reach Plan Treatment/Interventions Physical Therapy is recommended to address deficits. PT Frequency 3-5x/wk Precautions Precautions (fall ,ressure injury, contact d/t MDR-CRE) Learning Barriers Learning Barriers (PT/OT) Carryover; Impaired Cognition; Judgement; Language; Safety Cognition Arousal/Alertness Alert Follows Commands Inconsistently Memory UTA Safety Judgement Impaired Pain Screening/Assessment Screening/Pain Scale Used Face, Legs, Activity, Crying, Consolability (FLACC) Pain Score 5 (With L LE ROM) **Bed Mobility Rolling Dependent** Supine to Sit UTA Sit to Supine UTA Supine Scoot Dependent Reposition Soft heel boots Donned/doffed heel boots and repositioned patient for comfort and prevent pressure sores Gait/Stairs Gait /Functional Mobillity Assistance UTA Balance Sitting - Static Not tested Sitting - Dynamic Not tested Standing - Static Not tested Standing - Dynamic Not tested Exercise/Interventions Ankle Pumps Bilateral Exercise/Interventions Details PROM x 20 Heel slides Bilateral Exercise/Interventions Details PROM x 20 Supine Hip Abduction, SLR Bilateral Exercise/Interventions Details PROM x 20 Significant Time Spent Significant Time Spent On Encouragement Mobility - AM-PAC 6 CLICK Turning from your back to your side while in a flat bed without using bedrails? 1 Moving from lying on your back to sitting on the side of a flat bed without using bedrails? 1 Moving to and from a bed to a chair (including a wheelchair)? 1 Standing up from a chair using your arms (e.g., wheelchair, or bedside chair)? 1 To walk in hospital room? 1 Climbing 3-5 steps with a railing? 1 Mobility Score 6 Patient Safety Bed in lowest position Yes Side rails/Bed safety 3/4 Bed alarm on if indicated Yes Interdisciplinary Communication Interdisciplinary Communication spoke with RN Interdisciplinary Communication topic Mobility status Communication with Patient Reason for Communication Update on Condition/Status Type of Communication Face-to-Face

Electronically signed by Jince T at 08/28/2023 7:43 PM EDT PT/OT Progress Note - Sarah D - 08/28/2023 9:55 AM EDT Formatting of this note is different from the original.

08/28/23 1315 Time Detail OT Visit Number 5 (rm 475) Time Eval/Tx Initiated 0955 Total Eval/Tx Time (min) - individual 12 min **Event/Subjective** OT Received On 08/28/23 Event Note AMS, CT Brain (-), hx of anoxic brain injury, DM Subjective Pt. in bed and pulling at IV and PEg lines, Pt. very fidgety and allowed therapist to perform PROM exercises. Patient Goal Pt. unable to state (language barrier) Observation In Bed before Treatment; IV; PEG/PEJ Tube Assessment Assessment Tolerated eval/tx poor Tolerated eval/tx poor additional detail Pt. awake and fidgety, pulling at multiple lines. Pt. able to tolerate PROM exercises to UE's. Pt. limited by a language barrier. Therapy Problem List Impaired Bed Mobility; Impaired ROM; Impaired Cognition Goals Discussed With (Pt. unable due to cognition) How is your pain at the end of the therapy session? 1 Recommendation OT Discharge Instructions In progress OT Discharge Recommendations SAR (Subacute rehab) OT DME Recommendations To be determined PT/OT Post Treatment Post tx patient left in bed;Post tx left patient with lines intact;Post tx call light/phone within reach;Post tx RN informed patient location Plan Treatment Interventions UE strengthening/ROM;Cognitive reorientation;Bed mobility OT Frequency 3-5 x/wk Learning Barriers Learning Barriers (PT/OT) Carryover; Impaired Cognition Precautions Weight Bering Status During Session FWB Cognition Arousal/Alertness Alert Motivation Unmotivated Follows Commands Inconsistently Memory UTA Orientation Level Oriented to person Safety Judgement Impaired; Impulsive; Low Insight/Safety Awareness Awareness of Errors No awareness Insight into Deficits Not aware of deficits Problem Solving Assistance required to identify errors made Pain Screening/Assessment Screening/Pain Scale Used No/denies pain Pain Score 0 Bed Mobility **Rolling Dependent** (Pt. laying to his right side and gripping the hand rail, Pt. rolled onto his back) Transfers Sit to Stand UTA Gait/Stairs **Distance UTA** Balance Sitting - Static Absent Exercise/Interventions Exercise & Intervention Comment Bilateral UE AROM exercises laying supine with HOB slightly raised, Pt. able to tolerate therapist moving shoulder, elbow, wrist and digits through various planes/ranges in order to reduce joint stiffness. Significant Time Spent Significant Time Spent On Redirecting patient; Encouragement (Redirect back to task due to increased fidgeting.) Activities of Daily Living - AM-PAC 6 CLICK Putting on and taking off regular lower body clothing? 1 Bathing (including washing, rinsing, drying)? 1 Toileting, which includes using toilet, bedpan or urinal? 1 Putting on and taking off regular upper body clothing? 1 Taking care of personal grooming such as brushing teeth? 1 Eating meals? 1 Activities of Daily Living Score 6 Patient/Family Education/Training **Education Participants Patient** Patient Safety Bed in lowest position Yes

Side rails/Bed safety 2/4 Chair alarm on if indicated Not Indicated Bed alarm on if indicated Not Indicated Interdisciplinary Communication Interdisciplinary Communication spoke with RN Interdisciplinary Communication topic Tolerance of treatment

Electronically signed by Michelle A at 08/28/2023 3:20 PM EDT

Care Plan Note - Morgan H - 08/28/2023 7:58 AM EDT Formatting of this note might be different from the original.

Problem: Pulmonary Goal: Oxygenation and Ventilation to Baseline Outcome: Progressing

Electronically signed by Morgan H at 08/28/2023 7:58 AM EDT

Care Plan Note - Stewart I - 08/27/2023 9:31 PM EDT Formatting of this note might be different from the original.

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent infection will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Will remain free from infection Description: World Health Organization (WHO) identifies hands as the main mode of germ transmission in health care. Hand hygiene may be considered the most important measure performed to avoid transmission of germs and prevent health care associated infection. Outcome: Progressing

Problem: Respiratory: Goal: Will remain free from respiratory infection Outcome: Progressing

Problem: Skin Integrity: Goal: Remain free from infection at wound or surgical site Outcome: Progressing

Problem: Urinary Elimination: Goal: Will remain free from infection Description: See the Catheter-Associated Urinary Tract Infection Prevention module for interventions specific to this topic Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing Problem: Coping: Goal: Coping ability will improve Outcome: Progressing

Problem: Fluid Volume: Goal: Ability to maintain a balanced intake and output will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Signs and symptoms of infection will decrease Outcome: Progressing Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing

Problem: Respiratory: Goal: Will regain and/or maintain adequate ventilation Outcome: Progressing

Problem: Sensory: Goal: General experience of comfort will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Electronically signed by Stewart I at 08/27/2023 9:31 PM EDT RRT - Nursing Note - Jaynee S - 08/27/2023 5:48 PM EDT Formatting of this note is different from the original. BRAT FOLLOW UP NOTE

Reason for previous BRAT visit: Hypotension

Temp 100.1 °F (37.8 °C) (08/27/23 0715) Source Axillary (08/27/23 0715) BP 95/52 (manual) (08/27/23 1747) Heart Rate 88 (08/27/23 1530) Resp 16 (08/27/23 1530) O2 (L/min) 2 L/min (08/24/23 0702) SpO2 94 % (08/27/23 1535) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/23/23 0600) BMI 24.6 (08/23/23 0600)

WBC Hgb Hct Plt 7.3 (08/27 1608) 10.8 (08/27 1608) 34.0 (08/27 1608) 193 (08/27 1608) NA K CI CO2 138 (08/27 1608) 3.4 (08/27 1608) 105 (08/27 1608) 27 (08/27 1608) BUN Creat Glucose 14 (08/27 1608) 0.58 (08/27 1608) 108 (08/27 1608) PT PTT INR

Intake/Output Summary (Last 24 hours) at 8/27/2023 1748 Last data filed at 8/27/2023 1704 Gross per 24 hour Intake 100 ml Output 2500 ml Net -2400 ml

Further interventions required: NS 1 L bolus infused bp 95/52. Patient alert resting in bed. New orders for albumin.

BRAT FOLLOW UP DEBRIFING

Does this patient require further BRAT follow up's: As needed

Does this patient meet criteria for transfer to a higher level of care: no

Does this patient meet criteria for ICU consult: no

RN FOLLOW UP DEBRIFING

Primary RN name: Simi

Contact information for further questions or concerns: B service, RRT

Jaynee Stoscup, RN

Electronically signed by Jaynee S at 08/27/2023 6:19 PM EDT

RRT - Nursing Note - Jaynee S - 08/27/2023 4:44 PM EDT Formatting of this note is different from the original. Reason for call: Hypotension Prior BRAT visit: yes Time of call: 1543 Time of Arrival: 1545 End of call: 1610

Code Status

Code Status Comments No CPR Discussed with patient's daughter and patient's sister

Modified Resuscitation Specifics: In a non-arrest state, permit intubation?: No In a non-arrest state, permit vaso-active medications?: Yes In a non-arrest state, permit antiarrhythmics?: Yes In a non-arrest state, permit cardioversion?: Yes Decision Arrived By:: Decision discussed with patient/decision-maker 8/1/2023 5:23 PM

Altered mental status, unspecified altered mental status type [R41.82] Respiratory failure (CMS/HCC) [J96.90]

Not on File

No past medical history on file. No past surgical history on file. No family history on file. Social History

Socioeconomic History Marital status: Divorced

Temp 100.1 °F (37.8 °C) (08/27/23 0715) Source Axillary (08/27/23 0715) BP (!) 80/45 (08/27/23 1535) Heart Rate 88 (08/27/23 1530) Resp 16 (08/27/23 1530) O2 (L/min) 2 L/min (08/24/23 0702) SpO2 94 % (08/27/23 1535) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/23/23 0600) BMI 24.6 (08/23/23 0600)

WBC Hgb Hct Plt 7.3 (08/27 1608) 10.8 (08/27 1608) 34.0 (08/27 1608) 193 (08/27 1608) NA K CI CO2 138 (08/27 1608) 3.4 (08/27 1608) 105 (08/27 1608) 27 (08/27 1608) BUN Creat Glucose 14 (08/27 1608) 0.58 (08/27 1608) 108 (08/27 1608) PT PTT INR

Intake/Output Summary (Last 24 hours) at 8/27/2023 1644 Last data filed at 8/27/2023 0500 Gross per 24 hour Intake 100 ml Output 1500 ml Net -1400 ml

Assessment: Patient alert sitting up in bed with sister at bedside. BP 80/45 HR 88 Sent LA, Phos, Mag, RFP to lab Blood cultures pending from yesterday. Patient receiving scheduled antibiotics. ID following, discharge on hold. Bladder scan 837, foley adjust and 1 L of output.

Medications given during call: 500 ml bolus Plan of Care: monitor BP Physician consulted: B service Follow up needed: As needed

BRAT CALL DEBRIFING

Does this patient meet criteria for transfer to a higher level of care: no

Does this pt require an ICU consult at this time: no

PRIMARY RN DEBRIFING

Primary RN name: Simi Signs and symptoms to monitor for: Worsening s/s or any concerns Who to contact with new or further concerns: B service, RRT

Jaynee Stoscup, RN

Pager # 1234

Electronically signed by Jaynee S at 08/27/2023 5:48 PM EDT

Nsg Progress Note - Simi A - 08/27/2023 4:42 PM EDT

Formatting of this note might be different from the original.

Pts bp drop to 80/45 afternoon notified B service Corina np and got order for 500ml bolus ,brat nurse also notified .bp was 80/50 after bolus so got order for another bolus . Pt urine out putvery low today. Pt was keep pulling on his foley this morning so bladderscan the pt and found 837 ml so pushed the foley in more and drain 1000ml urine .pts bp came back up to 98/60 more alert and started his agitation and pulling on line and tubes . Pts son is at the bedside .

Electronically signed by Simi A at 08/27/2023 6:38 PM EDT

Care Management - Elizabeth R - 08/27/2023 4:07 PM EDT

Formatting of this note might be different from the original.

Pt discussed with Dr Rudy- per Dr Rudy pt is not stable for discharge today. CM spoke with pt's sister Vicki. Per Vicki plan is for pt to go to her group home at discharge. Vicki states she can accept pt tomorrow afternoon if he is stable for discharge. CM dept to follow and will coordinate discharge once pt is medically stable.

E. Robertson, CM ext 8901

Electronically signed by Elizabeth R at 08/27/2023 4:12 PM EDT Care Plan Note - Simi A - 08/27/2023 12:02 PM EDT Formatting of this note might be different from the original.

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent infection will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Will remain free from infection Description: World Health Organization (WHO) identifies hands as the main mode of germ transmission in health care. Hand hygiene may be considered the most important measure performed to avoid transmission of germs and prevent health care associated infection. Outcome: Progressing

Problem: Respiratory: Goal: Will remain free from respiratory infection Outcome: Progressing

Problem: Skin Integrity: Goal: Remain free from infection at wound or surgical site Outcome: Progressing

Problem: Urinary Elimination: Goal: Will remain free from infection Description: See the Catheter-Associated Urinary Tract Infection Prevention module for interventions specific to this topic Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Cognitive:

Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Coping: Goal: Coping ability will improve Outcome: Progressing

Problem: Fluid Volume: Goal: Ability to maintain a balanced intake and output will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Signs and symptoms of infection will decrease Outcome: Progressing Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing

Problem: Respiratory: Goal: Will regain and/or maintain adequate ventilation Outcome: Progressing

Problem: Sensory: Goal: General experience of comfort will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Electronically signed by Simi A at 08/27/2023 12:02 PM EDT

Pharmacist Progress Note - Jennifer L - 08/27/2023 10:18 AM EDT

Formatting of this note is different from the original. Images from the original note were not included. Pharmacy Dosing Consult: Vancomycin Initial Consult Drug: Vancomycin Indication: Pneumonia Indication for MRSA nasal screen: Yes Target: AUC 400-600 and Trough < = 20 mcg/mL Other Antimicrobials: azithromycin, ceftriaxone, flagyl

Patient Specific Parameters and Labs Vital Signs: BP 126/64 | Pulse 106 | Temp 100.1 °F (37.8 °C) (Axillary) | Resp 18 | Ht 188 cm (6' 2.02") | Wt 87.1 kg (192 lb 0.3 oz) | SpO2 97% | BMI 24.64 kg/m² Temp (24hrs), Avg:99.5 °F (37.5 °C), Min:98.2 °F (36.8 °C), Max:101.3 °F (38.5 °C)

Total body weight: 87.1 kg (192 lb 0.3 oz) Ideal body weight: 82.2 kg (181 lb 4.8 oz) Adjusted ideal body weight: 84.2 kg (185 lb 9.4 oz) Body mass index is 24.64 kg/m².

Weight used to calculate CrCl and Ke: ideal body weight (IBW) CrCl or renal function: ~60 mL/min - based on patient's age for more realistic estimation I/O: Recent Labs 08/26/23 1230 08/23/23 0036 08/20/23 1417 08/18/23 0403 WBC 7.0 12.4* 9.8 8.8 CREAT 0.57* 0.64 0.60 0.62 BUN 12 16 13 13 ALB 2.4* -- 2.6* 2.6*

Pharmacokinetics Recent vancomycin history: Yes - Reviewed for dosing

Estimated Ke: 0.054 hr-1 Estimated Vd: 56.6 L (Vd coefficient used: 0.65) Estimated T1/2: 12.8 hours

Microbiology Blood: Results from last 7 days Lab Units 08/23/23 0042 08/23/23 0036 LAB CP CULTURE, BLOOD No growth at 3 days No growth at 3 days

MRSA nasal swab:

Assessment

62 YO male with PMH DM type 2, A flutter, urinary retention and prior V tach cardiac arrest resulting in anoxic brain injury in May 2023. Was admitted on 8/1/23 with CC AMS. Was previously on vanco during this admission for sepsis. ID has now been reconsulted for new onset fever. Pharmacy is consulted to dose vanco for PNA. Renal function/baseline SCr: stable, WNL and at baseline Meets criteria for levels after 72 hrs?: Yes Current risk factors for nephrotoxicity: No current risk factors

Plan

Vancomycin 1250 mg every 12 hours based on previous dosing and levels during this same admission Plan to check levels after 72 hours of initiation Next Level(s): Date: 8/29 or when clinically indicated Monitor SCr every other day MRSA nares ordered? No - already cultured with positive result on 8/12/23 Pharmacy will continue to monitor renal function, WBC, cultures and the clinical progress of the patient.

Please do not hesitate to contact us with comments or questions.

Thank you, Jennifer M Lada, PHARMACIST, 8/27/2023 Available on Mobile Heartbeat

Vancomycin Calculator Adult Vancomycin Pharmacy Dosing Guideline

Electronically signed by Jennifer L at 08/27/2023 10:18 AM EDT Care Plan Note - Hala R - 08/26/2023 10:42 PM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Coping: Goal: Coping ability will improve Outcome: Progressing

Problem: Fluid Volume: Goal: Ability to maintain a balanced intake and output will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing

Problem: Physical Regulation: Goal: Signs and symptoms of infection will decrease Outcome: Progressing

Problem: Sensory: Goal: General experience of comfort will improve Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Respiratory: Goal: Will remain free from respiratory infection Outcome: Progressing

Electronically signed by Hala R at 08/26/2023 10:43 PM EDT RRT - Nursing Note - Jaynee S - 08/26/2023 6:18 PM EDT Formatting of this note is different from the original. BRAT FOLLOW UP NOTE

Reason for previous BRAT visit: sepsis, hypotension, AMS

Temp 98.2 °F (36.8 °C) (08/26/23 1800) Source Axillary (08/26/23 1800) BP 101/65 (08/26/23 1800) Heart Rate 91 (08/26/23 1800) Resp 18 (08/26/23 1800) O2 (L/min) 2 L/min (08/24/23 0702) SpO2 97 % (08/26/23 1800) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/23/23 0600) BMI 24.6 (08/23/23 0600)

WBC Hgb Hct Plt 7.0 (08/26 1230) 11.6 (08/26 1230) 36.7 (08/26 1230) 189 (08/26 1230) NA K Cl CO2 136 (08/26 1230) 3.0 (08/26 1230) 103 (08/26 1230) 23 (08/26 1230) BUN Creat Glucose 12 (08/26 1230) 0.57 (08/26 1230) 131 (08/26 1230) PT PTT INR

Intake/Output Summary (Last 24 hours) at 8/26/2023 1819 Last data filed at 8/26/2023 1200 Gross per 24 hour Intake 1905 ml Output 2600 ml Net -695 ml

Further interventions required: No further interventions needed. Blood pressure stable. No concerns from nursing staff.

BRAT FOLLOW UP DEBRIFING

Does this patient require further BRAT follow up's: As needed

Does this patient meet criteria for transfer to a higher level of care: No

Does this patient meet criteria for ICU consult: No

RN FOLLOW UP DEBRIFING

Primary RN name: Jessica

Contact information for further questions or concerns: B service, RRT

Jaynee Stoscup, RN

Pager # 1234 Electronically signed by Jaynee S at 08/26/2023 6:20 PM EDT RRT - Nursing Note - Jaynee S - 08/26/2023 3:15 PM EDT Formatting of this note is different from the original. Reason for call: Hypotension, sepsis, AMS Prior BRAT visit: NA Time of call: 1510 Time of Arrival: 1515 End of call: 1610

Code Status

Code Status Comments No CPR Discussed with patient's daughter and patient's sister

Modified Resuscitation Specifics: In a non-arrest state, permit intubation?: No In a non-arrest state, permit vaso-active medications?: Yes In a non-arrest state, permit antiarrhythmics?: Yes In a non-arrest state, permit cardioversion?: Yes Decision Arrived By:: Decision discussed with patient/decision-maker 8/1/2023 5:23 PM

Altered mental status, unspecified altered mental status type [R41.82] Respiratory failure (CMS/HCC) [J96.90]

Not on File

No past medical history on file. No past surgical history on file. No family history on file. Social History

Socioeconomic History Marital status: Divorced

Temp 99.3 °F (37.4 °C) (08/26/23 1506) Source Axillary (08/26/23 1506) BP (!) 89/59 (R/N notified) (08/26/23 1506) Heart Rate 98 (08/26/23 1506) Resp 17 (08/26/23 1506) O2 (L/min) 2 L/min (08/24/23 0702) SpO2 95 % (08/26/23 1506) O2% 21 % (08/17/23 0645) Height 188 cm (6' 2.02") (08/10/23 2300) Weight 87.1 kg (192 lb 0.3 oz) (08/23/23 0600) BMI 24.6 (08/23/23 0600)

WBC Hgb Hct Plt 7.0 (08/26 1230) 11.6 (08/26 1230) 36.7 (08/26 1230) 189 (08/26 1230) NA K CI CO2 136 (08/26 1230) 3.0 (08/26 1230) 103 (08/26 1230) 23 (08/26 1230) BUN Creat Glucose 12 (08/26 1230) 0.57 (08/26 1230) 131 (08/26 1230) PT PTT INR

Intake/Output Summary (Last 24 hours) at 8/26/2023 1609 Last data filed at 8/26/2023 1200 Gross per 24 hour Intake 1905 ml Output 3000 ml Net -1095 ml

Assessment: Patient lethargic laying in bed. Baseline A&Ox0 due to anoxic brain injury. Per nursing staff and patient son, Patient is more lethargic then yesterday. Fever 101.3 tylenol given. BP 89/59 500 ml LR bolus infusing. Orders for chest xray, blood cultures, and labs completed. IV team able to place ultrasound IV and power glide for antibiotics and fluids. Contacted Dr. Paris regarding altered mental status. Verbal orders to hold Klonopin dose tonight. K 3.0 supplements ordered. New orders for rocephin, flagyl, and zithro antibiotics.

Medications given during call: 500 ML bolus Plan of Care: Monitor for worsening s/s of sensis, hold off on disc

Plan of Care: Monitor for worsening s/s of sepsis, hold off on discharge. Physician consulted: Infectious disease, b service. Follow up needed: As needed

BRAT CALL DEBRIFING

Does this patient meet criteria for transfer to a higher level of care: No

Does this pt require an ICU consult at this time: No

PRIMARY RN DEBRIFING

Primary RN name: Jessica Signs and symptoms to monitor for: worsening s/s or any concerns Who to contact with new or further concerns: B service, RRT

Jaynee Stoscup, RN

Electronically signed by Jaynee S at 08/26/2023 4:15 PM EDT Nsg Progress Note - Jessica D - 08/26/2023 11:56 AM EDT Formatting of this note might be different from the original. 1156 RN messaged Dr Manju the following: pt temp is 101.3 and he is having rigors. Tylenol given. Will recheck temp in 1 hour. Pls advise. Also his skin looks like its mottled. - a picture was sent with this message to show how his skin looked) 1406 Rn messaged Dr Manju the following. Pt k+ is 3, creatinine is 0.57. pls advise. 1408 Orders received. Pls see emar 1515 RRT called to evaluate patient 1521 RN messaged Dr Manju the following: Just fyi RRT is at the bedside. Pt bp is 89/59. They are asking for fluids to be ordered. 1536 Advise to reach out to Dr Sauerbeck, he is now covering b service. Rn message Dr Sauerbeck and updated him on the patient. 1900 DDr Sauerbeck notified pt lactic acid is 2.4. Electronically signed by Jessica D at 08/26/2023 8:03 PM EDT Care Plan Note - Jessica D - 08/26/2023 7:31 AM EDT Formatting of this note might be different from the original. Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing Problem: Health Behavior: Goal: Ability to manage health-related needs will improve 8/26/2023 0731 by Desouza, Jessica C, RN **Outcome: Progressing** 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing Problem: Skin Integrity: Goal: Skin integrity will be maintained 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing Goal: Will remain free from infection 8/26/2023 0731 by Desouza, Jessica C, RN **Outcome: Progressing** 8/25/2023 1739 by Desouza, Jessica C, RN **Outcome: Progressing** Problem: Cognitive: Goal: Understanding of ways to prevent infection will improve 8/26/2023 0731 by Desouza, Jessica C, RN **Outcome: Progressing** 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing Problem: Physical Regulation: Goal: Will remain free from infection Description: World Health Organization (WHO) identifies hands as the main mode of germ transmission in health care. Hand hygiene may be considered the most important measure performed to avoid transmission of germs and prevent health care associated infection. 8/26/2023 0731 by Desouza, Jessica C, RN

Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing

Problem: Respiratory: Goal: Will remain free from respiratory infection 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing

Problem: Skin Integrity: Goal: Remain free from infection at wound or surgical site 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing

Problem: Urinary Elimination: Goal: Will remain free from infection Description: See the Catheter-Associated Urinary Tract Infection Prevention module for interventions specific to this topic 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing

Problem: Coping: Goal: Coping ability will improve 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing

Problem: Fluid Volume: Goal: Ability to maintain a balanced intake and output will improve 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing

Problem: Physical Regulation: Goal: Signs and symptoms of infection will decrease 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing Goal: Complications related to the disease process, condition or treatment will be avoided or minimized 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN

Problem: Respiratory: Goal: Will regain and/or maintain adequate ventilation 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing

Problem: Sensory: Goal: General experience of comfort will improve 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing Goal: Will verbalize understanding of the information provided 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing Goal: Will identify and develop effective coping behavior 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve 8/26/2023 0731 by Desouza, Jessica C, RN Outcome: Progressing 8/25/2023 1739 by Desouza, Jessica C, RN **Outcome: Progressing**

Electronically signed by Jessica D at 08/26/2023 7:31 AM EDT Care Plan Note - Jessica D - 08/25/2023 5:39 PM EDT Formatting of this note might be different from the original.

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent infection will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Will remain free from infection Description: World Health Organization (WHO) identifies hands as the main mode of germ transmission in health care. Hand hygiene may be considered the most important measure performed to avoid transmission of germs and prevent health care associated infection. Outcome: Progressing

Problem: Respiratory: Goal: Will remain free from respiratory infection Outcome: Progressing

Problem: Skin Integrity: Goal: Remain free from infection at wound or surgical site Outcome: Progressing

Problem: Urinary Elimination: Goal: Will remain free from infection Description: See the Catheter-Associated Urinary Tract Infection Prevention module for interventions specific to this topic Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Coping: Goal: Coping ability will improve Outcome: Progressing

Problem: Fluid Volume: Goal: Ability to maintain a balanced intake and output will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Signs and symptoms of infection will decrease Outcome: Progressing Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing

Problem: Respiratory: Goal: Will regain and/or maintain adequate ventilation Outcome: Progressing

Problem: Sensory: Goal: General experience of comfort will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing Electronically signed by Jessica D at 08/25/2023 5:39 PM EDT Care Management - Melanie H - 08/25/2023 2:23 PM EDT Formatting of this note might be different from the original. DC order noted, spoke with Vicki and informed her, she will visit pt today to assess if she can bring him back to GH. She asked if pt could stay until next week, discussed that dc order placed and ins would not cover pt to stay at hospital. Meanwhile pt does not have restraints and CM contacting RN about one to one sitter. Meanwhile writer will reach out to facilities for LTC bed. List printed and left at bedside for choices. 1617: tasked to afternoons and weekends to f/u for dc plan or choices. Electronically signed by Melanie H at 08/25/2023 4:20 PM EDT

Nsg Progress Note - Breanna B - 08/25/2023 7:48 AM EDT Formatting of this note might be different from the original. Pt slept through the night except when being woken up to be changed/turned. Electronically signed by Breanna B at 08/25/2023 7:49 AM EDT Care Plan Note - Breanna B - 08/25/2023 3:38 AM EDT

Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Not Progressing

Problem: Fluid Volume: Goal: Ability to maintain a balanced intake and output will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Signs and symptoms of infection will decrease Outcome: Progressing

Problem: Respiratory: Goal: Will regain and/or maintain adequate ventilation Outcome: Progressing

Problem: Sensory: Goal: General experience of comfort will improve Outcome: Progressing

Electronically signed by Breanna B at 08/25/2023 3:38 AM EDT

Nsg Progress Note - Jessica Z - 08/24/2023 3:27 PM EDT

Formatting of this note might be different from the original.

Pt has been intermittently agitated today with staff. Pt is confused A/Ox0 and has language barrier. Pt has been resting and not pulling at lines unless pt is incontinent and uncomfortable. RN and LPN hourly rounding and PRN checking in on pt more often, as well as discussing pt condition changes with 1-1 sitter at bedside. 1-1 sitter is aware to report any changes to RN or LPN.

Klonopin AM dose was held as pt is lethargic at 0900. Zyprexa given as scheduled. Discussed plan of care with Dr. Omar on 8/23 at the bedside. Per Dr. Omar, it is okay with her if a dose or two is held if pt is more lethargic and not pulling at lines. Pt requires klonopin at 1400 dose due to agitation with changing sheets. Once linen is changed, pt falls to sleep and lines and tubes can be hidden for pt safety.

Pt son was also at bedside yesterday evening and states he is concerned of pt lethargy. He requests that we hold sedating medications during the daytime unless neccessary for pt and staff safety. Pt son agrees to sedating medications on night shift so he can sleep at night and have more alertness during the day. Electronically signed by Jessica Z at 08/24/2023 3:41 PM EDT

Nsg Progress Note - Jessica Z - 08/24/2023 11:35 AM EDT

Formatting of this note might be different from the original. Pt had previous foley, foley changed per Dr. Grandy orders.

Indwelling Urinary Catheter was inserted per physician order. RN washed hands prior to procedure. Peri-Care provided with pericare kit. RN washed hands prior to insertion. Pt was covered with sterile drapes. Urethra and surrounding tissue was prepped and cleaned using a povidone-iodine solution. Catheter was appropriately lubricated and inserted into the urinary meatus. Catheter was advanced with no difficulty using a 18 fr catheter. Immediate urine return of 50 ml of yellow/straw colored urine. Balloon inflated without complications. Catheter tubing was secured to the Right leg using a STAT lock device. Drainage bag was secured at the foot of the bed without dependent loops in the tubing. Strict aseptic technique was observed and verified by Crystal LPN. Electronically signed by Jessica Z at 08/24/2023 11:38 AM EDT

Care Plan Note - Jessica Z - 08/24/2023 7:39 AM EDT Formatting of this note might be different from the original.

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent infection will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Will remain free from infection Description: World Health Organization (WHO) identifies hands as the main mode of germ transmission in health care. Hand hygiene may be considered the most important measure performed to avoid transmission of germs and prevent health care associated infection. Outcome: Progressing

Problem: Respiratory: Goal: Will remain free from respiratory infection Outcome: Progressing

Problem: Skin Integrity: Goal: Remain free from infection at wound or surgical site Outcome: Progressing

Problem: Urinary Elimination: Goal: Will remain free from infection Description: See the Catheter-Associated Urinary Tract Infection Prevention module for interventions specific to this topic Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Coping: Goal: Coping ability will improve Outcome: Progressing

Problem: Fluid Volume: Goal: Ability to maintain a balanced intake and output will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Signs and symptoms of infection will decrease Outcome: Progressing Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing

Problem: Respiratory: Goal: Will regain and/or maintain adequate ventilation Outcome: Progressing

Problem: Sensory: Goal: General experience of comfort will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Electronically signed by Jessica Z at 08/24/2023 7:39 AM EDT

Communication - Briana P - 08/24/2023 7:12 AM EDT Formatting of this note might be different from the original. Patient slept about three hours. Patient demeanor was calm overnight. Required no PRN medications. Electronically signed by Briana P at 08/24/2023 7:15 AM EDT

Care Management - Deborah A - 08/23/2023 3:59 PM EDT

Formatting of this note might be different from the original.

Patient continues with 1:1 sitter in place. Spoke with sister, Vicki, via phone. Vicki reports is still considering accepting patient to her group home- but patient needs to sleep more at night. Spoke with nurse, Jessica, and advised to document and ask midnight staff to document how will patient is sleeping at night. Message to NP Saunders to advise regarding above. Department following. Ph 521-7800

Electronically signed by Deborah A at 08/23/2023 4:13 PM EDT PT/OT Progress Note - Vinod D - 08/23/2023 3:52 PM EDT Formatting of this note is different from the original.

08/23/23 0947 Event/Subjective Event Note Attempted PT/OT today. Patient is with respiratory therapy. Will follow up later.

Electronically signed by Vinod D at 08/23/2023 3:52 PM EDT PT/OT Progress Note - Sara R - 08/23/2023 2:29 PM EDT Formatting of this note is different from the original.

08/23/23 1228 Event/Subjective Event Note Attempted PT/OT and pt with Respiratory therapy. To come back, time permitting and continue to follow.

Electronically signed by Rochelle W at 08/24/2023 7:10 AM EDT Care Plan Note - Jessica Z - 08/23/2023 12:02 PM EDT Formatting of this note might be different from the original.

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent infection will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Will remain free from infection Description: World Health Organization (WHO) identifies hands as the main mode of germ transmission in health care. Hand hygiene may be considered the most important measure performed to avoid transmission of germs and prevent health care associated infection. Outcome: Progressing

Problem: Respiratory: Goal: Will remain free from respiratory infection Outcome: Progressing

Problem: Skin Integrity: Goal: Remain free from infection at wound or surgical site Outcome: Progressing

Problem: Urinary Elimination: Goal: Will remain free from infection Description: See the Catheter-Associated Urinary Tract Infection Prevention module for interventions specific to this topic Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Coping: Goal: Coping ability will improve Outcome: Progressing

Problem: Fluid Volume: Goal: Ability to maintain a balanced intake and output will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Signs and symptoms of infection will decrease Outcome: Progressing Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing

Problem: Respiratory: Goal: Will regain and/or maintain adequate ventilation Outcome: Progressing Problem: Sensory: Goal: General experience of comfort will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Electronically signed by Jessica Z at 08/23/2023 12:02 PM EDT Pharmacist Progress Note - Maria S - 08/23/2023 3:44 AM EDT

Formatting of this note is different from the original. Pharmacy Dosing Consult: Vancomycin Initial Consult Drug: Vancomycin Indication: Pneumonia Target: Trough 15-20 mcg/mL Other Antimicrobials: Cefepime Patient Specific Parameters and Labs Vital Signs: BP (!) 89/65 | Pulse 120 | Temp 98.7 °F (37.1 °C) (Axillary) | Resp 22 | Ht 188 cm (6' 2.02") | Wt 87.1 kg (192 lb 0.3 oz) | SpO2 95% | BMI 24.64 kg/m² Temp (24hrs), Avg:99 °F (37.2 °C), Min:98.3 °F (36.8 °C), Max:101.6 °F (38.7 °C) Total body weight: 87.1 kg (192 lb 0.3 oz) Ideal body weight: 82.2 kg (181 lb 4.8 oz) Adjusted ideal body weight: 84.2 kg (185 lb 9.4 oz) Body mass index is 24.64 kg/m^2 . Weight used to calculate CrCl and Ke: ideal body weight (IBW) CrCl or renal function: Estimated CrCl (based on Cockcroft and Gault) = 71 mL/min , Scr used: 1 Recent Labs 08/23/23 0036 08/20/23 1417 08/18/23 0403 08/17/23 0310 WBC 12.4* 9.8 8.8 9.7 CREAT 0.64 0.60 0.62 0.65 BUN 16 13 13 16 ALB -- 2.6* 2.6* 2.6* Pharmacokinetics Recent vancomycin history: Yes - Reviewed for dosing Estimated Ke: 0.064 hr-1 Estimated Vd: 56.6 L (Vd coefficient used: 0.65) Estimated T1/2: 10.9 hours Microbiology Cultures pending Assessment Renal function/baseline SCr: est = 1 Meets criteria for levels after 72 hrs?: No - patient is hemodynamically unstable Current risk factors for nephrotoxicity: ICU residence Plan Vancomycin 2250 mg IVPB x1 followed by Vancomycin 1000 mg every 12 hours to achieve a predicted AUC 554 and Cmin 16 mcg/ mL Plan to check levels within 72 hours of initiation Monitor SCr daily Pharmacy will continue to monitor renal function, WBC, cultures and the clinical progress of the patient. Please do not hesitate to contact us with comments or questions. Thank you, Maria Szewc, PHARMACIST, 8/23/2023 Available on Mobile Heartbeat Vancomvcin Calculator Adult Vancomycin Pharmacy Dosing Guideline Electronically signed by Maria S at 08/23/2023 3:44 AM EDT

RRT - Mid-Level Provider - Camilla A - 08/23/2023 12:19 AM EDT

Formatting of this note might be different from the original. RRT - Mid-Level Provider

Reason for Call: temp

Subjective: pt admitted through ER via EMS with mental status changes from a+o x 1 to a+o x 0 and hypoglycemia on 8/1/23. Pt has hx VT arrest and subsequent anoxic brain injury. History for atrial flutter on eliquis. Called regarding elevated temp 101.6. pt evaluated in room, displaying congested lower airway lung sounds audible without

stethoscope. Attempt at NT suctioning first pass ended up causing TF emesis and possible aspiration.

Pertinent history: No past medical history on file. No past surgical history on file.

Allergies: Not on File

Objective:

Pertinent examination findings:

Constitutional: sitting up at 60 degrees, intermittently coughing, appears in nad Vital signs: BP 139/86 | Pulse (!) 129 | Temp (!) 101.6 °F (38.7 °C) (Axillary) | Resp 22 | Ht 188 cm (6' 2.02") | Wt 87.1 kg (192 lb 0.3 oz) | SpO2 95% | BMI 24.64 kg/m² Cardiovascular: tachycardic in 120s with temp 101 Respiratory: Coarse and rate in mid 20s. Gastrointestinal: Distension tube feeding infusing at 10cc/hr Neurological: at baseline; awake, alert but sleepy. Head: Atraumatic normocephalic ENT: Mucus membranes pink & moist Eyes: na Neck: non-stridorous breathing, traceha midline. Genitourinary/Anorectal: Not assessed Musculoskeletal: Normal ROM Skin: Intact, Warm, and Dry Psych: Not assessed

Pertinent investigation findings reviewed:

WBC/Hg/Hct/Plt: pending Na/K/Cl/CO2: 139/3.6/104/25 (08/20 1417) BUN/CREAT: 13/0.60 (08/20 1417) Glucose: 159/-- (08/22 2351)

CXR - 8/21/23 no acute cp process CT Head CT - na CT Chest - na CT Abdomen - NA ECG - PENDING

Assessment/Diagnosis: PT WITH ATELECTASIS, COARSE RHONCHI AND TEMP

Plan:

ATTEMPT AT NT SUCTION FAILED AND RESULTED IN EMESIS OF TUBE FEEDING -STAT CXR EVAL FOR ASPIRATION -KUB TO EVAL FOR ILEUS- LARGE EMESIS OF TUBE FEEDING RESIDUAL IN SYRINGE <10CC -HOLD TUBE FEEDING OVERNIGHT -CHEST PT QID -BRONCHODILATOR PROTOCOL -MUCOMYST TREATMENTS

Critical care time: 30

I have reviewed and discussed the above findings and plans with attending Dr. William M Rudy

PA / NP Signature: Name:Camilla T Arcand, RN NP-C Date: 8/23/2023, 12:41 AM

Pager Number: PH PAGER B SVC

Nutr Serv Progress Note - Rima C - 08/22/2023 11:33 AM EDT Formatting of this note is different from the original.

NUTRITION SERVICES - FOLLOW-UP ASSESSMENT Name: Ioan Suiugan-62y.o.Male MRN: 9942681 LOS: 21 Room:475/475 Reason for Visit: Nutrition Reassessment Nutrition Therapy Protocol Yes 8/18- stable for discharge from internal medicine perspective since 8/9/23. Discharge delay 2/2 psychiatric component and psych interventions. Per IM goals of care discussions ongoing,hospice vs sons hesitation to stop TF.

8/15 - With agitation pt pulling at PEG tube. Pt with 1:1 sitter. Per case management 8/13, planning for pt discharge to SNF once pt is restraint and sitter free for 24 hrs.

8/9 - Pt had toxic metabolic encephalopathy superimposed on anoxic brain injury secondary to sepsis/UTI per Internal medicine NP. Pt is still disoriented and aggressive, is on restraints, and requires TF. Per Internal Medicine Physician, no acute medical problems. Antibiotics completed, adjusted IVF, dc planning.

HPI: 62y.o.M presented to ED c/o altered mental status. Per Emergency Medicine Resident 8/1, pt is A&Ox1 and had a V. Tach cardiac arrest with subsequent anoxic brain injury in May 2023. Per Internal medicine Resident H&P 8/2, pt is currently on restraints. Pt hyperglycemic upon admission but decreased glucose levels to 137.

Subjective: Pt visited, sitter in room. Patient tolerating TF at goal 70 mL/hr. Oral intakes on puree 1:1 remain noncontributory often does not eat a bite of food orally at meal time. FOOD AND NUTRITION HISTORY: Current Diet Order Orders Placed This Encounter Adult Diet - Diet Consistency: Dysphagia; Dysphagia Diet: Pureed; Additional Restrictions: 1:1 Feed; Non Room Service Tube Feeding with Oral Diet - Tube Feed: Tube Feeding,; Product: Glucerna 1.5; Rate Goal ml/hr: 70; Tube Feeding Water Flush (mL):

75; Water Flush Frequency: Other (specify) (q1hr); Non Room Service

Food Allergies: NKFA per chart.

Cultural/Religious Practices: na

Appetite: na Intake: Pt's current Glucerna 1.5 is 70 mL/hr and 75 mL water flush. Oral intake remains minimal. Chewing/Swallowing: na

GI: LBM 8/21 per chart. Skin: PI Stage 1 sacrum , Wound r anterior knee per chart. Edema: RLE +1 and LLE +1 per chart.

BIOCHEMICAL DATA/ MEDICATIONS/ TESTS / PROCEDURES: Recent Labs 08/20/23 1417 08/20/23 1617 08/21/23 2028 08/22/23 0604 08/22/23 1121 NA 139 -- -- --К 3.6 -- -- --CL 104 -- -- --CO2 25 -- -- --GLU 135* < > 157* 142* 186* BUN 13 -- -- --CREAT 0.60 -- -- --EGFR 109 -- -- --CALCIUM 8.3* -- -- --MG 2.0 -- -- --ALB 2.6* -- -- --AST 24 -- -- --ALT 19 -- -- --ALP 133* -- -- --< > = values in this interval not displayed.

Medications: SCHEDULED: amiodarone, 200 mg, PEG Tube, DAILY apixaban (ELIQUIS) tablet DVT/PE TREATMENT CONTINUATION BEYOND 7 DAYS, 5 mg, Oral, Q 12 H atorvastatin, 40 mg, PEG Tube, Q HS clonazePAM, 1 mg, PEG Tube, TID clopidogrel, 75 mg, Oral, DAILY insulin regular human, 2-5 Units, Subcutaneous, Q 6 H metoprolol, 25 mg, PEG Tube, BID OLANZapine, 10 mg, Oral, BID sodium chloride, 10 mL, Intravenous, Q 12 H valproate, 1,000 mg, Oral, BID

IVF:

PRN:

- acetaminophen
- LORazepam
- sodium chloride
- sodium chloride
- sodium chloride
- sodium chloride 0.9%

Tests/Procedures:

8/2 CT chest IV contrast - pleural effusion, emphysematous changes, L renal simple cyst, and PEG tube noted in appropriate positioning.

NUTRITION FOCUSED PHYSICAL FINDINGS: Nutrition Focused Physical Exam: Subcutaneous Fat Depletion Musculoskeletal Depletion Classification: Moderate [x] Orbital region [x] Upper arm region -triceps/biceps [] Thoracic & lumbar region - ribs, lower back, midaxillary line Classification: Moderate [x] Temporalis [x] Clavicle & acromion bone region [x] Clavicle bone region [] Scapular bone region [] Dorsal hand [x] Patellar region [x] Anterior thigh region [x] Posterior calf region

ANTHROPOMETRICS: Admit Weight: 99.8 kg (220 lb), Weight Source: Bed scale Current Weight: 87.1 kg (192 lb 0.3 oz), Weight Source: Bed scale Body mass index is 24.64 kg/m². BMI Classification: WNL

IBW: 86.4 kg UBW: na kg All weight readings from this encounter 08/11/23 0800 87.1 kg (192 lb 0.3 oz) 08/10/23 2300 84.8 kg (186 lb 15.2 oz) 08/08/23 0600 85.3 kg (188 lb 0.8 oz) 08/07/23 0549 87.4 kg (192 lb 10.9 oz) 08/06/23 0424 85.2 kg (187 lb 13.3 oz) 08/05/23 0340 85.2 kg (187 lb 13.3 oz) 08/02/23 0300 99.8 kg (220 lb) 08/01/23 1727 99.8 kg (220 lb)

Weight Trend: 12.7% weight loss in the last 1.5 weeks per Epic weight history. Weight seems to improve. Question previous weight bed scale accuracy. Pt appears thinner than previous visit suspect fluid related.

ESTIMATED NUTRITIONAL NEEDS: Calories: 2177+ kcal/day based on 25 kcal/kg using current body weight (87.1 kg) Protein: 105-131 gm/day based on 1.2-1.5 gm/kg using current body weight Fluid: 2177 mL based on 1 mL/kcal or per provider. Adjust fluids based on intake and output to maintain fluid balance and hemodynamic stability

NUTRITION DIAGNOSIS:

Increased protein needs related to wounds as evidenced by Pressure injury Stage II center Sacrum. - N/A pressure injury now

documented as stage 1

NEW

Alteration in GI function related to dysphagia/mental status as evidenced by need for alternate means of nutrition, modified textures and consistencies/

INTERVENTION: Intervention(s): Saw pt, follow-up completed. Chart reviewed. Assessed TF

Goal(s): TF to provide >90% nutrient needs. - met, ongoing. Prevent significant/unintentional weight loss. - met, ongoing. Pt to have evidence of wound healing. - now noted to be stage 1, improvement

MONITORING & EVALUATING TF tolerance. Pertinent labs. Weight trends.

Nutrition related discharge needs at this time - TF

Follow Up Range: based on patient care goals, 5-7 days

RECOMMENDATIONS: Continue TF: Glucerna 1.5 at 70 mL/hr. TF at goal provides: 2520 kcal, 138 gm protein, 1276 mL free H2O Enteral H2O: defer to provider. Aspiration precautions, HOB > 30-45 degrees at all times.

947-521-8220 Available via Mobile Heartbeat" Electronically signed by Rima C at 08/22/2023 11:43 AM EDT Care Plan Note - Simi A - 08/22/2023 10:51 AM EDT

Formatting of this note might be different from the original.

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent infection will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Will remain free from infection Description: World Health Organization (WHO) identifies hands as the main mode of germ transmission in health care. Hand hygiene may be considered the most important measure performed to avoid transmission of germs and prevent health care associated infection. Outcome: Progressing

Problem: Respiratory: Goal: Will remain free from respiratory infection **Outcome: Progressing**

Problem: Skin Integrity: Goal: Remain free from infection at wound or surgical site Outcome: Progressing

Problem: Urinary Elimination: Goal: Will remain free from infection Description: See the Catheter-Associated Urinary Tract Infection Prevention module for interventions specific to this topic Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Coping: Goal: Coping ability will improve Outcome: Progressing

Problem: Fluid Volume: Goal: Ability to maintain a balanced intake and output will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Signs and symptoms of infection will decrease Outcome: Progressing Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing

Problem: Respiratory: Goal: Will regain and/or maintain adequate ventilation Outcome: Progressing

Problem: Sensory: Goal: General experience of comfort will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Electronically signed by Simi A at 08/22/2023 10:51 AM EDT PT/OT Progress Note - Jais M - 08/22/2023 9:36 AM EDT Formatting of this note is different from the original.

08/22/23 0900 Event/Subjective Event Note PT Attempted for reevaluation.Pt sleeping unable to be awake to be compliant with PT.Sitter informed Pt had a rough night sleeping since 7 am.PT will follow up.

Electronically signed by Jais M at 08/22/2023 9:38 AM EDT Care Plan Note - Turquoise H - 08/21/2023 11:32 PM EDT Formatting of this note might be different from the original.

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent infection will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Will remain free from infection Description: World Health Organization (WHO) identifies hands as the main mode of germ transmission in health care. Hand hygiene may be considered the most important measure performed to avoid transmission of germs and prevent health care associated infection. Outcome: Progressing

Problem: Respiratory: Goal: Will remain free from respiratory infection Outcome: Progressing

Problem: Skin Integrity: Goal: Remain free from infection at wound or surgical site Outcome: Progressing

Problem: Urinary Elimination: Goal: Will remain free from infection Description: See the Catheter-Associated Urinary Tract Infection Prevention module for interventions specific to this topic Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Coping: Goal: Coping ability will improve Outcome: Progressing

Problem: Fluid Volume: Goal: Ability to maintain a balanced intake and output will improve Outcome: Progressing Problem: Physical Regulation: Goal: Signs and symptoms of infection will decrease Outcome: Progressing Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing

Problem: Respiratory: Goal: Will regain and/or maintain adequate ventilation Outcome: Progressing

Problem: Sensory: Goal: General experience of comfort will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Electronically signed by Turquoise H at 08/21/2023 11:32 PM EDT PT/OT Progress Note - Mansoora A - 08/21/2023 5:24 PM EDT Formatting of this note is different from the original.

08/21/23 1217 Time Detail PT Visit Number 5 (seen in 475) Time Eval/Tx Initiated 1217 Total Eval/Tx Time (min) - individual 30 min Event/Subjective PT Received On 08/21/23 Event Note AMS, CT Brain (-), hx of anoxic brain injury, DM Subjective Lethargic, sleepy, non - verbal Patient Goal unable to state Observation In Bed before Treatment; Bed Alarm (son and 1:1 sitter present) Assessment Assessment Tolerated eval/tx poor Tolerated eval/tx poor additional detail patient lethargic; waking up more toward end of treatment with more active participation Therapy Problem List Impaired Bed Mobility; Impaired Transfers; Impaired Functional Mobility; Impaired Gait Skills; Impaired Balance; Impaired Strength; Impaired Functional Endurance Rehab Potential Poor; Other (Comments) (quarded) Goals Discussed With Family (son at bed side) How is your pain at the end of the therapy session? 0 Recommendation PT Discharge Instructions In progress PT Discharge Recommendations SAR (Subacute rehab) PT DME Recommendations To be determined PT/OT Post Treatment Post tx patient left in bed;Post tx left patient with lines intact;Post tx call light/phone within reach Plan

Treatment/Interventions Physical Therapy is recommended to address deficits.

PT Frequency 3-5x/wk Precautions Precautions Other (Add Comment) (fall ,ressure injury, contact d/t MDR-CRE) Learning Barriers Learning Barriers (PT/OT) Carryover; Impaired Cognition; Judgement; Language; Safety Cognition Arousal/Alertness Lethargic Follows Commands Inconsistently (followed a few commands from son in Romanian) Memory UTA Safety Judgement Impaired Pain Screening/Assessment Screening/Pain Scale Used Face, Legs, Activity, Crying, Consolability (FLACC) Pain Score 4 (Left hip with rolling) Bed Mobility **Rolling Dependent** Supine to Sit Dependent (long sit) Sit to Supine Dependent (from long sit to supine) Supine Scoot Dependent Transfers Sit to Stand UTA Gait/Stairs Gait /Functional Mobillity Assistance UTA Balance Sitting - Static Absent Sitting - Dynamic Not tested Standing - Static Not tested Standing - Dynamic Not tested Exercise/Interventions Ankle Pumps Bilateral Exercise/Interventions Details x15 PROM Short Arc Quad Bilateral Exercise/Interventions Details PROM x 10 x 2 Supine Hip Abduction Bilateral Exercise/Interventions Details PROM x 10 x 2 Significant Time Spent Significant Time Spent On Encouragement Mobility - AM-PAC 6 CLICK Turning from your back to your side while in a flat bed without using bedrails? 1 Moving from lying on your back to sitting on the side of a flat bed without using bedrails? 1 Moving to and from a bed to a chair (including a wheelchair)? 1 Standing up from a chair using your arms (e.g., wheelchair, or bedside chair)? 1 To walk in hospital room? 1 Climbing 3-5 steps with a railing? 1 Mobility Score 6 Patient Safety Bed in lowest position Yes Side rails/Bed safety 3/4 Bed alarm on if indicated Yes Interdisciplinary Communication Interdisciplinary Communication spoke with OT;RN Interdisciplinary Communication topic Mobility status **Communication with Patient** Reason for Communication Update on Condition/Status Type of Communication Face-to-Face

Electronically signed by Mansoora A at 08/21/2023 5:24 PM EDT PT/OT Progress Note - Heather S - 08/21/2023 4:51 PM EDT Formatting of this note is different from the original.

08/21/23 1245 Time Detail OT Visit Number 4 (475) Time Eval/Tx Initiated 1245 Total Eval/Tx Time (min) - individual 30 min **Event/Subjective** OT Received On 08/21/23 Event Note AMS, CT Brain (-), hx of anoxic brain injury, DM Patient Goal unable to state **Observation In Bed before Treatment** Assessment Assessment Tolerated eval/tx poor Tolerated eval/tx poor additional detail patient lethargic; waking up more toward end of treatment with more active participation Therapy Problem List Impaired Bed Mobility; Impaired Transfers; Impaired Functional Mobility; Impaired Balance; Impaired Strength;Impaired Cognition;Impaired Upper Body Dressing;Impaired Lower Body Dressing;Impaired Upper Body Bathing;Impaired Lower Body Bathing; Impaired Toileting; Impaired Grooming; Impaired Eating; Impaired Functional Endurance **Rehab Potential** (guarded) Recommendation OT Discharge Instructions In progress OT Discharge Recommendations SAR (Subacute rehab) OT DME Recommendations To be determined PT/OT Post Treatment Post tx patient left in bed;Post tx left patient with lines intact;Post tx call light/phone within reach Plan Treatment Interventions ADL retraining; Functional transfer training; Mobility/transfer training as related to ADLs; UE strengthening/ ROM; Endurance training; Cognitive reorientation; Patient/Family training; Equipment eval/education; Education on diagnosis specific precautions;Bed mobility;Balance;Therapeutic activities;Therapeutic exercises;Energy conservation;Pain management techniques and education;Recommend DME OT Frequency 3-5 x/wk Learning Barriers Learning Barriers (PT/OT) Carryover; Impaired Cognition; Judgement; Language; Safety Precautions Precautions (fall, pressure) Cognition Arousal/Alertness Lethargic Follows Commands Inconsistently (followed a few commands from son in Romanian) Pain Screening/Assessment Screening/Pain Scale Used Face, Legs, Activity, Crying, Consolability (FLACC) Pain Score 4 (Left hip with rolling) **Bed Mobility** Rolling Dependent Supine to Sit Dependent (lona sit) Supine Scoot Dependent Transfers Sit to Stand UTA Balance Sitting - Static Absent Sitting - Dynamic Not tested Exercise/Interventions Exercise & Intervention Comment b/I UE PROM to all joints; as patient starting becoming more alert active movement of b/I arms was noted. followed a few instructions from son to lift/move arms Activities of Daily Living - AM-PAC 6 CLICK Putting on and taking off regular lower body clothing? 1 Bathing (including washing, rinsing, drying)? 1 Toileting, which includes using toilet, bedpan or urinal? 1 Putting on and taking off regular upper body clothing? 1 Taking care of personal grooming such as brushing teeth? 1 Eating meals? 1 Activities of Daily Living Score 6 Patient Safety Bed in lowest position Yes Side rails/Bed safety 3/4 Bed alarm on if indicated Yes Interdisciplinary Communication Interdisciplinary Communication spoke with PT Interdisciplinary Communication topic Mobility status

Care Plan Note - Lauren O - 08/21/2023 11:28 AM EDT Formatting of this note might be different from the original.

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent infection will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Will remain free from infection Description: World Health Organization (WHO) identifies hands as the main mode of germ transmission in health care. Hand hygiene may be considered the most important measure performed to avoid transmission of germs and prevent health care associated infection. Outcome: Progressing

Problem: Respiratory: Goal: Will remain free from respiratory infection Outcome: Progressing

Problem: Skin Integrity: Goal: Remain free from infection at wound or surgical site Outcome: Progressing

Problem: Urinary Elimination: Goal: Will remain free from infection Description: See the Catheter-Associated Urinary Tract Infection Prevention module for interventions specific to this topic Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Coping: Goal: Coping ability will improve Outcome: Progressing

Problem: Fluid Volume: Goal: Ability to maintain a balanced intake and output will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Signs and symptoms of infection will decrease Outcome: Progressing Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing

Problem: Respiratory: Goal: Will regain and/or maintain adequate ventilation **Outcome: Progressing**

Problem: Sensory: Goal: General experience of comfort will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Electronically signed by Lauren O at 08/21/2023 11:28 AM EDT

Social Work - Christina L - 08/21/2023 10:36 AM EDT

Formatting of this note might be different from the original.

Chart reviewed. Patient currently has 1:1 sitter, mittens discharged. Patient's sister requesting re-eval for potential return to group home.SAR referrals also sent. Discharge pending final recommendations. Will need updated PT/OT clinical for SAR should plan be to D/C to SAR.

Christina LLMSW 520-5958 Electronically signed by Christina L at 08/21/2023 1:02 PM EDT

Nsg Progress Note - Lauren O - 08/21/2023 10:33 AM EDT

Formatting of this note might be different from the original.

Upon assessment, writer noted that patient sounds congested with respirations. Auscultation with stethscope lung sounds clear. Saunders NP notified of findings. Pt O2 sat 93% and greater, no respiratory distress noted. Will continue plan of care. Electronically signed by Lauren O at 08/21/2023 10:51 AM EDT

Care Plan Note - Jessica Z - 08/20/2023 7:55 AM EDT

Formatting of this note might be different from the original.

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent infection will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Will remain free from infection Description: World Health Organization (WHO) identifies hands as the main mode of germ transmission in health care. Hand hygiene may be considered the most important measure performed to avoid transmission of germs and prevent health care associated infection. Outcome: Progressing

Problem: Respiratory: Goal: Will remain free from respiratory infection Outcome: Progressing

Problem: Skin Integrity: Goal: Remain free from infection at wound or surgical site Outcome: Progressing

Problem: Urinary Elimination: Goal: Will remain free from infection Description: See the Catheter-Associated Urinary Tract Infection Prevention module for interventions specific to this topic Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Coping: Goal: Coping ability will improve Outcome: Progressing

Problem: Fluid Volume: Goal: Ability to maintain a balanced intake and output will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Signs and symptoms of infection will decrease Outcome: Progressing Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing

Problem: Respiratory: Goal: Will regain and/or maintain adequate ventilation Outcome: Progressing

Problem: Sensory: Goal: General experience of comfort will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

```
Electronically signed by Jessica Z at 08/20/2023 7:55 AM EDT
Care Plan Note - Jessica Z - 08/19/2023 10:34 AM EDT
```

Formatting of this note might be different from the original.

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent infection will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Will remain free from infection Description: World Health Organization (WHO) identifies hands as the main mode of germ transmission in health care. Hand hygiene may be considered the most important measure performed to avoid transmission of germs and prevent health care associated infection. Outcome: Progressing

Problem: Respiratory: Goal: Will remain free from respiratory infection Outcome: Progressing

Problem: Skin Integrity: Goal: Remain free from infection at wound or surgical site Outcome: Progressing

Problem: Urinary Elimination: Goal: Will remain free from infection Description: See the Catheter-Associated Urinary Tract Infection Prevention module for interventions specific to this topic Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Coping: Goal: Coping ability will improve Outcome: Progressing

Problem: Fluid Volume: Goal: Ability to maintain a balanced intake and output will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Signs and symptoms of infection will decrease Outcome: Progressing Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing

Problem: Respiratory: Goal: Will regain and/or maintain adequate ventilation Outcome: Progressing Problem: Sensory: Goal: General experience of comfort will improve Outcome: Progressing

Electronically signed by Jessica Z at 08/19/2023 10:37 AM EDT Nsg Progress Note - Tri D - 08/19/2023 1:58 AM EDT Formatting of this note is different from the original.

August 2023

Sunday Monday Tuesday Wednesday Thursday Friday Saturday

1

Admission 5:23 PM Korkigian, Armen A, DO 4 SOUTH FH (Discharge: 8/21/2023) ZZ IP XRY 15 5:40 PM (5 min.) IP RAD GEN EC FH RAD GEN EC FH ZZ IP CT 30 6:00 PM (5 min.) IP RAD CT FH Beaumont Hospital, Farmington Hills, Professional Center North Suite 101N 2 ZZ IP CT 30 12:40 AM (5 min.) IP RAD CT FH Beaumont Hospital, Farmington Hills, Professional Center North Suite 101N 3 ZZ IP EDX 05 9:20 AM (5 min.) EEG FH Beaumont Hospital, Farmington Hills 4 5 6 7 8 9 10 11 12 13 14

16

15

- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31

Pt Name: Ioan Suiugan Code: No CPR Sex: male DOB: 2/27/1961 AGE: 62y.o. MRN: 9942681 CSN: 291554894 Primary Support Person: Password:

CC: had concerns including Altered Mental Status (Patient arrived to ER from group home via EMS. Per EMS pts baseline is a+ox1+combative, family says he has been a+ox0 for the last 24 hours. POC at group home was 32 1 amp given by EMS). Primary Dx: Altered mental status, unspecified altered mental status type * No surgery found *

Events:

Plan of Care: DC to SAR

FYI: BL Mitts Attending MD: Rudy, William M, DO Consulting MD's: Consult To: OMAR, SABIHA J Specialty: Psychiatry Reason for Consult: aggitation Consult To: Specialty: Reason for Consult: Consult To: Specialty: Reason for Consult: Room: 4SFH/475 Date of Admit: 8/1/2023 LOS: 18 Days Activity: Bed Rest

Vital Signsq8: BP 132/90 | Pulse 104 | Temp 98.2 °F (36.8 °C) (Axillary) | Resp 18 | Ht 188 cm (6' 2.02") | Wt 87.1 kg (192 lb 0.3 oz) | SpO2 97% | BMI 24.64 kg/m² Ortho's: N/A Isolation: Contact MDR ESBL in Urine

Allergies: Not on File

Diet: Tube Feeding with Oral Diet - Tube Feed: Tube Feeding,; Product: Glucerna 1.5; Rate Goal ml/hr: 70; Tube Feeding Water Flush (mL): 75; Water Flush Frequency: Other (specify) (q1hr); Non Room Service (and additional linked orders) Adult Diet - Diet Consistency: Dysphagia; Dysphagia Diet: Pureed; Additional Restrictions: 1:1 Feed; Non Room Service (and additional linked orders)

Medical Hx: No past medical history on file.

Surgical Hx: No past surgical history on file.

Neurological/Psychological: A&OX: 1 Neuro: N/A Renal: Foley (Chronic) Foley Reason (when applicable): Neurogenic bladder 2/2 Anoxic Brain injury HD: Fluid removed: N/A Bowel/Bladder: Incontinent bowel and bladder Respiratory: RESP: RA Incentive Spirometer: []Ordered []Given to Pt: GI: Last BM: Chemsticks: Daily weight: I/O's: LBM: 8/18 IIT: N/A Pills: PC thru PEG/Corpak GI/Diet: Orders Placed This Encounter Adult Diet - Diet Consistency: Dysphagia; Dysphagia Diet: Pureed; Additional Restrictions: 1:1 Feed; Non Room Service Tube Feeding with Oral Diet - Tube Feed: Tube Feeding;; Product: Glucerna 1.5; Rate Goal ml/hr: 70; Tube Feeding Water Flush (mL): 75; Water Flush Frequency: Other (specify) (q1hr); Non Room Service
Cardiovascular: No telemetry orders placed this encounter. Box # TMS Box: N/A Cardiac/Rhythm: N/A Admission VTE/DVT Risk: High/Moderate/Low
SCD's On: []Yes []No Skin: Moisture Associated Dermititis
Right Knee Mepilex
Mepilex to Coccyx
BL Heel Lift Boots
Pain Medication: At high Risk for Resp Dep./ Opiate IV Sedation: []Yes []No Pain Management: Other Belongings Documented upon unit Admission: []Yes Belongings in security/Cashier: []Yes []No Home Rx in Pharmacy: []Yes []No Potential for Violence Security Notified at:

Vaccine Needed: []Yes []No Meds to Bed: []Yes []No Communications about Rx/Purpose/Side Effects Medications Reviewed/Information Sheet given Day 1: ______ Night 1: ______ Day 2: _____ Night 2: _____ Day 3: _____ Night 3: _____ Fall Risk/Safety
Fall Band on: []Yes
Morris Score on Admission: _____ Today's Score: _____
High Risk: _____
Bed Alarm/Chair Alarm: []Yes []No
Fall this Hospital Stay: []Yes []No
*If Morris Score Increases, Interventions should be changed/added and Documented on Care Plan Ortho
C Collar: _____
Immobilizer/Brace: _____
Traction: _____

Lines, Drains, and Airways

Drain Duration

Gastrostomy/Enterostomy Percutaneous endoscopic gastrostomy-jejunal (PEG/J) LUQ 17 days Urethral Catheter Temperature probe 126 Fr. 17 days

Pressure Injury Duration

Pressure Injury 08/02/23 Sacrum Center 17 days

Wound Duration

Wound 08/02/23 Abrasion Right; Anterior Knee 16 days

Electronically signed by Tri D at 08/19/2023 2:07 AM EDT

Nsg Progress Note - Jessica Z - 08/18/2023 5:44 PM EDT

Formatting of this note might be different from the original.

Pt pulling at PEG tube and Foley. Pt also has been leaning over the side of the bed reaching towards to floor. When RN asks what pt is doing or looking for, he mumbles incoherent speech. Pt cleaned up and offered food and drink, pt refused and pushed RN hand away. Pt has mitts for safety and a 1-1 sitter for safety. Pt given ativan PRN at 1630 and this seemed to help pt restlessness. Electronically signed by Jessica Z at 08/18/2023 6:36 PM EDT

PT/OT Progress Note - Beth C - 08/18/2023 1:50 PM EDT Formatting of this note is different from the original.

08/18/23 1203 Time Detail OT Visit Number 3 (475)Time Eval/Tx Initiated 0930 Total Eval/Tx Time (min) - individual 24 min Event/Subjective OT Received On 08/18/23 Event Note AMS, CT Brain (-), hx of anoxic brain injury, DM Subjective Pt lethargic Patient Goal unable to state Observation In Bed before Treatment;IV;Multiple tubes and lines requiring additional assistance;PEG/PEJ Tube Assessment Assessment Tolerated eval/tx poor Therapy Problem List Impaired Bed Mobility; Impaired Transfers; Impaired Functional Mobility; Impaired Balance; Impaired Strength; Impaired Cognition; Impaired Lower Body Dressing; Impaired Upper Body Dressing; Impaired Upper Body Bathing; Impaired Lower Body Bathing; Impaired Toileting; Impaired Grooming; Impaired Functional Endurance **Rehab Potential Poor**

(unable, pt lethargic) How is your pain at the end of the therapy session? 0 (FLACC) Recommendation OT Discharge Instructions In progress OT Discharge Recommendations SAR (Subacute rehab) OT DME Recommendations To be determined PT/OT Post Treatment Post tx patient left in bed;Post tx left patient with lines intact;Post tx call light/phone within reach (1-1 sitter) Plan Treatment Interventions ADL retraining; Mobility/transfer training as related to ADLs; UE strengthening/ROM; Bed mobility; Balance OT Frequency 3-5 x/wk Precautions Precautions (fall, pressure, contact) Cognition Arousal/Alertness Lethargic Follows Commands Does not follow any commands Memory UTA **Orientation Level UTA** Pain Screening/Assessment Screening/Pain Scale Used Face, Legs, Activity, Crying, Consolability (FLACC) Pain Score 0 Bed Mobility **Rolling Dependent** Supine to Sit UTA Balance Sitting - Static Not Tested Exercise/Interventions Shoulder Horizontal Abduction Bilateral Exercise/Interventions Details PROM x10 Shoulder Horizontal Adduction Bilateral Exercise/Interventions Details PROM x10 Shoulder Flexion Bilateral Exercise/Interventions Details PROM x10 Elbow Flexion Bilateral Exercise/Interventions Details PROM x10 Elbow Extension Bilateral Exercise/Interventions Details PROM x10 Wrist Flexion Bilateral Exercise/Interventions Details PROM x10 Wrist Extension Bilateral Exercise/Interventions Details PROM x10 **Open Hand Bilateral** Exercise/Interventions Details PROM x10 Closed Hand Bilateral Exercise/Interventions Details PROM x10 Activities of Daily Living - AM-PAC 6 CLICK Putting on and taking off regular lower body clothing? 1 Bathing (including washing, rinsing, drying)? 1 Toileting, which includes using toilet, bedpan or urinal? 1 Putting on and taking off regular upper body clothing? 1 Taking care of personal grooming such as brushing teeth? 1 Eating meals? 1 Activities of Daily Living Score 6 Patient Safety Bed in lowest position Yes Side rails/Bed safety 3/4 Bed alarm on if indicated Yes Interdisciplinary Communication Interdisciplinary Communication spoke with PT Interdisciplinary Communication topic Tolerance of treatment

Electronically signed by Beth C at 08/18/2023 1:51 PM EDT PT/OT Progress Note - Sandra R - 08/18/2023 12:26 PM EDT Formatting of this note is different from the original.

Goals Discussed With

Time Detail PT Visit Number 4 Time Eval/Tx Initiated 0955 Total Eval/Tx Time (min) - individual 24 min Event/Subjective PT Received On 08/18/23 Event Note AMS, CT brain (-), hx of anoxic brain injury, DM Subjective pt lethargic/sedated Patient Goal none noted Observation In Bed before Treatment; IV; PEG/PEJ Tube (soft prafos-right turned sideways, soft mittens, 1:1 sitter) Assessment Assessment Tolerated eval/tx poor **Rehab Potential Poor** Goals Discussed With (no family present) Recommendation PT Discharge Instructions In progress PT Discharge Recommendations SAR (Subacute rehab) (vs long term care) PT DME Recommendations To be determined PT/OT Post Treatment Post tx patient left in bed;Post tx left patient with lines intact;Post tx call light/phone within reach Plan Treatment/Interventions Physical Therapy is recommended to address deficits. PT Frequency 3-5x/wk Cognition Arousal/Alertness Lethargic Follows Commands Does not follow any commands Memory UTA **Orientation Level UTA** Safety Judgement UTA Awareness of Errors UTA Insight into Deficits UTA Pain Screening/Assessment Screening/Pain Scale Used Face, Legs, Activity, Crying, Consolability (FLACC) Pain Score 0 Bed Mobility Rolling Dependent Supine to Sit UTA Sit to Supine UTA Transfers Sit to Stand UTA Balance Sitting - Static Not Tested Sitting - Dynamic Not tested Standing - Static Not tested Standing - Dynamic Not tested Exercise/Interventions Exercise/Intervention Details PROM x 15 reps Ankle Circles Bilateral Ankle Pumps Bilateral Short Arc Quad Bilateral Heelslides Bilateral Straight Leg Raises Bilateral Supine Hip Abduction Bilateral Significant Time Spent Significant Time Spent On Other (add comment);Line management (repositioning pt and PRAFO's) Mobility - AM-PAC 6 CLICK Turning from your back to your side while in a flat bed without using bedrails? 1 Moving from lying on your back to sitting on the side of a flat bed without using bedrails? 1 Moving to and from a bed to a chair (including a wheelchair)? 1 Standing up from a chair using your arms (e.g., wheelchair, or bedside chair)? 1 To walk in hospital room? 1 Climbing 3-5 steps with a railing? 1 Mobility Score 6 Patient Safety Bed in lowest position Yes Side rails/Bed safety 3/4

08/18/23 1020

Chair alarm on if indicated Not Indicated Bed alarm on if indicated Yes Interdisciplinary Communication Interdisciplinary Communication spoke with RN Interdisciplinary Communication topic Tolerance of treatment Communication with Patient Reason for Communication Update on Condition/Status Type of Communication Face-to-Face

Electronically signed by Rana K at 08/18/2023 4:04 PM EDT Care Plan Note - Jessica Z - 08/18/2023 11:38 AM EDT Formatting of this note might be different from the original.

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent infection will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Will remain free from infection Description: World Health Organization (WHO) identifies hands as the main mode of germ transmission in health care. Hand hygiene may be considered the most important measure performed to avoid transmission of germs and prevent health care associated infection. Outcome: Progressing

Problem: Respiratory: Goal: Will remain free from respiratory infection Outcome: Progressing

Problem: Skin Integrity: Goal: Remain free from infection at wound or surgical site Outcome: Progressing

Problem: Urinary Elimination: Goal: Will remain free from infection Description: See the Catheter-Associated Urinary Tract Infection Prevention module for interventions specific to this topic Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Coping: Goal: Coping ability will improve Outcome: Progressing

Problem: Fluid Volume:

Goal: Ability to maintain a balanced intake and output will improve Outcome: Progressing

Problem: Physical Regulation: Goal: Signs and symptoms of infection will decrease Outcome: Progressing Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing

Problem: Respiratory: Goal: Will regain and/or maintain adequate ventilation Outcome: Progressing

Problem: Sensory: Goal: General experience of comfort will improve Outcome: Progressing

Electronically signed by Jessica Z at 08/18/2023 11:38 AM EDT

Nsg Progress Note - Holly P - 08/17/2023 8:54 PM EDT Formatting of this note might be different from the original.

Ioan Suiugan is a 62y.o. male who is A&O x3 with VSS. Pt is here for AMS, UTI and Sepsis. Pt has history of anoxic brain injury 2nd to cardiac arrest back in May 2023. Pt is bed rest. Pt has history of being aggressive, impulsive. Pt is a 1:1 safety sit and BUE soft mitt restraints maintained. Pt has PEG tube. IV is in right brachial. Pt resting comfortably in bed with no signs/symptoms of respiratory distress, chest pain, or N/V. Pt is tolerating TF diet.

Pt is pleasant and cooperative with care. Full assessment completed in flow-sheet. Pt updated on POC, verbalized understanding with no further questions/concerns at this time.

8:54 PM - Pt is agitated and trying to get out of bed pull foley, IV and peg tube. No violent soft mittens applied to both hands. Scheduled Klonopin given. Resident paged for restraint orders.

Electronically signed by Holly P at 08/17/2023 8:57 PM EDT

Nsg Progress Note - Marlyn P - 08/17/2023 6:09 PM EDT

Formatting of this note might be different from the original.

Received pt on bed asleep with PEG tube infusing well. Pt is on 1:1 sitter for safety. Ar around 4pm visited by brother, pt becomes emotional, crying and little agitated. Keep pt calm. Repositioned frequently. Safety precaution maintained.

Electronically signed by Marlyn P at 08/17/2023 6:13 PM EDT

Care Plan Note - Marlyn P - 08/17/2023 3:39 PM EDT

Formatting of this note might be different from the original.

Problem: Cognitive:

Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Adequate for Discharge

Problem: Safety: Goal: Will remain free from falls in 4 hours Description: Assess for poly-pharmacy and drug to drug interactions Outcome: Adequate for Discharge Goal: Will remain free of falls with the implementation of Universal Precautions Outcome: Adequate for Discharge Goal: Will remain free of falls with the implementation of High Risk Fall precautions Outcome: Adequate for Discharge

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Adequate for Discharge

Problem: Safety: Goal: Will remain free of falls with the implementation of Universal Precautions Outcome: Adequate for Discharge

Problem: Safety: Goal: Will remain free of falls with the implementation of High Risk Fall precautions Outcome: Adequate for Discharge

Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care Outcome: Adequate for Discharge

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Adequate for Discharge

Problem: Medication: Goal: Will comply with prescribed medication regimen Outcome: Adequate for Discharge

Problem: Nutritional: Goal: Nutritional status will be supported Outcome: Adequate for Discharge

Problem: Physical Regulation: Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Adequate for Discharge Goal: Will remain free from infection Outcome: Adequate for Discharge

Problem: Self-Care: Goal: Ability to participate in self-care as condition permits will be supported Outcome: Adequate for Discharge

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Adequate for Discharge

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Adequate for Discharge

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Adequate for Discharge

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Adequate for Discharge

Problem: Safety:

Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Adequate for Discharge Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Adequate for Discharge Goal: Ability to use alternate options when emotions escalate will improve Outcome: Adequate for Discharge

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Adequate for Discharge Goal: Will verbalize understanding of the information provided Outcome: Adequate for Discharge

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Adequate for Discharge Goal: Will verbalize understanding of the information provided Outcome: Adequate for Discharge

Problem: Coping: Goal: Will verbalize feelings Outcome: Adequate for Discharge Goal: Will identify and develop effective coping behavior Outcome: Adequate for Discharge

Electronically signed by Marlyn P at 08/17/2023 3:40 PM EDT

Care Management - Deborah A - 08/17/2023 11:21 AM EDT

Formatting of this note might be different from the original. Discussed on progression rounds. Soft writs restraints and mitts have been discontinued. Patient continues with 1:1 sitter in place. Follow-up call to sister, Vicki, to update. Vicki reports will to hospital to re-evaluate patient for potential group home return. Updated facility referrals faxed. Department following. Ph 521-7800 Electronically signed by Deborah A at 08/17/2023 11:25 AM EDT Nsg Progress Note - Holly P - 08/16/2023 11:54 PM EDT

Formatting of this note might be different from the original.

Ioan Suiugan is a 62y.o. male who is A&O x3 with VSS. Pt is here for AMS, UTI and Sepsis. Pt has history of anoxic brain injury 2nd to cardiac arrest back in May 2023. Pt is bed rest. Pt has history of being aggressive, impulsive. Pt is a 1:1 safety sit and BUE soft mitt restraints maintained. Pt has PEG tube. IV is in right brachial. Pt resting comfortably in bed with no signs/symptoms of respiratory distress, chest pain, or N/V. Pt is tolerating TF diet.

Pt is pleasant and cooperative with care. Full assessment completed in flow-sheet. Pt updated on POC, verbalized understanding with no further questions/concerns at this time.

Electronically signed by Holly P at 08/16/2023 11:54 PM EDT

Social Work - Christina L - 08/16/2023 3:01 PM EDT

Formatting of this note might be different from the original. Patient sedated and not in restraints, but still has mittens. 1:1 sitter in place and restraint free. Discharge pending long-term placement once 1:1 sitter and restraint free.

Christina L. LLMSW Ph: 521-5958

Electronically signed by Christina L at 08/16/2023 3:03 PM EDT

Nsg Progress Note - Holly P - 08/16/2023 4:24 AM EDT

Formatting of this note might be different from the original.

Ioan Suiugan is a 62y.o. male who is A&O x3 with VSS. Pt is here for AMS, UTI and Sepsis. Pt has history of anoxic brain injury 2nd to cardiac arrest back in May 2023. Pt is bed rest. Pt has history of being aggressive, impulsive. Pt is a 1:1 safety sit and BUE soft mitt restraints maintained. Pt has PEG tube. IV is in right brachial. Pt resting comfortably in bed with no signs/symptoms of respiratory distress, chest pain, or N/V. Pt is tolerating TF diet.

Pt is pleasant and cooperative with care. Full assessment completed in flow-sheet. Pt updated on POC, verbalized understanding with no further questions/concerns at this time.

Electronically signed by Holly P at 08/16/2023 4:28 AM EDT Care Plan Note - Andrew M - 08/15/2023 11:06 AM EDT Formatting of this note might be different from the original.

Problem: Coping: Goal: Will verbalize feelings Outcome: Not Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Not Progressing

Electronically signed by Andrew M at 08/15/2023 11:06 AM EDT Nutr Serv Progress Note - Vuk V - 08/15/2023 8:06 AM EDT Formatting of this note is different from the original.

NUTRITION SERVICES - FOLLOW-UP ASSESSMENT Name: Ioan Suiugan-62y.o.Male MRN: 9942681 LOS: 14 Room:475/475 Reason for Visit: Nutrition Reassessment Nutrition Therapy Protocol Yes

8/15 - With agitation pt pulling at PEG tube. Pt with 1:1 sitter. Per case management 8/13, planning for pt discharge to SNF once pt is restraint and sitter free for 24 hrs.

8/9 - Pt had toxic metabolic encephalopathy superimposed on anoxic brain injury secondary to sepsis/UTI per Internal medicine NP. Pt is still disoriented and aggressive, is on restraints, and requires TF. Per Internal Medicine Physician, no acute medical problems. Antibiotics completed, adjusted IVF, dc planning.

HPI: 62y.o.M presented to ED c/o altered mental status. Per Emergency Medicine Resident 8/1, pt is A&Ox1 and had a V. Tach cardiac arrest with subsequent anoxic brain injury in May 2023. Per Internal medicine Resident H&P 8/2, pt is currently on restraints. Pt hyperglycemic upon admission but decreased glucose levels to 137.

Subjective: Pt visited, lying in bed, sitter in room. TF running at goal of 70 mL/hr with 75 mL flushes. FOOD AND NUTRITION HISTORY: Current Diet Order Orders Placed This Encounter Adult Diet - Diet Consistency: Dysphagia; Dysphagia Diet: Pureed; Additional Restrictions: 1:1 Feed; Non Room Service Tube Feeding with Oral Diet - Tube Feed: Tube Feeding,; Product: Glucerna 1.5; Rate Goal ml/hr: 70; Tube Feeding Water Flush (mL): 75; Water Flush Frequency: Other (specify) (q1hr); Non Room Service Food Allergies: NKFA per chart. Cultural/Religious Practices: na Appetite: na Intake: Pt's current Glucerna 1.5 is 70 mL/hr and 75 mL water flush. Oral intake remains minimal. Chewing/Swallowing: na GI: LBM 8/15 per chart. Skin: PI Stage II Sacrum Center, Wound r anterior knee per chart. Edema: RLE +1 and LLE +1 per chart. BIOCHEMICAL DATA/ MEDICATIONS/ TESTS / PROCEDURES: Recent Labs 08/13/23 0323 08/13/23 0527 08/14/23 0258 08/14/23 1200 08/14/23 2345 08/15/23 0421 08/15/23 0527 NA 138 -- 140 -- -- 141 --К 3.3* -- 3.8 -- -- 3.7 --CL 104 -- 105 -- -- 108 --CO2 27 -- 27 -- -- 26 --GLU 103* < > 119* < > 118 97 102 BUN 14 -- 12 -- -- 13 --CREAT 0.56* -- 0.64 -- -- 0.56* --EGFR 111 -- 107 -- -- 111 --CALCIUM 8.0* -- 8.3* -- -- 8.5 --MG 2.0 -- 2.0 -- -- 2.0 --PHOS 3.0 -- 3.2 -- -- 3.7 --ALB 2.6* -- 2.7* -- -- 2.6* --< > = values in this interval not displayed. Medications: SCHEDULED: amiodarone, 200 mg, PEG Tube, DAILY apixaban (ELIQUIS) tablet DVT/PE TREATMENT CONTINUATION BEYOND 7 DAYS, 5 mg, Oral, Q 12 H atorvastatin, 40 mg, PEG Tube, Q HS clonazePAM, 0.5 mg, PEG Tube, DAILY clonazePAM, 1 mg, PEG Tube, Q HS clopidogrel, 75 mg, Oral, DAILY insulin regular human, 2-5 Units, Subcutaneous, Q 6 H metoprolol, 25 mg, PEG Tube, BID OLANZapine, 10 mg, Oral, BID sodium chloride, 10 mL, Intravenous, Q 12 H valproate, 1,000 mg, Oral, BID IVF: PRN:

- acetaminophen
- LORazepam
- sodium chloride
- sodium chloride sodium chloride
- sodium chloride 0.9%

Tests/Procedures:

8/2 CT chest IV contrast - pleural effusion, emphysematous changes, L renal simple cyst, and PEG tube noted in appropriate positioning.

NUTRITION FOCUSED PHYSICAL FINDINGS:

Nutrition Focused Physical Exam: couldn't complete exam due to pt asleep. Pt seems thinner than the previous visit.

Subcutaneous Fat Depletion Musculoskeletal Depletion

- Classification: Moderate
- [x] Orbital region
- [x] Upper arm region -triceps/biceps
- [] Thoracic & lumbar region ribs, lower back, midaxillary line
- Classification: Moderate
- [x] Temporalis
- [x] Clavicle & acromion bone region
- [x] Clavicle bone region
- [] Scapular bone region
- [] Dorsal hand
- [x] Patellar region
- [x] Anterior thigh region
- [x] Posterior calf region

ANTHROPOMETRICS: Admit Weight: 99.8 kg (220 lb), Weight Source: Bed scale Current Weight: 87.1 kg (192 lb 0.3 oz), Weight Source: Bed scale Body mass index is 24.64 kg/m². BMI Classification: WNL

IBW: 86.4 kg UBW: na kg All weight readings from this encounter 08/11/23 0800 87.1 kg (192 lb 0.3 oz) 08/10/23 2300 84.8 kg (186 lb 15.2 oz) 08/08/23 0600 85.3 kg (188 lb 0.8 oz) 08/07/23 0549 87.4 kg (192 lb 10.9 oz) 08/06/23 0424 85.2 kg (187 lb 13.3 oz) 08/05/23 0340 85.2 kg (187 lb 13.3 oz) 08/02/23 0300 99.8 kg (220 lb) 08/01/23 1727 99.8 kg (220 lb)

Weight Trend: 12.7% weight loss in the last 1.5 weeks per Epic weight history. Weight seems to improve. Question previous weight bed scale accuracy. Pt appears thinner than previous visit suspect fluid related.

ESTIMATED NUTRITIONAL NEEDS:

Calories: 2177+ kcal/day based on 25 kcal/kg using current body weight (87.1 kg) Protein: 109-131 gm/day based on 1.25-1.5 gm/kg using current body weight note PI stage II Fluid: 2177 mL based on 1 mL/kcal or per provider. Adjust fluids based on intake and output to maintain fluid balance and hemodynamic stability

NUTRITION DIAGNOSIS: Increased protein needs related to wounds as evidenced by Pressure injury Stage II center Sacrum. - active

INTERVENTION: Intervention(s): Saw pt, follow-up completed. Chart reviewed. Assessed TF

Goal(s): TF to provide >90% nutrient needs. - met, ongoing. Prevent significant/unintentional weight loss. - met, ongoing. Pt to have evidence of wound healing. - not met, ongoing.

MONITORING & EVALUATING TF tolerance. Pertinent labs. Weight trends.

Nutrition related discharge needs at this time - Pending clinical course.

Follow Up Range: based on patient care goals, 5-7 days

RECOMMENDATIONS: Glucerna 1.5 goal = 70 mL/hr. TF at goal provides: 2520 kcal, 138 gm protein, 1276 mL free H2O Enteral H2O: defer to provider. Aspiration precautions, HOB >30-45 degrees at all times.

Dietetic Intern: Vuk Vuckovic Available via Mobile Heartbeat" Electronically signed by Natalie F at 08/15/2023 12:01 PM EDT

Associated attestation - Natalie F - 08/15/2023 12:01 PM EDT Formatting of this note might be different from the original. 475/475 Name: Ioan Suiugan MRN: 9942681 DOB: 2/27/1961

I saw and evaluated the patient. Discussed with the dietetic intern and agree with the dietetic intern's findings and plan as documented in the dietetic intern's note.

Tolerating TF at goal. Intermittent periods of inadequate intake due to pt's agitation/pulling at PEG. Oral intake non-contributory. Usually spits food back out.

Natalie Frayer, MS RD Available via mobile heartbeat

Care Plan Note - Monique T - 08/14/2023 11:35 PM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Not Progressing Note: Patient confused in addition to language barrier; unable to use translator phone secondary to confusion.

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing Note: Patient frequently attempting to pull at lines including PEG tube and foley catheter.

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing

Problem: Medication: Goal: Will comply with prescribed medication regimen Outcome: Progressing

Problem: Nutritional: Goal: Nutritional status will be supported Outcome: Progressing Note: Tolerating tube feeding at goal. Noncompliant with positioning to decrease risk for aspiration; repositioned frequently; patient has spit at staff during repositioning and oral care.

Problem: Sensory: Goal: Pain level will decrease Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Electronically signed by Monique T at 08/14/2023 11:35 PM EDT

Nsg Progress Note - Jennifer G - 08/14/2023 2:44 PM EDT

Formatting of this note might be different from the original.

Attempted removal of restraints, while pt was calm with eye closed. With in the hours patient disconnected tube feeding, continued to pull and hank at foley. Pt yelling and spit in sitter face. Restraints placed back on patient to protect staff and patient, PRN Ativan given at time. Son and sitter at bedside, will continue to monitor. Electronically signed by Jennifer G at 08/14/2023 2:47 PM EDT Care Plan Note - Jennifer G - 08/14/2023 10:08 AM EDT Formatting of this note might be different from the original. Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Progressing Problem: Safety: Goal: Will remain free from falls in 4 hours Description: Assess for poly-pharmacy and drug to drug interactions **Outcome: Progressing** Goal: Will remain free of falls with the implementation of Universal Precautions Outcome: Progressing Goal: Will remain free of falls with the implementation of High Risk Fall precautions Outcome: Progressing Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care **Outcome: Progressing** Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing Problem: Medication: Goal: Will comply with prescribed medication regimen Outcome: Progressing Problem: Nutritional: Goal: Nutritional status will be supported **Outcome: Progressing** Problem: Physical Regulation: Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing Goal: Will remain free from infection **Outcome:** Progressing Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing Goal: Risk of venous thrombosis will decrease Outcome: Progressing Problem: Self-Care: Goal: Ability to participate in self-care as condition permits will be supported Outcome: Progressing Problem: Sensory: Goal: Pain level will decrease Outcome: Progressing Problem: Tissue Perfusion: Goal: Will regain and/or maintain adequate tissue perfusion **Outcome: Progressing** Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Cognitive:

Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Skin Integrity: Goal: Will show signs of wound healing Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Electronically signed by Jennifer G at 08/14/2023 10:08 AM EDT Care Management - Deborah A - 08/14/2023 9:40 AM EDT Formatting of this note might be different from the original.

Patient with 1:1 sitter in place and soft writs restraints with mits. Department following for anticipated long term placement once 1:1 sitter and restraint free. Ph 521-7800

Electronically signed by Deborah A at 08/14/2023 9:41 AM EDT

Nsg Progress Note - Angelina B - 08/14/2023 3:35 AM EDT

Formatting of this note might be different from the original.

Patient is still restless, pulling on tubes and lines - restraints SWR B/L and mittens B/L renewed, pt has one to one observation for safety in place.

Electronically signed by Angelina B at 08/14/2023 8:05 AM EDT

Care Management - Elizabeth R - 08/13/2023 9:03 AM EDT

Formatting of this note might be different from the original.

Discharge plan is SNF for long term care. Pt remains in restraints- will have to be out of restraints prior to transferring to SNF. psych adjusting medications. SNF referrals sent- CM department to follow for accepting facility and will coordinate transfer once pt has been restraint and sitter free for 24 hrs.

E. Robertson, CM ext 8901

Electronically signed by Elizabeth R at 08/13/2023 9:08 AM EDT

Care Plan Note - Hala R - 08/12/2023 9:55 PM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Progressing

Problem: Safety: Goal: Will remain free of falls with the implementation of High Risk Fall precautions Outcome: Progressing

Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care Outcome: Progressing

Problem: Nutritional: Goal: Nutritional status will be supported Outcome: Progressing

Problem: Physical Regulation: Goal: Will remain free from infection Outcome: Progressing

Problem: Safety: Goal: Risk of venous thrombosis will decrease Outcome: Progressing

Problem: Sensory: Goal: Pain level will decrease Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing

Electronically signed by Hala R at 08/12/2023 9:56 PM EDT Care Plan Note - Shaterica B - 08/12/2023 3:59 PM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Progressing

Electronically signed by Shaterica B at 08/12/2023 3:59 PM EDT Care Management - Elizabeth R - 08/12/2023 10:41 AM EDT Formatting of this note might be different from the original.

Discharge plan is SNF for long term care. Pt will have to be out of restraints prior to transferring to SNF. Pt remains in restraints, psych adjusting medications. SNF referrals sent- CM department to follow for accepting facility and will coordinate transfer once pt has been restraint and sitter free for 24 hrs.

E. Robertson, CM ext 8901 Electronically signed by Elizabeth R at 08/12/2023 10:43 AM EDT Care Plan Note - Hala R - 08/12/2023 12:43 AM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Progressing

Problem: Safety: Goal: Will remain free of falls with the implementation of High Risk Fall precautions Outcome: Progressing

Problem: Medication: Goal: Will comply with prescribed medication regimen Outcome: Progressing

Problem: Nutritional: Goal: Nutritional status will be supported Outcome: Progressing

Problem: Physical Regulation: Goal: Will remain free from infection Outcome: Progressing

Problem: Safety: Goal: Risk of venous thrombosis will decrease Outcome: Progressing

Problem: Sensory: Goal: Pain level will decrease Outcome: Progressing

Electronically signed by Hala R at 08/12/2023 12:44 AM EDT PT/OT Progress Note - Mansoora A - 08/11/2023 5:00 PM EDT Formatting of this note is different from the original.

08/11/23 1053 Time Detail PT Visit Number 3 (seen in 475) Time Eval/Tx Initiated 1053 Total Eval/Tx Time (min) - individual 38 min Event/Subjective PT Received On 08/11/23 Event Note AMS, CT brain (-), hx of anoxic brain injury, DM Subjective non-verbal, also with language barrier. Patient Goal none verbalized Observation In Bed before Treatment;Bed Alarm (bilateral soft wrist restraints on , peg tube, Avasure observer present) Assessment Assessment Tolerated eval/tx poor Tolerated eval/tx poor additional detail Pt's baseline is unknown at this time, very limited participation in tx this date secondary to cognition. PROM BLE's significant edema all 4 extremities, max Ax1-2 for rolling, pt did attempt to assist holding on to bed rails, max Ax 2 for long sit . . Therapy Problem List Impaired Bed Mobility; Impaired Transfers; Impaired Functional Mobility; Impaired Gait Skills; Impaired Strength;Impaired Balance;Impaired Cognition;Impaired Functional Endurance Rehab Potential Poor:Fair Goals Discussed With (unable to discuss goals with patient at this time) How is your pain at the end of the therapy session? 0 (FLACC) Recommendation PT Discharge Instructions In progress

PT Discharge Recommendations SAR (Subacute rehab) PT DME Recommendations To be determined PT/OT Post Treatment Post tx patient left in bed;Post tx call light/phone within reach;Post tx left patient with lines intact (bed alrm on , avasure observer present) Plan Treatment/Interventions Physical Therapy is recommended to address deficits. PT Frequency 3-5x/wk Precautions Precautions Other (Add Comment) (fall, pressure injury, Contact d/t MDR -CRE) Learning Barriers Learning Barriers (PT/OT) Carryover; Impaired Cognition; Judgement; Language; Safety Cognition Arousal/Alertness Lethargic Follows Commands Does not follow any commands Orientation Level Oriented to person Safety Judgement Impaired; Slow Processing; Low Insight/Safety Awareness; Decreased Attention Span Pain Screening/Assessment Screening/Pain Scale Used Face, Legs, Activity, Crying, Consolability (FLACC) Pain Score 0 **Bed Mobility** Rolling Max assistance; Additional Person Physical Assistance Supine to Sit Dependent (long sitting x2 PA) Sit to Supine Dependent (long sitting x2 PA) Supine Scoot Dependent Transfers Sit to Stand UTA Gait/Stairs Gait /Functional Mobillity Assistance UTA Balance Sitting - Static Absent Sitting - Dynamic Not tested Standing - Static Not tested Standing - Dynamic Not tested **RLE** Assessment **RLE** Assessment (pt with no volitional movement bilaterally, hypotonic) LLE Assessment LLE Assessment (pt with no volitional movement bilaterally, hypotonic) Exercise/Interventions Ankle Pumps Bilateral Exercise/Interventions Details x15 PROM Short Arc Quad Bilateral Exercise/Interventions Details PROM x 10 x 2 Supine Hip Abduction Bilateral Exercise/Interventions Details PROM x 10 x 2 Significant Time Spent Significant Time Spent On Communication;Line management Mobility - AM-PAC 6 CLICK Turning from your back to your side while in a flat bed without using bedrails? 2 Moving from lying on your back to sitting on the side of a flat bed without using bedrails? 1 Moving to and from a bed to a chair (including a wheelchair)? 1 Standing up from a chair using your arms (e.g., wheelchair, or bedside chair)? 1 To walk in hospital room? 1 Climbing 3-5 steps with a railing? 1 Mobility Score 7 Patient Safety Bed in lowest position Yes Side rails/Bed safety 2/4 Bed alarm on if indicated Yes Interdisciplinary Communication Interdisciplinary Communication spoke with RN;NA Interdisciplinary Communication topic Tolerance of treatment; Mobility status **Communication with Patient** Reason for Communication Update on Condition/Status Type of Communication Face-to-Face

Electronically signed by Mansoora A at 08/11/2023 5:00 PM EDT

Nsg Progress Note - Maria L - 08/11/2023 4:00 PM EDT

Formatting of this note might be different from the original.

Since the beginning of this shift at 0700, patient has had an Avasure (video monitor) present in the room, along with bilateral soft wrist restraints and mittens on him for safety. This am when RN assessed and medicated the patient, he was drowsy and lethargic (per report, he went to sleep at around 0600 this am).

RN took patient's mittens off at 1030, as patient was calm and was not pulling at anything; RN left the soft wrist restraints in place. At 1220 RN had to place the mittens back on patient's hands, as he started loosening the wrist restraints with his arms and pulling at the statlock & foley catheter.

AT 1540, RN discontinued the Avasure order and placed an order for a one to one sit for safety, as patient had been trying to pull at his foley catheter (or statlock) many times throughout the shift, and RN had to run into patient's room many times when the Avasure was beeping an alert.

Patient's sister Vicky visited the patient this afternoon/early evening, and she informed RN that she would be willing to take the patient to her AFC home in restraints, as long as he would sleep at night; she also asked if the psychiatrist would make adjustments to the patient's medications, so he would remain calm for longer and would be able to sleep at night. RN messaged CM Deborah at 1420 about what Vicky said in regards to taking the patient to her AFC home. RN also messaged Dr Omar at 1355 if she would make adjustments to patient's medications; she messaged RN that she would address the medications tomorrow.

At 1528, RN messaged Dr Omar asking if the patient can have a medication for anxiety, as he has been getting more agitated in the bed this evening. Per Dr Omar, RN ordered oral Ativan 0.5 mg Q6 hrs PRN. RN then also messaged Dr Omar about what the patient's sister Vicky mentioned in regards to taking the patient to her AFC home.

Electronically signed by Maria L at 08/11/2023 5:36 PM EDT Care Plan Note - Maria L - 08/11/2023 3:24 PM EDT

Formatting of this note might be different from the original.

Problem: Safety:

Goal: Will remain free from falls in 4 hours

Description: Assess for poly-pharmacy and drug to drug interactions

Outcome: Progressing

Bed in lowest position; wheels locked; call light and table within reach

Bed alarm ON

Patient has yellow wristband and socks on

Patient has bilateral soft wrist restraints and mittens on, as he tries to pull at the foley catheter

Problem: Patient and Family Engagement (PFCC):

Goal: Patient/family will be actively engaged in their plan of care

Outcome: Progressing

RN taught pt plan of care and treatment regimen for today; pt accepted care, but declines food

Patient has confusion and forgetfulness, and needs reinforcement of information

RN communicates with patient in the Romanian language, as this RN is Romanian and is a certified medical interpreter for the Romanian language

Electronically signed by Maria L at 08/11/2023 3:31 PM EDT

Care Management - Deborah A - 08/11/2023 2:43 PM EDT

Formatting of this note might be different from the original.

Discussed with nurse, Maria. Patient still with soft wrist restraints and mits. Psych continues with medication adjustments. Department following. Ph 521-7800

Electronically signed by Deborah A at 08/11/2023 2:44 PM EDT

Nsg Progress Note - Lourdes Q - 08/11/2023 7:00 AM EDT

Formatting of this note might be different from the original.

Pt started sleeping @ 0500. Abdominal binder applied to protect peg tube. Mittens maintained to b/l hands and B/l soft wrist restraints maintained.

Electronically signed by Lourdes Q at 08/11/2023 7:02 AM EDT

Nsg Progress Note - Lourdes Q - 08/11/2023 3:13 AM EDT

Formatting of this note might be different from the original.

Pt's tube feed dislodged (by pt?) and bed wet w/ tube feed formula at 0145. Linens completely changed, left hand mitten and restraints changed. Pt cooperative and followed instructions. Pt doozed off for few minutes, woke up and started self-talking in Romanian. Will continue to monitor.

Electronically signed by Lourdes Q at 08/11/2023 3:18 AM EDT

Nsg Admit Note - Lourdes Q - 08/11/2023 2:43 AM EDT

Formatting of this note might be different from the original. RN Admit Note

Patient received from: PCU

Admitted to room: 475

Reason for admit: further management

Condition of patient and pertinent physical findings on arrival:Pt alert, O x 1, w/ laguage barrier. Pt speaks Romanian w/ few basic English.

Presence of pain/score: UTA

4-eye skin assessment completed with: Annette, NA

Description of skin alterations: w/ peg tube to mid abd., excoriation to buttock w/ Mepilex..

Patient/family oriented to room, white board, hourly rounding explained and fall prevention techniques implemented. Call light and phone placed within reach. Bed low and wheels locked.

Electronically signed by Lourdes Q at 08/11/2023 2:52 AM EDT

Nsg Progress Note - Lourdes Q - 08/11/2023 12:49 AM EDT

Formatting of this note might be different from the original.

Called by AVASURE staff informing this writer that pt's left mitten is off. I wonder how pt did it . Mitten placed back.

Electronically signed by Lourdes Q at 08/11/2023 3:11 AM EDT

Nsg Transfer Note - Lourdes Q - 08/10/2023 11:48 PM EDT

Formatting of this note might be different from the original.

Report taken from Dee, PCU staff, @ 2245. Received pt from PCU @ 2314, alert, O x 1. Barrier communication since pt speaks Romanian. Pt came w/ TF Glucerna on flow, b/l hands w/ mittens and b/l wrists on soft restraints, foley cath in situ flowing well, heel lift boots to feet and w/ AVASURE. Pt calm but continuously talking which this writer can't understand. Admission care rendered, kept comfortable. Will continue to monitor.

Electronically signed by Lourdes Q at 08/11/2023 3:13 AM EDT

```
PT/OT Progress Note - Samantha C - 08/10/2023 2:19 PM EDT
```

Formatting of this note is different from the original.

08/10/23 0907

Event/Subjective

Event Note PT hold note. Staff attempted to wake pt up from sleep, but pt could not keep his eyes open to work with PT. Will continue to monitor.

Electronically signed by Vinod D at 08/10/2023 3:44 PM EDT Care Management - Sarah I - 08/10/2023 9:54 AM EDT

Formatting of this note might be different from the original.

Following for discharge plan, long term medicaid bed at SNF. Per psychiatry note, checking valproic acid level. Patient in bilateral mitts and wrist restraints, attempting to hit staff per nursing note. Will need patient's agitation more controlled for patient to be placed in SNF. Department to follow.

1345: SNF referral sent in Allscripts to 150 facilities requesting long term medicaid + isolation bed availability and if they can accept patient.

Electronically signed by Sarah I at 08/10/2023 1:47 PM EDT Care Plan Note - Sarah P - 08/10/2023 5:01 AM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Not Progressing

Problem: Safety: Goal: Will remain free from falls in 4 hours Description: Assess for poly-pharmacy and drug to drug interactions Outcome: Progressing Goal: Will remain free of falls with the implementation of Universal Precautions Outcome: Progressing Goal: Will remain free of falls with the implementation of High Risk Fall precautions Outcome: Progressing

Problem: Cognitive:

Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Not Progressing

Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Not Progressing

Problem: Medication: Goal: Will comply with prescribed medication regimen Outcome: Progressing

Problem: Nutritional: Goal: Nutritional status will be supported Outcome: Progressing

Problem: Physical Regulation: Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing Goal: Risk of venous thrombosis will decrease Outcome: Progressing

Problem: Self-Care: Goal: Ability to participate in self-care as condition permits will be supported Outcome: Not Progressing

Problem: Sensory: Goal: Pain level will decrease Outcome: Progressing

Problem: Tissue Perfusion: Goal: Will regain and/or maintain adequate tissue perfusion Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Not Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing Goal: Will verbalize understanding of the information provided Outcome: Not Progressing

Problem: Skin Integrity: Goal: Will show signs of wound healing Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing

Problem: Safety:

Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing Goal: Will verbalize understanding of the information provided Outcome: Not Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Not Progressing Goal: Will identify and develop effective coping behavior Outcome: Not Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing Goal: Will verbalize understanding of the information provided Outcome: Not Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Not Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Electronically signed by Sarah P at 08/10/2023 5:02 AM EDT Care Management - Sarah I - 08/09/2023 2:32 PM EDT Formatting of this note is different from the original. Care Management Initial Discharge Assessment Needs

Discharge Assessment: Initial Assessment Completed?: (P) Yes Patient Assessment: Chart and in person interview with family Patient Mental Status: Disoriented Decision Maker: Son/Daughter

Prior Living Arrangements: Residence/Services/DME Prior to Admit (Check all that apply): Group Home, DME Pt Lives With: Other (add Comment) (Group home residents) Home Equipment (DME): (P) Dependent lift, Hospital bed, Feeding equipment

Prior Level of Functioning: Prior Level of Functioning: (P) Needs Assistance Needs assistance with:: (P) Medications, Toileting, Bathing, Dressing, Meal Prep, Ambulation

Plan for Discharge: Patient to return to prior residential situation at discharge: (P) No Anticipated DC Plan A: (P) SNF

Prescription Coverage: Does Patient have insurance coverage for prescriptions?: (P) Yes

Transportation Plan: Transportation Planned Method of Transport at Discharge: (P) Ambulance

Signed: Sarah D Imburgia RN Pager/Phone: 947-521-6321 Date/Time: 8/9/2023, 2:32 PM

Writer called patient's daughter, Iona, to discuss SNF, HHC, DME and private hire. Iona provided patient's medical history from the past few months. Patient was a trucker and found down in parking lot sustained cardiac arrest, was in hospital in Buffalo NY from 5/11-6/16. Patient then transferred to Regency Livonia for SAR d/t family location in Michigan, patient now has Michigan Medicaid. Patient was impulsive and agitated at Regency Livonia, patient brought to Trinity Health Livonia for further management and stayed there from 6/21-7/26. Review of Care Everywhere at Trinity Health shows that RIM/U of M/St Joes Ann Arbor reviewed patient for TBI criteria but denied due to lack of therapy participation and behaviors. Patient was also not accepted to any SNFs due to agitation as well as patient requiring restraints continuously.

Patient's daughter, Iona, arranged for patient to go to her aunt Vickie's group home for placement, Vickie was agreeable to handle tube feeding and pts dependent mobility status with hoyer lift. Patient was at Fox Creek group home (21207 Parker, Farmington Hills) using Corpo Sano HHC services, from 7/26-8/1 when he was admitted to Beaumont FH. Iona reports that they were not paying her aunt as they do not have the means to, and it was a favor to the family to care for him. Iona states that her and her brother had been alternating caring for patient 24 hrs (in between care provided by aunt Vickie). She states that patient was even requiring continuous restraints at the group home and was still agitated/combative, they were giving PO medications for agitation but these did not help. Iona states that her aunt Vickie feels patient's care level too high to accommodate at group home level with behaviors/agitation. Iona states she has petitioned to be patient's legal guardian, case was accepted and will have a hearing 8/28/23 to be granted patient's full legal guardian.

Discussed case with supervisor Kristin M, she concurs with plan that patient not appropriate to return to group home level. More appropriate for SNF level of care. Patient will need to be out of restraints and agitation/behaviors controlled before placement can be pursued at SNF. Writer messaged Dr. Paris with psychiatry to adjust patient's medications for agitation management. Department to follow for agitation management, discontinuation of restraints, and will send SNF referrals looking for long term medicaid bed. Writer updated NP Danielle Saunders on the above.

Electronically signed by Sarah I at 08/09/2023 2:51 PM EDT Nutr Serv Progress Note - Vuk V - 08/09/2023 1:39 PM EDT

Formatting of this note is different from the original.

NUTRITION SERVICES - FOLLOW-UP ASSESSMENT Name: Ioan Suiugan-62y.o.Male MRN: 9942681 LOS: 8 Room:219A/B/219A Reason for Visit: Nutrition Reassessment Nutrition Therapy Protocol Yes

8/9 - Pt had toxic metabolic encephalopathy superimposed on anoxic brain injury secondary to sepsis/UTI per Internal medicine NP. Pt is still disoriented and aggressive, is on restraints, and requires TF. Per Internal Medicine Physician, no acute medical

problems. Antibiotics completed, adjusted IVF, dc planning.

Subjective: Pt visited, lying in bed. TF running at goal of 70 mL/hr with 75 mL flushes.

FOOD AND NUTRITION HISTORY: Current Diet Order Orders Placed This Encounter Adult Diet - Diet Consistency: Dysphagia; Dysphagia Diet: Pureed; Additional Restrictions: 1:1 Feed; Non Room Service Tube Feeding with Oral Diet - Tube Feed: Tube Feeding,; Product: Glucerna 1.5; Rate Goal ml/hr: 70; Tube Feeding Water Flush (mL): 75; Water Flush Frequency: Other (specify) (q1hr); Non Room Service Food Allergies: NKFA per chart. Cultural/Religious Practices: na Appetite: na Intake: Pt's current Glucerna 1.5 is 70 mL/hr and 75 mL water flush. Chewing/Swallowing: na GI: LBM 8/8 per chart. Skin: PI Stage II Sacrum Center, Wound r anterior knee per chart. Edema: None per chart. BIOCHEMICAL DATA/ MEDICATIONS/ TESTS / PROCEDURES: Recent Labs 08/07/23 0331 08/07/23 0557 08/08/23 0322 08/08/23 0555 08/09/23 0339 08/09/23 0631 08/09/23 1209 NA 143 -- 141 -- 139 -- --К 2.9* -- 3.3* -- 3.7 -- --CL 112* -- 111 -- 108 -- --CO2 24 -- 24 -- 26 -- --GLU 116* < > 136* < > 119* 118 164* BUN 12 -- 11 -- 11 -- --CREAT 0.55* -- 0.58* -- 0.55* -- --EGFR 112 -- 110 -- 112 -- --CALCIUM 7.5* -- 7.9* -- 7.8* -- --MG 1.8 -- 1.9 -- 2.0 -- --PHOS 2.6 -- 2.5 -- 2.5 -- --ALB 2.5* -- 2.4* -- 2.5* -- --<> = values in this interval not displayed. Medications: SCHEDULED: amiodarone, 200 mg, PEG Tube, DAILY apixaban (ELIQUIS) tablet DVT/PE TREATMENT CONTINUATION BEYOND 7 DAYS, 5 mg, Oral, Q 12 H atorvastatin, 40 mg, PEG Tube, Q HS clopidogrel, 75 mg, Oral, DAILY insulin regular human, 2-5 Units, Subcutaneous, Q 6 H metoprolol, 25 mg, PEG Tube, BID OLANZapine, 10 mg, Oral, BID sodium chloride, 10 mL, Intravenous, Q 12 H valproate, 1,000 mg, Oral, BID

IVF:

PRN:

- acetaminophen
- sodium chloride
- sodium chloride
- sodium chloride
- sodium chloride 0.9%

Tests/Procedures:

8/2 CT chest IV contrast - pleural effusion, emphysematous changes, L renal simple cyst, and PEG tube noted in appropriate positioning.

NUTRITION FOCUSED PHYSICAL FINDINGS: Nutrition Focused Physical Exam: Able to evaluate better, moderate depletion observed throughout, cannot exclude component of chronic debility. Subcutaneous Fat Depletion Musculoskeletal Depletion Classification: Moderate [x] Orbital region [x] Upper arm region -triceps/biceps

- [] Thoracic & lumbar region ribs, lower back, midaxillary line
- Classification: Moderate
- [x] Temporalis
- [x] Clavicle & acromion bone region
- [x] Clavicle bone region
- [] Scapular bone region
- [] Dorsal hand
- [x] Patellar region
- [x] Anterior thigh region
- [x] Posterior calf region

ANTHROPOMETRICS: Admit Weight: 99.8 kg (220 lb), Weight Source: Bed scale Current Weight: 85.3 kg (188 lb 0.8 oz), Weight Source: Bed scale Body mass index is 24.14 kg/m². BMI Classification: WNL

IBW: 86.4 kg UBW: na kg All weight readings from this encounter 08/08/23 0600 85.3 kg (188 lb 0.8 oz) 08/07/23 0549 87.4 kg (192 lb 10.9 oz) 08/06/23 0424 85.2 kg (187 lb 13.3 oz) 08/05/23 0340 85.2 kg (187 lb 13.3 oz) 08/02/23 0300 99.8 kg (220 lb) 08/01/23 1727 99.8 kg (220 lb)

Weight Trend: 14.5% weight loss in the last 7 days per Epic weight history. Questions accuracy.

ESTIMATED NUTRITIONAL NEEDS:

Calories: 2132+ kcal/day based on 25 kcal/kg using current body weight (85.3 kg) Protein: 106-128 gm/day based on 1.25-1.5 gm/kg using current body weight note PI stage II Fluid: 2132 mL based on 1 mL/kcal or per provider. Adjust fluids based on intake and output to maintain fluid balance and hemodynamic stability

NUTRITION DIAGNOSIS: Inadequate enteral infusion related to altered mental status as evidenced by TF not meeting goal. - resolved, pt is at 70 mL/hr.

Increased protein needs related to wounds as evidenced by Pressure injury Stage II center Sacrum. - active

INTERVENTION: Intervention(s): Saw pt /consult completed. Chart reviewed. Assessed TF

Goal(s): TF to provide >90% nutrient needs. - not met, ongoing. Prevent significant/unintentional weight loss. - not met, ongoing. Pt to have evidence of wound healing. - not met, ongoing.

MONITORING & EVALUATING TF tolerance. Pertinent labs. Weight trends.

Nutrition related discharge needs at this time - Pending clinical course.

Follow Up Range: based on patient care goals, 5-7 days

RECOMMENDATIONS:

Glucerna 1.5 goal = 70 mL/hr. TF at goal provides: 2520 kcal, 138 gm protein, 1276 mL free H2O Enteral H2O: defer to provider. Aspiration precautions, HOB > 30-45 degrees at all times.

Dietetic Intern: Vuk Vuckovic Available via Mobile Heartbeat" Electronically signed by Natalie F at 08/10/2023 10:03 AM EDT

Associated attestation - Natalie F - 08/10/2023 10:03 AM EDT Formatting of this note might be different from the original. 219A/B/219A Name: Ioan Suiugan MRN: 9942681 DOB: 2/27/1961

I saw and evaluated the patient on 8/9/23. Discussed with the dietetic intern and agree with the dietetic intern's findings and plan as documented in the dietetic intern's note.

Spoke with RN, tolerating TF at goal. Not receptive to PO intake.

Agree with moderate depletions observed in physical exam however pt does have chronic debility and has been meeting nutrition needs. Suspect this is multifactorial and unable to justify pcm at this time.

Noted changed with water flush. IVF heplocked. Defer to attending.

Natalie Frayer, MS, RD Available via mobile heartbeat

PT/OT Progress Note - Katherine F - 08/09/2023 12:48 PM EDT Formatting of this note is different from the original.

08/09/23 1317 Time Detail OT Visit Number 2 (Room 219A) Time Eval/Tx Initiated 1248 Total Eval/Tx Time (min) - individual 23 min Event/Subjective OT Received On 08/09/23 Event Note AMS, CT Brain (-), hx of anoxic brain injury, DM Subjective RN cleared pt for therapy Patient Goal none stated Observation In Bed before Treatment; PEG/PEJ Tube; Urinary Catheter Assessment Assessment Tolerated eval/tx poor Tolerated eval/tx poor additional detail Pt limited by impaired cognition. Pt was more alert today and not resistant with exercises. Performed 2x long sitting with patient. Patient did not follow any commands/exercises. Trial 1-2 more times and if patient has not been able to participate with skilled therapy then discharge patient from OT. **Rehab Potential** (quarded) Goals Discussed With (unable to discuss meaningful goals with patient due to impaired cognition) Recommendation OT Discharge Instructions In progress OT Discharge Recommendations SAR (Subacute rehab) (Pt unable to tolerate 3 hours of therapy a day) OT DME Recommendations To be determined PT/OT Post Treatment Post tx patient left in bed;Post tx call light/phone within reach;Post tx left patient with lines intact Plan Treatment Interventions ADL retraining;UE strengthening/ROM;Endurance training;Cognitive reorientation;Bed mobility;Balance;Therapeutic activities;Therapeutic exercises;Energy conservation OT Frequency 3-5 x/wk Precautions Precautions (Fall, Contact) Weight Bering Status During Session FWB Cognition Arousal/Alertness Alert Motivation Motivated **Follows Commands**

(Did not follow commands) Memory Impaired Orientation Level Oriented to person Safety Judgement Impaired; Decreased Attention Span; Slow Processing; Low Insight/Safety Awareness Awareness of Errors No awareness Insight into Deficits Not aware of deficits Problem Solving Assistance required to identify errors made Pain Screening/Assessment Screening/Pain Scale Used Face, Legs, Activity, Crying, Consolability (FLACC) Pain Score 0 Bed Mobility **Rolling Dependent** Supine to Sit Dependent Sit to Supine Dependent Supine Scoot Dependent Transfers Sit to Stand UTA Balance Sitting - Static Absent (Long sit 2x) Sitting - Dynamic Not tested Standing - Static Not tested Standing - Dynamic Not tested ADL Where Assessed Supine, bed LE Dressing Assistance Dependent Exercise/Interventions Exercise & Intervention Comment Bilateral UE PROM exercises (horizontal arm punches, elbow flex/ext, shoulder flex/ext) 10 reps each Significant Time Spent Significant Time Spent On Encouragement Activities of Daily Living - AM-PAC 6 CLICK Putting on and taking off regular lower body clothing? 1 Bathing (including washing, rinsing, drying)? 1 Toileting, which includes using toilet, bedpan or urinal? 1 Putting on and taking off regular upper body clothing? 1 Taking care of personal grooming such as brushing teeth? 1 Eating meals? 1 Activities of Daily Living Score 6 Patient/Family Education/Training **Education Participants Patient** Educated On Yes Patient Safety Bed in lowest position Yes Side rails/Bed safety 2/4 Chair alarm on if indicated Not Indicated Bed alarm on if indicated Yes Interdisciplinary Communication Interdisciplinary Communication spoke with RN Interdisciplinary Communication topic Tolerance of treatment Electronically signed by Rochelle W at 08/09/2023 1:53 PM EDT PT/OT Progress Note - Kelsey W - 08/09/2023 9:32 AM EDT Formatting of this note is different from the original. 08/09/23 0932 Time Detail PT Visit Number 2 Time Eval/Tx Initiated 0932 Total Eval/Tx Time (min) - individual 23 min

Event/Subjective PT Received On 08/09/23 Event Note AMS, CT brain (-), hx of anoxic brain injury, DM Subjective RN cleared pt for therapy. Pt confused but cooperative at this time Patient Goal None stated Observation In Bed before Treatment;PEG/PEJ Tube;Urinary Catheter Assessment Assessment Tolerated eval/tx poor BLEs as well as repositioning during todays tx session without any resistance noted. Will trial 1-2 more tx session to assess pt progress and ability to actively participate in skilled PT. Therapy Problem List Impaired Bed Mobility:Impaired Transfers:Impaired Functional Mobility:Impaired Gait Skills:Impaired Stair Mobility;Impaired Balance;Impaired Strength;Impaired ROM;Impaired Cognition;Impaired Endurance;Impaired Functional Endurance **Rehab Potential** (Guarded) Goals Discussed With (unable to discuss meaningful goals with pt d/t impaired cognition) How is your pain at the end of the therapy session? 0 Recommendation PT Discharge Instructions In progress PT Discharge Recommendations SAR (Subacute rehab) PT DME Recommendations To be determined PT/OT Post Treatment Pt/Family informed of benefit/risk of tx;Post tx patient left in bed;Post tx left patient with lines intact;Post tx call light/phone within reach;Post tx RN informed patient location Plan PT Frequency 3-5x/wk Precautions Precautions (High fall risk, MDR isolation) Weight Bering Status During Session FWB Learning Barriers Learning Barriers (PT/OT) Carryover; Impaired Cognition; Judgement; Language; Safety Cognition Arousal/Alertness Alert Follows Commands Does not follow any commands Memory Impaired Orientation Level Oriented to person Safety Judgement Low Insight/Safety Awareness;Slow Processing;Impulsive;Decreased Attention Span;Impaired Awareness of Errors No awareness Insight into Deficits Not aware of deficits Problem Solving Assistance required to identify errors made Pain Screening/Assessment Screening/Pain Scale Used No/denies pain **Bed Mobility Rolling Dependent** Supine to Sit Dependent (long sitting x2 PA) Sit to Supine Dependent (From long sitting to supine) Supine Scoot Dependent Transfers Sit to Stand UTA Balance Sitting - Static Absent (long sitting) Sitting - Dynamic Not tested Standing - Static Not tested Standing - Dynamic Not tested Exercise/Interventions Ankle Circles Bilateral Exercise/Interventions Details x15 PROM Ankle Pumps Bilateral Exercise/Interventions Details x15 PROM Heelslides Bilateral Exercise/Interventions Details x15 PROM Straight Leg Raises Bilateral Exercise/Interventions Details x15 PROM Supine Hip Abduction Bilateral Exercise/Interventions Details x15 PROM Significant Time Spent Significant Time Spent On Encouragement;Redirecting patient;Communication Mobility - AM-PAC 6 CLICK Turning from your back to your side while in a flat bed without using bedrails? 1 Moving from lying on your back to sitting on the side of a flat bed without using bedrails? 1 Moving to and from a bed to a chair (including a wheelchair)? 1 Standing up from a chair using your arms (e.g., wheelchair, or bedside chair)? 1 To walk in hospital room? 1 Climbing 3-5 steps with a railing? 1

Tolerated eval/tx poor additional detail Pt continues to be limited by impaired cognition. Pt allowing writer to perform PROM to

Mobility Score 6 Patient/Family Education/Training Education Participants Patient Patient Safety Bed in lowest position Yes Side rails/Bed safety 2/4 Bed alarm on if indicated Yes Interdisciplinary Communication Interdisciplinary Communication spoke with RN Interdisciplinary Communication topic Mobility status;Tolerance of treatment

Electronically signed by Katie L at 08/09/2023 3:03 PM EDT

Care Plan Note - Sarah P - 08/09/2023 5:08 AM EDT Formatting of this note is different from the original. PROGRESS NOTE

NEURO: A&Ox1, no changes in mentation, displays agitated behavior shown by verbal insult and attempting to hit staff while repositioning

VS: VSS

Last Filed Vitals: BP 137/90 (08/09/23 0435) HR 80 (08/09/23 0435) RR 22 (08/09/23 0435) Temp 98.2 °F (36.8 °C) (08/08/23 2011) SpO2 99 % (08/09/23 0435) O2 (L/min) (not recorded)

ACTIVITY: Repositioned q2 hours, heels elevated; fall precautions maintained

FAMILY/PATIENT CONCERNS: N/A

SIGNIFICANT EVENTS: bilateral mitts and wrist restraints remain in place due to agitaion and pulling at medical equipment Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Not Progressing

Problem: Safety: Goal: Will remain free from falls in 4 hours Description: Assess for poly-pharmacy and drug to drug interactions Outcome: Progressing Goal: Will remain free of falls with the implementation of Universal Precautions Outcome: Progressing Goal: Will remain free of falls with the implementation of High Risk Fall precautions Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Not Progressing

Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Not Progressing

Problem: Medication: Goal: Will comply with prescribed medication regimen Outcome: Progressing

Problem: Nutritional: Goal: Nutritional status will be supported Outcome: Progressing

Problem: Physical Regulation:

Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing Goal: Risk of venous thrombosis will decrease Outcome: Progressing

Problem: Self-Care: Goal: Ability to participate in self-care as condition permits will be supported Outcome: Not Progressing

Problem: Sensory: Goal: Pain level will decrease Outcome: Progressing

Problem: Tissue Perfusion: Goal: Will regain and/or maintain adequate tissue perfusion Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Not Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing Goal: Will verbalize understanding of the information provided Outcome: Not Progressing

Problem: Skin Integrity: Goal: Will show signs of wound healing Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing Goal: Will verbalize understanding of the information provided Outcome: Not Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Not Progressing Goal: Will identify and develop effective coping behavior Outcome: Not Progressing Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing Goal: Will verbalize understanding of the information provided Outcome: Not Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Not Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Electronically signed by Sarah P at 08/09/2023 5:10 AM EDT Care Plan Note - Brianna M - 08/08/2023 6:50 PM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing

Electronically signed by Brianna M at 08/08/2023 6:50 PM EDT

Care Management - Sarah I - 08/08/2023 9:49 AM EDT

Formatting of this note might be different from the original. Left VM for son and daughter with callback number requesting return call to complete initial assessment. Will attempt to call again at a later time.

Electronically signed by Sarah I at 08/08/2023 9:49 AM EDT

Nsg Progress Note - Brianna M - 08/08/2023 8:56 AM EDT

Formatting of this note might be different from the original.

Patient agitated this morning, pulling at medical equipment, telemetry, and patient unable to be reoriented. Attempted to swing at staff, patient better once medications given. Around 10am patient was more calm, but consistently pulling at equipment despite restraints.

Neuro: aox0-1 Resp: RA no SOB Card: NSR, BP normal GI: bm today, soft nontender GU: foley for retention IV: right upperarm powerglide Skin: sacrum mepelex stage 2 Right knee looks scarred- covered with mepelex Electronically signed by Brianna M at 08/08/2023 6:24 PM EDT Care Plan Note - Shaniqua H - 08/07/2023 9:55 PM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Not Progressing

Problem: Safety: Goal: Will remain free from falls in 4 hours Description: Assess for poly-pharmacy and drug to drug interactions Outcome: Progressing Goal: Will remain free of falls with the implementation of Universal Precautions Outcome: Progressing Goal: Will remain free of falls with the implementation of High Risk Fall precautions Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Not Progressing

Problem: Medication: Goal: Will comply with prescribed medication regimen Outcome: Progressing

Problem: Nutritional: Goal: Nutritional status will be supported Outcome: Progressing

Problem: Physical Regulation: Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing Goal: Risk of venous thrombosis will decrease Outcome: Progressing

Problem: Self-Care: Goal: Ability to participate in self-care as condition permits will be supported Outcome: Not Progressing

Problem: Sensory: Goal: Pain level will decrease Outcome: Progressing

Problem: Tissue Perfusion: Goal: Will regain and/or maintain adequate tissue perfusion Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Not Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing Goal: Will verbalize understanding of the information provided Outcome: Not Progressing

Problem: Skin Integrity: Goal: Will show signs of wound healing Outcome: Progressing

Problem: Cognitive:

Goal: Periods of time without restraints will increase Outcome: Not Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Not Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing Goal: Will verbalize understanding of the information provided Outcome: Not Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Not Progressing Goal: Will identify and develop effective coping behavior Outcome: Not Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing Goal: Will verbalize understanding of the information provided Outcome: Not Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Not Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety:

Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Electronically signed by Shaniqua H at 08/07/2023 9:55 PM EDT PT/OT Progress Note - Samantha C - 08/07/2023 1:15 PM EDT Formatting of this note is different from the original. 08/07/23 0923 Time Detail PT Visit Number 1 Time Eval/Tx Initiated 0923 Total Eval/Tx Time (min) - individual 8 min **Event/Subjective** PT Received On 08/07/23 Event Note AMS, CT brain (-), hx of anoxic brain injury, DM Subjective RN cleared pt for tx. Pt very confused and needs increased re-direction. Patient Goal none stated Observation In Bed before Treatment; Restraints; Multiple tubes and lines requiring additional assistance (hands mits) Assessment Assessment Tolerated eval/tx poor Tolerated eval/tx poor additional detail Pt is limited by decreased cognition, very resistive, language barrier, and strength. Pt would benefit from continued skilled PT to improve his deficits. Therapy Problem List Impaired Bed Mobility; Impaired Transfers; Impaired Functional Mobility; Impaired Gait Skills; Impaired Stair Mobility;Impaired Balance;Impaired Strength;Impaired ROM;Impaired Cognition;Impaired Endurance;Impaired Functional Endurance **Rehab Potential Poor** Goals Discussed With Patient How is your pain at the end of the therapy session? 0 Recommendation PT Discharge Instructions In progress PT Discharge Recommendations SAR (Subacute rehab) (pt could not tolerate 3 hours of therapy per day) PT DME Recommendations To be determined PT/OT Post Treatment Pt/Family informed of benefit/risk of tx;Post tx patient left in bed;Post tx left patient with lines intact;Post tx call light/phone within reach;Post tx RN informed patient location Plan Treatment/Interventions Physical Therapy is recommended to address deficits. PT Frequency 3-5x/wk Precautions Precautions (high risk fall) Weight Bering Status During Session FWB Learning Barriers Learning Barriers (PT/OT) Impaired Cognition Cognition Arousal/Alertness Lethargic Motivation Motivated Follows Commands Does not follow any commands Memory Impaired Orientation Level Oriented to person Safety Judgement Low Insight/Safety Awareness Awareness of Errors Decreased awareness Insight into Deficits Decreased awareness of deficits Problem Solving Assistance required to identify errors made Pain Screening/Assessment Screening/Pain Scale Used No/denies pain Pain Score 0 **Bed Mobility Rolling UTA** (unable to perform any bed mobility due to pts confusion) Transfers Sit to Stand UTA Gait/Stairs Distance UTA Balance Sitting - Static Not Tested Sitting - Dynamic Not tested Standing - Static Not tested Standing - Dynamic Not tested

Exercise/Interventions Ankle Circles Bilateral Exercise/Interventions Details x10 Ankle Pumps Bilateral Exercise/Interventions Details x10 Supine Hip Abduction Bilateral Exercise/Interventions Details x10 Significant Time Spent Significant Time Spent On Encouragement;Communication;Redirecting patient;Line management Mobility - AM-PAC 6 CLICK Turning from your back to your side while in a flat bed without using bedrails? 2 Moving from lying on your back to sitting on the side of a flat bed without using bedrails? 1 Moving to and from a bed to a chair (including a wheelchair)? 1 Standing up from a chair using your arms (e.g., wheelchair, or bedside chair)? 1 To walk in hospital room? 1 Climbing 3-5 steps with a railing? 1 Mobility Score 7 Patient/Family Education/Training **Education Participants Patient** Patient Safety Bed in lowest position Yes Side rails/Bed safety 2/4 Chair alarm on if indicated Not Indicated Bed alarm on if indicated Yes Interdisciplinary Communication Interdisciplinary Communication spoke with RN;OT Interdisciplinary Communication topic Tolerance of treatment **Communication with Patient** Reason for Communication Update on Condition/Status Type of Communication Face-to-Face Electronically signed by Alyssa V at 08/07/2023 3:55 PM EDT

Electronically signed by Alyssa V at 06/07/2025 5.55 PW EDT

PT/OT Progress Note - Katherine F - 08/07/2023 1:02 PM EDT

Formatting of this note is different from the original.

08/07/23 1507 Time Detail OT Visit Number 1 (Room 219A) Time Eval/Tx Initiated 1302 Total Eval/Tx Time (min) - individual 8 min **Event/Subjective** OT Received On 08/07/23 Event Note AMS, CT brain (-), hx of anoxic brain injury, DM Subjective RN cleared pt for therapy Patient Goal none stated Observation In Bed before Treatment;Nasal Cannula O2 L/min;IV;PEG/PEJ Tube;Urinary Catheter;Bed Alarm Assessment Assessment Tolerated eval/tx poor Tolerated eval/tx poor additional detail Pt is limited by decreased cognition. Pt was very resistive with UE exercises. Language barrier **Rehab Potential Poor** Goals Discussed With Patient Recommendation OT Discharge Instructions In progress OT Discharge Recommendations SAR (Subacute rehab) (Pt unable to tolerate 3 hours of therapy a day) OT DME Recommendations To be determined Plan Treatment Interventions UE strengthening/ROM;Cognitive reorientation;Therapeutic exercises OT Frequency 3-5 x/wk Learning Barriers Learning Barriers (PT/OT) Impaired Cognition; Language Precautions Precautions (Fall) Weight Bering Status During Session FWB Cognition Arousal/Alertness Alert

Follows Commands Does not follow any commands Memory Impaired Orientation Level Oriented to person Safety Judgement Impaired;Impulsive;Low Insight/Safety Awareness;Agitated;Decreased Attention Span Awareness of Errors Decreased awareness Insight into Deficits Decreased awareness of deficits Problem Solving Assistance required to identify errors made Pain Screening/Assessment Screening/Pain Scale Used Face, Legs, Activity, Crying, Consolability (FLACC) Pain Score 0 Bed Mobility Rolling UTA (Pt not safe to sit EOB due to confusion and agitation) Supine Scoot Dependent Balance Sitting - Static Not Tested Sitting - Dynamic Not tested Standing - Static Not tested Standing - Dynamic Not tested Exercise/Interventions Exercise & Intervention Comment Bilateral UE PROM exercises (elbow flex/ext, shoulder flex/ext) 5 reps each. Pt very resistant with exercises. Significant Time Spent Significant Time Spent On Communication; Encouragement Activities of Daily Living - AM-PAC 6 CLICK Putting on and taking off regular lower body clothing? 1 Bathing (including washing, rinsing, drying)? 1 Toileting, which includes using toilet, bedpan or urinal? 1 Putting on and taking off regular upper body clothing? 1 Taking care of personal grooming such as brushing teeth? 1 Eating meals? 1 Activities of Daily Living Score 6 Patient/Family Education/Training **Education Participants Patient** Patient Safety Bed in lowest position Yes Side rails/Bed safety 2/4 Chair alarm on if indicated Not Indicated Bed alarm on if indicated Yes Interdisciplinary Communication Interdisciplinary Communication spoke with RN Interdisciplinary Communication topic Tolerance of treatment

Electronically signed by Terry G at 08/08/2023 7:45 AM EDT Care Plan Note - Brianna M - 08/07/2023 12:35 PM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Electronically signed by Brianna M at 08/07/2023 12:36 PM EDT Care Plan Note - Shaniqua H - 08/06/2023 9:08 PM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Not Progressing

Problem: Safety:

Goal: Will remain free from falls in 4 hours Description: Assess for poly-pharmacy and drug to drug interactions Outcome: Progressing Goal: Will remain free of falls with the implementation of Universal Precautions Outcome: Progressing Goal: Will remain free of falls with the implementation of High Risk Fall precautions Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Not Progressing

Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Not Progressing

Problem: Medication: Goal: Will comply with prescribed medication regimen Outcome: Progressing

Problem: Nutritional: Goal: Nutritional status will be supported Outcome: Progressing

Problem: Physical Regulation: Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing Goal: Risk of venous thrombosis will decrease Outcome: Progressing

Problem: Self-Care: Goal: Ability to participate in self-care as condition permits will be supported Outcome: Not Progressing

Problem: Sensory: Goal: Pain level will decrease Outcome: Progressing

Problem: Tissue Perfusion: Goal: Will regain and/or maintain adequate tissue perfusion Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Not Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Skin Integrity: Goal: Will show signs of wound healing Outcome: Progressing Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Not Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Not Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Not Progressing Goal: Will identify and develop effective coping behavior Outcome: Not Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing

Electronically signed by Shaniqua H at 08/06/2023 9:08 PM EDT Care Plan Note - Tiffanie C - 08/06/2023 6:38 PM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Progressing

Problem: Safety: Goal: Will remain free from falls in 4 hours Description: Assess for poly-pharmacy and drug to drug interactions Outcome: Progressing Goal: Will remain free of falls with the implementation of Universal Precautions Outcome: Progressing Goal: Will remain free of falls with the implementation of High Risk Fall precautions Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Medication: Goal: Will comply with prescribed medication regimen Outcome: Progressing

Problem: Nutritional: Goal: Nutritional status will be supported Outcome: Progressing

Problem: Physical Regulation: Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing Goal: Risk of venous thrombosis will decrease Outcome: Progressing

Problem: Self-Care: Goal: Ability to participate in self-care as condition permits will be supported Outcome: Progressing

Problem: Sensory: Goal: Pain level will decrease Outcome: Progressing

Problem: Tissue Perfusion: Goal: Will regain and/or maintain adequate tissue perfusion Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Skin Integrity: Goal: Will show signs of wound healing Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase **Outcome: Progressing**

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing

Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Progressing

Problem: Safety: Goal: Will remain free from falls in 4 hours Description: Assess for poly-pharmacy and drug to drug interactions Outcome: Progressing Goal: Will remain free of falls with the implementation of Universal Precautions Outcome: Progressing Goal: Will remain free of falls with the implementation of High Risk Fall precautions Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care Outcome: Progressing Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Medication: Goal: Will comply with prescribed medication regimen Outcome: Progressing

Problem: Nutritional: Goal: Nutritional status will be supported Outcome: Progressing

Problem: Physical Regulation: Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing Goal: Risk of venous thrombosis will decrease Outcome: Progressing

Problem: Self-Care: Goal: Ability to participate in self-care as condition permits will be supported Outcome: Progressing

Problem: Sensory: Goal: Pain level will decrease Outcome: Progressing

Problem: Tissue Perfusion: Goal: Will regain and/or maintain adequate tissue perfusion Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Skin Integrity: Goal: Will show signs of wound healing Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing

Electronically signed by Tiffanie C at 08/06/2023 6:38 PM EDT Care Plan Note - Lori S - 08/06/2023 3:06 AM EDT Formatting of this note might be different from the original.

Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Medication: Goal: Will comply with prescribed medication regimen Outcome: Progressing

Electronically signed by Lori S at 08/06/2023 3:06 AM EDT Nsg Progress Note - Lori S - 08/06/2023 12:00 AM EDT Formatting of this note is different from the original. **PROGRESS NOTE**

NEURO: , , Periods of aggitation. On Zyprexa. Had Tylenoo for pain as pt yells out when being turned and giving per care.

VS: vss

Last Filed Vitals: BP 116/84 (08/06/23 0423) HR 63 (08/06/23 0423) RR 18 (08/06/23 0423) Temp 98.2 °F (36.8 °C) (08/06/23 0423) SpO2 98 % (08/06/23 0423) O2 (L/min) (not recorded)

ACTIVITY: Pt turned at least every 2 hours

FAMILY/PATIENT CONCERNS: no voiced concerns can speak in small sentences or fragments. Confused

SIGNIFICANT EVENTS: no noted changes in vs. Or tele. Pt is confused per daughter Vicky. She was speaking Romanian and asking him questioins and cinfused responses. Language barrier Romanian Electronically signed by Lori S at 08/06/2023 5:30 AM EDT

Pharmacist Progress Note - Linda W - 08/05/2023 12:04 PM EDT

Formatting of this note is different from the original. Pharmacy Dosing Service: Vancomycin Level Evaluation Current Regimen: Vancomycin 1500 mg IV every 12 hours Indication: Sepsis (unknown source) Target: AUC 400-600 and Trough < = 20 mcg/mL Day of Therapy: 5 Other Antimicrobials: Cefepime, Metronidazole

Labs and Renal Function Temp (24hrs), Avg:98.1 °F (36.7 °C), Min:97.7 °F (36.5 °C), Max:98.8 °F (37.1 °C)

Recent Labs 08/04/23 0614 08/03/23 0626 08/02/23 0632 08/02/23 0541 08/01/23 1731 WBC 13.3* 16.0* 11.4* -- 13.7* CREAT 0.64 0.73 -- 0.67 0.77 BUN 26* 27* -- 24 23

CrCl or renal function: Estimated Creatinine Clearance: 139.1 mL/min (by C-G formula based on SCr of 0.64 mg/dL). Note: Albumin = 2.7 I/O: UOP: 0.7 ml/kg/hr

Pharmacokinetics

Lab Results Component Value Date/Time VANCOMYCINPK 14.6 (L) 08/04/2023 2201

Levels: 1 Level at steady state drawn following the dose on date:08/04/23 time: 09:49 (10.5 hours post-infusion)

Pharmacokinetic parameters based on level(s): Vd: 55.4 L Ke: 0.095 hr -1 T1/2: 7.3 hr AUC: 570.2 mcg*h/mL Cmin: 14.9 mcg/mL Cmax: 40.3

Microbiology

Blood: Results from last 7 days Lab Units 08/01/23 1755 08/01/23 1731 LAB CP CULTURE, BLOOD No growth at 3 days No growth at 3 days , Lower respiratory: , Tissue/Wound/Surgical: , Urine: Results from last 7 days Lab Units 08/01/23 2252 LAB CP CULTURE, URINE 10,000-100,000 CFU/ml Enterobacter cloacae complex* , Fluid: , MRSA nasal swab: Assessment This is a 62y.o. male with past medical history of type 2 diabetes, atrial flutter, urinary retention and prior V. tach arrest with resulting anoxic brain injury on 5/23 who presents with altered mental status over the last several days. Vancomycin Level(s): IV access was lost yesterday evening and Vancomycin dose missed. No peak level. Trough level is good and will dose from that. Trough level resulted in target range. Since the extrapolated Cmax is high end of range, today is day 5 of 7 days of Vancomycin, and baseline renal impairment is likely d/ t age, DM, etc., there is concern for Vancomycin accumulation. For these reasons the Vancomycin dose will be adjusted down slightly. Renal function: stable Current risk factors for nephrotoxicity: Baseline renal impairment Plan Change Vancomycin to 1250 mg IVPB every 12 hours to achieve a predicted AUC 474.5 and Cmin 11.4 mcg/mL Not Ordered- Levels(s) to be drawn once weekly (follow-up levels for q12h or q24h regimen) Monitor SCr daily Pharmacy will continue to monitor renal function, WBC, cultures and the clinical progress of the patient. Please do not hesitate to contact us with comments or questions. Thank you, Linda S Webb, PHARMACIST, 8/5/2023 Available on Mobile Heartbeat Vancomycin Calculator Adult Vancomycin Pharmacy Dosing Guideline Electronically signed by Linda W at 08/05/2023 12:04 PM EDT Care Plan Note - Lori S - 08/05/2023 1:53 AM EDT Formatting of this note might be different from the original. Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN **Outcome:** Progressing Problem: Safety: Goal: Will remain free from falls in 4 hours Description: Assess for poly-pharmacy and drug to drug interactions 8/5/2023 0153 by Sharp, Lori J, RN **Outcome: Progressing** 8/5/2023 0151 by Sharp, Lori J, RN **Outcome: Progressing** Goal: Will remain free of falls with the implementation of Universal Precautions 8/5/2023 0153 by Sharp, Lori J, RN **Outcome: Progressing** 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing Goal: Will remain free of falls with the implementation of High Risk Fall precautions 8/5/2023 0153 by Sharp, Lori J, RN **Outcome: Progressing**

Problem: Cognitive:

Outcome: Progressing

8/5/2023 0151 by Sharp, Lori J, RN

Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Medication: Goal: Will comply with prescribed medication regimen 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Nutritional: Goal: Nutritional status will be supported 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Physical Regulation: Goal: Complications related to the disease process, condition or treatment will be avoided or minimized 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing Goal: Will remain free from infection 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN

Problem: Safety: Goal: Ability to remain free from injury will improve 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing Goal: Risk of venous thrombosis will decrease 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Self-Care: Goal: Ability to participate in self-care as condition permits will be supported 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Sensory: Goal: Pain level will decrease 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Tissue Perfusion: Goal: Will regain and/or maintain adequate tissue perfusion 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing Goal: Will verbalize understanding of the information provided 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Skin Integrity: Goal: Will show signs of wound healing 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve 8/5/2023 0153 by Sharp, Lori J, RN
Outcome: Progressing
8/5/2023 0151 by Sharp, Lori J, RN
Outcome: Progressing
Goal: Ability to use alternate options when emotions escalate will improve
8/5/2023 0153 by Sharp, Lori J, RN
Outcome: Progressing
8/5/2023 0151 by Sharp, Lori J, RN
Outcome: Progressing
8/5/2023 0151 by Sharp, Lori J, RN
Outcome: Progressing
Problem: Cognitive/Learning Needs:
Goal: Knowledge of disease or condition and prescribed therapeutic regiments

Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing Goal: Will remain free from infection 8/5/2023 0153 by Sharp, Lori J, RN Outcome: Progressing 8/5/2023 0151 by Sharp, Lori J, RN Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing Goal: Will identify and develop effective coping behavior Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Electronically signed by Lori S at 08/05/2023 1:53 AM EDT Care Plan Note - Lori S - 08/05/2023 1:51 AM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Progressing

Problem: Safety: Goal: Will remain free from falls in 4 hours Description: Assess for poly-pharmacy and drug to drug interactions Outcome: Progressing Goal: Will remain free of falls with the implementation of Universal Precautions Outcome: Progressing Goal: Will remain free of falls with the implementation of High Risk Fall precautions Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Medication: Goal: Will comply with prescribed medication regimen Outcome: Progressing

Problem: Nutritional: Goal: Nutritional status will be supported Outcome: Progressing

Problem: Physical Regulation: Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing Goal: Risk of venous thrombosis will decrease Outcome: Progressing

Problem: Self-Care: Goal: Ability to participate in self-care as condition permits will be supported Outcome: Progressing

Problem: Sensory: Goal: Pain level will decrease Outcome: Progressing

Problem: Tissue Perfusion: Goal: Will regain and/or maintain adequate tissue perfusion Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Skin Integrity: Goal: Will show signs of wound healing Outcome: Progressing

Problem: Cognitive:

Goal: Periods of time without restraints will increase Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Problem: Cognitive/Learning Needs: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Health Behavior: Goal: Ability to manage health-related needs will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Urinary Elimination: Goal: Ability to achieve a balanced intake and output will improve Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Electronically signed by Lori S at 08/05/2023 1:51 AM EDT

Nsg Progress Note - Lori S - 08/05/2023 12:00 AM EDT Formatting of this note is different from the original. PROGRESS NOTE

NEURO: , , pt aggitated at times but on Zyprexa and does calm pt. SWR and Mitts are still needed for pt attempts to pull at tubing

VS: vss

Last Filed Vitals: BP 133/78 (08/05/23 0400) HR 71 (08/05/23 0400) RR 20 (08/05/23 0400) Temp 98.3 °F (36.8 °C) (08/05/23 0400) SpO2 98 % (08/05/23 0400) O2 (L/min) (not recorded)

ACTIVITY: turned q 2 hours atc

FAMILY/PATIENT CONCERNS: sister in room at beginning of this shift. "My brother has been confused with some words I can understand since May." Language barrier Romanian and Hungarian

SIGNIFICANT EVENTS: no significant events noted thusfqr this shift Electronically signed by Lori S at 08/05/2023 5:27 AM EDT PT/OT Progress Note - Samantha C - 08/04/2023 11:53 AM EDT Formatting of this note is different from the original.

08/04/23 1007 Event/Subjective Event Note PT/OT hold note. Pt was getting a bath when staff attempted to work with him, will continue to monitor and come back if time permits.

Electronically signed by Alyssa V at 08/04/2023 4:08 PM EDT Nutr Serv Progress Note - Vuk V - 08/04/2023 7:06 AM EDT Formatting of this note is different from the original.

NUTRITION SERVICES - FOLLOW-UP ASSESSMENT Name: Ioan Suiugan-62y.o.Male MRN: 9942681 LOS: 3 Room:219A/B/219A Reason for Visit: Nutrition Reassessment Nutrition Therapy Protocol Yes

8/4 - increased leukocytosis, ID following, possible CT/AP, continue abx.

Subjective: Per SLP 8/2, pt to continue TF as primary nutrition and puree/thin for pleasure with 1:1, slow rate, small bites. Per Internal medicine NP 8/3, pt has AMS, toxic metabolic encephalopathy superimposed on anoxic brain injury. Per SLP 8/3, pt sips through straw on thin water and a few bites of apple sauce.

Pt visited, lying in bed. Pt reported feeling very ill and refused to answer any questions. Pt stated "I want to go back to Romania to get treatment".

FOOD AND NUTRITION HISTORY: Current Diet Order Orders Placed This Encounter Adult Diet - Diet Consistency: Dysphagia; Dysphagia Diet: Pureed; Additional Restrictions: 1:1 Feed; Non Room Service Tube Feeding with Oral Diet - Tube Feed: Tube Feeding,; Product: Glucerna 1.5; Tube Feeding Continuous Rate (mL/hr): 20; Rate Goal ml/hr: 70; Tube Feeding Water Flush (mL): 20; Water Flush Frequency: Other (specify) (q1hr); Non Room Service

Food Allergies: NKFA per chart.

Cultural/Religious Practices: na

PHOS 2.7 -- 3.2 -- 3.3 -- -- --ALB 2.9* -- 2.7* | 2.7* -- 2.9* -- --

AST 21 -- 17 -- -- -- --

Appetite: na Intake: Note oral intake spitting out food per RN. Pt's current Glucerna 1.5 is 25 mL/hr. Chewing/Swallowing: na

GI: LBM 8/3 per chart. Skin: PI Stage II Sacrum Center, Wound r anterior knee per chart. Edema: None per chart.

BIOCHEMICAL DATA/ MEDICATIONS/ TESTS / PROCEDURES: Recent Labs 08/01/23 1731 08/02/23 0159 08/02/23 0541 08/02/23 0602 08/03/23 0626 08/03/23 1714 08/03/23 2317 08/04/23 0621 NA 142 -- 148* -- 146* -- -- --К 4.6 -- 4.0 -- 3.4* -- -- --CL 112* -- 117* -- 117* -- --CO2 23 -- 26 -- 24 -- -- --GLU 432* < > 137* < > 176* 163* 165* 143* BUN 23 -- 24 -- 27* -- --CREAT 0.77 -- 0.67 -- 0.73 -- --EGFR 101 -- 106 -- 103 -- -- --CALCIUM 8.3* -- 8.2* -- 8.4* -- -- --MG 2.1 -- 2.1 -- 2.0 -- -- --

ALT 14 -- 12 -- -- --ALP 113 -- 90 -- -- --LIPASE 10 -- -- -- --< > = values in this interval not displayed.

Medications: SCHEDULED: amiodarone, 200 mg, PEG Tube, DAILY apixaban (ELIQUIS) tablet DVT/PE TREATMENT CONTINUATION BEYOND 7 DAYS, 5 mg, Oral, Q 12 H atorvastatin, 40 mg, PEG Tube, Q HS cefepime (MAXIPIME) IVPB, 2 g, Intravenous, Q 8 H clopidogrel, 75 mg, Oral, DAILY insulin regular human, 2-5 Units, Subcutaneous, Q 6 H metoprolol, 25 mg, PEG Tube, BID metroNIDAZOLE (FLAGYL) intermittent infusion, 500 mg, Intravenous, Q 8 H OLANZapine, 10 mg, Oral, BID valproate, 1,000 mg, Oral, BID vancomycin, 1,500 mg, Intravenous, Q 12 H

IVF:

PRN:

- acetaminophen
- sodium chloride
- sodium chloride 0.9%

Tests/Procedures:

8/2 CT chest IV contrast - pleural effusion, emphysematous changes, L renal simple cyst, and PEG tube noted in appropriate positioning.

NUTRITION FOCUSED PHYSICAL FINDINGS: Nutrition Focused Physical Exam: Subcutaneous Fat Depletion Musculoskeletal Depletion Classification: Mild [x] Orbital region [x] Upper arm region -triceps/biceps [] Thoracic & lumbar region - ribs, lower back, midaxillary line Classification: Mild [x] Temporalis [x] Clavicle & acromion bone region [x] Clavicle bone region [] Scapular bone region [] Dorsal hand [x] Patellar region [x] Anterior thigh region [x] Posterior calf region ANTHROPOMETRICS:

Admit Weight: 99.8 kg (220 lb), Weight Source: Bed scale Current Weight: 99.8 kg (220 lb), Weight Source: Bed scale Body mass index is 28.25 kg/m². BMI Classification: overweight

IBW: 86.4 kg UBW: na kg All weight readings from this encounter 08/02/23 0300 99.8 kg (220 lb) 08/01/23 1727 99.8 kg (220 lb)

Weight Trend: Limited weight history in Epic.

ESTIMATED NUTRITIONAL NEEDS: Calories: 2495+ kcal/day based on 25 kcal/kg using current body weight (99.8 kg) Protein: 125-150 gm/day based on 1.25-1.5 gm/kg using current body weight note PI stage II Fluid: 2495-2994 mL based on 1 mL/kcal or per provider. Adjust fluids based on intake and output to maintain fluid balance and hemodynamic stability

NUTRITION DIAGNOSIS: Inadequate enteral infusion related to altered mental status as evidenced by TF not meeting goal. - active. Increased protein needs related to wounds as evidenced by Pressure injury Stage II center Sacrum. - active

INTERVENTION: Intervention(s): Saw pt /consult completed. Chart reviewed. Assessed TF

Goal(s): TF to provide >90% nutrient needs. - not met, ongoing. Prevent significant/unintentional weight loss. - to be determined, ongoing. Pt to have evidence of wound healing. - not met, ongoing.

MONITORING & EVALUATING TF tolerance. Pertinent labs. Weight trends.

Nutrition related discharge needs at this time - Pending clinical course.

Follow Up Range: 3-5 days

RECOMMENDATIONS: Recommendations: Glucerna 1.5 goal = 70 mL/hr. TF at goal provides: 2520 kcal, 138 gm protein, 1276 mL free H2O Enteral H2O: 40cc/hr Aspiration precautions, HOB > 30-45 degrees at all times. Add MVI.

Dietetic Intern: Vuk Vuckovic Available via Mobile Heartbeat" Electronically signed by Natalie F at 08/04/2023 2:35 PM EDT

Associated attestation - Natalie F - 08/04/2023 2:35 PM EDT Formatting of this note might be different from the original. 219A/B/219A Name: Ioan Suiugan MRN: 9942681 DOB: 2/27/1961

I saw and evaluated the patient. Discussed with the dietetic intern and agree with the dietetic intern's findings and plan as documented in the dietetic intern's note.

Pt's TF has been running at 20cc/hr since initiation. Some confusion in regards to advancement. Discussed with RN, pt has had PEG since May and generally receives TF at ECF. Ok to advance to goal. RN advanced while RD in room. Given decreased TF and water flush, messaged NP for recommendations to increase FWF. Will defer H2O rate to NP/attending.

In regards to care, remains A+Ox 0 per notes. Increasing WBC, ?GU vs aspiration vs other. ID following. Pending cx's. ID following. Psych following for behavioral management. Neuro eval noted, with possible EEG pending.

Natalie Frayer, MS, RD Available via mobile heartbeat Nsg Progress Note - Danitra A - 08/04/2023 5:13 AM EDT Formatting of this note is different from the original. PROGRESS NOTE

NEURO: A&Ox0, no changes in mentation, displays agitated behavior shown by restlessness, swinging at NA when trying to get blood sugar, yelling out loud

VS: VSS

Last Filed Vitals: BP 123/83 (08/04/23 0443) HR 87 (08/04/23 0443) RR 18 (08/04/23 0443) Temp 98 °F (36.7 °C) (08/04/23 0443) SpO2 97 % (08/04/23 0443) O2 (L/min) (not recorded)

ACTIVITY: Repositioned q2 hours, heels elevated; fall precautions maintained

FAMILY/PATIENT CONCERNS: N/A

SIGNIFICANT EVENTS: urine sample taken and sent Electronically signed by Danitra A at 08/04/2023 5:14 AM EDT Care Plan Note - Danitra A - 08/03/2023 9:40 PM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Not Progressing

Problem: Safety: Goal: Will remain free from falls in 4 hours Description: Assess for poly-pharmacy and drug to drug interactions Outcome: Progressing Goal: Will remain free of falls with the implementation of Universal Precautions Outcome: Progressing Goal: Will remain free of falls with the implementation of High Risk Fall precautions Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Not Progressing

Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Not Progressing

Problem: Medication: Goal: Will comply with prescribed medication regimen Outcome: Progressing

Problem: Nutritional: Goal: Nutritional status will be supported Outcome: Progressing

Problem: Physical Regulation: Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing Goal: Risk of venous thrombosis will decrease **Outcome: Progressing**

Problem: Self-Care: Goal: Ability to participate in self-care as condition permits will be supported Outcome: Progressing

Problem: Sensory: Goal: Pain level will decrease Outcome: Progressing

Problem: Tissue Perfusion: Goal: Will regain and/or maintain adequate tissue perfusion Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Not Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing Goal: Will verbalize understanding of the information provided Outcome: Not Progressing

Problem: Skin Integrity: Goal: Will show signs of wound healing Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Not Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Electronically signed by Danitra A at 08/03/2023 9:40 PM EDT Nsg Progress Note - Holly F - 08/03/2023 6:50 PM EDT Formatting of this note is different from the original. **PROGRESS NOTE**

NEURO: A&Ox0, no changes in mentation, displays dangerous behavior shown by pulling at lines and tubed or attempting to get up from bed whenever hands are momentarily free.

VS: stable

Last Filed Vitals: BP 142/88 (08/03/23 1517) HR 87 (08/03/23 1517) RR 20 (08/03/23 1517) Temp 98.6 °F (37 °C) (08/03/23 1517) SpO2 100 % (08/03/23 1517) O2 (L/min) (not recorded)

ACTIVITY: Repositioned q2 hours, heels elevated; fall precautions maintained

FAMILY/PATIENT CONCERNS: Updated family on plan of care

SIGNIFICANT EVENTS: Pt received EEG, pt speaks in forgien language, no family at bedside today. Pt had a BM and a complete linen change. Pt alert but not oriented to self, place or situation.Pt spitting out food when attempts are made to feed pt. Electronically signed by Holly F at 08/03/2023 6:52 PM EDT

SLP Progress Note - Carley A - 08/03/2023 10:29 AM EDT Formatting of this note is different from the original. ACUTE CARE SPEECH-LANGUAGE PATHOLOGY TREATMENT NOTE

Patient Name: Ioan Suiugan Date/Time: 8/3/23, 0900 MRN: 9942681 Medical Diagnosis: AMS DOB: 2/27/1961 Visit Diagnosis: dysphagia Total Treatment Minutes: 20

Procedure: Swallow treatment

Chart Reviewed: Yes Patient Seen: Bedside Mental Status: Lethargic Orientation: x0

Patient reports pain level of 0/10 NPRS.

Oral Trials Given: apple sauce water

Assessment: Pt seen at bedside for dysphagia management. Patient lethargic although did open eyes when communicated to. Patient accepted serial straw sips of thin water and four bites of apple sauce without overt signs of aspiration. PEG in place and patient in restraints due to reports of agitation. Pt appears to be tolerating baseline diet. No further ST services indicated at this time.

Diet Recommendations: Continue tube feeds as primary nutrition Puree/thin for pleasure with 1:1, slow rate, small bites

Goals:

SLP will reassess swallow status in 1-2 meals to insure safety and follow through with recommended diet and swallow strategies.-MET

Plan: Interdisciplinary Communication: Collaborated with RN regarding discharge plan Discharge from ST

Therapist: Carley M Abel, SLP Date: 8/3/2023 Time: 10:29 AM Electronically signed by: Carley Abel, M.A. CCC-SLP 8/3/2023 10:30 AM

Electronically signed by Carley A at 08/03/2023 10:31 AM EDT

Nsg Progress Note - Netra V - 08/03/2023 5:51 AM EDT Formatting of this note is different from the original. PROGRESS NOTE

NEURO: A&Ox0, no changes in mentation, displays agitated behavior shown by pulling on wires and equipments.

VS: VSS, baseline hypertensive

Last Filed Vitals: BP 148/99 (08/03/23 0532) HR 98 (08/03/23 0532) RR 18 (08/03/23 0406) Temp 97.7 °F (36.5 °C) (08/03/23 0406) SpO2 98 % (08/03/23 0406) O2 (L/min) (not recorded)

ACTIVITY: Repositioned q2 hours, heels elevated; fall precautions maintained

FAMILY/PATIENT CONCERNS: Family at bedside, all questions answered

SIGNIFICANT EVENTS: Bilateral SWR and mitts continued as patient is still agitated, Nursing care and precautions provided as per protocol.

Electronically signed by Netra V at 08/03/2023 5:55 AM EDT Care Plan Note - Netra V - 08/03/2023 3:04 AM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Progressing

Problem: Safety: Goal: Will remain free from falls in 4 hours Description: Assess for poly-pharmacy and drug to drug interactions Outcome: Progressing Goal: Will remain free of falls with the implementation of Universal Precautions Outcome: Progressing Goal: Will remain free of falls with the implementation of High Risk Fall precautions Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Medication: Goal: Will comply with prescribed medication regimen Outcome: Progressing

Problem: Nutritional: Goal: Nutritional status will be supported Outcome: Progressing

Problem: Physical Regulation: Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing Goal: Risk of venous thrombosis will decrease Outcome: Progressing

Problem: Self-Care: Goal: Ability to participate in self-care as condition permits will be supported Outcome: Progressing

Problem: Sensory: Goal: Pain level will decrease Outcome: Progressing

Problem: Tissue Perfusion: Goal: Will regain and/or maintain adequate tissue perfusion Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Skin Integrity: Goal: Will show signs of wound healing Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Electronically signed by Netra V at 08/03/2023 3:04 AM EDT Care Plan Note - Michelle A - 08/02/2023 1:01 PM EDT Formatting of this note might be different from the original.

Problem: Balance: Goal: Increase sitting balance to poor Outcome: Progressing

Problem: Functional Mobility/Transfers: Goal: Increase bed mobility to mod A Outcome: Progressing

Problem: Grooming Skills: Goal: Increase grooming skills to mod A Outcome: Progressing

Problem: Feeding Skills: Goal: Increase feeding skills to mod A Outcome: Progressing

Electronically signed by Michelle A at 08/02/2023 1:02 PM EDT SLP Initial Evaluation Report - Carley A - 08/02/2023 12:28 PM EDT Formatting of this note is different from the original. Beaumont Farmington Hills 28100 Grand River Ave, Suite 210 Farmington Hills MI 48336 Phone 248-471-8648 Fax 248-471-8781 Acute Care CLINICAL SWALLOW EVALUATION

Patient Name: Ioan Suiugan Date/Time of Eval: 8/2/23, 1115 MRN: 9942681 Medical Diagnosis: AMS Date of Onset: 8/1/23 Visit Diagnosis: dysphagia Reason for referral: swallow evaluation secondary to tube feeding Referring Physician: Hubbard, Cameron Christopher, DO Past Medical History: no medical hx of file

History of Present Illness: This is a 62y.o. male with past medical history of type 2 diabetes, atrial flutter, urinary retention and prior V. tach arrest with resulting anoxic brain injury on 5/23 who presents with altered mental status over the last several days. History was significantly limited secondary to lack of reliable historians at bedside, as well as trouble reaching the primary caretaker via phone. Per patient's son, patient had been at an acute care facility for brain injury from 5/11 until 6/16, at which time he was intubated, and was later discharged to SAR for rehabilitation. At SAR, patient was noted to have agitation and impulsive behavior and became combative with staff - necessitating restraints and the addition of psychiatric medication. At that time, it was suggested that this might be the patient's new baseline. However, family has been concerned that the patient has progressively worsened and that he has been cared for inadequately and may require arrangements for a new facility. On arrival, patient was noted to be severely agitated as well and was pulling lines, leading to placement of restraints.

Treatment Type: Individual

Procedures: Evaluation of oral/pharyngeal swallow funtion

Prior level of function: pt from ECF s/p TBI with PEG tube in place and on a puree/thin diet with 1:1 feed for assistance. No prior encounters in chart

Pain: At Rest: 0 /10 Post Treatment: 0 /10

Subjective: Symptoms reported by patient: none, pt unintelligible and mumbling Current functional limitations: not intelligible speech, AMS Patient report: none Patient/Caregiver goals: to safely tolerate least restrictive diet

Current Diet: PEG tube feedings

Feeding Method: Dependent for feeding

Endurance During Meals: Fair

Observations/Informal Assessment Speech Severe poor intelligibility Language Severe Cognition Severe confused and not able to understand. Pt is intermittently following commands

Mental Status: Lethargic and Combative (in restraints)

Objective Assessment

Oral Status: Dentition: Edentulous

Lips: symmetrical

Tongue: unable to fully view

Soft Palate: unable to view

Voice: WFL

Food and Liquid Trials: apple sauce, water

Position During Assessment: Upright Comments: upright in bed

Factors affecting performance: Impairment/difficulty noted in mental status, Impairment/difficulty noted following directions, and Impairment/difficulty noted in endurance

Oral Phase: slow oral transit, edentia

Pharyngeal Phase: WFL

Impressions: Pt presents with moderate oral dysphagia characterized by edentia and slow oral transit. Mentation is contributing factor to dysphagia. Pt with PEG tube as primary nutrition and appears to be tolerating baseline diet of PEG tube feeding with pleasure feeds of thin liquids and puree consistencies with 1:1 feed and use of slow rate and small bites. RN and dietician endorsed understanding of recommendations. Pt not receptive to education at this time. ST to follow-up 1-2 times.

Severity: Moderate

Prognosis: Good

RECOMMENDATIONS: Continue tube feeds as primary nutrition Puree/thin for pleasure with 1:1, slow rate, small bites ST to monitor for diet tolerance x1-2

Impact on Safety and Functioning: Risk for Aspiration: mild on modified diet with `:`

Problem List: Slowed oral transit

PLAN: Continue Treatment: yes Frequency of Treatment: 1-2x Future Treatment will Include: Patient/Family education. Speech therapy directed at short and long term goals. Treatment will be implemented and progressed as ordered, indicated and tolerated.

GOALS

Short Term Goals: SLP will reassess swallow status in 1-2 meals to insure safety and follow through with recommended diet and swallow strategies.

Long term Goal: Patient will tolerate the least restrictive diet without any signs or symptoms of aspiration by discharge from the hospital or discharge from Speech Therapy. Therapist: Carley M Abel, SLP Date: 8/2/2023 TIME: 12:28 PM

Electronically signed by: Carley Abel, M.A. CCC-SLP 8/2/2023

Electronically signed by Carley A at 08/02/2023 12:35 PM EDT Plan of Care - Michelle A - 08/02/2023 12:01 PM EDT Formatting of this note is different from the original. 08/02/23 1201 Time Detail OT Visit Number (OT Evaluation in room 219A) Time Eval/Tx Initiated 1201 Total Eval/Tx Time (min) - individual 20 min Event/Subjective OT Received On 08/02/23 Event Note AMS, CT brain (-), hx of anoxic brain injury, DM Subjective Patient moaned and at times yelled during evaluation; no purposeful speech. Cleared for therapy by RN Patient Goal Unable to determine any goal at this time. Assessment Assessment Tolerated eval/tx poor Tolerated eval/tx poor additional detail Patient will be placed on a trial of skilled OT to improve seated ADLs and bed mobility skills. Patient's functional baseline is unknown at this time. Will determine patient's appropriateness for skilled OT with a trial of OT. Therapy Problem List Impaired Bed Mobility; Impaired Transfers; Impaired Functional Mobility; Impaired Balance; Impaired Strength;Impaired Upper Body Dressing;Impaired Lower Body Dressing;Impaired Upper Body Bathing;Impaired Lower Body Bathing; Impaired Toileting; Impaired Grooming; Impaired Functional Endurance; Impaired Cognition **Rehab Potential Poor** Goals Discussed With (Unable to discuss goals with patient at this time) Recommendation OT Discharge Instructions In progress OT Discharge Recommendations SAR (Subacute rehab) (patient is unable to tolerate 3 hours of therapy per day) OT DME Recommendations To be determined Plan Treatment Interventions ADL retraining; Functional transfer training; Mobility/transfer training as related to ADLs; UE strengthening/ ROM; Endurance training; Cognitive reorientation; Patient/Family training; Equipment eval/education; Education on diagnosis specific precautions;Bed mobility;Balance;Therapeutic activities;Therapeutic exercises;Energy conservation;Pain management techniques and education;Recommend DME OT Frequency 3-5 x/wk Learning Barriers Learning Barriers (PT/OT) Impaired Cognition Precautions Weight Bering Status During Session FWB Pain Screening/Assessment Screening/Pain Scale Used Face, Legs, Activity, Crying, Consolability (FLACC) Pain Score 0 Vital Signs SpO2 100 % O2 Device None (Room air) Social History Pt Lives With (Per chart, patient has been at an SAR since his anoxic brain injury.) **Prior Function** Level of Independence (Unknown) ADL Where Assessed Supine, bed Eating Assistance Dependent Grooming Assistance Dependent **Bathing Assistance Dependent UE Dressing Assistance Dependent** LE Dressing Assistance Dependent Toileting Assistance Dependent Additional Comments Total assistance for all ADLs; limited by cognition. Cognition Arousal/Alertness Lethargic Follows Commands Does not follow any commands **Orientation Level UTA** Sensation

Light Touch (UTA due to cognition) Coordination **Coordination Movement Description** (UTA due to cognition) Proprioception Proprioception (UTA due to cognition) **RUE** Assessment **RUE** Assessment (ROM WFL and unable to assess MMT due to cognition.) LUE Assessment LUE Assessment (ROM WFL and unable to assess MMT due to cognition.) Bed Mobility **Rolling Dependent** Supine Scoot Dependent Balance Sitting - Static Not Tested Sitting - Dynamic Not tested Standing - Static Not tested Standing - Dynamic Not tested Activities of Daily Living - AM-PAC 6 CLICK Putting on and taking off regular lower body clothing? 1 Bathing (including washing, rinsing, drying)? 1 Toileting, which includes using toilet, bedpan or urinal? 1 Putting on and taking off regular upper body clothing? 1 Taking care of personal grooming such as brushing teeth? 1 Eating meals? 1 Activities of Daily Living Score 6 Interdisciplinary Communication Interdisciplinary Communication spoke with RN;PT Interdisciplinary Communication topic Mobility status; Tolerance of treatment; Self-Care Status; Discharge plan

Electronically signed by Michelle A at 08/02/2023 1:14 PM EDT Care Plan Note - Katie L - 08/02/2023 11:47 AM EDT Formatting of this note might be different from the original.

Problem: Balance: Goal: Increase sitting balance Outcome: Progressing Pt will demonstrate Poor sitting balance.

Problem: Functional Mobility/Transfers: Goal: Increase bed mobility Outcome: Progressing Pt will perform bed mobility with maximal assistance.

Electronically signed by Katie L at 08/02/2023 11:47 AM EDT Plan of Care - Katie L - 08/02/2023 10:02 AM EDT Formatting of this note is different from the original.

08/02/23 1002 Time Detail PT Visit Number (evaluation in 219A) Time Eval/Tx Initiated 1002 Total Eval/Tx Time (min) - individual 20 min Event/Subjective PT Received On 08/02/23 Event Note AMS, CT brain (-), hx of anoxic brain injury, DM Subjective Pt moaning out throughout tx, no purposeful speech. Patient Goal unable to determine Assessment Assessment Tolerated eval/tx poor Tolerated eval/tx poor additional detail Pt's baseline is unknown at this time, very limited participation in tx this date secondary to cognition, will trial skilled PT to determine appropriateness for continued intervention.

Therapy Problem List Impaired Bed Mobility; Impaired Transfers; Impaired Gait Skills; Impaired Balance; Impaired Strength; Impaired

Cognition;Impaired Endurance **Rehab Potential Poor** Goals Discussed With (unable to discuss goals with patient at this time) Recommendation PT Discharge Recommendations SAR (Subacute rehab) (unable to tolerate 3 hours of therapy per day) PT DME Recommendations To be determined Plan Treatment/Interventions Physical Therapy is recommended to address deficits.;Endurance training;Patient/family training;Bed mobility;Balance training;Therapeutic exercises per clinical pathway PT Frequency 3-5x/wk Precautions Weight Bering Status During Session FWB Pain Screening/Assessment Screening/Pain Scale Used (0/10 per FLACC) Social History Pt Lives With (per chart, pt has been at SAR since his hospitalization for anoxic brain injury from May to June of 2023) **Prior Function** Level of Independence (unknown at this time, pt nonverbal) Cognition Arousal/Alertness Lethargic Follows Commands Does not follow any commands **Orientation Level UTA** Coordination **Coordination Movement Description** (UTA secondary to cognition) Sensation Light Touch (UTA secondary to cognition) Proprioception Proprioception (UTA secondary to cognition) **RLE** Assessment **RLE** Assessment (pt with no volitional movement bilaterally, hypotonic) **Bed Mobility** Rolling Dependent Supine Scoot Dependent Balance Sitting - Static Not Tested Sitting - Dynamic Not tested Standing - Static Not tested Standing - Dynamic Not tested Mobility - AM-PAC 6 CLICK Turning from your back to your side while in a flat bed without using bedrails? 1 Moving from lying on your back to sitting on the side of a flat bed without using bedrails? 1 Moving to and from a bed to a chair (including a wheelchair)? 1 Standing up from a chair using your arms (e.g., wheelchair, or bedside chair)? 1 To walk in hospital room? 1 Climbing 3-5 steps with a railing? 1 Mobility Score 6 Learning Barriers Learning Barriers (PT/OT) Impaired Cognition Electronically signed by Katie L at 08/02/2023 11:52 AM EDT

Care Plan Note - Netra V - 08/02/2023 6:07 AM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve 8/2/2023 0606 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Problem: Safety: Goal: Will remain free from falls in 4 hours Description: Assess for poly-pharmacy and drug to drug interactions 8/2/2023 0606 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0503 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Goal: Will remain free of falls with the implementation of Universal Precautions 8/2/2023 0606 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0503 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing Goal: Will remain free of falls with the implementation of High Risk Fall precautions 8/2/2023 0606 by Vaddi, Netra P, RN **Outcome:** Progressing 8/2/2023 0503 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve 8/2/2023 0606 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care 8/2/2023 0606 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0503 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve 8/2/2023 0606 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0503 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Problem: Medication: Goal: Will comply with prescribed medication regimen 8/2/2023 0606 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0503 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Problem: Nutritional: Goal: Nutritional status will be supported 8/2/2023 0606 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing

8/2/2023 0302 by Vaddi, Netra P, RN

Outcome: Progressing

Problem: Physical Regulation: Goal: Complications related to the disease process, condition or treatment will be avoided or minimized 8/2/2023 0606 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Goal: Will remain free from infection 8/2/2023 0606 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Problem: Safety: Goal: Ability to remain free from injury will improve 8/2/2023 0606 by Vaddi, Netra P, RN **Outcome:** Progressing 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing Goal: Risk of venous thrombosis will decrease 8/2/2023 0606 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Problem: Self-Care: Goal: Ability to participate in self-care as condition permits will be supported 8/2/2023 0606 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Problem: Sensory: Goal: Pain level will decrease 8/2/2023 0606 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing Problem: Tissue Perfusion: Goal: Will regain and/or maintain adequate tissue perfusion 8/2/2023 0606 by Vaddi, Netra P, RN **Outcome:** Progressing 8/2/2023 0503 by Vaddi, Netra P, RN **Outcome:** Progressing 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve 8/2/2023 0606 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained 8/2/2023 0606 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase 8/2/2023 0606 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0503 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0458 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing Goal: Will verbalize understanding of the information provided 8/2/2023 0606 by Vaddi, Netra P, RN **Outcome:** Progressing 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing

Problem: Skin Integrity: Goal: Will show signs of wound healing 8/2/2023 0606 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0458 by Vaddi, Netra P, RN Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase 8/2/2023 0606 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings 8/2/2023 0606 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement 8/2/2023 0606 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement 8/2/2023 0606 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve 8/2/2023 0606 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve 8/2/2023 0606 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing

Electronically signed by Netra V at 08/02/2023 6:07 AM EDT Nsg Progress Note - Netra V - 08/02/2023 5:52 AM EDT Formatting of this note is different from the original. PROGRESS NOTE

NEURO: A&Ox0, no changes in mentation, displays agitated behavior shown by pulling on wires, IV tubings.

VS: VSS

Last Filed Vitals: BP 120/86 (08/02/23 0425) HR 90 (08/02/23 0425) RR 18 (08/02/23 0425) Temp 97 °F (36.1 °C) (08/02/23 0425) SpO2 99 % (08/02/23 0425) O2 (L/min) (not recorded)

ACTIVITY: Repositioned q2 hours, heels elevated; fall precautions maintained

FAMILY/PATIENT CONCERNS: N/A

SIGNIFICANT EVENTS: Bilateral soft restraints and mitts continued as patient remains agitated. Electronically signed by Netra V at 08/02/2023 5:54 AM EDT Care Plan Note - Netra V - 08/02/2023 5:03 AM EDT

Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing

Problem: Safety: Goal: Will remain free from falls in 4 hours Description: Assess for poly-pharmacy and drug to drug interactions 8/2/2023 0503 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome:** Progressing Goal: Will remain free of falls with the implementation of Universal Precautions 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing Goal: Will remain free of falls with the implementation of High Risk Fall precautions 8/2/2023 0503 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome:** Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing

Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve 8/2/2023 0503 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Problem: Medication: Goal: Will comply with prescribed medication regimen 8/2/2023 0503 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Problem: Nutritional: Goal: Nutritional status will be supported 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Problem: Physical Regulation: Goal: Complications related to the disease process, condition or treatment will be avoided or minimized 8/2/2023 0503 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Goal: Will remain free from infection 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Problem: Safety: Goal: Ability to remain free from injury will improve 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing Goal: Risk of venous thrombosis will decrease 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Problem: Self-Care: Goal: Ability to participate in self-care as condition permits will be supported 8/2/2023 0503 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Problem: Sensory: Goal: Pain level will decrease 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing Problem: Tissue Perfusion: Goal: Will regain and/or maintain adequate tissue perfusion 8/2/2023 0503 by Vaddi, Netra P, RN **Outcome: Progressing** 8/2/2023 0302 by Vaddi, Netra P, RN **Outcome: Progressing** Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve

8/2/2023 0503 by Vaddi, Netra P, RN

Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0458 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing Goal: Will verbalize understanding of the information provided 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN

Problem: Skin Integrity: Goal: Will show signs of wound healing 8/2/2023 0503 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0458 by Vaddi, Netra P, RN Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing

Problem: Coping: Goal: Will verbalize feelings Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing

Problem: Safety: Goal: Patient will remain free from injury and restraint will be used only as needed per assessement Outcome: Progressing Goal: Ability to verbalize frustrations and anger appropriately will improve Outcome: Progressing Goal: Ability to use alternate options when emotions escalate will improve Outcome: Progressing

Electronically signed by Netra V at 08/02/2023 5:03 AM EDT Care Plan Note - Netra V - 08/02/2023 4:58 AM EDT Formatting of this note might be different from the original.

Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Progressing

Problem: Safety: Goal: Will remain free from falls in 4 hours Description: Assess for poly-pharmacy and drug to drug interactions Outcome: Progressing Goal: Will remain free of falls with the implementation of Universal Precautions Outcome: Progressing Goal: Will remain free of falls with the implementation of High Risk Fall precautions Outcome: Progressing Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Medication: Goal: Will comply with prescribed medication regimen Outcome: Progressing

Problem: Nutritional: Goal: Nutritional status will be supported Outcome: Progressing

Problem: Physical Regulation: Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing Goal: Risk of venous thrombosis will decrease Outcome: Progressing

Problem: Self-Care: Goal: Ability to participate in self-care as condition permits will be supported Outcome: Progressing

Problem: Sensory: Goal: Pain level will decrease Outcome: Progressing

Problem: Tissue Perfusion: Goal: Will regain and/or maintain adequate tissue perfusion Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase 8/2/2023 0458 by Vaddi, Netra P, RN Outcome: Progressing 8/2/2023 0302 by Vaddi, Netra P, RN Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing

Problem: Skin Integrity: Goal: Will show signs of wound healing Outcome: Progressing

Electronically signed by Netra V at 08/02/2023 4:58 AM EDT Care Plan Note - Netra V - 08/02/2023 3:02 AM EDT Formatting of this note might be different from the original. Problem: Cognitive: Goal: Ability to state ways to decrease the risk of falls will improve Outcome: Progressing

Problem: Safety: Goal: Will remain free from falls in 4 hours Description: Assess for poly-pharmacy and drug to drug interactions Outcome: Progressing Goal: Will remain free of falls with the implementation of Universal Precautions Outcome: Progressing Goal: Will remain free of falls with the implementation of High Risk Fall precautions Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Patient and Family Engagement (PFCC): Goal: Patient/family will be actively engaged in their plan of care Outcome: Progressing

Problem: Cognitive: Goal: Knowledge of disease or condition and prescribed therapeutic regimen will improve Outcome: Progressing

Problem: Medication: Goal: Will comply with prescribed medication regimen Outcome: Progressing

Problem: Nutritional: Goal: Nutritional status will be supported Outcome: Progressing

Problem: Physical Regulation: Goal: Complications related to the disease process, condition or treatment will be avoided or minimized Outcome: Progressing Goal: Will remain free from infection Outcome: Progressing

Problem: Safety: Goal: Ability to remain free from injury will improve Outcome: Progressing Goal: Risk of venous thrombosis will decrease Outcome: Progressing

Problem: Self-Care: Goal: Ability to participate in self-care as condition permits will be supported Outcome: Progressing

Problem: Sensory: Goal: Pain level will decrease Outcome: Progressing

Problem: Tissue Perfusion: Goal: Will regain and/or maintain adequate tissue perfusion Outcome: Progressing

Problem: Cognitive: Goal: Understanding of ways to prevent future skin breakdown will improve Outcome: Progressing

Problem: Skin Integrity: Goal: Skin integrity will be maintained Outcome: Progressing

Problem: Cognitive: Goal: Periods of time without restraints will increase Outcome: Progressing Goal: Will verbalize understanding of the information provided Outcome: Progressing Electronically signed by Netra V at 08/02/2023 3:02 AM EDT Nsg Progress Note - Netra V - 08/02/2023 2:08 AM EDT Formatting of this note might be different from the original. RN Admit Note

Patient received from: ER

Admitted to room: 219 A

Reason for admit ; AMS, UTI, SEPSIS

Condition of patient and pertinent physical findings on arrival: Alert and oriented x 0, vitals are stable.

Presence of pain/score: UTA

4-eye skin assessment completed with: Malva NA

Description of skin alterations: red area and skin excoriation noted at sacrum

Patient/family oriented to room, white board, hourly rounding explained and fall prevention techniques implemented. Call light and phone placed within reach. Bed low and wheels locked.

Electronically signed by Netra V at 08/02/2023 2:11 AM EDT

ED Nurse Notes - Brynn H - 08/01/2023 7:20 PM EDT

Formatting of this note might be different from the original.

RN assumed care of patient at this time. Initial encounter. Pt arrived to ED via EMS with cc of altered mental status. Per family, pt is never oriented following TBI but became increasingly confused with rambled speech.

RN to bedside for introduction of self. Pt resting supine in bed with eyes closed. Pt not oriented, history of TBI. Respirations are spontaneous, even and unlabored on RA. Even chest rise and fall noted. Pt does not appear to be in any respiratory distress. Abdomen soft and nontender. Skin is warm and dry. Peripheral IV intact and flushed. Pt placed on cardiac monitor and continuous pulse ox. Bed is locked and in lowest position. Pt and family updated on plan of care and agreeable. VSS. RN awaiting further orders. RN addressed all patient needs, pt repositioned for comfort.

Electronically signed by Brynn H at 08/02/2023 12:09 AM EDT Pharmacist Progress Note - Sarah C - 08/01/2023 7:00 PM EDT Formatting of this note is different from the original. Images from the original note were not included.

Pharmacy Dosing Consult: Vancomycin Initial Consult Drug: Vancomycin Indication: Sepsis (unknown source) Indication for MRSA nasal screen: No- Not indicated based on infection Target: AUC 400-600 and Trough < = 20 mcg/mL Other Antimicrobials: Zosyn Patient Specific Parameters and Labs Vital Signs: BP 134/82 | Pulse 102 | Temp (!) 100.6 °F (38.1 °C) | Resp 20 | Ht 188 cm (6' 2") | Wt 99.8 kg (220 lb) | SpO2 96% | BMI 28.25 kg/m² Temp (24hrs), Avg:100.5 °F (38.1 °C), Min:100.4 °F (38 °C), Max:100.6 °F (38.1 °C) Total body weight: 99.8 kg (220 lb) Ideal body weight: 82.2 kg (181 lb 3.5 oz) Adjusted ideal body weight: 89.2 kg (196 lb 11.7 oz) Body mass index is 28.25 kg/m². Weight used to calculate CrCl and Ke: ideal body weight (IBW) CrCl or renal function: Estimated CrCl (based on Cockcroft and Gault) = 125 mL/min , Scr used: 0.77 I/O: Not Charted Adequately Recent Labs 08/01/23 1731 WBC 13.7* **CREAT 0.77 BUN 23** ALB 2.9* Pharmacokinetics Recent vancomycin history: No - Dosing empirically Microbiology Blood and urine cultures in process Assessment 62 yo male of T2DM, cardiac arrest, PEG placement and paraplegia sent from group home for AMS. Febrile and leukocytosis on admission. CXR showing bibasilar atelectasis. Blood cultures in process Renal function/baseline SCr: Scr 0.77. at baseline Meets criteria for levels after 72 hrs?: No - patient is receiving concomitant nephrotoxic agents Current risk factors for nephrotoxicity: Concomitant piperacillin/tazobactam Plan Vancomycin 2500 mg IVPB x1 followed by Vancomycin 1500 mg every 12 hours to achieve a predicted AUC 459 and Cmin 11.5 mcg/mL Plan to check levels within 72 hours of initiation Next Level(s): Date: 8/3/23 or when clinically indicated Monitor SCr daily MRSA nares ordered? No - Not Indicated Pharmacy will continue to monitor renal function, WBC, cultures and the clinical progress of the patient. Please do not hesitate to contact us with comments or questions. Thank you, Sarah A Creed, PHARMACIST, 8/1/2023 Available on Mobile Heartbeat

Vancomycin Calculator Adult Vancomycin Pharmacy Dosing Guideline

Electronically signed by Sarah C at 08/01/2023 7:01 PM EDT Nsg Progress Note - Catherine G - 08/01/2023 6:05 PM EDT Formatting of this note might be different from the original.

Upon initial assessment, pt presents to the ED with chief complaint of AMS, pt is aggressive and combative at baseline. . Pt is A&Ox1, in no observable stress. Pt is placed on cardiac monitor. VSS. EKG given to doctors. Breathing even and unlabored. Pt cooperative at this time. Bed locked in low position, side rails up x2. Doctors notified of patient tempature - tylenol ordered. Electronically signed by Catherine G at 08/01/2023 6:08 PM EDT

ED Procedure Note - Diane Kaiser Alexander - 08/01/2023 5:14 PM EDT

Associated Order(s): ECG

Formatting of this note might be different from the original. Procedure ECG

Date/Time: 8/1/2023 5:47 PM

Performed by: Kaiser Alexander, Diane L, DO Authorized by: Carline, Christine, DO Contemporaneously ECG reviewed by ED Physician in the absence of a cardiologist: yes Interpretation: Interpretation: non-specific Rate: ECG rate assessment: tachycardic Rhythm: Rhythm: sinus tachycardia Ectopy: Ectopy: none QRS: QRS axis: Right Conduction: Conduction: normal ST segments: ST segments: Normal T waves: T waves: normal

O2 SATURATION INTERPRETATION

Date: 8/1/2023 Time: 5:47 PM

Performed by Diane Kaiser Alexander, DO

Consent: Verbal consent was obtained from patient following explanation of procedure, including risks and benefits. All questions were answered. Risks and benefits discussed with patient.

Consent obtained from: patient

Sa02: 97% Normal

Oxygen: Room Air

Kaiser Alexander, Diane L, DO 08/01/23 1748

Electronically signed by Diane Kaiser Alexander at 08/01/2023 5:48 PM EDT

Plan of Treatment - documented as of this encounter Not on file

Procedures - documented in this encounter							
Procedure Name	Priority	Date/Time	Associated Diagnosis Comments				
CHEST PHYSIOTHERAPY	Routine	08/29/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/29/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/28/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/28/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/28/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/28/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/27/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/27/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/27/2023 12:15 AM EDT					
PROCEDURALIST LINE INSERTION	Routine	08/26/2023 4:46 PM EDT					
CHEST PHYSIOTHERAPY	Routine	08/26/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/26/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/26/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/26/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/25/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/25/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/25/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/25/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/24/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/24/2023 12:15 AM EDT					
CHEST PHYSIOTHERAPY	Routine	08/24/2023 12:15 AM EDT					
ECG	STAT	08/23/2023 2:20 AM EDT	Sepsis without acute organ dysfunction, due to unspecified organism				
CHEST PHYSIOTHERAPY	Routine	08/22/2023 11:49 PM EDT					
CHEST PHYSIOTHERAPY	Routine	08/22/2023 11:49 PM EDT					
CHEST PHYSIOTHERAPY	Routine	08/22/2023 11:49 PM EDT					
PROCEDURALIST LINE INSERTION	Routine	08/05/2023 9:27 AM EDT					
EEG:ROUTINE	Routine	08/03/2023 12:49 PM EDT	Altered mental status, unspecified altered mental status type				
CONTINUE SPEECH SERVICES PER PLAN OF CARE	Routine	08/02/2023 12:03 PM EDT					
CONSULT SPEECH & LANGUAGE PATHOLOGY	STAT	08/02/2023 12:48 AM EDT					

Procedure Name	Priority	Date/Time	Associated Diagnosis	Comments
ECG	STAT	08/01/2023 5:47 PM EDT		

Results - documented in this encounter								
GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/29/2023 1:27 PM EDT)								
Comment	\	Ref		Analysis		Dethels wist Circustore		
Component Glucose	Value 135	Range 60 - 139 mg/dL	Test Method	Time 08/29/2023 1:34 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	Pathologist Signature		
Comment: Capillary					23D0363256)			
Performed By	Vasser, Ashley			08/29/2023	BEAUMONT			
renormed by	NA			1:34 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
	Anatomical Lo	cation /	Collection Method /					
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time		
Blood	WHOLE BLOO SPECIMEN / U			08/29/202	23 1:27 PM EDT	08/29/2023 1:34 PM EDT		
Narrative								
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	08/29/2023	1:34 PM EDT			
Authorizing Provider	Result Type							
William Rudy	BH LAB POC T	EST DOCKI	ED DEVICE UNSOLICITED) RESULTS				
Performing Organization	Address City/State/ZIP Code Phone Number				mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave Farmington Hills, MI 800-551-0488 48336							
(ABNORMAL) CBC W/	AUTO DIFF - I	Final resu Ref		Analysis				
Component	Value	Range	Test Method	Time		Pathologist Signature		
WBC	6.9	3.5 - 10.1 bil/L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
RBC	4.15 (L)	4.31 - 5.48 tril/ L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Hemoglobin	12.0 (L)	13.5 - 17.0 g/ dL		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Hematocrit	38.4 (L)	40.1 - 50.1 %		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
MCV	93	80 - 100 fL		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			

Component	Value	Ref		Analysis	Daufanna ad At Dathala aist Cianatura
Component MCH	Value 29	Range 28 - 33	Test Method	Time 08/29/2023	Performed At Pathologist Signature BEAUMONT
		pg		7:57 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСНС	31 (L)	32 - 36 g/dL		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RDW-CV	17 (H)	12 - 15 %		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Platelets	294	150 - 400 bil/L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Nucleated Red Blood Cells	0.0	<=0.0 %		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Neutrophils	4.2	1.6 - 7.2 bil/L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Lymphocytes	1.0 (L)	1.1 - 4.0 bil/L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Monocytes	1.4 (H)	0.0 - 0.9 bil/L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Eosinophils	0.2	0.0 - 0.4 bil/L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Basophils	0.0	0.0 - 0.1 bil/L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Immature Granulocytes	0.12 (H)	0.00 - 0.04 bil/L		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Immature Granulocyte %	1.7	%		08/29/2023 7:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

	Anatomical Locat	ion /	Collection Method /			
Specimen (Source)	Laterality		Volume Collection Time			Received Time
Blood	VENOUS BLOOD SPECIMEN / Unknown		Venipuncture / Unknowi	n 08/29/202	3 6:01 AM EDT	08/29/2023 6:32 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOD C	RDERAE	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		Farmington Hills, MI 48336	800-551-0	488	
PHOSPHORUS LEVEL - F				Averalise		
Component		ef ange		Analysis Time	Performed At	Pathologist Signature
Phosphorus	2.8 2.	3 - 4.4 ig/dL		08/29/2023 8:40 AM EDT		
Specimen (Source)	Anatomical Locat Laterality	ion /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOOD SPECIMEN / Unknown		Venipuncture / Unknown 08/29/2023 6:01 AM EDT			08/29/2023 6:42 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOD C	RDERAE	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Rive	er Ave	Farmington Hills, MI 48336	800-551-0	488	
MAGNESIUM LEVEL - Fi		'2023 6: ef		Analysis		
Component		ange		Time	Performed At	Pathologist Signature
Magnesium		7 - 2.5 ng/dL		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Locat	ion /	Collection Method /		T :	
Specimen (Source) Blood	Laterality VENOUS BLOOD SPECIMEN / Unkr	nown	Volume Venipuncture / Unknown	Collection n 08/29/202		Received Time 08/29/2023 6:42 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOD ORDERABLES					

Performing Organization	Address	City/State/ZIP Code	Phone Number
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0488

(ABNORMAL) BASIC METABOLIC PANEL (BMP) - Final result (08/29/2023 6:01 AM EDT)

		Ref	T I M II I	Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Sodium	137	135 - 145 mmol/L		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Potassium	3.4 (L)	3.5 - 5.2 mmol/L		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	103	98 - 111 mmol/L		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	27	20 - 29 mmol/L		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	7	5 - 17		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose Comment: Fasting Blood Glucos Random Blood Glucose	- · ·			08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Blood Urea Nitrogen -BUN	10	7 - 25 mg/dL		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.59 (L)	0.60 - 1.30 mg/ dL		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	110	>60 mL/ min/ 1.73m2		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Comment: Calculation based on without adjustment fo gender using the CKD [.]	or race. Glom	erular Fi				
G3a: Mildly to mo G3b: Moderately	eased GFR: 60 oderately dec to severely d creased GFR:	reased GF ecreased				
GS. Kluney lain	ule GFR. <15					
Calcium	8.0 (L)	8.5 - 10.5 mg/dL		08/29/2023 8:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /	Callestian	Τ'	Descrived Times
Specimen (Source) Blood	Laterality VENOUS BLOC	חו	Volume	Collection		Received Time 08/29/2023 6:42 AM EDT
blood	SPECIMEN / U			WIT 00/29/202	.5 0.01 AIVI EDT	00/29/2023 0.42 AIVI EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOD	ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) GLUCOS	E, POINT OF	CARE (GL Ref	UCOSE, POC) - Final	result (08/2 Analysis	9/2023 5:50 /	AM EDT)
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	145 (H)	60 - 139 mg/dL		08/29/2023 5:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Mmwiry, Elena NA TN			08/29/2023 5:57 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Apotomical -	cotion /	Collection Method /			
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOI SPECIMEN / U			08/29/202	23 5:50 AM EDT	08/29/2023 5:57 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	08/29/2023	5:57 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKI	ED DEVICE UNSOLICITE	D RESULTS		

Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA	ARE (GLUCOSE,	POC) - Fi Ref	nal result (08/29/2023	3 12:16 AM E Analysis	DT)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	128	60 - 139 mg/dL		08/29/2023 12:23 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary					,	
Performed By	Mmwiry, Elena NA TN			08/29/2023 12:23 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loc	ration /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/29/202 EDT	3 12:16 AM	08/29/2023 12:23 AM EDT
Narrative				00 (00 (0000	10 00	
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/o	dL .	(A #: 23D0363256) -	08/29/2023	12:23 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCK	ED DEVICE UNSOLICITED	O RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
					-	
GLUCOSE, POINT OF CA	ARE (GLUCOSE,	POC) - Fi Ref	nal result (08/28/2023	3 6:35 PM ED Analysis	1)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	114	60 - 139 mg/dL		08/28/2023 6:42 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary Performed By	Kewley, Tesia			08/28/2023	BEAUMONT	
renormed by	NA TN			6:42 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loc	ation /	Collection Method /		- .	
Specimen (Source) Blood	Laterality WHOLE BLOOD SPECIMEN / Ur		Volume	Collection 08/28/202		Received Time 08/28/2023 6:42 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/o	dL -	IA #: 23D0363256) -	08/28/2023	6:42 PM EDT	

Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCKE	D DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	
GLUCOSE, POINT OF CA Narrative	RE - Final resu	lt (08/28/	2023 6:00 PM EDT)			
Authorizing Provider Tiffany Marchewka	Result Type WBH HBS NSG					
	WDITTID5 1450	I OC LAD				
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi	nal result (08/28/2023	12:23 PM EI Analysis)TC	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	139	60 - 139 mg/dL		08/28/2023 12:29 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Kewley, Tesia NA TN			08/28/2023 12:29 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loc Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur				3 12:23 PM	08/28/2023 12:29 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/c	ΊL	A #: 23D0363256) - 0	08/28/2023 I	12:29 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCKE	D DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0		
GLUCOSE, POINT OF CA Narrative	RE - Final resu	lt (08/28/	2023 12:00 PM EDT)			
	Deput Trees					
Authorizing Provider Tiffany Marchewka	Result Type WBH HBS NSG	POCIAR				
(ABNORMAL) CBC W/A	AUTO DIFF - F	inal resul	t (08/28/2023 6:20 A	M EDT)		

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
WBC	5.6	3.5 - 10.1 bil/L		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RBC	3.53 (L)	4.31 - 5.48 tril/ L		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	10.5 (L)	13.5 - 17.0 g/ dL		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hematocrit	32.6 (L)	40.1 - 50.1 %		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
MCV	92	80 - 100 fL		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСН	30	28 - 33 pg		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСНС	32	32 - 36 g/dL		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RDW-CV	16 (H)	12 - 15 %		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Platelets	191	150 - 400 bil/L		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Nucleated Red Blood Cells	0.0	<=0.0 %		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Neutrophils	3.7	1.6 - 7.2 bil/L		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Lymphocytes	0.8 (L)	1.1 - 4.0 bil/L		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Authorizing Provider Danielle S	Result Type BH LAB BLOOE) ORDERAI	BLES			
Narrative						
Blood	VENOUS BLOC SPECIMEN / U					08/28/2023 6:44 AM EDT
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	23D0363256) Time	Received Time
Phosphorus	2.6	2.3 - 4.4 mg/dL		08/28/2023 7:38 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #:	
PHOSPHORUS LEVEL - F	Value	Ref Range	6:20 AM EDT) Test Method	Analysis Time		Pathologist Signature
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0		
Performing Organization			City/State/ZIP Code	Phone Nu	mber	
Authorizing Provider Danielle S	Result Type BH LAB BLOOE) ORDERAI	BLES			
Narrative						
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknow	vn 08/28/202	23 6:20 AM EDT	08/28/2023 6:41 AM EDT
Specimen (Source)	Anatomical Lo Laterality		Collection Method / Volume	Collection	23D0363256) Time	Received Time
Immature Granulocyte %	1.2	%		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	
Immature Granulocytes	0.07 (H)	0.00 - 0.04 bil/L		08/28/2023 7:16 AM EDT		
Basophils	0.0	0.0 - 0.1 bil/L		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Eosinophils	0.1	0.0 - 0.4 bil/L		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Monocytes	1.0 (H)	0.0 - 0.9 bil/L		08/28/2023 7:16 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature

Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	
MAGNESIUM LEVEL - Fi	nal result (08/2	2 <mark>8/2023</mark> 6 Ref	:20 AM EDT)	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Magnesium	1.7	1.7 - 2.5 mg/dL		08/28/2023 7:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U					08/28/2023 6:44 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOE) ORDERA	BLES			
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) BASIC N		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Sodium	139	135 - 145 mmol/L		08/28/2023 7:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Potassium	3.3 (L)	3.5 - 5.2 mmol/L		08/28/2023 7:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	106	98 - 111 mmol/L		08/28/2023 7:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	24	20 - 29		08/28/2023		

mmol/L

5 - 17

9

Anion Gap

7:39 AM

7:39 AM

EDT

EDT

LABORATORY,

FARMINGTON HILLS (CLIA #: 23D0363256)

LABORATORY,

FARMINGTON HILLS (CLIA #: 23D0363256)

08/28/2023 BEAUMONT

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose Comment: Fasting Blood Glucose Random Blood Glucose				08/28/2023 7:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Blood Urea Nitrogen	: 60-139 mg	7 - 25		08/28/2023	BEAUMONT	
-BUN		mg/dL		7:39 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.50 (L)	0.60 - 1.30 mg/ dL		08/28/2023 7:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	115	>60 mL/ min/ 1.73m2		08/28/2023 7:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Calculation based on without adjustment fo gender using the CKD-	or race. Glom	erular F				
G3a: Mildly to mo G3b: Moderately 1	eased GFR: 60 oderately dec to severely d creased GFR:	reased G ecreased				
Calcium	7.8 (L)	8.5 - 10.5		08/28/2023	BEAUMONT	
		mg/dL		7:39 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOO SPECIMEN / U					08/28/2023 6:44 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOI	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0	0488	
GLUCOSE, POINT OF CA Narrative	RE - Final resu	ılt (08/28/	2023 6:00 AM EDT)			

Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
			nal regult (00/20/2022		T)	
GLUCOSE, POINT OF CA	IRE (GLUCUSE,	Ref	nai result (08/28/2023	Analysis	1)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	137	60 - 139 mg/dL		08/28/2023 6:06 AM EDT		
Comment: Capillary				00/00/00000		
Performed By	Jackson, Regina NA			08/28/2023 6:06 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loc Laterality	ation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD)				08/28/2023 6:06 AM EDT
	SPECIMEN / Ur	nknown		-		
Narrative						
BEAUMONT LABORATORY,			A #: 23D0363256) - (08/28/2023	6:06 AM EDT	
Fasting Blood Glucose Random Blood Glucose						
Authorizing Provider	Result Type					
William Rudy		ST DOCKE	D DEVICE UNSOLICITED	RESULTS		
Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Address 28050 Grand R	iver Ave	City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu 800-551-0		
GLUCOSE, POINT OF CA Narrative	RE - Final resu	lt (08/28/	2023 12:00 AM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi Ref	nal result (08/27/2023	11:52 PM El Analysis	OT)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	137	60 - 139 mg/dL		08/27/2023 11:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON	
Comment: Capillary		ing, at		EDI	HILLS (CLIA #: 23D0363256)	
Comment: Capillary Performed By	Jackson, Regina NA	ing, a			HILLS (CLIA #:	

	Anatomical Location /	Collection Method /		
Specimen (Source)	Laterality	Volume	Collection Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Unknown		08/27/2023 11:52 PM EDT	08/27/2023 11:59 PM EDT
Narrative				
	e: 60-99 mg/d∟	IA #: 23D0363256) -	08/27/2023 11:59 PM EDT	
Authorizing Provider	Result Type			
William Rudy	BH LAB POC TEST DOCK	ED DEVICE UNSOLICITE	D RESULTS	
Performing Organization	Address	City/State/ZIP Code	Phone Number	
BEAUMONT	28050 Grand River Ave	Farmington Hills, MI	800-551-0488	
LABORATORY, FARMINGTON HILLS		48336		
(CLIA #: 23D0363256)				
GLUCOSE, POINT OF CA	RE (GLUCOSE POC) - E	inal result (08/27/202		
	Ref		Analysis	
Component	Value Range	Test Method		Pathologist Signature
Glucose	131 60 - 139		08/27/2023 BEAUMONT	
	mg/dL		6:15 PM LABORATORY EDT FARMINGTON	
			HILLS (CLIA #	
			23D0363256)	
Comment: Capillary	Durana a va			
Performed By	Dunmore, Androni NA		08/27/2023 BEAUMONT 6:15 PM LABORATORY	
			EDT FARMINGTON	l
			HILLS (CLIA # 23D0363256)	
			2500505250)	
	Anatomical Location /	Collection Method /		
Specimen (Source)	Laterality	Volume	Collection Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Unknown		08/2//2023 6:08 PM EDI	08/27/2023 6:15 PM EDT
Narrative		TA #1 2200262266)	08/27/2023 6:15 PM EDT	
Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/d∟	IA #: 2300303230) -	06/2//2023 6:13 PM EDT	
Authorizing Provider	Result Type			
William Rudy	BH LAB POC TEST DOCK	ED DEVICE UNSOLICITE	D RESULTS	
Performing Organization	Address	City/State/ZIP Code	Phone Number	
BEAUMONT	28050 Grand River Ave	Farmington Hills, MI	800-551-0488	
LABORATORY,		48336		
FARMINGTON HILLS (CLIA #: 23D0363256)				
(CERT ". 2500505250)				
GLUCOSE, POINT OF CA	RE - Final result (08/27,	(2023 6:00 PM EDT)		
Narrative				
Authorizing Provider	Result Type WBH HBS NSG POC LAB			
Tiffany Marchewka				
(ABNORMAL) CBC W/	AUTO DIFF - Final resu	lt (08/27/2023 4:08	PM EDT)	

Component	Value	Ref Range Test Method	Analysis Time	Performed At Pathologist Signature
WBC	7.3	3.5 - 10.1 bil/L	08/27/2023 4:20 PM EDT	
RBC	3.67 (L)	4.31 - 5.48 tril/ L	08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hemoglobin	10.8 (L)	13.5 - 17.0 g/ dL	08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hematocrit	34.0 (L)	40.1 - 50.1 %	08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
MCV	93	80 - 100 fL	08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСН	29	28 - 33 pg	08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСНС	32	32 - 36 g/dL	08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RDW-CV	16 (H)	12 - 15 %	08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Platelets	193	150 - 400 bil/L	08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Nucleated Red Blood Cells	0.0	<=0.0 %	08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Neutrophils	5.0	1.6 - 7.2 bil/L	08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Lymphocytes	0.8 (L)	1.1 - 4.0 bil/L	08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Monocytes	1.3 (H)	0.0 - 0.9 bil/L		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Eosinophils	0.2	0.0 - 0.4 bil/L		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.0	0.0 - 0.1 bil/L		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.08 (H)	0.00 - 0.04 bil/L		08/27/2023 4:20 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %		%		08/27/2023 4:20 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Spaciman (Source)	Anatomical Lo	cation /	Collection Method / Volume	Collection	Time	Received Time
Specimen (Source) Blood	Laterality VENOUS BLOC SPECIMEN / U					08/27/2023 4:14 PM EDT
Narrative						
Authorizing Provider	Result Type					
William Rudy	BH LAB BLOOD	O ORDERAI	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0		
PHOSPHORUS LEVEL - F	Final result (08,	/27/2023 - Ref	4:08 PM EDT)	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Phosphorus	2.5	2.3 - 4.4 mg/dL		08/27/2023 4:42 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknow	vn 08/27/202	23 4:08 PM EDT	08/27/2023 4:14 PM EDT
Narrative						
Authorizing Provider	Result Type					
William Rudy	BH LAB BLOOD	O ORDERAI	BLES			

Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0	1488	
MAGNESIUM LEVEL - Fi	nal result (08/2	27/2023 4 Ref	:08 PM EDT)	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Magnesium	1.8	1.7 - 2.5 mg/dL		08/27/2023 4:45 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /	- II		- 1 1
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	VENOUS BLOC SPECIMEN / Ur		Venipuncture / Unknow	wn 08/27/202	:3 4:08 PM EDT	08/27/2023 4:14 PM EDT
Narrative						
Authorizing Drovidor	Decult Turpe					
Authorizing Provider William Rudy	Result Type BH LAB BLOOD					
William Ruuy			DLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Address 28050 Grand R	liver Ave	City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu 800-551-0		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R		Farmington Hills, MI 48336	800-551-0)488	
BEAUMONT LABORATORY, FARMINGTON HILLS	28050 Grand R	ANEL (BM	Farmington Hills, MI 48336	800-551-0 2 7/2023 4:0)488	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) BASIC N	28050 Grand R	NEL (BM Ref	Farmington Hills, MI 48336 IP) - Final result (08/	800-551-0 2 7/2023 4:0 Analysis)488) 8 PM EDT)	Pathologist Signature
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	ANEL (BM	Farmington Hills, MI 48336	800-551-0 2 7/2023 4:0	0488 0 8 PM EDT) Performed At	Pathologist Signature
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) BASIC N Component	28050 Grand R METABOLIC PA Value	NEL (BM Ref Range 135 - 145	Farmington Hills, MI 48336 IP) - Final result (08/	800-551-0 27/2023 4:0 Analysis Time 08/27/2023 4:43 PM	0488 8 PM EDT) Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Pathologist Signature
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) BASIC N Component Sodium	28050 Grand R AETABOLIC PA Value 138	NEL (BM Ref Range 135 - 145 mmol/L 3.5 - 5.2	Farmington Hills, MI 48336 IP) - Final result (08/	800-551-0 27/2023 4:0 Analysis Time 08/27/2023 4:43 PM EDT 08/27/2023 4:43 PM	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Pathologist Signature

Carbon Dioxide -CO2 27 20 - 29 08/27/2023 BEAUMONT mmol/L 4:43 PM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) 6 5 - 17 Anion Gap 08/27/2023 BEAUMONT 4:43 PM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose Comment: Fasting Blood Glucose	108 (H)	60 - 99 mg/dL		08/27/2023 4:43 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Random Blood Glucose	-	/d∟				
Blood Urea Nitrogen -BUN	14	7 - 25 mg/dL		08/27/2023 4:43 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.58 (L)	0.60 - 1.30 mg/ dL		08/27/2023 4:43 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	110	>60 mL/ min/ 1.73m2		08/27/2023 4:43 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Calculation based on without adjustment for gender using the CKD- G1: Normal GFR: G2: Mildly decro G3a: Mildly to mo G3b: Moderately for G4: Severely dec G5: Kidney faile	or race. Glom -EPI equation >=90 eased GFR: 60 oderately dec to severely d creased GFR:	erular Fi : -89 reased GF ecreased	ltration Rate is es			
Calcium	7.8 (L)	8.5 - 10.5 mg/dL		08/27/2023 4:43 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Seurce)	Anatomical Lo	cation /	Collection Method /	Collection	Time	Received Time
Specimen (Source) Blood	Laterality VENOUS BLOC	חנ	Volume Venipuncture / Unknow			08/27/2023 4:14 PM EDT
21000	SPECIMEN / U					00,27,2020
Narrative						
Authorizing Provider	Result Type					
William Rudy	BH LAB BLOOI) orderae	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	
Lactic Acid, plasma -	Final result (0	8/27/2023	3 4:08 PM EDT)			

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Lactic Acid	1.3	0.5 - 2.0 mmol/L		08/27/2023 4:40 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC	D				08/27/2023 4:14 PM EDT
	SPECIMEN / Ur	nknown				
Narrative						
Authorizing Provider	Result Type					
William Rudy	BH LAB BLOOD	ORDERA	BLES			
Performing Organization	Addrocc		City/State/ZIP Code	Phone Nu	mbor	
BEAUMONT	28050 Grand R	iver Ave	Farmington Hills, MI	800-551-0		
LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			48336			
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi Ref		12:08 PM EI Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose	129	60 - 139 mg/dL		08/27/2023 12:14 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary	_					
Performed By	Dunmore, Androni NA			08/27/2023 12:14 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD				3 12:08 PM	08/27/2023 12:14 PM
	SPECIMEN / Ur	nknown		EDT		EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	: 60-99 mg/	d∟	IA #: 23D0363256) -	08/27/2023	12:14 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TI	EST DOCKI	ED DEVICE UNSOLICITED	O RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	1488	
GLUCOSE, POINT OF CA Narrative	RE - Final resu	lt (08/27/	2023 12:00 PM EDT)			

Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
CULICOSE DOINT OF C		1. (00 /07 ·				
GLUCOSE, POINT OF CA	ARE - Final resu	lt (08/27/	2023 6:00 AM EDT)			
Narrative						
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
GLUCOSE, POINT OF CA	ARE (GLUCOSE,	POC) - Fi	nal result (08/27/2023	1:42 AM ED	T)	
		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose	117	60 - 139			BEAUMONT	
		mg/dL		1:50 AM	LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
					HILLS (CLIA #: 23D0363256)	
Comment: Capillary					2300303230,	
Performed By	Jackson,			08/27/2023	BEAUMONT	
Terrormed by	Regina NA			1:50 AM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #:	
					23D0363256)	
		· ,				
Contract (Contract)	Anatomical Loo	cation /	Collection Method /	Collection		Durational Times
Specimen (Source)			Volume	Collection		Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			U8/21/202	3 1:42 AIVI EUT	08/27/2023 1:50 AM EDT
	SFECHVILIN / OF	IKHOWH				
Narrative						
INALIALIVE						
BEAUMONT LABORATORY,			(A #: 23D0363256) -	08/27/2023	1:50 AM EDT	
BEAUMONT LABORATORY, Fasting Blood Glucos	e: 60-99 mg/0	d∟	IA #: 23D0363256) -	08/27/2023	1:50 AM EDT	
BEAUMONT LABORATORY,	e: 60-99 mg/0	d∟	IA #: 23D0363256) -	08/27/2023	1:50 AM EDT	
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg/0 : 60-139 mg,	d∟	IA #: 23D0363256) -	08/27/2023	1:50 AM EDT	
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose Authorizing Provider	e: 60-99 mg/o : 60-139 mg, Result Type	d∟ ∕d∟			1:50 AM EDT	
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg/o : 60-139 mg, Result Type	d∟ ∕d∟	EA #: 2300363256) - (1:50 AM EDT	
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose Authorizing Provider	e: 60-99 mg/o : 60-139 mg, Result Type BH LAB POC TE	d∟ ∕d∟				
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose Authorizing Provider William Rudy	e: 60-99 mg/o : 60-139 mg, Result Type BH LAB POC TE	dl /dl EST DOCK	ED DEVICE UNSOLICITED) RESULTS	mber	
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY,	e: 60-99 mg/o : 60-139 mg, Result Type BH LAB POC TH Address	dl /dl EST DOCK	ED DEVICE UNSOLICITED City/State/ZIP Code	O RESULTS Phone Nu	mber	
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS	e: 60-99 mg/o : 60-139 mg, Result Type BH LAB POC TH Address	dl /dl EST DOCK	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI	O RESULTS Phone Nu	mber	
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY,	e: 60-99 mg/o : 60-139 mg, Result Type BH LAB POC TH Address	dl /dl EST DOCK	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI	O RESULTS Phone Nu	mber	
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS	e: 60-99 mg/o : 60-139 mg, Result Type BH LAB POC TH Address	dl /dl EST DOCK	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI	O RESULTS Phone Nu	mber	
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	e: 60-99 mg/o : 60-139 mg, Result Type BH LAB POC TF Address 28050 Grand R	dL /dL EST DOCKE	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI 48336	P RESULTS Phone Nu 800-551-0	mber 1488	
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS	e: 60-99 mg/o : 60-139 mg, Result Type BH LAB POC TF Address 28050 Grand R	dL /dL EST DOCKE River Ave A - Final 1	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI 48336	2 RESULTS Phone Nu 800-551-0 22 PM EDT	mber 1488	
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) LACTIC	e: 60-99 mg/ : 60-139 mg, Result Type BH LAB POC TH Address 28050 Grand R ACID, PLASM	dL /dL EST DOCKE River Ave A - Final P Ref	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI 48336 result (08/26/2023 8:	Phone Nu Phone Nu 800-551-0	mber)488	Pathologist Signature
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) LACTIC Component	e: 60-99 mg/ : 60-139 mg/ Result Type BH LAB POC TE Address 28050 Grand R ACID, PLASM/ Value	dL /dL EST DOCKE River Ave River Ave Ref Range	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI 48336	P RESULTS Phone Nu 800-551-0 :22 PM EDT Analysis Time	mber 1488 Performed At	Pathologist Signature
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) LACTIC	e: 60-99 mg/ : 60-139 mg, Result Type BH LAB POC TH Address 28050 Grand R ACID, PLASM	dL /dL EST DOCKE River Ave River Ave Ref Range 0.5 - 2.0	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI 48336 result (08/26/2023 8:	Phone Nu 800-551-0 :22 PM EDT Analysis Time 08/26/2023	mber 1488 Performed At BEAUMONT	Pathologist Signature
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) LACTIC Component	e: 60-99 mg/ : 60-139 mg/ Result Type BH LAB POC TE Address 28050 Grand R ACID, PLASM/ Value	dL /dL EST DOCKE River Ave River Ave Ref Range	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI 48336 result (08/26/2023 8:	P RESULTS Phone Nu 800-551-0 :22 PM EDT Analysis Time	mber 1488 Performed At	Pathologist Signature
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) LACTIC Component	e: 60-99 mg/ : 60-139 mg/ Result Type BH LAB POC TE Address 28050 Grand R ACID, PLASM/ Value	dL /dL EST DOCKE River Ave River Ave Ref Range 0.5 - 2.0	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI 48336 result (08/26/2023 8:	2 RESULTS Phone Nu 800-551-0 :22 PM EDT Analysis Time 08/26/2023 9:45 PM	mber 1488 Performed At BEAUMONT LABORATORY,	Pathologist Signature
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) LACTIC Component	e: 60-99 mg/ : 60-139 mg/ Result Type BH LAB POC TE Address 28050 Grand R ACID, PLASM/ Value	dL /dL EST DOCKE River Ave River Ave Ref Range 0.5 - 2.0	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI 48336 result (08/26/2023 8:	2 RESULTS Phone Nu 800-551-0 :22 PM EDT Analysis Time 08/26/2023 9:45 PM	mber 2488 Performed At BEAUMONT LABORATORY, FARMINGTON	Pathologist Signature
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) LACTIC Component	e: 60-99 mg/ : 60-139 mg/ Result Type BH LAB POC TE Address 28050 Grand R ACID, PLASM/ Value	dL /dL EST DOCKE River Ave River Ave Ref Range 0.5 - 2.0	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI 48336 result (08/26/2023 8:	2 RESULTS Phone Nu 800-551-0 :22 PM EDT Analysis Time 08/26/2023 9:45 PM	mber 2488 Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	Pathologist Signature
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) LACTIC Component Lactic Acid	e: 60-99 mg/d : 60-139 mg, Result Type BH LAB POC TE Address 28050 Grand R ACID, PLASM/ Value 2.2 (H)	dL /dL EST DOCKE River Ave River Ave Ref Range 0.5 - 2.0 mmol/L	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI 48336 result (08/26/2023 8: Test Method Collection Method /	Phone Nu 800-551-0 :22 PM EDT Analysis Time 08/26/2023 9:45 PM EDT	mber 1488 Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
BEAUMONT LABORATORY, Fasting Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) LACTIC Component Lactic Acid	e: 60-99 mg/d : 60-139 mg, Result Type BH LAB POC TH Address 28050 Grand R ACID, PLASMA Value 2.2 (H) Anatomical Loc Laterality	dL /dL EST DOCKE River Ave A - Final n Ref Range 0.5 - 2.0 mmol/L	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI 48336 result (08/26/2023 8: Test Method Collection Method / Volume	Phone Nu 800-551-0 22 PM EDT Analysis Time 08/26/2023 9:45 PM EDT Collection	mber 2488 Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Time	Received Time
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) LACTIC Component Lactic Acid	e: 60-99 mg/d : 60-139 mg/ Result Type BH LAB POC TH Address 28050 Grand R Value 2.2 (H) Anatomical Loc Laterality VENOUS BLOC	dL /dL EST DOCKE River Ave A - Final n Ref Range 0.5 - 2.0 mmol/L cation /	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI 48336 result (08/26/2023 8: Test Method Collection Method / Volume	Phone Nu 800-551-0 22 PM EDT Analysis Time 08/26/2023 9:45 PM EDT Collection	mber 2488 Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Time	
BEAUMONT LABORATORY, Fasting Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) LACTIC Component Lactic Acid	e: 60-99 mg/d : 60-139 mg, Result Type BH LAB POC TH Address 28050 Grand R ACID, PLASMA Value 2.2 (H) Anatomical Loc Laterality	dL /dL EST DOCKE River Ave A - Final n Ref Range 0.5 - 2.0 mmol/L cation /	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI 48336 result (08/26/2023 8: Test Method Collection Method / Volume	Phone Nu 800-551-0 22 PM EDT Analysis Time 08/26/2023 9:45 PM EDT Collection	mber 2488 Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Time	Received Time
BEAUMONT LABORATORY, Fasting Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) LACTIC Component Lactic Acid Specimen (Source) Blood	e: 60-99 mg/d : 60-139 mg/ Result Type BH LAB POC TH Address 28050 Grand R Value 2.2 (H) Anatomical Loc Laterality VENOUS BLOC	dL /dL EST DOCKE River Ave A - Final n Ref Range 0.5 - 2.0 mmol/L cation /	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI 48336 result (08/26/2023 8: Test Method Collection Method / Volume	Phone Nu 800-551-0 22 PM EDT Analysis Time 08/26/2023 9:45 PM EDT Collection	mber 2488 Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Time	Received Time
BEAUMONT LABORATORY, Fasting Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) LACTIC Component Lactic Acid	e: 60-99 mg/d : 60-139 mg/ Result Type BH LAB POC TH Address 28050 Grand R Value 2.2 (H) Anatomical Loc Laterality VENOUS BLOC	dL /dL EST DOCKE River Ave A - Final n Ref Range 0.5 - 2.0 mmol/L cation /	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI 48336 result (08/26/2023 8: Test Method Collection Method / Volume	Phone Nu 800-551-0 22 PM EDT Analysis Time 08/26/2023 9:45 PM EDT Collection	mber 2488 Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Time	Received Time
BEAUMONT LABORATORY, Fasting Blood Glucose Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) LACTIC Component Lactic Acid Specimen (Source) Blood	e: 60-99 mg/d : 60-139 mg/ Result Type BH LAB POC TH Address 28050 Grand R Value 2.2 (H) Anatomical Loc Laterality VENOUS BLOC	dL /dL EST DOCKE River Ave A - Final n Ref Range 0.5 - 2.0 mmol/L cation /	ED DEVICE UNSOLICITED City/State/ZIP Code Farmington Hills, MI 48336 result (08/26/2023 8: Test Method Collection Method / Volume	Phone Nu 800-551-0 22 PM EDT Analysis Time 08/26/2023 9:45 PM EDT Collection	mber 2488 Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Time	Received Time

Authorizing Provider	Result Type					
William Rudy	BH LAB BLOOD	ORDERA	3LES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Ri	ver Ave	Farmington Hills, MI 48336	800-551-0	488	
GLUCOSE, POINT OF CA Narrative	.RE - Final resul	t (08/26/	2023 6:00 PM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
GLUCOSE, POINT OF CA Component Glucose	Value	POC) - Fi Ref Range 60 - 139 mg/dL	nal result (08/26/2023 Test Method	Analysis Time		Pathologist Signature
Comment: Capillary					,	
Performed By	Dunmore, Androni NA			08/26/2023 5:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loc	ation (Collection Mathead (
Specimen (Source)	Laterality	ation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Un					08/26/2023 5:59 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/d	1L	A #: 23D0363256) - (08/26/2023	5:59 PM EDI	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCKE	D DEVICE UNSOLICITED	RESULTS		
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Ri	ver Ave	Farmington Hills, MI 48336	800-551-0	488	
(ABNORMAL) LACTIC	ACID, PLASMA	A - Final ı Ref	result (08/26/2023 5:	4 4 PM EDT) Analysis)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Lactic Acid		0.5 - 2.0		08/26/2023	BEAUMONT	

Component	Value	Range Test Method	Time	Performed At	Pathologist Signature
Lactic Acid	2.4 (H)	0.5 - 2.0 mmol/L	08/26/2023 6:51 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	la la surs a las sa al Das				

Comment: Sample is hemolzyed. Result may be falsely increased.

	Anatomical Location /	Collection Method /					
Specimen (Source)	Laterality	Volume	Collection Time	Received Time			
Blood	VENOUS BLOOD SPECIMEN / Unknown	Venipuncture / Unknown	08/26/2023 5:44 PM EDT	08/26/2023 6:11 PM EDT			
Narrative							
Authorizing Provider	Result Type						
William Rudy	BH LAB BLOOD ORDERA	BLES					
Performing Organization	Address	City/State/ZIP Code	Phone Number				
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, Ml 48336	800-551-0488				
PROCEDURALIST LINE II Narrative Kelli V - 08/26/2023 Vanoverbeke, Kelli M, Proceduralist Line Ir	4:46 PM EDT , RN 8/26/2023 4:	t Line Insertion) - Final re	esult (08/26/2023 4:46 P	M EDT)			
Date/Time: 8/26/2023	4:46 PM						
Performed by: Vanover	rbeke, Kelli M, RN						
Authorized by: Rudy,	William M, DO						
Patient Properly Posi Hand Hygiene Complete Maximum Barrier Used:	ine/PICC: Difficult A itioned: Yes ed: Yes : Yes mmediately Prior: Yes intained: Yes						
Inserted By: RN Team: FMH-IV Team Supervising Physician: Na Catheter size (Fr): 18 (gauge) Vein diameter (mm): Na Catheter to Vein percentage: 29% Catheter to Vein percentage: 29% Catheter type: Non-valved, Non-tunneled and Power injectable Lot#/: REHQ4269 Manufacturer and Device type: BARD/POWERGLIDE PRO MIDLINE Catheter length (cm): 10 Initial Exposed Catheter: 0 Initial Extremity Circumference: 33 Custom cut tip: No Orientation: Right Location: Brachial							
Contraindications Placement Verified: Ultrasound used? US u Securement Method: S Acknowledge the guide Name of person who ac Guidewire integrity Insertion attempts: Complications: Succe Patient tolerance: T	Securement device (sta ewire was removed: Ye cknowledged guidewire intact: Yes 2 essful insertion (comm	ion ement unless subclavian at lock) es (part of device) was removed: NA ment)	n: Yes				
Authorizing Provider William Rudy	Result Type BH IP BEDSIDE ORDERAB	LE					

(ABNORMAL) LACTIC ACID, PLASMA - Final result (08/26/2023 3:56 PM EDT)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Lactic Acid	2.5 (H)	0.5 - 2.0 mmol/L		08/26/2023 4:58 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical L	ocation /	Collection Method /			
Specimen (Source) Blood	Laterality VENOUS BLC		Volume	Collection		Received Time 08/26/2023 4:26 PM EDT
blood	SPECIMEN / I	-		11 00/20/202		00/20/2023 4.20 FWI EDI
Narrative						
Authorizing Provider	Result Type					
William Rudy	BH LAB BLOC	D ORDERA	BLES			
,						
Performing Organization		<u> </u>	City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand	River Ave	Farmington Hills, MI 48336	800-551-0	1488	
CHEST 1 VIEW AP/PA - F Anatomical Region	Final result (0 Lateral		1:12 PM EDT) Modality			
Chest			Radiograp	hic Imaging		
Specimen (Source)	Anatomical L Laterality	ocation /	Collection Method / Volume		Time 23 12:33 PM	Received Time
				EDT		
Narrative						
08/26/2023 12:34 PM E	EDT					
INDICATION: Fever.						
COMPARISON: Chest rad	diograph 8/2	3/2023. 8/	/21/2023.			
TECHNIQUE: Frontal po 8/26/2023				hours on		
FINDINGS: Patient is	rotated to	the left.				
Lungs: Persistent str exam. Left lung remai					ent	
Vasculature: Normal.						
Heart: Normal in size	2.					
Mediastinum: within r		5.				
Musculoskeletal: Dege process.	enerative ch	anges thro	oughout the spine. No	acute oss	eous	
Other findings: No si	ignificant					
-	igiri icalle.					
IMPRESSION: Persistent right basi atelectasis versus ai	ilar streaky irspace proc	opacities ess.	s again either from s	ubsegmenta	1	
Procedure Note						

Timothy McKnight - 08/26/2023

Procedure Note					
	ight be different from the	original.			
INDICATION: Fever.					
COMPARISON: Chest radi	ograph 8/23/2023, 8/21/20	023.			
TECHNIQUE: Frontal porta 8/26/2023	able chest radiograph obta	iined at 1224 hours on			
FINDINGS: Patient is rotat	ed to the left.				
	opacities at the right lung l lear. No pleural effusions c				
Vasculature: Normal.					
Heart: Normal in size.					
Mediastinum: within norn	nal limits.				
Musculoskeletal: Degener process.	rative changes throughout	the spine. No acute ossee	ous		
Other findings: No signific	cant.				
IMPRESSION:	eaky opacities again either	from subsegmental			
atelectasis versus airspace		C C			
Authorizing Provider	Result Type				
Manju G	WBH IMG GENERAL ORD	ERABLES			
Culture, Blood (CULTURI	E, BLOOD) - Final result (08/26/2023 12:31 PM E	EDT)		
	Ref		Analysis		
Component Culture, Blood	Value Range		Time 08/31/2023	BEAUMONT	Pathologist Signature
Culture, bloba	No growth at 5 days		6:00 PM EDT	LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	
Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection	Time	Received Time
Blood	VENIPUNCTURE FOR BLOOD TEST / Unknown	Venipuncture / Unknowr	08/26/202 EDT	3 12:31 PM	08/26/2023 12:38 PM EDT
Narrative					
Authorizing Provider	Result Type				
Manju G	BH LAB MICROBIOLOGY -	GENERAL ORDERABLES			
Performing Organization	Address	City/State/ZIP Code	Phone Nur	mber	
BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	3601 W. 13 Mile Rd	Royal Oak, MI 48073	800-551-0	488	
- /					

(ABNORMAL) CBC W/AUTO DIFF - Final result (08/26/2023 12:30 PM EDT)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
WBC	7.0	3.5 - 10.1 bil/L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RBC	4.04 (L)	4.31 - 5.48 tril/ L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	11.6 (L)	13.5 - 17.0 g/ dL		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hematocrit	36.7 (L)	40.1 - 50.1 %		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
MCV	91	80 - 100 fL		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСН	29	28 - 33 pg		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСНС	32	32 - 36 g/dL		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RDW-CV	16 (H)	12 - 15 %		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Platelets	189	150 - 400 bil/L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Nucleated Red Blood Cells	0.0	<=0.0 %		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Neutrophils	5.0	1.6 - 7.2 bil/L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Lymphocytes	0.6 (L)	1.1 - 4.0 bil/L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Monocytes	1.3 (H)	0.0 - 0.9 bil/L		08/26/2023 12:50 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Eosinophils	0.1	0.0 - 0.4 bil/L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.0	0.0 - 0.1 bil/L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.05 (H)	0.00 - 0.04 bil/L		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %		%		08/26/2023 12:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method / Volume	Collection	Time	Received Time
Specimen (Source) Blood	Laterality VENOUS BLOC SPECIMEN / U		Venipuncture / Unknow			08/26/2023 12:37 PM EDT
Narrative						
Authorizing Provider	Result Type					
Manju G	BH LAB BLOOD	O ORDERAI	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0		
PHOSPHORUS LEVEL - F	Final result (08,	/26/2023 Ref	12:30 PM EDT)	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Phosphorus	2.5	2.3 - 4.4 mg/dL		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknow	n 08/26/202 EDT	3 12:30 PM	08/26/2023 12:38 PM EDT
Narrative						
Authorizing Provider	Result Type					
Manju G	BH LAB BLOOI	O ORDERA	BLES			

Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	River Ave	Farmington Hills, MI 48336	800-551-0	488	
MAGNESIUM LEVEL - Fi	nal result (08/2	26/2023 1	2:30 PM EDT)			
		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Magnesium	1.7	1.7 - 2.5 mg/dL		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknov	vn 08/26/202 EDT	3 12:30 PM	08/26/2023 12:38 PM EDT
Narrative						
Authorizing Provider	Result Type					
Manju G	BH LAB BLOOD	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	River Ave	Farmington Hills, MI 48336	800-551-0	488	

(ABNORMAL) COMPREHENSIVE METABOLIC PANEL (CMP) - Final result (08/26/2023 12:30 PM EDT)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Sodium	136	135 - 145 mmol/L		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Potassium	3.0 (L)	3.5 - 5.2 mmol/L		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	103	98 - 111 mmol/L		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	23	20 - 29 mmol/L		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	10	5 - 17		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose Comment: Fasting Blood Glucos Random Blood Glucose	-	60 - 99 mg/dL ∕d∟		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Blood Urea Nitrogen -BUN	12	7 - 25 mg/dL		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.57 (L)	0.60 - 1.30 mg/ dL		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	111	>60 mL/ min/ 1.73m2		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Comment:

Calculation based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation refit without adjustment for race. Glomerular Filtration Rate is estimated from serum creatinine, age and gender using the CKD-EPI equation:

G1:	Normal GFR: >=90
G2:	Mildly decreased GFR: 60-89
G3a:	Mildly to moderately decreased GFR: 45-59
G3b:	Moderately to severely decreased GFR: 30-44
G4:	Severely decreased GFR: 15-29
G5:	Kidney failure GFR: <15

Calcium	8.2 (L)	8.5 - 10.5 mg/dL	08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Protein Total	6.0 (L)	6.2 - 8.1 g/dL	08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Albumin	2.4 (L)	3.5 - 4.9 g/dL	08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Globulin	3.6	2.2 - 3.7 g/dL	08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Albumin/Globulin Ratio	0.7		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Alkaline Phosphatase	123 (H)	33 - 120 U/L		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Aspartate Aminotransferase -AST	46 (H)	<35 U/L		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Alanine Aminotransferase -ALT	39	9 - 47 U/ L		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Bilirubin Total	0.2 (L)	0.3 - 1.2 mg/dL		08/26/2023 1:26 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOO SPECIMEN / U		Venipuncture / Unknow	vn 08/26/202 EDT	3 12:30 PM	08/26/2023 12:38 PM EDT
Narrative						
Authorizing Provider	Result Type					
Manju G	BH LAB BLOOI					
Manja G		BONDERV				
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0	488	
Culture, Blood (CULTUR	e, blood) - Fi	nal result Ref	(08/26/2023 12:30 PM	EDT) Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Culture, Blood	No growth at 5 days		CULTURE, BLOOD	08/31/2023 6:00 PM EDT	BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	
_Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENIPUNCTUF BLOOD TEST /		Venipuncture / Unknow	vn 08/26/202 EDT	3 12:30 PM	08/26/2023 1:18 PM EDT
Narrative						
Authorizing Provider	Result Type					
Manju G	21	DBIOLOGY	- GENERAL ORDERABLES	5		
Destan i O i ii	A .1.1				l	
Performing Organization BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	Address 3601 W. 13 Mi	le Rd	City/State/ZIP Code Royal Oak, MI 48073	Phone Nu 800-551-0		

GLUCOSE, POINT OF CARE - Final result (08/26/2023 12:00 PM EDT)

Narrative		11 (00/20/	2023 12:00 1 10 2017			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
,						
glucose, point of ca	RE (GLUCOSE,	POC) - Fi Ref	nal result (08/26/2023	11:32 AM E Analysis	DT)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	120	60 - 139 mg/dL		08/26/2023 11:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Dunmore, Androni NA			08/26/2023 11:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loc Laterality	cation /	Collection Method / Volume	Collection	Timo	Received Time
Blood	WHOLE BLOOD)	volume		3 11:32 AM	08/26/2023 11:39 AM
	SPECIMEN / Ur			EDT	5 TT.52 AIVI	EDT
Narrative BEAUMONT LABORATORY,			. #. 2200262256) 0	0 /26 /2022	11.30 AM EDT	
Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/o	ΊL	A #: 2500565256) - 0	18/20/2023	II:39 AM EDI	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCKE	D DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0		
GLUCOSE, POINT OF CA Component	RE (GLUCOSE, Value	POC) - Fi Ref Range	nal result (08/26/2023 Test Method	5:23 AM ED Analysis Time		Pathologist Signature
Glucose	128	60 - 139 mg/dL		08/26/2023 5:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary				00/06/00000		
Performed By	Vinales, Robin NA			08/26/2023 5:31 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Apotomical	otics /	Collection Mathematic			
Specimen (Source)	Anatomical Loc Laterality	.auon /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur					08/26/2023 5:31 AM EDT

Narrative P_{A} Normalize										
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/26/2023 5:31 AM EDT Fasting Blood Glucose: 60-99 mg/dL										
Random Blood Glucose	: 60-139 mg/	∕d∟								
Authorizing Provider	Result Type									
William Rudy		BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS								
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber					
BEAUMONT	28050 Grand R	iver Ave	Farmington Hills, MI	800-551-0	488					
LABORATORY, FARMINGTON HILLS			48336							
(CLIA #: 23D0363256)										
GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/26/2023 12:15 AM EDT)										
		Ref		Analysis						
Component	Value	Range	Test Method	Time		Pathologist Signature				
Glucose	115	60 - 139 mg/dL		08/26/2023 12:21 AM	BEAUMONT LABORATORY,					
		mg/uL		EDT	FARMINGTON					
					HILLS (CLIA #:					
Comment: Capillary					23D0363256)					
Performed By	Anderson,			08/26/2023	BEAUMONT					
· · · · ,	Shamika NA			12:21 AM	LABORATORY,					
				EDT	FARMINGTON HILLS (CLIA #:					
					23D0363256)					
Specimen (Source)	Anatomical Loc Laterality	ation /	Collection Method / Volume	Collection	Time	Received Time				
Blood	WHOLE BLOOD)	volume		3 12:15 AM	08/26/2023 12:21 AM				
	SPECIMEN / Ur	nknown		EDT		EDT				
Narrative										
BEAUMONT LABORATORY,	FARMINGTON H	LLS (CL	(A #: 23D0363256) - (08/26/2023	12:21 AM EDT					
Fasting Blood Glucos Random Blood Glucose										
Authorizing Provider	Result Type		ED DEVICE UNSOLICITED							
William Rudy	BH LAB PUC TE	ST DOCK	ED DEVICE UNSOLICITED	RESULIS						
Performing Organization			City/State/ZIP Code	Phone Nu						
BEAUMONT LABORATORY,	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488					
FARMINGTON HILLS			40550							
(CLIA #: 23D0363256)										
GLUCOSE, POINT OF CA	RE - Final resul	lt (08/25/	2023 6:00 PM EDT)							
Narrative										
Authorizing Provider	Result Type									
Tiffany Marchewka	WBH HBS NSG	POC LAB								
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi Ref	nal result (08/25/2023	5:36 PM ED Analysis	T)					
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature				
Glucose	129	60 - 139			BEAUMONT					
		mg/dL		5:43 PM EDT	LABORATORY, FARMINGTON					
					HILLS (CLIA #:					
					23D0363256)					

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Performed By	MALLORY, DANYEL NA			08/25/2023 5:43 PM	BEAUMONT LABORATORY,	
	27.11122.101			EDT	FARMINGTON	
					HILLS (CLIA #:	
	Anatomical Lo	cation /	Collection Method /		23D0363256)	
Specimen (Source)	Laterality	cation /	Volume	Collection	Time	Received Time
Blood	WHOLE BLOO	D		08/25/202	23 5:36 PM EDT	08/25/2023 5:43 PM EDT
	SPECIMEN / U	nknown				
Narrative						
BEAUMONT LABORATORY,			IA #: 23D0363256) -	08/25/2023	5:43 PM EDT	
Fasting Blood Glucose Random Blood Glucose:						
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCK	ED DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT	28050 Grand F	River Ave	Farmington Hills, MI	800-551-0		
LABORATORY,			48336			
FARMINGTON HILLS (CLIA #: 23D0363256)						
(CLIA #. 23D0303230)						
GLUCOSE, POINT OF CA	RE - Final resu	ılt (08/25/	/2023 12:00 PM EDT)			
Narrative						
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSC	5 POC LAB				
GLUCOSE, POINT OF CA			inal result (08/25/202	3 11·56 ΔM F		
		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	126	60 - 139			BEAUMONT	
		mg/dL		12:02 PM EDT	LABORATORY, FARMINGTON	
				LDT	HILLS (CLIA #:	
					23D0363256)	
Comment: Capillary					B	
Performed By	Vasser, Ashley NA			08/25/2023 12:02 PM	BEAUMONT LABORATORY,	
	NA			EDT	FARMINGTON	
					HILLS (CLIA #:	
					23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOO				23 11:56 AM	08/25/2023 12:02 PM
	SPECIMEN / U	nknown		EDT		EDT
Narrative						
BEAUMONT LABORATORY,			IA #: 23D0363256) -	08/25/2023	12:02 PM EDT	
Fasting Blood Glucose Random Blood Glucose						
Authorizing Provider	Result Type					
William Rudy	21	EST DOCK	ED DEVICE UNSOLICITE	D RESULTS		
-						

Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi Ref	nal result (08/25/2023	3 6:04 AM ED Analysis	T)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	89	60 - 139 mg/dL		08/25/2023 6:10 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary					,	
Performed By	Anderson, Shamika NA			08/25/2023 6:10 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loc	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOE SPECIMEN / Ur			08/25/202	23 6:04 AM EDT	08/25/2023 6:10 AM EDT
Narrative				00 /25 /2022	6.10 AM EDT	
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/o	dL	LA #: 23D0363256) -	08/25/2023	6:10 AM EDI	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	EST DOCK	ED DEVICE UNSOLICITED	O RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
glucose, point of ca	NRE (GLUCOSE,	POC) - Fi	nal result (08/25/2023	3 12:24 AM E	DT)	
		Ref	—	Analysis		
Component Glucose	Value 115	Range 60 - 139	Test Method	Time	BEAUMONT	Pathologist Signature
	115	mg/dL		12:32 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary Performed By	Anderson,			08/25/2023	BEAUMONT	
Tenomica by	Shamika NA			12:32 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /	_		
Specimen (Source) Blood	Laterality WHOLE BLOOE SPECIMEN / Ur		Volume	Collection 08/25/202 EDT	Time 23 12:24 AM	Received Time 08/25/2023 12:32 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/0	dL .	IA #: 23D0363256) -	08/25/2023	12:32 AM EDT	

Authorizing Provider	Result Type						
William Rudy	21	EST DOCKI	D DEVICE UNSOLICITED	D RESULTS			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0488			
(ABNORMAL) GLUCOS	E, POINT OF	CARE (GL Ref	UCOSE, POC) - Final	• •	4/2023 6:05 I	PM EDT)	
Component	Value	Range	Test Method	Analysis Time	Performed At	Pathologist Signature	
Glucose Comment: Capillary	150 (H)	60 - 139 mg/dL		08/24/2023 6:12 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Performed By	Vasser, Ashley			08/24/2023	BEAUMONT		
	NA			6:12 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
	Anatomical Lo	cation /	Collection Method /				
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time	
Blood	WHOLE BLOOD SPECIMEN / Unknown			08/24/202	23 6:05 PM EDT	08/24/2023 6:12 PM EDT	
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose Authorizing Provider William Rudy	e: 60-99 mg/ : 60-139 mg Result Type	d∟ ∕d∟	ED DEVICE UNSOLICITED				
Deufeuncies Ourseniesties			City (Chata /ZID Carda	Dhana Nu	un la nu		
Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu 800-551-0			
GLUCOSE, POINT OF CA Narrative	RE - Final resu	ılt (08/24/	2023 6:00 PM EDT)				
Authorizing Provider	Result Type						
Tiffany Marchewka	WBH HBS NSC	5 POC LAB					
GLUCOSE, POINT OF CA	RE (GLUCOSE)		nal result (08/24/2023	3 12:05 PM E Analysis	DT)		
Component	Value	Ref Range	Test Method	~	Performed At	Pathologist Signature	
Component	Value	Range	Test Method	Time		Pathologist Signature	
Component Glucose	Value 105		Test Method	Time	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	Pathologist Signature	
		Range 60 - 139	Test Method	Time 08/24/2023 12:12 PM	BEAUMONT LABORATORY, FARMINGTON	Pathologist Signature	

Component	Value	Ref Range	Test Method	Analysis Time	Darformed At	Pathologist Signature
Performed By	Vasser, Ashley NA	Kange	lest Method		BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loc Laterality	ation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/24/202 EDT	23 12:05 PM	08/24/2023 12:12 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/c	1L	A #: 23D0363256) -	08/24/2023	12:12 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCK	ED DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Ri	iver Ave	Farmington Hills, MI 48336	800-551-0	9488	
GLUCOSE, POINT OF CA Narrative	RE - Final resu	lt (08/24/	2023 12:00 PM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
GLUCOSE, POINT OF CA Narrative	RE - Final resu	lt (08/24/	2023 6:00 AM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi Ref		5:19 AM ED Analysis	T)	
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose	106	60 - 139 mg/dL		08/24/2023 5:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Harvey, Jaice NA			08/24/2023 5:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loc	ation /	Collection Method / Volume	Collection	Time	Received Time
Blood	Laterality WHOLE BLOOD SPECIMEN / Ur		volume			08/24/2023 5:25 AM EDT

Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose	e: 60-99 mg/o		EA #: 23D0363256) - (08/24/2023	5:25 AM EDT	
Random Blood Glucose	: 60-139 mg/	∕d∟				
Authorizing Provider	Result Type					
William Rudy		ST DOCK	ED DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mher	
BEAUMONT	28050 Grand R	iver Ave	Farmington Hills, MI	800-551-0		
LABORATORY,			48336			
FARMINGTON HILLS (CLIA #: 23D0363256)						
(CEIA ". 2300303230)						
GLUCOSE, POINT OF CA	ARE (GLUCOSE,		inal result (08/24/2023		T)	
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	108	60 - 139		08/24/2023	BEAUMONT	
		mg/dL		1:23 AM	LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	
Comment: Capillary						
Performed By	Harvey, Jaice NA			08/24/2023 1:23 AM	BEAUMONT LABORATORY,	
	NA			EDT	FARMINGTON	
					HILLS (CLIA #:	
					23D0363256)	
	Anatomical Loc	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD			08/24/202	3 1:17 AM EDT	08/24/2023 1:23 AM EDT
	SPECIMEN / Ur	IKNOWN				
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucos	FARMINGTON Hi e: 60-99 mg/d	CLLS (CL)	IA #: 23D0363256) - (08/24/2023	1:23 AM EDT	
Random Blood Glucose	: 60-139 mg/					
Authorizing Provider	Result Type					
William Rudy			ED DEVICE UNSOLICITED	RESULTS		
,						
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY,	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	
FARMINGTON HILLS						
(CLIA #: 23D0363256)						
GLUCOSE, POINT OF CA	RE - Final resu	lt (08/24/	(2023 12:00 AM EDT)			
Narrative						
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi Ref	inal result (08/23/2023	4:17 PM ED Analysis	T)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	127	60 - 139		08/23/2023	BEAUMONT	
		mg/dL		4:24 PM	LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Comment: Capillary						
Performed By	Carr, Kennadi NA			08/23/2023 4:24 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	WHOLE BLOOD SPECIMEN / UI	_		08/23/202	23 4:17 PM EDT	08/23/2023 4:24 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	:A #: 23D0363256) -	08/23/2023	4:24 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TI	EST DOCKI	ED DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA Narrative	NRE - Final resu	lt (08/23/	2023 12:00 PM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
GLUCOSE, POINT OF CA	•	Ref	• • •	Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose	119	60 - 139 mg/dL		08/23/2023 11:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Jones, Yazmyn NA			08/23/2023 11:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur	_		08/23/202 EDT	23 11:33 AM	08/23/2023 11:39 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	:A #: 23D0363256) -	08/23/2023	11:39 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TI	EST DOCKI	ED DEVICE UNSOLICITE	D RESULTS		

Performing Organization	Address		City/State/ZIP Code	Phone Number		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		Farmington Hills, MI 48336	800-551-0488		
(CLIA #: 23D0363256)						
GLUCOSE, POINT OF CA Narrative	ARE - Final resu	lt (08/23/	2023 6:00 AM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
GLUCOSE, POINT OF CA	ARE (GLUCOSE,	POC) - Fi Ref	nal result (08/23/2023	5:38 AM ED Analysis	DT)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	111	60 - 139 mg/dL		08/23/2023 5:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Harvey, Jaice NA			08/23/2023 5:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Los	sation /	Collection Method /			
Specimen (Source)	Anatomical Location / Laterality		Volume	Collection Time		Received Time
Blood	WHOLE BLOOD SPECIMEN / Unknown			08/23/2023 5:38 AM EDT		08/23/2023 5:44 AM EDT
Narrative BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/0	dL	IA #: 23D0363256) - (08/23/2023	5:44 AM EDT	
Authorizing Provider	Result Type					
William Rudy	21	ST DOCK	ED DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address City/State/ZIP Code Phone Number					
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		Farmington Hills, MI 48336	800-551-0488		
LACTIC ACID, PLASMA -	- Final result (08	8/23/2023 Ref	3 4:27 AM EDT)	Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Lactic Acid	1.6	0.5 - 2.0 mmol/L		08/23/2023 4:53 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loc	cation /	Collection Method /			
Specimen (Source) Blood	Laterality VENOUS BLOOD		VolumeCollection TimeVenipuncture / Unknown08/23/2023 4:27 AM EDT		Received Time	
ыооц	SPECIMEN / Ur				00/23/2023 4.33 AIVI EDI	

Narrative					
Authorizing Provider	Result Type				
Sara W	BH LAB BLOOD ORDERA	BLES			
Performing Organization	Address	City/State/ZIP Code	Phone Number		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336			
CHEST 1 VIEW AP/PA - F Anatomical Region	Final result (08/23/2023 Laterality	3:56 AM EDT) Modality			
Chest	,	Radiograph	nic Imaging		
Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time	
			08/23/2023 6:50 AM EDT	-	
Narrative					
08/23/2023 6:52 AM ED	т				
INDICATION: Evaluate	for aspiration.				
COMPARISON: Chest rac	diograph 8/21/2023, 8	/1/2023.			
TECHNIQUE: Frontal pc 8/23/2023	ortable chest radiogra	aph obtained at 0316	hours on		
FINDINGS: Patient is	rotated to the right				
Lungs: Streaky right effusions or pneumoth		e new. Left lung is c	lear. No pleural		
Vasculature: Normal.					
Heart: Normal in size.					
Mediastinum: within normal limits.					
Musculoskeletal: The	osseous structures a	re intact.			
Other findings: No si	ignificant.				
IMPRESSION: New streaky right bas airspace process such			telectasis or		
Procedure Note					
Timothy McKnight - 08/	/23/2023				

Procedure Note
Formatting of this note might be different from the original.
INDICATION: Evaluate for aspiration.
COMPARISON: Chest radiograph 8/21/2023, 8/1/2023.
TECHNIQUE: Frontal portable chest radiograph obtained at 0316 hours on 8/23/2023
FINDINGS: Patient is rotated to the right
Lungs: Streaky right basilar opacities are new. Left lung is clear. No pleural effusions or pneumothorax.
Vasculature: Normal.
Heart: Normal in size.
Mediastinum: within normal limits.
Musculoskeletal: The osseous structures are intact.
Other findings: No significant.
IMPRESSION: New streaky right basilar opacities either from subsegmental atelectasis or airspace process such as pneumonitis/pneumonia
Authorizing Provider Result Type Camilla A WBH IMG GENERAL ORDERABLES
ABDOMEN KUB OR ABDOMEN 1 VIEW - Final result (08/23/2023 3:56 AM EDT) Anatomical Region Laterality Modality
Abdomen Radiographic Imaging
Anatomical Location / Collection Method / Specimen (Source) Laterality Volume Collection Time Received Time
08/23/2023 6:49 AM EDT
Narrative 08/23/2023 6:50 AM EDT
CLINICAL INDICATION: Concern for ileus, altered mental status and sepsis
COMPARISON: Chest radiographs 8/23/2023 and 8/21/2023
TECHNIQUE: Single view frontal supine radiographs of the abdomen obtained portably at 0318 hours on 3/23/2023.
FINDINGS: PEG tube projects over the left upper abdomen. Air-filled loops of colon and small bowel without abnormal dilatation are scattered throughout the abdomen and pelvis. There is no evidence for organomegaly. No abnormal calcifications. The osseous structures are intact.
IMPRESSION
1. No current radiographic evidence for acute process
2. PEG tube present

Procedure Note Timothy McKnight - 08/23/2023 Formatting of this note might be different from the original. CLINICAL INDICATION: Concern for ileus, altered mental status and sepsis COMPARISON: Chest radiographs 8/23/2023 and 8/21/2023 TECHNIQUE: Single view frontal supine radiographs of the abdomen obtained portably at 0318 hours on 3/23/2023. FINDINGS: PEG tube projects over the left upper abdomen. Air-filled loops of colon and small bowel without abnormal dilatation are scattered throughout the abdomen and pelvis. There is no evidence for organomegaly. No abnormal calcifications. The osseous structures are intact. **IMPRESSION** 1. No current radiographic evidence for acute process 2. PEG tube present Authorizing Provider **Result Type** Camilla A WBH IMG GENERAL ORDERABLES (ABNORMAL) LACTIC ACID, PLASMA - Final result (08/23/2023 2:31 AM EDT) Ref Analysis Component Value Range Test Method Time Performed At Pathologist Signature 08/23/2023 BEAUMONT Lactic Acid 2.1 (H) 0.5 - 2.0 mmol/L 3:15 AM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) Collection Method / Anatomical Location / Collection Time Specimen (Source) Laterality Volume **Received Time** Blood **VENOUS BLOOD** Venipuncture / Unknown 08/23/2023 2:31 AM EDT 08/23/2023 2:48 AM EDT SPECIMEN / Unknown Narrative Authorizing Provider **Result Type** Sara W BH LAB BLOOD ORDERABLES . . .

Performing Organization	Address	City/State/ZIP Code	Phone Number
BEAUMONT	28050 Grand River Ave	Farmington Hills, MI	800-551-0488
LABORATORY,		48336	
FARMINGTON HILLS			
(CLIA #: 23D0363256)			

ECG - Final result (08/23/2023 2:20 AM EDT)

		Ref		Analysis	Performed	
Component	Value	Range	Test Method	Time	At	Pathologist Signature
QT INTERVAL	322	ms			MISYS	
QTC CALCULATION	460	ms			MISYS	

	Anatomical Location /	Collection Method /			
Specimen (Source)	Laterality	Volume	Collection		Received Time
			08/23/2023	3 2:20 AM EDT	
Narrative					
MISYS - 08/25/2023 10):45 AM EDT				
Test Reason : Blood Pressure : */ Vent. Rate : 123 BPM P-R Int : 148 ms QT Int : 322 ms QTC Int : 460 ms	/* mmHG Atrial Rate : 123 QRS Dur : 88	ms			
No significant change	CG of 01-AUG-2023 17:3				
Referred By:	Confirmed By: Robe	ert Grodman			
Procedure Note	F (2022)				
Test Reason : Blood Pressure : */* mmH Vent. Rate : 123 BPM Atria P-R Int : 148 ms QRS Dur QT Int : 322 ms P-R-T Axe QTc Int : 460 ms Sinus tachycardia Nonspecific ST abnormali Abnormal ECG When compared with ECC No significant change wa	ight be different from the IG al Rate : 123 BPM : 88 ms es : 63 68 69 degrees ity G of 01-AUG-2023 17:39, s found Robert (486) on 8/25/2023				
Daufaunaia a Ousanization	Adduces	City (Ctata /ZID Cada	Dis an a Nive		
Performing Organization MISYS	Address	City/State/ZIP Code	Phone Nur	nber	
Culture, Blood (CULTUR Component Culture, Blood	E, BLOOD) - Final result (Ref Value Range No growth at 5 days	Test Method	Analysis Time	Performed At BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	Pathologist Signature
Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection	Time	Received Time
Blood	VENIPUNCTURE FOR BLOOD TEST / Unknown	Venipuncture / Unknow	n 08/23/2023 EDT	3 12:42 AM	08/23/2023 12:53 AM EDT
Narrative					
Authorizing Provider	Result Type				
Sara W	BH LAB MICROBIOLOGY	- GENERAL ORDERABLES			

Performing Organization	Address		City/State/ZIP Code	Phone Nu	Phone Number		
BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	3601 W. 13 Mile Rd		Royal Oak, MI 48073	800-551-0488			
(ABNORMAL) PROCAL	CITONIN PLASM	Δ - Fi	nal result (08/23/20)	23 12·36 ΔΝ			
	Ref		nui result (00, 25, 201	Analysis			
Component	Value Rang	ge	Test Method	Time	Performed At	Pathologist Signature	
Procalcitonin, Plasma	0.27 (H) 0.00 0.25 mL		i2000SR	08/23/2023 3:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
	Anatomical Location	n /	Collection Method /				
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time	
Blood	VENOUS BLOOD SPECIMEN / Unknow	wn	Venipuncture / Unknown 08/23/2023 7 EDT		3 12:36 AM	08/23/2023 12:54 AM EDT	
BEAUMONT LABORATORY, Interpretive criteria If using as an aid in infections, providers - PCT <0.10 ng/mL - a - PCT 0.10-0.25 ng/mL - PCT 0.26-0.50 ng/mL - PCT > 0.50 ng/mL - If using as an aid in sepsis, providers sho - PCT <= 0.50 ng/mL of - antibiotics - PCT > 0.50 ng/mL an - antibiotics - PCT > 0.50 ng/mL an - antibiotics	a for results: n deciding on whe s should use the antibiotics strong L - antibiotics d L - antibiotics en antibiotics stron n deciding on whe buld use the follo for > 80% decrease discouraged nd < 80% decrease	ther follo gly d iscou ncour ngly ther owing from	or not to start ant wing guidance: iscouraged raged aged encouraged or not to disconting guidance: peak/baseline value	ibiotics fo ue antibiot	r lower resp		
Camilla A	BH LAB BLOOD ORI						
	DIT LAD DLOOD ORL		JLLJ				
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber		
BEAUMONT LABORATORY, FARMINGTON HILLS	28050 Grand River A	Ave	Farmington Hills, MI 48336	800-551-0	488		

(CLIA #: 23D0363256)

(ABNORMAL) BLOOD GASES, VENOUS (VBG) - Final result (08/23/2023 12:36 AM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Sample Type	Blood, venous			08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
рН	7.51 (H)	7.32 - 7.42		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
PCO2	35 (L)	41 - 51 mmHg		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref	T	Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Bicarbonate	28 (H)	19 - 27 mmol/L		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Total CO2	29	20 - 29 mmol/L		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Base Excess	5	-5 - 5 mmol/L		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Oxyhemoglobin	76	55 - 85 %		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carboxyhemoglobin	1.2	<1.5 %		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Non-smoker: Less that Heavy smoker: Less that Toxic: Greater than 2	han 9%					
Methemoglobin	0.4	0.0 - 2.0 %		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	15.0	13.5 - 17.0 g/ dL		08/23/2023 12:59 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)			Volume	Collection		Received Time
Blood, Whole	VENOUS BLOC SPECIMEN / U			08/23/202 EDT	23 12:36 AM	08/23/2023 12:51 AM EDT
Narrative						
Authorizing Provider	Result Type					
Sara W	BH LAB BLOOI	ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0		
Culture, Blood (CULTUR		nal result	(08/22/2022 12:26 11)			
Culture, Blood (CULIUR	ς, δισου) - Fi	nai result	(U0/23/2U23 12:36 AN	יובטו)		

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Culture, Blood	No growth at 5 days		CULTURE, BLOOD	08/28/2023 11:01 AM EDT	BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	<u> </u>
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection		Received Time
Blood	VENIPUNCTUR BLOOD TEST /		Venipuncture / Unknow	n 08/23/202 EDT	3 12:36 AM	08/23/2023 12:54 AM EDT
Narrative						
Indirative						
Authorizing Provider	Result Type					
Sara W	BH LAB MICRC	BIOLOGY	- GENERAL ORDERABLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nur	mher	
BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	3601 W. 13 Mil	e Rd	Royal Oak, MI 48073	800-551-0		
23D0667009)						
(ABNORMAL) LACTIC	ACID, PLASM	A - Final Ref		::36 AM ED Analysis	Г)	
Component	Value	Range		Time	Performed At	Pathologist Signature
Lactic Acid	2.4 (H)	0.5 - 2.0 mmol/L		08/23/2023 1:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / Ur		Venipuncture / Unknow	n 08/23/202 EDT	3 12:36 AM	08/23/2023 12:54 AM EDT
Narrative						
Authorizing Provider	Result Type					
Sara W	BH LAB BLOOD	ORDERA	BLES			
Porforming Organization	Addross		City/State/7ID Code	Phone Nur	mbor	
Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0		
(ABNORMAL) BASIC N	IETABOLIC PA Value	NEL (BM Ref Range		3/2023 12: Analysis Time	-	Pathologist Signature
	405	105				

Component	Value	Range	Test Method	Time	Performed At Pathologist Signature
Sodium	135	135 -		08/23/2023	BEAUMONT
		145		1:29 AM	LABORATORY,
		mmol/L		EDT	FARMINGTON
					HILLS (CLIA #:
					23D0363256)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Potassium	4.1	3.5 - 5.2 mmol/L		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	101	98 - 111 mmol/L		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	24	20 - 29 mmol/L		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	10	5 - 17		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose	176 (H)	60 - 99 mg/dL		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Fasting Blood Glucos Random Blood Glucose						
Blood Urea Nitrogen -BUN	16	7 - 25 mg/dL		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.64	0.60 - 1.30 mg/ dL		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	107	>60 mL/ min/ 1.73m2		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Calculation based on without adjustment f gender using the CKD	or race. Glom	erular Fi				
G1: Normal GFR: G2: Mildly decr G3a: Mildly to m G3b: Moderately G4: Severely de G5: Kidney fail	eased GFR: 60 oderately dec to severely d creased GFR:	reased GF ecreased				
Calcium	8.6	8.5 - 10.5 mg/dL		08/23/2023 1:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality		Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOO SPECIMEN / U		Venipuncture / Unknov	vn 08/23/202 EDT	23 12:36 AM	08/23/2023 12:54 AM EDT

Authorizing Provider	Result Type		
Sara W	BH LAB BLOOD ORDERAE	BLES	
Performing Organization	Address	City/State/ZIP Code	Phone Number
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0488

(ABNORMAL) COMPLETE BLOOD COUNT - Final result (08/23/2023 12:36 AM EDT)

Narrative

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
WBC	12.4 (H)	3.5 - 10.1 bil/L		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RBC	4.91	4.31 - 5.48 tril/ L		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	14.5	13.5 - 17.0 g/ dL		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hematocrit	45.1	40.1 - 50.1 %		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
MCV	92	80 - 100 fL		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСН	30	28 - 33 pg		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСНС	32	32 - 36 g/dL		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RDW-CV	16 (H)	12 - 15 %		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Platelets	201	150 - 400 bil/L		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Nucleated Red Blood Cells	0.0	<=0.0 %		08/23/2023 1:12 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOO SPECIMEN / Ur		Venipuncture / Unknow	wn 08/23/202 EDT	23 12:36 AM	08/23/2023 12:54 AM EDT
Narrative						
Authorizing Provider	Result Type					
Sara W	BH LAB BLOOD	ORDERA	BLES			
Performing Organization	Addross		City/State/ZIP Code	Phone Nu	mbor	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0		
GLUCOSE, POINT OF CA Narrative Authorizing Provider	Result Type		2023 12:00 AM EDT)			
Tiffany Marchewka	WBH HBS NSG	POC LAB				
(ABNORMAL) GLUCOS			UCOSE, POC) - Final Test Method			PM EDT) Pathologist Signature
Glucose	159 (H)	60 - 139 mg/dL			BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Harvey, Jaice NA			08/22/2023 11:58 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loc	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/22/202 EDT	23 11:51 PM	08/22/2023 11:58 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/d	dL	A #: 23D0363256) -	08/22/2023	11:58 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCK	D DEVICE UNSOLICITED	D RESULTS		

Performing Organization	Address		City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Ri	ver Ave	Farmington Hills, MI 48336	800-551-0488		
GLUCOSE, POINT OF CA	RE - Final resul	t (08/22/	2023 6:00 PM EDT)			
Narrative						
Authorizing Drevider	De eult Ture e					
Authorizing Provider Tiffany Marchewka	Result Type WBH HBS NSG	POCIAB				
(ABNORMAL) GLUCOS		ARE (GI	LICOSE POC) - Fina	l rosult (08/2	2/2023 3.46	
		Ref	00052, 1 00) - 1 ma	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	179 (H)	60 - 139 mg/dL		08/22/2023 3:53 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Jones, Yazmyn NA			08/22/2023 3:53 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loc Laterality	ation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Un			08/22/202	23 3:46 PM EDT	08/22/2023 3:53 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/c	IL .	:A #: 23D0363256) -	08/22/2023	3:53 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCK	ED DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Ri	ver Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA Narrative	RE - Final resul	t (08/22/	2023 12:00 PM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
(ABNORMAL) GLUCOS	E. POINT OF C	ARE (GI	UCOSE, POC) - Fina	l result (08/2	2/2023 11.21	AM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	186 (H)	60 - 139 mg/dL		08/22/2023 11:27 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary				00/22/2022		
Performed By	Jones, Yazmyn NA		Collection Mathead (08/22/2023 11:27 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOO SPECIMEN / U			08/22/202 EDT	23 11:21 AM	08/22/2023 11:27 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	08/22/2023	11:27 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKI	D DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) GLUCOS	SE, POINT OF		UCOSE, POC) - Final		2/2023 6:04 /	AM EDT)
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	142 (H)	60 - 139	lest Method	08/22/2023		
Comment: Capillary		mg/dL		6:11 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Hall, LaKeela			08/22/2023	BEAUMONT	
	NA			6:11 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOO	D				08/22/2023 6:11 AM EDT
2.000	SPECIMEN / U			<i>,,</i>		
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	08/22/2023	6:11 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCK	ED DEVICE UNSOLICITE	D RESULTS		

Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Ri	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA Narrative	RE - Final resu	lt (08/22/	2023 6:00 AM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
GLUCOSE, POINT OF CA Narrative	RE - Final resu	lt (08/22/	2023 12:00 AM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
(ABNORMAL) GLUCOS		Ref	-	Analysis		
Component	Value	Range 60 - 139	Test Method	Time		Pathologist Signature
Glucose	157 (H)	mg/dL		08/21/2023 8:34 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary					2320303230)	
Performed By	Hall, LaKeela NA			08/21/2023 8:34 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loc Laterality	ation /	Collection Method / Volume	Collection	Timo	Received Time
Blood	WHOLE BLOOD		Volume			08/21/2023 8:34 PM EDT
	SPECIMEN / Ur	iknown				
Narrative				00 (01 (0000	0.04	
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/c	1L	A #: 23D0363256) -	08/21/2023	8:34 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCKE	D DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY,	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
FARMINGTON HILLS (CLIA #: 23D0363256)						
GLUCOSE, POINT OF CA Narrative	RE - Final resu	lt (08/21/	2023 6:00 PM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				

GLUCOSE, POINT OF CA		,	nal result (08/21/2023		T)	
Common and	Re		Test Methesd	Analysis	Daufaura ad At	Dath allo gist Cignature
Component		nge	Test Method	Time		Pathologist Signature
Glucose		- 139 g/dL		4:24 PM	BEAUMONT LABORATORY,	
		g/aL		EDT	FARMINGTON	
					HILLS (CLIA #:	
					23D0363256)	
Comment: Capillary						
Performed By	Jones, Yazmyn				BEAUMONT	
	NA			4:24 PM EDT	LABORATORY, FARMINGTON	
				EDI	HILLS (CLIA #:	
					23D0363256)	
	Anatomical Location	on /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	_	Received Time
Blood	WHOLE BLOOD			08/21/202	23 4:18 PM EDT	08/21/2023 4:24 PM EDT
	SPECIMEN / Unkno	own				
Narrative						
BEAUMONT LABORATORY,		S (CLI	A #: 23D0363256) - (08/21/2023	4:24 PM EDT	
Fasting Blood Glucose Random Blood Glucose						
	. 00 155 llig/ dE					
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TEST	DOCKE	D DEVICE UNSOLICITED	RESULTS		
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT	28050 Grand River	r Ave	Farmington Hills, MI	800-551-0	9488	
LABORATORY, FARMINGTON HILLS			48336			
(CLIA #: 23D0363256)						
(021/ 0/ 20000000000)						
CHEST 1 VIEW AP/PA - I	inal result (08/21	/2023	12:59 PM EDT)			
Anatomical Region	Laterality		Modality			
Chest			Radiograp	hic Imaging		
	A sector sector and the sector	/				
Specimen (Source)	Anatomical Location	on /	Collection Method / Volume	Collection	Time	Received Time
Specifien (Source)	Lateranty		Volume		23 1:04 PM EDT	
				00,21,202	.5 1.04 1 101 201	
Narrative						
08/21/2023 1:05 PM EE						
CLINICAL INDICATION:	Other cough					
COMPARISON: 8/1/2023						
TECHNIQUE: Single vie	ew chest in semi	uprigh	t AP projection			
FINDINGS: Cardiac siz	ze appears norma	1. Тhe	trachea is not abno	ormally dev	iated.	
No focal airspace opa effusion/pneumothora						
	Seem Sore ers	Juci a	and sony cuye appear			
IMPRESSION: No acute cardiopulmor	nary process					
	iai y process					
Procedure Note						
Naveen Malay - 08/21/2	2023					

Procedure Note

Formatting of this note might be different from the original. CLINICAL INDICATION: Other cough

COMPARISON: 8/1/2023

TECHNIQUE: Single view chest in semiupright AP projection

FINDINGS: Cardiac size appears normal. The trachea is not abnormally deviated. No focal airspace opacities identified bilateral lungs. No pleural effusion/pneumothorax seen. Soft tissues and bony cage appear normal.

IMPRESSION:

No acute cardiopulmonary process

Authorizing Provider	Result Type
Danielle S	WBH IMG GENERAL ORDERABLES

(ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/21/2023 12:01 PM EDT)

· · ·	-	Ref		Analysis	-	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	179 (H)	60 - 139 mg/dL		08/21/2023 12:08 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Jones, Yazmyn NA			08/21/2023 12:08 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur				3 12:01 PM	08/21/2023 12:08 PM EDT
Narrative BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/ : 60-139 mg,	d∟	A #: 23D0363256) -	08/21/2023	12:08 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB PUC TI	EST DUCKE		J RESULIS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	
GLUCOSE, POINT OF CA Narrative	ARE - Final resu	lt (08/21/	2023 12:00 PM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				

Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
				1. (00.(0		
(ABNORMAL) GLUCOS	E, POINT OF C	-	UCOSE, POC) - Final	• •	1/2023 5:46 /	AM EDT)
Component	Value	Ref	Test Mathad	Analysis	Darfarmand At	Dathalagist Cignatura
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose	154 (H)	60 - 139 mg/dL		08/21/2023 5:53 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Floyd, Jesse NA			08/21/2023 5:53 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/21/202	23 5:46 AM EDT	08/21/2023 5:53 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/0	d∟	A #: 23D0363256) - (08/21/2023	5:53 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	est docke	D DEVICE UNSOLICITED	RESULTS		
Performing Organization		• •	City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	Iver Ave	Farmington Hills, MI 48336	800-551-0	1488	
GLUCOSE, POINT OF CA Narrative	RE - Final resu	lt (08/21/	2023 12:00 AM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi Ref	nal result (08/20/2023	11:29 PM El Analysis	DT)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	139	60 - 139 mg/dL		08/20/2023 11:35 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Floyd, Jesse NA			08/20/2023 11:35 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

	Anatomical Location /	Collection Method /		
Specimen (Source)	Laterality	Volume	Collection Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Unknown		08/20/2023 11:29 PM EDT	08/20/2023 11:35 PM EDT
Narrative				
	e: 60-99 mg/d∟	IA #: 23D0363256) -	08/20/2023 11:35 PM EDT	
Authorizing Provider	Result Type			
William Rudy	BH LAB POC TEST DOCK	ED DEVICE UNSOLICITED	O RESULTS	
Performing Organization	Address	City/State/ZIP Code	Phone Number	
BEAUMONT	28050 Grand River Ave	Farmington Hills, MI	800-551-0488	
LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		48336		
GLUCOSE, POINT OF CA	RE (GLUCOSE, POC) - F Ref	inal result (08/20/2023	3 7:27 PM EDT) Analysis	
Component	Value Range	Test Method		Pathologist Signature
Glucose	129 60 - 139 mg/dL		08/20/2023 BEAUMONT 7:34 PM LABORATORY EDT FARMINGTON HILLS (CLIA # 23D0363256)	l
Comment: Capillary				
Performed By	Floyd, Jesse NA		08/20/2023 BEAUMONT 7:34 PM LABORATORY EDT FARMINGTON HILLS (CLIA # 23D0363256)	l
Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Unknown			08/20/2023 7:34 PM EDT
Narrative				
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/d∟	IA #: 23D0363256) -	08/20/2023 7:34 PM EDT	
Authorizing Provider	Result Type			
William Rudy	BH LAB POC TEST DOCK	ED DEVICE UNSOLICITED	D RESULTS	
Performing Organization	Address	City/State/ZIP Code	Phone Number	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0488	
GLUCOSE, POINT OF CA Narrative	ARE - Final result (08/20/	/2023 6:00 PM EDT)		
Authorizing Provider	Result Type			
Tiffany Marchewka	Result Type WBH HBS NSG POC LAB			
GLUCOSE, POINT OF CA	ARE (GLUCOSE, POC) - F	inal result (08/20/2023	3 4:17 PM EDT)	

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	120	60 - 139 mg/dL			BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary	labaaaa			00/20/2022		
Performed By	Johnson, Rachel NA			4:23 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality		Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOO SPECIMEN / U			08/20/202	23 4:17 PM EDT	08/20/2023 4:23 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	′d∟	A #: 23D0363256) -	08/20/2023	4:23 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKE	ED DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand I	River Ave	Farmington Hills, MI 48336	800-551-0	0488	
(ABNORMAL) CBC W/	AUTO DIFF -	Final resu	lt (08/20/2023 2:17	PM EDT)		
Component	Value	Ref Range	Test Method	Analysis Time	Porformed At	Pathologist Signature
WBC	9.8	3.5 - 10.1 bil/L		08/20/2023 2:59 PM EDT		
RBC	4.70	4.31 - 5.48 tril/ L		08/20/2023 2:59 PM EDT		
Hemoglobin	13.8	13.5 - 17.0 g/ dL		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hematocrit	43.7	40.1 - 50.1 %		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
MCV	93	80 - 100 fL		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
МСН	29	28 - 33 pg		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	<u> </u>
МСНС	32	32 - 36 g/dL		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RDW-CV	16 (H)	12 - 15 %		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Platelets	216	150 - 400 bil/L		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Nucleated Red Blood Cells	0.0	<=0.0 %		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Neutrophils	6.3	1.6 - 7.2 bil/L		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Lymphocytes	1.6	1.1 - 4.0 bil/L		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Monocytes	1.5 (H)	0.0 - 0.9 bil/L		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Eosinophils	0.3	0.0 - 0.4 bil/L		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.1	0.0 - 0.1 bil/L		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.03	0.00 - 0.04 bil/L		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %	0.3	%		08/20/2023 2:59 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

	Anatomical Loc	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	-	Received Time
Blood	VENOUS BLOO SPECIMEN / Ur		Venipuncture / Unknowi	n 08/20/202	3 2:17 PM EDT	08/20/2023 2:51 PM EDT
Narrative						
Authorizing Provider	Result Type					
Emily G	BH LAB BLOOD	ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	
MAGNESIUM LEVEL - Fi	nal result (08/2	0/2023 2 Ref		Analysis		
Component	Value	Range		Time	Performed At	Pathologist Signature
Magnesium	2.0	1.7 - 2.5 mg/dL		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	VENOUS BLOO SPECIMEN / Ur		Venipuncture / Unknowi	n 08/20/202	3 2:17 PM EDT	08/20/2023 2:51 PM EDT
Narrative						
Authorizine Durviden	Da sult Turs s					
Authorizing Provider	Result Type					
Emily G	BH LAB BLOOD	ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	
(ABNORMAL) COMPR	EHENSIVE ME			-	20/2023 2:17	PM EDT)
Component	Value	Ref		Analysis Time	Performed A+	Pathologist Signature
Sodium	139	Range 135 -		08/20/2023		
Sodium	123	135 - 145 mmol/L		3:22 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Potassium	3.6	3.5 - 5.2 mmol/L		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	104	98 - 111 mmol/L		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Carbon Dioxide -CO2	25	20 - 29 mmol/L		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	10	5 - 17		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose	135 (H)	60 - 99 mg/dL		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Fasting Blood Glucos Random Blood Glucose						
Blood Urea Nitrogen -BUN	13	7 - 25 mg/dL		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.60	0.60 - 1.30 mg/ dL		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	109	>60 mL/ min/ 1.73m2		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Calculation based on without adjustment f gender using the CKD	or race. Glom	erular F				
G3a: Mildly to m G3b: Moderately G4: Severely de	eased GFR: 60 oderately dec	reased G lecreased				
Calcium	8.3 (L)	8.5 - 10.5 mg/dL		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Protein Total	6.3	6.2 - 8.1 g/dL		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON	

			EDT	FARMINGTON HILLS (CLIA #: 23D0363256)
Albumin	2.6 (L)	3.5 - 4.9 g/dL	08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Globulin	3.7	2.2 - 3.7 g/dL		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Albumin/Globulin Ratio	0.7			08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Alkaline Phosphatase	133 (H)	33 - 120 U/L		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Aspartate Aminotransferase -AST	24	<35 U/L		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Alanine Aminotransferase -ALT	19	9 - 47 U/ L		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Bilirubin Total	0.3	0.3 - 1.2 mg/dL		08/20/2023 3:22 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknov	vn 08/20/202	23 2:17 PM EDT	08/20/2023 2:51 PM EDT
Narrative						
Authorizing Dravidor	Descult Tures					
Authorizing Provider Emily G	Result Type BH LAB BLOOD	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0		
GLUCOSE, POINT OF CA Narrative	ARE - Final resu	ılt (08/20/	2023 12:00 PM EDT)			
Authorizing Provider Tiffany Marchewka	Result Type WBH HBS NSC					
-						
(ABNORMAL) GLUCOS	E, POINT OF	CARE (GL	UCOSE, POC) - Final	result (08/2	0/2023 10:54	AM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	143 (H)	60 - 139 mg/dL		08/20/2023 11:01 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Johnson,			08/20/2023	BEAUMONT	
Tenomica by	Rachel NA			11:01 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOI	רררר	volume		23 10:54 AM	08/20/2023 11:01 AM
	SPECIMEN / U			EDT	J 10.34 AW	EDT
Narrative	FARMENCTON II		A #+ 2250262256)	00 /20 /2022	11.01 AM EDT	
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/	d∟	A #: 23D0363256) - (08/20/2023	II:UI AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKE	D DEVICE UNSOLICITED	RESULTS		
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA Narrative	RE - Final resu	ilt (08/20/2	2023 6:00 AM EDT)			
Tiffany Marchewka	WBH HBS NSG					
					_	
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fil Ref	nal result (08/20/2023	5:55 AM ED Analysis)))	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	137	60 - 139 mg/dL		08/20/2023 6:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Floyd, Jesse NA			08/20/2023 6:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	-	Received Time
Blood	WHOLE BLOOD SPECIMEN / UI	_		08/20/202	23 5:55 AM EDT	08/20/2023 6:02 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) - (08/20/2023	6:02 AM EDT	

Authorizing Provider	Result Type							
William Rudy	BH LAB POC TEST D	DOCKE	D DEVICE UNSOLICITED	RESULTS				
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River	Ave	Farmington Hills, MI 48336	800-551-0	488			
GLUCOSE, POINT OF CA Narrative	RE - Final result (0	8/20/2	2023 12:00 AM EDT)					
Authorizing Provider	Result Type							
Tiffany Marchewka	WBH HBS NSG POC	C LAB						
CULICOSE DOINT OF CA		-) F.			-			
GLUCOSE, POINT OF CA	RE (GLUCOSE, POC Ref		nal result (08/19/2023	7:42 PM ED Analysis	1)			
Component	Value Ran		Test Method	Time	Performed At	Pathologist Signature		
Glucose	123 60 - mg,	- 139 /dL		08/19/2023 7:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Comment: Capillary					,			
Performed By	Floyd, Jesse NA			08/19/2023 7:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
					,			
Specimen (Source)	Anatomical Location Laterality	n /	Collection Method / Volume	Collection	Time	Received Time		
Blood	WHOLE BLOOD SPECIMEN / Unkno	wn	Volume		_	08/19/2023 7:50 PM EDT		
Narrative								
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/d∟	(CLI	A #: 23D0363256) -	08/19/2023	7:50 PM EDT			
Authorizing Provider	Result Type							
William Rudy	BH LAB POC TEST D	DOCKE	D DEVICE UNSOLICITED	RESULTS				
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River	Ave	Farmington Hills, MI 48336	800-551-0	488			
GLUCOSE, POINT OF CA Narrative	RE - Final result (08	8/19/2	2023 6:00 PM EDT)					
	D							
Authorizing Provider	Result Type WBH HBS NSG POC							
Tiffany Marchewka		LAD						
GLUCOSE, POINT OF CA	RE (GLUCOSE, POC	C) - Fi	nal result (08/19/2023	4:54 PM ED	Τ)			

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	125	60 - 139 mg/dL		08/19/2023 5:01 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Jenkins,			08/19/2023	BEAUMONT	
,	Diamond NA			5:01 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loc Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/19/202	23 4:54 PM EDT	08/19/2023 5:01 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg/0	dL	A #: 23D0363256)	- 08/19/2023	5:01 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TI	EST DOCKI	D DEVICE UNSOLICIT	ED RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
(CEIA #. 2500505250)						
GLUCOSE, POINT OF CA	ARE (GLUCOSE,	POC) - Fi	nal result (08/19/20	23 11:34 AM E	DT)	
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose Comment: Capillary	134	60 - 139 mg/dL		08/19/2023 11:41 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Johnson,			08/19/2023	BEAUMONT	
renormed by	Rachel NA			11:41 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOE	<u>ר</u>	volume		23 11:34 AM	08/19/2023 11:41 AM
biood	SPECIMEN / Ur			EDT	-5 TT.34 AIVI	EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256)	- 08/19/2023	11:41 AM EDT	
Authorizing Provider	Result Type					
William Rudy	21	EST DOCKE	D DEVICE UNSOLICIT	ED RESULTS		

Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River A	Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA Narrative	RE - Final result (08	3/19/2	2023 6:00 AM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG POC	LAB				
GLUCOSE, POINT OF CA	RE (GLUCOSE, POC Ref	C) - Fii	nal result (08/19/2023	5:58 AM ED Analysis	T)	
Component	Value Ran	ge	Test Method	Time	Performed At	Pathologist Signature
Glucose		139		08/19/2023 6:04 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Greenbay, Alexis NA			08/19/2023 6:04 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Location	n /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	WHOLE BLOOD SPECIMEN / Unknow	wn		08/19/202	23 5:58 AM EDT	08/19/2023 6:04 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/d∟	(CLI	A #: 23D0363256) -	08/19/2023	6:04 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TEST D	OCKE	D DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River A	Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA Narrative	RE - Final result (08	3/19/2	2023 12:00 AM EDT)			
Authorizing Dravidar	Pocult Tree					
Authorizing Provider Tiffany Marchewka	Result Type WBH HBS NSG POC	ΊΔR				
GLUCOSE, POINT OF CA	RE (GLUCOSE, POC	C) - Fii	nal result (08/18/2023	8:42 PM ED	T)	

		Ref		Analysis				
Component	Value	Range	Test Method	Time		Pathologist Signature		
Glucose	139	60 - 139 mg/dL		08/18/2023 8:50 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #:			
					23D0363256)			
Performed By	Greenbay, Alexis NA			08/18/2023 8:50 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time		
Blood	WHOLE BLOOD SPECIMEN / Ur			08/18/202	3 8:42 PM EDT	08/18/2023 8:50 PM EDT		
Narrative								
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/18/2023 8:50 PM EDT Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL								
Authorizing Provider	Result Type							
William Rudy	BH LAB POC TE	EST DOCKI	ED DEVICE UNSOLICITE	O RESULTS				
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, Ml 48336	800-551-0)488			
GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 3:45 PM EDT) Ref Analysis								
Component	Value	Range	Test Method	Time		Pathologist Signature		
Glucose	126	60 - 139 mg/dL		08/18/2023 3:52 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Comment: Capillary								
Performed By	Smith, Noah NA A			08/18/2023 3:52 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
		,						
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time		
Blood	WHOLE BLOOD SPECIMEN / Ur		volume			08/18/2023 3:52 PM EDT		
Narrative BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/18/2023 3:52 PM EDT Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL								
Authorizing Provider	Result Type							
William Rudy	BH LAB POC TE	EST DOCKI	ED DEVICE UNSOLICITE	O RESULTS				
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0				

Authorizing Provider Result Type Tiffany Marchewka WBH HBS NSG POC LAB (ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 11:01 AM EDT) Component Value Ref Analysis Glucose 153 (H) 60 - 139 mg/dL 11:06 AM LABORATORY, EDT Pathologist Signature Comment: Capillary 08/18/2023 BEAUMONT Comment: Gapillary 08/18/2023 BEAUMONT, HILLS (CLLA #: 2300363256) Comment: Capillary Anatomical Location / Volume Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD 08/18/2023 11:01 AM EDT 08/18/2023 11:08 AM EDT Narative EXEMPTORY PREMINISTON HILLS (CLLA #: 2300363255) - 08/18/2023 11:08 AM EDT Performing Organization Address City/State/ZIP Code Phone Number Performing Organization Result Type Farmington Hills, MI 48336 800-551-0488 CLUCOSE, POINT OF CARE - Final result (08/18/2023 6:00 AM EDT) Inalysis Inalysis Randon Blood Glucoses: 60 - 139 mg/dL Authorizing Provider Result Type Billiam Rudy BH LAB POC TEST DOCKED DEV	GLUCOSE, POINT OF CA Narrative	ARE - Final resu	ult (08/18/	2023 12:00 PM EDT)			
Tiffany Marchewka WBH HBS NSG POC LAB (ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 11:01 AM EDT) Analysis Component Value Range Test Method Time Performed At Pathologist Signature Glucose 153 (H) 60 - 139 08/18/2023 BEALMONT Comment: Capillary Formed At Pathologist Signature 08/18/2023 BEALMONT Performed By Smith, Noah 08/18/2023 BEALMONT LABORATORY, EDT FARMINGTON Performed By Smith, Noah Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown EDT Received Time EDT Narative BeAUMONT LABORATORY, FARMINGTON HILLS (CLLA #: 2300363256) - 08/18/2023 11:01 AM BQ/18/2023 11:08 AM EDT Narative BeAUMONT LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-04							
(ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 11:01 AM EDT) Reig Analysis Component Value Range Test Method Glucose 153 (H) 60 - 139 mg/dL 1108 AM LABCRATCRY, EDT Faraminet Capillary Performed By Smith, Noah 08/18/2023 BEAUMONT HILLS (CLI & #: 2300363256) Comment: Capillary Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time 08/18/2023 BEAUMONT B0/18/2023 11:01 AM 08/18/2023 11:01 AM Blood WHOLE BLOOD 08/18/2023 11:01 AM 08/18/2023 11:08 AM EDT Specimen (Source) Laterality Volume Collection Time Received Time EAUMONT Anatomical Location / SPECIMEN / Unknown 08/18/2023 11:08 AM EDT 08/18/2023 11:08 AM EDT Narrative Easting Blood Glucose: 60-39 mg/dL EDT EDT EDT Petforming Organization Address City/State/ZIP Code Phone Number Petforming Organization Address City/State/ZIP Code Phone Number EAUMONT 28050 Grand Ri	Authorizing Provider	Result Type					
Ref Analysis Glucose 153 (H) 60 - 139 mg/dL Time Performed At Pathologist Signature Glucose 153 (H) 60 - 139 mg/dL Blocot Blocot Blocot Comment: Capillary Performed By Smith, Noah Blocot Blocot Blocot Performed By Smith, Noah Anatomical Location / Laterality Collection Method / Volume Blocot Blocot <t< td=""><td>Tiffany Marchewka</td><td>WBH HBS NSC</td><td>G POC LAB</td><td></td><td></td><td></td><td></td></t<>	Tiffany Marchewka	WBH HBS NSC	G POC LAB				
Glucose 153 (H) 60 - 139 mg/dL 08/18/2023 BEALMONT Comment: Capillary Performed By Smith, Noah 08/18/2023 BEALMONT Performed By Smith, Noah 08/18/2023 BEALMONT LABORATORY, EDT FARMINGTON, HILLS (CLLA #; 23D0363256) Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/18/2023 11:08 AM EDT 80/18/2023 Narative Feature Stood Glucose: 60-99 mg/dL 08/18/2023 11:08 AM EDT Performed Of Glucose: 60-139 mg/dL 50-99 mg/dL 60-9139 mg/dL 60/18/2023 11:08 AM EDT Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave 48336 800-551-0488 GLUCOSE, POINT OF CARE - Final result (08/18/2023 6:00 AM EDT) Authorizing Provider Result Type 100/18/2023 5:21 AM EDT) Authorizing Provider Result Type Time Performed At Pathologist Signature GLUCOSE, POINT OF CARE - Final result (08/18/2023 6:00 AM EDT) Analysis Analysis Marative			Ref	-	Analysis		
mg/dL 11:08 AM L&BORTORY, FARMINGTON, HILLS (CLIA #; 2300363256) Performed By Smith, Noah NA A 08/18/2023 BEAUMONT, LABORATORY, EDT LABORATORY, HILLS (CLIA #; 2300363256) Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOE BLOOD SPECIMEN / Unknown 08/18/2023 11:01 AM 08/18/2023 08/18/2023 Narrative Performed of Clucose: 60-39 mg/dt 2300363256) 08/18/2023 11:08 AM EDT Pasting Blood WHOE BLOOD SPECIMEN / Unknown 08/18/2023 11:08 AM EDT BOY18/2023 11:08 AM EDT Narrative Performig of Clucose: 60-39 mg/dt - 08/18/2023 11:08 AM EDT William Rudy BI LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 EAUMORT LABORATORY, EAUM TOF CARE - Final result (08/18/2023 6:00 AM EDT - Narrative Authorizing Provider Result Type - (ILLA #: 23D0363256) Clucose, POC) - Final result (08/18/2023 5:21 AM EDT) Narrative MBH HBS NSG POC LAB Time Performed At Pathologist Signature				Test Method			Pathologist Signature
Performed By Smith, Noah 08/18/2023 BEAUMONT NA A 11:08 AM LABORATORY, FARMINGTON FARMINGTON Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD 08/18/2023 11:01 AM 08/18/2023 11:08 AM EDT Performed Of Glucose: 60-139 mg/dL 60/18/2023 11:08 AM EDT EDT Pasting Flood Glucose: 60-91 mg/dL 60-139 mg/dL EDT EDT Authorizing Provider Result Type Eltype EDT EDT EDT BEAUMONT 28050 Grand River Ave City/State/ZIP Code Phone Number ED BEAUMONT LABORATORY, FARMINGTON HILLS (CLLA #: 2300363256) 28050 Grand River Ave Farmington Hills, MI 48336 800-551-0488 ED GLUCOSE, POINT OF CARE - Final result (08/18/2023 6:00 AM EDT) Intrave Intrave Intrave ED Authorizing Provider Result Type Educose, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 5:21 AM EDT) Intrave Authorizing Provider Result Type Intrave Performed At Pathologist Signature Gucose 147 (H)	Glucose	153 (H)			11:08 AM	LABORATORY, FARMINGTON HILLS (CLIA #:	
NA A 11:08 AM LABORATORY, FARMINGTON Specimen (Source) Anatomical Location / Laterality Collection Method / Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/18/2023 11:01 AM 08/18/2023 11:03 AM EDT Narrative Performing Organization 60-99 mg/dL - 08/18/2023 11:08 AM EDT Authorizing Provider Result Type - - 08/18/2023 11:08 AM EDT Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave 48336 Farmington Hills, MI 48336 800-551-0488 GLUCOSE, POINT OF CARE - Final result (08/18/2023 6:00 AM EDT) Narrative - Authorizing Provider Result Type - - GLUCOSE, POINT OF CARE - Final result (08/18/2023 6:00 AM EDT) - - Narrative - - - - Authorizing Provider Result Type - - - GLUCOSE, POINT OF CARE - Final result (08/18/2023 6:00 AM EDT) - - - Narrative - - - - - Gucose </td <td>Comment: Capillary</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Comment: Capillary						
Specimen (Source) Laterality Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/18/2023 11:01 AM EDT 08/18/2023 11:08 AM EDT Narrative BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/18/2023 11:08 AM EDT Fasting Blood Glucose: 60-99 mg/dL Authorizing Provider Result Type	Performed By				11:08 AM	LABORATORY, FARMINGTON HILLS (CLIA #:	
Specimen (Source) Laterality Volume Collection Time Received Time Blood WHOLE BLOOD SPECIMEN / Unknown 08/18/2023 11:01 AM EDT 08/18/2023 11:08 AM EDT Narrative BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/18/2023 11:08 AM EDT Fasting Blood Glucose: 60-99 mg/dL Authorizing Provider Result Type		A					
Blood WHOLE BLOOD SPECIMEN / Unknown 08/18/2023 11:01 AM 08/18/2023 11:01 AM 08/18/2023 11:08 AM Narrative BEAUMONT LABORATORY, FARMINGTON HILLS (CLTA #: 23D0363256) - 08/18/2023 11:08 AM EDT Fasting Blood Glucose: 60-99 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CARE - Final result (08/18/2023 6:00 AM EDT) Narrative Authorizing Provider Result Type Tiffany Marchewka WBH HBS NSG POC LAB (ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 5:21 AM EDT) Analysis Time Glucose 147 (H) 60 - 139 mg/dL 5:27 AM LABORATORY, EARMONT S:27 AM LABORATORY, EARMONT 5:27 AM Component Value Rafge Time Performed At Pathologist Signature 08/18/2023 BEAUMONT 5:27 AM Glucose 147 (H)	Specimen (Source)		cation /		Collection	Time	Received Time
BEAUMONT LABORATORY, FARMINGTON HILLS (CLLA #: 2300363256) - 08/18/2023 11:08 AM EDT Fasting Blood Glucose: 60-39 mg/dL Random Blood Glucose: 60-139 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, Farmington Hills, MI FARMINGTON HILLS (CLLA #: 23D0363256) GLUCOSE, POINT OF CARE - Final result (08/18/2023 6:00 AM EDT) Narrative Authorizing Provider Result Type Tiffany Marchewka WBH HBS NSG POC LAB (ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 5:21 AM EDT) Analysis Analysis Component Value Range Test Method Time Performed At Pathologist Signature Glucose 147 (H) 60 - 139 08/18/2023 BEAUMONT Si27 AM LABORATORY, EDT FARMINGTON, HULS (CLLA #: 23D0363256) 23D0363256)		WHOLE BLOO			08/18/202		08/18/2023 11:08 AM
Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave FARMINGTON HILLS 48336 (CLIA #: 23D0363256) 48336 GLUCOSE, POINT OF CARE - Final result (08/18/2023 6:00 AM EDT) Narrative Authorizing Provider Authorizing Provider Result Type Tiffany Marchewka WBH HBS NSG POC LAB (ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 5:21 AM EDT) Component Ref Range Test Method mg/dL 60/139 mg/dL Glucose 147 (H) 60 - 139 mg/dL Marchael Guarder 527 AM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) 147 (H)	Narrative						
William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, 48336 48336 FARMINGTON HILLS (CLIA #: 23D0363256) 6:00 AM EDT) Marrative Authorizing Provider Result Type Tiffany Marchewka WBH HBS NSG POC LAB (08/18/2023 5:21 AM EDT) ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 5:21 AM EDT) Ref Gucose 147 (H) 60 - 139 08/18/2023 BEAUMONT Glucose 147 (H) 60 - 139 08/18/2023 BEAUMONT Fize A malysis 5:27 AM LABORATORY, EDT HILLS (CLIA #: 23D0363256) 23D0363256) 23D0363256)	Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg/ : 60-139 mg	′d∟	A #: 23D0363256) -	08/18/2023	11:08 AM EDT	
Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, 48336 48336 FARMINGTON HILLS (CLIA #: 23D0363256) 800-551-0488 GLUCOSE, POINT OF CARE - Final result (08/18/2023 6:00 AM EDT) Narrative Authorizing Provider Result Type Tiffany Marchewka WBH HBS NSG POC LAB (ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 5:21 AM EDT) Aralysis Analysis Component Value Range Glucose 147 (H) 60 - 139 08/18/2023 BEAUMONT Glucose 147 (H) 60 - 139 08/18/2023 BEAUMONT LABORATORY, EDT FARMINGTON FARMINGTON HLLS (CLIA #: 23D0363256) 23D0363256) BEAUMONT	0	21					
BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, 48336 48336 FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CARE - Final result (08/18/2023 6:00 AM EDT) Marrative Narrative Authorizing Provider Result Type Tiffany Marchewka WBH HBS NSG POC LAB 4000000000000000000000000000000000000	william Rudy	BH LAB POC I	EST DOCK	D DEVICE UNSOLICITE	D RESULTS		
LABORATORY, 48336 FARMINGTON HILLS (CLIA #: 23D0363256) 48336 GLUCOSE, POINT OF CARE - Final result (08/18/2023 6:00 AM EDT) Narrative	Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
Narrative Authorizing Provider Result Type Tiffany Marchewka WBH HBS NSG POC LAB (ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 5:21 AM EDT) Ref Analysis Component Value Range Test Method Time Performed At Pathologist Signature Glucose 147 (H) 60 - 139 08/18/2023 BEAUMONT St.27 AM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) Zith Amage in the second in th	BEAUMONT LABORATORY, FARMINGTON HILLS		River Ave	Farmington Hills, MI	800-551-0)488	
Tiffany Marchewka WBH HBS NSG POC LAB (ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 5:21 AM EDT) Ref Analysis Component Value Range Test Method Time Performed At Pathologist Signature Glucose 147 (H) 60 - 139 mg/dL 08/18/2023 BEAUMONT FARMINGTON HILLS (CLIA #: 23D0363256) Signature		ARE - Final resu	ult (08/18/	2023 6:00 AM EDT)			
Tiffany Marchewka WBH HBS NSG POC LAB (ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 5:21 AM EDT) Ref Analysis Component Value Range Test Method Time Performed At Pathologist Signature Glucose 147 (H) 60 - 139 mg/dL 08/18/2023 BEAUMONT EDT FARMINGTON HILLS (CLIA #: 23D0363256) Farming the second se	Authorizing Provider	Result Type					
(ABNORMAL) GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/18/2023 5:21 AM EDT) Ref Analysis Component Value Range Test Method Time Performed At Pathologist Signature Glucose 147 (H) 60 - 139 mg/dL 08/18/2023 BEAUMONT Start 5:27 AM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) 23D0363256)		21	G POC LAB				
Glucose 147 (H) 60 - 139 mg/dL 08/18/2023 BEAUMONT Siz7 AM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256)			CARE (GL			8/2023 5:21 /	AM EDT)
mg/dL 5:27 AM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256)				Test Method			Pathologist Signature
	Glucose Comment: Capillary	147 (H)			5:27 AM	LABORATORY, FARMINGTON HILLS (CLIA #:	

	F	Ref		Analysis				
Component	Value F	Range 1	Fest Method	Time	Performed At	Pathologist Signature		
Performed By	Flagg, LaTora NA			08/18/2023 5:27 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
	Anatomical Loca	-	Collection Method /					
Specimen (Source)	Laterality	\	/olume	Collection	Time	Received Time		
Blood	WHOLE BLOOD SPECIMEN / Unk	known		08/18/202	3 5:21 AM EDT	08/18/2023 5:27 AM EDT		
Narrative								
Fasting Blood Glucos	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/18/2023 5:27 AM EDT Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL							
Authorizing Provider	Result Type							
William Rudy	BH LAB POC TES	ST DOCKED	DEVICE UNSOLICITE	O RESULTS				
Performing Organization	Address	(City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Riv		armington Hills, MI 18336	800-551-0	488			

(ABNORMAL) CBC W/AUTO DIFF - Final result (08/18/2023 4:03 AM EDT)

Comment	\/_l	Ref	Analysis	Deuferment At. Dethale sist Circustum
Component WBC	Value 8.8	Range Test Method 3.5 - 10.1 bil/L	Time 08/18/2023 4:26 AM EDT	Performed At Pathologist Signature BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RBC	4.49	4.31 - 5.48 tril/ L	08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hemoglobin	13.1 (L)	13.5 - 17.0 g/ dL	08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hematocrit	41.9	40.1 - 50.1 %	08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
MCV	93	80 - 100 fL	08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСН	29	28 - 33 pg	08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСНС	31 (L)	32 - 36 g/dL	08/18/2023 4:26 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

Comment		Ref		Analysis	Deufeure el At	Dath also sist Cine struct
Component RDW-CV	Value 16 (H)	Range 12 - 15	Test Method	Time 08/18/2023		Pathologist Signature
		%		4:26 AM EDT	LABORATORY, FARMINGTON	
				EDI	HILLS (CLIA #:	
Platelets	256	150 -		08/18/2023	23D0363256) BEAUMONT	
Platelets	250	400 bil/L		4:26 AM	LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	
Nucleated Red Blood Cells	0.0	<=0.0 %		08/18/2023 4:26 AM	BEAUMONT LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	
Neutrophils	5.3	1.6 - 7.2 bil/L		08/18/2023 4:26 AM	BEAUMONT LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Lymphocytes	2.0	1.1 - 4.0 bil/L		08/18/2023 4:26 AM	BEAUMONT LABORATORY,	
		DII/L		EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Monocytes	1.1 (H)	0.0 - 0.9		08/18/2023	BEAUMONT	
		bil/L		4:26 AM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Eosinophils	0.3	0.0 - 0.4		08/18/2023	BEAUMONT	
		bil/L		4:26 AM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Basophils	0.0	0.0 - 0.1		08/18/2023	BEAUMONT	
		bil/L		4:26 AM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.02	0.00 -		08/18/2023	BEAUMONT	
		0.04 bil/L		4:26 AM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #:	
Immature Granulocyte %	0.2	%		08/18/2023		
				4:26 AM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #:	
	Anatomical Lo	cation /	Collection Method /		23D0363256)	
Specimen (Source) Blood	Laterality VENOUS BLOO	חו	Volume	Collection		Received Time 08/18/2023 4:18 AM EDT
51000	SPECIMEN / U			wii 00/10/202	-5 4.05 AIVI EDI	00/ 10/2023 4.10 AW EDI
Narrative						
Authorizing Provider	Result Type	0.000-0				
Danielle S	BH LAB BLOOI) ORDERAI	BLES			

Performing Organization	Address		City/State/ZIP Code	Phone Number		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	liver Ave	Farmington Hills, MI 48336	800-551-0	488	
MAGNESIUM LEVEL - Fi	nal result (08/	18/2023 4 _{Ref}	:03 AM EDT)	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Magnesium	1.9	1.7 - 2.5 mg/dL		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknow	wn 08/18/202	3 4:03 AM EDT	08/18/2023 4:18 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOD	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	28050 Grand River Ave Farmington Hills, MI 800-551-0488 48336		488		
(ABNORMAL) RENAL	UNCTION PA		nal result (08/18/202		DT)	
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Sodium	138	135 - 145 mmol/L		08/18/2023 4:47 AM EDT		
Potassium	3.6	3.5 - 5.2 mmol/L		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Chloride	105	98 - 111 mmol/L		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Carbon Dioxide -CO2	26	20 - 29 mmol/L		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	7	5 - 17		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Fasting Blood Glucos Random Blood Glucose				08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Blood Urea Nitrogen -BUN	13	7 - 25 mg/dL		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.62	0.60 - 1.30 mg/ dL		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	108	>60 mL/ min/ 1.73m2		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
G3a: Mildly to m G3b: Moderately G4: Severely de G5: Kidney fail	or race. Glom -EPI equation >=90 eased GFR: 60 oderately dec to severely c creased GFR: ure GFR: <15	erular Fi 1: 0-89 creased GF decreased 15-29	ltration Rate is es	timated fro	m serum creat	
Calcium	8.6	8.5 - 10.5 mg/dL		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Phosphorus	3.5	2.3 - 4.4 mg/dL		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Albumin	2.6 (L)	3.5 - 4.9 g/dL		08/18/2023 4:47 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Spacimon (Source)	Anatomical Lo	ocation /	Collection Method /	Collection	Timo	Received Time
Specimen (Source) Blood	Laterality VENOUS BLOO SPECIMEN / U		Volume Venipuncture / Unknov			08/18/2023 4:18 AM EDT
Narrative						
Authorizing Provider	Result Type					

Danielle S

BH LAB BLOOD ORDERABLES

Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Riv	ver Ave	Farmington Hills, MI 48336	800-551-0488		
GLUCOSE, POINT OF CA	RF - Final result	. (08/18/	2023 12·00 AM FDT)			
Narrative		. (00, 10,	2023 12.00 / (() 201)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
(ABNORMAL) GLUCOS	E, POINT OF C	ARE (GL	UCOSE, POC) - Fina	l result (08/1	7/2023 9:32	PM EDT)
Component		Ref	Test Method	Analysis Time	Dorformed At	Pathologist Signature
Component Glucose		Range 60 - 139	lest Method	08/17/2023	BEAUMONT	Fathologist Signature
Glucosc		mg/dL		9:39 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary					2320303230)	
Performed By	Flagg, LaTora NA			08/17/2023 9:39 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
					2300303230)	
Specimen (Source)	Anatomical Loca Laterality	ation /	Collection Method / Volume	Collection		Received Time
Blood	WHOLE BLOOD SPECIMEN / Un	known		08/17/202	23 9:32 PM EDT	08/17/2023 9:39 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/d	L	[A #: 23D0363256) -	08/17/2023	9:39 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCKI	ED DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Riv	ver Ave	Farmington Hills, MI 48336	800-551-0	0488	
GLUCOSE, POINT OF CA Narrative	RE - Final result	: (08/17/	2023 6:00 PM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
(ABNORMAL) GLUCOS	E. POINT OF C	ARE (GL	UCOSE, POC) - Fina	l result (08/1	7/2023 4:18	PM EDT)

Component		Ref	Test Methed	Analysis	Daufaura ad At	Dath allo sist Cignature
Component Glucose	Value 144 (H)	Range 60 - 139	Test Method	Time 08/17/2023		Pathologist Signature
Glucose	144 (П)	mg/dL		4:25 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary					200000200)	
Performed By	Venkatesan, Kavitha NA			08/17/2023 4:25 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOI SPECIMEN / U			08/17/202	23 4:18 PM EDT	08/17/2023 4:25 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	TA #: 23D0363256) -	08/17/2023	4:25 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKI	ED DEVICE UNSOLICITED	O RESULTS		
Performing Organization			City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0)488	
(
GLUCOSE, POINT OF CA Narrative	RE - Final resu	llt (08/17/	2023 12:00 PM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	PUC LAB				
GLUCOSE, POINT OF CA	NRE (GLUCOSE,		nal result (08/17/2023		DT)	
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	127	60 - 139 mg/dL		08/17/2023 11:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Venkatesan, Kavitha NA			08/17/2023 11:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOI SPECIMEN / U	_		08/17/202 EDT	3 11:19 AM	08/17/2023 11:25 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	08/17/2023	11:25 AM EDT	

Authorizing Provider	Result Type						
William Rudy	21	DOCKE	D DEVICE UNSOLICITE	D RESULTS			
·							
Performing Organization		•	City/State/ZIP Code	Phone Nu			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Rive	er Ave	Farmington Hills, Ml 48336	800-551-0	488		
GLUCOSE, POINT OF CA Narrative	RE - Final result ((08/17/2	2023 6:00 AM EDT)				
Authorizing Provider	Result Type						
Tiffany Marchewka	WBH HBS NSG PO	DC LAB					
-							
glucose, point of ca		DC) - Fir ef		3 5:32 AM ED Analysis			
Component		ange	Test Method	Time		Pathologist Signature	
Glucose		0 - 139 ıg/dL		08/17/2023 5:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Comment: Capillary							
Performed By	Flagg, LaTora NA			08/17/2023 5:40 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
	Anatomical Locat	ion /	Collection Method /				
Specimen (Source)	Laterality	1011 /	Volume	Collection	Time	Received Time	
Blood	WHOLE BLOOD SPECIMEN / Unkr	nown		08/17/202	3 5:32 AM EDT	08/17/2023 5:40 AM EDT	
Narrative							
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	: 60-99 mg/dL		A #: 23D0363256) -	08/17/2023	5:40 AM EDT		
Authorizing Provider	Result Type						
William Rudy	21	DOCKE	D DEVICE UNSOLICITE	D RESULTS			
Performing Organization			City/State/ZIP Code	Phone Nu			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Rive	er Ave	Farmington Hills, Ml 48336	800-551-0	488		
(ABNORMAL) CBC W/AUTO DIFF - Final result (08/17/2023 3:10 AM EDT)							
Component	Re Value Ra	et ange	Test Method	Analysis Time	Performed At	Pathologist Signature	
WBC	9.7 3.	5 - 10.1 I/L	iest metriou	08/17/2023 4:11 AM EDT			

Component	Value	Ref Range	Test Method	Analysis Time	Performed At Pathologist Signature
RBC	4.44	4.31 - 5.48 tril/ L		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hemoglobin	13.0 (L)	13.5 - 17.0 g/ dL		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hematocrit	41.8	40.1 - 50.1 %		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
MCV	94	80 - 100 fL		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСН	29	28 - 33 pg		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСНС	31 (L)	32 - 36 g/dL		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RDW-CV	16 (H)	12 - 15 %		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Platelets	286	150 - 400 bil/L		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Nucleated Red Blood Cells	0.0	<=0.0 %		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Neutrophils	5.7	1.6 - 7.2 bil/L		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Lymphocytes	2.6	1.1 - 4.0 bil/L		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Monocytes	1.0 (H)	0.0 - 0.9 bil/L		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Eosinophils	0.3	0.0 - 0.4 bil/L		08/17/2023 4:11 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.0	0.0 - 0.1 bil/L		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.01	0.00 - 0.04 bil/L		08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %		%	Collection Mathematy	08/17/2023 4:11 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U					08/17/2023 4:06 AM EDT
Narrative						
Authorizing Provider	Docult Turpo					
Danielle S	Result Type BH LAB BLOOD		RI FS			
Dumene S						
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0	488	
MAGNESIUM LEVEL - Fi	nal result (08/1	17/2023 3 Ref	10 AM EDT)	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Magnesium	1.9	1.7 - 2.5 mg/dL		08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknow	vn 08/17/202	3 3:10 AM EDT	08/17/2023 4:06 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOD	ORDERA	BLES			
				DhamaN	m h o r	
Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Address 28050 Grand R	liver Ave	City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu 800-551-0		

(ABNORMAL) RENAL FUNCTION PANEL - Final result (08/17/2023 3:10 AM EDT)							
Component	Value	Ref Range Test Method	Analysis Time	Performed At Pathologist Signature			
Sodium	140	135 - 145 mmol/L	08/17/2023 4:35 AM EDT				
Potassium	4.6	3.5 - 5.2 mmol/L	08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Chloride	104	98 - 111 mmol/L	08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Carbon Dioxide -CO2	28	20 - 29 mmol/L	08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Anion Gap	8	5 - 17	08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Glucose	126 (H)	60 - 99 mg/dL	08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Comment: Fasting Blood Glucos Random Blood Glucose							
Blood Urea Nitrogen -BUN	16	7 - 25 mg/dL	08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Creatinine	0.65	0.60 - 1.30 mg/ dL	08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
eGFR By Creatinine	107	>60 mL/ min/ 1.73m2	08/17/2023 4:35 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			

Comment:

Calculation based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation refit without adjustment for race. Glomerular Filtration Rate is estimated from serum creatinine, age and gender using the CKD-EPI equation:

G1: Normal GFR: >=90
G2: Mildly decreased GFR: 60-89
G3a: Mildly to moderately decreased GFR: 45-59
G3b: Moderately to severely decreased GFR: 30-44
G4: Severely decreased GFR: 15-29
G5: Kidney failure GFR: <15</pre>

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Calcium	8.4 (L)	8.5 - 10.5		08/17/2023		
		mg/dL		4:35 AM	LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	
Phosphorus	3.3	2.3 - 4.4 mg/dL		08/17/2023 4:35 AM	BEAUMONT LABORATORY,	
		mg/uL		4.55 AIVI EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Albumin	2.6 (L)	3.5 - 4.9		08/17/2023		
		g/dL		4:35 AM	LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC				-	08/17/2023 4:06 AM EDT
	SPECIMEN / U	nknown				
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOD	O ORDERAE	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT	28050 Grand R	River Ave	Farmington Hills, MI	800-551-0		
			48336			
FARMINGTON HILLS (CLIA #: 23D0363256)						
(CENT #: ESB0505E50)						
	E, POINT OF	CARE (GL	UCOSE, POC) - Final	result (08/1	7/2023 12:08	AM EDT)
(ABNORMAL) GLUCOS	-	Ref		Analysis		
(ABNORMAL) GLUCOS	Value	Ref Range	UCOSE, POC) - Final Test Method	Analysis Time	Performed At	AM EDT) Pathologist Signature
(ABNORMAL) GLUCOS	-	Ref		Analysis	Performed At	
(ABNORMAL) GLUCOS	Value	Ref Range 60 - 139		Analysis Time 08/17/2023	Performed At BEAUMONT LABORATORY, FARMINGTON	
(ABNORMAL) GLUCOS	Value	Ref Range 60 - 139		Analysis Time 08/17/2023 12:17 AM	Performed At BEAUMONT LABORATORY,	
(ABNORMAL) GLUCOS	Value 142 (H) Vedolich,	Ref Range 60 - 139		Analysis Time 08/17/2023 12:17 AM EDT 08/17/2023	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT	
(ABNORMAL) GLUCOS Component Glucose	Value 142 (H)	Ref Range 60 - 139		Analysis Time 08/17/2023 12:17 AM EDT 08/17/2023 12:17 AM	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY,	
(ABNORMAL) GLUCOS Component Glucose	Value 142 (H) Vedolich,	Ref Range 60 - 139		Analysis Time 08/17/2023 12:17 AM EDT 08/17/2023	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	
(ABNORMAL) GLUCOS Component Glucose	Value 142 (H) Vedolich,	Ref Range 60 - 139		Analysis Time 08/17/2023 12:17 AM EDT 08/17/2023 12:17 AM	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON	
(ABNORMAL) GLUCOS Component Glucose	Value 142 (H) Vedolich, Holly RN Anatomical Lo	Ref Range 60 - 139 mg/dL	Test Method	Analysis Time 08/17/2023 12:17 AM EDT 08/17/2023 12:17 AM EDT	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Pathologist Signature
(ABNORMAL) GLUCOS Component Glucose Performed By Specimen (Source)	Value 142 (H) Vedolich, Holly RN Anatomical Lo Laterality	Ref Range 60 - 139 mg/dL	Test Method	Analysis Time 08/17/2023 12:17 AM EDT 08/17/2023 12:17 AM EDT Collection	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Time	Pathologist Signature
(ABNORMAL) GLUCOS Component Glucose	Value 142 (H) Vedolich, Holly RN Anatomical Lo	Ref Range 60 - 139 mg/dL cation /	Test Method	Analysis Time 08/17/2023 12:17 AM EDT 08/17/2023 12:17 AM EDT Collection	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Pathologist Signature
(ABNORMAL) GLUCOS Component Glucose Performed By Specimen (Source) Blood	Value 142 (H) Vedolich, Holly RN Anatomical Lo Laterality WHOLE BLOOM	Ref Range 60 - 139 mg/dL cation /	Test Method	Analysis Time 08/17/2023 12:17 AM EDT 08/17/2023 12:17 AM EDT Collection 08/17/202	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Time	Pathologist Signature Received Time 08/17/2023 12:17 AM
(ABNORMAL) GLUCOS Component Glucose Performed By Specimen (Source)	Value 142 (H) Vedolich, Holly RN Anatomical Lo Laterality WHOLE BLOOI SPECIMEN / U	Ref Range 60 - 139 mg/dL cation / D nknown	Test Method	Analysis Time 08/17/2023 12:17 AM EDT 08/17/2023 12:17 AM EDT Collection 08/17/202 EDT	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Time 23 12:08 AM	Pathologist Signature Received Time 08/17/2023 12:17 AM
(ABNORMAL) GLUCOS Component Glucose Performed By Specimen (Source) Blood Narrative	Value 142 (H) Vedolich, Holly RN Anatomical Lo Laterality WHOLE BLOOI SPECIMEN / U FARMINGTON H =: 60-99 mg/	Ref Range 60 - 139 mg/dL cation / D nknown ILLS (CLI dL	Test Method	Analysis Time 08/17/2023 12:17 AM EDT 08/17/2023 12:17 AM EDT Collection 08/17/202 EDT	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Time 23 12:08 AM	Pathologist Signature Received Time 08/17/2023 12:17 AM
(ABNORMAL) GLUCOS Component Glucose Performed By Specimen (Source) Blood Narrative BEAUMONT LABORATORY, Fasting Blood Glucose	Value 142 (H) Vedolich, Holly RN Anatomical Lo Laterality WHOLE BLOOI SPECIMEN / U FARMINGTON H e: 60-99 mg/	Ref Range 60 - 139 mg/dL cation / D nknown ILLS (CLI dL	Test Method	Analysis Time 08/17/2023 12:17 AM EDT 08/17/2023 12:17 AM EDT Collection 08/17/202 EDT	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Time 23 12:08 AM	Pathologist Signature Received Time 08/17/2023 12:17 AM
(ABNORMAL) GLUCOS Component Glucose Performed By Specimen (Source) Blood Narrative BEAUMONT LABORATORY, Fasting Blood Glucose	Value 142 (H) Vedolich, Holly RN Anatomical Lo Laterality WHOLE BLOOI SPECIMEN / U FARMINGTON H a: 60-99 mg/ : 60-139 mg Result Type	Ref Range 60 - 139 mg/dL cation / D nknown ILLS (CLI dL /dL	Test Method	Analysis Time 08/17/2023 12:17 AM EDT 08/17/2023 12:17 AM EDT Collection 08/17/202 EDT 08/17/2023	Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) Time 23 12:08 AM	Pathologist Signature Received Time 08/17/2023 12:17 AM

Performing Organization	Address	City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA Narrative	RE - Final result (08/17	/2023 12:00 AM EDT)			
Authorizing Provider	Result Type				
Tiffany Marchewka	WBH HBS NSG POC LAB	5			
GLUCOSE, POINT OF CA	RE (GLUCOSE, POC) - F	inal result (08/16/2023	8 8:47 PM ED	T)	
Component	Ref	Ta at Matha d	Analysis	Deuteurseed At	Dath als sist Cisuature
Component Glucose	Value Range 117 60 - 139	Test Method	Time 08/16/2023	BEAUMONT	Pathologist Signature
Glucose	mg/dL		8:54 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary					
Performed By	Flagg, LaTora NA		08/16/2023 8:54 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Unknown		08/16/202	23 8:47 PM EDT	08/16/2023 8:54 PM EDT
Narrative					
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/d∟	IA #: 23D0363256) -	08/16/2023	8:54 PM EDT	
Authorizing Provider	Result Type				
William Rudy	BH LAB POC TEST DOCK	ED DEVICE UNSOLICITED	O RESULTS		
Performing Organization	Address	City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA Narrative	RE - Final result (08/16	/2023 6:00 PM EDT)			
Authorizing Provider	Result Type				
Tiffany Marchewka	WBH HBS NSG POC LAB	}			
, - <u>-</u>					
(ABNORMAL) GLUCOS	SE, POINT OF CARE (G	LUCOSE, POC) - Final	result (08/1	6/2023 3:57	PM EDT)

	N/ 1	Ref	T (M (I)	Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose	153 (H)	60 - 139 mg/dL		08/16/2023 4:04 PM	BEAUMONT LABORATORY,	
		mg/uL		EDT	FARMINGTON	
				LDT	HILLS (CLIA #:	
					23D0363256)	
Comment: Capillary						
Performed By	Smith, Noah				BEAUMONT	
	NA A			4:04 PM	LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	
	Anatomical Lo	cation /	Collection Method /		,	
Specimen (Source)	Laterality	,	Volume	Collection	Time	Received Time
Blood	WHOLE BLOO	D		08/16/202	3 3:57 PM EDT	08/16/2023 4:04 PM EDT
	SPECIMEN / U	Inknown				
NI I						
Narrative BEAUMONT LABORATORY,			- (۵.2563DAD	08/16/2023		
Fasting Blood Glucos	e: 60-99 mg/	′d∟	.A #. 2500505250) -	00/10/2023	4.04 PM LD1	
Random Blood Glucose	: 60-139 mg	g∕d∟				
Authorizing Provider	Result Type					
Authorizing Provider William Rudy	21					
william Rudy	BIT LAB FOC I	L31 DOCK		DIRESOLIS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT	28050 Grand	River Ave	Farmington Hills, MI	800-551-0	488	
LABORATORY,			48336			
FARMINGTON HILLS						
(CLIA #: 23D0363256)						
(ABNORMAL) GLUCO	SE, POINT OF	CARE (GL	UCOSE, POC) - Final	result (08/1	6/2023 12:22	PM EDT)
		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose	153 (H)	60 - 139		08/16/2023		
		mg/dL		12:29 PM	LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	
Comment: Capillary						
Performed By	Khoshaba,			08/16/2023	BEAUMONT	
,	Rawaa NA			12:29 PM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #:	
					23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
					Time	Received Time
Specimen (Source)	Laterality		Volume	Collection	lime	Received Time
Specimen (Source) Blood	WHOLE BLOO		Volume	08/16/202	11me 23 12:22 PM	08/16/2023 12:29 PM
	,		Volume			
Blood	WHOLE BLOO		Volume	08/16/202		08/16/2023 12:29 PM
Blood	WHOLE BLOO SPECIMEN / U	Inknown		08/16/202 EDT	23 12:22 PM	08/16/2023 12:29 PM
Blood Narrative BEAUMONT LABORATORY, Fasting Blood Glucos	WHOLE BLOO SPECIMEN / U FARMINGTON F e: 60-99 mg/	Inknown HILLS (CLI ÍdL		08/16/202 EDT	23 12:22 PM	08/16/2023 12:29 PM
Blood Narrative BEAUMONT LABORATORY,	WHOLE BLOO SPECIMEN / U FARMINGTON F e: 60-99 mg/	Inknown HILLS (CLI ÍdL		08/16/202 EDT	23 12:22 PM	08/16/2023 12:29 PM
Blood Narrative BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	WHOLE BLOO SPECIMEN / U FARMINGTON H e: 60-99 mg/ : 60-139 mg	Inknown HILLS (CLI ÍdL		08/16/202 EDT	23 12:22 PM	08/16/2023 12:29 PM
Blood Narrative BEAUMONT LABORATORY, Fasting Blood Glucos	WHOLE BLOO SPECIMEN / U FARMINGTON H e: 60-99 mg/ : 60-139 mg Result Type	Inknown IILLS (CLI (dL g/dL		08/16/202 EDT 08/16/2023	23 12:22 PM	08/16/2023 12:29 PM

Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Ri	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA Narrative	ARE - Final resul	lt (08/16/	2023 12:00 PM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
GLUCOSE, POINT OF CA Narrative	ARE - Final resul	lt (08/16/	2023 6:00 AM EDT)			
Authorizing Provider Tiffany Marchewka	Result Type WBH HBS NSG					
		PUC LAB				
GLUCOSE, POINT OF CA	ARE (GLUCOSE,	POC) - Fi Ref	nal result (08/16/2023	5:52 AM ED Analysis	T)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	122	60 - 139 mg/dL		08/16/2023 6:00 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary	Darbar			00/16/2022		
Performed By	Barber, Annette NA TN			6:00 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loc	ation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/16/202	23 5:52 AM EDT	08/16/2023 6:00 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg/c	1L	IA #: 23D0363256) -	08/16/2023	6:00 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCK	ED DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) CBC W/	AUTO DIFF - F	inal resu	lt (08/16/2023 3:13 /	AM EDT)		

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
WBC	9.7	3.5 - 10.1 bil/L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RBC	4.36	4.31 - 5.48 tril/ L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	13.0 (L)	13.5 - 17.0 g/ dL		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hematocrit	40.8	40.1 - 50.1 %		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
MCV	94	80 - 100 fL		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСН	30	28 - 33 pg		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСНС	32	32 - 36 g/dL		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RDW-CV	16 (H)	12 - 15 %		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Platelets	284	150 - 400 bil/L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Nucleated Red Blood Cells	0.0	<=0.0 %		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Neutrophils	5.9	1.6 - 7.2 bil/L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Lymphocytes	2.4	1.1 - 4.0 bil/L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Monocytes	1.0 (H)	0.0 - 0.9 bil/L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	
Eosinophils	0.4	0.0 - 0.4 bil/L		08/16/2023 3:44 AM EDT	23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.0	0.0 - 0.1 bil/L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.03	0.00 - 0.04 bil/L		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %	0.3	%		08/16/2023 3:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /	C all a ati a a	T :	Dessional Times
Specimen (Source) Blood	Laterality VENOUS BLOC SPECIMEN / U		Volume Venipuncture / Unknow	Collection vn 08/16/202		Received Time 08/16/2023 3:33 AM EDT
Narrative						
Authorizing Provider	Result Type					
Danielle S	BH LAB BLOOD	ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mher	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0		
MAGNESIUM LEVEL - Fi	nal result (08/1	16/2023 3 Ref	:13 AM EDT)	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Magnesium	2.0	1.7 - 2.5 mg/dL		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknow	vn 08/16/202	23 3:13 AM EDT	08/16/2023 3:33 AM EDT
Narrative						
Authorizing Provider	Result Type					
Authorizing Provider Danielle S	Result Type BH LAB BLOOD) ORDERAI	BLES			

Performing Organization Address	City/State/ZIP Code	Phone Number
BEAUMONT 28050 Grand River Av LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	ve Farmington Hills, MI 48336	800-551-0488

(ABNORMAL) RENAL FUNCTION PANEL - Final result (08/16/2023 3:13 AM EDT)

(· · · · · · · · · · · · · · · · · · ·		Ref		Analysis	
Component	Value	Range	Test Method	Time	Performed At Pathologist Signature
Sodium	138	135 - 145 mmol/L		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Potassium	3.7	3.5 - 5.2 mmol/L		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Chloride	106	98 - 111 mmol/L		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Carbon Dioxide -CO2	25	20 - 29 mmol/L		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Anion Gap	7	5 - 17		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Glucose	123 (H)	60 - 99 mg/dL		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Comment: Fasting Blood Glucos Random Blood Glucose	- · ·				
Blood Urea Nitrogen -BUN	17	7 - 25 mg/dL		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Creatinine	0.61	0.60 - 1.30 mg/ dL		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
eGFR By Creatinine	109	>60 mL/ min/ 1.73m2		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Comment: Calculation based on without adjustment fo gender using the CKD	or race. Glom	nerular F				
G3a: Mildly to m G3b: Moderately G4: Severely de	eased GFR: 60 oderately dec	reased GI lecreased				
Calcium	8.3 (L)	8.5 - 10.5 mg/dL		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Phosphorus	3.3	2.3 - 4.4 mg/dL		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Albumin	2.5 (L)	3.5 - 4.9 g/dL		08/16/2023 4:29 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOO SPECIMEN / U	-				08/16/2023 3:33 AM EDT
Narrative						
Authorizing Provider Danielle S	Result Type BH LAB BLOO					
Danielle 5			DELS			
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	
(ABNORMAL) GLUCOS	E, POINT OF		UCOSE, POC) - Final	-	6/2023 12:05	AM EDT)
Component	Value	Ref Range	Test Method	Analysis Time	Performed A+	Pathologist Signature
Glucose	164 (H)	60 - 139		08/16/2023		
Comment: Capillary		mg/dL		12:12 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Barber,			08/16/2023	BEAUMONT	
,	Annette NA			12:12 AM	LABORATORY,	
	TN			EDT	FARMINGTON HILLS (CLIA #: 23D0363256)	
I						

	Anatomical Location /	Collection Method /			
Specimen (Source)	Laterality	Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Unknown		08/16/202 EDT	3 12:05 AM	08/16/2023 12:12 AM EDT
Narrative					
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/d∟	CLIA #: 23D0363256) -	08/16/2023	12:12 AM EDT	
Authorizing Provider	Result Type				
William Rudy	BH LAB POC TEST DOC	CKED DEVICE UNSOLICITE	D RESULTS		
Performing Organization		City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0	488	
GLUCOSE, POINT OF CA Narrative	RE - Final result (08/1	6/2023 12:00 AM EDT)			
Authorizing Provider	Result Type				
Tiffany Marchewka	WBH HBS NSG POC LA	AВ			
GLUCOSE, POINT OF CA	Ref		Analysis		Dathala sist Cispatura
Component	Value Range	Test Method	Time		Pathologist Signature
Glucose Comment: Capillary	127 60 - 13 mg/dL	9	4:35 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Poole, Alana		08/15/2023	BEAUMONT	
Tenomica by	NA		4:35 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Unknown				08/15/2023 4:35 PM EDT
Narrative			AA /4 = /2		
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/d∟	LIA #: 23D0363256) -	U8/15/2023 /	4:35 PM EDT	
Authorizing Provider	Result Type				
William Rudy		CKED DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address	City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-0	488	

GLUCOSE, POINT OF CARE - Final result (08/15/2023 12:00 PM EDT)

Narrative						
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG					
(ABNORMAL) GLUCOS	E, POINT OF (CARE (GL Ref	UCOSE, POC) - Final	result (08/1 Analysis	5/2023 11:39	AM EDT)
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	180 (H)	60 - 139 mg/dL		08/15/2023 11:48 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Poole, Alana NA			08/15/2023 11:48 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anotomical Lo	cation /	Collection Mathed (
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur				3 11:39 AM	08/15/2023 11:48 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/0	d∟	A #: 23D0363256) -	08/15/2023	11:48 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	EST DOCKE	D DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	
GLUCOSE, POINT OF CA Narrative	RE - Final resu	lt (08/15/	2023 6:00 AM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
GLUCOSE, POINT OF CA	ARE (GLUCOSE,	POC) - Fi Ref	nal result (08/15/202	3 5:27 AM ED Analysis	T)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	102	60 - 139 mg/dL		08/15/2023 5:34 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary				00/15/0000		
Performed By	TYYNISMAA, Monique RN			08/15/2023 5:34 AM	BEAUMONT LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #: 23D0363256)	

(Course)	Anatomical Location /	Collection Method /		Descined Time
Specimen (Source)	Laterality	Volume	Collection Time	Received Time
Blood	WHOLE BLOOD		08/15/2023 5:27 AM EDT	08/15/2023 5:34 AM EDT
	SPECIMEN / Unknown			
Narrative				
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg/d∟	IA #: 23D0363256) - (08/15/2023 5:34 AM EDT	
Authorizing Provider	Result Type			
William Rudy	BH LAB POC TEST DOCK	ED DEVICE UNSOLICITED	RESULTS	
Performing Organization	Address	City/State/ZIP Code	Phone Number	
BEAUMONT	28050 Grand River Ave	Farmington Hills, MI	800-551-0488	
LABORATORY,		48336		
FARMINGTON HILLS				
(CLIA #: 23D0363256)				

(ABNORMAL) CBC W/AUTO DIFF - Final result (08/15/2023 4:21 AM EDT)

(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Ref	11 (00/15/2025 4.217	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
WBC	9.6	3.5 - 10.1 bil/L		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RBC	4.47	4.31 - 5.48 tril/ L		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	13.2 (L)	13.5 - 17.0 g/ dL		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hematocrit	41.4	40.1 - 50.1 %		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
MCV	93	80 - 100 fL		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСН	30	28 - 33 pg		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСНС	32	32 - 36 g/dL		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RDW-CV	17 (H)	12 - 15 %		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Platelets	316	150 - 400 bil/L		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Nucleated Red Blood Cells	0.0	<=0.0 %		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Neutrophils	5.4	1.6 - 7.2 bil/L		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Lymphocytes	2.7	1.1 - 4.0 bil/L		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Monocytes	1.0 (H)	0.0 - 0.9 bil/L		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Eosinophils	0.4	0.0 - 0.4 bil/L		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.0	0.0 - 0.1 bil/L		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.03	0.00 - 0.04 bil/L		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %		%		08/15/2023 4:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U					08/15/2023 4:33 AM EDT
Narrative						
Authorizing Provider	Result Type					
Fawaz Habba	BH LAB BLOOD	O ORDERAE	BLES			
Performing Organization	Addross		City/State/71D Cada	Phone Nu	mbor	
BEAUMONT	28050 Grand R	iver Ave	City/State/ZIP Code Farmington Hills, MI	800-551-0		
LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			48336			

(ABNORMAL) RENAL	FUNCTION PA	ANEL - Fir	nal result (08/15/202	3 4:21 AM E	DT)
		Ref		Analysis	
<u>Component</u> Sodium	Value 141	Range 135 - 145 mmol/L	Test Method	Time 08/15/2023 5:02 AM EDT	Performed At Pathologist Signature BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Potassium	3.7	3.5 - 5.2 mmol/L		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Chloride	108	98 - 111 mmol/L		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Carbon Dioxide -CO2	26	20 - 29 mmol/L		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Anion Gap	7	5 - 17		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Glucose Comment: Fasting Blood Glucos Random Blood Glucose				08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Blood Urea Nitrogen -BUN	13	7 - 25 mg/dL		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Creatinine	0.56 (L)	0.60 - 1.30 mg/ dL		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
eGFR By Creatinine	111	>60 mL/ min/ 1.73m2		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

Comment:

Calculation based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation refit without adjustment for race. Glomerular Filtration Rate is estimated from serum creatinine, age and gender using the CKD-EPI equation:

G1: Normal GFR: >=90
G2: Mildly decreased GFR: 60-89
G3a: Mildly to moderately decreased GFR: 45-59
G3b: Moderately to severely decreased GFR: 30-44
G4: Severely decreased GFR: 15-29
G5: Kidney failure GFR: <15</pre>

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Calcium	8.5	8.5 - 10.5 mg/dL		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Phosphorus	3.7	2.3 - 4.4 mg/dL		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Albumin	2.6 (L)	3.5 - 4.9 g/dL		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U		Venipuncture / Unknov	vn 08/15/202	3 4:21 AM EDT	08/15/2023 4:33 AM EDT
Narrative						
Authorizing Provider	Result Type					
Fawaz Habba	BH LAB BLOOD	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mher	
BEAUMONT	28050 Grand R	liver Ave	Farmington Hills, MI	800-551-0		
LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			48336			
MAGNESIUM LEVEL - Fi	nal result (08/	15/2023 4:	21 AM EDT)			
		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Magnesium	2.0	1.7 - 2.5 mg/dL		08/15/2023 5:02 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Seuree)	Anatomical Lo	cation /	Collection Method / Volume	Collection	Time	Received Time
Specimen (Source) Blood	Laterality VENOUS BLOC	D				08/15/2023 4:33 AM EDT
	SPECIMEN / U					
Narrative						
Natione						
Authorizing Dravidor	Descult Tures					
Authorizing Provider Fawaz Habba	Result Type BH LAB BLOOI	O ORDFRAF	BLES			
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	aver ave	Farmington Hills, MI 48336	800-551-0	400	

GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/14/2023 11:45 PM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose	118	60 - 139 mg/dL		08/14/2023 11:51 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary				00/14/2022		
Performed By	TYYNISMAA, Monique RN		Collection Mathematic	08/14/2023 11:51 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOO SPECIMEN / U			08/14/202 EDT	23 11:45 PM	08/14/2023 11:51 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	08/14/2023	11:51 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKI	D DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, Ml 48336	800-551-0)488	
(ABNORMAL) GLUCOS	E, POINT OF		UCOSE, POC) - Final		4/2023 6:36	PM EDT)
Component	Value	Ref Range	Test Method	Analysis Time	Porformed At	Pathologist Signature
Glucose	141 (H)	60 - 139	lest Method	08/14/2023		
Comment: Capillary		mg/dL		6:45 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Galloway,			08/14/2023	BEAUMONT	
	Jennifer RN			6:45 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOO	D				08/14/2023 6:45 PM EDT
	SPECIMEN / U					
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	′d∟	A #: 23D0363256) -	08/14/2023	6:45 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCK	ED DEVICE UNSOLICITE	D RESULTS		

Performing Organization	Address	City/State/ZIP Code	Phone Nu	mber	
BEAUMONT	28050 Grand River Ave	Farmington Hills, MI	800-551-0	488	
LABORATORY,		48336			
FARMINGTON HILLS (CLIA #: 23D0363256)					
(CLIA #. 23D0303230)					
GLUCOSE, POINT OF CA	RE - Final result (08/14	/2023 6:00 PM EDT)			
Narrative					
Authorizing Provider	Decult Type				
Authorizing Provider Tiffany Marchewka	Result Type WBH HBS NSG POC LA	2			
	WDITTIDS NSG FOC LAI)			
GLUCOSE, POINT OF CA	RE - Final result (08/14	/2023 12:00 PM EDT)			
Narrative					
Authorizing Provider	Pocult Turce				
	Result Type WBH HBS NSG POC LA	2			
Tiffany Marchewka		ί			
GLUCOSE, POINT OF CA	RE (GLUCOSE, POC) - I	Final result (08/14/2023	3 12:00 PM E	DT)	
	Ref		Analysis		
Component	Value Range	Test Method	Time		Pathologist Signature
Glucose	135 60 - 139			BEAUMONT	
	mg/dL		12:07 PM EDT	LABORATORY, FARMINGTON	
			LUT	HILLS (CLIA #:	
				23D0363256)	
Comment: Capillary					
Performed By	Poole, Alana			BEAUMONT	
	NA		12:07 PM	LABORATORY,	
			EDT	FARMINGTON HILLS (CLIA #:	
				23D0363256)	
	Anatomical Location /	Collection Method /		- .	D . IT.
Specimen (Source)	Laterality	Volume	Collection		Received Time
Blood	WHOLE BLOOD SPECIMEN / Unknown		08/14/202 EDT	3 12:00 PM	08/14/2023 12:07 PM EDT
	Si Echinery Officiowi		LDT		
Narrative					
BEAUMONT LABORATORY,		IA #: 23D0363256) -	08/14/2023	12:07 PM EDT	
Fasting Blood Glucos Random Blood Glucose					
Authorizing Provider	Result Type				
William Rudy	BH LAB POC TEST DOCH	KED DEVICE UNSOLICITED	O RESULTS		
Porforming Organization	Addross	City/State/7ID Code	Phone Nu	mbor	
Performing Organization BEAUMONT	28050 Grand River Ave	City/State/ZIP Code Farmington Hills, MI	800-551-0		
LABORATORY,		48336	000-001-0	UU	
FARMINGTON HILLS					
(CLIA #: 23D0363256)					
GLUCOSE, POINT OF CA	RE - Final recult (00/14				
Narrative	14 - Thai lesuit (00/14	72023 0.00 AIVI EDI)			
Authorizing Provider	Result Type				
Tiffany Marchewka	WBH HBS NSG POC LAR	3			

(ABNORMAL) CBC W/	AUTO DIFF -	Final result (08/14/2023 2:58 Ref		
Component	Value	Range Test Method	Analysis Time	Performed At Pathologist Signature
WBC	10.6 (H)	3.5 - 10.1 bil/L	08/14/2023 4:14 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RBC	4.51	4.31 - 5.48 tril/ L	08/14/2023 4:14 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hemoglobin	13.2 (L)	13.5 - 17.0 g/ dL	08/14/2023 4:14 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hematocrit	42.0	40.1 - 50.1 %	08/14/2023 4:14 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
MCV	93	80 - 100 fL	08/14/2023 4:14 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСН	29	28 - 33 pg	08/14/2023 4:14 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСНС	31 (L)	32 - 36 g/dL	08/14/2023 4:14 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RDW-CV	17 (H)	12 - 15 %	08/14/2023 4:14 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Platelets	319	150 - 400 bil/L	08/14/2023 4:14 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Nucleated Red Blood Cells	0.0	<=0.0 %	08/14/2023 4:14 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Neutrophils	6.6	1.6 - 7.2 bil/L	08/14/2023 4:14 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Lymphocytes	2.4	1.1 - 4.0 bil/L	08/14/2023 4:14 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

Component	Value	Ref Range	Test Method	Analysis Time	Darformad At	Pathologist Signature
Monocytes	1.1 (H)	0.0 - 0.9		08/14/2023		
Monocytes	(,	bil/L		4:14 AM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Eosinophils	0.4	0.0 - 0.4		08/14/2023		
		bil/L		4:14 AM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Basophils	0.0	0.0 - 0.1		08/14/2023	BEAUMONT	
		bil/L		4:14 AM	LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	
Immature Granulocytes	0.05 (H)	0.00 -		08/14/2023		
		0.04 bil/L		4:14 AM EDT	LABORATORY, FARMINGTON	
					HILLS (CLIA #:	
	<u> </u>	01		00/14/00000	23D0363256)	
Immature Granulocyte %	0.5	%		08/14/2023 4:14 AM	BEAUMONT LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #:	
	Anatomical Lo	cation /	Collection Method /		23D0363256)	
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	VENOUS BLOC		Venipuncture / Unknow	wn 08/14/202	23 2:58 AM EDT	08/14/2023 4:11 AM EDT
	SPECIMEN / U	nknown				
Narrative						
	Result Type					
	Result Type BH LAB BLOOI) orderae	BLES			
Authorizing Provider	BH LAB BLOOD	D ORDERA	BLES City/State/ZIP Code	Phone Nu	mber	
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT	BH LAB BLOOD		City/State/ZIP Code Farmington Hills, MI	Phone Nu 800-551-0		
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY,	BH LAB BLOOD		City/State/ZIP Code			
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS	BH LAB BLOOD		City/State/ZIP Code Farmington Hills, MI			
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY,	BH LAB BLOOD		City/State/ZIP Code Farmington Hills, MI			
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	BH LAB BLOOD Address 28050 Grand R	River Ave	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0)488	
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS	BH LAB BLOOD Address 28050 Grand R	River Ave	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0 3 2:58 AM E)488	
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	BH LAB BLOOD Address 28050 Grand R	River Ave	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0	0488 DT)	Pathologist Signature
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) RENAL F	BH LAB BLOOD Address 28050 Grand R	River Ave NEL - Fin Ref Range 135 -	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0 3 2:58 AM E Analysis Time 08/14/2023	0488 DT) Performed At BEAUMONT	Pathologist Signature
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) RENAL F Component	BH LAB BLOOD Address 28050 Grand R EUNCTION PA Value	River Ave NEL - Fin Ref Range 135 - 145	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0 3 2:58 AM E Analysis Time 08/14/2023 4:39 AM	DT) Performed At BEAUMONT LABORATORY,	Pathologist Signature
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) RENAL F Component	BH LAB BLOOD Address 28050 Grand R EUNCTION PA Value	River Ave NEL - Fin Ref Range 135 -	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0 3 2:58 AM E Analysis Time 08/14/2023	0488 DT) Performed At BEAUMONT	Pathologist Signature
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) RENAL F Component Sodium	BH LAB BLOOD Address 28050 Grand R UNCTION PA Value 140	River Ave NEL - Fin Ref Range 135 - 145 mmol/L	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0 3 2:58 AM E Analysis Time 08/14/2023 4:39 AM EDT	D488 DT) Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Pathologist Signature
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) RENAL F Component	BH LAB BLOOD Address 28050 Grand R EUNCTION PA Value	River Ave NEL - Fin Ref Range 135 - 145 mmol/L 3.5 - 5.2	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0 3 2:58 AM E Analysis Time 08/14/2023 4:39 AM EDT 08/14/2023	DT) Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT	Pathologist Signature
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) RENAL F Component Sodium	BH LAB BLOOD Address 28050 Grand R UNCTION PA Value 140	River Ave NEL - Fin Ref Range 135 - 145 mmol/L	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0 3 2:58 AM E Analysis Time 08/14/2023 4:39 AM EDT	D488 DT) Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Pathologist Signature
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) RENAL F Component Sodium	BH LAB BLOOD Address 28050 Grand R UNCTION PA Value 140	River Ave NEL - Fin Ref Range 135 - 145 mmol/L 3.5 - 5.2	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0 3 2:58 AM E Analysis Time 08/14/2023 4:39 AM EDT 08/14/2023 4:39 AM	DT) Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	Pathologist Signature
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) RENAL F Component Sodium	BH LAB BLOOD Address 28050 Grand R UNCTION PA Value 140 3.8	River Ave NEL - Fin Ref Range 135 - 145 mmol/L 3.5 - 5.2 mmol/L	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0 3 2:58 AM E Analysis Time 08/14/2023 4:39 AM EDT 08/14/2023 4:39 AM EDT	DT) Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Pathologist Signature
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) RENAL F Component Sodium	BH LAB BLOOD Address 28050 Grand R UNCTION PA Value 140	River Ave NEL - Fin Ref Range 135 - 145 mmol/L 3.5 - 5.2 mmol/L 98 - 111	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0 3 2:58 AM E Analysis Time 08/14/2023 4:39 AM EDT 08/14/2023 4:39 AM EDT 08/14/2023 4:39 AM EDT	DT) Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT	Pathologist Signature
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) RENAL F Component Sodium	BH LAB BLOOD Address 28050 Grand R UNCTION PA Value 140 3.8	River Ave NEL - Fin Ref Range 135 - 145 mmol/L 3.5 - 5.2 mmol/L	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0 3 2:58 AM E Analysis Time 08/14/2023 4:39 AM EDT 08/14/2023 4:39 AM EDT	DT) Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Pathologist Signature
Authorizing Provider Fawaz Habba Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) (ABNORMAL) RENAL F Component Sodium	BH LAB BLOOD Address 28050 Grand R UNCTION PA Value 140 3.8	River Ave NEL - Fin Ref Range 135 - 145 mmol/L 3.5 - 5.2 mmol/L 98 - 111	City/State/ZIP Code Farmington Hills, MI 48336	800-551-0 3 2:58 AM E Analysis Time 08/14/2023 4:39 AM EDT 08/14/2023 4:39 AM EDT 08/14/2023 4:39 AM EDT	DT) Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY,	Pathologist Signature

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Carbon Dioxide -CO2	27	20 - 29 mmol/L		08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	8	5 - 17		08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose Comment: Fasting Blood Glucos Random Blood Glucose				08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Blood Urea Nitrogen	12	7 - 25		08/14/2023	BEAUMONT	
-BUN		mg/dL		4:39 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.64	0.60 - 1.30 mg/ dL		08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	107	>60 mL/ min/ 1.73m2		08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Calculation based on without adjustment f gender using the CKD	or race. Glom	nerular Fi				
G3a: Mildly to m G3b: Moderately G4: Severely de	eased GFR: 60 oderately dec	reased GF lecreased				
Calcium	8.3 (L)	8.5 - 10.5 mg/dL		08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Phosphorus	3.2	2.3 - 4.4 mg/dL		08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Albumin	2.7 (L)	3.5 - 4.9 g/dL		08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lc Laterality	ocation /	Collection Method / Volume	Collection	Time	Received Time
		~~	voluitie			

Blood VENOUS BLOOD Venipuncture / Unknown 08/14/2023 2:58 AM EDT 08/14/2023 4:11 AM EDT SPECIMEN / Unknown

Narrative						
Authorizing Provider	Result Type					
Fawaz Habba	BH LAB BLOOD	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		Farmington Hills, MI 48336	800-551-0)488	
MAGNESIUM LEVEL - Fi	nal result (08/		:58 AM EDT)			
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Magnesium	2.0	1.7 - 2.5 mg/dL		08/14/2023 4:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOC SPECIMEN / U					08/14/2023 4:11 AM EDT
Narrative						
Authorizing Provider	Result Type					
Fawaz Habba	BH LAB BLOOD	O ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0		
GLUCOSE, POINT OF CA Narrative	RE - Final resu	ılt (08/14/	2023 12:00 AM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	5 POC LAB				
(ABNORMAL) GLUCOS		Ref	-	Analysis		-
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose	141 (H)	60 - 139 mg/dL		08/13/2023 11:29 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary	Hamiou later			00/10/2022	DEALINAONIT	
Performed By	Harvey, Jaice NA			08/13/2023 11:29 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

	Anatomical Loo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur			08/13/202 EDT	23 11:21 PM	08/13/2023 11:29 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/0	d∟	IA #: 23D0363256) -	08/13/2023	11:29 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	EST DOCKI	ED DEVICE UNSOLICITE	O RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, Ml 48336	800-551-0	0488	
(ABNORMAL) GLUCOS	E, POINT OF	CARE (GL Ref	UCOSE, POC) - Final	result (08/1 Analysis	3/2023 6:00	PM EDT)
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose Comment: Capillary	159 (H)	60 - 139 mg/dL		08/13/2023 6:07 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	I
Performed By	Dunmore,			08/13/2023	BEAUMONT	
	Androni NA			6:07 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	I
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur					08/13/2023 6:07 PM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/0	d∟	IA #: 23D0363256) -	08/13/2023	6:07 PM EDT	
Authorizing Provider	Result Type					
William Rudy	· · · · · · · · · · · · · · · · · · ·	EST DOCKE	ED DEVICE UNSOLICITE	O RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave.	Farmington Hills, Ml 48336	800-551-0)488	
(ABNORMAL) GLUCOS	SE, POINT OF (CARE (GL	UCOSE, POC) - Final	result (08/1	3/2023 1:40	PM EDT)
		Ref		Analysis		

Glucose 160 (H) 60 - 139 08/13/2023 BEAUMONT	omponent	Performed At Pathologist Sig	Analysis Test Method Time	Pathologist Signature
mg/dL 1:47 PM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256)		LABORATORY, FARMINGTON HILLS (CLIA #:	1:47 PM	1

		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Performed By	Dunmore, Androni NA			08/13/2023 1:47 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOO SPECIMEN / U			08/13/202	23 1:40 PM EDT	08/13/2023 1:47 PM EDT
Narrative BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	:A #: 23D0363256) -	08/13/2023	1:47 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKI	ED DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA		Ref		Analysis		
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose	134	60 - 139 mg/dL		08/13/2023 5:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary						
Performed By	Harvey, Jaice NA			08/13/2023 5:39 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOP SPECIMEN / U					08/13/2023 5:39 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	08/13/2023	5:39 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCK	ED DEVICE UNSOLICITE	D RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-0)488	

(ABNORMAL) CBC W/AUTO DIFF - Final result (08/13/2023 3:23 AM EDT)

Component	Value	Ref Range	Test Method	Analysis Time	Performed At Pa	athologist Signature
WBC	9.8	3.5 - 10.1 bil/L		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RBC	4.26 (L)	4.31 - 5.48 tril/ L		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hemoglobin	12.6 (L)	13.5 - 17.0 g/ dL		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Hematocrit	39.7 (L)	40.1 - 50.1 %		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
MCV	93	80 - 100 fL		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСН	30	28 - 33 pg		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
МСНС	32	32 - 36 g/dL		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
RDW-CV	17 (H)	12 - 15 %		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Platelets	306	150 - 400 bil/L		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Nucleated Red Blood Cells	0.0	<=0.0 %		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Neutrophils	5.5	1.6 - 7.2 bil/L		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Lymphocytes	2.8	1.1 - 4.0 bil/L		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Monocytes	0.9	0.0 - 0.9 bil/L		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Eosinophils	0.5 (H)	0.0 - 0.4 bil/L		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Basophils	0.1	0.0 - 0.1 bil/L		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocytes	0.03	0.00 - 0.04 bil/L		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Immature Granulocyte %		%		08/13/2023 4:56 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loc Laterality	ation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOO SPECIMEN / Ur		Venipuncture / Unknow			08/13/2023 4:53 AM EDT
Narrative						
Authorizing Provider	Result Type					
Fawaz Habba	BH LAB BLOOD) ORDERAE	3LES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	488	
(ABNORMAL) RENAL F	UNCTION PA		al result (08/13/202		DT)	
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Sodium	138	135 - 145 mmol/L			BEAUMONT LABORATORY, FARMINGTON	

		mmol/L	EDT	FARMINGTON HILLS (CLIA #: 23D0363256)
Potassium	3.3 (L)	3.5 - 5.2 mmol/L	08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Chloride	104	98 - 111 mmol/L	08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Carbon Dioxide -CO2	27	20 - 29 mmol/L		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Anion Gap	7	5 - 17		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Glucose Comment: Fasting Blood Glucos Random Blood Glucose	-			08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Blood Urea Nitrogen	14	7 - 25		08/13/2023		
-BUN		mg/dL		6:49 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Creatinine	0.56 (L)	0.60 - 1.30 mg/ dL		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
eGFR By Creatinine	111	>60 mL/ min/ 1.73m2		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Calculation based on without adjustment f gender using the CKD	or race. Glom	erular Fi				•
G3a: Mildly to m G3b: Moderately G4: Severely de	eased GFR: 60 oderately dec	reased GF ecreased				
Calcium	8.0 (L)	8.5 - 10.5 mg/dL		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Phosphorus	3.0	2.3 - 4.4 mg/dL		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Albumin	2.6 (L)	3.5 - 4.9 g/dL		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo	cation /	Collection Method / Volume	Collection	Timo	Received Time
specifier (source)	Laterality		volume	Collection		

Blood VENOUS BLOOD Venipuncture / Unknown 08/13/2023 3:23 AM EDT 08/13/2023 4:52 AM EDT SPECIMEN / Unknown

Narrative						
Authorizing Provider	Result Type					
Fawaz Habba	BH LAB BLOOD	ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-C	9488	
MAGNESIUM LEVEL - Fi	nal result (08/1	3/2023 3 Ref	:23 AM EDT)	Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Magnesium	2.0	1.7 - 2.5 mg/dL		08/13/2023 6:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loc	cation /	Collection Method /			
Specimen (Source) Blood	Laterality VENOUS BLOO	חי	Volume	Collection		Received Time 08/13/2023 4:52 AM EDT
blood	SPECIMEN / Ur			WIT 00/15/202	.5 5.25 AWI LDT	00/13/2023 4.32 ANI EDI
Narrative						
Authorizing Provider	Result Type					
Fawaz Habba	BH LAB BLOOD	ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA	RE (GLUCOSE,	POC) - Fi	nal result (08/12/202	3 11:29 PM EI	DT)	
Component	Value	Ref Range	Test Method	Analysis Time	Deuteurseed At	Pathologist Signature
Component Glucose Comment: Capillary	136	60 - 139 mg/dL		08/12/2023 11:36 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Harvey, Jaice			08/12/2023	BEAUMONT	
	NA			11:36 PM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loc	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	WHOLE BLOOD SPECIMEN / Ur	-		08/12/202 EDT	23 11:29 PM	08/12/2023 11:36 PM EDT
Narrative BEAUMONT LABORATORY,	EADMINICTON		A #+ 3200263265	08/10/2022	11.26 04 507	
Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/o	d∟	LA #. 2300303230J -	00/ 12/ 2023	11.30 PM EUI	

Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	est docke	ED DEVICE UNSOLICITE	O RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0		
GLUCOSE, POINT OF CA	RE - Final resu	lt (08/12/	2023 6:00 PM EDT)			
Narrative						
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
(ABNORMAL) GLUCOS	E, POINT OF		UCOSE, POC) - Final		2/2023 4:48 I	PM EDT)
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	148 (H)	60 - 139 mg/dL		08/12/2023 4:55 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary					2500505250)	
Performed By	Jenkins, Diamond NA			08/12/2023 4:55 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
					2500505250)	
Spacimon (Source)	Anatomical Lo	cation /	Collection Method / Volume	Collection	Time	Received Time
Specimen (Source) Blood	Laterality WHOLE BLOOD)	volume		_	08/12/2023 4:55 PM EDT
	SPECIMEN / U	nknown				
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/	d∟	A #: 23D0363256) -	08/12/2023	4:55 PM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	est docke	ED DEVICE UNSOLICITE	O RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	liver Ave	Farmington Hills, MI 48336	800-551-0		
GLUCOSE, POINT OF CA Narrative	.RE - Final resu	llt (08/12/	2023 12:00 PM EDT)			
Authorizing Provider	Result Type					
Tiffany Marchewka	WBH HBS NSG	POC LAB				
(ABNORMAL) GLUCOS	E, POINT OF	CARE (GL	UCOSE, POC) - Final	result (08/1	2/2023 11:18	AM EDT)

		Ref		Analysis		
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	152 (H)	60 - 139 mg/dL		08/12/2023 11:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Jenkins,			08/12/2023	BEAUMONT	
	Diamond NA			11:25 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOO SPECIMEN / U			08/12/202 EDT	23 11:18 AM	08/12/2023 11:25 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	IA #: 23D0363256) -	- 08/12/2023	11:25 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKI	ED DEVICE UNSOLICIT	ED RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand F	River Ave	Farmington Hills, MI 48336	800-551-()488	
(02						
GLUCOSE, POINT OF CA	ARE (GLUCOSE,				DT)	
Component	Value	Ret Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	127	60 - 139	lest Method		BEAUMONT	
Comment: Capillary		mg/dL		5:53 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Harvey, Jaice			08/12/2023	BEAUMONT	
Tenomica by	NA			5:53 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Lo Laterality	cation /	Collection Method / Volume	Collection	Timo	Received Time
Blood	WHOLE BLOO		volume			08/12/2023 5:53 AM EDT
blood	SPECIMEN / U			00/12/202		00/12/2025 5.55 AW LD1
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/	d∟	A #: 23D0363256) -	- 08/12/2023	5:53 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCK	D DEVICE UNSOLICIT	ED RESULTS		

Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT	28050 Grand R	liver Ave	Farmington Hills, MI	800-551-0)488	
			48336			
FARMINGTON HILLS (CLIA #: 23D0363256)						
(ABNORMAL) GLUCOS	E, POINT OF	-	UCOSE, POC) - Final	• •	2/2023 12:03	AM EDT)
Component	Value	Ref Range	Test Method	Analysis Time	Porformed At	Pathologist Signature
Glucose	149 (H)	60 - 139	lest method		BEAUMONT	
Giucose	,,,,	mg/dL		12:10 AM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Comment: Capillary					20000022-2,	
Performed By	Harvey, Jaice			08/12/2023	BEAUMONT	
	NA			12:10 AM	LABORATORY,	
				EDT	FARMINGTON HILLS (CLIA #:	
					23D0363256)	
		. ,				
Specimen (Source)	Anatomical Loo Laterality	cation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD	5	Volume		23 12:03 AM	08/12/2023 12:10 AM
	SPECIMEN / Ur			EDT		EDT
Narrative						
BEAUMONT LABORATORY,	FARMINGTON H	ILLS (CLJ	A #: 23D0363256) -	08/12/2023	12:10 AM EDT	
Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/0	d∟		•-,, _		
	D					
Authorizing Provider	Result Type					
	21	EST DOCKE	ED DEVICE UNSOLICITEI	O RESULTS		
Authorizing Provider William Rudy Performing Organization	BH LAB POC TE		City/State/ZIP Code	Phone Nu		
Authorizing Provider William Rudy Performing Organization BEAUMONT	BH LAB POC TE		City/State/ZIP Code Farmington Hills, MI			
Authorizing Provider William Rudy Performing Organization	BH LAB POC TE		City/State/ZIP Code	Phone Nu		
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY,	BH LAB POC TE		City/State/ZIP Code Farmington Hills, MI	Phone Nu		
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS	BH LAB POC TE		City/State/ZIP Code Farmington Hills, MI	Phone Nu		
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	BH LAB POC TH Address 28050 Grand R	River Ave	City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu		
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CA	BH LAB POC TH Address 28050 Grand R	River Ave	City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu		
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	BH LAB POC TH Address 28050 Grand R	River Ave	City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu		
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CA Narrative	BH LAB POC TH Address 28050 Grand R	River Ave	City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu		
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CA Narrative Authorizing Provider	BH LAB POC TH Address 28050 Grand R ARE - Final resu Result Type	River Ave Ilt (08/12/	City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu		
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CA Narrative	BH LAB POC TH Address 28050 Grand R	River Ave Ilt (08/12/	City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu		
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CA Narrative Authorizing Provider	BH LAB POC TH Address 28050 Grand R ARE - Final resu Result Type	River Ave Ilt (08/12/	City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu		
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CA Narrative Authorizing Provider	BH LAB POC TH Address 28050 Grand R ARE - Final resu Result Type WBH HBS NSG	River Ave Ilt (08/12/ F POC LAB	City/State/ZIP Code Farmington Hills, MI 48336 2023 12:00 AM EDT)	Phone Nu 800-551-0)488	PM EDT)
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CA Narrative Authorizing Provider Tiffany Marchewka	BH LAB POC TH Address 28050 Grand R RE - Final resu Result Type WBH HBS NSG E, POINT OF (River Ave Ilt (08/12/ F POC LAB CARE (GL Ref	City/State/ZIP Code Farmington Hills, MI 48336 2023 12:00 AM EDT)	Phone Nu 800-551-0 result (08/1 Analysis)488 1/2023 6:01	
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CA Narrative Authorizing Provider Tiffany Marchewka (ABNORMAL) GLUCOS Component	BH LAB POC TH Address 28050 Grand R 28050 Grand R RE - Final resu Result Type WBH HBS NSG E, POINT OF (Value	River Ave Ilt (08/12/ F POC LAB CARE (GL Ref Range	City/State/ZIP Code Farmington Hills, MI 48336 2023 12:00 AM EDT)	Phone Nu 800-551-0 result (08/1 Analysis Time	0488 1/2023 6:01 Performed At	PM EDT) Pathologist Signature
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CA Narrative Authorizing Provider Tiffany Marchewka	BH LAB POC TH Address 28050 Grand R RE - Final resu Result Type WBH HBS NSG E, POINT OF (River Ave Ilt (08/12/ F POC LAB CARE (GL Ref	City/State/ZIP Code Farmington Hills, MI 48336 2023 12:00 AM EDT)	Phone Nu 800-551-0 result (08/1 Analysis Time)488 1/2023 6:01	
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CA Narrative Authorizing Provider Tiffany Marchewka (ABNORMAL) GLUCOS Component	BH LAB POC TH Address 28050 Grand R 28050 Grand R RE - Final resu Result Type WBH HBS NSG E, POINT OF (Value	River Ave alt (08/12/ 5 POC LAB CARE (GL Ref Range 60 - 139	City/State/ZIP Code Farmington Hills, MI 48336 2023 12:00 AM EDT)	Phone Nu 800-551-0 result (08/1 Analysis Time 08/11/2023	0488 1/2023 6:01 Performed At BEAUMONT LABORATORY, FARMINGTON	Pathologist Signature
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CA Narrative Authorizing Provider Tiffany Marchewka (ABNORMAL) GLUCOS Component	BH LAB POC TH Address 28050 Grand R 28050 Grand R RE - Final resu Result Type WBH HBS NSG E, POINT OF (Value	River Ave alt (08/12/ 5 POC LAB CARE (GL Ref Range 60 - 139	City/State/ZIP Code Farmington Hills, MI 48336 2023 12:00 AM EDT)	Phone Nu 800-551-0 result (08/1 Analysis Time 08/11/2023 6:10 PM	0488 1/2023 6:01 Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	Pathologist Signature
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CA Narrative Authorizing Provider Tiffany Marchewka (ABNORMAL) GLUCOS Component Glucose	BH LAB POC TH Address 28050 Grand R 28050 Grand R RE - Final resu Result Type WBH HBS NSG E, POINT OF (Value	River Ave alt (08/12/ 5 POC LAB CARE (GL Ref Range 60 - 139	City/State/ZIP Code Farmington Hills, MI 48336 2023 12:00 AM EDT)	Phone Nu 800-551-0 result (08/1 Analysis Time 08/11/2023 6:10 PM	0488 1/2023 6:01 Performed At BEAUMONT LABORATORY, FARMINGTON	Pathologist Signature
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CA Narrative Authorizing Provider Tiffany Marchewka (ABNORMAL) GLUCOS Component	BH LAB POC TH Address 28050 Grand R 28050 Grand R RE - Final resu Result Type WBH HBS NSG E, POINT OF (Value	River Ave alt (08/12/ 5 POC LAB CARE (GL Ref Range 60 - 139	City/State/ZIP Code Farmington Hills, MI 48336 2023 12:00 AM EDT)	Phone Nu 800-551-0 result (08/1 Analysis Time 08/11/2023 6:10 PM EDT	0488 1/2023 6:01 Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	Pathologist Signature
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CA Narrative Authorizing Provider Tiffany Marchewka (ABNORMAL) GLUCOS Component Glucose Comment: Capillary	BH LAB POC TH Address 28050 Grand R 28050 Grand R ARE - Final resu Result Type WBH HBS NSG 5E, POINT OF (Value 150 (H)	River Ave alt (08/12/ 5 POC LAB CARE (GL Ref Range 60 - 139	City/State/ZIP Code Farmington Hills, MI 48336 2023 12:00 AM EDT)	Phone Nu 800-551-0 result (08/1 Analysis Time 08/11/2023 6:10 PM EDT 08/11/2023 6:10 PM	0488 1/2023 6:01 Performed At BEAUMONT HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY,	Pathologist Signature
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CA Narrative Authorizing Provider Tiffany Marchewka (ABNORMAL) GLUCOS Component Glucose Comment: Capillary	BH LAB POC TH Address 28050 Grand R 28050 Grand R RE - Final resu Result Type WBH HBS NSG SE, POINT OF (Value 150 (H)	River Ave alt (08/12/ 5 POC LAB CARE (GL Ref Range 60 - 139	City/State/ZIP Code Farmington Hills, MI 48336 2023 12:00 AM EDT)	Phone Nu 800-551-0 result (08/1 Analysis Time 08/11/2023 6:10 PM EDT 08/11/2023	0488 1/2023 6:01 Performed At BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY, FARMINGTON	Pathologist Signature
Authorizing Provider William Rudy Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CA Narrative Authorizing Provider Tiffany Marchewka (ABNORMAL) GLUCOS Component Glucose Comment: Capillary	BH LAB POC TH Address 28050 Grand R 28050 Grand R RE - Final resu Result Type WBH HBS NSG SE, POINT OF (Value 150 (H)	River Ave alt (08/12/ 5 POC LAB CARE (GL Ref Range 60 - 139	City/State/ZIP Code Farmington Hills, MI 48336 2023 12:00 AM EDT)	Phone Nu 800-551-0 result (08/1 Analysis Time 08/11/2023 6:10 PM EDT 08/11/2023 6:10 PM	0488 1/2023 6:01 Performed At BEAUMONT HILLS (CLIA #: 23D0363256) BEAUMONT LABORATORY,	Pathologist Signature

Specimen (Source)LateralityVolumeCollection TimeReceived TimeBloodWHOLE BLOOD SPECIMEN / Unknown08/11/2023 6:01 PM EDT08/11/2023 6:NarrativeBEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/11/2023 6:10 PM EDT Fasting Blood Glucose:60-99 mg/dLAuthorizing ProviderResult TypeWilliam RudyBH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTSPerforming OrganizationAddressCity/State/ZIP CodePhone NumberBEAUMONT LABORATORY, FARMINGTON HILLS28050 Grand River Ave 48336Farmington Hills, MI C(LIA #: 23D0363256)800-551-0488GLUCOSE, POINT OF CARE - Final result (08/11/2023 6:00 PM EDT) Narrative	
SPECIMEN / Unknown Narrative BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/11/2023 6:10 PM EDT Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, 48336 48336 FARMINGTON HILLS CLUCOSE, POINT OF CARE - Final result (08/11/2023 6:00 PM EDT)	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/11/2023 6:10 PM EDT Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, 48336 FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CARE - Final result (08/11/2023 6:00 PM EDT)	
Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL Authorizing Provider Result Type William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, 48336 FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CARE - Final result (08/11/2023 6:00 PM EDT)	
William Rudy BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, 48336 FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CARE - Final result (08/11/2023 6:00 PM EDT)	
Performing Organization Address City/State/ZIP Code Phone Number BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, 48336 48336 FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CARE - Final result (08/11/2023 6:00 PM EDT)	
BEAUMONT 28050 Grand River Ave Farmington Hills, MI 800-551-0488 LABORATORY, 48336 FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CARE - Final result (08/11/2023 6:00 PM EDT)	
LABORATORY, 48336 FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CARE - Final result (08/11/2023 6:00 PM EDT)	
FARMINGTON HILLS (CLIA #: 23D0363256) GLUCOSE, POINT OF CARE - Final result (08/11/2023 6:00 PM EDT)	
(CLIA #: 23D0363256) GLUCOSE, POINT OF CARE - Final result (08/11/2023 6:00 PM EDT)	
Authorizing Provider Result Type	
Tiffany Marchewka WBH HBS NSG POC LAB	
GLUCOSE, POINT OF CARE - Final result (08/11/2023 12:00 PM EDT) Narrative	
Authorizing Provider Result Type	
Tiffany Marchewka WBH HBS NSG POC LAB	
(ABNORMAL) STAPHYLOCOCCUS AUREUS/MRSA BY PCR, NARES (STAPHYLOCOCCUS AUREUS/MRSA B	BY NAA,
NARES) - Final result (08/11/2023 11:25 AM EDT)	
Ref Analysis	
Component Value Range Test Method Time Performed At Pathologist Signal Si	gnature
Staphylococcus aureus Detected (A) Not 08/12/2023 BEAUMONT Detected 1:50 PM LABORATORY, EDT ROYAL OAK (CLIA#: 23D0667009) 23D067009)	
Methicillin Resistant Detected (A) Not 08/12/2023 BEAUMONT	
Detected 1:50 PM LABORATORY,	
EDT ROYAL OAK (CLIA#: 23D0667009)	
Anatomical Location /Collection Method /Specimen (Source)LateralityVolumeCollection TimeReceived Time	5
SwabANTERIOR NARES SWAB / UnknownNon-blood Collection / Unknown08/11/2023 11:25 AM EDT08/11/2023 11 EDT	1:53 AM
Narrative	
BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009) - 08/12/2023 1:50 PM EDT Methodology: Nucleic acid amplification (FDA-approved)	
Methodology: Nucleic acid amplification (FDA-approved)	
BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D066/009) - 08/12/2023 1:50 PM EDT Methodology: Nucleic acid amplification (FDA-approved) Authorizing Provider Result Type Kristin Derderian BH LAB MICROBIOLOGY - GENERAL ORDERABLES	

Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, ROYAL OAK (CLIA#: 23D0667009)	3601 W. 13 Mil	e Rd	Royal Oak, MI 48073	800-551-0		
230007003						
(ABNORMAL) GLUCOS	SE, POINT OF (CARE (GL Ref	UCOSE, POC) - Final	result (08/1 Analysis	1/2023 11:15	AM EDT)
Component	Value	Range	Test Method	Time		Pathologist Signature
Glucose	143 (H)	60 - 139 mg/dL		08/11/2023 11:22 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary Performed By	Johnson,			00/11/2023	BEAUMONT	
Реполнеа ву	Rachel NA			08/11/2023 11:22 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	ration /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOE SPECIMEN / Ur	-		08/11/202 EDT	23 11:15 AM	08/11/2023 11:22 AM EDT
Narrative BEAUMONT LABORATORY,	FARMINGTON H		▲ #: 2300363256) -	08/11/2023	11:22 AM EDT	
Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg/0 : 60-139 mg,	dL	~ *· _J		11122 / 01	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC 11	EST DUCKI	ED DEVICE UNSOLICITEE	O RESULIS		
Performing Organization			City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0)488	
GLUCOSE, POINT OF CA	ARE (GLUCOSE,	POC) - Fi Ref	nal result (08/11/2023	3 5:37 AM ED Analysis	T)	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose Comment: Capillary	104	60 - 139 mg/dL		08/11/2023 5:44 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Performed By	Alagon, Elaine			08/11/2023	BEAUMONT	
	NA			5:44 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
	Anatomical Loo	cation /	Collection Method /	- ••		
Specimen (Source) Blood	Laterality WHOLE BLOOE SPECIMEN / Ur		Volume	Collection 08/11/202		Received Time 08/11/2023 5:44 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose	e: 60-99 mg/0	dL	A #: 23D0363256) -	08/11/2023	5:44 AM EDT	

Authorizing Provider	Result Type					
William Rudy		ST DOCKE	D DEVICE UNSOLICITED	RESULTS		
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Ri	ver Ave	Farmington Hills, MI 48336	800-551-0		
VALPROIC ACID LEVEL -	Final result (08		3 1:21 AM EDT)			
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Valproic Acid		50.0 - 100.0 ug/mL		08/11/2023 2:14 AM EDT		
Specimen (Source)	Anatomical Loc Laterality	ation /	Collection Method / Volume	Collection	Time	Received Time
Blood	VENOUS BLOO SPECIMEN / Un		Venipuncture / Unknow	n 08/11/202/	3 1:21 AM EDT	08/11/2023 1:50 AM EDT
Narrative						
Authorize Dury idea						
Authorizing Provider Igor Paris	Result Type BH LAB BLOOD	ORDERA	BLES			
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand Ri	ver Ave	Farmington Hills, MI 48336	800-551-0	488	
GLUCOSE, POINT OF CA	.RE (GLUCOSE,	POC) - Fi	nal result (08/11/2023	12:12 AM E	DT)	
Component	Value	Ref Range	Test Method	Analysis Time	Porformed At	Pathologist Signature
Glucose		60 - 139 mg/dL			BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Comment: Capillary Performed By	Alagon, Elaine NA			08/11/2023 12:19 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	
Specimen (Source)	Anatomical Loc Laterality	ation /	Collection Method / Volume	Collection	Time	Received Time
Blood	WHOLE BLOOD SPECIMEN / Un				3 12:12 AM	08/11/2023 12:19 AM EDT
Narrative						
BEAUMONT LABORATORY, Fasting Blood Glucose Random Blood Glucose:	e: 60-99 mg/d	L	:A #: 23D0363256) - (08/11/2023	12:19 AM EDT	
Authorizing Provider	Result Type					
William Rudy	BH LAB POC TE	ST DOCKE	ED DEVICE UNSOLICITED	RESULTS		

Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber	
BEAUMONT	28050 Grand R	River Ave	Farmington Hills, MI	800-551-0		
LABORATORY,			48336			
FARMINGTON HILLS						
(CLIA #: 23D0363256)						
(ABNORMAL) GLUCOS	SE, POINT OF		UCOSE, POC) - Final		0/2023 4:52 I	PM EDT)
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Glucose	162 (H)	60 - 139			BEAUMONT	
		mg/dL		4:59 PM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Comment: Capillary					2500505250)	
Performed By	Johnson, Jack			08/10/2023	BEAUMONT	
	NA			4:59 PM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #:	
					23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time
Blood	WHOLE BLOOI			08/10/202	3 4:52 PM EDT	08/10/2023 4:59 PM EDT
	SPECIMEN / U	nknown				
Narrative						
BEAUMONT LABORATORY,			IA #: 23D0363256) -	08/10/2023	4:59 PM EDT	
Fasting Blood Glucos Random Blood Glucose						
Random Brood Grucose	. 00-139 liig	/uL				
Authorizing Provider	Result Type					
William Rudy	BH LAB POC T	EST DOCKI	ED DEVICE UNSOLICITE	O RESULTS		
Performing Organization	28050 Grand R	iver Ave	City/State/ZIP Code	Phone Nu		
BEAUMONT LABORATORY,	28050 Grand P	aver Ave	Farmington Hills, MI 48336	800-551-0	488	
FARMINGTON HILLS			10000			
(CLIA #: 23D0363256)						
(ABNORMAL) GLUCOS		CARE (GI	LICOSE POC) - Final	result (08/1	0/2023 12.52	
		Ref		Analysis	0,2023 12.32	
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature
Glucose	163 (H)	60 - 139		08/10/2023	BEAUMONT	
		mg/dL		12:59 PM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
Comment: Capillary					_0_00000000)	
Performed By	Hatcher,			08/10/2023	BEAUMONT	
	Camille NA			12:59 PM	LABORATORY,	
				EDT	FARMINGTON	
					HILLS (CLIA #: 23D0363256)	
	Anatomical Lo	cation /	Collection Method /			
Specimen (Source)	Laterality		Volume	Collection		Received Time
Blood	WHOLE BLOOI	2		08/10/202	3 12:52 PM	08/10/2023 12:59 PM
	CDECINAENT / · ·			FOT		FDT
	SPECIMEN / U	nknown		EDT		EDT
Narrative	SPECIMEN / U	nknown		EDT		EDT
Narrative BEAUMONT LABORATORY,			IA #: 23D0363256) -		12:59 PM EDT	EDT

Narrative								
Fasting Blood Glucos Random Blood Glucose								
Authorizing Provider	Result Type							
William Rudy	BH LAB POC	TEST DOCK	ED DEVICE UNSOLICITE	D RESULTS				
Performing Organization			City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		Farmington Hills, MI 48336	800-551-0488				
GLUCOSE, POINT OF CA	ARE (GLUCOS	E, POC) - Fi	nal result (08/10/202	3 6:31 AM ED	DT)			
Component	Value	Ref	Test Method	Analysis Time	Derfermed At	Dath alogist Cignature		
Component Glucose	120	Range 60 - 139 mg/dL		08/10/2023 6:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #:	Pathologist Signature		
Comment: Capillary					23D0363256)			
Performed By	Heaven, Lauren NA			08/10/2023 6:37 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
	Anatomical I	ocation /	Collection Method /					
Specimen (Source)	Anatomical Location / Laterality		Volume	Collection	Time	Received Time		
Blood	WHOLE BLOOD SPECIMEN / Unknown			08/10/2023 6:31 AM EDT		08/10/2023 6:37 AM EDT		
Narrative								
BEAUMONT LABORATORY, Fasting Blood Glucos Random Blood Glucose	e: 60-99 mg	ı∕d∟	IA #: 23D0363256) -	08/10/2023	6:37 AM EDT			
Authorizing Provider	Result Type							
William Rudy		BH LAB POC TEST DOCKED DEVICE UNSOLICITED RESULTS						
Performing Organization BEAUMONT			City/State/ZIP Code Farmington Hills, MI	Phone Number 800-551-0488				
LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		48336	600-551-0466				
GLUCOSE, POINT OF CA Narrative	ARE - Final res	sult (08/10/	2023 6:00 AM EDT)					
Authorizing Duradan								
Authorizing Provider Tiffany Marchewka	Result Type WBH HBS NS							
THIATTY MAICHEWKA	כאו כסדרויסיי							
(ABNORMAL) CBC W/	AUTO DIFF -		lt (08/10/2023 3:00	-				
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature		
WBC	11.6 (H)	3.5 - 10.1 bil/L		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			

Component	Value	Ref Range	Test Method	Analysis Time	Performed At Pathologist Signature
RBC	4.43	4.31 - 5.48 tril/ L		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hemoglobin	13.0 (L)	13.5 - 17.0 g/ dL		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Hematocrit	41.5	40.1 - 50.1 %		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
MCV	94	80 - 100 fL		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСН	29	28 - 33 pg		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
МСНС	31 (L)	32 - 36 g/dL		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
RDW-CV	17 (H)	12 - 15 %		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Platelets	310	150 - 400 bil/L		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Nucleated Red Blood Cells	0.0	<=0.0 %		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Neutrophils	7.9 (H)	1.6 - 7.2 bil/L		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Lymphocytes	2.3	1.1 - 4.0 bil/L		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)
Monocytes	1.1 (H)	0.0 - 0.9 bil/L		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)

		Ref		Analysis				
Component	Value	Range	Test Method	Time	Performed At	Pathologist Signature		
Eosinophils	0.3	0.0 - 0.4 bil/L		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Basophils	0.0	0.0 - 0.1 bil/L		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Immature Granulocytes	0.04	0.00 - 0.04 bil/L		08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Immature Granulocyte %	0.3 Anatomical Loo	%	Collection Method /	08/10/2023 3:25 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time		
Blood	VENOUS BLOC SPECIMEN / Ur		Venipuncture / Unknor	wn 08/10/202	23 3:00 AM EDT	08/10/2023 3:22 AM EDT		
Narrative								
Authorizing Provider	Result Type							
Danielle S	BH LAB BLOOD	ORDERA	BLES					
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave		Farmington Hills, MI 48336	800-551-0488				
(ABNORMAL) RENAL FUNCTION PANEL - Final result (08/10/2023 3:00 AM EDT)								
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature		
Sodium	138	135 - 145 mmol/L		08/10/2023 3:49 AM EDT				
Potassium	3.8	3.5 - 5.2 mmol/L		08/10/2023 3:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Chloride	105	98 - 111 mmol/L		08/10/2023 3:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Carbon Dioxide -CO2	27	20 - 29 mmol/L		08/10/2023 3:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature	
Anion Gap	6	5 - 17		08/10/2023 3:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Glucose	130 (H)	60 - 99 mg/dL		08/10/2023 3:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Comment: Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL							
Blood Urea Nitrogen -BUN	13	7 - 25 mg/dL		08/10/2023 3:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
Creatinine	0.59 (L)	0.60 - 1.30 mg/ dL		08/10/2023 3:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		
eGFR By Creatinine	110	>60 mL/ min/ 1.73m2		08/10/2023 3:49 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)		

Comment:

Calculation based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation refit without adjustment for race. Glomerular Filtration Rate is estimated from serum creatinine, age and gender using the CKD-EPI equation:

G1: Normal GFR: >=90
G2: Mildly decreased GFR: 60-89
G3a: Mildly to moderately decreased GFR: 45-59
G3b: Moderately to severely decreased GFR: 30-44
G4: Severely decreased GFR: 15-29
G5: Kidney failure GFR: <15</pre>

Calcium 8.5 - 10.5 08/10/2023 BEAUMONT 8.1 (L) mg/dL 3:49 AM LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) Phosphorus 3.0 2.3 - 4.4 08/10/2023 BEAUMONT 3:49 AM LABORATORY, mg/dL EDT FARMINGTON HILLS (CLIA #: 23D0363256) Albumin 2.6 (L) 3.5 - 4.9 08/10/2023 BEAUMONT 3:49 AM g/dL LABORATORY, EDT FARMINGTON HILLS (CLIA #: 23D0363256) Anatomical Location / Collection Method / Specimen (Source) Laterality Volume Collection Time **Received Time** Blood **VENOUS BLOOD** Venipuncture / Unknown 08/10/2023 3:00 AM EDT 08/10/2023 3:22 AM EDT SPECIMEN / Unknown Narrative

Authorizing Provider	Result Type		Result Type					
Danielle S	BH LAB BLOOD ORDERABLES							
Performing Organization	Address		City/State/ZIP Code	Phone Nu	mber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand R	iver Ave	Farmington Hills, MI 48336	800-551-0	9488			
MAGNESIUM LEVEL - Final result (08/10/2023 3:00 AM EDT)								
Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature		
Magnesium	1.9	1.7 - 2.5 mg/dL		08/10/2023 3:49 AM EDT				
	Anatomical Loo	cation /	Collection Method /	Callection	Time	Descived Times		
Specimen (Source) Blood	Laterality VENOUS BLOC		Volume	Collection		Received Time 08/10/2023 3:22 AM EDT		
DIOOU	SPECIMEN / Ur			wii 00/10/202	.5 5.00 AIVI EDI	00/10/2023 3.22 AIVI EDI		
Narrative								
INATTALIVE								
Authorizing Provider Danielle S	Result Type BH LAB BLOOD							
Damene S	DH LAD BLOOL	ORDERA	DLES					
Performing Organization BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	Address 28050 Grand R	iver Ave	City/State/ZIP Code Farmington Hills, MI 48336	Phone Nu 800-551-0				
GLUCOSE, POINT OF CA		Ref		Analysis		Dethala sist Circustory		
Component Glucose	Value 128	Range 60 - 139	Test Method	Time	BEAUMONT	Pathologist Signature		
Glucose	120	mg/dL		12:21 AM EDT	LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
Comment: Capillary								
Performed By	Heaven, Lauren NA			08/10/2023 12:21 AM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)			
	Anatomical Loo	sation /	Collection Method /					
Specimen (Source)	Laterality		Volume	Collection	Time	Received Time		
Blood	WHOLE BLOOD SPECIMEN / Ur			08/10/202 EDT	23 12:14 AM	08/10/2023 12:21 AM EDT		
Narrative BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256) - 08/10/2023 12:21 AM EDT Fasting Blood Glucose: 60-99 mg/dL Random Blood Glucose: 60-139 mg/dL								
Authorizing Provider	Result Type							
William Rudy	BH LAB POC TE	ST DOCK	ED DEVICE UNSOLICITE	O RESULTS				

Performing Organization	Address	City/State/ZIP Code	Phone Nu	ımber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-(0488			
(CLIA #. 23D0303230)							
GLUCOSE, POINT OF CA Narrative	ARE - Final result (08/10)/2023 12:00 AM EDT)					
Authorizing Provider	Result Type						
Tiffany Marchewka	WBH HBS NSG POC LA	3					
GLUCOSE, POINT OF CARE (GLUCOSE, POC) - Final result (08/09/2023 8:51 PM EDT) Ref Analysis							
Component	Value Range	Test Method	Time	Performed At	Pathologist Signature		
Glucose	130 60 - 139 mg/dL)	08/09/2023 8:58 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	l i i i i i i i i i i i i i i i i i i i		
Comment: Capillary							
Performed By	Heaven, Lauren NA		08/09/2023 8:58 PM EDT	BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	l		
Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection	Time	Received Time		
Blood	WHOLE BLOOD SPECIMEN / Unknown		08/09/202	23 8:51 PM EDT	08/09/2023 8:58 PM EDT		
Narrative							
	e: 60-99 mg/d∟	IA #: 23D0363256) -	08/09/2023	8:58 PM EDT			
Authorizing Provider	Result Type						
William Rudy	BH LAB POC TEST DOC	KED DEVICE UNSOLICITED	RESULTS				
Performing Organization	Address	City/State/ZIP Code	Phone Nu	ımber			
BEAUMONT LABORATORY, FARMINGTON HILLS (CLIA #: 23D0363256)	28050 Grand River Ave	Farmington Hills, MI 48336	800-551-(0488			
List stopped at 200 resul	ts. Some data may be o	mitted.					
Visit Diagnoses - c Diagnosis							
Altered mental status, unspecified altered mental status type - Primary							
Altered mental status, unspecified altered mental status type							
Community acquired pneumonia, unspecified laterality							
Urinary tract infection associated with indwelling urethral catheter, initial encounter Sepsis without acute organ dysfunction, due to unspecified organism							
Other cough							
Fever, unspecified fever cause							
Sepsis without acute organ	•						
Urinary tract infection asso		rethral catheter					
Community acquired pneu	umonia						

Administered Medications - documented in this encounter						
Inactive Administered Medications - up to 3 m Medication Order	o <mark>st recent adm</mark> MAR Action	inistrations Action Date	Dose	Rate	Site	
acetaminophen (TYLENOL) solution 32 mg/mL 1,000 mg 1,000 mg, PEG Tube, ONCE, On Tue 8/1/23 at 1830, For 1 dose, Routine	Given	08/01/2023 6:29 PM EDT	1,000 mg	Kale	Site	
acetaminophen (TYLENOL) tablet 650 mg 650 mg EVERY 4 HOURS AS NEEDED, PEG Tube, FOR MODERATE PAIN, FOR MILD PAIN, Starting on Wed 8/2/23 at 0010, For 5759 hours	Given Given Given	08/28/2023 4:48 AM EDT 08/27/2023 8:18 AM EDT 08/26/2023	650 mg 650 mg 650 mg			
albumin human 25 % IVPB 25 g	Bolus From	11:39 AM EDT 08/27/2023	25 g			
25 g ONCE, Intravenous, On Sun 8/27/23 at 1900, For 1 dose, Do not refrigerate.	Bag/Syringe	6:01 PM EDT	5			
albuterol-ipratropium (DUONEB) nebulizer solution 3 mL 3 mL, Inhalation, EVERY 4 HOURS AS NEEDED, FOR SHORTNESS OF BREATH, Starting on Wed 8/23/23 at 0617, For 240 days, Routine	Given	08/23/2023 8:05 AM EDT	3 mL			
albuterol-ipratropium (DUONEB) nebulizer solution 3 mL	Given	08/29/2023 7:36 AM EDT	3 mL			
3 mL, Inhalation, RT-QID, First dose on Wed 8/23/23 at 1130, For 240 days, Routine	Given	08/28/2023 11:35 AM EDT	3 mL			
o, _o, _o at 1.00, 101 _ 10 aujo, 10 auto	Given	08/28/2023 7:55 AM EDT	3 mL			
amiodarone (CORDARONE, PACERONE) tablet 200 mg	Given	08/29/2023 9:35 AM EDT	200 mg			
200 mg, PEG Tube, DAILY, First dose (after last modification) on Wed 8/2/23 at 0900, For 240 days,	Given	08/28/2023 9:51 AM EDT	200 mg			
Routine	Given	08/27/2023 8:19 AM EDT	200 mg			
apixaban (ELIQUIS) tablet 5 mg 5 mg, Oral, EVERY 12 HOURS, First dose on Wed	Given	08/29/2023 9:35 AM EDT	5 mg			
8/2/23 at 0100, For 240 days, Routine	Given	08/28/2023 10:23 PM EDT	5 mg			
	Given	08/28/2023 9:51 AM EDT	5 mg			
atorvastatin (LIPITOR) tablet 40 mg 40 mg, PEG Tube, EVERY NIGHT AT BEDTIME, First	Given	08/28/2023 10:23 PM EDT	40 mg			
dose (after last modification) on Wed 8/2/23 at 2100, For 239 doses, Routine	Given	08/27/2023 8:56 PM EDT	40 mg			
	Given	08/26/2023 8:02 PM EDT	40 mg			
azithromycin (ZITHROMAX) 500 mg in sodium chloride 0.9 % 255 mL IVPB	New Bag	08/24/2023 4:08 AM EDT	500 mg	255 mL/hr		
500 mg, at 255 mL/hr, Administer over 60 Minutes, Intravenous, EVERY 24 HOURS, First dose on Wed 8/23/23 at 0430, For 3 days, Routine	New Bag	08/23/2023 4:21 AM EDT	500 mg	255 mL/hr		
azithromycin (ZITHROMAX) 500 mg in sodium chloride 0.9 % 255 mL IVPB	New Bag	08/27/2023 12:34 PM EDT	500 mg	255 mL/hr		
500 mg, at 255 mL/hr, Administer over 60 Minutes, Intravenous, EVERY 24 HOURS, First dose on Sat 8/26/23 at 1400, For 3 days, Routine	New Bag	08/26/2023 4:46 PM EDT	500 mg	255 mL/hr		

Medication Order	MAR Action	Action Date	Dose	Rate	Site
cefepime (MAXIPIME) 2 g in sodium chloride 0.9 %	New Bag	08/07/2023	2 g	200 mL/hr	
2 g, at 200 mL/hr, Administer over 30 Minutes,		9:14 PM EDT	-		
Intravenous, EVERY 8 HOURS, First dose on Wed	New Bag	08/07/2023 11:51 AM EDT	2 g	200 mL/hr	
8/2/23 at 0100, For 19 doses, Routine	New Bag	08/07/2023 4:24 AM EDT	2 g	200 mL/hr	
cefepime (MAXIPIME) 2 g in sodium chloride 0.9 % 100 mL IVPB	New Bag	08/24/2023 3:33 AM EDT	2 g	200 mL/hr	
2 g, at 200 mL/hr, Administer over 30 Minutes, Intravenous, EVERY 8 HOURS, First dose on Wed	New Bag	08/23/2023 8:12 PM EDT	2 g	200 mL/hr	
8/23/23 at 0430, For 7 days, Routine	New Bag	08/23/2023 1:23 PM EDT	2 g	200 mL/hr	
cefTRIAXone (ROCEPHIN) 1 g in sodium chloride 0.9 % 100 mL IVPB	New Bag	08/27/2023 2:38 PM EDT	1 g	200 mL/hr	
1 g, at 200 mL/hr, Administer over 30 Minutes, Intravenous, EVERY 24 HOURS, First dose on Sat 8/26/23 at 1400, For 5 days, Routine	New Bag	08/26/2023 4:01 PM EDT	1 g	200 mL/hr	
clonazePAM (KlonoPIN) tablet 0.5 mg 0.5 mg, Oral, EVERY NIGHT AT BEDTIME, First	Given	08/13/2023 11:04 PM EDT	0.5 mg		
dose on Sat 8/12/23 at 2100, For 240 days, Routine	Given	08/12/2023 9:41 PM EDT	0.5 mg		
clonazePAM (KlonoPIN) tablet 0.5 mg 0.5 mg, PEG Tube, DAILY, First dose on Mon	Given	08/15/2023 10:22 AM EDT	0.5 mg		
8/14/23 at 1330, For 240 days, Routine	Given	08/14/2023 1:43 PM EDT	0.5 mg		
clonazePAM (KlonoPIN) tablet 0.5 mg 0.5 mg, Oral, TWICE DAILY, First dose on Wed	Given	08/25/2023 10:54 AM EDT	0.5 mg		
8/23/23 at 1400, For 240 days, Routine	Given	08/24/2023 2:36 PM EDT	0.5 mg		
	Given	08/23/2023 1:23 PM EDT	0.5 mg		
clonazePAM (KlonoPIN) tablet 0.5 mg 0.5 mg, Oral, DAILY, First dose (after last	Given	08/28/2023 12:46 PM EDT	0.5 mg		
modification) on Sat 8/26/23 at 0900, Routine	Given	08/27/2023 9:03 AM EDT	0.5 mg		
	Given	08/26/2023 8:26 AM EDT	0.5 mg		
clonazePAM (KlonoPIN) tablet 0.5 mg 0.5 mg, Oral, TWICE DAILY, First dose (after last modification) on Tue 8/29/23 at 1400, Routine	Given	08/29/2023 1:18 PM EDT	0.5 mg		
clonazePAM (KlonoPIN) tablet 1 mg 1 mg, PEG Tube, EVERY NIGHT AT BEDTIME, First dose (after last modification) on Mon 8/14/23 at 2100, For 238 doses, Routine	Given	08/14/2023 8:46 PM EDT	1 mg		
clonazePAM (KlonoPIN) tablet 1 mg 1 mg, PEG Tube, THREE TIMES DAILY, First dose	Given	08/22/2023 10:37 PM EDT	1 mg		
(after last modification) on Tue 8/15/23 at 1300, Routine	Given	08/22/2023 1:33 PM EDT	1 mg		
	Given	08/22/2023 6:50 AM EDT	1 mg		
clonazePAM (KlonoPIN) tablet 1 mg	Given	08/28/2023 10:23 PM EDT	1 mg		

Medication Order	MAR Action	Action Date	Dose	Rate	Site
1 mg, PEG Tube, EVERY NIGHT AT BEDTIME, First dose (after last modification) on Wed 8/23/23 at	Given	08/27/2023 8:57 PM EDT	1 mg		
2100, Routine	Given	08/25/2023 10:44 PM EDT	1 mg		
clopidogrel (PLAVIX) tablet 75 mg 75 mg, Oral, DAILY, First dose on Wed 8/2/23 at	Given	08/29/2023 9:35 AM EDT	75 mg		
0900, For 240 days, Routine	Given	08/28/2023 9:51 AM EDT	75 mg		
	Given	08/27/2023 8:19 AM EDT	75 mg		
dextrose 5 % infusion at 100 mL/hr, Intravenous, CONTINUOUS, Starting on Fri 8/4/23 at 1030, For 8 hours, Routine	New Bag	08/04/2023 9:48 AM EDT		100 mL/hr	
dextrose 5 % infusion at 50 mL/hr, Intravenous, CONTINUOUS, Starting	Rate/Dose Change	08/07/2023 12:24 PM EDT		50 mL/hr	
on Sat 8/5/23 at 1300, For 240 days, Routine	New Bag	08/07/2023 11:54 AM EDT		75 mL/hr	
	New Bag	08/06/2023 11:08 PM EDT		75 mL/hr	Right Arm
gentamicin (GARAMYCIN) 0.1 % cream Topical, THREE TIMES DAILY, First dose on Wed	Given	08/28/2023 12:20 PM EDT			
8/23/23 at 2230, For 5 days, Routine	Given	08/28/2023 4:48 AM EDT			
	Given	08/27/2023 9:09 PM EDT			
hydrocortisone (HYTONE) 1 % ointment Topical, DAILY, First dose on Thu 8/24/23 at 1000,	Given	08/26/2023 8:30 AM EDT			
For 3 days, Routine	Given	08/24/2023 11:20 AM EDT			
hydrOXYzine HCl (ATARAX) syrup 2 mg/mL 10 mg 10 mg, Oral, EVERY NIGHT AT BEDTIME, First dose on Fri 8/11/23 at 2100, For 240 days, Routine	Given	08/12/2023 12:53 AM EDT	10 mg		
insulin regular human (HumuLIN R, NovoLIN R) injection HIGH ALERT 2-5 Units	Given	08/09/2023 6:36 PM EDT	2 Units		
2-5 Units, Subcutaneous, EVERY 6 HOURS, First dose on Wed 8/2/23 at 0100, For 240 days, Routine					
iopamidol (ISOVUE-370) 76 % injection 75 mL 75 mL IMG once PRN, Intravenous, FOR	Given	08/02/2023 1:22 AM EDT	75 mL		
CONTRAST, Starting on Wed 8/2/23 at 0122, For 1 dose					
lactated ringers bolus 500 mL 500 mL, at 500 mL/hr, Administer over 60 Minutes, Intravenous, ONCE, On Sat 8/26/23 at	New Bag	08/26/2023 4:49 PM EDT	500 mL	500 mL/hr	
1700, For 1 dose, Routine					
loperamide (IMODIUM) suspension 1 mg/7.5 mL 1 mg	Given	08/05/2023 9:51 PM EDT	1 mg		
1 mg, PEG Tube, ONCE, On Sat 8/5/23 at 2130, For 1 dose, Routine					
LORazepam (ATIVAN) 2 MG/ML injection Cabinet Override					
Starting on Tue 8/1/23 at 1846, For 1 dose					

Medication Order	MAR Action	Action Date	Dose	Rate	Site
LORazepam (ATIVAN) injection 1.5 mg 1.5 mg, Intravenous, ONCE, On Tue 8/1/23 at 1900, For 1 dose, Routine	Given	08/01/2023 7:03 PM EDT	1.5 mg		
LORazepam (ATIVAN) tablet 0.5 mg 0.5 mg, Oral, EVERY 6 HOURS AS NEEDED, FOR ANXIETY, Starting on Fri 8/11/23 at 1540, For 240 days, Routine	Given Given Given	08/28/2023 12:50 PM EDT 08/26/2023 3:38 AM EDT 08/23/2023 3:30 PM EDT	0.5 mg 0.5 mg 0.5 mg		
melatonin tablet 3 mg 3 mg, Oral, ONCE, On Wed 8/2/23 at 2300, For 1 dose, Routine	Given	08/02/2023 10:04 PM EDT	3 mg		
metoprolol (LOPRESSOR) tablet 25 mg 25 mg, PEG Tube, TWICE DAILY, First dose (after last modification) on Wed 8/2/23 at 0900, For 479 doses	Given Given Given	08/29/2023 9:36 AM EDT 08/28/2023 10:22 PM EDT 08/28/2023 9:51 AM EDT	25 mg 25 mg 25 mg		
metroNIDAZOLE (FLAGYL) infusion 500 mg 500 mg, at 200 mL/hr, Administer over 30 Minutes, Intravenous, EVERY 8 HOURS, First dose on Wed 8/2/23 at 0100, For 18 doses, Routine	New Bag New Bag New Bag	08/07/2023 5:55 PM EDT 08/07/2023 8:52 AM EDT 08/07/2023 12:38 AM EDT	500 mg 500 mg 500 mg	200 mL/hr 200 mL/hr 200 mL/hr	
metroNIDAZOLE (FLAGYL) infusion 500 mg 500 mg, at 200 mL/hr, Administer over 30 Minutes, Intravenous, EVERY 8 HOURS, First dose on Sat 8/26/23 at 1430, For 5 days, Routine	New Bag New Bag New Bag	08/28/2023 4:54 AM EDT 08/27/2023 9:45 PM EDT 08/27/2023 1:59 PM EDT	500 mg 500 mg 500 mg	200 mL/hr 200 mL/hr 200 mL/hr	
OLANZapine (ZyPREXA) tablet 10 mg 10 mg, Oral, TWICE DAILY, First dose on Thu 8/3/23 at 1000, For 240 days, Routine	Given Given Given	08/29/2023 9:35 AM EDT 08/28/2023 10:23 PM EDT 08/28/2023 9:51 AM EDT	10 mg 10 mg 10 mg		
piperacillin-tazobactam (ZOSYN) 4.5 g in sodium chloride 0.9 % 100 mL infusion 4.5 g, Administer over 30 Minutes, Intravenous, EVERY 6 HOURS, First dose on Tue 8/1/23 at 1730, For 1 dose, STAT	New Bag	08/01/2023 5:55 PM EDT	4.5 g		
piperacillin-tazobactam (ZOSYN) 4.5 g in sodium chloride 0.9 % 100 mL infusion 4.5 g, Administer over 240 Minutes, Intravenous, EVERY 8 HOURS, First dose on Tue 8/1/23 at 2330, For 5 days, Routine	New Bag	08/01/2023 11:36 PM EDT	4.5 g		
potassium chloride (KCL) 20 MEQ/15ML (10%) oral liquid 1.33mEq/mL 40 mEq 40 mEq, Oral, ONCE, On Thu 8/3/23 at 1000, For 1 dose, Routine	Given	08/03/2023 9:08 AM EDT	40 mEq		
potassium chloride (KCL) 20 MEQ/15ML (10%) oral liquid 1.33mEq/mL 40 mEq	Given	08/04/2023 9:46 AM EDT	40 mEq		

Medication Order	MAR Action	Action Date	Dose	Rate	Site
40 mEq, PEG Tube, ONCE, On Fri 8/4/23 at 1030, For 1 dose, Routine					
potassium chloride (KCL) 20 MEQ/15ML (10%) oral liquid 1.33mEq/mL 40 mEq	Given	08/04/2023 9:31 PM EDT	40 mEq		
40 mEq, PEG Tube, TWICE DAILY, First dose on Fri 8/4/23 at 1200, For 2 doses, Routine	Given	08/04/2023 1:29 PM EDT	40 mEq		
potassium chloride (KCL) 20 MEQ/15ML (10%) oral liquid 1.33mEq/mL 40 mEq 40 mEq, Oral, ONCE, On Mon 8/7/23 at 1130, For 1 dose, Routine	Given	08/07/2023 11:50 AM EDT	40 mEq		
potassium chloride (KCL) 20 MEQ/15ML (10%) oral liquid 1.33mEq/mL 40 mEq	Given	08/08/2023 8:54 PM EDT	40 mEq		
40 mEq, PEG Tube, TWICE DAILY, First dose on Tue 8/8/23 at 1100, For 2 doses, Routine	Given	08/08/2023 11:54 AM EDT	40 mEq		
potassium chloride (KCL) 20 MEQ/15ML (10%) oral liquid 1.33mEq/mL 40 mEq	Given	08/26/2023 8:02 PM EDT	40 mEq		
40 mEq, Oral, THREE TIMES DAILY, First dose (after last modification) on Sat 8/26/23 at 1800, For 2 doses, Routine	Given	08/26/2023 5:11 PM EDT	40 mEq		
potassium chloride (KCL) 20 MEQ/15ML (10%) oral liquid 1.33mEq/mL 40 mEq 40 mEq, PEG Tube, ONCE, On Mon 8/28/23 at 1100, For 1 dose, Routine	Given	08/28/2023 9:59 AM EDT	40 mEq		
potassium chloride 20 mEq IVPB 20 mEq EVERY 2 HOURS, Intravenous, Administer	New Bag	08/07/2023 1:58 PM EDT	20 mEq	50 mL/hr	
over 2 Hours, First dose on Mon 8/7/23 at 1200, For 2 doses,	New Bag	08/07/2023 11:50 AM EDT	20 mEq	50 mL/hr	
potassium chloride 20 mEq IVPB 20 mEq ONCE, Intravenous, Administer over 2 Hours, On Tue 8/8/23 at 1100, For 1 dose,	New Bag	08/08/2023 11:54 AM EDT	20 mEq	50 mL/hr	
potassium chloride 20 mEq IVPB 20 mEq ONCE, Intravenous, Administer over 2 Hours, On Sun 8/13/23 at 1230, For 1 dose,	New Bag	08/13/2023 1:04 PM EDT	20 mEq	50 mL/hr	
potassium chloride 20 mEq IVPB 20 mEq ONCE, Intravenous, Administer over 2 Hours, On Mon 8/28/23 at 1100, For 1 dose	New Bag	08/28/2023 12:15 PM EDT	20 mEq	50 mL/hr	
sodium chloride 0.9 % bolus 1,000 mL 1,000 mL ONCE, Intravenous, Administer over 60 Minutes, On Tue 8/1/23 at 1730, For 1 dose, Consider the use of a pressure bag (clarify with prescriber) for rapid fluid administration. Notify physician if SBP is less than or equal to 90 mmHg after bolus infusion is completed.	New Bag	08/01/2023 5:46 PM EDT	1,000 mL	1000 mL/hr	
sodium chloride 0.9 % bolus 1,000 mL 1,000 mL, Intravenous, ONCE, On Wed 8/23/23 at 0330, For 1 dose, Routine	New Bag	08/23/2023 3:15 AM EDT	1,000 mL		
sodium chloride 0.9 % bolus 500 mL 500 mL, at 1,500 mL/hr, Administer over 20 Minutes, Intravenous, ONCE, On Sun 8/27/23 at 1700, For 1 dose, STAT	New Bag	08/27/2023 3:51 PM EDT	500 mL	1500 mL/hr	

Medication Order	MAR Action	Action Date	Dose	Rate	Site
sodium chloride 0.9 % bolus 500 mL 500 mL, at 1,500 mL/hr, Administer over 20 Minutes, Intravenous, ONCE, On Sun 8/27/23 at 1830, For 1 dose, STAT	New Bag	08/27/2023 5:04 PM EDT	500 mL	1500 mL/hr	
sodium chloride 0.9 % flush injection 10 mL 10 mL, Intravenous, AS NEEDED PER ADMINISTRATION INSTRUCTIONS, FOR FLUSH AND MAINTAIN IV, Starting on Sat 8/5/23 at 0853, For 240 days, Routine					
sodium chloride 0.9 % flush injection 10 mL 10 mL, Intravenous, EVERY 12 HOURS, First dose	Given	08/29/2023 9:36 AM EDT	10 mL		
on Sat 8/5/23 at 1000, For 240 days, Routine	Given	08/28/2023	10 mL		
	Given	9:59 AM EDT 08/27/2023 8:57 PM EDT	10 mL		
sodium chloride 0.9 % flush injection 10 mL 10 mL, Intravenous, AS NEEDED PER ADMINISTRATION INSTRUCTIONS, FOR FLUSH AND MAINTAIN IV, Starting on Sat 8/26/23 at 1645, For 240 days, Routine					
sodium chloride 0.9 % flush injection 10 mL	Given	08/29/2023	10 mL		
10 mL, Intravenous, EVERY 12 HOURS, First dose on Sat 8/26/23 at 2100, For 240 days, Routine	Given	9:36 AM EDT 08/28/2023	10 mL		
	Given	10:26 PM EDT 08/28/2023 9:59 AM EDT	10 mL		
sodium chloride 0.9 % flush injection 20 mL 20 mL, Intravenous, AS NEEDED PER ADMINISTRATION INSTRUCTIONS, FOR FLUSH AND MAINTAIN IV, Starting on Sat 8/5/23 at 0853, For 240 days, Routine					
sodium chloride 0.9 % flush injection 20 mL 20 mL, Intravenous, AS NEEDED PER ADMINISTRATION INSTRUCTIONS, FOR FLUSH AND MAINTAIN IV, Starting on Sat 8/26/23 at 1645, For 240 days, Routine					
sodium chloride 0.9 % flush injection 3 mL 3 mL, Intravenous, AS NEEDED, FOR FLUSH AND MAINTAIN IV, Starting on Tue 8/1/23 at 1724, For 240 days, Routine					
sodium chloride 0.9% flush injection 10 mL 10 mL IMG once PRN, Intravenous, FOR LINE CARE, FOR CONTRAST, Starting on Wed 8/2/23 at 0122, For 1 dose					
valproate (DEPAKENE) syrup 250 mg/5 mL 1,000 mg	Given	08/29/2023 9:35 AM EDT	1,000 mg		
1,000 mg, Oral, TWICE DAILY, First dose on Thu 8/3/23 at 1000, For 240 days, Routine	Given	08/28/2023	1,000 mg		
0, 5, 25 ut 1000, 1 01 240 udys, Noutine	Given	10:23 PM EDT 08/28/2023 9:52 AM EDT	1,000 mg		
vancomycin (VANCOCIN) 1,250 mg in sodium chloride 0.9 % 275 mL IVPB	New Bag	08/07/2023 8:52 AM EDT	1,250 mg	183 mL/hr	
	New Bag	08/06/2023 8:27 PM EDT	1,250 mg	183 mL/hr	

Medication Order	MAR Action	Action Date	Dose	Rate	Site
1,250 mg, at 183 mL/hr, Administer over 1.5 Hours, Intravenous, EVERY 12 HOURS, First dose (after last modification) on Sat 8/5/23 at 2000, For 8 doses, Routine	New Bag	08/06/2023 10:13 AM EDT	1,250 mg	183 mL/hr	
vancomycin (VANCOCIN) 1,250 mg in sodium chloride 0.9 % 275 mL IVPB	New Bag	08/28/2023 12:20 PM EDT	1,250 mg	183 mL/hr	
1,250 mg, at 183 mL/hr, Administer over 1.5 Hours, Intravenous, EVERY 12 HOURS, First dose on	New Bag	08/27/2023 11:33 PM EDT	1,250 mg	183 mL/hr	
Sun 8/27/23 at 1130, For 5 days, Routine	New Bag	08/27/2023 1:34 PM EDT	1,250 mg	183 mL/hr	
vancomycin (VANCOCIN) 1,500 mg in sodium chloride 0.9 % 280 mL IVPB	New Bag	08/05/2023 10:21 AM EDT	1,500 mg	187 mL/hr	
1,500 mg, at 187 mL/hr, Administer over 1.5 Hours, Intravenous, EVERY 12 HOURS, First dose on Wed 8/2/23 at 0800, For 15 doses, Routine	New Bag	08/04/2023 9:49 AM EDT	1,500 mg	187 mL/hr	
	New Bag	08/03/2023 7:53 PM EDT	1,500 mg	187 mL/hr	
vancomycin (VANCOCIN) 2,250 mg in sodium chloride 0.9 % 545 mL IVPB 2,250 mg (rounded from 2,177.5 mg = 25 mg/kg/ dose × 87.1 kg), at 218 mL/hr, Administer over 2.5 Hours, Intravenous, ONCE, On Wed 8/23/23 at 0530, For 1 dose, Routine	New Bag	08/23/2023 5:50 AM EDT	2,250 mg	218 mL/hr	
vancomycin (VANCOCIN) 2,500 mg in sodium chloride 0.9 % 550 mL IVPB 2,500 mg, at 220 mL/hr, Administer over 2.5 Hours, Intravenous, ONCE, On Tue 8/1/23 at 1800, For 1 dose, STAT	New Bag	08/01/2023 6:37 PM EDT	2,500 mg	220 mL/hr	

Advance Directives

For more information, please contact: 947-522-1948

No CPR (Latest Code Status on File)

No el la lest code sta	tus on the		
Date Activated	Date Inactivated		Comments
9/7/2023 7:43 AM	9/15/2023 3:07 AN	1	Spoke to Vicki, the sister
Question	Answer	Comments	
In a non-arrest state, permit intubation?	No		
In a non-arrest state, permit vaso-active medications?	Yes		
In a non-arrest state, permit antiarrhythmics?	Yes		
In a non-arrest state, permit cardioversion?	Yes		
Decision Arrived By:	Decision discussed with patient/decision-maker		
No CPR			
Date Activated	Date Inactivated		Comments
		4	
8/1/2023 8:53 PM	8/29/2023 4:49 PN	1	Discussed with patient's daughter and patient's sister
Question	Answer	Comments	
In a non-arrest state, permit intubation?	No		
In a non-arrest state, permit vaso-active medications?	Yes		
In a non-arrest state, permit antiarrhythmics?	Yes		

Document Information

In a non-arrest state,

permit cardioversion? Decision Arrived By:

Team Member

Per Unknown

NPI: 1639171770

Yes

Care Teams - documented as of this encounter

Decision discussed with patient/decision-maker

Relationship

PCP - General

Specialty

Obstetrics and Gynecology

Start Date

8/1/23

End Date

9/5/23

Diane Kaiser Alexander (Attending) Armen Korktigian (Attending). Admitting) Aug. 01, 2023 - Aug. 29, 2023 PNE 10395001 NPE 103693934 248-471-73564 (Work) 248-547-2512 (Work) 248-471-73565 (Mork) 248-547-2512 (Work) 248-517-7301 (Katending) Chattending Termington Hills, ML48335 Berkley, ML48072-0921 Emergency Medicine Internal Medicine VIIIam Rudy (Matending) Chattending) NPE 107907707 NPE 100340939 Ads-517-2301 (Work) 2248-615-7266 (Foa) 248-517-2312 (Frax) 2248-615-7266 (Foa) 248-517-2312 (Work) 2248-615-7266 (Foa) 248-517-2312 (Work) 2248-615-7266 (Foa) 248-517-2312 (Work) 2248-615-7266 (Foa) 248-517-2312 (Work) 2248-615-7266 (Foa) 253 Coolidge Hwy Earonery Medicine Bryn H (Attending) Michele C (Attending) Madia L (Attending) Michele C (Attending) NPI: 1703-12032 (Frax) 224-515-7266 (Foa) 248-551-721 (Work) 248-551-721 (Work) 2592 Ochard Atkending) Metal (Attending) NPI:	Encounter Providers				Encounter Date
NPE 179075207 AVE 179075207 NPE 1003480330 AVE 179075207 AVE 10747	NPI: 1013958016 248-471-8564 (Work) 248-615-7390 (Fax) 28050 Grand River Ave. Farmington Hills, MI 48336	NPI: 10 248-54 248-54 2635 C Berkley	03893934 1-2512 (Work) 1-0232 (Fax) oolidge Hwy 7 MI 48072-0921	g, Admitting)	Aug. 01, 2023 - Aug. 29, 2023
Nadia L (Attending) Holly F (Attending) Michelle A (Attending) Carley A (Attending) Sarah I (Attending) William Boudouris (Attending) Nev: 1205806577 248-553-0010 (Work) 248-553-0010 (Work) 248-553-0010 (Work) 248-553-0010 (Work) 248-553-5957 (Fax) 28950 Crchard Lake Rd #200 Farmington Hills, MI 48334 Neurology Sabiha Omar (Attending) Dasha R (Attending) NPI: 1790146009 248-655-7271 (Work) 947-521-9220 (Work) 248-655-7271 (Work) 947-521-9220 (Work) 248-655-7271 (Work) 248-471-8864 (Fax) 248-655-7271 (Work) 248-471-8864 (Fax) 248-655-7271 (Work) 248-71-8864 (Fax) 248-655-7271 (Work) 248-71-8864 (Fax) 248-655-7271 (Work) 248-71-8864 (Fax) 248-65-7271 (Work) 248-71-8864 (Fax) 248-65-7271 (Work) 248-71-8864 (Fax) 248-65-7271 (Work) 248-71-8864 (Fax) 248-753-724 (Fax) 248-71-8864 (Fax) 2502 Orchard Lake Rd #333 28080 Grand River Ave Ste 306N Parmington Hills, MI 48334 FarMINGTON HILLS, MI 48336 Paychiatry Infectious Disease Danitra A (A	NPI: 1790797207 248-541-2512 (Work) 248-541-0232 (Fax) 2635 Coolidge Hwy Berkley, MI 48072-0921	NPI: 1003480930 248-471-8566 (W 248-615-7266 (Fa 28050 Grand Rive FARMINGTON HII	ork) x) er Ave LLS, MI 48336	herine G (Attending)	
Occupational Therapy Carley A (Attending) Sarah I (Attending) William Boudouris (Attending) NPI: 1205806577 248-553-9957 (Fax) 28595 Orchard Lake Rd #200 Farmington Hills, MI 48334 Neurology Sabiha Omar (Attending) Dasha R (Attending) Ade astrongy Samantha C (Attending) Danitra A (Attending) Sara R (Attending) Melanie H (Attending) Cacupational Therapy Lori S (Attending) Sarah P (Attending) Melanie H (Attending) Physical Therapy Lori S (Attending) Timitas S (Attending) Cacupational Therapy Lori S (Attending) Timika S (Attending) <td>Brynn H (Attending) Mich</td> <td>ael C (Attending)</td> <td>Netra V (Attendir</td> <td></td> <td></td>	Brynn H (Attending) Mich	ael C (Attending)	Netra V (Attendir		
NPI: 1205806577 248-553-0010 (Work) 248-553-0957 (Fax) 28595 Orchard Lake Rd #200 Farmington Hills, MI 48334 Neurology Sabiha Omar (Attending) Dasha R (Attending) Amal Khalife (Attending) NPI: 1841272259 NPI: 1790146009 248-655-7271 (Work) 248-471-8864 (Fax) 248-655-7271 (Kork) 248-471-8864 (Fax) 248-655-7271 (Kork) 248-471-8864 (Fax) 2592 Orchard Lake Rd #333 28080 Grand River Ave Ste 306N Farmington Hills, MI 48334 FARMINGTON HILLS, MI 48336 Psychiatry Infectious Disease Danitra A (Attending) Katherine F (Attending) Occupational Therapy Coccupational Therapy Samantha C (Attending) Katherine F (Attending) Occupational Therapy Christopher M (Attending) Physical Therapy Brainna M (Attending) Brooke D (Attending) Timika S (Attending) Christopher M (Attending) Physical Therapy Braina B (Attending) Carries (Attending) Mansoora A (Attending) Maria L (Attending) Christopher M (Attending) Mansoora A (Attending) Maria L (Attending) Cheristine B (Attending) <	Nadia L (Attending) Holly				
NPI: 1841272259 NPI: 1790146009 248-865-7271 (Work) 947-521-8920 (Work) 248-865-7274 (Fax) 248-471-8864 (Fax) 28592 Orchard Lake Rd #333 28080 Grand River Ave Ste 306N Farmington Hills, MI 48334 FARMINGTON HILLS, MI 48336 Psychiatry Infectious Disease Danitra A (Attending) Sara R (Attending) Tiffanie C (Attending) Occupational Therapy Occupational Therapy Lori S (Attending) Shaniqua H (Attending) Melanie H (Attending) Physical Therapy Occupational Therapy Christopher M (Attending) Physical Therapy Sarah P (Attending) Christopher M (Attending) Physical Therapy Timika S (Attending) Fatema B (Attending) Physical Therapy Dragica S (Attending) Lourdes Q (Attending) Brooke D (Attending) Maria L (Attending) Lourdes Q (Attending) Mansoora A (Attending) Maria L (Attending) Christine B (Attending) Physical Therapy Denise B (Attending) Jaana P (Attending) Joan O (Attending) Angelina B (Attending) Denise B (Attending) Joan O (Attending) Jennifer G (Attending) Alana P (Attending) <	Carley A (Attending) Saral	h l (Attending)	NPI: 1205806577 248-553-0010 (Work 248-553-5957 (Fax) 28595 Orchard Lake Farmington Hills, MI) Rd #200	
Occupational Therapy Samantha C (Attending) Katherine F (Attending) Melanie H (Attending) Physical Therapy Occupational Therapy Occupational Therapy Lori S (Attending) Shaniqua H (Attending) Brianna M (Attending) Kelsey W (Attending) Sarah P (Attending) Christopher M (Attending) Physical Therapy Brooke D (Attending) Timika S (Attending) Fatema B (Attending) Brooke D (Attending) Timika S (Attending) Fatema B (Attending) Camille H (Attending) Mansoora A (Attending) Maria L (Attending) Christine B (Attending) Maria L (Attending) Physical Therapy Maria L (Attending) Hala R (Attending) Deloorah A (Attending) Joan O (Attending) Joan O (Attending) Jennifer G (Attending) Alana P (Attending) Shelly P (Attending) Shelly P (Attending) Jennifer G (Attending) Alana P (Attending) Shelly P (Attending) Physical Therapy Legal Authenticator Legal Authenticator Legal Authenticator	NPI: 1841272259 248-865-7271 (Work) 248-865-7274 (Fax) 28592 Orchard Lake Rd #333 Farmington Hills, MI 48334	Dasha R (Atter	NPI: 179014 947-521-89 248-471-88 28080 Gran FARMINGTO	46009 120 (Work) 164 (Fax) 1d River Ave Ste 306N DN HILLS, MI 48336	
Physical Therapy Occupational Therapy Lori S (Attending) Shaniqua H (Attending) Brianna M (Attending) Kelsey W (Attending) Sarah P (Attending) Christopher M (Attending) Physical Therapy Sarah P (Attending) Christopher M (Attending) Brooke D (Attending) Timika S (Attending) Fatema B (Attending) Camille H (Attending) Dragica S (Attending) Lourdes Q (Attending) Mansoora A (Attending) Maria L (Attending) Christine B (Attending) Physical Therapy Deborah A (Attending) Angelina B (Attending) Joan O (Attending) Shaterica B (Attending) Denise B (Attending) Gloria B (Attending) Jennifer G (Attending) Alana P (Attending) Physical Therapy Legal Authenticator Legal Authenticator				ding)	
Kelsey W (Attending) Sarah P (Attending) Christopher M (Attending) Brooke D (Attending) Timika S (Attending) Fatema B (Attending) Camille H (Attending) Dragica S (Attending) Lourdes Q (Attending) Mansoora A (Attending) Maria L (Attending) Christine B (Attending) Physical Therapy Maria L (Attending) Christine B (Attending) Deborah A (Attending) Angelina B (Attending) Hala R (Attending) Joan O (Attending) Shaterica B (Attending) Denise B (Attending) Gloria B (Attending) Jennifer G (Attending) Alana P (Attending) Shelly P (Attending) Jennifer G (Attending) Alana P (Attending) Legal Authenticator Legal Authenticator Legal Authenticator				(Attending)	
Physical Therapy Brooke D (Attending) Timika S (Attending) Fatema B (Attending) Camille H (Attending) Dragica S (Attending) Lourdes Q (Attending) Mansoora A (Attending) Maria L (Attending) Christine B (Attending) Physical Therapy Deborah A (Attending) Angelina B (Attending) Joan O (Attending) Shaterica B (Attending) Denise B (Attending) Gloria B (Attending) Jennifer G (Attending) Alana P (Attending) Shelly P (Attending) Physical Therapy Legal Authenticator	Lori S (Attending) Shaniqu	ua H (Attending)	Brianna M (Attend	ling)	
Camille H (Attending) Dragica S (Attending) Lourdes Q (Attending) Mansoora A (Attending) Maria L (Attending) Christine B (Attending) Physical Therapy Deborah A (Attending) Angelina B (Attending) Hala R (Attending) Joan O (Attending) Shaterica B (Attending) Denise B (Attending) Gloria B (Attending) Jennifer G (Attending) Alana P (Attending) Shelly P (Attending) Physical Therapy		ah P (Attending)	Christopher M (At	tending)	
Mansoora A (Attending) Maria L (Attending) Christine B (Attending) Physical Therapy Deborah A (Attending) Angelina B (Attending) Joan O (Attending) Shaterica B (Attending) Denise B (Attending) Gloria B (Attending) Jennifer G (Attending) Alana P (Attending) Shelly P (Attending) Physical Therapy Legal Authenticator Legal Authenticator	Brooke D (Attending) Tim	ika S (Attending)	Fatema B (Attend	ing)	
Physical Therapy Deborah A (Attending) Angelina B (Attending) Hala R (Attending) Joan O (Attending) Shaterica B (Attending) Denise B (Attending) Gloria B (Attending) Jennifer G (Attending) Alana P (Attending) Shelly P (Attending) Physical Therapy Legal Authenticator	Camille H (Attending) Dra	igica S (Attending) Lourdes Q (Atte	nding)	
Joan O (Attending) Shaterica B (Attending) Denise B (Attending) Gloria B (Attending) Jennifer G (Attending) Alana P (Attending) Shelly P (Attending) Physical Therapy Legal Authenticator Legal Authenticator		Maria L (Attending	g) Christine B (Att	ending)	
Gloria B (Attending) Jennifer G (Attending) Alana P (Attending) Shelly P (Attending) Physical Therapy Legal Authenticator	Deborah A (Attending) Ar	ngelina B (Attendi	ng) Hala R (Atten	ding)	
Shelly P (Attending) Physical Therapy Legal Authenticator	Joan O (Attending) Shater	rica B (Attending)	Denise B (Attend	ing)	
Physical Therapy Legal Authenticator	Gloria B (Attending) Jenni	ifer G (Attending)	Alana P (Attendir	ng)	
Susan T					
	Susan T				